

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:51:52 ; Search time 11 Seconds  
(without alignments)  
3.823 Million cell updates/sec

Title: US-10-664-775-4  
Perfect score: 2279  
Sequence: 1 gatcactctctagtgaag.....ttgtaattctaggtctgtat 2279

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 20 seqs, 9225 residues 40

Total number of hits satisfying chosen parameters:

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rni:db:\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20.6	0.9	1440	1 US-07-882-202A-3	Sequence 3, Appli
C 2	20.6	0.9	1440	1 US-08-021-615A-3	Sequence 3, Appli
C 3	20.6	0.9	1440	1 US-08-321-777-3	Sequence 3, Appli
C 4	20.6	0.9	1440	1 US-09-009-217-13	Sequence 13, Appli
C 5	20.6	0.9	1440	1 US-09-009-656-13	Sequence 13, Appli
C 6	20.6	0.9	1440	1 PCT-US93-04493-3	Sequence 3, Appli
C 7	16.6	0.7	1440	1 US-07-882-202A-3	Sequence 3, Appli
C 8	16.6	0.7	1440	1 US-08-021-615A-3	Sequence 3, Appli
C 9	16.6	0.7	1440	1 US-08-321-777-3	Sequence 3, Appli
C 10	16.6	0.7	1440	1 US-09-009-217-13	Sequence 13, Appli
C 11	16.6	0.7	1440	1 US-09-009-656-13	Sequence 13, Appli
C 12	16.6	0.7	1440	1 PCT-US93-04493-3	Sequence 3, Appli
C 13	14.0	0.6	38	1 US-09-558-027-4	Sequence 4, Appli
C 14	12.8	0.6	141	1 US-08-849-248-6	Sequence 6, Appli
C 15	12.6	0.6	141	1 US-08-849-248-6	Sequence 6, Appli
C 16	12.0	0.5	38	1 US-09-558-027-4	Sequence 4, Appli
C 17	11.2	0.5	27	1 US-08-293-778-16	Sequence 16, Appli
C 18	11.0	0.5	27	1 US-08-293-778-16	Sequence 16, Appli
C 19	10.6	0.5	42	1 US-08-955-636-9	Sequence 9, Appli
C 20	10.6	0.5	45	1 US-08-756-506-13	Sequence 13, Appli
C 21	10.4	0.5	45	1 US-08-756-506-13	Sequence 13, Appli
C 22	10.0	0.4	35	1 US-07-998-972A-7	Sequence 7, Appli
C 23	10.0	0.4	35	1 US-08-463-953-7	Sequence 7, Appli
C 24	10.0	0.4	35	1 US-08-463-953-7	Sequence 7, Appli
C 25	10.0	0.4	35	1 PCT-US92-11357-7	Sequence 7, Appli
C 26	9.8	0.4	27	1 US-08-293-778-16	Sequence 16, Appli
C 27	9.4	0.4	27	1 US-08-293-778-16	Sequence 16, Appli
C 28	9.4	0.4	35	1 US-07-998-972A-7	Sequence 7, Appli
C 29	9.4	0.4	35	1 US-08-463-953-7	Sequence 7, Appli
C 30	9.4	0.4	35	1 PCT-US92-11357-7	Sequence 7, Appli
C 31	9.4	0.4	35	1 PCT-US92-11357-7	Sequence 7, Appli
C 32	9.4	0.4	36	1 US-08-955-636-9	Sequence 9, Appli
C 33	9.4	0.4	36	1 US-08-955-636-10	Sequence 10, Appli

Sequence 22, Appli  
Sequence 20, Appli  
Sequence 8, Appli  
Sequence 22, Appli  
Sequence 20, Appli  
Sequence 9, Appli  
Sequence 10, Appli

ALIGNMENTS

RESULT 1

US-07-882-202A-3/c  
; Sequence 3, Application US/07882202A  
; Patent No. 5374617  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/882,202A  
; FILING DATE: 13-MAY-1992  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRF B34290  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: CDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note="Coding portion of human  
; OTHER INFORMATION: factor VII cDNA"  
US-07-882-202A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.99; Indels 0; Gaps 0;  
Matches 35; Conservative 0; Mismatches 24;

QY 440 TTCAATGCTTTTATCTGCGAGACTTGTCTTTTGTGAAATGATGATTCATTTTGG 498  
DB 659 TTGCTGCAATCTTTTCTTCTTAGAATAGGATTTTCCACATGGATTCACATGTTGG 601

RESULT 2  
US-08-021-615A-3/c  
; Sequence 3, Application US/08021615A  
; Patent No. 5504064  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of  
; TITLE OF INVENTION: FVII  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/021,615A  
; FILING DATE: 19-FEB-1993  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/882,202  
; FILING DATE: 13-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRP B34290CIP  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4600  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; OTHER INFORMATION: factor VII cDNA"  
US-08-021-615A-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.99;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTTGAATATGATTCATTTGG 498  
DB 659 TTGCTGCAATTCCTTTTCTAGATAGGTATTTTCCACATGATATTCACACTGTGG 601

RESULT 3  
US-08-321-777-3/c  
; Sequence 3, Application US/08321777  
; Patent No. 5504067  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified

; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/321,777  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/892202  
; FILING DATE: 13-MAY-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRP B34290C  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; OTHER INFORMATION: factor VII cDNA"  
US-08-321-777-3

Query Match 0.9%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.99;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTTGAATATGATTCATTTGG 498  
DB 659 TTGCTGCAATTCCTTTTCTAGATAGGTATTTTCCACATGATATTCACACTGTGG 601

RESULT 4  
US-09-009-217-13/c  
; Sequence 13, Application US/09009217  
; Patent No. 6132729  
; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E.  
; APPLICANT: King, Steven W.  
; APPLICANT: Gao, Boning  
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND  
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION  
; TITLE OF INVENTION: AND TUMOR TREATMENT  
; NUMBER OF SEQUENCES: 27  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Arnold, White & Durkee  
; STREET: P.O. Box 4433  
; CITY: Houston  
; STATE: Texas



COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,217  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:537  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-656-13  
Query Match 0.9%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.99;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGTGTTTGAATATGATTCATTTGG 498  
Db 659 TTGCTGCAATTTCTTTTCTAGATAGTATTTTCCATGGATATCAACTGG 601  
RESULT 6  
PCT-US93-04493-3/c  
Sequence 3, Application PC/TUS9304493  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or  
TITLE OF INVENTION: FVII Activator for Blood Coagulation  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/04493  
FILING DATE: 19930512  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882202  
FILING DATE: 13-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/021615  
FILING DATE: 19-FEB-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Trujillo, Doreen Y.  
REGISTRATION NUMBER: 35,719  
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs

COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,217  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:536  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-217-13  
Query Match 0.9%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.99;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTTGTGTTTGAATATGATTCATTTGG 498  
Db 659 TTGCTGCAATTTCTTTTCTAGATAGTATTTTCCATGGATATCAACTGG 601  
RESULT 5  
US-09-009-656-13/c  
Sequence 13, Application US/09009656  
Patent No. 6132730  
GENERAL INFORMATION:  
APPLICANT: Thorpe, Philip E.  
APPLICANT: King, Steven W.  
APPLICANT: Gao, Boning  
TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa  
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR  
TITLE OF INVENTION: TREATMENT  
NUMBER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P.O. Box 4433  
CITY: Houston  
STATE: Texas  
COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,656  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:

```

; TYPE: NUCLEIC ACID
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /product= "Tissue Factor"
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /citation= ([1])
PCT-US93-04493-3

Query Match
Best Local Similarity 59.3%; Pred. No. 0.99; Length 1440;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATTGCTTTATCTGCGAGACTGCTTTGTTTTCGAATATGTAATTCATTTGG 498
Db 659 TTGCTGCGAATTCCTTTTCTAGAAATAGGTATTTTCCACATGGGATATTCACCTGTGG 601

RESULT 7
US-07-882-202A-3
; Sequence 3, Application US/07882202A
; Patent No. 5374617
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/882, 202A
; FILING DATE: 13-MAY-1992
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882, 202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"
; OTHER INFORMATION: /factor VII cDNA"
US-08-021-615A-3
Query Match
Best Local Similarity 64.1%; Pred. No. 12; Length 1440;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-07-882-202A-3
Query Match
Best Local Similarity 64.1%; Pred. No. 12; Length 1440;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1761 TCCTTTGGTTTTCATAGTCTCTCTGGCTTCCTCGATG 1799
Db 58 TCCTCTGCTTCTGTTGGGCTTCAGGGCTGCTGCTGCTG 96

RESULT 8
US-08-021-615A-3
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; TITLE OF INVENTION: Tissue Factor in Combination with an Activator of
; TITLE OF INVENTION: FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021, 615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882, 202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; OTHER INFORMATION: factor VII cDNA"
US-08-021-615A-3
Query Match
Best Local Similarity 64.1%; Pred. No. 12; Length 1440;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;
```

```

; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; TITLE OF INVENTION: CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TITLE OF INVENTION: AND TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009.217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 12;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGCATAGTCTCTGGCTTCCTGGATG 1799
Db 58 TCCTCTGCCTTCTGCTTGGCTTCAGGCGTCTGGCTG 96

RESULT 11
US-09-009-656-13
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433

```

CITY: Houston  
STATE: Texas  
COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,656  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:537  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-656-13

Query Match 0.7%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 1761 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTGGATG 1799  
|||||  
Db 58 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 96

RESULT 12  
PCT-US93-04493-3  
Sequence 3, Application PC/TUS9304493  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
APPLICANT: Comp, Philip C.  
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or  
TITLE OF INVENTION: FVII Activator for Blood Coagulation  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSES: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/04493  
FILING DATE: 19930512  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882202

FILING DATE: 13-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/021615  
FILING DATE: 19-FEB-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Trujillo, Doreen Y.  
REGISTRATION NUMBER: 35,719  
REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433  
OTHER INFORMATION: /product= "Tissue Factor"  
OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"  
OTHER INFORMATION: /citation= {[1]}  
PCT-US93-04493-3

Query Match 0.7%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 1761 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTGGATG 1799  
|||||  
Db 58 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTG 96

RESULT 13  
US-09-558-027-4  
Sequence 4, Application US/09558027  
Patent No. 6329176  
GENERAL INFORMATION:  
APPLICANT: Woldike, Helle  
APPLICANT: Wiberg, Finn  
APPLICANT: Nielsen, Lars  
TITLE OF INVENTION: Method for the Production of FVII  
FILE REFERENCE: 5565.204-US  
CURRENT APPLICATION NUMBER: US/09/558,027  
CURRENT FILING DATE: 2000-04-25  
PRIOR APPLICATION NUMBER: 60/108,065  
PRIOR FILING DATE: 1998-11-12  
NUMBER OF SEQ ID NOS: 4  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 4  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Saccharomyces cerevisiae  
US-09-558-027-4

Query Match 0.6%; Score 14; DB 1; Length 38;  
Best Local Similarity 77.3%; Pred. No. 8;  
Matches 17; Conservative 0; Mismatches 5; Indels 0; Gaps 0;  
QY 3 TCACCTCTCTAGTGAAGGTGG 24  
|||||  
Db 8 TCACCTAGTCTAGGGAATGGGG 29

RESULT 14  
US-08-849-248-6/c

; Sequence 6, Application US/08849248  
; Patent No. 5948759  
; GENERAL INFORMATION:  
; APPLICANT: Husbyn, Mette  
; APPLICANT: Fischer, Peter  
; APPLICANT: Orning, Lars  
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use  
; TITLE OF INVENTION: in blood clotting disorders  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Bacon and Thomas  
; STREET: 625 Slaters Lane, 4th Floor  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/849,248  
; FILING DATE: 27 Aug 1997  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 141 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid  
; DESCRIPTION: /desc = "recombinant DNA"  
; US-08-849-248-6

Query Match 0.6%; Score 12.8; DB 1; Length 141;  
Best Local Similarity 70.8%; Pred. No. 65;  
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 147 TCTGCTGGCAATCTCTGGGCT 170  
DB 25 TCAGCTGGTCATCTCTGGGCT 2

## RESULT 15:

; US-08-849-248-6  
; Sequence 6, Application US/08849248  
; Patent No. 5948759  
; GENERAL INFORMATION:  
; APPLICANT: Husbyn, Mette  
; APPLICANT: Fischer, Peter  
; APPLICANT: Orning, Lars  
; TITLE OF INVENTION: Factor VII Fragment 82-128 and its use  
; TITLE OF INVENTION: in blood clotting disorders  
; NUMBER OF SEQUENCES: 6  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Bacon and Thomas  
; STREET: 625 Slaters Lane, 4th Floor  
; CITY: Alexandria  
; STATE: Virginia  
; COUNTRY: USA  
; ZIP: 22314  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/849,248  
; FILING DATE: 27 Aug 1997  
; INFORMATION FOR SEQ ID NO: 6:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 141 base pairs  
; TYPE: nucleic acid

; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: other nucleic acid  
; DESCRIPTION: /desc = "recombinant DNA"  
; US-08-849-248-6

Query Match 0.6%; Score 12.6; DB 1; Length 141;  
Best Local Similarity 55.8%; Pred. No. 73;  
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1394 TTCTAAGTGCAGTACTGTGGCTGACATCTGTAGTCTCTTGA 1436  
DB 97 TGCACGAGGGTACTCTCTGCTGCACACGGGGTCTCTGCA 139

## RESULT 16

; US-09-558-027-4/c  
; Sequence 4, Application US/09558027  
; Patent No. 6329176  
; GENERAL INFORMATION:  
; APPLICANT: Woldike, Helle  
; APPLICANT: Wiberg, Finn  
; APPLICANT: Nielsen, Lars  
; TITLE OF INVENTION: Method for the Production of FVII  
; FILE REFERENCE: 5565.204-US  
; CURRENT APPLICATION NUMBER: US/09/558,027  
; CURRENT FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 60/108,065  
; PRIOR FILING DATE: 1998-11-12  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Saccharomyces cerevisiae  
; US-09-558-027-4

Query Match 0.5%; Score 12; DB 1; Length 38;  
Best Local Similarity 75.0%; Pred. No. 45;  
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 893 AGGGCCATTTCCTTAGAATA 912  
DB 31 AGCCCATTCCTTAGACTA 12

## RESULT 17

; US-06-293-778-17/c  
; Sequence 17, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaissen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No 55805600 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-17

Query Match 0.5%; Score 11.2; DB 1; Length 27;
Best Local Similarity 81.2%; Pred. No. 63;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1788 GCTTCTCGATGTTT 1803
Db 23 GCGTCTCGAAGATT 8

RESULT 18
US-08-293-778-16
; Sequence 16, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149

```

```

; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;
Best Local Similarity 100.0%; Pred. No. 75;
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 2087 TCTTCAAGGAC 2097
Db 11 TCTTCAAGGAC 21

RESULT 19
US-08-955-636-8
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 1.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 238 CACTTCTGGCCAGGCTAGGGGAC 262
Db 2 CACTCCGCTCCAGGCTCTGGGAC 26

RESULT 20
US-08-756-506-13/c
; Sequence 13, Application US/08756506
; Patent No. 5905185
; GENERAL INFORMATION:
; APPLICANT: Garner, Ian
; APPLICANT: Cottingham, Ian R.
; APPLICANT: Temperley, Simon M.
; APPLICANT: Foster, Donald C.
; APPLICANT: Sprecher, Cindy A.
; APPLICANT: Prunkard, Donna E.

```

;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
;; TITLE OF INVENTION: ANIMALS  
;; NUMBER OF SEQUENCES: 25  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: ZymoGenetics, Inc.  
;; STREET: 1201 Eastlake Avenue East  
;; CITY: Seattle  
;; STATE: WA  
;; COUNTRY: USA  
;; ZIP: 98102  
;;  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: Patent In Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/756,506  
;; FILING DATE:  
;; CLASSIFICATION: 800  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Sawislak, Deborah A  
;; REGISTRATION NUMBER: 37,438  
;; REFERENCE/DOCKET NUMBER: 95-28  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 206-442-6672  
;; TELEFAX: 206-442-6678  
;; INFORMATION FOR SEQ ID NO: 13:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 45 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; IMMEDIATE SOURCE:  
;; CLONE: ZC6337  
;;  
;; US-08-756-506-13  
;;  
Query Match 0.5%; Score 10.6; DB 1; Length 45;  
Best Local Similarity 57.6%; Pred. No. 1.5e+02;  
Matches 19; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
;;  
QY 241 TTCTGGCGCAGGTAGGCGCTACTCCGATTC 273  
DB 35 TGTCTCAACGGCGCAAGCGCGCAACTCCTTC 3  
;;  
RESULT 21  
US-08-756-506-13  
; Sequence 13, Application US/08/756506  
; Patent No. 5905185  
; GENERAL INFORMATION:  
; APPLICANT: Garner, Ian R.  
; APPLICANT: Cottingham, Ian R.  
; APPLICANT: Temperley, Simon M.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Frankard, Donna E.  
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
; TITLE OF INVENTION: ANIMALS  
; NUMBER OF SEQUENCES: 25  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ZymoGenetics, Inc.  
; STREET: 1201 Eastlake Avenue East  
; CITY: Seattle  
; STATE: WA  
; COUNTRY: USA  
; ZIP: 98102  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/756,506

;; FILING DATE:  
;; CLASSIFICATION: 800  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Sawislak, Deborah A  
;; REGISTRATION NUMBER: 37,438  
;; REFERENCE/DOCKET NUMBER: 95-28  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 206-442-6672  
;; TELEFAX: 206-442-6678  
;; INFORMATION FOR SEQ ID NO: 13:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 45 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; IMMEDIATE SOURCE:  
;; CLONE: ZC6337  
;;  
;; US-08-756-506-13  
;;  
Query Match 0.5%; Score 10.4; DB 1; Length 45;  
Best Local Similarity 60.7%; Pred. No. 1.7e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;  
;;  
QY 642 GTTGAGAGAAATGGGTATTGAAGTAGC 669  
DB 10 GTTGCGCGCTTGCCTGACGACC 37  
;;  
RESULT 22  
US-07-998-972A-7/c  
; Sequence 7, Application US/07998972A  
; Patent No. 5476777  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; STREET: Twentieth Floor  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/998,972A  
; FILING DATE: 19921230  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/816,281  
; FILING DATE: 31-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear

```
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-07-998-972A-7

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGGCCTGAC 1419
Db 21 GGAGTTGGCTGCCGGAC 4

RESULT 23
US-08-463-953-7/c
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-462-261-7

Query Match 0.4%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 2e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGGCCTGAC 1419
Db 21 GGAGTTGGCTGCCGGAC 4

RESULT 25
PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; STREET: Twentieth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```



ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US92/11357  
FILING DATE: 19921230  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
PCT-US92-11357-7

Query Match 0.4%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 2e+02;  
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1402 GCAGTAGTCTGCCTGAC 1419  
Db 21 GCAGTTGGCTCGCGGAC 4

RESULT 26  
US-08-293-778-16/c  
Sequence 16, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agiris, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-08-293-778-16

Query Match 0.4%; Score 9.8; DB 1; Length 27;  
Best Local Similarity 66.7%; Pred. No. 1.9e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 553 GTCTCTAAATATCTCTAGGTC 573  
Db 21 GTCTTGAAGATCTCCCGGC 1

RESULT 27  
US-08-293-778-17  
Sequence 17, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/898,248  
;; FILING DATE: 12-JUN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Agis, Cheryl H.  
;; REGISTRATION NUMBER: 34,086  
;; REFERENCE/DOCKET NUMBER: 3129,224-US  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 212-867-0123  
;; TELEFAX: 212-867-0298  
;; INFORMATION FOR SEQ ID NO: 17:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 27 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: cDNA  
;; US-08-293-778-17

Query Match 0.4%; Score 9.4; DB 1; Length 27;  
Best Local Similarity 90.9%; Pred. No. 2.6e+02;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 2087 TCTTCAGGAC 2097  
Db 11 TCTTCAGGAC 21

RESULT 28  
US-07-998-972A-7  
; Sequence 7, Application US/07998972A  
; Patent No. 5476777  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/998,972A  
; FILING DATE: 19921230  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: ZC1324  
; US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;  
Best Local Similarity 90.9%; Pred. No. 2.9e+02;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTCGGATG 1799  
Db 21 CTTCTCGGAGG 31

RESULT 30  
US-08-462-261-7

;; IMMEDIATE SOURCE:  
;; CLONE: ZC1324  
;; US-07-998-972A-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;  
Best Local Similarity 90.9%; Pred. No. 2.9e+02;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTCGGATG 1799  
Db 21 CTTCTCGGAGG 31

RESULT 29  
US-08-463-953-7  
; Sequence 7, Application US/08463953  
; Patent No. 5502034  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/463,953  
; FILING DATE:  
; CLASSIFICATION: 514  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/816,281  
; FILING DATE: 31-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; IMMEDIATE SOURCE:  
; CLONE: ZC1324  
; US-08-463-953-7

Query Match 0.4%; Score 9.4; DB 1; Length 35;  
Best Local Similarity 90.9%; Pred. No. 2.9e+02;  
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTCGGATG 1799  
Db 21 CTTCTCGGAGG 31

RESULT 30  
US-08-462-261-7

```
; Sequence 7, Application US/08462261
; Patent No. 5537692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08462261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION INFORMATION:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/850,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

; Query Match 0.4%; Score 9.4; DB 1; Length 35;
; Best Local Similarity 90.9%; Pred. No. 2.9e+02;
; Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1789 CTTCTGTGGATG 1799
Db 21 CTTCTGTGGAGG 31

RESULT 32
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

; Query Match 0.4%; Score 9.4; DB 1; Length 36;
; Best Local Similarity 68.4%; Pred. No. 2.9e+02;
; Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 259 GCACTACCGCATCTCTCT 277
Db 13 GCGGCGCGCAGCTCTCTCT 31

RESULT 33
```

US-08-955-636-10/c  
; Sequence 10, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelsesuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; POLYPEPTIDES  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 10  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-10

Query Match 0.4%; Score 9.4; DB 1; Length 36;  
Best Local Similarity 68.4%; Pred. No. 2.9e+02;  
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 259 GCCTAGCGGCTTCCTCT 277  
Db 24 GCGGTGCGGAGCTCTCT 6

## RESULT 34

US-08-293-778-22/c  
; Sequence 22, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293, 778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129,224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs

REFERENCE/DOCKET NUMBER: 3129,224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 22:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 26 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
US-08-293-778-22

Query Match 0.4%; Score 9.2; DB 1; Length 26;  
Best Local Similarity 78.6%; Pred. No. 2.9e+02;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1920 GTCTCTGAGGTTC 1933  
Db 25 GTCTCGACCTTC 12

## RESULT 35

US-08-293-778-20  
; Sequence 20, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent In Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129,224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs

TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-293-778-20

Query Match 0.4%; Score 9.2; DB 1; Length 27;  
Best Local Similarity 78.6%; Pred No. 2.9e+02;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 240 CTTCTGGCCAGGG 253  
|| ||||| |||||  
Db 2 CTGCTGGACCTGGG 15

RESULT 36  
US-08-955-636-8/c  
; Sequence 8, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelsetuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-8

Query Match 0.4%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 52.8%; Pred No. 3.8e+02;  
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 136 TTCTGAAGCCTCTGTCGCATACTTCTGGGCTG 171  
|| ||||| || ||||| ||||| |||||  
Db 42 TTCTGGAGGAGCTCGTCCAGCAGCCTGGAGCG 7

RESULT 37  
US-08-293-778-22  
; Sequence 22, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989

APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 26 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: CDNA  
US-08-293-778-22

Query Match 0.4%; Score 8.6; DB 1; Length 26;  
Best Local Similarity 73.3%; Pred No. 4.2e+02;  
Matches 11; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 16 GAAAGTGGGGTCT 30  
|| ||||| || |||||  
Db 12 GGAAGTCGAGACT 26

RESULT 38  
US-08-293-778-20/c  
; Sequence 20, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989

;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: PCT/DR88/00103  
;; FILING DATE: 24-JUN-1988  
;; PRIOR APPLICATION DATA:  
;; APPLICATION NUMBER: US 07/898,248  
;; FILING DATE: 12-JUN-1992  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Agtis, Cheryl H.  
;; REGISTRATION NUMBER: 34,086  
;; REFERENCE/DOCKET NUMBER: 3129,224-US  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 212-867-0123  
;; TELEFAX: 212-867-0298  
;; INFORMATION FOR SEQ ID NO: 20:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 27 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; MOLECULE TYPE: cdna  
US-08-293-778-20

Query Match 0.4%; Score 8.6; DB 1; Length 27;  
Best Local Similarity 60.9%; Pred. No. 4.2e+02;  
Matches 14; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 509 AGGCTGCTGACAGAGAGGTACAG 531  
Db 27 AGGCGCTGGCGGCCCGCTCCAG 5

## RESULT 39

US-08-955-636-9/c  
;; Sequence 9, Application US/08955636A  
;; Patent No. 6017882  
;; GENERAL INFORMATION:  
;; APPLICANT: Nelstuen, Gary  
;; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
;; FILE OF INVENTION: POLYPEPTIDES  
;; FILE REFERENCE: 09531/002001  
;; CURRENT APPLICATION NUMBER: US/08/955,636A  
;; CURRENT FILING DATE: 1997-10-23  
;; NUMBER OF SEQ ID NOS: 35  
;; SOFTWARE: FastSeq for Windows Version 3.0  
;; SEQ ID NO 9  
;; LENGTH: 36  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-9

Query Match 0.4%; Score 8.4; DB 1; Length 36;  
Best Local Similarity 66.7%; Pred. No. 4.5e+02;  
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 158 TACTTCTGGGCTGCTGC 175  
Db 35 TCCTAGAGGAGCTGCGGC 18

## RESULT 40

US-08-955-636-10  
;; Sequence 10, Application US/08955636A  
;; Patent No. 6017882  
;; GENERAL INFORMATION:  
;; APPLICANT: Nelstuen, Gary  
;; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
;; FILE OF INVENTION: POLYPEPTIDES  
;; FILE REFERENCE: 09531/002001  
;; CURRENT APPLICATION NUMBER: US/08/955,636A  
;; CURRENT FILING DATE: 1997-10-23  
;; NUMBER OF SEQ ID NOS: 35

;; SOFTWARE: FastSeq for Windows Version 3.0  
;; SEQ ID NO 10  
;; LENGTH: 36  
;; TYPE: DNA  
;; ORGANISM: Artificial Sequence  
;; FEATURE:  
;; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-10

Query Match 0.4%; Score 8.4; DB 1; Length 36;  
Best Local Similarity 66.7%; Pred. No. 4.5e+02;  
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

Qy 158 TACTTCTGGGCTGCTGC 175  
Db 2 TCCTAGAGGAGCTGCGGC 19

Search completed: August 9, 2004, 16:52:04  
Job time : 12 secs

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:54:36 ; Search time 31 Seconds

(without alignments)  
3.697 Million cell updates/sec

Title: us-10-664-775-4

Perfect score: 2279  
Sequence: 1 gatcactctctagtgaag.....ttgtaattctagtgctgat 2279

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rnpsdb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	0.9	1332	1	US-10-411-037-7
C 2	20.6	0.9	1332	1	US-10-411-026-7
C 3	20.6	0.9	1332	1	US-10-410-962-7
C 4	20.6	0.9	1332	1	US-10-411-049-7
C 5	20.6	0.9	1332	1	US-10-410-930-7
C 6	20.6	0.9	1332	1	US-10-410-997-7
C 7	20.6	0.9	1332	1	US-10-411-012-7
C 8	20.6	0.9	1332	1	US-10-287-994-7
C 9	20.6	0.9	1332	1	US-10-410-913-7
C 10	20.6	0.9	1440	1	US-10-375-741-13
C 11	20.6	0.9	2040	1	US-10-617-619-12
C 12	20.6	0.9	2106	1	US-10-617-619-9
C 13	19.4	0.9	1361	1	US-10-382-248-35
C 14	17.2	0.8	1361	1	US-10-382-248-35
C 15	17	0.7	483	1	US-09-918-995-8429
C 16	17	0.7	1332	1	US-10-411-037-7
C 17	17	0.7	1332	1	US-10-411-026-7
C 18	17	0.7	1332	1	US-10-410-962-7
C 19	17	0.7	1332	1	US-10-411-049-7
C 20	17	0.7	1332	1	US-10-410-930-7
C 21	17	0.7	1332	1	US-10-410-997-7
C 22	17	0.7	1332	1	US-10-411-012-7
C 23	17	0.7	1332	1	US-10-287-994-7
C 24	17	0.7	1332	1	US-10-410-913-7
C 25	17	0.7	2040	1	US-10-617-619-12
C 26	16.6	0.7	1338	1	US-09-782-587B-2
C 27	16.6	0.7	1357	1	US-09-782-587B-4
C 28	16.6	0.7	1400	1	US-10-375-741-13
C 29	16.6	0.7	2106	1	US-10-617-619-9
C 30	16.4	0.7	483	1	US-09-918-995-8429
C 31	14.8	0.6	555	1	US-10-029-386-9623
C 32	14.6	0.6	222	1	US-10-029-386-23323
C 33	14.6	0.6	555	1	US-10-029-386-9623

C 107 9.2 0.4 34 1 US-09-951-121A-3  
C 108 9.2 0.4 34 1 US-10-295-682-2  
C 109 9.2 0.4 34 1 US-10-295-682-3  
C 110 9.2 0.4 36 1 US-10-281-727-2  
C 111 9.2 0.4 36 1 US-10-281-727-3  
C 112 9 0.4 33 1 US-09-951-121A-14  
C 113 9 0.4 33 1 US-09-951-121A-15  
C 114 9 0.4 33 1 US-10-295-682-14  
C 115 9 0.4 33 1 US-10-295-682-15  
C 116 8.8 0.4 42 1 US-09-803-810-8  
C 117 8.8 0.4 42 1 US-10-298-330-8  
C 118 8.2 0.4 31 1 US-10-017-122-4  
C 119 7.8 0.3 34 1 US-09-951-121A-2  
C 120 7.8 0.3 34 1 US-09-951-121A-3  
C 121 7.8 0.3 34 1 US-10-295-682-2  
C 122 7.8 0.3 34 1 US-10-295-682-3

## ALIGNMENTS

RESULT 1  
US-10-411-037-7/c  
; Sequence 7, Application US/10411037  
; Publication No. US20040043446A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bowe, Caryn  
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA  
; FILE REFERENCE: 040853-01-5082  
; CURRENT APPLICATION NUMBER: US/10/411,037  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-411-037-7

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c

US-10-411-037-7/c



; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; TYPE: DNA
; LENGTH: 1332
; ORGANISM: Homo sapiens
US-10-410-962-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACGTGG 500

RESULT 4
US-10-411-049-7/c
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-049-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACGTGG 500

RESULT 5
US-10-410-930-7/c
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn

; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: Patent in version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTTCTTTGTTTGAATATGTTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACGTGG 500

RESULT 6
US-10-410-997-7/c
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75

```

; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-997-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 7
US-10-411-012-7/c
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; PRIOR FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 8
US-10-287-994-7/c
; Sequence 7, Application US/1028994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert

```

```

; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-287-994-7

Query Match
Best Local Similarity 0.9%; Score 20.6; DB 1; Length 1332;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 440 TTCAATGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGATTTCAATTTGG 498
Db 558 TTGCTGGCATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTTCAACTGTGG 500

RESULT 9
US-10-410-913-7/c
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: Defrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOCNJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5081
; CURRENT APPLICATION NUMBER: US/10/410,913
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332

```



```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match          0.8%; Score 19.4; DB 1; Length 1361;
Best Local Similarity 55.1%; Pred. No. 6.2;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;

Qy 2160 CTCAGGCGCTATTGTAATAGGGTTTACGAGGACATATGCTCTGGTTGTTATGTCG 2219
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1312 CTGCTGGCTAGGGAATGGGCTCGCAGGAGGACTCTCTGGGCTGCTGAGCGCATG 1253

Qy 2220 TGTGTTTGC 2228
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1252 AGCTTTTGC 1244

RESULT 14
US-10-382-248-35
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsbrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: Curaseq1ist version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)..(1301)
US-10-382-248-35

Query Match          0.8%; Score 17.2; DB 1; Length 1361;
Best Local Similarity 51.3%; Pred. No. 26;
Matches 40; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

Qy 6 CTCCTCTAGTGAAGGTGGGGCTGTGAGGCTCCAAATGGTTGTGATGGTAGAGTATCT 65
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 441 CTCCTCGCTTCGAGGGCCGGAAGTGTGAGAGCGTTGAATATCCATGTGAAAAATACCT 500

Qy 66 CATACAGAGGATAGCACT 83
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 501 ATTCTAGAAAAAGAAAT 518

RESULT 15
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
```

```
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: (1)..(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match          0.7%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 19;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGTCATAGTGTCTCTGGCTTCCTGGATGTTTTATGCCT 1809
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 122 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCGCTGCGCTGCTTCCT 170

RESULT 16
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match          0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGTCATAGTGTCTCTGGCTTCCTGGATGTTTTATGCCT 1809
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 23 TCCTCTGCCTTCGCTTGGGCTTCAGGGCTGCGCTGCGCTGCTTCCT 71

RESULT 17
US-10-411-026-7
; Sequence 7, Application US/10411026
```

Publication No. US2004006391A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: Defrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi

TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE

TITLE OF INVENTION: METHODS

FILE REFERENCE: 040853-01-5053

CURRENT APPLICATION NUMBER: US/10/411,026

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-411-026-7

Query Match 0.7%; Score 17; DB 1; Length 1332;

Best Local Similarity 59.2%; Pred. No. 28;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTGAGATTTTATGCCT 1809

Db 23 TCCTCTGCCTTCGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTCGT 71

RESULT 18

US-10-410-962-7

Sequence 7, Application US/10410962

Publication No. US20040077836A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND

TITLE OF INVENTION: GLYCOCONJUGATION OF G-CSF

FILE REFERENCE: 040853-01-5054

CURRENT APPLICATION NUMBER: US/10/410,962

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-410-962-7

Query Match 0.7%; Score 17; DB 1; Length 1332;

Best Local Similarity 59.2%; Pred. No. 28;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTGAGATTTTATGCCT 1809

Db 23 TCCTCTGCCTTCGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTCGT 71

RESULT 19

US-10-411-049-7

Sequence 7, Application US/10411049

Publication No. US20040082026A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

APPLICANT: Defrees, Shawn

APPLICANT: Zopf, David

APPLICANT: Bayer, Robert

APPLICANT: Hakes, David

APPLICANT: Chen, Xi

APPLICANT: Bove, Caryn

TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON

TITLE OF INVENTION: ALPHA

FILE REFERENCE: 040853-01-5055

CURRENT APPLICATION NUMBER: US/10/411,049

CURRENT FILING DATE: 2003-04-09

PRIOR APPLICATION NUMBER: US 60/328,523

PRIOR FILING DATE: 2001-10-10

PRIOR APPLICATION NUMBER: US 60/344,692

PRIOR FILING DATE: 2001-10-19

PRIOR APPLICATION NUMBER: US 60/387,292

PRIOR FILING DATE: 2002-06-07

PRIOR APPLICATION NUMBER: US 60/391,777

PRIOR FILING DATE: 2002-06-25

PRIOR APPLICATION NUMBER: US 60/396,594

PRIOR FILING DATE: 2002-07-17

PRIOR APPLICATION NUMBER: US 60/404,249

PRIOR FILING DATE: 2002-08-16

PRIOR APPLICATION NUMBER: US 60/407,527

PRIOR FILING DATE: 2002-08-28

NUMBER OF SEQ ID NOS: 75

SOFTWARE: PatentIn version 3.2

SEQ ID NO 7

LENGTH: 1332

TYPE: DNA

ORGANISM: Homo sapiens

US-10-411-049-7

Query Match 0.7%; Score 17; DB 1; Length 1332;

Best Local Similarity 59.2%; Pred. No. 28;

Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTGCATAGTCTCTGGCTTCCTGAGATTTTATGCCT 1809

Db 23 TCCTCTGCCTTCGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTCGT 71

RESULT 20

US-10-410-930-7

Sequence 7, Application US/10410930

Publication No. US20040115168A1

GENERAL INFORMATION:

APPLICANT: Neose Technologies, Inc.

```
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; TITLE OF INVENTION: BETA
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
    |||||
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCTGCTTCTGCT 71

RESULT 21
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; TITLE OF INVENTION: FSH
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-930-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
    |||||
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCTGCTTCTGCT 71

RESULT 22
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; TITLE OF INVENTION: METHODS
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-012-7

Query Match      0.7%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred.No. 28;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTCGGCTTCTCGATGTTTATGCCT 1809
    |||||
Db 23 TCCTCGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCTGCTTCTGCT 71

RESULT 23
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
```

APPLICANT: Bayer, Robert  
APPLICANT: Bove, Caryn  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES  
FILE REFERENCE: 040853-01-5052-00  
CURRENT APPLICATION NUMBER: US/10/287,994  
CURRENT FILING DATE: 2002-11-05  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 62  
SOFTWARE: PatentIn version 3.1  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-287-994-7

Query Match 0.7%; Score 17; DB 1; Length 1332;  
Best Local Similarity 59.2%; Pred. No. 28;  
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809  
|||||  
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 24  
US-10-410-913-7  
Sequence 7, Application US/10410913  
Publication No. US20040142856A1  
GENERAL INFORMATION:  
APPLICANT: Neose Technologies, Inc.  
APPLICANT: DeFrees, Shawn  
APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bove, Caryn  
TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
FILE REFERENCE: 040853-01-5081  
CURRENT APPLICATION NUMBER: US/10/410,913  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7

LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-410-913-7

Query Match 0.7%; Score 17; DB 1; Length 1332;  
Best Local Similarity 59.2%; Pred. No. 28;  
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809  
|||||  
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 25  
US-10-617-619-12  
Sequence 12, Application US/10617619  
Publication No. US20040110929A1  
GENERAL INFORMATION:  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Nicolaissen, Else M  
APPLICANT: Jorgensen, Anker S  
TITLE OF INVENTION: TF Binding Compound  
FILE REFERENCE: 6455.200-US  
CURRENT APPLICATION NUMBER: US/10/617,619  
CURRENT FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099  
PRIOR FILING DATE: 2002-07-12  
PRIOR APPLICATION NUMBER: US 60/404,568  
PRIOR FILING DATE: 2002-08-19  
NUMBER OF SEQ ID NOS: 13  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 12  
LENGTH: 2040  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-10-617-619-12

Query Match 0.7%; Score 17; DB 1; Length 2040;  
Best Local Similarity 59.2%; Pred. No. 24;  
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1761 TCCTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1809  
|||||  
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGGCTGCTGGCTGCAGTCTTCGT 71

RESULT 26  
US-09-782-587B-2/c  
Sequence 2, Application US/09782587B  
Publication No. US20030096338A1  
GENERAL INFORMATION:  
APPLICANT: PEDERSEN, ANDERS H.  
APPLICANT: ANDERSON, KIM V.  
APPLICANT: BORNAES, CLAUD  
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
FILE REFERENCE: 31-001100US  
CURRENT APPLICATION NUMBER: US/09/782,587B  
CURRENT FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: PA 2000 00218  
PRIOR FILING DATE: 2000-02-11  
PRIOR APPLICATION NUMBER: 60/184,036  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: 60/241,916  
PRIOR FILING DATE: 2000-10-18  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 1338  
TYPE: DNA  
ORGANISM: Homo sapiens

```
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match          0.7%; Score 16.6; DB 1; Length 1338;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1228 GGCCTGGAATTATTATTATTCATATTTCTTGAATGTG 1266
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 567 GCCCTGGGGTTGCTAGCGTTCGCTTTCTAGAAATGGG 529

RESULT 27
US-09-782-587B-4/c
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNHARS, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-00100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match          0.7%; Score 16.6; DB 1; Length 1357;
Best Local Similarity 64.1%; Pred. No. 32;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1228 GGCCTGGAATTATTATTATTCATATTTCTTGAATGTG 1266
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 580 GCCCTGGGGTTGCTAGCGTTCGCTTTCTAGAAATGGG 542

RESULT 28
US-10-375-741-13
; Sequence 13, Application US/10375741
; Publication No. US2003032753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boming
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; FILE REFERENCE: 4001,001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
```

```
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match          0.7%; Score 16.6; DB 1; Length 1440;
Best Local Similarity 64.1%; Pred. No. 31;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGCATAGTCTCTGGCTTCCTGGATG 1799
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 58 TCCTCTGCCTTCTCTGGGCTTCAGGGCTGCTGGCTG 96

RESULT 29
US-10-617-619-9
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolson, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TP Binding Compound
; FILE REFERENCE: 6455,200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match          0.7%; Score 16.6; DB 1; Length 2106;
Best Local Similarity 64.1%; Pred. No. 24;
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1761 TCCTTTGGTTTTGCATAGTCTCTGGCTTCCTGGATG 1799
      ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCTCTGGGCTTCAGGGCTGCTGGCTG 61

RESULT 30
US-09-918-995-8429/c
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; TITLE OF INVENTION: FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; CURRENT FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
```



```
/ FEATURE:
/ NAME/KEY: misc feature
/ LOCATION: (1) --(483)
/ OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match      0.7%; Score 16.4; DB 1; Length 483;
Best Local Similarity 55.2%; Pred. No. 30;
Matches 32; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 686 AGGTCATATCTGATTTTATGCTAGCTGTCTGTTTATGAACCTGGGTGACATG 743
DB 415 AGGACTGGAGCTGGTCTTTCGAGGAGCCCCCATCTTGGCATGGACTTGGAGCACATG 358

RESULT 31
US-10-029-386-9623
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
; OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match      0.6%; Score 14.8; DB 1; Length 555;
Best Local Similarity 56.0%; Pred. No. 75;
Matches 28; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 254 TAGGGCATACGATTCCTCTCTCTCCAAACACTTCTATTCTTGA 303
DB 12 TGGGAGTCTCCACCTCCGCTGCTGCTGAGGAGCTCTGGGTATCA 61

RESULT 32
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
```

```
/ TYPE: DNA
/ ORGANISM: Homo sapiens
/ FEATURE:
/ OTHER INFORMATION: MAP TO CHR13.3
/ OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
/ OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
/ OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
/ OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
/ OTHER INFORMATION: NT HIT: g114783796, EVALUE 1.00e-122
/ OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 3.00e-26
/ OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match      0.6%; Score 14.6; DB 1; Length 222;
Best Local Similarity 54.7%; Pred. No. 69;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 1905 CTGTCAGTGAGGCTTCTCTGAGGTTCTCTGTGGTTCTTAATTTTCATT 1957
DB 152 CTGCCGAACGAGCGTCTCTGAGGAGCGTCTGCGCTTCTGCGCTTCTCATT 100

RESULT 33
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Anomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
/ ORGANISM: Homo sapiens
/ FEATURE:
/ OTHER INFORMATION: MAP TO CHR13.3
/ OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
/ OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
/ OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
/ OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
/ OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
/ OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
/ OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63
/ OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00
/ OTHER INFORMATION: EST_HUMAN HIT: AL531727.1, EVALUE 5.00e-76
US-10-029-386-9623

Query Match      0.6%; Score 14.6; DB 1; Length 555;
Best Local Similarity 54.7%; Pred. No. 79;
Matches 29; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 1905 CTGTCAGTGAGGCTTCTCTGAGGTTCTCTGTGGTTCTTAATTTTCATT 1957
DB 188 CTGCCGAACGAGCGTCTCTGAGGAGCGTCTGCGCTTCTGCGCTTCTCATT 136

RESULT 34
US-10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
```



```
Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
Db 58 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 24

RESULT 38
US-10-272-665-107/c
; Sequence 107, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 39
US-10-273-321-107/c
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107
```

```
Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 40
US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match 0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1731 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1765
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 41
US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US2003020797A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107
```

```
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCTCTATTCCTT 1765
Db      38 TGTGGCCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 42
US-10-272-665-106/c
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106-
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCTCTATTCCTT 1765
Db      38 TGTGGCCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 43
US-10-273-321-106/c
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
```

```
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCTCTATTCCTT 1765
Db      38 TGTGGCCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 44
US-10-272-756-106/c
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCCTTCTTCCCTTCCTCTATTCCTT 1765
Db      38 TGTGGCCTCCACTGTCCCTTCGAGGAGTCCTT 4

RESULT 45
US-10-273-228-106/c
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
```

```
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-106

Query Match      0.6%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 53;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1731 TTTTGACCTGCTCTTCCCTTCTCTCTCTATTCCTT 1765
DB 38 TGTGGCCTCCACTGCTCCCTTTCGAGGAGTCCTT 4

RESULT 46
US-09-782-587B-2
; Sequence 2, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 1338
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (115)..(1332)
US-09-782-587B-2

Query Match      0.6%; Score 14.2; DB 1; Length 1338;
Best Local Similarity 70.4%; Pred. No. 38;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTTCTGGGGCTGCTG 174
DB 22 CTCCTGTGCTGCTCTCTGGGGCTGCAG 48

RESULT 47
US-09-782-587B-4
; Sequence 4, Application US/09782587B
; Publication No. US20030096338A1
; GENERAL INFORMATION:
; APPLICANT: PEDERSEN, ANDERS H.
; APPLICANT: ANDERSON, KIM V.
; APPLICANT: BORNAES, CLAUS
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES
; FILE REFERENCE: 31-001100US
; CURRENT APPLICATION NUMBER: US/09/782,587B
; CURRENT FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: PA 2000 00218
; PRIOR FILING DATE: 2000-02-11
; PRIOR APPLICATION NUMBER: 60/184,036
; PRIOR FILING DATE: 2000-02-22
; PRIOR APPLICATION NUMBER: 60/241,916
```

```
; PRIOR FILING DATE: 2000-10-18
; NUMBER OF SEQ ID NOS: 19
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 1357
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Expression
; OTHER INFORMATION: cassette for expression of FVII in mammalian cells
US-09-782-587B-4

Query Match      0.6%; Score 14.2; DB 1; Length 1357;
Best Local Similarity 70.4%; Pred. No. 37;
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 148 CTGCTGGCAATCTTCTGGGGCTGCTG 174
DB 35 CTCCTGTGCTGCTCTCTGGGGCTGCAG 61

RESULT 48
US-10-029-386-23323
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR G
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AROMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT HIT: G114783796, EVALUE 1.00e-122
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37
US-10-029-386-23323

Query Match      0.5%; Score 12; DB 1; Length 222;
Best Local Similarity 58.3%; Pred. No. 2.2e+02;
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 763 AAGATTGCAATGCTCTTGGTGGATTTCCTTGT 798
DB 112 ACGAAGCCAGCGCTCTCTCAGAGACGTCGCTTG 147

RESULT 49
US-10-349-858-8/c
; Sequence 8, Application US/10349858
; Publication No. US20030220247A1
; GENERAL INFORMATION:
; APPLICANT: The Children's Hospital of Philadelphia
; APPLICANT: HIGH, KATHERINE A.
; APPLICANT: CAMIRE, RODNEY M.
; APPLICANT: LARSON, PETER J.
; APPLICANT: STAFFORD, DAREL W.
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C
```

```
; TITLE OF INVENTION: FACTORS
; FILE REFERENCE: 018743-0301425
; CURRENT APPLICATION NUMBER: US/10/349,858
; CURRENT FILING DATE: 2003-01-22
; PRIOR APPLICATION NUMBER: 09/526,947
; PRIOR FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: 60/124,609
; PRIOR FILING DATE: 1999-03-16
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match          0.5%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.6%; Pred. No. 2.2e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1925 TGAGGTTCCCTGGTGGGTTCTTAA 1947
DB 29 TGGGCTTCCTCCCTGGGTACGAA 7

RESULT 50
US-10-281-727-6/c
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1999 TTCACCTTTCAGGTCCTG 2016
DB 26 TCCACCTTCCTCGTCTCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.5%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1999 TTCACCTTTCAGGTCCTG 2016
DB 26 TCCACCTTCCTCGTCTCTG 9

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match          0.5%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 2.4e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTTCTTGAAGCTCTCTGCTGGC 155
DB 10 TAAACGCTTTCCTCGAGGAGCTGGCGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
```

QY 127 TAATATATTTTCTTGAAGCCTCTGCTGGC 155  
Db 10 TAAACGGCTTTCTGAGGAGCTGCGGC 38

RESULT 55  
US-10-272-665-22  
; Sequence 22, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POI  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Probe  
US-10-272-665-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 3.1e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCTATTGTATAGGCTTTTACGAGGACATAT 2198  
Db 23 CAAGGACTCTGCAAGGGGAGACAGTGGAGCCCAT 59

RESULT 56  
US-10-273-321-22  
; Sequence 22, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING POI  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 22  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo Sapien  
; FEATURE:  
; OTHER INFORMATION: Primer

APPLICANT: Novo Nordisk Pharmaceuticals, Inc.  
APPLICANT: Pingel, Hans K  
APPLICANT: Klausen, Niels K  
TITLE OF INVENTION: Factor VII Glycoforms  
FILE REFERENCE: 6207.510-US  
CURRENT APPLICATION NUMBER: US/09/969,357  
CURRENT FILING DATE: 2002-10-02  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456  
PRIOR FILING DATE: 2000-10-02  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262  
PRIOR FILING DATE: 2001-02-16  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430  
PRIOR FILING DATE: 2001-03-14  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751  
PRIOR FILING DATE: 2001-05-14  
PRIOR APPLICATION NUMBER: US 60/238,944  
PRIOR FILING DATE: 2000-10-10  
PRIOR APPLICATION NUMBER: US 60/271,581  
PRIOR FILING DATE: 2001-02-26  
PRIOR APPLICATION NUMBER: US 60/276,322  
PRIOR FILING DATE: 2001-03-16  
NUMBER OF SEQ ID NOS: 2  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 2  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-09-969-357-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 2.4e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 127 TAATATATTTTCTTGAAGCCTCTGCTGGC 155  
Db 10 TAAACGGCTTTCTGAGGAGCTGCGGC 38

RESULT 54  
US-10-254-394-2  
; Sequence 2, Application US/10254394  
; Publication No. US20030096366A1  
; GENERAL INFORMATION:  
; APPLICANT: Knudsen, Ida Molgaard  
; TITLE OF INVENTION: Method for Production of Recombinant  
; Proteins in Eukaryote Cells  
; FILE REFERENCE: 6480.500-US  
; CURRENT APPLICATION NUMBER: US/10/254,394  
; CURRENT FILING DATE: 2002-09-25  
; PRIOR APPLICATION NUMBER: PCT/DK01/00632  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PCT/DK01/00634  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PA 2002 00460  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: 60/374,855  
; PRIOR FILING DATE: 2002-10-04  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-254-394-2

Query Match 0.5%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 2.4e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

OTHER INFORMATION: Probe  
US-10-273-321-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 3.1e+02;  
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCCTATTGTAATAGGTTTACGAGGACATAT 2198  
DB 23 CAAGGACTCTGCAAGGGGACAGTGGAGGCCACAT 59

## RESULT 57

US-10-272-756-22

Sequence 22, Application US/10272756  
Publication No. US20030190644A1

GENERAL INFORMATION:

APPLICANT: Braun et al.

TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

FILE REFERENCE: 24736-2033C

CURRENT APPLICATION NUMBER: US/10/272,756

CURRENT FILING DATE: 2002-10-15

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/687,483

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/217,658

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/159,176

PRIOR FILING DATE: 1999-10-13

PRIOR APPLICATION NUMBER: 60/217,251

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/663,968

PRIOR FILING DATE: 2000-09-19

NUMBER OF SEQ ID NOS: 118

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 22

LENGTH: 60

TYPE: DNA

ORGANISM: Homo Sapien

FEATURE:

OTHER INFORMATION: Probe

US-10-272-756-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;

Best Local Similarity 56.8%; Pred. No. 3.1e+02;

Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCCTATTGTAATAGGTTTACGAGGACATAT 2198

DB 23 CAAGGACTCTGCAAGGGGACAGTGGAGGCCACAT 59

## RESULT 58

US-10-273-228-22

Sequence 22, Application US/10273228

Publication No. US20030207297A1

GENERAL INFORMATION:

APPLICANT: Braun et al.

TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

FILE REFERENCE: 24736-2033D

CURRENT APPLICATION NUMBER: US/10/273,228

CURRENT FILING DATE: 2002-10-15

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/687,483

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/217,658

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/159,176

PRIOR FILING DATE: 1999-10-13

PRIOR APPLICATION NUMBER: 60/217,251

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/663,968

NUMBER OF SEQ ID NOS: 118  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 22

LENGTH: 60

TYPE: DNA

ORGANISM: Homo Sapien

FEATURE:

OTHER INFORMATION: Probe

US-10-273-228-22

Query Match 0.5%; Score 11.4; DB 1; Length 60;  
Best Local Similarity 56.8%; Pred. No. 3.1e+02;

Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCCTATTGTAATAGGTTTACGAGGACATAT 2198

DB 23 CAAGGACTCTGCAAGGGGACAGTGGAGGCCACAT 59

## RESULT 59

US-10-272-665-107

Sequence 107, Application US/10272665

Publication No. US20030180748A1

GENERAL INFORMATION:

APPLICANT: Braun et al.

TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

FILE REFERENCE: 24736-2033E

CURRENT APPLICATION NUMBER: US/10/272,665

CURRENT FILING DATE: 2002-10-15

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/687,483

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/217,658

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/159,176

PRIOR FILING DATE: 1999-10-13

PRIOR APPLICATION NUMBER: 60/217,251

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/663,968

PRIOR FILING DATE: 2000-09-19

NUMBER OF SEQ ID NOS: 118

SOFTWARE: FastSeq for Windows Version 4.0

SEQ ID NO 107

LENGTH: 100

TYPE: DNA

ORGANISM: Homo sapien

US-10-272-665-107

Query Match 0.5%; Score 11.4; DB 1; Length 100;

Best Local Similarity 56.8%; Pred. No. 3.1e+02;

Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGGCCTATTGTAATAGGTTTACGAGGACATAT 2198

DB 3 CAAGGACTCTGCAAGGGGACAGTGGAGGCCACAT 39

## RESULT 60

US-10-273-321-107

Sequence 107, Application US/10273321

Publication No. US20030180749A1

GENERAL INFORMATION:

APPLICANT: Braun et al.

TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO

FILE REFERENCE: 24736-2033B

CURRENT APPLICATION NUMBER: US/10/273,321

CURRENT FILING DATE: 2002-10-15

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 09/687,483

PRIOR FILING DATE: 2000-07-10

PRIOR APPLICATION NUMBER: 60/217,658

PRIOR FILING DATE: 2000-07-10



; PRIOR FILING DATE: 1999-10-13  
 ; PRIOR APPLICATION NUMBER: 60/217,251  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 09/663,968  
 ; PRIOR FILING DATE: 2000-09-19  
 ; NUMBER OF SEQ ID NOS: 118  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 107  
 ; LENGTH: 100  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapien  
 US-10-273-321-107  
  
 Query Match 0.5%; Score 11.4; DB 1; Length 100;  
 Best Local Similarity 56.8%; Pred. No. 3.6e+02;  
 Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
 QY 2162 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2198  
 DB 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39  
  
 RESULT 61  
 US-10-272-756-107  
 ; Sequence 107, Application US/10272756  
 ; Publication No. US20030190644A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Braun et al.  
 ; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
 ; FILE REFERENCE: 24736-2033C  
 ; CURRENT APPLICATION NUMBER: US/10/272,756  
 ; CURRENT FILING DATE: 2002-10-15  
 ; PRIOR APPLICATION NUMBER: 09/687,483  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/217,658  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/159,176  
 ; PRIOR FILING DATE: 1999-10-13  
 ; PRIOR APPLICATION NUMBER: 60/217,251  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 09/663,968  
 ; NUMBER OF SEQ ID NOS: 118  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 107  
 ; LENGTH: 100  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapien  
 US-10-272-756-107  
  
 Query Match 0.5%; Score 11.4; DB 1; Length 100;  
 Best Local Similarity 56.8%; Pred. No. 3.6e+02;  
 Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
 QY 2162 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2198  
 DB 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39  
  
 RESULT 62  
 US-10-273-228-107  
 ; Sequence 107, Application US/10273228  
 ; Publication No. US2003020297A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Braun et al.  
 ; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
 ; FILE REFERENCE: 24736-2033D  
 ; CURRENT APPLICATION NUMBER: US/10/273,228  
 ; CURRENT FILING DATE: 2002-10-15  
 ; PRIOR APPLICATION NUMBER: 09/687,483  
 ; PRIOR FILING DATE: 2000-07-10

; PRIOR APPLICATION NUMBER: 60/217,658  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/159,176  
 ; PRIOR FILING DATE: 1999-10-13  
 ; PRIOR APPLICATION NUMBER: 60/217,251  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 09/663,968  
 ; PRIOR FILING DATE: 2000-09-19  
 ; NUMBER OF SEQ ID NOS: 118  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 107  
 ; LENGTH: 100  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapien  
 US-10-273-228-107  
  
 Query Match 0.5%; Score 11.4; DB 1; Length 100;  
 Best Local Similarity 56.8%; Pred. No. 3.6e+02;  
 Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
 QY 2162 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2198  
 DB 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39  
  
 RESULT 63  
 US-10-272-665-106  
 ; Sequence 106, Application US/10272665  
 ; Publication No. US20030180748A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Braun et al.  
 ; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
 ; FILE REFERENCE: 24736-2033E  
 ; CURRENT APPLICATION NUMBER: US/10/272,665  
 ; CURRENT FILING DATE: 2002-10-15  
 ; PRIOR APPLICATION NUMBER: 09/687,483  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/217,658  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/159,176  
 ; PRIOR FILING DATE: 1999-10-13  
 ; PRIOR APPLICATION NUMBER: 60/217,251  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 09/663,968  
 ; NUMBER OF SEQ ID NOS: 118  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 106  
 ; LENGTH: 100  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapien  
 US-10-272-665-106  
  
 Query Match 0.5%; Score 11.4; DB 1; Length 100;  
 Best Local Similarity 56.8%; Pred. No. 3.6e+02;  
 Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
 QY 2162 CAGGGCCTATTGTAATAGGGTTTACGAGGGACATAT 2198  
 DB 3 CAAGGACTCTCTGCAAGGGGGACAGTGGAGGCCACAT 39  
  
 RESULT 64  
 US-10-273-321-106  
 ; Sequence 106, Application US/10273321  
 ; Publication No. US20030180749A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Braun et al.  
 ; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
 ; FILE REFERENCE: 24736-2033B  
 ; CURRENT APPLICATION NUMBER: US/10/273,321

```
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-273-321-106

Query Match      0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGCCTATTGTAATAGGTTTTCAGCAGGCACATAT 2198
Db 3 CAAGGACTCTCTGCAAGGGGACAGTGGAGGCCACAT 39

RESULT 65
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-272-756-106

Query Match      0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGCCTATTGTAATAGGTTTTCAGCAGGCACATAT 2198
Db 3 CAAGGACTCTCTGCAAGGGGACAGTGGAGGCCACAT 39

RESULT 66
US-10-273-228-106
; Sequence 106, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
; US-10-273-228-106

Query Match      0.5%; Score 11.4; DB 1; Length 100;
Best Local Similarity 56.8%; Pred. No. 3.6e+02;
Matches 21; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 2162 CAGGCCTATTGTAATAGGTTTTCAGCAGGCACATAT 2198
Db 3 CAAGGACTCTCTGCAAGGGGACAGTGGAGGCCACAT 39

RESULT 67
US-09-951-121A-14/c
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
; US-09-951-121A-14

Query Match      0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCCTGACATCTG 1424
Db 31 TGCAGGAGTCTTGGCGGCATCCG 8

RESULT 68
US-09-951-121A-15
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
```

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 3 TGCAGGAGTCTTGGCGCCATCCG 26

RESULT 69
US-10-295-682-14/c
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 31 TGCAGGAGTCTTGGCGCCATCCG 8

RESULT 70
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.5%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2.5e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1401 TGCAGTAGTCTGGCCTGACATCTG 1424
      ||||| ||||| ||||| ||||| |||||
Db 3 TGCAGGAGTCTTGGCGCCATCCG 26

RESULT 71
US-09-951-121A-8/c
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTGTAA 2018
      ||||| ||||| ||||| ||||| |||||
Db 33 CACGTTGAGGACCTGGA 17

RESULT 72
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
```

```
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20

RESULT 73
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1o No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTCTGAA 2018
DB 33 CACGTTGAGGACCTGGA 17

RESULT 74
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1o No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
```

```
QY 2002 CACTTTCAGGTCTCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20

RESULT 75
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTCTGAA 2018
DB 33 CACGTTGAGGACCTGGA 17

RESULT 76
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSEQ for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 4.2e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 2002 CACTTTCAGGTCTCTGAA 2018
DB 4 CACGTTGAGGACCTGGA 20
```

```
RESULT 77
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsethuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 78
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsethuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; POLYPEPTIDES
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; CURRENT FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match          0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 4.5e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

Qy 238 CACTTCTGGCCAGGCTAGGGGCAC 262
Db 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 79
US-10-272-665-23/c
; Sequence 23, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
```

```
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; OTHER INFORMATION:
US-10-272-665-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 1085 TGTGATCTCTTATCTTGCACCTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACCGTCCCCGGTAGTGGGTG 2

RESULT 80
US-10-273-321-23/c
; Sequence 23, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 23
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo sapien
; OTHER INFORMATION:
US-10-273-321-23

Query Match          0.5%; Score 10.6; DB 1; Length 60;
Best Local Similarity 53.7%; Pred. No. 5.1e+02;
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 1085 TGTGATCTCTTATCTTGCACCTGTGAAGTGTGTGTG 1125
Db 42 TGACGATGCCGTCAGGTACCGTCCCCGGTAGTGGGTG 2

RESULT 81
US-10-272-756-23/c
; Sequence 23, Application US/10272756
; Publication No. US20030190644A1
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO
```

GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 5.1e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTTATCTTCACCTGTGAGTGTGTGTG 1125  
DB 42 TGACGATGCCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 82  
US-10-273-228-23/c  
; Sequence 23, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; TITLE OF INVENTION: GENETIC MARKERS  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 5.1e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1085 TGTGGATTCTTGTTATCTTCACCTGTGAGTGTGTGTG 1125  
DB 42 TGACGATGCCCGTCAGGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 83

US-10-281-727-2/c  
; Sequence 2, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; TITLE OF INVENTION: Polypeptides  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-2

Query Match 0.5%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 60.7%; Pred. No. 4.8e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1911 GTGAGGCTTGTCTCTGAGGTTCCTCTGTG 1938  
DB 35 GGGAGTCTCCACGTCGGTTCCTCTGTG 8

RESULT 84  
US-10-281-727-3  
; Sequence 3, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; TITLE OF INVENTION: Polypeptides  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-3

Query Match 0.5%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 60.7%; Pred. No. 4.8e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1911 GTGAGGCTTGTCTCTGAGGTTCCTCTGTG 1938  
DB 2 GGGAGTCTCCACGTCGGTTCCTCTGTG 29

RESULT 85  
US-10-281-727-6  
; Sequence 6, Application US/10281727  
; Publication No. US20030130191A1

```

; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match          0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      16 GAAAGTGGGGTCT 30
Db      16 GGAAGTGGGAGCT 30

RESULT 86
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match          0.4%; Score 10.2; DB 1; Length 32;
Best Local Similarity 80.0%; Pred. No. 5.2e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      16 GAAAGTGGGGTCT 30
Db      17 GGAAGTGGGAGCT 30

RESULT 87
US-09-951-121A-8
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2135 CCTGTGCTTCAGCT 2149
Db      9 CCTGTGCTCCAGCT 23

RESULT 88
US-09-951-121A-9/c
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match          0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      2135 CCTGTGCTTCAGCT 2149
Db      28 CCTGTGCTCCAGCT 14

RESULT 89
US-10-255-032-8
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
```

```
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2135 CCTGTGCTTCAGCT 2149
Db 9 CCTGGTGCTCCAGGT 23

RESULT 92
US-10-295-682-9/c
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224-200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2135 CCTGTGCTTCAGCT 2149
Db 28 CCTGGTGCTCCAGGT 14

RESULT 93
US-10-398-422A-20/c
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270-204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DK01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
```

```
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2135 CCTGTGCTTCAGCT 2149
Db 9 CCTGGTGCTCCAGGT 23

RESULT 90
US-10-255-032-9/c
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A1c No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.4%; Score 10.2; DB 1; Length 36;
Best Local Similarity 80.0%; Pred. No. 5.5e+02;
Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 2135 CCTGTGCTTCAGCT 2149
Db 28 CCTGGTGCTCCAGGT 14

RESULT 91
US-10-295-682-8
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224-200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
```



SOFTWARE: PatentIn version 3.2  
SEQ ID NO 20  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: synthetic  
US-10-398-422A-20

Query Match 0.4%; Score 10.2; DB 1; Length 38;  
Best Local Similarity 58.1%; Pred. No. 5.6e+02;  
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171  
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 94  
US-09-969-357-2/c  
Sequence 2, Application US/09969357  
Publication No. US20020137673A1  
GENERAL INFORMATION:  
APPLICANT: Novo Nordisk Pharmaceuticals, Inc.  
APPLICANT: Pingel, Hans K  
APPLICANT: Klausen, Niels K  
TITLE OF INVENTION: Factor VII Glycoforms  
FILE REFERENCE: 6207.510-US  
CURRENT APPLICATION NUMBER: US/09/969,357  
CURRENT FILING DATE: 2002-10-02  
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2000 01456  
PRIORITY FILING DATE: 2000-10-02  
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00262  
PRIORITY FILING DATE: 2001-02-16  
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00430  
PRIORITY FILING DATE: 2001-03-14  
PRIORITY APPLICATION NUMBER: Danish Application No. PA 2001 00751  
PRIORITY FILING DATE: 2001-05-14  
PRIORITY APPLICATION NUMBER: US 60/238,944  
PRIORITY FILING DATE: 2000-10-10  
PRIORITY APPLICATION NUMBER: US 60/271,581  
PRIORITY FILING DATE: 2001-02-26  
PRIORITY APPLICATION NUMBER: US 60/276,322  
PRIORITY FILING DATE: 2001-03-16  
NUMBER OF SEQ ID NOS: 2  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 2  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-09-969-357-2

Query Match 0.4%; Score 10.2; DB 1; Length 38;  
Best Local Similarity 58.1%; Pred. No. 5.6e+02;  
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171  
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 95  
US-10-254-394-2/c  
Sequence 2, Application US/10254394  
Publication No. US2003009366A1  
GENERAL INFORMATION:  
APPLICANT: Knudsen, Ida Molgaard  
TITLE OF INVENTION: Method for Production of Recombinant  
TITLE OF INVENTION: Proteins in Eukaryote Cells  
FILE REFERENCE: 6480.500-US  
CURRENT APPLICATION NUMBER: US/10/254,394

CURRENT FILING DATE: 2002-09-25  
PRIORITY APPLICATION NUMBER: PCT/DK01/00632  
PRIORITY FILING DATE: 2001-10-02  
PRIORITY APPLICATION NUMBER: PCT/DK01/00634  
PRIORITY FILING DATE: 2001-10-02  
PRIORITY APPLICATION NUMBER: PA 2002 00460  
PRIORITY FILING DATE: 2002-03-26  
PRIORITY APPLICATION NUMBER: 60/374,855  
PRIORITY FILING DATE: 2002-10-04  
NUMBER OF SEQ ID NOS: 2  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 2  
LENGTH: 38  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Primer  
US-10-254-394-2

Query Match 0.4%; Score 10.2; DB 1; Length 38;  
Best Local Similarity 58.1%; Pred. No. 5.6e+02;  
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 141 GAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171  
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 96  
US-10-109-498-5/c  
Sequence 5, Application US/10109498  
Publication No. US20030044908A1  
GENERAL INFORMATION:  
APPLICANT: Persson, Egon  
TITLE OF INVENTION: Coagulation Factor VII Derivatives  
FILE REFERENCE: 6286.200-US  
CURRENT APPLICATION NUMBER: US/10/109,498  
CURRENT FILING DATE: 2002-03-22  
PRIORITY APPLICATION NUMBER: 60/281,261  
PRIORITY FILING DATE: 2001-04-03  
PRIORITY APPLICATION NUMBER: PA 2001 00477  
PRIORITY FILING DATE: 2001-03-22  
NUMBER OF SEQ ID NOS: 20  
SOFTWARE: FastSeq for Windows Version 4.0  
SEQ ID NO 5  
LENGTH: 35  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Nucleotide Primer  
US-10-109-498-5

Query Match 0.4%; Score 10; DB 1; Length 35;  
Best Local Similarity 55.9%; Pred. No. 6.2e+02;  
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 679 GTGTGTGAGGTCAATATGTGATTTAGTGTAGC 712  
Db 34 GTGAGTGGAGCCACGGGACAGTCGACGGCGGAGC 1

RESULT 97  
US-10-109-498-6  
Sequence 6, Application US/10109498  
Publication No. US20030044908A1  
GENERAL INFORMATION:  
APPLICANT: Persson, Egon  
TITLE OF INVENTION: Coagulation Factor VII Derivatives  
FILE REFERENCE: 6286.200-US  
CURRENT APPLICATION NUMBER: US/10/109,498  
CURRENT FILING DATE: 2002-03-22  
PRIORITY APPLICATION NUMBER: 60/281,261  
PRIORITY FILING DATE: 2001-04-03

; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Nucleotide Primer  
US-10-109-498-6

Query Match 0.4%; Score 10; DB 1; Length 35;  
Best Local Similarity 55.9%; Pred. No. 6.2e+02;  
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 679 GTGTGTCAGTCAATATGTGTTTACCTGTAGC 712  
DB 2 GTGAGTGGAGCCACCGGACAGTGCAGGCGGAGC 35

## RESULT 98

US-10-349-858-8  
; Sequence 8, Application US/10349858  
; Publication No. US20030220247A1  
; GENERAL INFORMATION:

; APPLICANT: The Children's Hospital of Philadelphia  
; APPLICANT: HIGH, KATHERINE A.  
; APPLICANT: CAMIRE, RODNEY M.  
; APPLICANT: LARSON, PETER J.  
; APPLICANT: STAFFORD, DARREL W.  
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C  
; TITLE OF INVENTION: FACTORS  
; FILE REFERENCE: 018743-0301425  
; CURRENT APPLICATION NUMBER: US/10/349,858  
; PRIOR FILING DATE: 2003-01-22  
; CURRENT APPLICATION NUMBER: 09/526,947  
; PRIOR FILING DATE: 2000-03-16  
; PRIOR APPLICATION NUMBER: 60/124,609  
; PRIOR FILING DATE: 1999-03-16  
; NUMBER OF SEQ ID NOS: 22  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 8  
; LENGTH: 54  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-349-858-8

Query Match 0.4%; Score 9.8; DB 1; Length 54;  
Best Local Similarity 84.6%; Pred. No. 7.3e+02;  
Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 117 AGAGCTTCATAA 129  
DB 1 AGAGCTTCGTAA 13

## RESULT 99

US-10-272-665-23  
; Sequence 23, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 7.1e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTCAGGT 689  
DB 4 CCCACTACCGGGCACGTGGT 24

## RESULT 100

US-10-273-321-23  
; Sequence 23, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-23

Query Match 0.4%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 7.1e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 669 CCCACTATCTGTGTGTCAGGT 689  
DB 4 CCCACTACCGGGCACGTGGT 24

## RESULT 101

US-10-272-756-23  
; Sequence 23, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; PRIOR FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176

; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-23  
Query Match 0.4%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 7.1e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
Qy 669 CCCACTATCTGTGTGTGAGGT 689  
Db 4 CCCACTACCGGGGCACGTGGT 24  
RESULT 102  
US-10-273-228-23  
; Sequence 23, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-23  
Query Match 0.4%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 7.1e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;  
Qy 669 CCCACTATCTGTGTGTGAGGT 689  
Db 4 CCCACTACCGGGGCACGTGGT 24  
RESULT 103  
US-10-109-498-5  
; Sequence 5, Application US/10109498  
; Publication No. US20030044908A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Coagulation Factor VII Derivatives  
; FILE REFERENCE: 6286.200-US  
; CURRENT APPLICATION NUMBER: US/10/109,498  
; CURRENT FILING DATE: 2002-03-22

; PRIOR APPLICATION NUMBER: 60/281,261  
; PRIOR FILING DATE: 2001-04-03  
; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 5  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Nucleotide Primer  
US-10-109-498-5  
Query Match 0.4%; Score 9.4; DB 1; Length 35;  
Best Local Similarity 68.4%; Pred. No. 8.8e+02;  
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
Qy 1599 TGCACGTGGGGAGTTTCT 1617  
Db 9 TGCACGTGCCCGTGTCT 27  
RESULT 104  
US-10-109-498-6/c  
; Sequence 6, Application US/10109498  
; Publication No. US20030044908A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Coagulation Factor VII Derivatives  
; FILE REFERENCE: 6286.200-US  
; CURRENT APPLICATION NUMBER: US/10/109,498  
; CURRENT FILING DATE: 2002-03-22  
; PRIOR APPLICATION NUMBER: 60/281,261  
; PRIOR FILING DATE: 2001-04-03  
; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 6  
; LENGTH: 35  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Nucleotide Primer  
US-10-109-498-6  
Query Match 0.4%; Score 9.4; DB 1; Length 35;  
Best Local Similarity 68.4%; Pred. No. 8.8e+02;  
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
Qy 1599 TGCACGTGGGGAGTTTCT 1617  
Db 27 TGCACGTGCCCGTGTCT 9  
RESULT 105  
US-10-017-122-4  
; Sequence 4, Application US/10017122  
; Publication No. US20030087244A1  
; GENERAL INFORMATION:  
; APPLICANT: McCarthy, Jeanette  
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE  
; FILE REFERENCE: MMI-007  
; CURRENT APPLICATION NUMBER: US/10/017,122  
; CURRENT FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: 60/327,487  
; PRIOR FILING DATE: 2001-10-09  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: PatentIn Ver. 2.0  
; SEQ ID NO 4  
; LENGTH: 31  
; TYPE: DNA

; ORGANISM: Homo sapiens  
US-10-017-122-4

Query Match 0.4%; Score 9.2; DB 1; Length 31;  
Best Local Similarity 56.7%; Pred. No. 9.6e+02;  
Matches 17; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1620 TCCGGTCCAAATCTATTGGTGTGTTTGATG 1649  
Db 2 TCTGTGCGTGCCATGAGGGGTACTCTCTG 31

## RESULT 106

US-09-951-121A-2  
; Sequence 2, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951.121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-2

Query Match 0.4%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 9.7e+02;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAACTGTGTGTGTGTGTGTG 1133  
Db 3 GAATTGTGGGGCGCGGTGTG 24

## RESULT 107

US-09-951-121A-3/c  
; Sequence 3, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951.121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-3

Query Match 0.4%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 9.7e+02;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
Qy 1112 GAACTGTGTGTGTGTGTGTG 1133  
Db 32 GAATTGTGGGGCGCGGTGTG 11

## RESULT 108

US-10-295-682-2  
; Sequence 2, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-2

Query Match 0.4%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 9.7e+02;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAACTGTGTGTGTGTGTGTG 1133  
Db 3 GAATTGTGGGGCGCGGTGTG 24

## RESULT 109

US-10-295-682-3/c  
; Sequence 3, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSEQ for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.4%; Score 9.2; DB 1; Length 34;  
Best Local Similarity 63.6%; Pred. No. 9.7e+02;  
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1112 GAACTGTGTGTGTGTGTGTG 1133  
Db 32 GAATTGTGGGGCGCGGTGTG 11

```

US-09-951-121A-14
; Sequence 14, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-14

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGCTGAGGTTACCACTGCT 217
DB 4 TACTCGGATGCGCGAAGGACTCCT 28

RESULT 113
US-09-951-121A-15/c
; Sequence 15, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-15

Query Match      0.4%; Score 9; DB 1; Length 33;
Best Local Similarity 60.0%; Pred. No. 1.1e+03;
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

QY 193 TCCTAGGCTGAGGTTACCACTGCT 217
DB 30 TACTCGGATGCGCGAAGGACTCCT 6

RESULT 114
US-10-295-682-14
; Sequence 14, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon

```

```

US-10-281-727-2
; Sequence 2, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-2

Query Match      0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATCGACGAGTA 981
DB 2 TGCCTGCACGAGGA 15

RESULT 111
US-10-281-727-3/c
; Sequence 3, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII
US-10-281-727-3

Query Match      0.4%; Score 9.2; DB 1; Length 36;
Best Local Similarity 78.6%; Pred. No. 9.7e+02;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 968 TGGATCGACGAGTA 981
DB 35 TGCCTGCACGAGGA 22

RESULT 112

```

; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 14  
; LENGTH: 33  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-14

Query Match 0.4%; Score 9; DB 1; Length 33;  
Best Local Similarity 60.0%; Pred. No. 1.1e+03;  
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 193 TCTAGGCTGAGGTTACCACTGCT 217  
Db 4 TACTCGGATGCGCGCAAGGACTCT 28

RESULT 115  
US-10-295-682-15/c  
; Sequence 15, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 15  
; LENGTH: 33  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-15

Query Match 0.4%; Score 9; DB 1; Length 33;  
Best Local Similarity 60.0%; Pred. No. 1.1e+03;  
Matches 15; Conservative 0; Mismatches 10; Indels 0; Gaps 0;

Qy 193 TCTAGGCTGAGGTTACCACTGCT 217  
Db 30 TACTCGGATGCGCGCAAGGACTCT 6

RESULT 116  
US-09-803-810-8/c  
; Sequence 8, Application US/09803810  
; Publication No. US20010018414A1  
; GENERAL INFORMATION:  
; APPLICANT: Nelsetuen, Gary L.  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; TITLE OF INVENTION: POLYPEPTIDES  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/09/803,810  
; CURRENT FILING DATE: 2001-03-12

; NUMBER OF SEQ ID NOS: 18  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-09-803-810-8

Query Match 0.4%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 52.8%; Pred. No. 1.1e+03;  
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 136 TTCTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171  
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCGG 7

RESULT 117  
US-10-298-330-8/c  
; Sequence 8, Application US/10298330  
; Publication No. US20030100506A1  
; GENERAL INFORMATION:  
; APPLICANT: Nelsetuen, Gary L.  
; TITLE OF INVENTION: Modified Vitamin K-Dependent  
; TITLE OF INVENTION: Polypeptides  
; FILE REFERENCE: 09531-127001  
; CURRENT APPLICATION NUMBER: US/10/298,330  
; CURRENT FILING DATE: 2002-11-18  
; PRIOR APPLICATION NUMBER: 09/497,591  
; PRIOR FILING DATE: 2000-02-03  
; PRIOR APPLICATION NUMBER: 09/302,239  
; PRIOR FILING DATE: 1999-04-29  
; PRIOR APPLICATION NUMBER: 08/955,636  
; PRIOR FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-298-330-8

Query Match 0.4%; Score 8.8; DB 1; Length 42;  
Best Local Similarity 52.8%; Pred. No. 1.1e+03;  
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 136 TTCTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 171  
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCGG 7

RESULT 118  
US-10-017-122-4/c  
; Sequence 4, Application US/10017122  
; Publication No. US20030087244A1  
; GENERAL INFORMATION:  
; APPLICANT: McCarthy, Jeanette  
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE  
; FILE REFERENCE: MM-007  
; CURRENT APPLICATION NUMBER: US/10/017,122  
; CURRENT FILING DATE: 2001-12-14  
; PRIOR APPLICATION NUMBER: 60/327,487  
; PRIOR FILING DATE: 2001-10-09  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: Patent in Ver. 2.0  
; SEQ ID NO 4  
; LENGTH: 31  
; TYPE: DNA  
; ORGANISM: Homo sapiens

US-10-017-122-4

Query Match 0.4%; Score 8.2; DB 1; Length 31;  
Best Local Similarity 61.9%; Pred. No. 1.4e+03;  
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1384 CAGAAAGTTTCTTAAGTGCA 1404  
|||||  
Db 31 CAGAGAGTACCCCTCATGGCA 11  
|||||

RESULT 119

US-09-951-121A-2/c  
; Sequence 2, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951.121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;  
Best Local Similarity 81.8%; Pred. No. 1.4e+03;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756  
|||||  
Db 31 TTGGGGCACA 21  
|||||

RESULT 120

US-09-951-121A-3  
; Sequence 3, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951.121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;  
Best Local Similarity 81.8%; Pred. No. 1.4e+03;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756  
|||||  
Db 4 TTGGGGCACA 14  
|||||

RESULT 121

US-10-295-682-2/c  
; Sequence 2, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-2

Query Match 0.3%; Score 7.8; DB 1; Length 34;  
Best Local Similarity 81.8%; Pred. No. 1.4e+03;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756  
|||||  
Db 31 TTGGGGCACA 21  
|||||

RESULT 122

US-10-295-682-3  
; Sequence 3, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/10/295,682  
; CURRENT FILING DATE: 2002-11-15  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 34  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-10-295-682-3

Query Match 0.3%; Score 7.8; DB 1; Length 34;  
Best Local Similarity 81.8%; Pred. No. 1.4e+03;  
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 746 TTGTGTGCATA 756  
|||||  
Db 4 TTGGGGCACA 14  
|||||

Mon Aug 9 17:47:28 2004

10664775-4.rnpb

Page 34

Search completed: August 9, 2004, 16:55:08  
Job time : 32 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:55:35 ; Search time 4 seconds  
(without alignments)  
3.139 Million cell updates/sec

Title: us-10-664-775-4  
Perfect score: 2279  
Sequence: 1 gatcactcctctagtgaag.....ttgtgaattctgtgtgat 2279

Scoring table: IDENTITY\_NUC  
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : rstdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	20.6	0.9	1201	1	AL531727
C 2	19.8	0.9	645	1	AL116939
C 3	18	0.8	1201	1	AL531727
C 4	17	0.7	300	1	AU099140
C 5	16.3	0.7	609	1	AI099321
C 6	14.4	0.6	609	1	AI099321
C 7	13.8	0.6	645	1	AL116939
C 8	13.6	0.6	300	1	AU099140

ALIGNMENTS

RESULT 1  
AL531727/c  
LOCUS  
DEFINITION  
AL531727 Homo sapiens FETAL LIVER Homo sapiens CDNA clone  
CS0DM003YI01 5-PRIME, mRNA sequence.

ACCESSION  
AL531727  
VERSION  
AL531727  
KEYWORDS  
EST.  
SOURCE  
Homo sapiens (human)

REFERENCE  
1 (bases 1 to 1201)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS  
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.  
TITLE  
Full-length cDNA libraries and normalization  
JOURNAL  
Unpublished (2001)  
COMMENT  
On Feb 13, 2001 this sequence version replaced gi:12795220.  
Contact: Genoscope  
Genoscope - Centre National de Sequencage  
BP 191 91006 EVRY cedex - France

Email: segref@genoscope.cns.fr, Web : www.genoscope.cns.fr  
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 7252.f For more information about this cluster, see  
http://www.genoscope.cns.fr/  
cgi-bin/cluster.cgi?seq=CS0DM003AE01Q1&cluster=7252.f. Contact : Feng Liang Email : fliang@lifetech.com URL :  
http://fulllength.invitrogen.com/ Invitrogen Corporation 1600 Paraday Avenue Genoscope sequence ID : CS0DM003AE01Q1.  
Location/Qualifiers  
1..1201  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CS0DM003YI01"  
/tissue\_type="FETAL LIVER"  
/dev\_stage="fetal"  
/clone\_lib="Homo sapiens FETAL LIVER"  
/notes="Organ: liver; Vector: pCMVSPORT 6; 1st strand cDNA was primed with a NotI-oligo(dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

FEATURES  
source

Query Match 0.9%; Score 20.6; DB 1; Length 1201;  
Best Local Similarity 59.3%; Pred.No. 0.31; 24; Indels 0; Gaps 0;  
Matches 35; Conservative 0; Mismatches 0;  
Qy 440 TTCAATTGCTTTTATCTGTCGAGACTGCTTTGTTTGAATATGTAATTTGG 498  
Db 648 TTTCGGCATTTCTTTTCTAGATAGTATTTTCCACATGATATTTCAACTGTGG 590

RESULT 2  
AL116939/c  
LOCUS

DEFINITION  
ue29g08.y1 Sugano mouse liver mlia Mus musculus CDNA clone  
IMAGE:1481822.5; similar to gb:M13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN);, mRNA sequence.

ACCESSION  
AL116939  
VERSION  
AL116939.1  
KEYWORDS  
EST.  
SOURCE  
Mus musculus (house mouse)

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 645)  
REFERENCE  
Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisel, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.  
TITLE  
The WashU-HMI Mouse EST Project  
JOURNAL  
Unpublished (1996)  
COMMENT  
Contact: Marra M/Mouse EST Project  
WashU-HMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810

FEATURES  
source

Email: mouseest@watson.wustl.edu  
This clone is available royalty-free through LLNL ; contact the IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930178  
Seq primer: custom primer used  
High quality sequence stop: 483.  
Location/Qualifiers  
1..645  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1481822"



TITLE  
JOURNAL  
COMMENT

The WashU-HHMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of MedicineP  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930865  
Seq primer: custom primer used  
High quality sequence stop: 289.

FEATURES  
source  
1. 609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII  
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA  
was primed with an oligo(dT) primer  
[ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was  
ligated to a DraIII adaptor [GTGTGGCTACTGG], digested  
and cloned into distinct DraIII sites of the pME18S-FL3  
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should  
be used to isolate the cDNA insert. Size selection was  
performed to exclude fragments <1.5kb. Library  
constructed by Dr. Sumio Sugano (University of Tokyo  
Institute of Medical Science). Custom primers for  
sequencing: 5' end primer CTCTCTGCTCTAAAGCTGG and 3' end  
primer CGACCTGCAGCTCGACACA."

Query Match 0.7%; Score 16.3; DB 1; Length 609;  
Best Local Similarity 63.5%; Pred. No. 4.3;  
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

Qy 166 GGCTGCTGCTTTCTTCTCTGTCATCTCTAGGTGGGTAC-CACTGCTCTCTC 224  
|||||  
Db 209 GGGCTCTTGAAGATCTCCGGGCTCTCTCAAGAGAGACATGTCCTCATGCACTCTCTC 150  
|||||

Qy 225 TCC 227  
Db 149 TCC 147

RESULT 6  
AI099321  
LOCUS  
DEFINITION  
ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone  
IMAGE:1482509.5, similar to gb:M13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN); mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
1 (bases 1 to 609)  
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.  
The WashU-HHMI Mouse EST Project  
Unpublished (1996)

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
COMMENT

AI099321 609 bp mRNA linear EST 20-AUG-1998  
ue37b03.y1 Sugano mouse liver mlia Mus musculus cDNA clone  
IMAGE:1482509.5, similar to gb:M13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN); mRNA sequence.

AI099321.1 GI:3448846  
Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
1 (bases 1 to 609)  
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.  
The WashU-HHMI Mouse EST Project  
Unpublished (1996)

TITLE  
JOURNAL  
COMMENT

The WashU-HHMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of MedicineP  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930865  
Seq primer: custom primer used  
High quality sequence stop: 289.

FEATURES  
source  
1. 609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DraIII  
(CACTGTGTG); Site 2: DraIII (CACCATGTG); 1st strand cDNA  
was primed with an oligo(dT) primer  
[ATGTGGCTTTTCTTTTCTTTT]; double-stranded cDNA was  
ligated to a DraIII adaptor [GTGTGGCTACTGG], digested  
and cloned into distinct DraIII sites of the pME18S-FL3  
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should  
be used to isolate the cDNA insert. Size selection was  
performed to exclude fragments <1.5kb. Library  
constructed by Dr. Sumio Sugano (University of Tokyo  
Institute of Medical Science). Custom primers for  
sequencing: 5' end primer CTCTCTGCTCTAAAGCTGG and 3' end  
primer CGACCTGCAGCTCGACACA."

Query Match 0.6%; Score 14.4; DB 1; Length 609;  
Best Local Similarity 65.8%; Pred. No. 7.4;  
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

Qy 519 CAAGAAGTACAGTCTTTGTGTTTGGTGAA 550  
|||||  
Db 360 CAAGATGAACAGTTGATCTGTGCAATGAA 391  
|||||

RESULT 7  
AI116939  
LOCUS  
DEFINITION  
ue29g08.y1 Sugano mouse liver mlia Mus musculus cDNA clone  
IMAGE:1481822.5, similar to gb:M13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN); mRNA sequence.

AI116939.1 GI:3517263  
Mus musculus (house mouse)  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
1 (bases 1 to 645)  
Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.  
The WashU-HHMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of MedicineP  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810

Email: mouseest@watson.wustl.edu  
This clone is available royalty-free through LLNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930178

Seq primer: custom primer used  
High quality sequence stop: 483.

## FEATURES

```

source
1..645
  Location/Qualifiers
    /organism="Mus musculus"
    /mol_type="mRNA"
    /strain="C57BL"
    /db_xref="taxon:10090"
    /clone="IMAGE:1481822"
    /sex="female"
    /dev_stage="adult"
    /lab_host="DH10B"
    /clone_lib="Sugano mouse liver mlia"
    /notes="Organ: liver; Vector: pME18S-FL3; Site_1: DraIII
(CACTGTGTG); Site_2: DraIII (CACCATGTG); 1st strand cDNA
was primed with an oligo(dT) primer
[ATGTGGCCCTTTTCTTTTCTTTT]; double-stranded cDNA was
ligated to a DraIII adaptor [GTGTGGCCCTACTGG], digested
and cloned into distinct DraIII sites of the pME18S-FL3
vector (5' site CACTGTGTG, 3' site CACCATGTG). XhoI should
be used to isolate the cDNA insert. Size selection was
performed to exclude fragments <1.5kb. Library
constructed by Dr. Sumio Sugano (University of Tokyo
Institute of Medical Science). Custom primers for
sequencing: 5' end primer CTCTCTCTCTTAAAGCTGG and 3' end
primer CGACCTGCAGCTCGACACA."

```

```

Query Match          0.6%; Score 13.8; DB 1; Length 645;
Best Local Similarity 56.4%; Pred. No. 7.7;
Matches 44; Conservative 0; Mismatches 32; Indels 2; Gaps 1;

QY 2129 TCCTTGGCTTGTCTTCAGCTATGTTCATTCCTCAGGCG--CTATTGTATAGGGTTTTA 2186
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 50 TCCTTGGCTTGTCTTCAGCTTCAGGAGCTCTAGGAGCTGCAGTTTCATTAACCCAGGA 109

QY 2187 GCAGGGACATATTGTCT 2204
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 110 GGAAGCACATGGTGTCT 127

```

## RESULT 8

```

AU099140/c
LOCUS
DEFINITION
  AU099140 Sugano Homo sapiens cDNA library Homo sapiens cDNA clone
  HEP20983 similar to Human factor VII serine protease precursor mRNA
  clone lambda-HVII2463, mRNA sequence.
ACCESSION
  AU099140
VERSION
  AU099140.1 GI:13550269
KEYWORDS
  EST.
SOURCE
  Homo sapiens (human)
  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
  Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
  1 (bases 1 to 300)
  Hata,H., Oka,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S.,
  Suzuki,Y., Tsunoda,T., Taira,H., Mizushima-Sugano,J., Sese,J.,
  Okubo,K., Suyama,A. and Sugano,S.
  In silico mapping of the 5'-ends of human mRNAs using full-length
  enriched and 5'-end enriched cDNA libraries constructed by
  oligo-capping method
  Unpublished (2001)
JOURNAL
  Contact: Yutaka Suzuki
  Department of Virology
  Institute of Medical Science, University of Tokyo
  4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan
  Email: ysuzuki@ims.u-tokyo.ac.jp
  Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and
  Sugano,S. Construction and characterization of a full
  length-enriched and a 5'-end-enriched cDNA library. Gene 200 (1-2),

```

```

FEATURES
source
149-156 (1997).
  Location/Qualifiers
    1..300
    /organism="Homo sapiens"
    /mol_type="mRNA"
    /db_xref="taxon:9606"
    /clone="HEP20983"
    /clone_lib="Sugano Homo sapiens cDNA library"

Query Match          0.6%; Score 13.6; DB 1; Length 300;
Best Local Similarity 61.1%; Pred. No. 17;
Matches 22; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 756 AGACATTAAAGAAATTGCAATGTCCTCTTGGTGATTT 791
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 277 AGAATCCAGAACAGCTTCGTCTCTCGCGTCCTT 242

```

Search completed: August 9, 2004, 16:55:39  
Job time : 4 secs

GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:38:01 ; Search time 629 Seconds  
(without alignments)  
3.846 Million cell updates/sec

Title: us-10-664-775-3  
Perfect score: 2003  
Sequence: 1 agcttcacagagacttca.....tcaaggacatttatgaatt 2003

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 1439 seqs, 603848 residues

Total number of hits satisfying chosen parameters: 2878

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : rgedb:\*\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
C 1	44.7	2.2	289	1 AR162089	ACCESSION:AR162089
C 2	44.7	2.2	289	1 AR166814	ACCESSION:AR166814
C 3	43	2.1	2422	1 AR030786	ACCESSION:AR030786
C 4	43	2.1	2422	1 AR045090	ACCESSION:AR045090
C 5	43	2.1	2422	1 AR052946	ACCESSION:AR052946
C 6	43	2.1	2422	1 AR122899	ACCESSION:AR122899
C 7	43	2.1	2422	1 AR127821	ACCESSION:AR127821
C 8	43	2.1	2462	1 AR095304	ACCESSION:AR095304
C 9	43	2.1	2462	1 AR103988	ACCESSION:AR103988
C 10	43	2.1	2462	1 AX335083	ACCESSION:AX335083
C 11	43	2.1	2462	1 AX409604	ACCESSION:AX409604
C 12	43	2.1	2462	1 HUMFV11	ACCESSION:AX409604
C 13	43	2.1	2483	1 E01076	ACCESSION:E01076
C 14	43	2.1	2483	1 I07990	ACCESSION:I07990
C 15	41.6	2.1	2177	1 E01075	ACCESSION:E01075
C 16	41.6	2.1	2438	1 I07991	ACCESSION:I07991
C 17	37.4	1.9	1573	1 BC040125	ACCESSION:BC040125
C 18	32.4	1.6	300	1 BD211952	ACCESSION:BD211952
C 19	28	1.4	1403	1 BC009726	ACCESSION:BC009726
C 20	27.2	1.4	1792	1 BC034377	ACCESSION:BC034377
C 21	25.2	1.3	1843	1 AR390759	ACCESSION:AR390759
C 22	25.2	1.3	1843	1 AX411026	ACCESSION:AX411026
C 23	25.2	1.3	1843	1 HSPROT	ACCESSION:X02750
C 24	24.4	1.2	251	1 AY083553	ACCESSION:AY083553
C 25	24	1.2	1499	1 MUSCP	ACCESSION:D10445
C 26	24	1.2	1580	1 AF318182	ACCESSION:AF318182
C 27	24	1.2	1603	1 BC013896	ACCESSION:BC013896
C 28	23.8	1.2	364	1 AR425705	ACCESSION:AR425705
C 29	23.8	1.2	364	1 BD212158	ACCESSION:BD212158
C 30	23.8	1.2	394	1 AX839180	ACCESSION:AX839180
C 31	23.8	1.2	868	1 BD124660	ACCESSION:BD124660
C 32	23.8	1.2	868	1 BD126609	ACCESSION:BD126609
C 33	23.6	1.2	1671	1 AY040345	ACCESSION:AY040345

C 34	23	1.1	364	1 AR425705	ACCESSION:AR425705
C 35	23	1.1	364	1 BD212158	ACCESSION:BD212158
C 36	23	1.1	1329	1 AF465274	ACCESSION:AF465274
C 37	23	1.1	1507	1 AX774765	ACCESSION:AX774765
C 38	23	1.1	1507	1 HUMFACX	ACCESSION:M57285
C 39	22	1.1	193	1 HUMKALR4	ACCESSION:M31108
C 40	22	1.1	385	1 AX892787	ACCESSION:AX892787
C 41	22	1.1	385	1 BD028320	ACCESSION:BD028320
C 42	22	1.1	409	1 AX839163	ACCESSION:AX839163
C 43	21.8	1.1	274	1 AF306920	ACCESSION:AF306920
C 44	21.6	1.1	860	1 AF011898	ACCESSION:AF011898
C 45	21.6	1.1	861	1 AF011352	ACCESSION:AF011352
C 46	21.6	1.1	1869	1 BC061149	ACCESSION:BC061149
C 47	21.4	1.1	1129	1 AX464088	ACCESSION:AX464088
C 48	21.4	1.1	1129	1 AX359106	ACCESSION:AX359106
C 49	21.4	1.1	6098	1 AX565990	ACCESSION:AX565990
C 50	21.2	1.1	1541	1 BC046125	ACCESSION:BC046125
C 51	21	1.0	267	1 BD060364	ACCESSION:BD060364
C 52	21	1.0	289	1 AR162089	ACCESSION:AR162089
C 53	21	1.0	289	1 AR166614	ACCESSION:AR166614
C 54	21	1.0	1722	1 AF515269	ACCESSION:AF515269
C 55	20.8	1.0	484	1 RATCFX	ACCESSION:D21215
C 56	20.6	1.0	1206	1 E63001	ACCESSION:E63001
C 57	20.6	1.0	1206	1 E63002	ACCESSION:E63002
C 58	20.6	1.0	1221	1 E62997	ACCESSION:E62997
C 59	20.6	1.0	1221	1 E62998	ACCESSION:E62998
C 60	20.6	1.0	1221	1 E62999	ACCESSION:E62999
C 61	20.6	1.0	1221	1 E63000	ACCESSION:E63000
C 62	20.6	1.0	1440	1 AR112953	ACCESSION:AR112953
C 63	20.6	1.0	1440	1 AR112969	ACCESSION:AR112969
C 64	20.6	1.0	1440	1 I19358	ACCESSION:I19358
C 65	20.6	1.0	1440	1 I19360	ACCESSION:I19360
C 66	20.6	1.0	1440	1 BD194674	ACCESSION:BD194674
C 67	20.6	1.0	6098	1 AX565990	ACCESSION:AX565990
C 68	20.4	1.0	223	1 AX908508	ACCESSION:AX908508
C 69	20.4	1.0	223	1 BD044041	ACCESSION:BD044041
C 70	20.4	1.0	280	1 AF306917	ACCESSION:AF306917
C 71	20.4	1.0	280	1 AF306913	ACCESSION:AF306913
C 72	20.4	1.0	280	1 AF306914	ACCESSION:AF306914
C 73	20.4	1.0	280	1 AF306915	ACCESSION:AF306915
C 74	20.4	1.0	280	1 AF306919	ACCESSION:AF306919
C 75	20.4	1.0	2072	1 AF272774	ACCESSION:AF272774
C 76	20.2	1.0	183	1 AY155152	ACCESSION:AY155152
C 77	20.2	1.0	214	1 AB083386	ACCESSION:AB083386
C 78	20.2	1.0	214	1 AB084901	ACCESSION:AB084901
C 79	20.2	1.0	227	1 AY022473	ACCESSION:AY022473
C 80	20.2	1.0	227	1 AY023221	ACCESSION:AY023221
C 81	20.2	1.0	272	1 HUMPROS01	ACCESSION:M36551
C 82	20.2	1.0	352	1 HUMP02	ACCESSION:M57841
C 83	20.2	1.0	885	1 AR108139	ACCESSION:AR108139
C 84	20.2	1.0	1543	1 AX401899	ACCESSION:AX401899
C 85	20.2	1.0	1543	1 RNPROC	ACCESSION:X64336
C 86	20	1.0	855	1 AF011899	ACCESSION:AF011899
C 87	20	1.0	1130	1 AR234337	ACCESSION:AR234337
C 88	20	1.0	1142	1 AR219285	ACCESSION:AR219285
C 89	20	1.0	1166	1 AR212173	ACCESSION:AR212173
C 90	20	1.0	1169	1 AR219284	ACCESSION:AR219284
C 91	20	1.0	1722	1 AF515269	ACCESSION:AF515269
C 92	19.8	1.0	254	1 AX587861	ACCESSION:AX587861
C 93	19.8	1.0	268	1 HSLKB1P07	ACCESSION:AX587861
C 94	19.8	1.0	384	1 BD095271	ACCESSION:BD095271
C 95	19.8	1.0	394	1 AX814618	ACCESSION:AX814618
C 96	19.8	1.0	556	1 BV036036	ACCESSION:BV036036
C 97	19.8	1.0	813	1 PIGRIFA	ACCESSION:M26235
C 98	19.8	1.0	1850	1 MMU44795	ACCESSION:U44795
C 99	19.8	1.0	2078	1 AF272773	ACCESSION:AF272773
C 100	19.6	1.0	484	1 HAMCFX	ACCESSION:D21216
C 101	19.6	1.0	596	1 AX193364	ACCESSION:AX193364
C 102	19.6	1.0	609	1 AX763043	ACCESSION:AX763043
C 103	19.6	1.0	873	1 HUMCFIX	ACCESSION:M35672
C 104	19.6	1.0	882	1 AX675583	ACCESSION:AX675583
C 105	19.6	1.0	1142	1 AR219285	ACCESSION:AR219285
C 106	19.6	1.0	1161	1 AX675581	ACCESSION:AX675581

C 107	19.6	1.0	1169	1	AR219284	ACCESSION:AR219284	C 180	18.6	0.9	1467	1	AX082959	ACCESSION:AX082959
C 108	19.4	1.0	177	1	AR109618	ACCESSION:AR109618	C 181	18.6	0.9	1467	1	BD070392	ACCESSION:BD070392
C 109	19.4	1.0	177	1	AR150638	ACCESSION:AR150638	C 182	18.6	0.9	1467	1	BD070435	ACCESSION:BD070435
C 110	19.4	1.0	177	1	E16187	ACCESSION:E16187	C 183	18.6	0.9	1514	1	AF191307	ACCESSION:AF191307
C 111	19.4	1.0	177	1	E27213	ACCESSION:E27213	C 184	18.4	0.9	193	1	HUMKALR4	ACCESSION:HUMKALR4
C 112	19.4	1.0	177	1	E28271	ACCESSION:E28271	C 185	18.4	0.9	249	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 113	19.4	1.0	177	1	AR300928	ACCESSION:AR300928	C 186	18.4	0.9	249	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 114	19.4	1.0	204	1	AR109885	ACCESSION:AR109885	C 187	18.4	0.9	249	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 115	19.4	1.0	204	1	AR150703	ACCESSION:AR150703	C 188	18.4	0.9	249	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 116	19.4	1.0	249	1	AX586104	ACCESSION:AX586104	C 189	18.4	0.9	249	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 117	19.4	1.0	249	1	AX839191	ACCESSION:AX839191	C 190	18.4	0.9	256	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 118	19.4	1.0	352	1	HUMS02	ACCESSION:HUMS02	C 191	18.4	0.9	264	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 119	19.4	1.0	394	1	AX839160	ACCESSION:AX839160	C 192	18.4	0.9	279	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 120	19.4	1.0	471	1	DOGA2	ACCESSION:DOGA2	C 193	18.4	0.9	279	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 121	19.4	1.0	823	1	SHPTFXA	ACCESSION:SHPTFXA	C 194	18.4	0.9	279	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 122	19.4	1.0	829	1	BC061135	ACCESSION:BC061135	C 195	18.4	0.9	279	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 123	19.4	1.0	1126	1	AR095306	ACCESSION:AR095306	C 196	18.4	0.9	283	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 124	19.4	1.0	1126	1	AR103990	ACCESSION:AR103990	C 197	18.4	0.9	285	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 125	19.4	1.0	1126	1	HUMFX	ACCESSION:HUMFX	C 198	18.4	0.9	285	1	HUMDEPIA	ACCESSION:HUMDEPIA
C 126	19.4	1.0	1404	1	A93124	ACCESSION:A93124	C 199	18.4	0.9	804	1	AF312826	ACCESSION:AF312826
C 127	19.4	1.0	1414	1	HUMCFX	ACCESSION:HUMCFX	C 200	18.4	0.9	823	1	SHPTFXA	ACCESSION:SHPTFXA
C 128	19.4	1.0	1551	1	AX147505	ACCESSION:AX147505	C 201	18.4	0.9	832	1	AF011900	ACCESSION:AF011900
C 129	19.4	1.0	1850	1	MMU44795	ACCESSION:MMU44795	C 202	18.4	0.9	1293	1	AF465275	ACCESSION:AF465275
C 130	19.4	1.0	1869	1	BC061149	ACCESSION:BC061149	C 203	18.4	0.9	1505	1	AX523898	ACCESSION:AX523898
C 131	19.2	1.0	281	1	MUSACROS02	ACCESSION:MUSACROS02	C 204	18.2	0.9	171	1	S78934	ACCESSION:S78934
C 132	19.2	1.0	471	1	GOTR3	ACCESSION:GOTR3	C 205	18.2	0.9	240	1	AX318568	ACCESSION:AX318568
C 133	19.2	1.0	596	1	BOV094002	ACCESSION:BOV094002	C 206	18.2	0.9	251	1	AY083553	ACCESSION:AY083553
C 134	19.2	1.0	826	1	RABTHRO	ACCESSION:RABTHRO	C 207	18.2	0.9	265	1	HSTCRB9	ACCESSION:HSTCRB9
C 135	19.2	1.0	1302	1	AF465270	ACCESSION:AF465270	C 208	18.2	0.9	836	1	AF011901	ACCESSION:AF011901
C 136	19.2	1.0	1373	1	BOV094002	ACCESSION:BOV094002	C 209	18.2	0.9	987	1	AF542056	ACCESSION:AF542056
C 137	19.2	1.0	1619	1	OCU77477	ACCESSION:OCU77477	C 210	18.2	0.9	1558	1	AX523898	ACCESSION:AX523898
C 138	19.2	1.0	244	1	HSCRYBB2S3	ACCESSION:HSCRYBB2S3	C 211	18	0.9	199	1	S68634	ACCESSION:S68634
C 139	18.8	0.9	340	1	AR263850	ACCESSION:AR263850	C 212	18	0.9	276	1	AY267909S2	ACCESSION:AY267909S2
C 140	18.8	0.9	340	1	AR263851	ACCESSION:AR263851	C 213	18	0.9	276	1	HSAS07648	ACCESSION:HSAS07648
C 141	18.8	0.9	352	1	DMU58868	ACCESSION:DMU58868	C 214	18	0.9	276	1	HSAS07648	ACCESSION:HSAS07648
C 142	18.8	0.9	596	1	AX193364	ACCESSION:AX193364	C 215	18	0.9	290	1	AR249144	ACCESSION:AR249144
C 143	18.8	0.9	882	1	AX675583	ACCESSION:AX675583	C 216	18	0.9	299	1	AX312474	ACCESSION:AX312474
C 144	18.8	0.9	1161	1	AX675581	ACCESSION:AX675581	C 217	18	0.9	302	1	AX312474	ACCESSION:AX312474
C 145	18.8	0.9	1505	1	AX523898	ACCESSION:AX523898	C 218	18	0.9	383	1	AX312474	ACCESSION:AX312474
C 146	18.8	0.9	1671	1	AY040345	ACCESSION:AY040345	C 219	18	0.9	815	1	AX312474	ACCESSION:AX312474
C 147	18.6	0.9	168	1	AR077689	ACCESSION:AR077689	C 220	18	0.9	873	1	HUMCFIX	ACCESSION:HUMCFIX
C 148	18.6	0.9	168	1	AR081819	ACCESSION:AR081819	C 221	18	0.9	1329	1	AF465274	ACCESSION:AF465274
C 149	18.6	0.9	168	1	AR081819	ACCESSION:AR081819	C 222	18	0.9	1389	1	E02492	ACCESSION:E02492
C 150	18.6	0.9	168	1	AR081819	ACCESSION:AR081819	C 223	18	0.9	177	1	AX3181010	ACCESSION:AX3181010
C 151	18.6	0.9	168	1	AR116830	ACCESSION:AR116830	C 224	17.8	0.9	239	1	AR152169	ACCESSION:AR152169
C 152	18.6	0.9	168	1	AR127061	ACCESSION:AR127061	C 225	17.8	0.9	239	1	AX040017	ACCESSION:AX040017
C 153	18.6	0.9	168	1	AR141647	ACCESSION:AR141647	C 226	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 154	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 227	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 155	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 228	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 156	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 229	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 157	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 230	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 158	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 231	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 159	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 232	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 160	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 233	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 161	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 234	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 162	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 235	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 163	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 236	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 164	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 237	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 165	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 238	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 166	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 239	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 167	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 240	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 168	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 241	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 169	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 242	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 170	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 243	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 171	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 244	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 172	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 245	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 173	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 246	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 174	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 247	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 175	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 248	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 176	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 249	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 177	18.6	0.9	168	1	AR151537	ACCESSION:AR151537	C 250	17.8	0.9	341	1	AX524243	ACCESSION:AX524243
C 178	18.6	0.9	168	1	AR151537	ACCESSION:AR151537							
C 179	18.6	0.9	168	1	AR151537	ACCESSION:AR151537							

## ALIGNMENTS

[illegible]

Query Match 2.1%; Score 43; DB 1; Length 2422;  
 Best Local Similarity 58.0%; Pred. No. 9.9e-05;  
 Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 952 TGTGTGAGAAATATCAATGACGAGCTGTTGTGGATCTCTTTATCTTGCACTGTGAAGTG 1011

Dd 1946 TGTGCATCTCTATGTCGCTGTGCATCGGTGTGTTTGGGTATCTCTGTGTGACCATCTG 1887





	Matches	76;	Conservative	0;	Mismatches	55;	Indels	0;	Gaps	0;
Qy	952	TGTTGAGATATTCAAATGACGAGCTTTTGTGGATCTCTGTATCTGTCCACTGTGAGCTG	1011							
Db	2007	TGTGCATATCTTATGTCGGTGGCATCGGTGTGTTTTCGGTATCTCTGTGTGACCACTGTG	1948							
Qy	1012	TG	1071							
Db	1947	TGTGTGCATCCGTGTGTGTGCATATCTCTGTGTGTGTGCATTCGCGTGTGTGTGTGTGCA	1888							

ACCESSION AX409604  
VERSION AX409604.1 GI:21442309  
KEYWORDS  
SOURCE Homo sapiens (human)

ORGANISM HOMO SAPIENS  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
REFERENCE  
AUTHORS Alvares, C., Horne, D., Peres-da-Silva, S. and Vockley, J. G.  
TITLE Gene expression profiles in liver cancer

JOURNAL  
FEATURES  
source  
1. .2462  
Location/Qualifiers  
GENE LOGIC INC (US)  
Patent: WO 0229103-A 2251 11-APR-2002;  
GENE LOGIC INC (US)

```

seq_name="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
/notes="EMBL/GenBank Accession No. M1232"

Query Match      2.1%; Score 43; DB 1; Length 2462;
Best Local Similarity 58.0%; Pred.No. 9.9e-05;
Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

Qy 952 TGTGAGAATATCAATGAGCAGTGTGTGCGATCTTTTATCTTGCATCTGTGAAGT 1011
      |||||
Db 2007 TGTGCATATCTATGTGCGTGCATCGGTGTGTTTGCGTACTCTGTGTGACCATCTG 1948
      |||||

```

[illegible]

RESULT 12	
HUMFVII/c	
LOCUS	HUMFVII 2462 bp mRNA linear PRI 13-FEB-1996
DEFINITION	Human factor VII serine protease precursor mRNA, complete cds, clone lambda-HVII2463.
ACCESSION	M12322
VERSION	M12322.1 GI:182799
KEYWORDS	factor VII; serine protease; serum glycoprotein.
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens
	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE	1 (bases 1 to 2462)
AUTHORS	Hagen, F.S., Gray, C.L., O'Hara, P.J., Grant, F.J., Saari, G.C., Woodbury, R.G., Hart, C.E., Insley, M., Kiesel, W., Kurachi, K. and

**TITLE** Characterization of a cDNA coding for human factor VII  
**JOURNAL** Proc. Natl. Acad. Sci. U.S.A. 83 (8), 2412-2416 (1986)  
 Davie, E.W.



DEFINITION	Sequence 3 from Patent EP 0200421.
ACCESSION	107990
VERSION	107990.1 GI:589296
KEYWORDS	
SOURCE	Unknown.
ORGANISM	Unknown.
REFERENCE	Unclassified.
AUTHORS	1 (bases 1 to 2483)
TITLE	Hagen,F.S., Murray,M.J., Busby,S.J., Berkner,K.L., Insley,M.Y., Woodbury,K.G. and Gray,C.L.
JOURNAL	Expression of factor VII and IX activities in mammalian cells
FEATURES	Patent: EP 0200421-A2 3 10-DEC-1986; Location/Qualifiers. 1. 2483 /organism="unknown" /mol_type="unassigned DNA"
Query Match	2.1%; Score 43; DB 1; Length 2483;
Best Local Similarity	58.0%; Pred. No. 9.9e-05;
Matches	76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;
QY	952 TGTGAGAAATTATCAATGACGACGTGTTCTGGATTCTTGTATTCTTGCACTTGGAAGTG 1011
Db	2007 TGTGCATATCTATGTGCGTGGCATCGGTGTGTTTCGTATCTCTGTGTGACCATCTG 1948
QY	1012 TG 1071
Db	1947 TGTGTGATCCGGTG 1888
QY	1072 TCTGTGTGTGT 1082
Db	1887 TCCATGTGTGT 1877
RESULT 15	
E01075/c	
LOCUS	E01075 2177 bp RNA linear PAT 29-SBP-1997
DEFINITION	cDNA sequence of factor VII fragment.
ACCESSION	E01075
VERSION	E01075.1 GI:2169334
KEYWORDS	JP 1987000283-A/1.
SOURCE	unidentified
ORGANISM	unclassified.
REFERENCE	1 (bases 1 to 2177)
AUTHORS	Furederitsuku,E.H., Maaku,J.M., Shiyaron,J.B., Kiyasuriin,E.B., Maagaretuto,W.I., Richiyaado,J.U. and Chiyaaruzu,E.G.
TITLE	DNA ENCODING FACTOR VII
JOURNAL	Patent: JP 1987000283-A 1 06-JAN-1987; HEMOTENETETSUKUSU INC NIPPON SODA CO LTD, NISSAN CHEM IND LTD, TOYO SODA MFG CO LTD
COMMENT	OS Human (Homo sapiens) PN JP 1987000283-A/1 PD 06-JAN-1987 PF 16-APR-1986 JP 1986087861 PR 17-APR-1985 US 85 724311, 16-DEC-1985 US 85 810002 PI FUREDERITSUKU ESU HAAGEN, MAAKU JIEI MARII, PI SHIYAARON JIEI BAZUBUI, PI KIIYASURIIN ERU BAAKUNAA, MAAGARETSUTO WAI INSUREE, PI RICHIYAADO JII UTSUDOBERRI, CHIYAARUZU ERU GUDEI PC C12N15/00,A61K37/465,C12N5/00,C12N9/50,C12N9/50,C12R1:91; CC strandedness: Double; CC topology: Linear; CC hypothetical: No; CC anti-sense: No; CC *source: tissue type=liver; CC *source: library=cDNA library, lambdaqlt11 cDNA library; CC *source: cloneslambdaVII 2115, lambdaVII 1923; FH Key Location/Qualifiers FH FT CDS 13. .1128 /product="factor VII peptide" FT polya_signal 2106. .2111

REFERENCE  
AUTHORS  
TITLE  
JOURNAL

REMARK  
COMMENT

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1 (bases 1 to 1573)  
Straussberg, R.  
Direct Submission  
Submitted (22-NOV-2002) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
Contact: MGC help desk  
Email: [cgpbbs@mail.nih.gov](mailto:cgpbbs@mail.nih.gov)  
Tissue Procurement: Life Technologies, Inc.  
cDNA Library Preparation: Life Technologies, Inc.  
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
DNA Sequencing by: Institute for Systems Biology  
<http://www.systemsbio.org>  
contact: [anadan@systemsbiology.org](mailto:anadan@systemsbiology.org)  
Anup Madan, Jessica Fahney, Erin Helton, Mark Kettelman, Anuradha  
Madan, Stephanie Rodrigues, Amy Sanchez and Michelle Whiting

Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAK plate: 84 Row: m Column: 9  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 9961350.  
Location/Qualifiers  
1..1573  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="IMAGE:5764698"  
/tissue\_type="Brain", adult, 6 pooled whole brains"  
/clone\_id="NIH MGC\_114"  
/lab\_host="DH10B"  
/note="Vector: pCMV-SPORT6"

Query Match 1.9%; Score 37.4; DB 1; Length 1573;  
Best Local Similarity 51.5%; Pred. No. 0.0028;  
Matches 86; Conservative 0; Mismatches 81; Indels 0; Gaps 0;

QY 1412 TTATATGTAATTCGCTTTTCCCTTGCATCTTTATATCTTCTCTCTTATA 1471  
Db 1564 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1505  
QY 1472 CTTTGTAGTATGATTATGACCTGTGGGAGTCTTTCCGTCCTCAATCTATTG 1531  
Db 1504 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1445  
QY 1532 GTGTTTGTATCTTCTGTACCTGTATGACATCTTTCTCAAGG 1578  
Db 1444 CTCGCGGCGATGCTCTTGTGCGCTGGGCAAGCCCTGCTTTCATGG 1398

RESULT 18  
BD211952  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BD211952 300 bp DNA linear PAT 17-JUL-2003  
Novel human genes and gene expression products ii.  
BD211952  
BD211952.1 GI:33021722  
JP 2002519000-A/94.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1 (bases 1 to 300)  
Williams, L.T., Escobedo, J., Innis, M.A., Garcia, P.D., Klinger, J.S.,  
Reinhard, C., Giese, K., Randazzo, F., Kennedy, G.C., Pot, D.,  
Kassam, A., Lamson, G., Drmanac, R., Crkvenjakov, R., Dickson, M.,  
Drmanac, S., Labat, I., Leshkowitz, D., Kita, D., Garcia, V., Jones, L.W.  
and Crain, B.S.  
Novel human genes and gene expression products ii  
Patent: JP 2002519000-A 94 02-JUL-2002;  
CHIRON CORP, HYSEQ INC

COMMENT  
OS Homo sapiens (human)  
PN JP 2002519000-A/94  
PD 02-JUL-2002  
PF 28-JAN-1998 JP 2000556580  
PR 28-JAN-1998 US 60/072910, 24-FEB-1998 US 60/075954 PR  
31-MAR-1998 US 60/080114, 03-APR-1998 US 60/080515 PR  
03-APR-1998 US 60/080666, 21-OCT-1998 US 60/105234 PR  
28-OCT-1998 US 60/105877  
PI LOUIS T WILLIAMS, JAIME ESCOBEDO, MICHAEL A INNIS, PABLO PI  
DOMINGUEZ GARCIA,  
PI JULIE SUDDUTH KLINGER, CHRISTOPH REINHARD, KLAUSE GIESE, FILIPPO  
PI GIULIA C KENNEDY, DAVID POT, ALPAP KASSAM, GEORGE LAMSON, RADOJE  
PI DRMANAC,  
PI RADOMIR CRKVENJAKOV, MARK DICKSON, SNEZANA DRMANAC, IVAN LABAT,  
PI DENA LESHKOWITZ, DAVID KITA, VERONICA GARCIA, LEE WILLIAM JONES,  
PI BIRJIT STACHE CRAIN  
PC C12N15/09, C12N15/09, C07K14/47, C07K14/82, C07K16/18, C12N1/15, PC  
C12N1/19,  
PC C12N1/21, C12N5/10, C12Q1/68, C12N15/00, C12N5/00, C12N15/00 CC  
= A, T, C or G  
FH Key Location/Qualifiers  
FT misc feature (1)..(300).  
Location/Qualifiers  
1..300  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"

FEATURES  
source  
Query Match 1.6%; Score 32.4; DB 1; Length 300;  
Best Local Similarity 78.0%; Pred. No. 0.047;  
Matches 39; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 997 TGCACCTTGTAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1046  
Db 89 TCCCTAGGCGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 138

RESULT 19  
BC009726/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BC009726 1403 bp mRNA linear PRI 12-NOV-2003  
Homo sapiens protease, serine, 22, mRNA (cDNA clone MGC:9599  
IMAGE:3899480), complete cds.  
BC009726  
BC009726.1 GI:16307274  
MGC.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1 (bases 1 to 1403)  
Straussberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,  
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,  
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
Scapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,  
Schetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
Carninci, P., Prange, C., Raja, S.S., Loquellano, N.A., Peters, G.J.,  
Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,  
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,  
Wotley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,  
Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
Fahey, J., Helton, E., Kettelman, M., Madan, A., Young, A.C., Shevchenko, Y.,  
Sanchay, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,  
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalhus, D.E.,  
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.  
Generation and initial analysis of more than 15,000 full-length  
human and mouse cDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
22388257

TITLE  
JOURNAL  
MEDLINE

VIIIA), mRNA (cDNA clone MGC:34565 IMAGE:5188604), complete cds.  
 BC034377  
 BC034377.1 GI:21707770  
 MGC.  
 Homo sapiens (human)  
 Homo sapiens  
 Eukaryota: Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 1 (bases 1 to 1792)  
 Strausberg,R.L., Feingold,E.A., Grouse,L.H., Derge,J.G.,  
 Klausner,R.D., Collins,F.S., Wagner,L., Shenmen,C.M., Schuler,G.D.,  
 Altshuler,S.F., Zeeberg,S., Buetow,K.H., Schaefer,C.F., Bhat,N.K.,  
 Hopkins,R.F., Jordan,H., Moore,T., Max,S.I., Wang,J., Hsieh,F.,  
 Diatchenko,L., Mariani,K., Farmer,A.A., Rubin,G.M., Hong,L.,  
 Stapleton,M., Soares,M.B., Bonaldo,M.F., Casavant,T.L.,  
 Scheetz,T.E., Brownstein,M.J., Usdin,T.B., Toshiyuki,S.,  
 Carninci,P., Prange,C., Rha,S.S., Loquellano,N.A., Peters,G.J.,  
 Abramson,R.D., Mullenbach,S.J., Bosak,S.A., McSwan,P.J.,  
 McKernan,K.J., Malek,J.A., Gunaratne,P.H., Richards,S.,  
 Worley,K.C., Hale,S., Garcia,A.M., Gay,L.J., Hulyk,S.W.,  
 Villalón,D.K., Muzny,D.M., Sodergren,E.J., Lu,X., Gibbs,R.A.,  
 Fahey,J., Helton,E., Kettelman,M., Madan,A., Rodrigues,S.,  
 Sanchez,A., Whiting,M., Madan,A., Young,A.C., Shevchenko,Y.,  
 Bouffard,G.G., Blakeley,R.W., Touchman,J.W., Green,E.D.,  
 Dickson,M.C., Rodriguez,A.C., Grimwood,J., Schmutz,J., Myers,R.M.,  
 Butlerfield,S., Krzywicki,W.I., Skalska,U., Smalzer,D.B.,  
 Schneringer,A., Schein,J.E., Jones,S.J., and Marra,M.A.  
 Generation and initial analysis of more than 15,000 full-length  
 human and mouse cDNA sequences  
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
 223388257  
 12477932  
 2 (bases 1 to 1792)  
 Strausberg,R.  
 Direct Submission  
 Submitted (02-JUL-2002) National Institutes of Health, Mammalian  
 Gene Collection (MGC), Cancer Genomics Office, National Cancer  
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
 USA  
 NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
 Contact: MGC help desk  
 Email: [ccapbs-remail.nih.gov](mailto:ccapbs-remail.nih.gov)  
 Tissue Procurement: Life Technologies, Inc.  
 cDNA Library Preparation: Life Technologies, Inc.  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Baylor College of Medicine Human Genome  
 Sequencing Center  
 Center code: BCM-HGSC  
 Web site: <http://www.hgsc.bcm.tmc.edu/cdna/>  
 Contact: [amg@bcm.tmc.edu](mailto:amg@bcm.tmc.edu)  
 Gunaratne, P.H., Garcia, A.M., Lu, X., Hulyk, S.W., Lounsbury, H.,  
 Kowis, C.R., Sneed, A.J., Martin, R.G., Muzny, D.M., Nanavati,  
 A.N., Gibbs, R.A.  
 A clone distribution: MGC clone distribution information can be found  
 through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAP plate: 50 Row: h Column: 4  
 This clone was selected for full length sequencing because it  
 passed the following selection criteria: matched mRNA gi: 4506114.  
 Location/Qualifiers  
 1. .1792  
 /organism="Homo sapiens"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:9606"  
 /clone="MGC:34565 IMAGE:5188604"  
 /tissue\_type="Colon, Kidney, S-mach, adult, whole pooled"  
 /clone\_lib="NIH MGC\_116"  
 /lab\_host="DH10B"  
 /note="Vector: pCMV-SPORT6"  
 1. .1792  
 /gene="PROC"  
 /db\_xref="LocusID:5624"  
 /db\_xref="WIM:176860"







```
mat_peptide      /product="activation peptide"
644..1393
/product="serine protease"

Query Match      1.2%; Score 24; DB 1; Length 1499;
Best Local Similarity 46.9%; Pred. No. 8.7;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1785 CTATCTCTGTTATCTGTCAGTGAGGCTGTCCTGAGGTCCTGTCGGTCTCTTAATTT 1844
Db 715 CTCTCTCTGTTATCTGTCAGTGAGGCTGTCCTGAGGTCCTGTCGGTCTCTTAATTT 1844
QY 1845 TTTCATTTCCAGATTTCCCTTCAGTTGGGTTTGTGTTTATTAATTTCACTTTTCAG 1904
Db 655 TCGTTGACTATCTGTTGATCTGTTTCCAGTTTCATCTTCTAAGCTGTGTCGTTTGAG 596
QY 1905 GTCTCTGAATGTTTACTCATTTTCTCTCCAGTATTAC 1944
Db 595 GATCTTGGCTTTCTCTCTATCCATCCCTCCAGTTTCCCA 556

RESULT 26
AF318182/c      1580 bp mRNA linear ROD 14-FEB-2001
LOCUS Mus musculus anticoagulant protein C mRNA, complete cds.
DEFINITION
ACCESSION AF318182
VERSION AF318182.1 GI:12802522
KEYWORDS Mus musculus (house mouse)
SOURCE Mus musculus
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 1580)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
Korf, I.
TITLE Complete sequence of UC72A01
JOURNAL Unpublished
REFERENCE 2 (bases 1 to 1580)
AUTHORS Korf, I.
TITLE Direct Submission
JOURNAL Submitted (02-NOV-2000) Genetics, Washington University, 4444
Forest Park Avenue, St. Louis, MO 63108, USA
FEATURES
source 1..1580
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL"
/db_xref="dbEST:AA986009"
/db_xref="taxon:10090"
72..1454
/codon_start=1
/product="anticoagulant protein C"
/protein_id="AAK07918.1"
/db_xref="GI:12802523"
/translation="MWQPRVPLLMSTWGISSPAHPDPVFSSESAHQVLRVRANS
FLEENRPGSLRECMERICDLEAEQIFQNVEDTLAFWIKYFDGDCSAPPLDHOCDS
PCGGHTGTCIDGIGSFSCSDKGWGFQCEQLRQDCVNVNGCLHYCLEENGRCA
CAGVELADHWRCKSTWPCGKLGRIEKKILKRTDLEDELEPPRIVNGTIL
KQGDSPWQAILLDSSKLLACGGVLIHYSWVLAHCVEGKLTUVRGEYDURRDHW
ELDDKEILVHPNTRESSDNDIALRLAOPATLSKTIIVPICLPNGLAQELTQAG
ETVVTWGYSQDRKIDGRNRNRTFLTIRIPLVARNECVEMKNVYSENNLCAGIIGD
TRDADGDSGGPMVWVFRGTWFLVGLVSGEGCGHTNNYGIYTKVGSYLKWIHSYIGE
KGVSLKSQL"
```

```
1785 CTATCTCTGTTATCTGTCAGTGAGGCTGTCCTGAGGTCCTGTCGGTCTCTTAATTT 1844
715 CTCTCTCTGTTATCTGTCAGTGAGGCTGTCCTGAGGTCCTGTCGGTCTCTTAATTT 1844
1845 TTTCATTTCCAGATTTCCCTTCAGTTGGGTTTGTGTTTATTAATTTCACTTTTCAG 1904
655 TCGTTGACTATCTGTTGATCTGTTTCCAGTTTCATCTTCTAAGCTGTGTCGTTTGAG 596
1905 GTCTCTGAATGTTTACTCATTTTCTCTCCAGTATTAC 1944
595 GATCTTGGCTTTCTCTCTATCCATCCCTCCAGTTTCCCA 556

RESULT 27
BC013896/c      1603 bp mRNA linear ROD 03-OCT-2003
LOCUS Mus musculus protein C, mRNA (cDNA clone MGC:13870 IMAGE:4211329),
DEFINITION complete cds.
ACCESSION BC013896
VERSION BC013896.1 GI:15530229
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
REFERENCE 1 (bases 1 to 1603)
AUTHORS Strausberg, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Scheetz, T.E., Brownstein, M.J., Udwin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
Abramson, R.D., Mullan, S.J., Bosak, S.A., McEwan, P.J.,
Kernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Sanchez, A., Whitting, M., Madan, A., Young, A.C., Rodriguez, S.,
Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,
Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,
Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smalls, D.E.,
Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.
Generation and initial analysis of more than 15,000 full-length
human and mouse cDNA sequences
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
22388257
MEDLINE 12477932
REFERENCE 2 (bases 1 to 1603)
AUTHORS Strausberg, R.
TITLE Direct Submission
JOURNAL Submitted (07-SEP-2001) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NTH-MGC Project URL: http://mgc.nci.nih.gov
COMMENT Contact: MGC help desk
Email: cgapbs-rc@mail.nih.gov
Tissue Procurement: Jeffrey E. Green, M.D.
DNA Library Preparation: Life Technologies, Inc.
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Institute for Systems Biology
http://www.systemsbio.org
contact: amadan@systemsbio.org
Anup Madan, Jessica Fahey, Erin Helton, Mark Kettman, Anuradha
Madan, Stephanie Rodriguez, Amy Sanchez and Michelle Whiting
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAC Plate: 18 Row: n Column: 8
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 6679476.
Location/Qualifiers
1..1603
/organism="Mus musculus"
/mol_type="mRNA"
/strain="FVB/N"
/db_xref="taxon:10090"
```



```
/clones="MGC:13870 IMAGE:4211329"
/tissue type="Liver, normal. 5 month old male mouse."
/clone lib="NCI CGAP_L19"
/lab host="DH10B"
/notes="vector: pCMV-SPORT6"
1..1603
/genes="Proc"
/notes="synonym: PC"
/db_xref="locusid:19123"
/db_xref="MGI:97771"
100..1482
/codon_start=1
/product="protein C"
/protein_id="AAH13896.1"
/db_xref="GI:15530210"
/db_xref="LocusID:19123"
/translaction="MMOFVFLLMSTMWISSIPAPHPDPVFSSSEHAHVLVRRANS
PCEMRGCSERCEMIEICFEAEQIFQVETDLAFWKYFDGDCSAPPLDHOCDS
FCCGHGTICDIGIFSCDCGKWEKFCQOELRQDCRVNNGGCLHYCLEESNGRCA
KAGVBLADHMRCKSVNFCCKGLRWIEKILKEDTDLDELEPDRIVNGTTLT
KQGSPEKAILLDSKKLACGGVLIHTSVLTAHCVETGKLTPLGIDYLRDRDH
ELDDIKELVHPNYTSSNDNIALRLAQPATLSKTIPIPCPNNGAQLQTOGQ
ETVVGWGYSDRIKDGRRKRTFILFIRPLVARNECVEMKNVSVENMLCAGLIGD
TRDACDGSQPMVVFVRGTWFLVGLVSGEGCGHTNNYGIYTKVGSYLKWIHSYIGE
KGVSLKSQL"
175..357
/notes="GLA; Region: Domain containing Gla
(gamma-carboxyglutamate) residues. A hyaluronan-binding
domain found in proteins associated with the extracellular
matrix, cell adhesion and cell migration"
/db_xref="CDD:smart00069"
400..489
/notes="EGF; Region: EGF-like domain. There is no clear
separation between noise and signal. pfam00053 is very
similar, but has 8 instead of 6 conserved cysteines.
Includes some cytokine receptors. The EGF domain misses
the N-terminus regions of the Ca2+ binding EGF domains.
The family is hard to model due to many similar but
different sub-types of EGF domains. Pfam certainly misses
a number of EGF domains"
/db_xref="CDD:pfam00008"
730..1431
/notes="Tryp SPc; Region: Trypsin-like serine protease"
/db_xref="CDD:smart00020"

Query Match 1.2%; Score 24; DB 1; Length 1603;
Best Local Similarity 46.9%; Pred. No. 8.8;
Matches 75; Conservative 0; Mismatches 85; Indels 0; Gaps 0;

QY 1785 CTATCTTGATCTGTGTCAGTGAGGCTGTCTCTGAGGTCCTGTTGGTCTTATTT 1844
|||
DB 804 CTTCTTCTTGAGTCCAGAGGATGCTGCCAGGACTGTACCCCTGCTTCGTACGCT 745
|||

QY 1845 TTTCATTTCCAGATTCCTTCAGTTTGGTTTGTATTATTAATCTATTTCCACTTCAG 1904
|||
DB 744 TCCGTTGACTATCTCTGGATCTGGTTCAGTTCATCTTAAAGTGTGTGTCTGTTTGA 685
|||

QY 1905 GPCCTGAATGTTTACATCTTTCCCTCCAGTATTACA 1944
|||
DB 684 GATCTTGCTTCTTCTATCCACCTCCCGAGTTCCCA 645
|||

RESULT 28
AR425705 364 bp DNA linear PAT 18-DEC-2003
LOCUS
DEFINITION
Sequence 17202 from patent US 6639063.
ACCESSION
AR425705
VERSION
AR425705.1 GI:40180815
KEYWORDS
Unknown.
SOURCE
Unknown.
ORGANISM
Unclassified.
REFERENCE
1 (bases 1 to 364)
```

```
EDWARDS,J.-B.D.M., JOBERT,S. and GIORDANO,J.-Y.
EST's and encoded human proteins
JOURNAL Patent: US 6639063-A 17202 28-OCT-2003;
FEATURES
Location/Qualifiers
source
1..364
/organism="unknown"
/mol_type="genomic DNA"

Query Match 1.2%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 8.5;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 88 CCTAGGGTGAGGGTTACCACTGCTCTCTCTCCCTTCTTAACACTTCTGGGCGAGG 147
|||
DB 27 MCKSRSYGRRSSCCGSMGWSGCCSKRSWSRCRCKMSWMMYMRSMKYKRSTCASCK 86
|||

QY 148 TAGGGGCACCTACCGCATTCCTCTCTTCCAAACACTTCTATTCTTG 196
|||
DB 87 YKGGMACMTCWSTGAMYRMASVGYWCYSYMARYYTCYSKYRMWKCYR 135
|||

RESULT 29
BD121258 364 bp DNA linear PAT 18-SEP-2002
LOCUS
DEFINITION
EST and encoded human protein.
ACCESSION
BD121258
VERSION
BD121258.1 GI:23216168
KEYWORDS
JP 2002010789-A/13335.
SOURCE
Homo sapiens (human)
ORGANISM
Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1 (bases 1 to 364)
AUTHORS
EDWARDS,J.B.D.M., JOBERT,S. and GIORDANO,J.E.
TITLE
EST and encoded human protein
JOURNAL
GENSET CORP
PATENT: JP 2002010789-A 13335 15-JAN-2002;
COMMENT
OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PR 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPTISTE DUMAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09,C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,PC
C12N1/21,
PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68,C12N15/00,C12N5/00,PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source
1..364
/organism="Homo sapiens (human)"
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match 1.2%; Score 23.8; DB 1; Length 364;
Best Local Similarity 14.7%; Pred. No. 8.5;
Matches 16; Conservative 53; Mismatches 40; Indels 0; Gaps 0;

QY 88 CCTAGGGTGAGGGTTACCACTGCTCTCTCTCCCTTCTTAACACTTCTGGGCGAGG 147
|||
DB 27 MCKSRSYGRRSSCCGSMGWSGCCSKRSWSRCRCKMSWMMYMRSMKYKRSTCASCK 86
|||

QY 148 TAGGGGCACCTACCGCATTCCTCTCTTCCAAACACTTCTATTCTTG 196
|||
DB 87 YKGGMACMTCWSTGAMYRMASVGYWCYSYMARYYTCYSKYRMWKCYR 135
|||

RESULT 30
AX839180
```



```

source
1. .364
/organism="unknown"
/mol_type="genomic DNA"

Query Match      1.1%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred.No.14;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

QY 554 TTGAAGTACCCACATCTCTGTGTGAGGTCAATATGTGATTTAGCTGTAGCTGTGCTT 613
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
277 WTGRMSNMKSTYKRWBSRAGSNWTGYTRNSKMTGTGSTRCSCTSKKXKKGSTSSKYASTSGK 218
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
614 GTTTTATGAACCTGGGTGCACATCTGTTTGGTGTCATAGACATTAAAGATTGCAATGTCCT 673
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
217 SSKYMSCTKSSKKCRYSATYYVSCMKWKKYCMMSATYSGCMWRWYCYSCMMSRYSCT 158
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

QY 674 CTTCGGTGGATTIT 686
   ::::|:::|:::
Db 157 SYSRGKCSCTGWK 145

RESULT 35
BD121258/c
LOCUS BD121258 364 bp DNA linear PAT 18-SEP-2002
DEFINITION EST and encoded human protein.
ACCESSION BD121258
VERSION BD121258.1 GI:23216168
KEYWORDS JP 2002010789-A/13335.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1 (bases 1 to 364)
AUTHORS Edwards,J.B.D.M., Jobert,S. and Giordano,J.E.
TITLE EST and encoded human protein
JOURNAL Patent: JP 2002010789-A 13335 15-JAN-2002;
GENSET CORP

OS Homo sapiens (human)
PN JP 2002010789-A/13335
PD 15-JAN-2002
PF 07-AUG-2000 JP 2000280989
PR 05-AUG-1999 US 60/147499
PI JEAN BAPTIST DUNAS MILNE EDWARDS, SEVELIN JOBERT, JEAN EVE PI
GIORDANO
PC C12N15/09,C12N15/09,C07K14/47,C07K16/18,C12N1/15,C12N1/19,PC
C12N1/21,
PC C12N5/10,C12P21/02,C12P21/08,C12Q1/68,C12N15/00,C12N5/00,PC
C12N15/00
CC EST and encoded human protein
FH Key Location/Qualifiers
FT source 1..364
FT /organism='Homo sapiens (human)'.

FEATURES
source
1. .364
Location/Qualifiers
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"

Query Match      1.1%; Score 23; DB 1; Length 364;
Best Local Similarity 10.5%; Pred.No.14;
Matches 14; Conservative 67; Mismatches 52; Indels 0; Gaps 0;

QY 554 TTGAAGTACCCACATCTCTGTGTGAGGTCAATATGTGATTTAGCTGTAGCTGTGCTT 613
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
277 WTGRMSNMKSTYKRWBSRAGSNWTGYTRNSKMTGTGSTRCSCTSKKXKKGSTSSKYASTSGK 218
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
614 GTTTTATGAACCTGGGTGCACATCTGTTTGGTGTCATAGACATTAAAGATTGCAATGTCCT 673
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|
217 SSKYMSCTKSSKKCRYSATYYVSCMKWKKYCMMSATYSGCMWRWYCYSCMMSRYSCT 158
   :|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|:::|

QY 674 CTTCGGTGGATTIT 686
   ::::|:::|:::
Db 157 SYSRGKCSCTGWK 145

```

```

REFERENCE 1
AUTHORS Raponi,M.
TITLE Methods for assessing and treating leukemia
JOURNAL Patent: WO 0308129-A 81 08-MAY-2003;
Ortho-Clinical Diagnostics, Inc. (US)
FEATURES
source
    Location/Qualifiers
        1..1507
            /organism="Homo sapiens"
            /mol_type="unassigned DNA"
            /db_xref="taxon:9606"
Query Match      1..1%; Score 23; DB 1; Length 1507;
Best Local Similarity 60.3%; Pred.No.16;
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;
QY 1528 TTGTGTTTTCATGCTCTTGTAACCTGTAGTAGGCATCTCTTCTCAAGGTTAGGAAT 1587
     ||| |||| | ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1506 TTTTITTTTTTTTTTTTTTTTTTTTTTTTTTTTGGTGGGATCTCATTAAATGGAGAGCGT 1447
     ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
QY 1588 TTT 1590
     |||
Db 1446 TAT 1444

RESULT 38
HUMFAX/c
LOCUS HUMFAX 1507 bp mRNA linear PRI 08-NOV-1994
DEFINITION Human coagulation factor X (F10) mRNA, complete cds.
ACCESSION M57285
VERSION M57285.1 GI:182389
KEYWORDS coagulation factor X.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Messier,T.L., Pittman,D.D., Long,G.L., Kaufman,R.J. and Church,W.R.
TITLE Cloning and expression in COS-1 cells of a full-length cDNA
encoding human coagulation factor X
JOURNAL Gene 99 (2), 291-294 (1991)
MEDLINE 91216473
PUBMED 1902434
COMMENT Original
FEATURES
source
    source text: Human, cDNA to mRNA.
    Location/Qualifiers
        1..1507
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /map="13q34"
            /tissue type="liver"
        1..1507
            /gene="F10"
        1..1467
            /gene="F10"
            /EC number="3.4.21.6"
            /codon_start=1
            /product="coagulation factor X"
            /protein_id="AAA52421.1"
            /db_xref="GI:182390"
            /db_xref="GDB:G00-119-890"
            /translation="MGKPLHLVLISLAGLLLGSLFTFRQQNNILARVTRANSF
LEEMKGHLRECEMETCSFEAREVFEDSDKTNEFWNKYGDCQCETSPQNGCKK
DGLGEYTCLEGEGKNCELFRKLCSLDNGCDQFCHEEQNSVVCSCARGYTLADN
KGACITPTGPYCGKGLTERRKRSVAQTSSSGEAPDSITWPKPYDAADLPDENPFOLL
DFNQTPERDNENLTIIVGQCKGDGCEPWALLINEENGFCGGTILGEFYLTAAH
CLYQAKRFKVRVDNRTEOBEGEAVEHEVVIKHNRFTKETYDFDIALRLKTPITF
RMNVATQCPERPDAESTLMTOKTGVISGGRTHKEGROSTRLMLEVEPVYDRNSCKL
SSSFILTNMF CAGYTIDKQBDACQSGGFHTRTFDTYFTVTGIVSWGEGCARRKYIG
IYTKVAFIAKWIDRSWKTRGLPAKSHAPEVITSSPLK"
        1004..1060
            /gene="F10"
            /notes="putative VECTOR sequence Bacteriophage lambda
(J02459); putative"
misc_feature

```

Query Match	1.1%;	Score 23;	DB 1;	Length 1507;	
Best Local Similarity	60.3%;	Pred. No. 16;			
Matches 38;	Conservative	0;	Mismatches 25;	Indels 0;	Gaps 0;
ay	1528	TTTGCTGTTTGTATGCTTCCTTGACCTTGATAGCATCTCTTTCTCAAGGTTAGGAAT	1587		
bb	1506	TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGGATGGGATCTC	1447		
ay	1588	TTT	1590		
bb	1446	TAT	1444		
RESULT 39					
HUMKALR4/c					
LOCUS	HUMKALR4	193 bp	DNA	linear	PRI 06-JAN-1995
DEFINITION	Human renal kallikrein, exon 4.				
ACCESSION	M33108				
VERSION	M33108.1	GI:186648			
KEYWORDS	kallikrein; kininogenase.				
SEGMENT	4 of 5				
SOURCE	Homo sapiens (human)				
ORGANISM	Homo sapiens				
REFERENCE	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;				
AUTHORS	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.				
	1 (bases 1 to 193)				
	Evans, B.A., Yun, Z.X., Close, J.A., Tregear, G.W., Kitamura, N.,				
	Nakanishi, S., Callen, D.F., Baker, E., Hyland, V.J., Sutherland, G.R.				
	and Richards, R.I.				
TITLE	Structure and chromosomal localization of the human renal				
	kallikrein gene				
JOURNAL	Biochemistry 27 (9), 3124-3129 (1988)				
MEDLINE	88269498				
PUBMED	2898948				
COMMENT	Original source text: Human parotid gland, cDNA to mRNA.				
FEATURES	Location/Qualifiers				
source	1..193				
	/organism="Homo sapiens"				
	/mol_type="genomic DNA"				
	/db_xref="taxon:9606"				
	/map="19q13.3"				
prim_transcript	<1..>193				
	/gene="kallikrein mRNA and introns"				
intron	<1..>29				
	/gene="KLK1"				
	/note="kallikrein intron C"				
exon	30..166				
	/gene="KLK1"				
	/note="G00-120-118"				
	/number=4				
intron	167..>193				
	/gene="KLK1"				
	/note="kallikrein intron D"				
Query Match	1.1%;	Score 22;	DB 1;	Length 193;	
Best Local Similarity	67.4%;	Pred. No. 23;			
Matches 31;	Conservative	0;	Mismatches 15;	Indels 0;	Gaps 0;
ay	847	GTAGGTGCTTTTGGATGCAGCAGTAGGATGATCTTTTTC	892		
db	104	GGAGCTGGGCTTTTTCATCTCATTCAGCAGGATTTGAGTC	59		
RESULT 40					
AX892787/c					
LOCUS	AX892787	385 bp	DNA	linear	PAT 18-DEC-2003
DEFINITION	Sequence 8650 from Patent EPI033401.				
ACCESSION	AX892787				
VERSION	AX892787.1	GI:40047671			
KEYWORDS	Homo sapiens (human)				
SOURCE					

DEFINITION Petromyzon marinus trypsinogen A1 mRNA, complete cds.  
ACCESSION AF011352

AF011352.1 GI:2293477  
 Petromyzon marinus (sea lamprey)  
 Petromyzon marinus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;  
 Petromyzontiformes; Petromyzontidae; Petromyzon.  
 1 (bases 1 to 861)  
 Roach, J.C.  
 The molecular evolution of the vertebrate trypsinogenase  
 TITLE  
 JOURNAL  
 MEDLINE  
 PUBLISHED  
 REFERENCE  
 2 (bases 1 to 861)  
 Roach, J.C.  
 Direct Submission  
 TITLE  
 JOURNAL  
 Submitted (25-JUN-1997) Molecular Biotechnology, University of  
 Washington, Seattle, WA 98195, USA  
 FEATURES  
 Location/Qualifiers  
 1..861  
 /organism="petromyzon marinus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:7757"  
 /tissue\_type="anterior intestine"  
 /dev\_stage="ammocoete"  
 6..749  
 /codon\_start=1  
 /product="trypsinogen A1"  
 /protein\_id="AAB65411.1"  
 /db\_xref="GI:2293478"  
 /translation="MHGILALLVGAAPYVYEDHIVGGSECAHSPWVSLNIG  
 YHFGGLINSQWVSAHCYQASRISVIGEHNFVNEGTEQOIQAKAIOHPQYN  
 SWTIDNIMLIKSSPATLQYQAIALPSSCVNTGVMCTISGKETQTSVSPVLM  
 CQAPVLSDSKYSFGDINNMICLGLGEGSDSCQSGSGGPFVVCNGELQIVSWG  
 RGVAPLPYGVYTCVKNVIAQTIAAN"  
 sig\_peptide  
 6..50  
 /evidence=not\_experimental  
 mat\_peptide  
 51..746  
 /product="trypsin A1"  
 /evidence=not\_experimental  
 Query Match 1.1; Score 21.6; DB 1; Length 861;  
 Best Local Similarity 68.2; Pred. No. 35;  
 Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
 QY 1446 TTTTAAATCTCTTCTTTGTTCTATCTTTAGTGATTCATTA 1489  
 DB 860 TTTTATTTTATGTTTACATTTTATTCATTTGTTA 817  
 RESULT 46  
 BC061149/c  
 LOCUS  
 DEFINITION  
 IMAGE:30305571, complete cds.  
 ACCESSION  
 BC061149  
 VERSION  
 BC061149.1 GI:38511701  
 KEYWORDS  
 MGC.  
 SOURCE  
 Mus musculus (house mouse)  
 ORGANISM  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 1869)  
 Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,  
 Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,  
 Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,  
 Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,  
 Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,  
 Stapleton, M., Soares, M.B., Bonaldo, M.P., Casavant, T.L.,  
 Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,  
 Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,  
 Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J.,  
 McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,  
 Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,  
 Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,  
 Fahey, J., Helton, E., Kettman, M., Mada, A., Rodriguez, S.,

Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y.,  
 Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D.,  
 Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M.,  
 Butterfield, Y.S., Krzyzanski, M.I., Skalska, U., Smalley, D.E.,  
 Schnerch, A., Schein, J.E., Jones, S.J., and Marra, M.A.  
 Generation and initial analysis of more than 15,000 full-length  
 human and mouse cDNA sequences  
 Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
 23388257  
 12477932  
 2 (bases 1 to 1869)  
 Strausberg, R.  
 Direct Submission  
 TITLE  
 JOURNAL  
 Submitted (03-NOV-2003) National Institutes of Health, Mammalian  
 Gene Collection (MGC), Cancer Genomics Office, National Cancer  
 Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
 USA  
 NIH-MGC Project URL: http://mgc.nci.nih.gov  
 Contact: MGC help desk  
 Email: cgapbs@mail.nih.gov  
 Tissue Procurement: Dr. Michael Brownstein  
 cDNA Library Preparation: Michael Brownstein / Ted Usdin  
 Laboratory  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Sequencing Group at the Stanford Human Genome  
 Center, Stanford University School of Medicine, Stanford, CA 94305  
 Web site: http://www-ehg.sc.stanford.edu  
 Contact: (Dickson, Mark) mcd@paxil.stanford.edu  
 Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,  
 R. M.  
 Clone distribution: MGC clone distribution information can be found  
 through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov  
 Series: IRAL Plate: 53 Row: n Column: 1  
 This clone was selected for full length sequencing because it  
 passed the following selection criteria: matched mRNA gi: 6753805.  
 FEATURES  
 Location/Qualifiers  
 1..1869  
 /organism="Mus musculus"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:10090"  
 /clone="MGC:74281 IMAGE:30305571"  
 /tissue\_type="Liver, mouse"  
 /clone\_1b="NIH MGC\_177"  
 /lab\_host="DH10E"  
 /notes="vector: pDNR-LIB"  
 1..1869  
 /gene="F7"  
 /note="synonyms: FVII, mfVII"  
 /db\_xref="LocusID:14068"  
 /db\_xref="MGI:109325"  
 10..1350  
 /codon\_start=1  
 /product="coagulation factor VII"  
 /protein\_id="AAH61149.1"  
 /db\_xref="GI:38511702"  
 /db\_xref="LocusID:14068"  
 /translations="MVPQAGLLLCFLQLQPLGTAVFTQEEAHGVLRQRANS  
 LLELPMSLERECNEOCSEAREIFKSPERTKQFVIVSDGDCASNPONGGTC  
 QDLKSVCFCLDPGRCKEKNQELICANENGDCDOYCRDHVTKETCSCHDYT  
 LQDEVSCKVEYPCGRIPVVEKNSRSQGRIVGVNCPGCEPQAVLKLINGLL  
 CGVLLDARVITPAHCFPIRYGNITVVMGEHDFSEKDGQVAVTQVIMPKRI  
 RGNIMDIALLRLHRRVTTDYVPLCLPEKFSSENTLARIIFRSRWGQLDRGAT  
 ALKIMIEVPLMTQCLERAKHSNTPKITENMFCAGMDGTCKACKDSCGPHATH  
 YHGTWLTGVSWGEGCAAIGHGVTVRSQYIDMLVREHMSKLVQGVFRLPL"  
 79..264  
 /notes="GLA; Region: Domain containing Gla  
 (gamma-carboxyglutamate) residues"  
 /db\_xref="CDD:smar00069"  
 268..378  
 /note="EGF CA; Region: Calcium-binding EGF-like domain,  
 present in a large number of membrane-bound and  
 extracellular (mostly animal) proteins. Many of these



proteins require calcium for their biological function and calcium-binding sites have been found to be located at the N-terminus of particular EGF-like domains"

misc\_feature 589..1302  
/db\_xref="CDD:cd00054"  
/note="Tryp SPG; Region: Trypsin-like serine protease"  
/db\_xref="CDD:cd00190"

Query Match 1.1%; Score 21.6; DB 1; Length 1869;  
Best Local Similarity 68.2%; Pred. No. 37;  
Matches 30; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

Qy 1587 TTTTCTTTTGGTTTCTGAAATATTTCCCTGCTTTGA 1630  
|||||  
Db 1860 TTTTCTTTTGGTTTCTGAAATATTTCCCTGCTTTGA 1817  
|||||

RESULT 47  
AX464088/c 1129 bp DNA linear PAT 16-JUL-2002  
LOCUS  
DEFINITION Sequence 221 from Patent WO0140466.  
ACCESSION AX464088  
VERSION AX464088.1 GI:121899060  
KEYWORDS Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1  
AUTHORS Baker, K.P., Beresini, M., Deforge, L., Desnoyers, L., Filvaroff, E., Cao, W.Q., Gerritsen, M.E., Goddard, A., Godowski, P.J., Gurney, A.L., Sherwood, S., Smith, V., Stewart, T.A., Tumas, D., Watanabe, C.K., Wood, W.L. and Zhang, Z.  
TITLE Secreted and transmembrane polypeptides and nucleic acids encoding same  
JOURNAL Patent: WO 0140466-A 221 07-JUN-2001;  
Genentech Inc. (US)  
FEATURES Location/Qualifiers  
source 1..1129  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 40;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1881  
|||||  
Db 1129 TTTTCTTTTTCATTTTCCTTCAGTTGGGTTTCTTT 1083  
|||||

RESULT 48  
AY359106/c 1129 bp mRNA linear PRI 03-OCT-2003  
LOCUS  
DEFINITION Homo sapiens clone DNA99391 MFN (UNQ1884); mRNA, complete cds.  
ACCESSION AY359106  
VERSION AY359106.1 GI:37183328  
KEYWORDS FLI-CDNA  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens

REFERENCE 1 (bases 1 to 1129)  
AUTHORS Clark, H.F., Gurney, A.L., Abaya, E., Baker, K., Baldwin, D., Brush, J., Chen, J., Chow, B., Chui, C., Crowley, C., Currell, B., Deuel, B., Dowd, P., Eaton, D., Foster, J., Grimaldi, C., Gu, Q., Hass, P.E., Heldens, S., Huang, A., Kim, H.S., Klimowski, L., Jin, Y., Johnson, S., Lee, J., Lewis, L., Liao, D., Mark, M., Robbie, E., Sanchez, C., Schoenfeld, J., Seshagiri, S., Simmons, L., Singh, J., Smith, V., Stinson, J., Vagts, A., Wandlen, R., Watanabe, C., Wieand, D., Woods, K., Xie, M.H., Yansura, D., Yi, S., Yu, G., Yuan, J., Zhang, M., Zhang, Z., Goddard, A., Wood, W.I. and Godowski, P.

TITLE The Secreted Protein Discovery Initiative (SPDI), a Large-Scale Effort to Identify Novel Human Secreted and Transmembrane Proteins: A Bioinformatics Assessment  
JOURNAL Genome Res. 13 (10), 2265-2270 (2003)  
PUBMED 12975309  
REFERENCE 2 (bases 1 to 1129)  
AUTHORS Clark, H.F.  
TITLE Direct Submission  
JOURNAL Submitted (01-AUG-2003) Department of Bioinformatics, Genentech, Inc., 1 DNA Way, South San Francisco, CA 94080, USA  
FEATURES Location/Qualifiers  
source 1..1129  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="DNA99391"

gene 1..1129  
/locus\_tag="UNQ1884"

CDS 36..908  
/locus\_tag="UNQ1884"  
/note="PRO4327"  
/codon\_start=1  
/product="MPN"  
/protein\_id="AAQ89464.1"  
/db\_xref="GI:37183329"

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 40;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1881  
|||||  
Db 1129 TTTTCTTTTTCATTTTCCTTCAGTTGGGTTTCTTT 1083  
|||||

RESULT 49  
AX565990 6098 bp DNA linear PAT 29-NOV-2002  
LOCUS  
DEFINITION Sequence 2 from Patent WO02077218.  
ACCESSION AX565990  
VERSION AX565990.1 GI:26001242  
KEYWORDS synthetic construct  
SOURCE synthetic construct  
ORGANISM artificial sequences.

REFERENCE 1  
AUTHORS Persson, E.  
TITLE Coagulation factor vii derivatives  
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;  
NOVO NORDISK A/S (DK)  
FEATURES Location/Qualifiers  
source 1..6098  
/organism="synthetic construct"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:32630"  
/note="Plasmid DNA pLN174"

Query Match 1.1%; Score 21.4; DB 1; Length 6098;  
Best Local Similarity 49.5%; Pred. No. 43;  
Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

Qy 1536 TTTGTATGCTTCTGTACCTTGATAGGCATCTCTTCTCAAGTTAGGAATTTCTTT 1595  
|||||  
Db 4429 TTTTACGGTTCCTGGGCTTTTCTGCGCTTTTCTGCATGTTCTTCTCGGTATCC 4488  
|||||  
Qy 1596 TTTGGTTTCTTGAATAATTTTCCCTGCTTTTGACCTGCTTCTTCCCT 1646  
|||||



Db 4489 CCGTATCTGTGATTAACCGTATTACCGCCTTTGAGTGAGTGATACCGCT 4539

RESULT 50  
BC046125/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BC046125 1541 bp mRNA linear PRI 07-OCT-2003  
IMAGE:5723510, Complete cds.  
BC046125  
MGC.  
BC046125.1 GI:28374355  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1 (bases 1 to 1541)  
Straussberg R.L., Feingold E.A., Grouse L.H., Derge J.G.,  
Klausner R.D., Collins F.S., Wagner L., Shenmen C.M., Schuler G.D.,  
Altschul S.F., Zeeberg B., Buetow K.H., Schaefer C.F., Bhat N.K.,  
Hopkins R.P., Jordan H., Moore T., Max S.I., Wang J., Hsieh F.,  
Diatchenko L., Marusina K., Farmer A.A., Rubin G.M., Hong L.,  
Stapleton M., Soares M.B., Bonaldo M.F., Casavant T.L.,  
Schetz T.E., Brownstein M.J., Ustin T.B., Tohiyuki S.,  
Carroll P., Prange C., Raha S., Loquellano N.A., Peters G.J.,  
Abramson R.D., Mullaly S.J., Bosak S.A., McEwan P.J.,  
McKernan K.J., Malek J.A., Gunaratne P.H., Richards S.,  
Worley K.C., Hale S., Garcia A.M., Gay D.J., Hulyk S.W.,  
Villalón D.K., Muzny D.M., Sodergren E.J., Lu X., Gibbs R.A.,  
Fahey J., Helton E., Kettner M., Madan A., Rodriguez S.,  
Santchez A., Whitting M., Madan A., Young A.C., Shevchenko Y.,  
Bouffard G.G., Blakesley R.W., Touchman J.W., Green E.D.,  
Dickson M.C., Rodriguez A.C., Grimwood J., Schmutz J., Myers R.M.,  
Butterfield Y.S., Krzyzanski M.I., Skalski U., Smalios D.E.,  
Schwarz A., Schein J.E., Jones S.J. and Marra M.A.  
Generation and initial analysis of more than 15,000 full-length  
human and mouse cDNA sequences  
Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
22388257  
12477932  
2 (bases 1 to 1541)  
Straussberg R.  
Direct Submission  
Submitted (31-JAN-2003) National Institutes of Health, Mammalian  
Gene Collection (MGC), Cancer Genomics Office, National Cancer  
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,  
USA  
NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
Contact: MGC help desk  
Email: [cgabbs@mail.nih.gov](mailto:cgabbs@mail.nih.gov)  
Tissue Procurement: Invitrogen  
CDNA Library Preparation: Life Technologies, Inc.  
DNA Sequencing by: The I.M.A.G.E. Consortium (LLNL)  
Center, Stanford University School of Medicine, Stanford, CA 94305  
Web site: <http://www-shgc.stanford.edu>  
Contact: (Dickson, Mark) [mcd@paxil.stanford.edu](mailto:mcd@paxil.stanford.edu)  
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,  
R. M.  
Clone distribution: MGC clone distribution information can be found  
through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
Series: IRAC Plate: 107 Row: h Column: 24  
This clone was selected for full length sequencing because it  
passed the following selection criteria: matched mRNA gi: 9961350.  
Location/Qualifiers  
1. 1541  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="MGC:57588 IMAGE:5723510"  
/tissue\_type="ovary, pooled from 3 adults"  
/clone\_lib="NIH MGC\_125"  
/lab\_host="DH10B"

gene  
CDS  
misc\_feature  
misc\_feature  
misc\_feature

/note="Vector: pCMV-SPORT6"  
1. 1541  
/gene="F10"  
/note="synonyms: FX, FXA"  
/db\_xref="LocusID:2159"  
/db\_xref="MIM:227600"  
39. 1505  
/codon\_start=1  
/product="coagulation factor X precursor"  
/protein\_id="AAH46125.1"  
/db\_xref="GI:28374356"  
/db\_xref="LocusID:2159"  
/translation="MGRPLHLVLLSASLAGLLIGSLFIRREQANNILARVTRANS  
LEMKGHLERECWETSCVVEAREVFEDSDKTNEFWNKYKDGDCETSPCONCKCK  
DGLGVETCTLEGEGKNGELFRKLCSLDNGDCDFCHERONSVCACAGETYLADN  
GKACIFGPPYCKQTLERKKSVAQTSSGEADPSITWKYDAADDPENPDLL  
DFNQTERGNNLNRIVGQCKGECQVQALLNEENEGFCGGTLLSEFVILLTAH  
CLYQAKFVVRGDRNTEEGEAEVHEVVKNNRFTKTYDIDIAVLKRTITF  
RMNAPALPERDWAESTLMTOKTGVSGFGRHEKQSRQSLKMLEVYVDNRNCKL  
SSSFIITQNNFCAGYDTKQBDACQDGGPHVTRFKDTYFTVTGIVSWGEGCARKGYG  
IYTKVFAFLXWIDRSMKTRGLPKAKSHAPEVITSSPLK"  
111. 293  
/note="GLA; Region: Domain containing Gla  
(gamma-carboxyglutamate) residues. A hyaluronan-binding  
domain found in proteins associated with the extracellular  
matrix, cell adhesion and cell migration"  
/db\_xref="CDD:smart00069"  
318. 401  
/note="EGF; Region: EGF-like domain. There is no clear  
separation between noise and signal. pfam00053 is very  
similar, but has 8 instead of 6 conserved cysteines.  
Includes some cytokine receptors. The EGF domain misses  
the N-terminus regions of the Ca2+ binding EGF domains.  
The family is hard to model due to many similar but  
different sub-types of EGF domains. Pfam certainly misses  
a number of EGF domains"  
/db\_xref="CDD:pfam00008"  
738. 1424  
/note="Tryp SPC; Region: Trypsin-like serine protease"  
/db\_xref="CDD:smart00020"

Query Match 1.1%; Score 21.2; DB 1; Length 1541;  
Best Local Similarity 60.3%; Pred. No. 46;  
Matches 35; Conservative 0; Mismatches 23; Indels 0; Gaps 0;  
QY 1533 TGTTCCTGATGCTTCTTGATAGGCACTCTTCTCAAGTTAGGAAATTT 1590  
DB 1539 TTTTITTTTTTTTTTTTTTTTTTTTGTGCGGATCTCACITTAATGAGAGGAGCTAT 1482

RESULT 51  
BD060364/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

BD060364 267 bp DNA linear PAT 27-AUG-2002  
Secreted expressed sequence tags (seSTs).  
BD060364  
BD060364.1 GI:22605970  
JP 2001518793-A/724.  
Zea mays  
Zea mays  
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;  
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; PACCAD  
clade; Panicoideae; Andropogoneae; Zea.  
1 (bases 1 to 267)  
Jacobs, K., Mccoy, J.M., Lavallie, E.R., Racie, L.A., Merberg, D.,  
Treacy, M., Spaulding V. and Agostino M.J.  
Secreted expressed sequence tags (seSTs)  
Patent: JP 2001518793-A 724 16-OCT-2001;  
GENETICS INSTITUTE INC  
PN JP 2001518793-A/724  
PD 16-OCT-2001  
PR 10-APR-1998 JP 1998543070  
PR 10-APR-1997 US 08/837312  
PI KENNETH JACOBS, JOHN M MCCOY, EDWARD R LAVALLIE, LISA A RACIE, PI



```

RESULT 55
RATCFX      484 bp      DNA      linear      ROD 05-FEB-1999
LOCUS      Rat gene for coagulation factors X, partial cds.
DEFINITION
ACCESSION  D21215
VERSION     D21215.1 GI:415309
KEYWORDS   coagulation factor X.
SOURCE     Rattus norvegicus (Norway rat)
ORGANISM   Rattus norvegicus

REFERENCE
AUTHORS    Murakawa,M., Okamura,T., Kamura,T., Kurciwa,M., Harada,M. and
           Niho,Y.
TITLE      Analysis of the partial nucleotide sequences and deduced primary
           structures of the protease domains of mammalian blood coagulation
           factors VII and X
JOURNAL    Eur. J. Haematol. 52 (3), 162-168 (1994)
MEDLINE    94222160
PUBMED     8168596
REFERENCE  2 (bases 1 to 484)
AUTHORS    Murakawa,M.
TITLE      Direct Submission
JOURNAL    Submitted (18-Oct-1993) Masahiro Murakawa, Harasanshin General
           Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku,
           Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)
           Submitted (18-Oct-1993) to DDBJ by:
           Masahiro Murakawa
           Division of Hematology
           Harasanshin General Hospital
           1-8 Taihaku-machi, Hakata-ku
           Fukuoka, Fukuoka 812
           Japan
           Phone: 092-291-3434
           Fax : 092-291-3266.
FEATURES   source
           1. 484
           Location/Qualifiers
           /organism="Rattus norvegicus"
           /mol_type="genomic DNA"
           /db_xref="taxon:10116"
           <1..>484
           /codon_start=2
           /product="coagulation factor X"
           /protein_id="BAA04756.1"
           /db_xref="GI:455396"
           /translation="PDGEMVHEVDMMIKRNKFORDTYDFDIAMLRKLTITRENVAP
           ACLPKQWAEATLMTQKTIQVSGFGRTHKGRQSKVLKMEVYVGNKRLSTFSFI
           TQNMFCAGYDAQSDACQSDSGGPHVTRFKDTYFTVTGIVSWGEGCARKGKIYTKV
           A"
CDS
           1.0%; Score 20.8; DB 1; Length 484;
           Query Match 57.8%; Pred. No. 53;
           Best Local Similarity 37; Conservative 0; Mismatches 27; Indels 0; Gaps 0;
           Matches 37;

QY 637 GTGTTGTGGATGACATTAAGATGCAATGCTCTTGGTGGATTTCCCTTTGATGC 636
Db 111 GTGATGGGGGCTTTCAGCCTCAGCATGCAATGTCGAAGTCGTAGGTGTCCTCTGAAC 52

QY 697 CTAT 700
Db 51 TTGT 48

RESULT 56
E63001/c
LOCUS      E63001      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION  E63001
VERSION     E63001.1 GI:18633643
KEYWORDS   JP 2001061479-A/5.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
JOURNAL    Patent: JP 2001061479-A 5 13-MAR-2001;
           JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
           A61K37/465
COMMENT
           Query Match 1.0%; Score 20.6; DB 1; Length 1206;
           Best Local Similarity 59.3%; Pred. No. 64;
           Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACGCTGCTTTGTTGAAATATATATTCATTGTTGG 392
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386

RESULT 57
E63002/c
LOCUS      E63002      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION  E63002
VERSION     E63002.1 GI:18633644
KEYWORDS   JP 2001061479-A/6.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
JOURNAL    Patent: JP 2001061479-A 6 13-MAR-2001;
           JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
           A61K37/465
COMMENT
           Query Match 1.0%; Score 20.6; DB 1; Length 1206;
           Best Local Similarity 59.3%; Pred. No. 64;
           Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACGCTGCTTTGTTGAAATATATATTCATTGTTGG 392
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386

```

```

artificial sequences.
1 (bases 1 to 1206)
Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
Hemocoagulation factor VII modification
Patent: JP 2001061479-A 5 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
OS Artificial Sequence
PN JP 2001061479-A/5
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR KENJI FUKUSHIMA, JUN MIZUGUCHI, MASATO YAGUCHI, TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1206
FT /organism="Artificial Sequence".
FT Location/Qualifiers
1..1206
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 20.6; DB 1; Length 1206;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACGCTGCTTTGTTGAAATATATATTCATTGTTGG 392
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386

RESULT 57
E63002/c
LOCUS      E63002      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION  E63002
VERSION     E63002.1 GI:18633644
KEYWORDS   JP 2001061479-A/6.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
JOURNAL    Patent: JP 2001061479-A 6 13-MAR-2001;
           JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
           A61K37/465
COMMENT
           Query Match 1.0%; Score 20.6; DB 1; Length 1206;
           Best Local Similarity 59.3%; Pred. No. 64;
           Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACGCTGCTTTGTTGAAATATATATTCATTGTTGG 392
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386

RESULT 56
E63001/c
LOCUS      E63001      1206 bp      DNA      linear      PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION  E63001
VERSION     E63001.1 GI:18633643
KEYWORDS   JP 2001061479-A/5.
SOURCE     synthetic construct
ORGANISM   synthetic construct

REFERENCE
AUTHORS    Fukushima,K., Mizuguchi,J., Yaguchi,M., Nakagaki,T. and Iwanaga,S.
TITLE      Hemocoagulation factor VII modification
JOURNAL    Patent: JP 2001061479-A 5 13-MAR-2001;
           JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
           A61K37/465
COMMENT
           Query Match 1.0%; Score 20.6; DB 1; Length 1206;
           Best Local Similarity 59.3%; Pred. No. 64;
           Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCATTGTCTTTATCTGTCGACGCTGCTTTGTTGAAATATATATTCATTGTTGG 392
Db 444 TTCTGCGCATTTCTTTTCTTAGATAGTATTTTCCACATGGATATCACTGTGG 386

```

```
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.

FEATURES
source
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATATGTAATTCATTTGG 392
DB 444 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 60
E62999/c
LOCUS E62999 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.
TITILE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 1 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS blood coagulation factor VII
PN JP 2001061479-A/1
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA,JUN MIZUGUCHI,MASATO YUGUCHI,TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='blood coagulation factor VII'.

FEATURES
source
1..1221
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATATGTAATTCATTTGG 392
DB 444 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 59
E62998/c
LOCUS E62998 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62998
VERSION E62998.1 GI:18633640
KEYWORDS JP 2001061479-A/2.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.
TITILE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 2 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/2
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA,JUN MIZUGUCHI,MASATO YUGUCHI,TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
```

```
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.

FEATURES
source
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATATGTAATTCATTTGG 392
DB 444 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 60
E62999/c
LOCUS E62999 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E62999
VERSION E62999.1 GI:18633641
KEYWORDS JP 2001061479-A/3.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 1221)
AUTHORS Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.
TITILE Hemocoagulation factor VII modification
JOURNAL Patent: JP 2001061479-A 3 13-MAR-2001;
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE
COMMENT OS Artificial Sequence
PN JP 2001061479-A/3
PD 13-MAR-2001
PF 24-AUG-1999 JP 1999237610
PR PI KENJI FUKUSHIMA,JUN MIZUGUCHI,MASATO YUGUCHI,TOMOHIRO
NAKAGAKI,
PI SADAOKI IWANAGA
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC
A61K37/465
CC
FH Key Location/Qualifiers
FT source 1..1221
FT /organism='Artificial Sequence'.

FEATURES
source
1..1221
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"

Query Match 1.0%; Score 20.6; DB 1; Length 1221;
Best Local Similarity 59.3%; Pred. No. 64;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTTATCTGCGAGACTTCTGTTGTTTGAATATGTAATTCATTTGG 392
DB 444 TTGCTGGCATTCTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGTGG 386

RESULT 61
E63000/c
LOCUS E63000 1221 bp DNA linear PAT 31-JAN-2002
DEFINITION Hemocoagulation factor VII modification.
ACCESSION E63000
VERSION E63000.1 GI:18633642
KEYWORDS JP 2001061479-A/4.
SOURCE synthetic construct
```

ORGANISM synthetic construct  
REFERENCE 1 (bases 1 to 1221)  
AUTHORS Fukushima,K., Mizuguchi,J., Yuguchi,M., Nakagaki,T. and Iwanaga,S.  
TITLE Hemocoagulation factor VII modification  
JOURNAL Patent: JP 2001061479-A 4 13-MAR-2001;  
JURIDICAL FOUNDATION THE CHEMO SERO THERAPEUTIC RESEARCH INSTITUTE  
COMMENT OS Artificial Sequence  
PN JP 2001061479-A/4  
PD 13-MAR-2001  
PF 24-AUG-1999 JP 1999237610  
PR KENJI FUKUSHIMA,JUN MIZUGUCHI,MASATO YUGUCHI,TOMOHIRO  
PI NAKAGAKI,  
PI SADAOKI IWANAGA  
PC C12N15/09,A61K38/43,A61P7/04,C07K14/755,C12N9/76,C12N15/00, PC  
A61K37/465  
CC  
FH Key Location/Qualifiers  
FT source 1..1221  
FT /organism="Artificial Sequence".  
FEATURES  
source  
1..1221  
Location/Qualifiers  
/organism="synthetic construct"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:32630"  
Query Match 1.0%; Score 20.6; DB 1; Length 1221;  
Best Local Similarity 59.3%; Pred. No. 64;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 334 TTCAATTGCTTTATCTGTCGAGACTTCCTTTGTTTGAATATGTAATTCATTTGG 392  
Db 444 TTTCGCTGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGTGG 386  
RESULT 62  
LOCUS AR112953 1440 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 13 from patent US 6132729.  
ACCESSION AR112953  
VERSION AR112953.1 GI:14093275  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1440)  
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.  
TITLE Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment  
JOURNAL Patent: US 6132729-A 13 17-OCT-2000;  
FEATURES  
source  
1..1440  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 65;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 334 TTCAATTGCTTTATCTGTCGAGACTTCCTTTGTTTGAATATGTAATTCATTTGG 392  
Db 659 TTTCGCTGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGTGG 601  
RESULT 63  
LOCUS AR112969 1440 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 13 from patent US 6132730.  
ACCESSION AR112969  
VERSION AR112969.1 GI:14093291  
KEYWORDS  
SOURCE Unknown.

ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1440)  
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.  
TITLE Combined tissue factor and factor VIIa methods and compositions for coagulation and tumor treatment  
JOURNAL Patent: US 6132730-A 13 17-OCT-2000;  
FEATURES  
source  
1..1440  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 65;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 334 TTCAATTGCTTTATCTGTCGAGACTTCCTTTGTTTGAATATGTAATTCATTTGG 392  
Db 659 TTTCGCTGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGTGG 601  
RESULT 64  
LOCUS I19358/c 1440 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 3 from patent US 5504064.  
ACCESSION I19358  
VERSION I19358.1 GI:1599713  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1440)  
AUTHORS Morrissey,J.H. and Comp.P.C.  
TITLE Treatment of bleeding with modified tissue factor in combination with an activator of FVII  
JOURNAL Patent: US 5504064-A 3 02-APR-1996;  
FEATURES  
source  
1..1440  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 65;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
Qy 334 TTCAATTGCTTTATCTGTCGAGACTTCCTTTGTTTGAATATGTAATTCATTTGG 392  
Db 659 TTTCGCTGCATTTCTTTTCTAGATAGTATTTTCCACATGGATATTCACCTGTGG 601  
RESULT 65  
LOCUS I19360/c 1440 bp DNA linear PAT 07-OCT-1996  
DEFINITION Sequence 3 from patent US 5504067.  
ACCESSION I19360  
VERSION I19360.1 GI:1599715  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1440)  
AUTHORS Morrissey,J.H. and Comp.P.C.  
TITLE Treatment of bleeding with modified tissue factor in combination with FVII  
JOURNAL Patent: US 5504067-A 3 02-APR-1996;  
FEATURES  
source  
1..1440  
Location/Qualifiers  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 65;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

```

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGATTCATTTGG 392
    |||
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGTGG 601

RESULT 66
BD194674 1440 bp DNA linear PAT 17-JUL-2003
LOCUS Tissue factor methods and compositions for coagulation and tumor
DEFINITION treatment.
ACCESSION BD194674
VERSION BD194674.1 GI:33004420
KEYWORDS JP 2002514201-A/3.
SOURCE unidentified
ORGANISM unclassified.
REFERENCE 1 (bases 1 to 1440)
AUTHORS Thorpe,P.E., King,S.W. and Gao,B.
TITLE Tissue factor methods and compositions for coagulation and tumor
JOURNAL treatment
COMMENT Patent: JP 2002514201-A 3 14-MAY-2002;
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM
OS Mammalian
PN JP 2002514201-A/3
PD 14-MAY-2002
PF 20-JAN-1998 JP 1998534630
PR 22-JAN-1997 US 60/035920,27-JAN-1997 US 60/036205 PR
27-MAR-1997 US 60/042427
PI PHILIP E THORPE,STEVEN W KING,BONING GAO
PC A61K47/48
CC Tissue factor methods and compositions for coagulation and CC
FH Key tumor treatment
FT source
FEATURES
    source
        Location/Qualifiers
            1..1440
                /organism="Mammalian".
                /mol_type="genomic DNA"
                /db_xref="taxon:32644"

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGATTCATTTGG 392
    |||
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGTGG 601

RESULT 67
AX565990/c 6098 bp DNA linear PAT 29-NOV-2002
LOCUS Sequence 2 from Patent WO02077218.
DEFINITION
ACCESSION AX565990
VERSION AX565990.1 GI:26001242
KEYWORDS synthetic construct
SOURCE synthetic construct
ORGANISM artificial sequences.
REFERENCE 1
AUTHORS Persson,E.
TITLE Coagulation factor vii derivatives
JOURNAL Patent: WO 02077218-A 2 03-OCT-2002;
NOVO NORDISK A/S (DK)
FEATURES
    source
        Location/Qualifiers
            1..6098
                /organism="synthetic construct"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32630"
                /note="Plasmid DNA pLN174"

```

```

Query Match 1.0%; Score 20.6; DB 1; Length 6098;
Best Local Similarity 59.3%; Pred. No. 65;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTCTTGTGTTTGAATATGATTCATTTGG 392
    |||
Db 728 TTGCTGGCAATTTCTTTTCTAGATAGGATTTTCCACATGGATATTCACACTGTGG 670

RESULT 68
AX908508 223 bp DNA linear PAT 18-DEC-2003
LOCUS Sequence 24371 from Patent EP1033401.
DEFINITION
ACCESSION AX908508
VERSION AX908508.1 GI:40064588
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
REFERENCE 1
AUTHORS Dumas Milne Edwards,J.B., Duclert,A. and Giordano,J.Y.
TITLE Expressed sequence tags and encoded human proteins
JOURNAL Patent: EP 1033401-A 24371 06-SEP-2000;
Genset (FR)
FEATURES
    source
        Location/Qualifiers
            1..223
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match 1.0%; Score 20.4; DB 1; Length 223;
Best Local Similarity 58.1%; Pred. No. 62;
Matches 36; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

QY 996 TTGCACCTGTGAAGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTG 1055
    |||
Db 4 TTGCACCTGTGTGGAGTTGTGGAGCGGCTTGTAGTCTAGTACGAGTGTGGTGTGTG 63

QY 1056 TG 1057
    |
Db 64 AG 65

RESULT 69
BD044041 223 bp DNA linear PAT 27-AUG-2002
LOCUS Sequence tag and encoded human protein.
DEFINITION
ACCESSION BD044041
VERSION BD044041.1 GI:22585783
KEYWORDS JP 2001269182-A/20287.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 223)
AUTHORS Edwards,J.B.D.M., Duclair,E. and Jordan,J.Y.
TITLE Sequence tag and encoded human protein
JOURNAL Patent: JP 2001269182-A 20287 02-OCT-2001;
GENSET
COMMENT OS Homo sapiens (human)
PN JP 2001269182-A/20287
PD 02-OCT-2001
PF 24-FEB-2000 JP 2000118773
PR 26-FEB-1999 US 60/122487
PI JEAN BAPTISTE DUMAS MILNE EDWARDS,EIMERIC DUCLAIR,JEAN YVES
PC C12N15/09,C07K14/435,C07K16/18,C12N1/15,C12N1/19,C12N1/21, PC
C12N5/10,
PC C12P21/02,C12P21/08,C12Q1/68//G06F17/30,C12N15/00,C12N5/00, PC
G06F15/40
CC
FH Key Location/Qualifiers.

```

[illegible]







FEATURES source

Location/Qualifiers  
1..2072  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
22..2061  
/note="hVilasm"

CDS

/codon\_start=1  
/product="factor VII active site mutant immunoconjugate"  
/protein\_id="AAK8686.2"  
/db\_xref="GI:28269794"  
translation="MWSQALRLCLLLGLGCLAAVFTQEAHGVLRHRRANAFLE  
ELRGLSECKEQCFEAREIFKDAERKLFWSYSDGQCASSPCQGGSKDQ  
LQSYICFLPAFERNCEHDKDLICVNEGGCEQYCDHTGTGTRSCRCHEGSLA  
DGVSTCTVEPCGKIPILEKRNASKPOGRI VGGKVPKGECPWVLLVNGAQCCGG  
TLNTIIVSAAHCPDKIKWRNLIAVLGHDLSHDGDEOSRVAOVII PSTYVPGI  
TNHIALRLHQPVLDTHVPLCLPCECTFSETLAFVRESLVSGWGLDDEGATALE  
LMLNVLRLMTQDCLQSRKVGDSNITTEYMFCAQYSDGSKSCAGDSGGPRATHRG  
TWYLTGVWGCGCATVGHFVIRVSKQIEMQKMRSEPRGVLVLRAPFPGSRAPK  
SCDTHCPCLGAPFELGGSPVLFPPKPKOTLMISRTPEVTCVVVDVSHEDPEVKFN  
YWDGVEVHNAKTPREEQNSTYRVVSVLTVLHODMNGKRYCKVKNSKALPAPIEK  
TISKAGQPRPQYTTTPPRLDTKNVSLTCLVRGFPSPDAIVAESNGQPFENYK  
TTPVLDSDGSFFLYSLKLTVDKSRWQGNVFCVSNVHEALHNHYTKSLSPGK"

Query Match

Best Local Similarity 1.0%; Score 20.4; DB 1; Length 2072;  
Matches 33; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
QY 339 TGTCTTTTATCTGTCGAGACTTCTGTTTGAATATGATTTCAATTTGG 392  
DB 574 TGGCAATCTTTTTCAGATAGGATATTTTCCACATGATATCAACTGTGG 521

RESULT 76

AY155152/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Drosophila straubae  
Eukaryota; Metazoa; Arthropoda; Hexapoda; Insecta; Pterygota;  
Neoptera; Endopterygota; Diptera; Brachycera; Muscomorpha;  
Ephydroidea; Drosophilidae; Drosophila; mayaguana subcluster.  
1 (bases 1 to 183)  
O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.  
and DeSalle, R.  
Genetic divergence within the Drosophila mayaguana subcluster, a  
closely related triad of Caribbean species in the repleta species  
group  
Unpublished  
2 (bases 1 to 183)  
O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.  
and DeSalle, R.  
Direct Submission  
Submitted (25-SEP-2002) Invertebrate Zoology, American Museum of  
Natural History, Central Park West at 79th Street, New York, NY  
10024, USA

REFERENCE

1 (bases 1 to 183)  
O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.  
and DeSalle, R.  
Genetic divergence within the Drosophila mayaguana subcluster, a  
closely related triad of Caribbean species in the repleta species  
group  
Unpublished  
2 (bases 1 to 183)  
O'Grady, P.M. II, Durando, C.M., Heed, W.B., Wasserman, M., Etges, W.  
and DeSalle, R.  
Direct Submission  
Submitted (25-SEP-2002) Invertebrate Zoology, American Museum of  
Natural History, Central Park West at 79th Street, New York, NY  
10024, USA

JOURNAL

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
Submitted (25-SEP-2002) Invertebrate Zoology, American Museum of  
Natural History, Central Park West at 79th Street, New York, NY  
10024, USA

FEATURES

Location/Qualifiers  
1..183  
/organism="Drosophila straubae"  
/mol\_type="genomic DNA"  
/isolate="5"  
/db\_xref="taxon:214823"  
/clone="12"  
/country="Navassa Island"  
1..>183  
/gene="mast"  
1..>183  
/gene="mast"  
/product="mastermind"  
1..>183

gene

mRNA

CDS

Query Match 1.0%; Score 20.2; DB 1; Length 214;  
Best Local Similarity 51.7%; Pred. No. 69;  
Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

/gene="mast"  
/codon\_start=3  
/product="mastermind"  
/protein\_id="AAO61936.1"  
/db\_xref="GI:28975317"  
/translation="DLKRLQQQAMQOQQOQHHAQQOQQOQHHPNGPKMGVPMGGAGNFA  
KQOQQOQVVTVXXQQQ"

Query Match 1.0%; Score 20.2; DB 1; Length 183;  
Best Local Similarity 53.1%; Pred. No. 68;  
Matches 43; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

QY 238 TGGTTTCCATAAGTTTGTAAAGTTTCTGTGTTCTGTGTTGTTGTTGTTTATCTAGATT 297  
DB 111 TGGGTACACCACTTTTGGGACCATTTGGGATGTTGTTGTTGTTGTTGTTGTTGTTGTT 52  
QY 298 TAGCTGTGTGTCAGATAG 318  
DB 51 GTTGCTGTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTTGTT 31

RESULT 77

AB083386/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Watanabe, K., Kurihara, M., Wada, Y. and Ono, M.  
Gene analysis of anticoagulation factors in Japanese thrombotic  
patients. Genetic background of thrombophilia in Japan  
Unpublished  
2 (bases 1 to 214)  
Hamasaki, N.  
Direct Submission  
Submitted (10-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidsashi, Higashi-ku Fukuoka, Fukuoka 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp; Tel:81-92-642-5770,  
Fax:81-92-642-5772)

REFERENCE

1  
Watanabe, K., Kurihara, M., Wada, Y. and Ono, M.  
Gene analysis of anticoagulation factors in Japanese thrombotic  
patients. Genetic background of thrombophilia in Japan  
Unpublished  
2 (bases 1 to 214)  
Hamasaki, N.  
Direct Submission  
Submitted (10-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidsashi, Higashi-ku Fukuoka, Fukuoka 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp; Tel:81-92-642-5770,  
Fax:81-92-642-5772)

JOURNAL

REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
Submitted (10-APR-2002) Naotaka Hamasaki, Kyushu University  
Hospital, Department of clinical chemistry and laboratory medicine;  
3-1-1 maidsashi, Higashi-ku Fukuoka, Fukuoka 812-8582, Japan  
(E-mail:hamasaki@cclm.med.kyushu-u.ac.jp; Tel:81-92-642-5770,  
Fax:81-92-642-5772)

FEATURES

Location/Qualifiers  
1..214  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="patient:PS 1"  
/db\_xref="taxon:9606"  
24  
/replaces="g"  
25..182  
/genes="PROS1"  
25..>182  
/genes="PROS1"  
/codon\_start=3  
/product="Protein S"  
/protein\_id="BAC54134.1"  
/db\_xref="GI:27531050"  
/translation="LSKQASQVLRKRANSLLEETKQGNLRECEELCNKEARE  
VFENDEET"  
25..182  
/genes="PROS1"  
/number=2

Query Match

Best Local Similarity 1.0%; Score 20.2; DB 1; Length 214;  
Matches 46; Conservative 0; Mismatches 43; Indels 0; Gaps 0;







Db 855 TTTTCTTTTTCAGTTCACATTTTATTCATTGGTTA 812

RESULT 87  
AR234337  
LOCUS AR234337 1130 bp DNA linear PAT 20-DEC-2002  
DEFINITION Sequence 8 from patent US 6458564.  
ACCESSION AR234337  
VERSION AR234337.1 GI:27277021  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1130)  
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.  
TITLE DNA encoding the human serine protease T  
JOURNAL Patent: US 6458564-A 8 01-OCT-2002;  
FEATURES Location/Qualifiers  
source 1..1130  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1130;  
Best Local Similarity 58.3%; Pred. No. 91;  
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;  
QY 609 TCGTTGTTTATGAACTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668  
Db 1059 TCGTTTATTGTGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1118

RESULT 88  
AR219285  
LOCUS AR219285 1142 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 8 from patent US 6420157.  
ACCESSION AR219285  
VERSION AR219285.1 GI:23320255  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1142)  
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.  
TITLE Zymogen activation system  
JOURNAL Patent: US 6420157-A 8 16-JUL-2002;  
FEATURES Location/Qualifiers  
source 1..1142  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1142;  
Best Local Similarity 58.3%; Pred. No. 91;  
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;  
QY 609 TCGTTGTTTATGAACTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668  
Db 1071 TCGTTTATTGTGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1130

RESULT 89  
AR221273  
LOCUS AR221273 1166 bp DNA linear PAT 26-SEP-2002  
DEFINITION Sequence 2 from patent US 6426199.  
ACCESSION AR221273  
VERSION AR221273.1 GI:23320188  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1166)  
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.  
TITLE DNA

JOURNAL Patent: US 6426199-A 2 10-JUL-2002;  
FEATURES Location/Qualifiers  
source 1..1166  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1166;  
Best Local Similarity 58.3%; Pred. No. 91;  
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;  
QY 609 TCGTTGTTTATGAACTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668  
Db 1095 TCGTTTATTGTGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1154

RESULT 90  
AR219284  
LOCUS AR219284 1169 bp DNA linear PAT 25-SEP-2002  
DEFINITION Sequence 7 from patent US 6420157.  
ACCESSION AR219284  
VERSION AR219284.1 GI:23320254  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 1169)  
AUTHORS Darrow, A., Qi, J. and Andrade-Grodon, P.  
TITLE Zymogen activation system  
JOURNAL Patent: US 6420157-A 7 16-JUL-2002;  
FEATURES Location/Qualifiers  
source 1..1169  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 1.0%; Score 20; DB 1; Length 1169;  
Best Local Similarity 58.3%; Pred. No. 91;  
Matches 35; Conservative 0; Mismatches 25; Indels 0; Gaps 0;  
QY 609 TCGTTGTTTATGAACTGGTGACATTTGTTGGTCATACACATTAAAGATTGCAAT 668  
Db 1098 TCGTTTATTGTGAAATTTGTGCTATTGCTTTATTGTAACCATTAAGCTGCAAT 1157

RESULT 91  
AF515269/c  
LOCUS AF515269/c 1722 bp mRNA linear VRT 15-NOV-2002  
DEFINITION Danio rerio coagulation factor VIIi mRNA, complete cds.  
ACCESSION AF515269  
VERSION AF515269.1 GI:25005098  
KEYWORDS  
SOURCE Danio rerio (zebrafish)  
ORGANISM Danio rerio  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Actinopterygii; Neopterygii; Teleostei; Ostariophysi;  
Cypriniformes; Cyprinidae; Danio.

REFERENCE 1 (bases 1 to 1722)  
AUTHORS Hanumanthaiah, R., Day, K. and Jagadeeswaran, P.  
TITLE Comprehensive analysis of blood coagulation pathways in teleostei:  
Evolution of coagulation factor genes and identification of  
zebrafish factor VIIi  
JOURNAL Blood Cells Mol. Dis. (2002) In press  
REFERENCE 2 (bases 1 to 1722)  
AUTHORS Jagadeeswaran, P. and Hanumanthaiah, R.  
TITLE Direct Submission  
JOURNAL Submitted (24-MAY-2002) Cellular & Structural Biology, University  
of Texas Health Science Center at San Antonio, 7703 Floyd Curl  
Drive, San Antonio, TX 78229, USA  
FEATURES Location/Qualifiers  
source 1..1722  
/organism="Danio rerio"  
/mol\_type="mRNA"  
/db\_xref="taxon:7955"  
27..1358  
CDS

```

/notes="clotting factor"
/codon_start=1
/product="coagulation factor VIII"
/protein_id="AAN71000.1"
/db_xref="GI:25005099"
/translation="MTLGAVALLCVLTSLTSAFLSKDASALLQRRFRANSGLFE
EMKAGNLESECEVEICDVEAEVEFDDRTKQWLSYKNEKCLTNPENNGTCVYL
ASDYCLGSEGVGYCKGLBETLKQYVNGSGEQCDGSGARRSCSGEYALADD
GRSCSVQDFYPCGKIPVQKNTSONQFLGHCPRGCFWQVLDINGESVCGALDEG
PMLTAAHCVHOKDRFLKAVTGEDHLDVDSBEPYEVSAVFHPNIDETLDSLA
LURLRVFVORSYAPVLCPTPOLARSELNAARFHTLSGWTGRTAGHNLREKGLKGP
ASGTLQRLAVPLPAAQCCNANTTANMFCAGYTEGDHSCRGHDGSLVTRYGETSFL
TGVVSGRGCGPPGYIYIKVENFLIMWDTVMKNTEDKSEQIANVSTKN"

Query Match
Best Local Similarity 50.0%; Pred. No. 92;
Matches 50; Conservative 0; Mismatches 50; Indels 0; Gaps 0;

Qy 858 TTTTGGATGACAGATAGATGATCTTTGTTTTCATATCATCTCTGTACCCAGTATCT 917
Db 1354 TTTTGTAGTGAACATAGCAATCTGCTGCTCTTATCTTCAGTGTGTTGTTTCATAAC 1295

Qy 918 TTTTCTAGAGAAATTAAGATCATGATGATGATGGA 957
Db 1294 GTGTCCATCCAGATCAGGAGTCTCCACTTTAGTGATGA 1255

RESULT 92
AX587861/c
LOCUS AX587861 254 bp DNA linear PAT 10-JAN-2003
DEFINITION Sequence 331 from Patent WO0246467.
ACCESSION AX587861
VERSION AX587861.1 GI:27656555
KEYWORDS
SOURCE
ORGANISM
synthetic construct
artificial sequences.
REFERENCE
1 Bertucci,F., Houlgatte,R., Birnbaum,D., Nguyen,C., Viens,P. and
Fert,V.
AUTHORS
TITLE Gene expression profiling of primary breast carcinomas using arrays
of candidate genes
JOURNAL Patent: WO 0246467-A 331 13-JUN-2002;
Ipsogen (FR)
FEATURES
Location/Qualifiers
source
1..254
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/notes="primer"
misc_feature
1..254
/notes="3' terminal sequence, macrophage stimulating
(hepatocyte growth factor-like) (MSR1) gene."

Query Match
Best Local Similarity 1.0%; Score 19.8; DB 1; Length 254;
Matches 45; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

Qy 1042 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1101
Db 136 TGTCTTACGCGTGTCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 77

Qy 1102 TCTCCCTCTTTGATTTTTCCTGG 1128
Db 76 GCCACGCTTGATGCATATGCTTGG 50

RESULT 93
HSLKBP7/c
LOCUS HSLKBP7 268 bp DNA linear PRI 02-MAY-1998
DEFINITION Homo sapiens Peutz-Jeghers syndrome protein (LKB1) gene, exon 8.
ACCESSION AF055326
VERSION AF055326.1 GI:3063582

```

```

KEYWORDS
SEGMENT 7 of 8
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 268)
AUTHORS Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Lothe,R.A.,
Stenwig,A.E., Fossa,S.D., Salovaara,R.E. and Aaltonen,I.A.
TITLE Somatic mutations in LKB1 are rare in sporadic colorectal and
testicular tumors
JOURNAL Cancer Res. (1998)
REFERENCE 2 (bases 1 to 268)
AUTHORS Bignell,G.R., Barfoot,R., Seal,S., Collins,N., Warren,W. and
Stratton,M.R.
TITLE Low frequency of somatic mutations in the LKB1/Peutz-Jeghers
syndrome gene in sporadic breast cancer
JOURNAL Cancer Res. 58 (7), 1384-1386 (1998)
MEDLINE 9537235-
PUBMED 9537235-
REFERENCE 3 (bases 1 to 268)
AUTHORS Avizienyte,E., Roth,S., Loukola,A., Hemminki,A., Bignell,G.R.,
Warren,W., Stratton,M.R. and Aaltonen,I.A.
TITLE Direct Submission
JOURNAL Submitted (25-MAR-1998) Department of Medical Genetics, Haartman
Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3),
Helsinki FIN-00014, Finland
FEATURES
Location/Qualifiers
source
1..268
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosomes="19"
/map="19p13.3"
41..228
/genes="LKB1"
/number=8
exon
Query Match
Best Local Similarity 1.0%; Score 19.8; DB 1; Length 268;
Matches 33; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

Qy 832 TGATGCTATCCATGATGATGCTCTTTTTCGATGCACGATGATGATGATGATGATGAT 886
Db 105 TGGTGCTCGGCTCGGTGGATGGCACTGGTCTCAGCCGGAGGATGTTCTT 51

RESULT 94
BD095271/c
LOCUS BD095271 384 bp DNA linear PAT 27-AUG-2002
DEFINITION Structural coordinate and NMR chemical shift of protein and
utilization thereof.
ACCESSION BD095271
VERSION BD095271.1 GI:22640859
KEYWORDS WO 0142453-A/3.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 384)
AUTHORS Koda,D., Hiroaki,H. and Sumimoto,H.
TITLE Structural coordinate and NMR chemical shift of protein and
utilization thereof
JOURNAL Patent: WO 0142453-A 3 14-JUN-2001;
BIOMOLECULAR ENGINEERING RESEARCH INSTITUTE,DAISUKE KODA, HIDEKAZU
HIROAKI, HIDEKI SUMIMOTO
COMMENT
OS Homo sapiens (human)
PD WO 0142453-A/3
PE 01-DEC-2000 WO 2000JP008501
PR 06-DEC-1999 JP 99P 346193
PI DAISUKE KODA,HIDEKAZU HIROAKI,HIDEKI SUMIMOTO PC

```

```

/codon_start=1
/protein_id="AAA31031.1"
/db_xref="GI:164451"
/translation="SHSPTTLTRA
IVGGENAKPGQFPQVLLNGKIDA
EETEPTQRRNVIRAIPIHHSYNAT

```

REFERENCE  
1 (bases 1 to 536)  
Mammalia; Euterria; Rodentia; Sciurognathii; Muridae; Murinae; Mus.  
AUTHORS  
Wade,C.N., Kulbokas,E.J. III, Kirby,A.W., Zody,M.C., Mullikin,J.C.,  
Lander,Z.S., Lindblad-Toh,K. and Daly,M.J.  
TITLE  
The mosaic structure of variation in the laboratory mouse genome  
JOURNAL  
Nature 420 (6915), 574-578 (2002)  
PAGES  
2235-2684  
MEDLINE  
12466852  
PUBLISHED







ACCESSION D21216  
 VERSION D21216.1 GI:415304  
 KEYWORDS coagulation factor X.  
 SOURCE Mesocricetus auratus (golden hamster)  
 ORGANISM Mesocricetus auratus  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Cricetinae;  
 Mesocricetus.  
 REFERENCE 1 (bases 1 to 484)  
 AUTHORS Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.  
 TITLE Analysis of the partial nucleotide sequences and deduced primary structures of the protease domains of mammalian blood coagulation factors VII and X (3), 162-168 (1994)  
 JOURNAL Eur. J. Haematol. 52 (3), 162-168 (1994)  
 MEDLINE 94222160  
 PUBMED 8168596  
 REFERENCE 2 (bases 1 to 484)  
 AUTHORS Murakawa, M.  
 TITLE Direct Submission  
 JOURNAL Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)  
 COMMENT Submitted (18-Oct-1993) to DDBJ by:  
 Masahiro Murakawa  
 Division of Hematology  
 Harasanshin General Hospital  
 1-8 Taihaku-machi, Hakata-ku  
 Fukuoka, Fukuoka 812  
 Japan  
 Phone: 092-291-3434  
 Fax: 092-291-3266.  
 FEATURES  
 source  
 1. 484  
 /organism="Mesocricetus auratus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10036"  
 <1..>484  
 /codon\_start=2  
 /product="coagulation factor X"  
 /protein\_id="BAA04757.1"  
 /db\_xref="GI:415304"  
 /translation="EGNEMTHEDVIVKHNKVFREYDFDIARLKTPIIFRMNVP  
 ACPKDWAEATLTKSGIVSGFGRTHKGRSHLLKLEVPYVDRNTCKLSFTI  
 TONMFCAGYDAKEDACQDSGGPHYTRFKDYFVTGIVSGEGCARKGVIYKVT  
 A"  
 CDS  
 634 ATTGCTGTTGGTCATAGACATTAAAGATTGCAATGCTCTCTGGTGGATTTCCTTTGA 693  
 114 AATGATGGGGTCTTCAGCTGAGCAGCGCATGTGGAAGTCGTAGTCTCCCTCACA 55  
 694 TGCTATGTAGTATCTTCCCAATCTCATCTGCTTAGT 731  
 54 AACTTGTGTGTTTATGACGACCATGTCACCTCATGTGT 17  
 Query Match 1.0%; Score 19.6; DB 1; Length 484;  
 Best Local Similarity 50.0%; Pred. No. 1.1e+02;  
 Matches 49; Conservative 0; Mismatches 49; Indels 0; Gaps 0;  
 Oy 634 ATTGCTGTTGGTCATAGACATTAAAGATTGCAATGCTCTCTGGTGGATTTCCTTTGA 693  
 Db 114 AATGATGGGGTCTTCAGCTGAGCAGCGCATGTGGAAGTCGTAGTCTCCCTCACA 55  
 Oy 694 TGCTATGTAGTATCTTCCCAATCTCATCTGCTTAGT 731  
 Db 54 AACTTGTGTGTTTATGACGACCATGTCACCTCATGTGT 17  
 RESULT 101  
 AX193364  
 LOCUS AX193364 596 bp DNA linear PAT 15-AUG-2001  
 DEFINITION Sequence 931 from Patent WO0149716.  
 ACCESSION AX193364  
 VERSION AX193364.1 GI:15211315  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Xu, J., Lodes, M.J., Secrist, H., Benson, D.R., Meagher, M.J.,

Stolk, J.A., King, G.E., Wang, T. and Jiang, Y.  
 Compounds for immunotherapy and diagnosis of colon cancer and methods for their use  
 Patent: WO 0149716-A 931 12-JUL-2001;  
 CORIXA CORPORATION (US)  
 FEATURES  
 source  
 1. 596  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 1.0%; Score 19.6; DB 1; Length 596;  
 Best Local Similarity 58.6%; Pred. No. 1.1e+02;  
 Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
 Oy 621 GAACCTGGGTGACATGCTGTTGGTGCATAGACATTGCAATGCTCTCTTGG 678  
 Db 122 GATGTAGCGGAGAGGTGATGGTCTGCTGAGTGGAGAGTGCATGTCGCCCTGG 179  
 RESULT 102  
 AX763043  
 LOCUS AX763043 609 bp DNA linear PAT 25-JUN-2003  
 DEFINITION Sequence 37 from Patent WO03040393.  
 ACCESSION AX763043  
 VERSION AX763043.1 GI:32257659  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Martinez, R.A. and Sigurdsson, G.T.  
 TITLE Nucleic acids encoding proteases  
 JOURNAL Patent: WO 03040393-A 37 15-MAY-2003;  
 Decode Genetics EHF. (IS)  
 FEATURES  
 source  
 1. 609  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"  
 Query Match 1.0%; Score 19.6; DB 1; Length 609;  
 Best Local Similarity 54.1%; Pred. No. 1.1e+02;  
 Matches 40; Conservative 0; Mismatches 34; Indels 0; Gaps 0;  
 Oy 329 ATTATTCAATGCTCTTTATCTGTCGAGACTGCTTGTGTTTGAATATGTTCAATT 388  
 142 ATTATTGCCATATATAGATCATGCTGTGGCCCTTTGTTTTCAAATTCCTCATT 201  
 Oy 389 TTGGAGAGTTTCAT 402  
 Db 202 TGGATGGGAACAT 215  
 RESULT 103  
 HUMCFIX/c  
 LOCUS HUMCFIX 873 bp mRNA linear PRI 01-NOV-1994  
 DEFINITION Human coagulation factor IX mRNA, partial cds.  
 ACCESSION M35672  
 VERSION M35672.1 GI:180287  
 KEYWORDS coagulation factor IX; serine protease.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 873)  
 AUTHORS Jagadeeswaran, P., Lavelle, D.E., Kaul, R., Mohandas, T. and Warren, S.T.  
 TITLE Isolation and characterization of human factor IX cDNA: identification of Tag I polymorphism and regional assignment  
 JOURNAL Somat. Cell Mol. Genet. 10 (5), 465-473 (1984)  
 MEDLINE 84300526

PUBMED 6089357  
COMMENT source text: Human adult liver, cDNA to mRNA.  
FEATURES Location/Qualifiers

source 1..873

organism="Homo sapiens"

/mol\_type="mRNA"

/db\_xref="taxon:9606"

/map="xq26.3-q27.1"

1..873

/gene="F9"

<1..873

/gene="F9"

/note="Coagulation factor IX"

/codon\_start=1

/protein\_id="AA51981.1"

/db\_xref="GI:180288"

/db\_xref="GDB:600-119-900"

/translation="NANKILRPRKYSKLEEFVQGNLRRCMEKSCFEEAREVFE

NTERTEFWQYVDQDQESNPLGNSCKDINSYECWPGFEGKNCGLDVTGNK

NGRCQFCNKSADNVCSCTEGYRLAENKSCPEAPVPPGGRVSVQSKLTRAETV

FPDQVNSTAEATILDNITQSTQSFNDFTRVGGEDAKQGFPMQWLNKGVDAFCG

GSIVNEKWTVTAAHCVETGVKITVVGAEHNEETEHEQXRVIRIIPHNYNAINK

YNHDLALLEDEPLV"

Query Match 1.0%; Score 19.6; DB 1; Length 873;

Best Local Similarity 56.1%; Pred. No. 1.1e+02;

Matches 37; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1830 TTGGGTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGTGTTTATTATTC 1889

Db 552 TTGGGTCCTTTCAGTCATGTTATCCAAATGTTTCAGTTCAGTAGAATTACATGATC 493

QY 1890 TATTTT 1895

Db 492 CACATC 487

RESULT 104

AX675583/c

LOCUS

Sequence 33 from Patent WO02055704.

AX675583

AX675583.1

GI:29333568

Version

Keywords

Source

Organism

Homo sapiens

(human)

REFERENCE

1

Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,

Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,

Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,

Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,

Edingermark, S., Rotherberg, M.E., Ellerman, K., Macdougall, J.,

Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and

Stone, D.J.

Proteins, polynucleotides encoding them and methods of using the

same

Patent: WO 02055704-A 33 18-JUL-2002;

Curagen Corporation (US)

Location/Qualifiers

1..882

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

source

Query Match

Best Local Similarity 1.0%; Score 19.6; DB 1; Length 882;

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATGTTGTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678

Db 369 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTCAATGTCGCCCTGG 312

RESULT 105

AX219285/c

LOCUS

Sequence 8 from patent US 6420157.

AX219285

AX219285.1

GI:23320255

Version

Keywords

Source

Organism

Unknown.

Unclassified.

1 (bases 1 to 1142)

Darrow, A., Qi, J. and Andrade-Gordon, P.

Zymogen activation system

Patent: US 6420157-A 8 16-JUL-2002;

Location/Qualifiers

1..1142

/organism="unknown"

/mol\_type="genomic DNA"

source

Query Match

Best Local Similarity 1.0%; Score 19.6; DB 1; Length 1142;

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATGTTGTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678

Db 456 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTCAATGTCGCCCTGG 399

RESULT 106

AX675581/c

LOCUS

Sequence 31 from Patent WO02055704.

AX675581

AX675581.1

GI:29333567

Version

Keywords

Source

Organism

Homo sapiens

(human)

REFERENCE

1

Padigaru, M., Li, L., Zerhusen, B.D., Casman, S.J., Shenoy, S.,

Spytek, K.A., Zhong, M., Gangolli, E.A., Burgess, C.E., Patturajan, M.,

Vernet, C.A., Taylor, S., Tchernev, V.T., Miller, C.E., Guo, X.,

Boldog, F.L., Grosse, W.M., Alsobrook, J.P., Gerlach, V.,

Edingermark, S., Rotherberg, M.E., Ellerman, K., Macdougall, J.,

Malyankar, U., Millet, I., Peyman, J., Smithson, G., Gunther, E. and

Stone, D.J.

Proteins, polynucleotides encoding them and methods of using the

same

Patent: WO 02055704-A 31 18-JUL-2002;

Curagen Corporation (US)

Location/Qualifiers

1..1161

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

source

Query Match

Best Local Similarity 1.0%; Score 19.6; DB 1; Length 1161;

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATGTTGTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678

Db 657 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTCAATGTCGCCCTGG 600

RESULT 107

AX219284/c

LOCUS

Sequence 7 from patent US 6420157.

AX219284

AX219284

Version

Keywords

Source

Organism

Unknown.

Unclassified.

1 (bases 1 to 1169)

Darrow, A., Qi, J. and Andrade-Gordon, P.

Zymogen activation system

Patent: US 6420157-A 8 16-JUL-2002;

Location/Qualifiers

1..1169

/organism="unknown"

/mol\_type="genomic DNA"

source

Query Match

Best Local Similarity 1.0%; Score 19.6; DB 1; Length 1169;

Matches 34; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 621 GAACCTGGGTGACATGTTGTTGGTCATAGACATTAAGAAATGCAATGCTCTTGG 678

Db 657 GATGTAGCGGAGAGGGTCTGCTGAGTTGGAGGAGTCAATGTCGCCCTGG 600



```
RESULT 111
E27213
LOCUS
DEFINITION Novel physiologically active substance, process for producing the
same and utilization thereof.
ACCESSION E27213
VERSION E27213.1 GI:13025230
KEYWORDS JP 1999009286-A/4.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 177)
AUTHORS Shuji H. and Shoji F.
TITLE Novel physiologically active substance, process for producing the
same and utilization thereof
JOURNAL Patent: JP 1999009286-A 4 19-JAN-1999;
TAKEDA CHEM IND LTD
COMMENT PN JP 1999009286-A/4
PD 19-JAN-1999
PF 27-APR-1998 JP 1998117189
PR
PI SHUJI HINUMA, SHUJI FUKUZUMI
PC C12N15/09, A01K67/027, A61K38/00, A61K38/00, C07K14/47, C07K16/18,
PC C12N1/21,
PC C12N5/10, C12P21/02, G01N33/53, G01N33/577//C12P21/08, (C12N15/09,
PC C12R1:91),
PC (C12N1/21, C12R1:19), (C12N5/10, C12R1:91), (C12P21/02, C12R1:19),
PC C12N15/00,
PC A61K37/02, A61K37/02, C12N5/00, (C12N15/00, C12R1:91), (C12N5/00,
PC C12R1:91)
CC Strandedness: Double;
CC Topology: Linear;
FH Key 1..177
FT source Location/Qualifiers
FEATURES
source
Location/Qualifiers
1..177
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGTGTTTGCATAGTGTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCTCTCTCTCTCTCTCTCTCTCTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 113
AR300928
LOCUS
DEFINITION Sequence 30 from patent US 6538107.
ACCESSION AR300928
VERSION AR300928.1 GI:31688601
KEYWORDS
SOURCE Unknown.
ORGANISM Unknown.
REFERENCE 1 (bases 1 to 177)
AUTHORS Hinuma, S., Ito, Y. and Fujii, R.
TITLE G protein coupled receptor protein production, and use thereof
JOURNAL Patent: US 6538107-A 30 25-MAR-2003;
FEATURES
source
Location/Qualifiers
1..177
/organism="unknown"
/mol_type="mRNA"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGTGTTTGCATAGTGTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCTCTCTCTCTCTCTCTCTCTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 114
AR109885
LOCUS
DEFINITION Sequence 310 from patent US 6114139.
ACCESSION AR109885
VERSION AR109885.1 GI:12826161
KEYWORDS
SOURCE AR109885
PD 16-MAR-1999
PF 22-JUN-1998 JP 1998175007
PR
PI SHUJI HINUMA, RYO FUJII, YUJI KAWAMATA, HIROKAZU MATSUMOTO PC
A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, A61K38/00, PC
A61K38/00,
PC A61K38/00, A61K38/00, C07K7/08, C07K14/705//C12N15/09, C12P21/02,
PC (C12P21/02, C12R1:91), A61K37/02, A61K37/02, A61K37/02, A61K37/02,
PC A61K37/02,
PC A61K37/02, A61K37/02, A61K37/02, A61K37/02, C12N15/00 CC
Strandedness: Double;
CC Topology: Linear;
FH Key 1..177
FT source Location/Qualifiers
FEATURES
source
Location/Qualifiers
1..177
/organism="unidentified"
/mol_type="genomic DNA"
/db_xref="taxon:32644"
Query Match 1.0%; Score 19.4; DB 1; Length 177;
Best Local Similarity 57.4%; Pred. No. 1.1e+02;
Matches 35; Conservative 0; Mismatches 26; Indels 0; Gaps 0;
Qy 1621 CTGCTTTGACCTGCTTCTCCCTTCTCTATTCCTTGTGTTTGCATAGTGTCT 1680
Db 7 CTGCTGTCACCTACCTGCTCTCTCTGCTGTCATCTCTCTCTCTCTCTCTCTCTCA 66
Qy 1681 G 1681
Db 67 G 67
RESULT 115
E28271
LOCUS
DEFINITION Utilization of peptide.
ACCESSION E28271
VERSION E28271.1 GI:13025305
KEYWORDS JP 1999071300-A/11.
SOURCE unclassified
ORGANISM unclassified
REFERENCE 1 (bases 1 to 177)
AUTHORS Shuji, H., Ryo, F., Yuji, K. and Hirokazu, M.
TITLE Utilization of peptide
JOURNAL Patent: JP 1999071300-A 11 16-MAR-1999;
TAKEDA CHEM IND LTD
COMMENT OS Unidentified
PN JP 1999071300-A/11
```

**TITLE** cDNA and genomic clones of *Festuca arundinacea* and *Lolium*  
**JOURNAL** multiflorum  
**REFERENCE** Unpublished  
**AUTHORS** 2 (bases 1 to 249)  
**TITLE** Bettany,A.J.E.  
**JOURNAL** Direct Submission  
Submitted (13-OCT-2003) Bettany A.J.E., Plant, Animal & Microbial  
Science, Inst. Grassland & Environmental Research, Plas Gogerddan,  
Aberystwyth, Ceredigion SY23 3EB, UNITED KINGDOM  
**FEATURES** Location/Qualifiers  
source  
1..249  
/organism="Lolium multiflorum"  
/mol\_type="mRNA"  
/cultivar="Trident"  
/db\_xref="taxon:4521"  
/tissue\_type="young leaves with leaf bases"  
/dev\_stage="seedlings"  
1..249  
/feature="4cl"  
<1..>249  
/feature="4cl"  
/EC\_number="6.2.1.12"  
/function="activation of thioester substrates for  
phenylpropanoid synthesis"  
/codon\_start=3  
/product="putative 4-coumarate coA ligase"  
/protein\_id="CAE51892.1"  
/db\_xref="GI:37805459"  
/translation="PFVKYSGSCSTVVRNAELKVDPDTCASLGRNQPGEICVRGKQI  
MLGYLNPSTXNTDKDGLWHTGDIGLVDDDEIFIV"  
Query Match 1.0%; Score 19.4; DB 1; Length 249;  
Best Local Similarity 50.4%; Pred. No. 1.1e+02;  
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
**QY** 1786 TATCTCTTGTATTCGTGTAGTAGAGCGTTGTCTCTGAGGTTCTCTTGCGTTCT 1838  
**DB** 210 TGTCCTCGGTGTGCAGCCAGCGCTCTTGTGATGGTGTCTTGTCGACTCT 158  
  
**RESULT 117**  
**AX839191/c**  
**LOCUS** AX839191 230 bp DNA linear PAT 15-DEC-2003  
**DEFINITION** Sequence 34 from Patent WO03076610.  
**ACCESSION** AX839191  
**VERSION** AX839191.1 GI:39922640  
**KEYWORDS**  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
**REFERENCE**  
**AUTHORS** 1 Bracco,L., Brinkman,B. and Coignard,F.  
**TITLE** Variants of human kallikrein-2 and kallikrein-3 and uses thereof  
**JOURNAL** Patent: WO 03076610-A 34 18-SEP-2003;  
Exonhit Therapeutics S.A. (FR)  
**FEATURES** Location/Qualifiers  
source  
1..290  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 1.0%; Score 19.4; DB 1; Length 290;  
Best Local Similarity 55.1%; Pred. No. 1.2e+02;  
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;  
**QY** 111 TCTCTCTCCCTTTCTCTAACACTTCTGGCCAGGTTAGGGGACATACCGCATTCCTC 170  
**DB** 113 TCTCGACTCCAGCTCCCACTCCAGACAGGATGAGGGTGCAGCACCATCCAG 54  
  
**QY** 171 TCTCTTCCA 179  
**DB** 53 TCACGGACA 45



```

ACCESSION M26233
VERSION M26233.1 GI:165878
KEYWORDS factor IX
SOURCE Ovis aries (sheep)
ORGANISM Ovis aries
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
Bovidae; Caprinae; Ovis.
REFERENCE 1 (bases 1 to 823)
AUTHORS Sarkar, G., Koerber, D.D. and Sommer, S.S.
TITLE Direct sequencing of the activation peptide and the catalytic
domain of the factor IX gene in six species
JOURNAL Genomics 6 (1), 133-143 (1990)
MEDLINE 90152675
PUBMED 2303254
COMMENT Original source text: Sheep liver, cDNA to mRNA.
Draft entry and computer-readable sequence for [1] kindly provided
by G.Sarkar, 18-JUL-1989.
FEATURES
source
1..823
/organism="Ovis aries"
/mol_type="mRNA"
/db_xref="taxon:9940"
<1..>823
/notes="factor IX"
/codon_start=1
/protein_id="AA31520.1"
/db_xref="GI:552419"
/translation="RASVLTSTKLTTRAETIFSNMVENSEAEIWDNVTQNSQFD
DFNRVGGEDAAAGQFPWQLLGEIAAFCGSGIVNEKVVTAHCIKGKIVTVAG
EHTKEPTEQKRNIVRAIPHYGNASINKYSHDLALLEDFELNSVYTPICIAI
REYTNILKFGYGVSGWVRNRSASILQYKVLVDRAICLARTFTIYNHMF
AGYHEGKDCSQDGGPHVTEVGTSLGIIISWGEACAMKGYIKYTKVSRVEY"
Query Match 1.0%; Score 19.4; DB 1; Length 823;
Best Local Similarity 55.1%; Pred. No. 1.3e+02;
Matches 38; Conservative 0; Mismatches 31; Indels 0; Gaps 0;
Qy 1569 TTTCTCAAGGTAGCAAAATTTCTTTTGGTTTCTTGAATAATTTCCCTGCTTT 1628
Db 93 TATTTTCACTTCAAGAAATTTTATAGTTCATATTCGAAATAATAGTCTCAGCAGGT 34
Qy 1629 GACCTGCT 1637
Db 33 GAGCTTCT 25
RESULT 122
BC061135/c
LOCUS BC061135 829 bp mRNA linear ROD 25-NOV-2003
DEFINITION Mus musculus trypsin 4, mRNA (cDNA clone MGC:74265 IMAGE:30306436),
complete cds.
ACCESSION BC061135
VERSION BC061135.1 GI:38511692
KEYWORDS MGC.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 829)
Straussberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G.,
Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D.,
Altshuler, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K.,
Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F.,
Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L.,
Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L.,
Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S.,
Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J.,
McKernan, R.D., Mullany, S.J., Bosak, S.A., McEwan, P.J.,
McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S.,
Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W.,
Villalón, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A.,
Fahey, J., Helton, E., Kettman, M., Madan, A., Rodriguez, S.,

```

```

TITLE human and mouse cDNA sequences
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)
MEDLINE 22388257
PUBMED 12477932
REFERENCE 2 (bases 1 to 829)
AUTHORS Straussberg, R.
TITLE Direct Submission
JOURNAL Submitted (03-NOV-2003) National Institutes of Health, Mammalian
Gene Collection (MGC), Cancer Genomics Office, National Cancer
Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590,
USA
REMARK NIH-MGC Project URL: http://mgc.mci.nih.gov
COMMENT Contact: MGC help desk
Email: cgabbs@mail.nih.gov
Tissue procurement: Dr. Michael Brownstein
CDNA Library Preparation: Michael Brownstein / Ted Usdin
Laboratory
CDNA Library Arrayed by: The I.M.A.G.E. Consortium (LNL)
DNA Sequencing by: Sequencing Group at the Stanford Human Genome
Center, Stanford University School of Medicine, Stanford, CA 94305
Web site: http://www-shgc.stanford.edu
Contact: (Dickson, Mark) mcd@paxil.stanford.edu
Dickson, M., Schmutz, J., Grimwood, J., Rodriguez, A., and Myers,
R. M.
Clone distribution: MGC clone distribution information can be found
through the I.M.A.G.E. Consortium/LLNL at: http://image.llnl.gov
Series: IRAL Plate: 53 Row: 0 Column: 2
This clone was selected for full length sequencing because it
passed the following selection criteria: matched mRNA gi: 6755892.
FEATURES
source
1..829
/organism="Mus musculus"
/mol_type="mRNA"
/db_xref="taxon:10090"
/clone="MGC:74265 IMAGE:30306436"
/tissue_type="Liver, mouse"
/clone_lib="NIH MGC_177"
/lab_host="DH10B"
/notes="Vector: pDNR-LTB"
1..829
/genes="Try4"
/notes="synonyms: 0910001B19rik, Tc"
/db_xref="locusid:22074"
/db_xref="MGI:102757"
14..754
/codon_start=1
/product="trypsin 4"
/protein_id="AAH61135.1"
/db_xref="GI:38511693"
/db_xref="LocusID:22074"
/translation="MRALLFLALVGAFAVPVDDDDKLVGGVTCRENSVPYQVSLNSG
YHFCGSGTINDQWVYSAARCYKSRIOVRLEHINIVLENGEQVNSAKIHKPFNSR
TLNNIMLIKASPVTLNARVATVALPSSCAPAGTQCLTSGMTLSFGVNNPDLQ
LDAPLPQADCEASVPGKITNNMICVGFLEGGKDCSQDGGPHVTEVGTSLGIIISW
GCALKDNPQVYTKVCNVYDWIQTIAAN"
misc_feature 83..739
/notes="tryp_SPC; Region: Trypsin-like serine protease"
/db_xref="CDS:cd00190"
Query Match 1.0%; Score 19.4; DB 1; Length 829;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;
Qy 1587 TTTTCTTTTGGTTTCTTGAATAATTTTCCCTGCTTTTACCTGCTTC 1639
Db 817 TTTTCTTTTGGTTTCTTGAATAATTTTCCCTGCTTTTACCTGCTTC 765

```



```

RESULT 123
AR095306/c
LOCUS
DEFINITION Sequence 27 from patent US 6004555.
ACCESSION AR095306
VERSION AR095306.1 GI:10023064
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 1126)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods for the specific coagulation of vasculature
JOURNAL Patent: US 6004555-A 27 21-DEC-1999;
FEATURES
    source
        Location/Qualifiers
            1..1126
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match
Best Local Similarity 1.0%; Score 19.4; DB 1; Length 1126;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGTCACCTAGCTTTATGACATGAGTTCCTCC 495
Db 596 TTGTGACCGTTGTGCTTGTGATGACCACTCCACCTCGTGCACCGCTCACCGCCCTCC 537
QY 496 AGCATTTCTCTGTTTCTGTTTGTGTGATGACCTAATCTTGTGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480

RESULT 124
AR103990/c
LOCUS
DEFINITION Sequence 27 from patent US 6093399.
ACCESSION AR103990
VERSION AR103990.1 GI:12816698
KEYWORDS
SOURCE
ORGANISM
REFERENCE 1 (bases 1 to 1126)
AUTHORS Thorpe,P.E. and Edgington,T.S.
TITLE Methods and compositions for the specific coagulation of
JOURNAL vasculature
FEATURES
    source
        Location/Qualifiers
            1..1126
            /organism="unknown"
            /mol_type="unassigned DNA"
Query Match
Best Local Similarity 1.0%; Score 19.4; DB 1; Length 1126;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGTCACCTAGCTTTATGACATGAGTTCCTCC 495
Db 596 TTGTGACCGTTGTGCTTGTGATGACCACTCCACCTCGTGCACCGCTCACCGCCCTCC 537
QY 496 AGCATTTCTCTGTTTCTGTTTGTGTGATGACCTAATCTTGTGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480

RESULT 125
HUMEX/c
LOCUS
DEFINITION Human factor X mRNA.
ACCESSION K01886
VERSION K01886.1 GI:182820

```

```

KEYWORDS Stuart factor; factor X; serine protease.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
REFERENCE 1 (bases 1 to 1126)
AUTHORS Mammalia; Eutheria; Primates; Catarhini; Hominidae; Homo.
TITLE Leytus,S.P., Chung,D.W., Kiesel,W., Kurachi,K. and Davie,E.W.
JOURNAL Characterization of a cDNA coding for human factor X
MEDLINE Proc Natl. Acad. Sci. U.S.A. 81 (12), 3699-3702 (1984)
84222026
PUBMED 8587384
COMMENT Original source text: Human liver, cDNA to mRNA, clone
        lambda-X-1137.
        In processing, factor X (Stuart factor) is converted to Xa by
        cleavage of a glycopeptide from the amino-terminal end of the heavy
        chain. It then acts as a serine protease in converting prothrombin
        to thrombin.
FEATURES
    source
        Location/Qualifiers
            1..1126
            /organism="Homo sapiens"
            /mol_type="mRNA"
            /db_xref="taxon:9606"
            /map="13q34"
            1..1126
            /gene="F10"
            <1..1126
            /gene="F10"
            /product="factor X mRNA"
            <1..1116
            /gene="F10"
            /note="factor X precursor peptide"
            /codon_start=1
            /protein_id="AAA52486.1"
            /db_xref="GI:182821"
            /db_xref="GDB:G00-119-890"
            /translation="GFECKNCELTRKLCSLDNGDCDFCHEONSVVCSARGVTLA
            DNGKACITGPYPCKQKQLERRKSVAGATSSSEAPDSITWKPYDAADLPDENPFD
            LLDNQTPERGDNNLRIVGGCKGCEGWQALLINEEGFCGGTILSEFVLTA
            AHCLYQARFEGDRNTEQEGGEAVHEVVEVVKINRFTKETDFDIARLKTPTFR
            MNVAPACLPERDWAESTLMTQKTGIVSGRTHKRGQSLKMLEVPYVDRNSCKLS
            SSFIITQMFCAVDYTKQEDACQDGSQSPHVRFDYFVTGIVSWGEGCARKKYGI
            YTKVTAFLKWDIRSNMKTGLPKAKSHAPEVITSSPLK"
            <1..195
            /gene="F10"
            /product="factor X light chain"
            205..1113
            /gene="F10"
            /product="factor X heavy chain"
            361..1113
            /gene="F10"
            /product="factor Xa heavy chain"
Query Match
Best Local Similarity 1.0%; Score 19.4; DB 1; Length 1126;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;
QY 436 TTGGTGAATAGTCTGTAATAATCTCTAGGTCACCTAGCTTTATGACATGAGTTCCTCC 495
Db 596 TTGTGACCGTTGTGCTTGTGATGACCACTCCACCTCGTGCACCGCTCACCGCCCTCC 537
QY 496 AGCATTTCTCTGTTTCTGTTTGTGTGATGACCTAATCTTGTGAGAGATGGGCT 552
Db 536 TCCTGCTCCGTTGTCGGTCCCTTCGAATCTCTTGGCTTGTAGACAGTGGCT 480

RESULT 126
A93124/c
LOCUS
DEFINITION Sequence 15 from Patent WO9747737.
ACCESSION A93124
VERSION A93124.1 GI:6741514
KEYWORDS
SOURCE unidentified

```



```
ORGANISM      unidentified
REFERENCE     1 (bases 1 to 1404)
AUTHORS       Kopeckzi, E. and Hopfner, K.
TITLE         RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL       Patent: WO 9747737-A 15 DEC-1997;
              KOPETZKI ERHARD (DE); BOEHRINGER MANNHEIM GMBH (DE)
FEATURES      Location/Qualifiers
             1..1404
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match   1.0%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 436 TTGGTGAATAGTCTGTAATATCTCTAGGTCACCTTGTGTTATGACATCAGTTAGTCC 495
      |||||
DB 884 TTGTGAACCGTGTGCTGTGATGACACCTCCACCTCGTCCACCGCTCCACCGCTCC 825
      |||||
QY 496 AGCATTTCTCTGTTGCTGTTTTGTTGATGACCTAACTCTTGAGAGAGAAATGGGT 552
      |||||
DB 824 TCTGCTCCGTTTCGGTCCCTTCGAATCTCTGCTTGGTTGATAGACAGTGGCT 768
      |||||

RESULT 127
HUMCFX/c      HUMCFX      1414 bp      mRNA      linear      PRI 01-NOV-1994
LOCUS         Human blood-coagulation factor X mRNA, complete cds.
DEFINITION    M22613
ACCESSION     M22613
VERSION       M22613.1 GI:180335
KEYWORDS      coagulation factor X.
SOURCE        Homo sapiens (human)
ORGANISM      Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE     1 (bases 1 to 1414)
AUTHORS       Kaul, R.K., Hildebrand, B., Roberts, S. and Jagadeeswaran, P.
TITLE         Isolation and characterization of human blood-coagulation factor X
              cDNA
JOURNAL       Gene 41 (2-3), 311-314 (1986)
MEDLINE       86221713
PUBMED        3011603
COMMENT       Original
FEATURES      Location/Qualifiers
             1..1414
                /organism="Homo sapiens"
                /mol_type="mRNA"
                /db_xref="taxon:9606"
                /map="113q34"
             1..1414
                /gene="F10"
                /gene="F10"
                /product="coagulation factor X mRNA"
                /gene="F10"
                /note="coagulation factor X precursor"
                /codon_start=1
                /protein_id="AA51984.1"
                /db_xref="GI:180336"
                /db_xref="GDB:G00-119-890"
                /translation="LIGESLFIREFQANILARVTRANSFLEEMKXGLHRECEMETC
              SYEAREVZSDKTFNFWKYKDGQCEPQCNQKCKDGLGEYTCCLGEPGKN
              CELFLKSLDNGCDQFCHEONSVCSCARGYTLADNGKACIPTPGPGKQTL
              RKRVAQATSSGGEAPDSITWKPYDAADLPTEPNPDLLFNQTOPERGDNLRTV
              GGCEKDGCPQWALLNENEGFCGGTILSEFYILFAHCLYQAKSGEDRNTQEE
              GGSAVEVEVINGHNFRTKETDYFDIIVLRKPTITFRNVAFLCFERDWAESTLMT
              KQTGVSGGPRTHKQRSLKMLEVYVDRNSCKLSSFIITONMFCAGYDTKQD
              ACQDGGGPHVTRFKDQTYGVTSVWGSGCAKRGKYIYTKVTAFLKWDIRSMKTRGL
              PKAKSHAPEVITSSPLK"
             <1..56
sig_peptide

ORGANISM      unidentified
REFERENCE     1 (bases 1 to 1404)
AUTHORS       Kopeckzi, E. and Hopfner, K.
TITLE         RECOMBINANT BLOOD-COAGULATION PROTEASES
JOURNAL       Patent: WO 9747737-A 15 DEC-1997;
              KOPETZKI ERHARD (DE); BOEHRINGER MANNHEIM GMBH (DE)
FEATURES      Location/Qualifiers
             1..1404
                /organism="unidentified"
                /mol_type="unassigned DNA"
                /db_xref="taxon:32644"

Query Match   1.0%; Score 19.4; DB 1; Length 1404;
Best Local Similarity 47.9%; Pred. No. 1.3e+02;
Matches 56; Conservative 0; Mismatches 61; Indels 0; Gaps 0;

QY 436 TTGGTGAATAGTCTGTAATATCTCTAGGTCACCTTGTGTTATGACATCAGTTAGTCC 495
      |||||
DB 884 TTGTGAACCGTGTGCTGTGATGACACCTCCACCTCGTCCACCGCTCCACCGCTCC 825
      |||||
QY 496 AGCATTTCTCTGTTGCTGTTTTGTTGATGACCTAACTCTTGAGAGAGAAATGGGT 552
      |||||
DB 824 TCTGCTCCGTTTCGGTCCCTTCGAATCTCTGCTTGGTTGATAGACAGTGGCT 768
      |||||

RESULT 128
AXI47505      AXI47505      1551 bp      DNA      linear      PAT 08-JUN-2001
LOCUS         Sequence 59 from Patent WO0136632.
DEFINITION    AXI47505
ACCESSION     AXI47505
VERSION       AXI47505.1 GI:14346662
KEYWORDS      Homo sapiens (human)
SOURCE        Homo sapiens
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
REFERENCE     1
AUTHORS       Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.
TITLE         Variants of alternative splicing
              Patent: WO 0136632-A 59 25-MAY-2001;
              Compugen Ltd. (IL)
FEATURES      Location/Qualifiers
             1..1551
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match   1.0%; Score 19.4; DB 1; Length 1551;
Best Local Similarity 60.4%; Pred. No. 1.3e+02;
Matches 32; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

QY 1042 TGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1094
      |||||
DB 1448 TGCATGTCGCGCTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGTGT 1500
      |||||

RESULT 129
MMU44795      MMU44795      1850 bp      mRNA      linear      ROD 23-MAY-1996
LOCUS         Mus musculus coagulation factor VII (FVII) mRNA, complete cds.
DEFINITION    U44795
ACCESSION     U44795
VERSION       U44795.1 GI:1184738
KEYWORDS      Mus musculus (house mouse)
SOURCE        Mus musculus
              Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
              Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
              1 (bases 1 to 1850)
REFERENCE     1
AUTHORS       Idusogie, E., Rosen, E., Geng, J.P., Carmeliet, P., Collen, D. and
              Castellino, F.J.
TITLE         Characterization of a cDNA encoding murine coagulation factor VII
              Thromb. Haemost. 75 (3), 481-487 (1996)
JOURNAL       96276538
MEDLINE
```



[illegible]

Murakawa, M., Okamura, T., Kamura, T., Kuroiwa, M., Harada, M. and Niho, Y.  
 A comparative study of partial primary structures of the catalytic region of mammalian protein C  
 Br. J. Haematol. 86 (3), 590-600 (1994)  
 94318474  
 PUBMED  
 8043441  
 2 (bases 1 to 471)  
 Murakawa, M.  
 Direct Submission  
 Submitted (06-DEC-1994) Masahiro Murakawa, Harasanshin General Hospital, Division of Hematology; 1-8 Taihaku-machi, Hakata-ku, Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)  
 Location/Qualifiers  
 1. 471  
 /organism="Capra hircus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9925"  
 <1..>471  
 /function="regulation of blood coagulation"  
 /note="catalytic region"  
 /codon\_start=1  
 /product="protein C"  
 /protein\_id="BAA07809.1"  
 /db\_xref="GI:1304982"  
 /translation="ESWEDVDLKEVIVRENYKTSDDNDIALHLAKPATLSQIVP  
 ICLPDSGERLKTGVGGTGVTVGWGYRDTKKRISILNFIKIPVVSINACVHAWEN  
 KVSNNLCAGILNPRDACEGSGPMVTFRTGFLVGLVSGEGCGGLNNYGI"  
 Query Match 1.0%; Score 19.2; DB 1; Length 471;  
 Best Local Similarity 50.0%; Pred. No. 1.4e+02;  
 Matches 48; Conservative 0; Mismatches 48; Indels 0; Gaps 0;  
 QY 1732 GACCRAGGATCCATTCTTCTATCTGTCTCTCACTGCCTGAGATCTCTCTATCTC 1791  
 DB 246 GATGAGGGTCCGGTTTCTTGCTCTGACGGTAGCCCGAGCTGCACCAAGTCTC 187  
 QY 1792 TTGTATTCTGTCTGAGTGAGCTTGTCTCTGAGGTTC 1827  
 DB 186 CTGCGCGACTGAGTGAGTGGTTCGCTCAGAGAGCC 151  
 RESULT 133  
 BV094002/c  
 LOCUS  
 DEFINITION  
 BV094002  
 BV094002.1 GI:37671481  
 STS.  
 Mus musculus (house mouse)  
 ORGANISM  
 Mus musculus  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
 1 (bases 1 to 596)  
 Usuka, J., Liao, G., Cheng, J., Nguyen, A., Bach, C., Puech, A.,  
 McPherson, J. D., Foerzner, D. and Peltz, G.  
 Mus musculus SNPs  
 Unpublished (2003)  
 TITLE  
 JOURNAL  
 COMMENT  
 Contact: Jonathan Usuka  
 Roche Palo Alto Genetics and Genomics Department  
 Roche Palo Alto  
 3431 Hillview Ave, Mailstop S3-1, Palo Alto, CA 94024, USA  
 Tel: 6508555807  
 Email: Jonathan.Usuka@roche.com  
 Primer A: No primer submitted  
 Primer B: No primer submitted.  
 Location/Qualifiers  
 1. 596  
 /organism="Mus musculus"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:10090"  
 FEATURES  
 source

```

/map="18-10064-9474-AC126686.3.1.232817"
/clone_lib="Roche Palo Alto"
/notes="SNPs developed from assay sequences derived from 15
different strains of mice (as of October 1, 2003). Those
strains include A/J, A/HeJ, -129/Sv, AKR/J, B10.D2-H2/OsNj,
BALB/cByJ, BALB/cJ, C3H/HeJ, C57BL/6J, -CAST/Ei, DBA/2J,
MEL/MpJ, NZB/BinJ, NZW/LaC, SPRET/Ei, -"
<1..5596

STS
Query Match 1.0%; Score 19.2; DB 1; Length 596;
Best Local Similarity 49.5%; Pred. No. 1.4e+02;
Matches 48; Conservative 0; Mismatches 49; Indels 0; Gaps 0;

QY 191 TTCTGATTTCTATCTTGGCTCAATTTAACTCAGTAGTGAGTTGTTGTTCCATAAG 250
Db 555 TTCTGCTCTNAAGGAGACACCTTTTCCCAATGTAAGTGAATCCATTGAGGTAG 496
QY 251 TTGTGAAGTTTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT 287
Db 495 CTCCACCTTGGTGTAGTCCATAGTTGTTGTTGT 459

RESULT 134
LOCUS RAETHRO 826 bp mRNA linear MAM 08-MAY-1993
DEFINITION Oryctolagus cuniculus thrombin mRNA, 3' end.
ACCESSION M81396
VERSION M81396.1 GI:165740
KEYWORDS thrombin.
SOURCE Oryctolagus cuniculus (rabbit)
ORGANISM Oryctolagus cuniculus
REFERENCE 1 (bases 1 to 826)
AUTHORS Bankfield,D.K. and MacGillivray,R.T.
TITLE Partial characterization of vertebrate prothrombin cDNAs:
amplification and sequence analysis of the B chain of thrombin from
nine different species
JOURNAL Proc. Natl. Acad. Sci. U.S.A. 89 (7), 2779-2783 (1992)
MEDLINE 92212913
PUBMED 1557383
COMMENT Original source text: Oryctolagus cuniculus adult liver cDNA to
mRNA.
FEATURES
source
Location/Qualifiers
1..826
/organism="Oryctolagus cuniculus"
/mol_type="mRNA"
/db_xref="taxon:9986"
/tissue_type="liver"
/dev_stages="adult"
1..826
/gene="thrombin"
<1..708
/gene="thrombin"
/codon_start=1
/product="thrombin"
/db_xref="GI:165741"
/translation="QELLCAASLISDRWLTAACHLLYPFPDKNFTVNDILVRIGKYA
RSRYRNMEKISTLEKIIHPGVNWRNEDRLMKLPKVPFADYIHPVCLPKQI
VTSLLAQHGKRTGVCNGLNEMVNNNEQVSLQVNLPLVPERPKCASTGIRVTD
NPFCAQYKPEBEGKGDCEGSGGPFVKNPNYNNRWYQMGIVSWGEGCDRDKGYFT
HVERLKKWIRKQWDRFG"
706..816
/gene="thrombin"

3'UTR
Query Match 1.0%; Score 19.2; DB 1; Length 826;
Best Local Similarity 51.1%; Pred. No. 1.4e+02;
Matches 45; Conservative 0; Mismatches 43; Indels 0; Gaps 0;

QY 892 CATATCCATTCTGTTACCCAGTATCTTTTCTAGAGAAATTAAGATCATTTGAGTCA 951
Db 714 CACACACATTTGGGCTCTCTCACTCGCATGTTACAGAAACCAACCCAGTCAAGATTGT 773

```

```

QY 952 TGTGGAATTATCAATGAGCAGTGT 979
Db 774 TTTTGTGTTGTGCGCTAAACGGTGT 801

RESULT 135
LOCUS AP465270 1302 bp mRNA linear VRT 02-FEB-2003
DEFINITION Gallus gallus anticoagulant protein C precursor (PROC) mRNA,
complete cds.
ACCESSION AP465270
VERSION AP465270.1 GI:28194011
KEYWORDS
SOURCE Gallus gallus (chicken)
ORGANISM Gallus gallus
REFERENCE 1 (bases 1 to 1302)
AUTHORS Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Archosauria; Aves; Neognathae; Galliformes; Phasianidae;
Phasianinae; Gallus.
1 (bases 1 to 1302)
Davidson,C.J., Hirt,R.P., Lal,K., Snell,P., Elgar,G.,
Tuddenham,E.G.D. and McVey,J.H.
Comparative sequence analysis and molecular evolution of blood
coagulation genes from Gallus gallus and Fugu rubripes
Unpublished
2 (bases 1 to 1302)
McVey,J.H., Davidson,C.J., Lal,K., Snell,P. and Elgar,G.
Direct Submission
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences
Centre, The Faculty of Medicine, Imperial College, Hammersmith
Campus, Du Cane Road, London W12 0NN, UK
FEATURES
source
Location/Qualifiers
1..1302
/organism="Gallus gallus"
/mol_type="mRNA"
/db_xref="taxon:9031"
1..1302
/gene="PROC"
1..1302
/gene="PROC"
/SC_number="3.4.21.69"
/function="inactivates factors Va and VIIIa in the
presence of Ca++ ions and phospholipids"
/note="vitamin K dependent serine protease;
autoprothrombin IIf; coagulation factor XIV, contains 2
EGF-like domains; member of peptidase family S1/trypsin
family; synthesized in the liver and found in plasma"
/codon_start=1
/product="anticoagulant protein C precursor"
/protein_id="AAO33365.1"
/db_xref="GI:28194012"
/translation="MWKLITIGVLLAACSSPVCHASIFSYKQDANQVLRKRNASFL
ELKPGSVERECNEERCFEASIFETKEATLEFWSKYVDGQCAQPCSGACKDN
IGSYSCIDKGWGAQCNVEYKNGKSVNDGGCHQCKEDPAKQCRVCSCASQVLTN
DHWCTPVYPCSGEVMQVTEGAEFNIPLGGSGSGFSPRYMVLONLAKGFLCG
GVLIHPSWLTAACHVETGETLKVRLGKYHRLRENSQIRVKKYRHNHYTKLSD
NDIAMLHLAEPVMNTYALPCLFDRLAHELTITKGRQMLVTGWGSTDEMNYSAL
LSYIETIPVPCNECAQVNTISDNLCAAGSLGDRKDCSGDSGGGPMATKYKDTWFLV
GLVSWGCGKKEKFGVVTYSQVLEWIIQHINKSGSWFG"

Query Match 1.0%; Score 19.2; DB 1; Length 1302;
Best Local Similarity 56.2%; Pred. No. 1.4e+02;
Matches 36; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY 949 TGATGTTGAGATTATCAATGAGCAGTGT 1008
Db 617 TTATGCTCAAAATCTGAAGGAGATTCTGTGTGAGGTGTTCTCATCCCGTCT 676

QY 1009 GTGT 1012
Db 677 GGCT 680

```

RESULT 136	BOVPBC/c	BOVPBC	1373 bp	mRNA	linear	MAM 27-APR-1993
LOCUS		Bovine protein C mRNA.				
DEFINITION		K02435				
ACCESSION		K02435.1 GI:163486				
VERSION		autoprothrombin IIA; protein C; serine protease.				
KEYWORDS		Bos taurus (cow)				
SOURCE		Bos taurus				
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae; Bovidae; Bovinae; Bos.				
		1 (Bases 1 to 1373)				
REFERENCE		Long, G.L., Belagaje, R.M. and MacGillivray, R.T.				
AUTHORS		Cloning and sequencing of liver cDNA coding for bovine protein C				
TITLE		Proc. Natl. Acad. Sci. U.S.A. 81 (18), 5653-5656 (1984)				
JOURNAL		85014826				
MEDLINE		60911009				
PUBMED		Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and pBC-7.				
COMMENT						

FEATURES	Location/Qualifiers
source	1. .1373
COMMENT	
Original source text: Bovine liver, cDNA to mRNA, clones pBC-2 and pBC-7.	
The sequence reported in [1] included homopolymeric tails on the 5' and 3' ends (not shown here).	

```

CDS
    cl_11370
    /locus_tag="CDS011370"
    /note="protein C prepropeptide"
    /codon_start=3
    /protein_id="AA030685.1"
    /db_xref="GI:1163487"
    /translation="TGLLEFVITWIGISSTPAPPDVSFSSORAHQVIRIKRANSELE

```

```
sig_peptide
<1. .85
ESQVP"
/note="protein C signal peptide"
117. .581
mat_peptide
/product="protein C light chain"
588..1367
mat_peptide
/product="protein C inactive heavy chain"
630. .1367
mat_peptide
/product="protein C active heavy chain"
```

	Query Match	1.08;	Score 19.2;	DB 1;	Length 1373;
	Best Local Similarity	50.0;	Prad. No. 1.4e+02;		
	Matches 48;	Conservative 0;	Mismatches 48;	Indels 0;	Gaps 0;
QY	1732	GACCAAGGTATCCATTCTTCTATCTGTCTCTCACTGCCTGAGATTCCTCTTCTATCTC	1791		
Db	1051	GACCAAGGTGCGGTTTCTCTTGGTCTCGTCAGTAGCCCGACCTGTCCACACAGTCTC	1002		
QY	1792	TTGTATCTGTGCTAGTGAGGCTTGTCTCTGAGGTTC	1827		
Db	1001	CTGCGCCACTGGGTGAGCTTGGCTCAGAGAGGC	966		

RESULT 137	
OCU77477/c	
LOCUS	1619 bp mRNA linear MAM 08-FEB-2002
DEFINITION	Cryptolagus cuniculus coagulation factor VII mRNA, complete cds.
ACCESSION	U77477 S56300
VERSION	U77477.1 GI:1698964
KEYWORDS	.
SOURCE	Cryptolagus cuniculus (rabbit)
ORGANISM	Cryptolagus cuniculus
	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;

REFERENCE AUTHORS TITLE	JOURNAL MEDLINE PUBMED	REFERENCE AUTHORS TITLE JOURNAL	COMMENT FEATURES source
-------------------------------	------------------------------	--	-------------------------------

CDS

Query Ma  
Best Loc  
Matches

RESULT 138	LOCUS	DEFINITION	KEYWORDS	ORGANISM
HSCRYBB2S3		ACCESSION	SEGMENT	
		VERSION	SOURCE	

REFERENCE AUTHORS	TITLE	JOURNAL
1	...	...
2	...	...
3	...	...
4	...	...
5	...	...
6	...	...
7	...	...
8	...	...
9	...	...
10	...	...
11	...	...
12	...	...
13	...	...
14	...	...
15	...	...
16	...	...
17	...	...
18	...	...
19	...	...
20	...	...
21	...	...
22	...	...
23	...	...
24	...	...
25	...	...
26	...	...
27	...	...
28	...	...
29	...	...
30	...	...
31	...	...
32	...	...
33	...	...
34	...	...
35	...	...
36	...	...
37	...	...
38	...	...
39	...	...
40	...	...
41	...	...
42	...	...
43	...	...
44	...	...
45	...	...
46	...	...
47	...	...
48	...	...
49	...	...
50	...	...
51	...	...
52	...	...
53	...	...
54	...	...
55	...	...
56	...	...
57	...	...
58	...	...
59	...	...
60	...	...
61	...	...
62	...	...
63	...	...
64	...	...
65	...	...
66	...	...
67	...	...
68	...	...
69	...	...
70	...	...
71	...	...
72	...	...
73	...	...
74	...	...
75	...	...
76	...	...
77	...	...
78	...	...
79	...	...
80	...	...
81	...	...
82	...	...
83	...	...
84	...	...
85	...	...
86	...	...
87	...	...
88	...	...
89	...	...
90	...	...
91	...	...
92	...	...
93	...	...
94	...	...
95	...	...
96	...	...
97	...	...
98	...	...
99	...	...
100	...	...

FEATURES  
SOURCE

Mammalia; Eutheria; Lagomorpha; Leporidae; Oryctolagus.  
1 (bases 1 to 1619)  
Brothers,A.B., Clarke,B.J., Sheffield,W.P. and Blajchman,M.A.  
Complete nucleotide sequence of the cDNA encoding rabbit  
coagulation factor VII  
Thromb. Res. 69 (2), 231-238 (1993)  
33190306  
3383365  
2 (bases 1 to 1619)  
Ruiz,S.R., Blajchman,M.A. and Clarke,B.J.  
Direct Submission  
Submitted (05-NOV-1996) Pathology, McMaster University, 1200 Main  
St. West, Hamilton, ON L8N 3Z5, Canada  
On Feb 5, 2000 this sequence version replaced gi:266294.  
Location/Qualifiers  
1. .1619  
/organism="Oryctolagus cuniculus"  
/mol\_type="mRNA"  
/db\_xref="taxon:9986"  
/tissue\_type="liver"  
22..1356  
/codon\_start=1  
/product="Coagulation factor VII"  
/protein\_id="BAB37326.1"  
/db\_xref="GI:1698965"  
/translation="MAPQARGDGLCSIIAQAASIAPVITQEAHSLVLPQRAANSFL  
ELRPGSLRSECKELCSFEARVVFSTERTQQTWITYNDGQCRASNFCQNGSGSD  
QIQSTICFLADPEGRNCKKNKQALNITGECQICSDHVGSCQSRACSGHYGLLQ  
PNGVSTCTPTVDPCKVPAKSGKSNQFQRI VGGKVQCPKGEQWQAALNMGKSTLQ  
GSLTDHVVSAACFKDLISRLNLTIVLGHDSLSEHGDEQVRHVQALIMPDKYVFG  
KTDHDIALLRLQPAALTNVTVLCLEFRNFSFSTALIFRSRVGQQLLYRGALAR  
ELMAIDVPLRMTDCEQSEHGKPGSPVITGNMFCAGYLDGSKACDGSQSPHATSY  
KTYLITVYGVNMGEGCAAGHVGVTVRSVITGNMLRSLKHLHGIRQHPFP"

h	Similarity	1.0%;	Score	19.2;	DB 1;	Length	1619;
227;	Conservative	67.5%;	Prod. No.	1.4e+02;			
			Mismatches	13;	Indels	0;	Gaps
0	GTTATCTTGCACCTGTGGAAGTGTGTGTGTGTGTGTG	1029					
0	GTTAAATGACACTCTCTGCAGGAAGTGTGTGTGCGGTG	1571					

HSCRYBB2S3  
Human beta B2 crystallin (CRYBB2) gene, exon 4.  
U72402  
U72402.1 GI:1763246  
3 of 5  
Homo sapiens (human)  
Homo sapiens

Mammalia; Eutheria; Primates; Catarrhini; Hominoidea; Homo.  
1. (bases 1 to 244)  
Carrero-Valenzuela, R., LaMorticella, D.M., Schultz, D.W., Mitchell, T.N., Kramer, P. and Maumenee, I.H.  
Autosomal dominant keratic cataract is associated with a chain termination mutation in the human beta crystallin gene CRYBB2  
Unpublished (1996)  
2. (bases 1 to 244)  
LaMorticella, D., Carrero-Valenzuela, R. and LaMorticella, D.  
Direct Submission  
Submitted (25-SEP-1996) Molecular and Medical Genetics, Oregon Health Sciences University, 3181 SW Sam Jackson Pk. Rd., Portland, OR 97231-3098, USA  
Location/Qualifiers  
1. .244  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/chromosome="22"



AX193364.1		GI:15211315	
VERSION	1	Homosapiens (human)	
KEYWORDS		Homosapiens	
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.	
REFERENCE			
AUTHORS		Xu,J., Lodes,M.J., Secrist,H., Benson,D.R., Meagher,M.J., Stokl,J.A., King,G.E., Wang,F. and Jiang,Y.	
TITLE		Compounds for immunotherapy and diagnosis of colon cancer and methods for their use	
JOURNAL		Patent: WO 0149716-A 931 12-JUL-2001;	
FEATURES		CORIXA CORPORATION (US)	
source		Location/Qualifiers	
		1..596	
		/organism="Homo sapiens"	
		/mol_type="unassigned DNA"	
		/db_xref="taxon:9606"	
Query Match	0.9%;	Score 18.8; DB 1; Length 596;	
Best Local Similarity	59.3%;	Pred. No. 1.7e+02;	
Matches	32; Conservative	0; Mismatches 22; Indels 0; Gaps 0;	
QY	239	GGTTCATCAAGTTGTAAGTTTCGTGTTTCGTGTTGTTGTTGTTGTTATCT	292
Db	376	GGCTCCATGTTGTTGGTGGCTCTCTCGTCTCTGAGCAGTGGGTCTGTCACT	323
RESULT 143			
LOCUS	AX675583	882 bp	DNA
DEFINITION	Sequence 33 from Patent WO02055704.		linear
ACCESSION	AX675583		PAT 27-MAR-2003
VERSION	AX675583.1	GI:29333568	
KEYWORDS			
SOURCE		Homosapiens (human)	
ORGANISM		Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Homidae; Homo.	
REFERENCE			
AUTHORS		Padigar,M., Li,L., Zerhusen,B.D., Casman,S.J., Shenoy,S., Spytek,K.A., Zhong,M., Gangalli,E.A., Burgess,C.E., Patturajan,M., Verne,C.A., Taylor,S., Tchernev,V.T., Miller,C.E., Guo,X., Bojdog,F.I., Grosse,W.M., Alsbrook,J.P., Gerlach,V., Edingermark,S., Rothenberg,M.E., Ellerman,K., Macdougall,J., Malyankar,U., Millett,I., Peyman,J., Smithson,G., Gunther,E. and Stone,D.J.	
TITLE		Proteins, polynucleotides encoding them and methods of using the same	
JOURNAL		Patent: WO 02055704-A 33 18-JUL-2002;	
FEATURES		Curagen Corporation (US)	
source		Location/Qualifiers	
		1..882	
		/organism="Homo sapiens"	
		/mol_type="unassigned DNA"	
		/db_xref="taxon:9606"	
Query Match	0.9%;	Score 18.8; DB 1; Length 882;	
Best Local Similarity	59.3%;	Pred. No. 1.8e+02;	
Matches	32; Conservative	0; Mismatches 22; Indels 0; Gaps 0;	
QY	239	GGTTCATCAAGTTGTAAGTTTCGTGTTTCGTGTTGTTGTTGTTATCT	292
Db	115	GGCTCCATGTTGTTGGTGGCTCTCTCGTCTCTGAGCAGTGGGTCTGTCACT	168
RESULT 144			
LOCUS	AX675581	1161 bp	DNA
DEFINITION	Sequence 31 from Patent WO02055704.		linear
ACCESSION	AX675581		PAT 27-MAR-2003
VERSION	AX675581.1	GI:29333567	
KEYWORDS			



Cypriniformes; Cyprinidae; Danio.  
 1 (bases 1 to 1671)  
 Sheehan, J., Templer, M., Gregory, M., Hanumanthaiah, R., Troyer, D.,  
 Phan, T., Thankavel, B. and Jagadeeswaran, P.  
 Demonstration of the extrinsic coagulation pathway in teleostei:  
 Identification of zebrafish coagulation factor VII  
 Proc. Natl. Acad. Sci. U.S.A. 98 (15), 8768-8773 (2001)  
 21353085  
 MEDLINE  
 PUBMED  
 11459993  
 REFERENCE  
 2 (bases 1 to 1671)  
 Sheehan, J., Templer, M., Gregory, M., Hanumanthaiah, R., Troyer, D.,  
 Phan, T., Thankavel, B. and Jagadeeswaran, P.  
 Direct Submission  
 Submitted (14-JUN-2001) Cellular and Structural Biology, University  
 of Texas Health Science Center at San Antonio, 7703 Floyd Curl  
 Drive, San Antonio, TX 78229, USA  
 FEATURES  
 Location/Qualifiers  
 source  
 1..1671  
 /organism="Danio rerio"  
 /mol\_type="mRNA"  
 /db\_xref="taxon:7955"  
 1..1302  
 /codon\_start=1  
 /product="coagulation factor VII"  
 /protein\_id="AAK74192.1"  
 /db\_xref="GI:15020318"  
 /translation="MSLLVPSLLWSLHYCHSAAFVHRDDEAEHLIRSKRANGWFE  
 ELKTNLRECELEKCEVEAREVEFHEATEINPEWKIVDKHCASSPCRHDLCTTQ  
 NADSYMLCAPGECRHCESQIGVLDSCLDHNGCEHFCETODGRNCSGADGYLD  
 NSGQCRSEVPPCKVPLLAGKAADQVLRISVGGSECEPKGCPQVLLKGEK  
 GCGGVITAPLLPACLEKIKVFRIVAGHDEHVEDEGEQIQVDMQFPEAY  
 VSETADSDALLRLPTPIVSYAVFVCLPLRENAERELWASKHTVSGWGRSEDPG  
 TRLRLRLVPRITQEVQVSNLTLSNMFCAQIEGRQDSCKGSDSGGLVTRVYRDT  
 AFLGLIVSGKGCARPGSYGIYTRVSNYLOWIROTTNTTIIH"  
 Query Match 0.9%; Score 18.8; DB 1; Length 1671;  
 Best Local Similarity 49.0%; Pred. No. 1.8e+02;  
 Matches 50; Conservative 0; Mismatches 52; Indels 0; Gaps 0;  
 Qy 1841 ATTTTTCATTTCCAGATTTCCTCAGTTGGTTGGTTGTTTAAATCTTATTCACATT 1900  
 Db 1547 ATCTGATATTTTGCACAGGTATATATGCAATTTTACAGAGGTATTAATGATTGTTGCTG 1606  
 Qy 1901 TCAGGTCCTGAATGTTTCTACCTATTTTCCCTCCAGTATTTA 1942  
 Db 1607 ATTAAACAGGAGTGTGCAGCTCATATCTCCATATTATTA 1648  
 RESULT 147  
 AR077689/c  
 LOCUS AR077689 168 bp DNA linear PAT 31-AUG-2000  
 DEFINITION Sequence 28 from patent US 5962257.  
 ACCESSION AR077689  
 VERSION AR077689.1 GI:10004435  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 168)  
 AUTHORS Grieve, R.B., Rushlow, K.E., Hunter, S.W., Frank, G.R. and Stiegler, G.L.  
 TITLE Flea aminopeptidase nucleic acid molecules  
 JOURNAL Patent: US 5962257-A 28 05-OCT-1999;  
 FEATURES Location/Qualifiers  
 source  
 1..168  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 0.9%; Score 18.6; DB 1; Length 168;  
 Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
 Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
 Qy 1552 ACCTGTATAGGCATCTCTTCTCAGGTTAGGAATTTTCTTTTGGTTTCTTCAATATAT 1611  
 Db 150 ATCAGGATAACAGCACAATATATTTGGGTAATATTATAGTCTCTTCAATATATATAT 91  
 Qy 1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCTCTTCTTCTTCTTCTTCTTCTT 1664  
 Db 90 AGTTTTCAGTGTAGTCAGTTAAACATAGTACCTTACATATATGCAATTGTT 38  
 RESULT 148  
 AR081819/c  
 LOCUS AR081819 168 bp DNA linear PAT 31-AUG-2000  
 DEFINITION Sequence 28 from patent US 5972645.  
 ACCESSION AR081819  
 VERSION AR081819.1 GI:10008545  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 168)  
 AUTHORS Grieve, R.B., Rushlow, K.E., Hunter, S.W., Frank, G.R. and Stiegler, G.L.  
 TITLE Flea serine protease nucleic acid molecules  
 JOURNAL Patent: US 5972645-A 28 26-OCT-1999;  
 FEATURES Location/Qualifiers  
 source  
 1..168  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 0.9%; Score 18.6; DB 1; Length 168;  
 Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
 Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
 Qy 1552 ACCTGTATAGGCATCTCTTCTCAGGTTAGGAATTTTCTTTTGGTTTCTTCAATATAT 1611  
 Db 150 ATCAGGATAACAGCACAATATATTTGGGTAATATTATAGTCTCTTCAATATATATAT 91  
 Qy 1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCTCTTCTTCTTCTTCTTCTTCTT 1664  
 Db 90 AGTTTTCAGTGTAGTCAGTTAAACATAGTACCTTACATATATGCAATTGTT 38  
 RESULT 149  
 AR098999/c  
 LOCUS AR098999 168 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 28 from patent US 6077687.  
 ACCESSION AR098999  
 VERSION AR098999.1 GI:12808765  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 168)  
 AUTHORS Grieve, R.B., Rushlow, K.E., Hunter, S.W., Frank, G.R., Stiegler, G.L. and Gaines, P.J.  
 TITLE Flea aminopeptidase nucleic acid molecules and uses thereof  
 JOURNAL Patent: US 6077687-A 28 20-JUN-2000;  
 FEATURES Location/Qualifiers  
 source  
 1..168  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 0.9%; Score 18.6; DB 1; Length 168;  
 Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
 Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
 Qy 1552 ACCTGTATAGGCATCTCTTCTCAGGTTAGGAATTTTCTTTTGGTTTCTTCAATATAT 1611  
 Db 150 ATCAGGATAACAGCACAATATATTTGGGTAATATTATAGTCTCTTCAATATATATAT 91  
 Qy 1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCTCTTCTTCTTCTTCTTCTTCTT 1664  
 Db 90 AGTTTTCAGTGTAGTCAGTTAAACATAGTACCTTACATATATGCAATTGTT 38  
 RESULT 150  
 AR098999/c  
 LOCUS AR098999 168 bp DNA linear PAT 14-FEB-2001  
 DEFINITION Sequence 28 from patent US 6077687.  
 ACCESSION AR098999  
 VERSION AR098999.1 GI:12808765  
 KEYWORDS  
 SOURCE Unknown.  
 ORGANISM Unknown.  
 REFERENCE 1 (bases 1 to 168)  
 AUTHORS Grieve, R.B., Rushlow, K.E., Hunter, S.W., Frank, G.R., Stiegler, G.L. and Gaines, P.J.  
 TITLE Flea aminopeptidase nucleic acid molecules and uses thereof  
 JOURNAL Patent: US 6077687-A 28 20-JUN-2000;  
 FEATURES Location/Qualifiers  
 source  
 1..168  
 /organism="unknown"  
 /mol\_type="unassigned DNA"  
 Query Match 0.9%; Score 18.6; DB 1; Length 168;  
 Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
 Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
 Qy 1552 ACCTGTATAGGCATCTCTTCTCAGGTTAGGAATTTTCTTTTGGTTTCTTCAATATAT 1611  
 Db 150 ATCAGGATAACAGCACAATATATTTGGGTAATATTATAGTCTCTTCAATATATATAT 91  
 Qy 1612 ATATTTTCCCTGCTTTTGACCTGCCTTCTCCCTTCTCTTCTTCTTCTTCTTCTTCTT 1664  
 Db 90 AGTTTTCAGTGTAGTCAGTTAAACATAGTACCTTACATATATGCAATTGTT 38



RESULT 150  
AR116830/c  
LOCUS 168 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 28 from patent US 6139840.  
ACCESSION AR116830  
VERSION AR116830.1 GI:14097736  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 168)  
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.  
TITLE Methods of eliciting an antibody response using flea protease proteins and homologs thereof  
JOURNAL Patent: US 6139840-A 28 31-OCT-2000;  
FEATURES Location/Qualifiers  
Source 1..168  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 18.6; DB 1; Length 168;  
Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
Qy 1552 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1611  
Db 150 ATCAGGATAACAGCACAATCATATTTGGGTAATATTAGTCCTTCATTTCCATATAT 91  
Qy 1612 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1664  
Db 90 AGTTTGCACTGAGTCCAGTTAAACAATAGTACCTTTACATATTCAGTTGTT 38  
RESULT 151  
AR127061/c  
LOCUS 168 bp DNA linear PAT 16-MAY-2001  
DEFINITION Sequence 28 from patent US 6180383.  
ACCESSION AR127061  
VERSION AR127061.1 GI:14113654  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 168)  
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.  
TITLE Flea leucine aminopeptidase proteins and uses thereof  
JOURNAL Patent: US 6180383-A 28 30-JAN-2001;  
FEATURES Location/Qualifiers  
Source 1..168  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 18.6; DB 1; Length 168;  
Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
Qy 1552 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1611  
Db 150 ATCAGGATAACAGCACAATCATATTTGGGTAATATTAGTCCTTCATTTCCATATAT 91  
Qy 1612 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1664  
Db 90 AGTTTGCACTGAGTCCAGTTAAACAATAGTACCTTTACATATTCAGTTGTT 38  
RESULT 152  
AR141647/c  
LOCUS 168 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 28 from patent US 6146870.  
ACCESSION AR141647

AR141647.1 GI:15101163  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 168)  
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and Stiegler,G.L.  
TITLE Flea protease proteins  
JOURNAL Patent: US 6146870-A 28 14-NOV-2000;  
FEATURES Location/Qualifiers  
Source 1..168  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 18.6; DB 1; Length 168;  
Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
Qy 1552 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1611  
Db 150 ATCAGGATAACAGCACAATCATATTTGGGTAATATTAGTCCTTCATTTCCATATAT 91  
Qy 1612 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1664  
Db 90 AGTTTGCACTGAGTCCAGTTAAACAATAGTACCTTTACATATTCAGTTGTT 38  
RESULT 153  
AR151537/c  
LOCUS 168 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 28 from patent US 6232096.  
ACCESSION AR151537  
VERSION AR151537.1 GI:15117587  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 168)  
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R., Stiegler,G.L., Gaines,P.J. and Silver,G.  
TITLE Flea serine protease nucleic acid molecules and uses thereof  
JOURNAL Patent: US 6232096-A 28 15-MAY-2001;  
FEATURES Location/Qualifiers  
Source 1..168  
/organism="unknown"  
/mol\_type="unassigned DNA"  
Query Match 0.9%; Score 18.6; DB 1; Length 168;  
Best Local Similarity 47.8%; Pred. No. 1.8e+02;  
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;  
Qy 1552 ACCTTGATAGGCATCTCTTCTCAAGGTTAGGAAATTTTCTTTTGGTTTCTTGAAA 1611  
Db 150 ATCAGGATAACAGCACAATCATATTTGGGTAATATTAGTCCTTCATTTCCATATAT 91  
Qy 1612 ATATTTCCCTGCTTTTGACCTGCTTCTCCCTTCTCTATTCCTTTGGTT 1664  
Db 90 AGTTTGCACTGAGTCCAGTTAAACAATAGTACCTTTACATATTCAGTTGTT 38  
RESULT 154  
AR2435/c  
LOCUS 168 bp DNA linear PAT 10-JUN-1998  
DEFINITION Sequence 28 from patent US 5712143.  
ACCESSION AR2435  
VERSION AR2435.1 GI:3210732  
KEYWORDS  
SOURCE Unknown.  
ORGANISM Unknown.  
REFERENCE 1 (bases 1 to 168)  
AUTHORS Grieve,R.B., Rushlow,K.E., Hunter,S.W., Frank,G.R. and

Stiegler, G.L.  
Flea protease proteins, nucleic acid molecules, and uses thereof  
Patent: US 5712143-A 28 27-JAN-1998;  
Location/Qualifiers  
1. .168  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match 0.9%; Score 18.6; DB 1; Length 168;  
Best Local Similarity 47.9%; Pred. No. 1.8e+02;  
Matches 54; Conservative 0; Mismatches 59; Indels 0; Gaps 0;

Qy 1552 ACCTGATAGGCATCTCTTCTCAAGGTAGGAATTTCTTTTGGTTTCTTGA 1611  
Dy 150 ATCAGGATACACGACAAATCATATTTTGGTAAATTATTAGTCTTCATTCATATAT 91  
Qy 1612 ATATTTTCTCTGTTTGGACCTGCTCTCTCCCTCTCTATTCCTTGGTT 1664  
Dy 90 AGTTTGCACGTGCTCCAGTACATAGGTACCTTACATATTCAGTTGTT 38

RESULT 155  
HUMPRBS01/c  
LOCUS Human protein S pseudogene beta (PS-beta), exon 1. PRI 08-JAN-1995  
DEFINITION Human protein S pseudogene beta (PS-beta), exon 1.  
ACCESSION M36565 J02918  
VERSION M36565.1 GI:190309  
KEYWORDS S protein.  
SEGMENT 1 of 12  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
AUTHORS Ploos van Amstel, H.K., Reitsma, P.H., van der Logt, C.P. and Bertina, R.M.  
TITLE Intron-exon organization of the active human protein S gene PS alpha and its pseudogene PS beta: duplication and silencing during primate evolution  
JOURNAL Biochemistry 29 (34), 7853-7861 (1990)  
MEDLINE 91084445  
PUBMED 2148111  
COMMENT Original source text: Human DNA.  
Draft entry and computer-readable sequence for [Biochemistry 29, 7853-4861 (1990)] kindly submitted by H.K. Ploos van Amstel, 13-JUL-1990.

FEATURES  
source  
1. .174  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9606"  
/map="3p21-cen"  
prim\_transcript <1..>174  
/note="protein S pseudogene beta mRNA and introns"  
exon 1..>168  
/gene="PROS2"  
/note="protein S pseudogene beta; G00-120-757"  
/number=1  
/pseudo  
exon 11..168  
/gene="PROS2"  
/note="protein S pseudogene beta, exon 1 (AA at 11); G00-120-757; putative"  
intron 169..>174  
/gene="PROS2"  
/note="intron 2"

Query Match 0.9%; Score 18.6; DB 1; Length 174;  
Best Local Similarity 57.9%; Pred. No. 1.8e+02;  
Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 204 TCTTGGCTCAATTTTAACTAGTAGTGGTTGGTTTCCATAGTTTGAAGTT 260

Db 116 TCTTGATGCATCTCTCTTCAAGATTACCTGTTGGTTTCTTCAAGTAAGAACTT 60

RESULT 156  
AY135778S1/c  
LOCUS Gorilla gorilla HCR (HCR) gene, exon 14. PRI 23-SEP-2002  
DEFINITION Gorilla gorilla HCR (HCR) gene, exon 14.  
ACCESSION AY135791  
VERSION AY135791.1 GI:23296123  
KEYWORDS  
SEGMENT 14 of 18  
SOURCE Gorilla gorilla (gorilla)  
ORGANISM Gorilla gorilla  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Gorilla.  
AUTHORS Asumalahti, K. and Kere, J.  
TITLE HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and orangutan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 189)  
AUTHORS Asumalahti, K. and Kere, J.  
TITLE Direct Submission  
JOURNAL Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum, University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki FIN-00014, Finland  
FEATURES  
source  
1. .189  
/organism="Gorilla gorilla"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9593"  
exon 1. .189  
/gene="HCR"  
/number=14

Query Match 0.9%; Score 18.6; DB 1; Length 189;  
Best Local Similarity 61.2%; Pred. No. 1.8e+02;  
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

Qy 31 TCTTGAAGCCTCTGCTGGCAATACCTCTGGGCTGCTGCTTCTCCCT 79  
Dy 52 TCTGCTCCAGCTGCTGGCCACCTTGTCTCAGCTGCTGCGCTGCT 4

RESULT 157  
AY135796S1/c  
LOCUS Pongo pygmaeus HCR (HCR) gene, exon 14. PRI 23-SEP-2002  
DEFINITION Pongo pygmaeus HCR (HCR) gene, exon 14.  
ACCESSION AY135809  
VERSION AY135809.1 GI:23296145  
KEYWORDS  
SEGMENT 14 of 18  
SOURCE Pongo pygmaeus (orangutan)  
ORGANISM Pongo pygmaeus  
REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Pongo.  
AUTHORS Asumalahti, K. and Kere, J.  
TITLE HCR gene orthologs in chimpanzee, pygmy chimpanzee, gorilla, and orangutan  
JOURNAL Unpublished  
REFERENCE 2 (bases 1 to 189)  
AUTHORS Asumalahti, K. and Kere, J.  
TITLE Direct Submission  
JOURNAL Submitted (25-JUL-2002) Department of Medical Genetics, Biomedicum, University of Helsinki, PO Box 63 (Haartmaninkatu 8), Helsinki FIN-00014, Finland  
FEATURES  
source  
1. .189  
/organism="Pongo pygmaeus"  
/mol\_type="genomic DNA"  
/db\_xref="taxon:9600"  
exon 1. .189





PURVED  
 REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 COMMENT

8168596  
 2 (bases 1 to 484)  
 Murakawa, M.  
 Submitted (18-OCT-1993) Masahiro Murakawa, Harasanshin General  
 Hospital, Division of Hematology, 1-8 Taihaku-machi, Hakata-ku,  
 Fukuoka, Fukuoka 812, Japan (Tel:092-291-3434, Fax:092-291-3266)  
 Submitted (18-Oct-1993) to DDBJ by:  
 Masahiro Murakawa  
 Division of Hematology  
 Harasanshin General Hospital  
 1-8 Taihaku-machi, Hakata-ku  
 Fukuoka, Fukuoka 812  
 Japan  
 Phone: 092-291-3434  
 Fax : 092-291-3266.

FEATURES  
 source  
 1. 484  
 /organism="Macaca mulatta"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9544"  
 <1..>484  
 /product="coagulation factor X"  
 /protein\_id="BAA04755.1"  
 /db\_xref="GI:455395"  
 /translation="EGGEAVHEVLIKHNRFTKTYDFDIKLVRLKSPITPRMNVAP  
 ACLPERWASTLTQKIGVSGFGRHEKRGQSTALKMLEVPPYVDRNSCKLSSFLI  
 .TQNNFCAGTHAQEDACQDSGGPHVTRFKDITFTVIGVSGEGCARKKGIYTKVT  
 A"

Query Match  
 Best Local Similarity 0.9%; Score 18.6; DB 1; Length 484;  
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312  
 Db 317 TGTCTGGTGATGAAGCTGCTGGAGAGCTTGCAGCTGTGGCGTC 269

RESULT 166  
 AX775014/c  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

AX775014  
 Sequence 330 from Patent WO03038129.  
 AX775014  
 GI:32486530  
 Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 COMMENT

Raponi, M.  
 Methods for assessing and treating leukemia  
 Patent: WO 03038129-A 330 08-MAY-2003;  
 Ortho-Clinical Diagnostics, Inc. (US)

FEATURES  
 source  
 1. 546  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9608"

Query Match  
 Best Local Similarity 0.9%; Score 18.6; DB 1; Length 546;  
 Matches 33; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 37 AGCCTCTGCTGGCAATCTTCTGGGGTGGTGCCTTCTCCCTGTTGATTCCTAGG 93  
 Db 336 AGCCTCTCTTCTTGACACACACAGGGGGCCCCCGCTGTCCTCCCTGGAGCTGTCCACG 280

RESULT 167  
 AX335885/c

LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SOURCE  
 ORGANISM

AX335885  
 Sequence 6394 from Patent WO0194629.  
 AX335885  
 GI:18126604  
 Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 AUTHORS  
 TITLE  
 JOURNAL  
 COMMENT

Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,  
 Horrigan, S., Soppet, D.R. and Weaver, Z.  
 Cancer gene determination and therapeutic screening using signature  
 gene sets  
 Patent: WO 0194629-A 6394 13-DEC-2001;  
 Avalon Pharmaceuticals (US)

FEATURES  
 source  
 1. 624  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

Query Match  
 Best Local Similarity 0.9%; Score 18.6; DB 1; Length 624;  
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312  
 Db 351 TGTCTGGTGATGAAGCTGCTGGACAGCTTGCAGCTGTGGCGTC 303

RESULT 168  
 HUMFX8/c  
 LOCUS  
 DEFINITION  
 ACCESSION  
 VERSION  
 KEYWORDS  
 SEGMENT  
 SOURCE  
 ORGANISM

HUMFX8  
 Human factor X (blood coagulation factor) gene, exon 8.  
 L29433 M14327 N00045  
 L29433.1 GI:459809  
 Stuart factor; blood coagulation factor; factor X; glycoprotein;  
 serine protease.  
 8 of 8  
 Homo sapiens (human)  
 Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE  
 AUTHORS  
 TITLE

Leytus, S.P., Foster, D.C., Kurachi, K. and Davie, E.W.  
 Gene for human factor X: a blood coagulation factor whose gene  
 organization is essentially identical with that of factor IX and  
 protein C  
 Biochemistry 25 (18), 5098-5102 (1986)

JOURNAL  
 MEDLINE  
 PUBMED  
 COMMENT

87026600  
 3768336  
 Original source text: Homo sapiens (tissue library: of Lawn et al.,  
 and Yoshitake et al.) DNA.  
 matp + 13 + 458 factor Xa heavy chain.

FEATURES  
 source  
 1. 624  
 Location/Qualifiers  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /map="13q34"  
 /tissue\_lib="of Lawn et al., and Yoshitake et al."  
 join(L00390.1:26..95,L00391.1:13..173,L00392.1:13..37,  
 L00393.1:13..126,L00394.1:13..144,L00395.1:13..257,  
 L00396.1:13..130,13..614)  
 /notes="preprofactor X"  
 /codon\_start=1  
 /product="coagulation factor X"  
 /protein\_id="AA52764.1"  
 /db\_xref="GI:182831"

CDS  
 1..624  
 /translation="MGRPLHIVLSASLGLLLGESLFTIREQANNILARVTRANSF  
 LEEMKGLHRECEMEETCSYEAREVFEDSKTNEFWNKYGDGCSTSPQNGKCK  
 DGLGEYTCLEGGFEGRKNCLELFTKRLKSLDNGDCDQFCHEEQNSVVCSCAGYTLADN



/db\_xref="SWISS-PROT:P00763"  
 /translations="LVGAFAVFDVDDDKIVGGTYCOENSVYQVSLNSGYHFCGSL  
 INQWVSAACHVKYRIQVRLGHEINVLGNEQFVNAKIIKHENPDKTLNNDIML  
 IKLSPPVKLNARVATVALPSSCAPAGTQCLISMGNTLSSGWNEDLLQCLDAPLLPQ  
 ADGEASYPKLTIDNMVGVFEGGKSCGSDGGPVCNGELQGIIVSGYGCALPDNE  
 GVYIKVYVDMVQDTIAAN"  
 <1..25  
 /notes="signal peptide"  
 773  
 /note="polyA addition site"

sig\_peptide

polyA\_site

Query Match 0.9%; Score 18.6; DB 1; Length 773;  
 Best Local Similarity 45.5%; Pred. No. 2e+02;  
 Matches 66; Conservative 0; Mismatches 79; Indels 0; Gaps 0;  
 QY 1552 ACCTGTAGGATCTCTTCTCAAGGTTAGGAAATTTCTTTTGGTTCTTGAA 1611  
 DB 315 AGCTTGATCAGATGATGTCATTTTCAGGCTTCTCTCGAAGTTGGATGCTG 256  
 QY 1612 ATATTTTCCCTGTTTGTACCTGCTCTTCCCTTCTCTTCTTCTTCTTCTG 1671  
 DB 255 ATCTGGCAGATTGACAACTGCTATTCCTCCCTCAGGACATGATGTTGCTCT 196  
 QY 1672 AGTCTCTCTGCTTCTCTGATGTTT 1696  
 DB 195 AGTCTCATTGGATGGGACTTAT 171

RESULT 172

DOGTYPY DOGTYPY 819 bp mRNA linear MAM 27-APR-1993  
 LOCUS Dog pancreatic anionic trypsinogen mRNA.  
 DEFINITION M11589  
 ACCESSION M11589  
 VERSION M11589.1 GI:164094  
 KEYWORDS  
 SOURCE Canis sp.

REFERENCE Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Carnivora; Fissipedia; Canidae; Canis.

AUTHORS Pinsky, S.D., LaForce, K.S. and Scheele, G.

TITLE Differential regulation of trypsinogen mRNA translation:  
 full-length mRNA sequences encoding two oppositely charged  
 trypsinogen isoenzymes in the dog pancreas

JOURNAL Mol. Cell. Biol. 5 (10), 2669-2676 (1985)

MEDLINE 86284628

PUBMED 3841794

COMMENT Original

FEATURES Location/Qualifiers

1..819 source text: Dog pancreas, cDNA to mRNA, clone pT1.

1..819 Location/Qualifiers

/organism="Canis sp."

/mol\_type="mRNA"

/db\_xref="taxon:9616"

1..819

/product="anionic trypsinogen mRNA"

15..758

/note="anionic trypsinogen precursor"

/codon\_start=1

/protein\_id="AAA30899.1"

/db\_xref="GI:164095"

/translation="MNPFLILAFGLAAVATPTDDDKIVGGTYCENSVYQVSLNAG  
 YHFCGSLIDQWVAHCKYRIQVRLGHEYNIDVLEGNQFINSKVRHPNYSW  
 ILNDIMLIKLSPPVKLNARVATISLPACAPGTQCLISMGNTLSSGWNEDLLQCLDAPLLPQ  
 LDAPILTAQCEASYPQGITENMICAGFLGEGKSCGSDGGPVCNGELQGIIVSGWY  
 GCAQKQKPGVTVKCNFVDWIQSTIAANS"

Query Match 0.9%; Score 18.6; DB 1; Length 819;  
 Best Local Similarity 50.6%; Pred. No. 2e+02;  
 Matches 45; Conservative 0; Mismatches 44; Indels 0; Gaps 0;

QY 776 GCTTCTTCTAGGGCCATTGTTAGATATCTTTTCCATCTCTTTTACTCTAAGTGAT 835

DB 531 GCCTCTACCCGCCAGATCACGAGAACATGATTGCGCGGCTCTCTTGAGGAGGC 590

QY 836 GTCTATCCATGGTAGGTGTGCTTTTGG 864

DB 591 AAGACTCTCCAGGAGTACTCTGCTGG 619

RESULT 173

PVTRYPSIN PVTRYPSIN 854 bp mRNA linear INV 01-OCT-1996

LOCUS P.vannamei mRNA for trypsin.

DEFINITION X86369

ACCESSION X86369.1 GI:785034

KEYWORDS trypsin.

SOURCE Litopenaeus vannamei (Pacific white shrimp)

ORGANISM Litopenaeus vannamei

REFERENCE Eukaryota; Metazoa; Arthropoda; Crustacea; Malacostraca;  
 Eumalacostraca; Eucarida; Decapoda; Dendrobranchiata; Penaeoidea;  
 Penaeidae; Litopenaeus.

AUTHORS Klein, B., Le Moullac G., Sellos, D. and Van Wormhoudt, A.

TITLE Molecular cloning and sequencing of trypsin cDNAs from Penaeus  
 vannamei (Crustacea, Decapoda): use in assessing gene expression  
 during the moult cycle

JOURNAL Int. J. Biochem. Cell Biol. 28 (5), 551-563 (1996)

MEDLINE 96252881

PUBMED 8697100

REFERENCE 2 (bases 1 to 854)

AUTHORS Van Wormhoudt, A.E.

TITLE Direct Submission

JOURNAL Submitted (18-APR-1995) A.E. Van Wormhoudt, College de France /  
 CNRS, Laboratoire de Biologie Marine, BP 225, 29182 Concarneau,  
 FRANCE

FEATURES Location/Qualifiers

1..854 source

/organism="Litopenaeus vannamei"

/mol\_type="mRNA"

/db\_xref="taxon:6689"

/tissue\_type="hepatopancreas"

/dev\_stage="adult"

3..803

/EC\_number="3.4.21.4"

/codon\_start=1

/product="trypsin"

/protein\_id="CAA60129.1"

/db\_xref="GI:785035"

/db\_xref="GOA:Q27761"

/translation="MKTLILCVLLAGFAAPSRKPTFRRLNKLIVGGTDAFGELPYQ  
 LSPQDISFGFAHFCGASYNENWAIACGHCQVQEDMNNPDYLVQVAGLNDVDEGT  
 EOTVILSKIIQHEHDYNGFTISDILKLSQPLSNDNNVRAIDIACGHAASGDCIVS  
 GAGTTSSEGSTSVLQKVTPIVSDDECDAYGQSDIEDSMICAGVPSGKDCSCQGS  
 GGFLACSDIASYLAGIVSGYGCARPGYGVYAEVSHVDWIKNAV"

sig\_peptide 3..41

Query Match 0.9%; Score 18.6; DB 1; Length 854;  
 Best Local Similarity 61.2%; Pred. No. 2e+02;  
 Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 613 TGTTTATGACCTGGGTGACATTTGTTGGTGATACACATTAAAGAA 661

DB 797 TGTTTATCAAGTTGTTTACATGTACTTACCTTGAACCAATAAGAA 845

RESULT 174

LOCUS AP465268 1278 bp mRNA linear VRT 02-FEB-2003

DEFINITION Gallus gallus coagulation factor VII precursor (F7) mRNA, complete  
 cds.

ACCESSION AP465268

VERSION AP465268.1 GI:28194007

KEYWORDS Gallus gallus (chicken)

SOURCE Gallus gallus

ORGANISM Gallus gallus









```

FEATURES             Baxter Aktiengesellschaft (AT)
source
  1..1467
  /organism="Homo sapiens"
  /mol_type="unassigned DNA"
  /db_xref="taxon:9606"

Query Match
Best Local Similarity 0.9%; Score 18.6; DB 1; Length 1467;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156

RESULT 181
BD070392/c
LOCUS             1467 bp DNA linear PAT 27-AUG-2002
DEFINITION       Factor X-analogues with modified protease cleavage site.
ACCESSION        BD070392
VERSION          BD070392.1 GI:22615995
KEYWORDS         unclassified.
SOURCE           unclassified
ORGANISM         unclassified.
REFERENCE        1 (bases 1 to 1467)
AUTHORS          Himmelspach, M., Schlokot, U., Dörner, F., Andreas, Fisch and Eibl, J.
TITLE            Factor X-analogues with modified protease cleavage site
JOURNAL          Patent: JP 2001513631-A 26 04-SEP-2001;
                  BAXTER AG
COMMENT          OS Unidentified
                  EN JP 2001513631-A/26
                  PD 04-SEP-2001
                  PR 27-FEB-1998 JP 1998537062
                  PI MICHELE HIMMELSPACH, UWE SCHLOKAT, FRIEDRICH DÖRNER, ANDREAS PI
                  FISCH, JOHANN EIBL
                  PC C12N15/57, C12N9/64, A61K38/48
                  CC Strandedness: Single;
                  CC Topology: Linear;
                  CC Factor X-analogues with modified protease cleavage site FH
                  Key
                  FT CDS
                     Location/Qualifiers
                     1..1467
                     /organism="unidentified"
                     /mol_type="genomic DNA"
                     /db_xref="taxon:32644"

FEATURES             source
  1..1467
  /organism="unidentified"
  /mol_type="genomic DNA"
  /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.9%; Score 18.6; DB 1; Length 1467;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156

RESULT 182
BD070435/c
LOCUS             1467 bp DNA linear PAT 27-AUG-2002
DEFINITION       Factor X deletion mutants and analogues thereof.
ACCESSION        BD070435
VERSION          BD070435.1 GI:22616038
KEYWORDS         unclassified.
SOURCE           unclassified
ORGANISM         unclassified.
REFERENCE        1 (bases 1 to 1467)
AUTHORS          Himmelspach, M., Pfeleiderer, M., Falkner, F.G., Eibl, J., Dörner, F. and
                  Schlokot, U.
TITLE            Factor X deletion mutants and analogues thereof

FEATURES             source
  1..1467
  /organism="unidentified"
  /mol_type="genomic DNA"
  /db_xref="taxon:32644"

Query Match
Best Local Similarity 0.9%; Score 18.6; DB 1; Length 1467;
Matches 30; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 264 TGTGTTCTGTTGTTGTTGTTATCTAGATTAGCTGTGGTGC 312
Db 1204 TGTTCGGGTGATGAGCTGCTGGACAGCTTGCAGCTGTGGGTC 1156

RESULT 183
AF191307/c
LOCUS             1514 bp mRNA linear MAM 01-NOV-2000
DEFINITION       Sus scrofa protein C mRNA, complete cds.
ACCESSION        AF191307
VERSION          AF191307.1 GI:11065893
KEYWORDS         Sus scrofa (pig)
SOURCE           Sus scrofa
ORGANISM         Sus scrofa
                  Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                  Mammalia; Eutheria; Cetartiodactyla; Suina; Suidae; Sus.
REFERENCE        1 (bases 1 to 1514)
AUTHORS          Grimm, D.R., Colter, M.B. and Kim, H.
TITLE            Cloning of the complete cDNA sequences encoding porcine factor V
                  and protein C
JOURNAL          Unpublished
REFERENCE        2 (bases 1 to 1514)
AUTHORS          Grimm, D.R., Colter, M.B. and Kim, H.
TITLE            Direct Submission
JOURNAL          Submitted (01-OCT-1999) Research/S.S.F., Shriners Hospital, 12502
                  North Pine Drive, Tampa, FL 33612, USA
FEATURES             Location/Qualifiers
source
  1..1514
  /organism="Sus scrofa"
  /mol_type="mRNA"
  /db_xref="taxon:9823"
  /clone="92N.4; 58/86.2; 12N3.1"
  /tissue_type="liver"
  22..1401
  /note="serine protease"
  /codon_start=1
  /product="protein C"
  /protein_id="AAG28380.1"
  /db_xref="GI:11065894"
  /translation="MWQASLLLLIIVASSTVPDPSVSSQRAHQMLRKRANS
  FLELRPSLSRECKEETCDFEAREIFONTENTNAFWSKHGDCQCAVFPPEHLCD
  PCGGRTGIDGLGFRCDCAWEGRCFHEVFNCSNCTNGSCAHCYCLEEGRRCA
  CAPGYLGDHLCQCFKVRSCGRIGNRMKRNKLRDQDVKKEDQDPLRVNGK
  QPWFSGEPQVILLDSKKLACGAVLIHVSWLTAARCLDDYKLTVLRLGEYDLRRE
  KFEVLDLKEFIVHPNTRSTSDNDIALRLAEPATFSQITVPLCPDPSGLSRELTR
  VCGETVVTGQVYRSEAKTRNSFLNFIKVPVAPNECVQAMHNKISNMCLCAGLGS
  RDACEGDSGPMVASFRGTWFLVGLVSGEGCGRLHNYGVYTKYSRVLDWIHGHIRE"

FEATURES             source
  1..1514
  /organism="Sus scrofa"
  /mol_type="mRNA"
  /db_xref="taxon:9823"
  /clone="92N.4; 58/86.2; 12N3.1"
  /tissue_type="liver"
  22..1401
  /note="serine protease"
  /codon_start=1
  /product="protein C"
  /protein_id="AAG28380.1"
  /db_xref="GI:11065894"
  /translation="MWQASLLLLIIVASSTVPDPSVSSQRAHQMLRKRANS
  FLELRPSLSRECKEETCDFEAREIFONTENTNAFWSKHGDCQCAVFPPEHLCD
  PCGGRTGIDGLGFRCDCAWEGRCFHEVFNCSNCTNGSCAHCYCLEEGRRCA
  CAPGYLGDHLCQCFKVRSCGRIGNRMKRNKLRDQDVKKEDQDPLRVNGK
  QPWFSGEPQVILLDSKKLACGAVLIHVSWLTAARCLDDYKLTVLRLGEYDLRRE
  KFEVLDLKEFIVHPNTRSTSDNDIALRLAEPATFSQITVPLCPDPSGLSRELTR
  VCGETVVTGQVYRSEAKTRNSFLNFIKVPVAPNECVQAMHNKISNMCLCAGLGS
  RDACEGDSGPMVASFRGTWFLVGLVSGEGCGRLHNYGVYTKYSRVLDWIHGHIRE"

```

SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 249)  
 AUTHORS Gao,X., Veale,A. and Serjeantson,S.  
 TITLE ABI: a novel HLA-DPB1 allele found in one third of an Australian population  
 JOURNAL Immunogenetics 36 (1), 64-66 (1992)  
 MEDLINE 92267574  
 PUBMED 1587554  
 COMMENT Original source text: Homo sapiens blood DNA.  
 FEATURES  
 source  
 1..249  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /map="6p21.3"  
 /cell\_type="lymphocyte"  
 /tissue\_type="blood"  
 gene  
 1..249  
 /gene="HLA-DPB1"  
 misc\_feature  
 1..249  
 /gene="HLA-DPB1"  
 /note="G00-120-636"  
 Query Match 0.9%; Score 18.4; DB 1; Length 249;  
 Best Local Similarity 56.7%; Pred. No. 2.1e+02;  
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
 Qy 1812 TTGCTCTCAGGTTCTGTTGGTCTTAATTTTCATTTCCAGATTCCTTCAGTTG 1871  
 Db 218 TTGTGTGCACATCTGTCGGCAGTCCTCTCTCTCCAGGATGTCTCTCTGCTG 159  
 RESULT 186  
 HUMDPBA/c 249 bp DNA linear PRI 14-APR-2000  
 LOCUS Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK1.  
 DEFINITION D10478  
 ACCESSION D10478.1 GI:219604  
 VERSION HLA-DP beta; DPB1; MHC; human leukocyte antigen; major histocompatibility complex class II molecule.  
 KEYWORDS Homo sapiens (human)  
 SOURCE Homo sapiens  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (sites)  
 AUTHORS Mitsunaga,S., Kuwata,S., Tokunaga,K., Uchikawa,C., Takahashi,K., Akaza,T., Mitomi,Y. and Juji,T.  
 TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with HLA-DR/DQ and two 'new' alleles  
 JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)  
 MEDLINE 93053849  
 PUBMED 1358967  
 REFERENCE 2 (bases 1 to 249)  
 AUTHORS Mitsunaga,S.  
 JOURNAL Unpublished  
 COMMENT Submitted (17-Feb-1992) to DDBJ by: Katsushi Tokunaga  
 Dept. of Transfusion Medicine and Immunohematology, Faculty of Medicine The University of Tokyo 7-3-1 Hongo, Bunkyo-ku Tokyo 113 Japan  
 Phone: 03-3815-5411 x8880  
 Fax: 03-3816-2516  
 FEATURES  
 source  
 1..249  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /isolate="THK"

EAFHKNQVP"  
 Query Match 0.9%; Score 18.6; DB 1; Length 1514;  
 Best Local Similarity 51.9%; Pred. No. 2e+02;  
 Matches 42; Conservative 0; Mismatches 39; Indels 0; Gaps 0;  
 Qy 1854 CAGATTCCTTCAGTTGGTTTGTATTAATTCATTTCCAGTCTCAGTCTGAAA 1913  
 Db 657 CGGATCATTTGCTCTCTTTTGTGCAACCTGGTCTGTATCACGCTTCAAGTCTTCGG 598  
 Qy 1914 TGTCTTACTCATTTCTCTCC 1934  
 Db 597 TTCTCTCATCGGATTC 577  
 RESULT 184  
 HUMKALR4 193 bp DNA linear PRI 06-JAN-1995  
 LOCUS Human renal kallikrein, exon 4.  
 DEFINITION M33108  
 ACCESSION M33108.1 GI:186648  
 VERSION kallikrein; kininogenase.  
 SEGMENT 4 of 5  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 193)  
 AUTHORS Evans,B.A., Yun,Z.X., Close,J.A., Tregear,G.W., Kitamura,N., Nakanishi,S., Callen,D.F., Baker,E., Hyland,V.J., Sutherland,G.R. and Richards,R.I.  
 TITLE Structure and chromosomal localization of the human renal kallikrein gene  
 JOURNAL Biochemistry 27 (9), 3124-3129 (1988)  
 MEDLINE 88269498  
 PUBMED 2898948  
 COMMENT Original source text: Human parotid gland, cDNA to mRNA.  
 FEATURES  
 source  
 1..193  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"  
 /map="19q13.3"  
 prim\_transcript <1..>193  
 /gene="KLK1"  
 /note="kallikrein mRNA and introns"  
 intron <1..>29  
 /gene="KLK1"  
 /note="kallikrein intron C"  
 exon 30..166  
 /gene="KLK1"  
 /note="G00-120-118"  
 intron 167..>193  
 /gene="KLK1"  
 /note="kallikrein intron D"  
 Query Match 0.9%; Score 18.4; DB 1; Length 193;  
 Best Local Similarity 69.4%; Pred. No. 2e+02;  
 Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;  
 Qy 1938 TTAATTTTCATTTCCAGATTCCTTCAGTTGGG 1873  
 Db 23 TTGCTAGTCATTTCCAGATGATCTCCAGTGTG 58  
 RESULT 185  
 HUMDPB1A/c 249 bp DNA linear PRI 07-NOV-1994  
 LOCUS Human DPB1 protein gene, partial cds.  
 DEFINITION M77674  
 ACCESSION M77674.1 GI:181735  
 VERSION DPB1 protein.  
 KEYWORDS

```

/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK1"
/cell_type="peripheral blood mononuclear cell"
1..249
/gene="DPB1"
<1..>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01281.1"
/db_xref="GI:219605"
/translation="LFGQRCYAFNGTQFLERYINREELVRFDSVGVGFRAVTEL
GRPEAYWNSQKILEKRAVPDMCRHNYELDEAVTLQ"
1..249
/gene="DPB1"
/number=2
old_sequence
1
/gene="DPB1"
/citation=[1]
/replace="cctcccgagagaattac"
249
old_sequence
1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgagggtc"

```

Query Match 0.9%; Score 18.4; DB 1; Length 249;  
 Best Local Similarity 56.7%; Pred. NO. 2.1e+02;  
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

```

QY 1812 TTGTCCTGAGGTCCTGCTGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 1871
      |||||
DB 218 TTGTCCTGAGGTCCTGCTGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 159
      |||||

```

```

RESULT 187
HUMDPBB/c HUMDPBB 249 bp DNA linear PRI 14-APR-2000
LOCUS
DEFINITION Homo sapiens gene for HLA-DP beta, partial cds, clone:SSK2.
ACCESSION D10479
VERSION D10479.1 GI:219606
KEYWORDS HLA-DP beta; DPB1; MHC; human leukocyte antigen; major histocompatibility complex class II molecule.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (sites)
REFERENCE
AUTHORS Mitsuhashi, S., Kuwata, S., Tokunaga, K., Uchikawa, C., Takahashi, K., Akaza, T., Mitomi, Y., and Ojii, T.
TITLE Family study on HLA-DPB1 polymorphism: linkage analysis with HLA-DR/DQ and two 'new' alleles
JOURNAL Hum. Immunol. 34 (3), 203-211 (1992)
MEDLINE 93053849
PUBMED 1358867
REFERENCE
AUTHORS Mitsuhashi, S.
JOURNAL Unpublished
COMMENT Submitted (17-Feb-1992) to DBJ by: Katsushi Tokunaga
Dept. of Transfusion Medicine and Immunohematology, Faculty of Medicine The University of Tokyo
7-3-1 Hongo, Bunkyo-ku Tokyo 113
Japan
Phone: 03-3815-5411 x8880
Fax: 03-3816-2516.
Location/Qualifiers
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/isolate="THM1"

```

```

/db_xref="taxon:9606"
/chromosome="6"
/clone="SSK2"
/cell_type="peripheral blood mononuclear cell"
1..249
/gene="DPB1"
<1..>249
/gene="DPB1"
/codon_start=1
/product="HLA-DP beta"
/protein_id="BAA01282.1"
/db_xref="GI:219607"
/translation="VYQLRQCYAFNGTQFLERYINREELVRFDSVGVGFRAVTEL
GRPEAYWNSQKILEKRAVPDMCRHNYELDEAVTLQ"
1..249
/gene="DPB1"
/number=2
old_sequence
1
/gene="DPB1"
/citation=[1]
/replace="cctcccgagagaattac"
249
old_sequence
1
/gene="DPB1"
/citation=[1]
/replace="cgccgaggtgagtgagggtc"

```

Query Match 0.9%; Score 18.4; DB 1; Length 249;  
 Best Local Similarity 56.7%; Pred. NO. 2.1e+02;  
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

```

QY 1812 TTGTCCTGAGGTCCTGCTGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 1871
      |||||
DB 218 TTGTCCTGAGGTCCTGCTGGTCTTAATTTTCATTTCCAGATTTCTTCAGTTG 159
      |||||

```

```

RESULT 188
HUMDPBB/c HUMDPBB 249 bp DNA linear PRI 07-JAN-1995
LOCUS
DEFINITION Human MHC class II HLA DP-beta gene, exon 2 allele DPB5.
ACCESSION M23680
VERSION M23680.1 GI:188070
KEYWORDS HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
1 (bases 1 to 249)
REFERENCE
AUTHORS Bugawan, T.L., Horn, G.T., Long, C.M., Mickelson, E., Hansen, J.A., Ferrara, G.B., Angelini, G., and Erlich, H.A.
TITLE Analysis of HLA-DP allelic sequence polymorphism using the in vitro enzymatic DNA amplification of DP-alpha and DP-beta loci
JOURNAL J. Immunol. 141 (11), 4024-4030 (1988)
MEDLINE 89035547
PUBMED 2460556
COMMENT Original source text: Human DNA allele DPB5.
FEATURES
source
1..249
/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/map="6p21.3"
1..249
/gene="HLA-DPB1"
<1..>249
/gene="HLA-DPB1"
/notes="MHC DP-beta, allele DPB5"
/number=2
/codon_start=1
/protein_id="AAA59745.1"
/db_xref="GI:188071"
/db_xref="GDB:G00-120-636"
/translation="LFGQRCYAFNGTQFLERYINREELVRFDSVGVGFRAVTEL"

```

GRPEAEYWN SOKDILLEEKRAVPDRMCRHNYELDEAVTLO"

Query Match	0.9%	Score 18.4	DB 1	Length 249
Best Local Similarity	56.7%	Prod. No. 2.1e+02		
Matches 34	Conservative	0	Mismatches 25	Indels 0
Gaps 0				
1812	TTGTCCTCAGGTTCTCTGTGGGTCTTAAATTTTTCATTTCACGATTTCTTTCAGTTG	1871		
QY				
218	TTGTGTCGCACATCTGTGCGGCACTGCCGCTTCTCCTCCAGAGTGTCTTCTGCGTG	159		
Db				

RESULT 189  
HUMMDPIH/c  
LOCUS HUMMDPIH  
256 bp DNA linear PRI 07-JAN-1995  
DEFINITION Human MHC class II HLA DP-beta (allele DPB5), partial cds.

**ACCESSION** M62333  
**VERSION** M62333.1  
**GI** 188036  
**KEYWORDS** HLA-DP antigen; cell surface glycoprotein; class II gene; integral membrane glycoprotein; major histocompatibility complex.

SOURCE ORGANISM	Homo sapiens (human)
Homo sapiens	
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	

1 (bases 1 to 256)  
 Bugawan, T.L.; Begovich, A.B. and Erlich H.A.  
 Authors  
 Rapid HLA-DRB typing using enzymatically amplified DNA and  
 Title  
 nonradioactive sequence-specific oligonucleotide probes

JOURNAL Immunogenetics 32 (4), 231-241 (1990)  
MEDLINE 91055805  
PUBMED 2242906  
COMMENT Original source text: Human DNA allele DPB5.

```

FEATURES
  source
    Location/Qualifiers
      1..256
        /organism="Homo sapiens"
        /mol_type="genomic DNA"
        /db_xref="Genebank"

```

```

/db xref="taxon:9606"
/map="6p21.3"
1. .256
/gene="HLA-DPB1"
1. .256

```

```

CDS
1..256
    /gene="HLA-DPB1"
    /codon_start=1
    /product="MHC class II HLA-DP-beta-1"
    /protein_id="AA022026.1"

```

```

/protein_id="AAA59726.1"
/db_xref="GI:553549"
/db_xref="GDB:G00-120-636"
/translation="LFGQECYAFNGTFLERYYNREELVYFSDVDGEFRAVTEL
GQAEAWMVCNLTIGQAEQACQVNFVRAVMTGDD#"

```

Query Match 0.9%; Score 18.4; DB 1; Length 256;  
Best Local Similarity 56.7%; Pred. NO. 2.1e+02;  
Marches 34. Conservative 26. Indels 0. Gaps 0.  
GRPEAEYWNQSDILLEEKNAVPDRMCRHNYELDEAVTLQRR"

Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0

1812 TTGTCTCTGAGGTTCTCTGTGGTTCCTTAATTTTTCATTTTCCAGATTTCTCTCAGTTTG 1871

218 TTGTTGTTGCATCTCTGTCCTGGCATCTGCGGCTTCTCTCTCAGATCTCTCTGCTG 159

RESULT 190  
 AR180970/C  
 Z18 TTGTGTCTGACATCCCTGTCCTGAGGATGTCCTCTGCGC  
 139

AF180970  
LOCUS  
DEFINITION Homo sapiens MHC class II antigen (HLA-DPB1) gene, HLA-DPB1 variant allele, partial cds.  
ACCESSION AF180970  
257 bp DNA linear PRI 02-JUN-2001

RECESSION  
AF180970.1  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 1 (bases 1 to 257)  
 Xu, A., Huang, H., Liu, Z., Chen, W., Pan, D., Lin, J., Xu, K., Chen, S.,  
 et al. (2015)

Wang, X. and Chen, R.

---

TITLE	A novel HLA-DPB1 allele in Chinese people
JOURNAL	Unpublished
REFERENCE	2 (bases 1 to 257)
AUTHORS	Xu, A., Huang, H., Liu, Z., Chen, W., Pan, D., Lin, J., Xu, K., Chen, S., Wang, X. and Chen, R.
TITLE	Direct Submission
JOURNAL	Submitted (26-AUG-1999) Biochemistry, School of Life Science, 135 Xingangxi Road, Guangzhou, Guangdong 540275, P.R.China
FEATURES	Location/Qualifiers

```

/organism="Homo sapiens"
/mol_type="genomic DNA"
/db_xref="taxon:9606"
/chromosome="6"
/map="6p21.3"

```

```
gene
<1..>257
/ gene="HLA-DPB1"
/ allele="HLA-DPB1 variant"
mRNA
<1..>257
```

```

/gene="HLA-DPB1"
/product="MHC class II antigen"
<1..>257
CDS
/gene="HLA-DPB1"

```

```

/note="membrane protein"
/codon_start=3
/product="MHC class II antigen"
/protein_id="AAK53508.1"

```

exon  
1, 257  
ELGRPEAEYWNQKDIKEKAVPDRMCRHNYDEAVTLQ"  
/translation="NYLPGQEQECYAFNGTCQFLRYNREELVRFDSVDGFRVAVT  
/db\_xref="GI:14279143"

Query Match	Score	DB 1	Length
Best local similarity:	55.7%	DB 1	257
Best local similarity:	55.7%	DB 2	18.02
Best local similarity:	55.7%	DB 3	18.02

1812 TTCTCTCAGGTTCCGTGTGGGTCTTAAATTTTCATTTCCAGATTCCTTCAGTTG 1871  
 0y  
 Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;  
 Best Local Similarity 56.7%; Pred. No. 2.1e-02;

Db 226 TTGTGTGCACATCTGTCCGGCACTGCCGCTTCTCTCCAGGATGCTCTTCTGGCTG 167

					PRI	14-APR-2000
RESULT 191	HUMDPB1KT/c	LOCUS	HUMDPB1KT	264 bp	DNA	linear
		DEFINITION	Human MHC classII HLA-DPB1 gene allele DPB1*KT.			
		ACCESSION	D10882			

**ACCESSION** D10882  
**VERSION** D10882.1  
**GI** 219602  
**KEYWORDS** H1A-DP antigen; cell surface glycoprotein; class II gene; integral membrane protein; major histocompatibility complex.  
**SOURCE** Homo sapiens (human)

SOURCE	ORGANISM	REFERENCE
Homo sapiens (human)	Homo sapiens	1 (bases 1 to 264)
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.		

REFERENCES  
Ogawa, K., Itoh, H., Nakaiyo, S., Kobayashi, K., Sekiguchi, S., Koshizaka, T., Taguchi, M., Onishi, H., Kobayashi, S. and Inoko, H. A novel HLA-DPB1 allele, DPB1\*3601 (DPB1\*KT). *Tissue Antigens* 44 (2), 134-136 (1994).

95117110  
MEDLINE  
PUBMED  
7817379  
REFERENCE  
2 (bases 1 to 264)  
AUTHORS  
Koshizaka, T.

**TITLE** Direct Submission  
**JOURNAL** Submitted (06-APR-1992) Takuya Koshizaka, Sumitomo Metal Industries, Ltd.; 14-15 Kobuchi 2-chome, Sagamihara, Kanagawa 229, Japan (Tel:0427-51-7568, Fax:0427-51-7519)

Submitted (06-Apr-1992) to DDBJ by:  
Takuya Koshizaka  
Sumitomo Metal Industries, Ltd.  
14-15 Kobuchi 2-chome

Sagamihara, Kanagawa 229

[illegible]





```

/isolates="SASBE41"
/db_xref="taxon:9606"
/map="6p"
/cell_type="granulocyte"
<1..19
/number=1
<20..>283
/codon_start=3
/label=exon 2
/product="MEC HLA DPB1"
/protein_id="AAA36266.1"
/db_xref="GI:553571"
/translation="NVVQLRQECVAFNGTORFLERYLNREELVRFDSVDGFRFVAT
ELGRPEAEYVNSQKLLLEKRAVPRMCRHNYELDEAVTLQRR"
284..>285
/number=2

Query Match      0.9%; Score 18.4; DB 1; Length 285;
Best Local Similarity 56.7%; Pred. No. 2.1e+02;
Matches 34; Conservative 0; Mismatches 26; Indels 0; Gaps 0;

Qy 1812 TTCTCTCTGAGTCTCTGTTGGTCTTAATTTTTCATTTCCAGATTCTCTCAGTTG 1871
Db 245 TTGTGTGACATCTCTGTCGCGACTCCCGCTCTCTCTCCAGATGTCCTTCTGCTG 186

RESULT 198
AF312826/c      804 bp      mRNA      linear      INV 02-MAR-2001
LOCUS          Luidia foliolata sea star regeneration-associated protease SRAP
DEFINITION     AF312826.1 GI:13183619
ACCESSION      AF312826
VERSION        AF312826
KEYWORDS       Luidia foliolata
SOURCE         Luidia foliolata
ORGANISM       Eukaryota; Metazoa; Echinodermata; Eleutherozoa; Asterozoa;
                Luidiida; Luidiidae; Luidia.
REFERENCE      1 (bases 1 to 804)
AUTHORS        Vickery,M.C., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE          Utilization of a novel deuterostome model for the study of
                regeneration genetics: molecular cloning of genes that are
                differentially expressed during early stages of larval sea star
                regeneration
JOURNAL        Gene 262 (1-2), 73-80 (2001)
MEDLINE        21100442
FUBMED         11179669
REFERENCE      2 (bases 1 to 804)
AUTHORS        Vickery,M.C.L., Vickery,M.S., McClintock,J.B. and Amsler,C.D.
TITLE          Direct Submission
JOURNAL        Submitted (12-OCT-2000) Department of Biology, University of
                Alabama at Birmingham, 1300 University Blvd., Birmingham, AL
                35294-1170, USA

FEATURES       Location/Qualifiers
source         1..804
               /organism="Luidia foliolata"
               /mol_type="mRNA"
               /db_xref="taxon:105861"
               /dev_stage="larva"
               1..804
               /note="serine protease"
               /codon_start=1
               /product="sea star regeneration-associated protease SRAP"
               /protein_id="AAK15274.1"
               /db_xref="GI:13183620"
               /translation="MLRLVLCALAAVADCGVQVNPVNLKINGDDEAVGSGPPWQ
                VNRKRYWAGDIFCGGLLISDEWASAACHFNIGNINHYAVGAHNRDSVDSIQT
                TVLQKGVFVHESYDITLNDLIALIKLSSPVSMNSVNCLEPTAATPTGTCVVTGW
                GQCEVADVPITLQVVPVLIISQCNATWYGEINDMNVCAGFKREGKDCQCGSGG
                PFVCSAGEYELGVWSWGCADARKPGVIKLVNYSWINNLVARN"

Query Match      0.9%; Score 18.4; DB 1; Length 804;
Best Local Similarity 59.6%; Pred. No. 2.2e+02;

Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy 517 TTGTTGATGACCTACTCTTGGGAGAGATGGGTATTGAAGTAGCCCACT 568
Db 251 TGGTTGATGTTGCCATAGTTATGGAAGCAATGGGCAGACAGACGCCCACT 200

RESULT 199
SHPFIXA
LOCUS          Sheep factor IX mRNA, partial cds.
DEFINITION     M26233
ACCESSION      M26233
VERSION        M26233.1 GI:165878
KEYWORDS       factor IX. (sheep)
SOURCE         Ovis aries (sheep)
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
                Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;
                Bovidae; Caprinae; Ovis.
REFERENCE      1 (bases 1 to 823)
AUTHORS        Sarkar,G., Koerber,D.D. and Sommer,S.S.
TITLE          Direct sequencing of the activation peptide and the catalytic
                domain of the factor IX gene in six species
JOURNAL        Genomics 6 (1), 133-143 (1990)
MEDLINE        90152675
FUBMED         2303254
COMMENT        Original source text: Sheep liver, cDNA to mRNA.
                Draft entry and computer-readable sequence for [1] kindly provided
                by G.Sarkar, 18-JUL-1989.

FEATURES       Location/Qualifiers
source         1..823
               /organism="Ovis aries"
               /mol_type="mRNA"
               /db_xref="taxon:9940"
               <1..>823
               /note="factor IX"
               /codon_start=1
               /protein_id="AA31520.1"
               /db_xref="GI:552413"
               /translation="RASVLTSSKLTAEITFSNNVNSSEAEIINDVNTQNSFD
                DNRVVGSDAARGQFPQVQLLHGEIAAFCGSVINRWVVAACHIKPGKIVTVAG
                EHNTKEPTEQRNVRIRAIYPHGXNASKYSHDIALLEDELELNSVYTPICID
                REYTNIFLKGFGYVSGWGRVFNRSASILQYLKVLPLVDRATCLRTKFTIYNMFC
                AGYHGGKDCSCQDGGPHVTEGTSFLTGLIISWGECAMKKGKGYIKVRSYEV"

Query Match      0.9%; Score 18.4; DB 1; Length 823;
Best Local Similarity 49.0%; Pred. No. 2.2e+02;
Matches 49; Conservative 0; Mismatches 51; Indels 0; Gaps 0;

Qy 189 ATTTCCTGATTTCTATCTGGCTCATTTTAACTCAGTAGTGAGTTGTTGCCATA 248
Db 207 AATTGCTGCATCTCTGGAGGTTCCATCGTTAATGAAAATGGGTTGTAACGTGCCCA 266

Qy 249 AGTTTGTAAGTTTCTGTTCTTCTCTGTTCTGTTGTTGTT 288
Db 267 CTGCATCAACCTGGTGTAAATTAATCTGTTGTCAGGT 306

RESULT 200
AF011900/c      832 bp      mRNA      linear      VRT 09-SEP-1997
LOCUS          Petromyzon marinus trypsinogen B1 (TRYPB1) mRNA, partial cds.
DEFINITION     AF011900
ACCESSION      AF011900
VERSION        AF011900.1 GI:2367498
KEYWORDS       Petromyzon marinus (sea lamprey)
SOURCE         Petromyzon marinus
ORGANISM       Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Hyperoartia;
                Petromyzontiformes; Petromyzontidae; Petromyzon.
REFERENCE      1 (bases 1 to 832)
AUTHORS        Roach,J.C.
TITLE          The Molecular Evolution of the Vertebrate Trypsinogens
JOURNAL        Unpublished

```



REFERENCE 2 (bases 1 to 832)  
Roach, J.C.  
Direct Submission  
Submitted (01-JUL-1997) Molecular Biotechnology, University of Washington, Seattle, WA 98195, USA  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..832  
/organism="Petrotyzon marinus"  
/mol\_type="mRNA"  
/db\_xref="taxon:7757"  
/dev\_stage="amocoete"  
/tissue\_lib="anterior intestine"  
<1..832  
/genes="TRYPB1"  
/db\_xref="GI:2367499"  
<1..736  
/genes="TRYPB1"  
/codon\_start=2  
/product="trypsinogen B1"  
/protein\_id="AAB69856.1"  
/db\_xref="GI:2367499"  
/translation="LIFALLVGTAAAPWYEDHIVGYECAAHQVQVSLNIGYHF CGSLSSWYVAAHYQATASRISVRIGEHNFVTEGTEQRIQAKAIRPQYSSAT INDIMLILSSPATLNOVAQVPLPSPSCVGTGVMCTISGAGETQTSVGSVDLMCVQ APVLSSTCRNSYPGDITNNMILCLYLEGGKDSQCGSGPVCNGLQGIWSNGRG.  
ALPNYGVTVKVCNYSWIASTMAAN"  
sig\_peptide  
1..37  
/gene="TRYPB1"  
/evidence=not\_experimental  
mat\_peptide  
38..733  
/gene="TRYPB1"  
/product="trypsin b1"  
/evidence=not\_experimental  
Query Match 0.9%; Score 18.4; DB 1; Length 832;  
Best Local Similarity 78.8%; Pred. No. 2.2e+02;  
Matches 22; Conservative 0; Mismatches 6; Indels 0; Gaps 0;  
QY 1591 TCTTTTGGTTTCTTGTGAATATTTT 1618  
DB 832 TTTTCTTTTCTTTTATTTTCAATATTTT 805  
RESULT 201  
AF465275/c  
LOCUS 1293 bp mRNA linear VRT 02-FEB-2003  
DEFINITION Takifugu rubripes coagulation factor VIIC precursor, mRNA, complete cds.  
ACCESSION AF465275  
VERSION AF465275.1 GI:28194021  
KEYWORDS Takifugu rubripes (Fugu rubripes)  
SOURCE Takifugu rubripes  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Actinopterygii; Neopterygii; Teleostei; Euteleostei; Neoteleostei; Acanthomorpha; Actinopterygii; Perciformes; Tetraodontiformes; Tetraodontidae; Tetraodontidae; Takifugu.  
REFERENCE 1 (bases 1 to 1293)  
Davidson, C.J., Hitt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G.D. and McVey, J.H.  
Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes  
Unpublished  
2 (bases 1 to 1293)  
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.  
Direct Submission  
Submitted (04-JAN-2002) Haemostasis Group, MRC Clinical Sciences Centre, The Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK  
JOURNAL Location/Qualifiers  
FEATURES  
source  
1..1293  
/organism="Takifugu rubripes"  
/mol\_type="mRNA"  
/db\_xref="taxon:31033"

CDS  
1..1293  
/SC\_number="3.4.21.21"  
/function="serum prothrombin conversion accelerator"  
/note="vitamin K dependent serine protease; similar to factor VII precursor; synthesized in liver; similar to Fugu rubripes FVII and FVIII; contains 2 EGF-like domains; member of peptidase family S1/trypsin family"  
/codon\_start=1  
/product="coagulation factor VIIC precursor"  
/protein\_id="AA033370.1"  
/db\_xref="GI:28194021"  
/translation="WASFRGKRLFFIKLFIIVPVCSPFAGVFNKEPEANVFLH RTRANFLPEELKAGNERIEKESYEAEKIFALPOOLEAFWRTYAVDCKLSP CKNGATCTRRFTYACKANGHNDKVALTNGCRNGGCEHFEPDRSYVC FCPAGVRLDKNSTCLPQVPCGRQLQIFSPRVINGLI CPKGCPCWAMLSNNIYV CGTIILSEOMVLAARHCVKRVKFLNVTVEGHDREIPEKTEQRRVTKVLIHSGYNNK TSSDKDLMLKLRVPKGLGVPICLPAONSTISRTIANIROSIVSGMGLSRFGPP APIQLRLTLPVPELOECBLHTNMLNLCAGLTKGRDACEGDSGSPVTVYEKTW FLTGVSWGKGCANENLYGVYVRVNFIDWIGNIATN"  
Query Match 0.9%; Score 18.4; DB 1; Length 1293;  
Best Local Similarity 69.4%; Pred. No. 2.2e+02;  
Matches 25; Conservative 0; Mismatches 11; Indels 0; Gaps 0;  
QY 1656 CCTTTCGTTTTCATAGTGTCTCTGGCTTCTCTGGA 1691  
DB 115 CCTCGGGTTTTCCATATAAACTCCGCTCCGAA 80  
RESULT 202  
AX523898  
LOCUS 1505 bp DNA linear PAT 24-OCT-2002  
DEFINITION Sequence 105 from Patent WO02064799.  
ACCESSION AX523898  
VERSION AX523898.1 GI:24412662  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
Seldon, R.F., Miller, A.M. and Treco, D.S.  
Optimized messenger rna  
Patent: WO 02064799-A 105 22-AUG-2002;  
TRANSLATION THERAPIES, INC. (US)  
FEATURES  
source  
1..1505  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 18.4; DB 1; Length 1505;  
Best Local Similarity 59.6%; Pred. No. 2.2e+02;  
Matches 31; Conservative 0; Mismatches 21; Indels 0; Gaps 0;  
QY 1709 ATTTAGCTTAACATTTTCTTTGACCAAGGTATCCATTTCTTCTTCTTGT 1760  
DB 1425 AATTGAATTAACAGGGCTCTCTACTAATCACTTCCATCTTTTGT 1476  
RESULT 203  
S78934  
LOCUS 171 nt DNA linear PRI 07-MAY-1993  
DEFINITION (Factor IX Madrid 2) (exon IV and intron d) [human, Genomic Mutant, 171 nt].  
ACCESSION S78934  
VERSION S78934.1 GI:244109  
KEYWORDS Homo sapiens (human)  
SOURCE Homo sapiens  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 171)

**AUTHORS** Solera,J., Magallon,M., Martin-Villar,J. and Coloma,A.  
**TITLE** Factor IXMadrid 2: a deletion/insertion in factor IX gene which abolishes the sequence of the donor junction at the exon IV-intron d splice site  
**JOURNAL** Am.J. Hum. Genet. 50 (2), 434-437 (1992)  
**MEDLINE** 92133619  
**PUBMED** 1346483  
**REMARK** GenBank staff at the National Library of Medicine created this entry [NCBI gisbq 78934] from the original journal article. This sequence comes from Fig 3A.

**FEATURES**  
 source  
 1..171  
 /organism="Homo sapiens"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9606"

**Query Match** 0.9%; Score 18.2; DB 1; Length 171;  
**Best Local Similarity** 51.9%; Pred. No. 2.2e+02;  
**Matches** 41; Conservative 0; Mismatches 38; Indels 0; Gaps 0;

**QY** 427 CTTTGTGTTTGGTCAATAGTCTGTAAATATCTTAGTCCACTTGGTTATGACATCA 486  
 |||||  
**Db** 84 CTTTGGATTGGAAGGAAGAACTGTGAATTTCCAGTTTCAACTGTTTTCAGAGGAAA 143  
 |||||

**QY** 487 GTTAGCTCCAGCAATTTCTC 505  
 |||||  
**Db** 144 CTTTGAACCATGAGTATTC 162  
 |||||

**RESULT 204**  
**AX318568** AX318568 240 bp DNA linear PAT 06-JUL-2002  
**LOCUS** Sequence 73 from Patent WO0177155.  
**DEFINITION** AX318568  
**ACCESSION** AX318568  
**VERSION** AX318568.2 GI:21713338  
**KEYWORDS**  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

**REFERENCE**  
**AUTHORS** 1 Fernandes,E., Vernet,C.A., Mishnu,V.S., Leach,M.D., Shimkets,R.A., Zerhusen,B.D. and Kekuda,R.  
**TITLE** Orfx polynucleotides and polypeptides  
**JOURNAL** Patent: WO 0177155-A 73 18-OCT-2001;  
 Curagen Corporation (US)  
**COMMENT** On Jul 8, 2002 this sequence version replaced gi:17900986.  
**FEATURES**  
 source  
 1..240  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

**Query Match** 0.9%; Score 18.2; DB 1; Length 240;  
**Best Local Similarity** 58.2%; Pred. No. 2.3e+02;  
**Matches** 32; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

**QY** 1646 TTCCTCATTCCTTGGTTTTCATAGTCTCTGGCTTCCTCGGATGTTTATG 1700  
 |||||  
**Db** 26 TCCCTCAGATCCTCTGAGTGTGGAGCGGCCCTCGCTTCCGGATAGTTGGT 80  
 |||||

**RESULT 205**  
**AY083553** AY083553 251 bp DNA linear PRI 13-APR-2002  
**LOCUS** Macaca mulatta growth associated protein 43 (GAP43) gene, 3' UTR.  
**DEFINITION** AY083553  
**ACCESSION** AY083553  
**VERSION** AY083553.1 GI:20146915  
**KEYWORDS**  
**SOURCE** Macaca mulatta (rhesus monkey)  
**ORGANISM** Macaca mulatta  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Cercopitheidae;

**REFERENCE** Cercopitheidae; Macaca.  
 1 (bases 1 to 251)  
**AUTHORS** Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.  
**TITLE** Construction of a targeted rhesus macaque microarray  
**JOURNAL** Unpublished  
**REFERENCE** 2 (bases 1 to 251)  
**AUTHORS** Norgren,R.B. Jr., Zink,M.A., Jia,Y., Ojeda,S.R. and Spindel,E.R.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (11-MAR-2002) Molecular and Cellular Biology Core, Oregon Regional Primate Research Center, 505 NW 185th Avenue, Beaverton, OR 97006, USA

**FEATURES**  
 Location/Qualifiers  
 1..251  
 /organism="Macaca mulatta"  
 /mol\_type="genomic DNA"  
 /db\_xref="taxon:9544"

gene

mrna

3'UTR

**Query Match** 0.9%; Score 18.2; DB 1; Length 251;  
**Best Local Similarity** 55.6%; Pred. No. 2.3e+02;  
**Matches** 35; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

**QY** 900 TTCTGTACCCAGTATCTTTTCTAGAGAAATAGATCAATTCATGATGTTGAGA 959  
 |||||  
**Db** 147 TTTTGTCTCTGCTGTGTATGGCGAGTTTGTGTAATGATGATCAATTTGGGA 206  
 |||||  
**QY** 960 ATT 962  
 |||||  
**Db** 207 AAT 209  
 |||||

**RESULT 206**  
**HSTCRB9** HSTCRB9 265 bp mRNA linear PRI 22-DEC-1993  
**LOCUS** H.sapiens (3.2) mRNA for T-cell receptor beta chain.  
**DEFINITION** X74849  
**ACCESSION** X74849  
**VERSION** X74849.1 GI:407455  
**KEYWORDS** T-cell receptor beta chain; TCR-b gene.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

**REFERENCE**  
**AUTHORS** Jores,R. and Neo,T.  
**TITLE** Few V gene segments dominate the T cell receptor beta-chain repertoire of the human thymus  
**JOURNAL** J. Immunol. 151 (11), 6110-6122 (1993)  
**MEDLINE** 94065165  
**PUBMED** 8245454  
**REFERENCE** 2 (bases 1 to 265)  
**AUTHORS** Jores,R.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (11-AUG-1993) R. Jores, Institut Pasteur, Unite d'Immunogenetique, Dept d'Immunologie, 25, rue du Dr. Roux, 75015 Paris, FRANCE

**FEATURES**  
 source  
 1..265  
 /organism="Homo sapiens"  
 /mol\_type="mrna"  
 /db\_xref="taxon:9606"  
 /clone="3.2"  
 /tissue\_type="thymus"  
 /clone\_lib="human thymus cdna"  
 1..265  
 /gene="TCR-b"  
 38..265  
 /gene="TCR-b"

gene

CDS





Db 238 CTGCGAGCCACTCCACGACGTCCTCCAGTAGGCTCTCCAGTCTCCGCTCATGG 179

Qy 123 TTCTCTTAACACTT 136

Db 178 GCCGTCTCCCACTT 165

RESULT 212  
AV267909S2/c  
LOCUS Homo sapiens MHC class I antigen (HLA-A) gene, HLA-A\*3401 variant  
DEFINITION allele, exon 3 and partial cds.  
ACCESSION AY267910  
VERSION AY267910.1 GI:30525804  
KEYWORDS  
SEGMENT  
SOURCE 2 of 2  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 276)  
AUTHORS Steinert, N.K., Fernandez-Vina, M. and Hurley, C.K.  
TITLE Novel HLA-A Allele  
JOURNAL Unpublished  
AUTHORS Steinert, N.K., Fernandez-Vina, M. and Hurley, C.K.  
DIRECT SUBMISSION  
TITLE Direct Submission  
JOURNAL Submitted (03-APR-2003) Lombardi Cancer Center, Georgetown  
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC  
20007, USA

FEATURES  
source  
1. .276  
Location/Qualifiers  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="GN00431"  
/db\_xref="taxon:9606"  
order(AY267909.1:<1..270,1..>276)  
/gene="HLA-A"  
/allele="HLA-A\*3401 variant"  
join(AY267909.1:<1..270,1..>276)  
/gene="HLA-A"  
/product="MHC class I antigen"  
join(AY267909.1:<1..270,1..>276)  
/gene="HLA-A"  
/codon\_start=3  
/product="MHC class I antigen"  
/protein\_id="AAP32699.1"  
/db\_xref="GI:30525805"  
translation="SSSMRYFYVTSVSRPGRGPRFTAVGVDDTQFVRFSDAASORM  
EPAPRTQSGPYWRNTRKVKYKQSTDRVLDGLRGYNQSESGSHTIQRMVCDY  
GPDRLRGQQDAYDKQITSLNEDRSWTADYAAQITQRKWEIAEAGWRAYLE  
GTCVWMLRYLNGKETLQKT"  
exon  
1. .276  
/gene="HLA-A"  
/number=3

Query Match 0.9%; Score 18; DB 1; Length 276;  
Best Local Similarity 52.7%; Pred. No. 2.6e+02;  
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

Qy 63 CTGCTGCCTTTCCCTGTCTGATCTCCTAGGGTGAGGTTACACGCTCTCTCTCC 122  
|||||  
Db 238 CTGCGAGCCACTCCACGACGTCCTCCAGTAGGCTCTCCAGTCTCCGCTCATGG 179  
|||||

Qy 123 TTCTCTTAACACTT 136  
|||||  
Db 178 GCCGTCTCCCACTT 165  
|||||

RESULT 214  
HSHLAAGN2/c  
LOCUS Human MHC class I antigen HLA-A gene (A\*2601 variant), exon 3 and  
DEFINITION partial cds.  
ACCESSION U90243  
VERSION U90243.1 GI:1905858  
KEYWORDS  
SEGMENT  
SOURCE 2 of 2  
ORGANISM Homo sapiens (human)  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 276)  
AUTHORS Hurley, C.K., Steiner, N., Kosman, C., Mitton, W., Koester, R., Bei, M.,  
Bush, J., McCormack, J., Hahn, A., Hanson, V., Hoyer, R., Wade, J.A.,  
Hartzman, R.J. and Ng, J.  
TITLE Novel HLA-A and HLA-B alleles  
JOURNAL Tissue Antigens 52 (1), 84-87 (1998)  
MEDLINE 98378282  
PUBMED 9714480  
REFERENCE 2 (bases 1 to 276)  
AUTHORS Bei, M. and Hurley, C.K.  
TITLE Direct Submission  
JOURNAL Submitted (20-FEB-1997) Microbiology & Immunology, Georgetown  
University Medical Center, 3970 Reservoir Rd. NW, Washington, DC

20007, USA

FEATURES  
source

1..276  
/location="Qualifiers"  
/organism="Homo sapiens"  
/mol\_type="genomic DNA"  
/isolate="GNO0158"  
/db\_xref="taxon:9606"  
Join(U90242.1:1..270,1..>276)  
/gene="HLA-A"  
Join(U90242.1:1..270,1..>276)  
/gene="HLA-A"  
/product="MHC class I antigen"  
Join(U90242.1:1..270,1..>276)  
/gene="HLA-A"  
/note="variant A\*2601"  
/codon\_start=3  
/product="MHC class I antigen"  
/protein\_id="AAB50149.1"  
/db\_xref="GI:1905860"  
/translation="SHSMRYFTSVSPGRGEPRFIAVGVDDTQFVRPDSDAASORM  
EPRAPIWEGPEYWDNRNKAHSQTDNRANGLTGLGYNQSDGSHIQRYMGCDV  
GTFGRFLRGYQDDAYDGRDYALNEDRSMTAAMAAQITQRKWEHAHEQWRAYLE  
GTCVNEWLRYLENGKETLQRT"  
1..276  
/gene="HLA-A"  
/number=3

Query Match 0.9%; Score 18; DB 1; Length 276;  
Best Local Similarity 52.7%; Pred. No. 2.6e+02;  
Matches 39; Conservative 0; Mismatches 35; Indels 0; Gaps 0;

QY 63 CTGCTGCCTTTCTCCTCTGATTCCTAGGAGGAGGTTACCACTGCTCTCTCTCCC 122  
DB 238 CTGCGAGCCACTCCACGACGCTGCCCTCCAGGTAGGCTCTCCACTGCTCCGCTCATG 179

QY 123 TTCTCTACACTT 136  
DB 178 GCCGTCTCCACTT 165

RESULT 215  
AR249144/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
source

AR249144  
Sequence 4503 from patent US 6476212.  
AR249144  
AR249144.1 GI:27297018

Unknown.  
Unknown.  
Unclassified.  
1 (bases 1 to 290)  
Lalquadi, R.V., Ito, L.Y. and Sherman, B.K.  
Polynucleotides and polypeptides derived from corn ear  
Patent: US 6476212-A 4503 05-NOV-2002;  
Location/Qualifiers  
1..290  
/organism="unknown"  
/mol\_type="genomic DNA"

Query Match 0.9%; Score 18; DB 1; Length 290;  
Best Local Similarity 51.2%; Pred. No. 2.6e+02;  
Matches 42; Conservative 0; Mismatches 40; Indels 0; Gaps 0;

QY 1577 GGTAGGAATTTCTTTTGTGTTTCTTGAAATATTTCCTCGCTTTGACCTGCC 1636  
DB 218 GCGCGAGAGATCTTGCCCTCTGCTGCCAGGAGGCTCGGCTCTCCAGGGGTGAC 159

QY 1637 TCTCTCCCTTCCTCTATTCCT 1658  
DB 158 TGCAGTCCATCTTCTCGGCT 137

RESULT 216

AX312474  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
JOURNAL  
FEATURES  
source

AX312474  
Sequence 5459 from Patent WO0190366.  
AX312474  
AX312474.1 GI:17897467  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
1  
Leach, M.D. and Shinkets, R.A.  
Human polynucleotides and polypeptides encoded thereby  
Patent: WO 0190366-A 5459 29-NOV-2001;  
Curagen Corporation (US)  
Location/Qualifiers  
1..299  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 18; DB 1; Length 299;  
Best Local Similarity 54.5%; Pred. No. 2.6e+02;  
Matches 36; Conservative 0; Mismatches 30; Indels 0; Gaps 0;

QY 1626 TTGACCTGCTTCTTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685  
DB 220 TTGACGTGCTTCCACCCATCTCTTCATGACTACATGCTTCCAGTCTGCCCTCCGAA 279

QY 1686 CCTGGA 1691  
DB 280 CCTGGA 285

RESULT 217  
BR271156/c  
LOCUS  
DEFINITION  
ACCESSION  
VERSION  
KEYWORDS  
SOURCE  
ORGANISM  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
REFERENCE  
AUTHORS  
TITLE  
JOURNAL  
source

BR271156  
Bos taurus partial mRNA for haptoglobin (hp gene).  
AJ271156  
AJ271156.1 GI:9581738  
haptoglobin; hp gene.  
Bos taurus (cow)  
Bos taurus  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Cetartiodactyla; Ruminantia; Pecora; Bovidae;  
Bovidae; Bos.  
1  
Lavery, K.S., Gabler, C. and Killian, G.J.  
Expression and localization of haptoglobin in the bovine female  
reproductive tract  
Unpublished  
2 (bases 1 to 302)  
Lavery, K.S.  
Direct Submission  
Submitted (28-JAN-2000) Lavery K.S., Dairy & Animal Science,  
Pennsylvania State University, The John O. Almquist Research  
Center, Fox Hollow Road, University Park, USA  
Location/Qualifiers  
1..302  
/organism="Bos taurus"  
/mol\_type="mRNA"  
/db\_xref="taxon:9913"  
/sex="female"  
/cell\_type="epithelial cell"  
/tissue\_type="oviduct"  
/dev\_stage="adult"  
1..302  
/gene="hp"  
/genes="hp"  
/function="acute phase protein"  
/codon\_start=3  
/product="haptoglobin"

		/protein_id="CAC00531.1"			
		/db_xref="GI:9561739"			
		/db_xref="GOA:Q9MYV8"			
		/db_xref="SPTREMBL:Q9MYV8"			
		/translation="KGSFFQAKMVSOHNLISGATLINERWLLTTAKNLYLGHSSDKK AKDITPLRLYVGKQLVEVEKXWLRPHDHSKVDIGLIKLRQKVPVNDKVMPICLPS"			
Query Match	0.9%	Score 18;	DB 1;	Length 302;	
Best Local Similarity	52.7%	Pred. No. 2	6e+02;		
Matches 39;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;	
QY	1550	GTACCTTGATAGGCACTCTTCTCAAGGTGTAGGAAATTTCTTTTTCGTTTCTGTGA	1609		
DB	297	GTAGCGAGATGGGCATTACTTTGTCAATGACAGGTACCTTCTGCTGAGTTTGATGAGCC	238		
QY	1610	AAATATTTTCCCTG	1623		
DB	237	CAATGCTAGCTTG	224		

RESULT 218	
AF266240	LOCUS
AF266240	383 bp mRNA linear VRT 15-FEB-2001
DEFINITION	Gillichthys seta trypsinogen 2 precursor, mRNA, partial cds.
ACCESSION	AF266240
VERSION	AF266240.1 GI:10121759
KEYWORDS	Gillichthys seta
SOURCE	Gillichthys seta
ORGANISM	Gillichthys seta
	Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;
	Actinopterygii; Neopterygii; Teleostei; Euteleostei; Necteleostei;
	Acanthomorpha; Acanthopterygii; Percomorpha; Perciformes;
	Gobioidae; Gobiidae; Gillichthys.
	1 (bases 1 to 383)
REFERENCE	Gracey,A.Y., Troll,J.V. and Somero,G.N.
AUTHORS	Hypoxia-induced gene expression profiling in the euryoxic fish
TITLE	Gillichthys mirabilis
JOURNAL	Proc. Natl. Acad. Sci. U.S.A. 98 (4), 1993-1998 (2001)
MEDLINE	21117151
PMID	11172064
REFERENCE	2 (bases 1 to 383)
AUTHORS	Gracey,A.Y., Troll,J.V. and Somero,G.N.
TITLE	Direct Submission
JOURNAL	Submitted (10-May-2000) Biological Sciences, Stanford University,
	Hopkins Marine Station, Oceanview Blvd., Pacific Grove, CA 93950,
	USA

```

1. .383
/organism="Gilllichthys seta"
/mol_type="mRNA"
/db_xref="taxon:79683"
/tissue_type="liver"
33. -383
/codon_start=1
/product="tyrosinogen 2 precursor"
/protein_id="AAGI3359.1"
/db_xref="GI:10121760"
/translation="MCLVFILLIGAFAEDDKIVGGVECTPHSQAHQVSLNSGYHFC
GGSILVNAEWVYSAAHGYCKRVEVRLEGHNIRLTGTEQFISSSRVIRHPNYSYINDI
DIMLIKLSKPSANL"

```

Query Match	0.98;	Score 18;	DB 1;	Length 383;
Best Local Similarity	52.7%;	Pred. No. 2.7e+02;		
Matches 39;	Conservative 0;	Mismatches 35;	Indels 0;	Gaps 0;
QY	135	TCATTTCTATCTGGCTCATTTTAACTCAGTAGTGAGTGTGTGTTTCCATGAAGTTG	254	
DB	155	TCATCTCTGCGAGGCTCTCTGTCACGCGAATGGGTGTGTCTGTCTCACTGCTA	214	
QY	255	TAAGTTTTCTGTTG	268	
DB	215	CAAGTCTCGTGTG	228	

RESULT	219
AX9211761	
LOCUS	
DEFINITION	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
REFERENCE	
AUTHORS	
JOURNAL	
FEATURES	
source	
Query Map	
Best Locc	
Matches	
QY	1
Ddb	
RESULT	220
HUMCFIX	
LOCUS	
DEFINITION	
ACCESSION	
VERSION	
KEYWORDS	
SOURCE	
ORGANISM	
REFERENCE	
AUTHORS	
TITLE	
JOURNAL	
MEDLINE	
PUBLISHED	
COMMENT	
FEATURES	
source	
gene	
CDS	

```

AX9211761      815 bp      DNA      linear      PAT 18-DEC-2003
Sequence 101 from Patent WO02068649.
AX921761
AX921761.1    GI:40215332
               Homo sapiens (human)
               Homo sapiens
               Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
               Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.
               1
               Patent: WO 02068649-A 101 06-SEP-2002;
               Curagen Corporation (US)
               Location/Qualifiers
                   1..815
                       /organism="Homo sapiens"
                       /mol_type="unassigned DNA"
                       /db_xref="taxon:9606"

               Similarity      0.9%;      Score 18;      DB 1;      Length 815;
               27;      Conservative      0;      Mismatches      15;      Indels      0;      Gaps      0;

14      TTTTGCATAGTCTCTGGCTTCCTGGATGTTTATGCTGG      1705
TCTTGCAGATGTGGCTTGCAGCTGCTGGAGATGCCGG      80

```

HUMCFFIX 873 bp mRNA linear PRI 01-NOV-1994  
Human coagulation factor IX mRNA, partial cds.  
M35672  
M35672.1 GI:180287  
coagulation factor IX; serine protease.  
Homo sapiens (human)  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Caearrhini; Homiidae; Homo.  
1 (bases 1 to 873)  
Jagadeeswaran,P., Lavelle,D.E., Kaul,R., Mohandas,T. and  
Warren,S.T.  
Isolation and characterization of human factor IX cDNA:  
identification of Tag I polymorphism and regional assignment  
Sonat. Cell Mol. Genet. 10 (S), 465-473 (1984)  
84300526  
6089357  
Original source text: Human adult liver, cDNA to mRNA.

```

location/Qualifiers
1..873
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/map="Xq26.3-q27.1"
1..873
/gene="F9"
<1..>873
/gene="F9"
/note="coagulation factor IX"
/codon_start=1
/protein_id="AA51981.1"
/db_xref="GI:180288"
/translaton="NANKILANPKRYNSKGKLEEFVQGNLERECMEKSCFSBAREVFVE
NTEATITFKQIVDQCESNCLNGSKCKDINSYECQPFGEKQCELDVTCNIK
NGRCQFKNSADNKKVCSCTEGYRLASNQSCSEPAVFPCCGRVSVSQTSLKTRAETV
FPDQVYNSTAEAILDNITQSTGDNFTRVVGEDAKPGQFPQWVLNGKVDAPCG
GSIVNEKIVTAAHCVEGVKTIIVAGEHNIEETETHTBQKRNVIIRIIPHNNYNAAIK
YNNKILVLELDEPLV"

```







Query Match  
Best Local Similarity 0.9%; Score 17.8; DB 1; Length 177;  
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

QY 42 CTGTGGCAATACCTCTGGGGGTGCTGCTTCTCCCTGCTGCTGATTCCTAGGG 94  
Db 93 CCGGAGGTGCTTGTGTGTGCGGCTTCACGCGCTGCTCTCTCATTAGGG 41

RESULT 224  
AX52169/C  
LOCUS AX52169 239 bp DNA linear PAT 08-AUG-2001  
DEFINITION Sequence 3 from patent US 6232456.  
ACCESSION AR152169  
VERSION AR152169.1 GI:15118219  
KEYWORDS Unknown.  
SOURCE Unknown.  
ORGANISM Unclassified.  
REFERENCE Cohen, M., Colpitts, T.L., Friedman, P.N., Granados, E., Klass, M.R.,  
AUTHORS Russell, J.C., Stewart, K.D. and Stroupe, S.D.  
TITLE Serine protease reagents and methods useful for detecting and  
treating diseases of the prostate  
JOURNAL Patent: US 6232456-A 3 15-MAY-2001;  
FEATURES Location/Qualifiers  
source  
1..239  
/organism="unknown"  
/mol\_type="unassigned DNA"

Query Match  
Best Local Similarity 0.9%; Score 17.8; DB 1; Length 239;  
Matches 34; Conservative 0; Mismatches 27; Indels 0; Gaps 0;  
/mol\_type="unassigned DNA"

QY 137 CTGGCCAGGTAGGGCACTACCGCATTCCTCTCTCCACACATCTATTTCTTG 196  
Db 196 CCGGGTGGGGAAGACTCAGTGCTGTCGGGTCTGCTCACAGCCCTCTCTCTGG 137

QY 197 A 197  
Db 136 A 136

RESULT 225  
AX040017  
LOCUS AX040017 315 bp DNA linear PAT 18-NOV-2000  
DEFINITION Sequence 33 from Patent WO0063435.  
ACCESSION AX040017  
VERSION AX040017.1 GI:11230031  
KEYWORDS Rattus sp.  
SOURCE Rattus sp.  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae;  
Rattus.  
REFERENCE Gould-Rothberg, B.E. and Dipippo, V.A.  
AUTHORS Method of identifying toxic agents using differential gene express  
TITLE ion  
JOURNAL Patent: WO 0063435-A 33 26-OCT-2000;  
Curagen Corporation (US)  
FEATURES Location/Qualifiers  
source  
1..315  
/organism="Rattus sp."  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10118"

QY 688 CTTTGATCGCTATCTAGTATCTTCCCAATCTCACTGCTTAGTT 732  
Db 163 CTTTCATTCGACTGAGTTTCTTCCAAATCCAGTCCACATCTT 207

RESULT 226  
AX524243  
LOCUS AX524243 341 bp DNA linear PAT 21-NOV-2002  
DEFINITION Sequence 273 from Patent EP1236798.  
ACCESSION AX524243  
VERSION AX524243.1 GI:25169339  
KEYWORDS Mus musculus (house mouse)  
SOURCE Mus musculus  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and  
AUTHORS Schluster, T.  
TITLE Gene library and method for its production  
JOURNAL Patent: EP 1236798-A 273 04-SEP-2002;  
FEATURES Location/Qualifiers  
source  
1..341  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match  
Best Local Similarity 0.9%; Score 17.8; DB 1; Length 341;  
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;  
/mol\_type="unassigned DNA"

QY 448 TCTGTAATATCTAGTCCACTTGGTTTATGACATCATCTAGTCCAGCAT 500  
Db 254 TCTGTGACTTCTGTAGTAGACTTTGGCACAGTTCTCATTGGCAGGAGCGT 306

RESULT 227  
AX552981  
LOCUS AX552981 341 bp DNA linear PAT 27-NOV-2002  
DEFINITION Sequence 273 from Patent WO02074953.  
ACCESSION AX552981  
VERSION AX552981.1 GI:25896981  
KEYWORDS Mus musculus (house mouse)  
SOURCE Mus musculus  
ORGANISM Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.  
REFERENCE Hoefler, M., Hofmann, M., Kaiser, C., Kranz, H., Loebbert, R. and  
AUTHORS Schluster, T.  
TITLE Gene library and a method for producing the same  
JOURNAL Patent: WO 02074953-A 273 26-SEP-2002;  
FEATURES Location/Qualifiers  
source  
1..341  
/organism="Mus musculus"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:10090"

Query Match  
Best Local Similarity 0.9%; Score 17.8; DB 1; Length 341;  
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;  
/mol\_type="unassigned DNA"

QY 448 TCTGTAATATCTAGTCCACTTGGTTTATGACATCATCTAGTCCAGCAT 500  
Db 254 TCTGTGACTTCTGTAGTAGACTTTGGCACAGTTCTCATTGGCAGGAGCGT 306

```

RESULT 228
AX375719/c
LOCUS AX375719 927 bp DNA linear PAT 01-MAR-2002
DEFINITION Sequence 26 from Patent WO0196378.
ACCESSION AX375719
VERSION AX375719.1 GI:19170240
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1. Xiao,Y.
Regulation of human epithin-like serine protease
Patent: WO 0196378-A 26 20-DEC-2001;
Bayer Aktiengesellschaft (DE)
Location/Qualifiers
1. .927
/organism="Homo sapiens"
/mol_type="unassigned DNA"
/db_xref="taxon:9606"
FEATURES
source
Query Match 0.9%; Score 17.8; DB 1; Length 927;
Best Local Similarity 67.6%; Pred. No. 3.1e-02;
Matches 25; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

Qy 35 GAAGCTCTCTGCGCAATCTTCTGGGCTGCTGCT 71
|||||
Db 54 GAAACTCAGCAGGAAAGGACATCGGCTGCTGCTT 28
|||||

RESULT 229
AY030095
LOCUS AY030095 1077 bp mRNA linear PRI 24-JAN-2003
DEFINITION Homo sapiens pancreasin mRNA, complete cds.
ACCESSION AY030095
VERSION AY030095.1 GI:20384683
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1. (bases 1 to 1077)
Bhagwandin,V.J., Hau,L.W.T., Mallen-St. Clair,J., Walters,P.J. and
Caughey,G.H.
Structure and activity of human pancreasin, a novel tryptic serine
peptidase expressed primarily by the pancreas
J. Biol. Chem. 278 (5), 3363-3371 (2003)
12441343
2. (bases 1 to 1077)
Hau,L.W.T. and Caughey,G.H.
Direct Submission
Submitted (11-APR-2001) Medicine, UCSF, 90 Medical Center Way, San
Francisco, CA 94143-0911, USA
Location/Qualifiers
1. .1077
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="16"
/map="16p"
1. .873
/notes="CAPH2; channel-activating protease 2; tryptic
serine protease; similar to marapsin"
/codon_start=1
/product="pancreasin"
/protein_id="AAK169.1"
CDS
FEATURES
source
Query Match 0.9%; Score 17.8; DB 1; Length 1125;
Best Local Similarity 53.6%; Pred. No. 3e-02;
Matches 37; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

PKLQFQPARLGGOK"
Query Match 0.9%; Score 17.8; DB 1; Length 1077;
Best Local Similarity 53.6%; Pred. No. 3e-02;
Matches 37; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

Qy 1225 TTCTTACATCTGATTTATCTTAGAATGCTTTCTTCTCCAACTATTGTGACGAAAG 1284
|||||
Db 1005 TTCTCCCTCTCAATACCTTATTTATTATGTTTCTCCATATAAAACCCAGCCTG 1064
|||||

Qy 1285 TTTTCTTAA 1293
Db 1065 TGTGCCAAA 1073

RESULT 230
AB056161
LOCUS AB056161 1125 bp mRNA linear PRI 04-MAR-2003
DEFINITION Homo sapiens PRSS27 mRNA for serine protease 27, complete cds.
ACCESSION AB056161
VERSION AB056161.1 GI:18916397
KEYWORDS Homo sapiens (human)
SOURCE Homo sapiens
ORGANISM Homo sapiens
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Euthera; Primates; Catarrhini; Hominidae; Homo.
REFERENCE
1. Okaze,H., Hayashi,A., Kozuma,S. and Saito,T.
G3VTS2083
Unpublished
2. (bases 1 to 1125)
Okaze,H., Hayashi,A., Kozuma,S. and Saito,T.
Direct Submission
Submitted (23-FEB-2001) Toshiyuki Saito, National Institute of
Radiological Sciences, Genome Research Group, 4-9-1, Anagawa,
Inage-ku, Chiba, Chiba 263-8555, Japan (E-mail:ts_saito@nirs.go.jp,
Tel:81-43-206-3135, Fax:81-43-251-9818)
Location/Qualifiers
1. .1125
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="taxon:9606"
/chromosome="16"
/cell_type="pool"
1. .1125
/genes="PRSS27"
51. .923
/genes="PRSS27"
/codon_start=1
/product="serine protease 27"
/protein_id="BAB85497.1"
/db_xref="GI:18916398"
/translators="MRRPAVLLLLLCFSGRAAATACGPRMLNMVGQDPTOEG
EMQVSIORNGSHFCGSLIAEOMVLTAAHCFRTSLSYQLVLGARQLVQGPBA
MYARVQVSNPLVYQGTASSADVALVEAPVFTNYILPCLPDPSPVIFETGNCWV
TGMGSEEDLLEPEPRILQKLAVIDITPKNLLYSKOTEFYQPKTKINDMLCAGFE
EGKDKADGSGGLVCLVQSWLQAGVLSWEGGCARONRPGVYIRVTAHENVHRII
PKLQFQPARLGGOK"
1098. .1103
/genes="PRSS27"
1120
/genes="PRSS27"
polyA_signal
polyA_site
Query Match 0.9%; Score 17.8; DB 1; Length 1125;
Best Local Similarity 53.6%; Pred. No. 3e-02;
Matches 37; Conservative 0; Mismatches 32; Indels 0; Gaps 0;

```

Db 1115 TGTGCCAA 1123

RESULT 231  
AF465268 1278 bp mRNA linear VRT 02-FEB-2003  
DEFINITION Gallus gallus coagulation factor VII precursor (F7) mRNA, complete cds.

ACCESSION AP465268  
VERSION AP465268.1 GI:28194007  
SOURCE Gallus gallus (chicken)  
ORGANISM Gallus gallus  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Archosauria; Aves; Neognathae; Galliformes; Phasianidae; Phasianinae; Gallus.  
1 (bases 1 to 1278)  
Davidson, C.J., Hirt, R.P., Lal, K., Snell, P., Elgar, G., Tuddenham, E.G.D. and McVey, J.H.  
Comparative sequence analysis and molecular evolution of blood coagulation genes from Gallus gallus and Fugu rubripes  
2 (bases 1 to 1278)  
McVey, J.H., Davidson, C.J., Lal, K., Snell, P. and Elgar, G.  
Direct Submission  
Submitted (04-JAN-2002) Haemostasis Group, MAC Clinical Sciences Centre, the Faculty of Medicine, Imperial College, Hammersmith Campus, Du Cane Road, London W12 0NN, UK  
LOCATION/Qualifiers  
1. .1278  
/organism="Gallus gallus"  
/mol\_type="mRNA"  
/db\_xref="taxon:9031"  
1. .1278  
/gene="F7"  
1. .1278  
/gene="F7"  
/EC number="3.4.21.21"  
/functions="serum prothrombin conversion accelerator"  
/note="vitamin K dependent serine protease; contains 2 BGP-like domains; member of peptidase family S1/trypsin family"  
/codon\_start=1  
/product="coagulation factor VII precursor"  
/protein\_id="AAO33363.1"  
/db\_xref="GI:28194008"  
/translation="MVSQRQVALLCPPLVPPSPLEAVFLKQEAANSIFQRHRRANSF  
FEELKGLPERECIEKCSFEAREIYRDDERTKEFWHIYSDPNQSDSPCQNGSCD  
DOFQDYVRCRPEYEGKSCITVAENLKCIYDNGCEQYCADQSCRVCFCAEGVAL  
ASDGVSCIPVQKPGCTIPLVARKNTAQGRIVGGVTPQCPQWALLIQDQKQCG  
GSLSPFWVTAACLYAASKQLRVLGRYSVYAEKVEQSESVKLIIRHEVYTIQ  
VMDIALKLSTIPVNLIDFVVPICPEKPAVYELSKISFWSWGRGLDGAISTF  
LMRHLPRVKTOECKQANLNINPFCAGLDTGKDKSDCKSGSGGPHRYKNTWFLT  
GIVSWGRCAGEVGYVTVRSYINWLKHEM"

Query Match 0.9%; Score 17.8; DB 1; Length 1278;  
Best Local Similarity 51.9%; Pred. No. 3e+02;  
Matches 40; Conservative 0; Mismatches 37; Indels 0; Gaps 0;

Qy 35 GAAGCCTCTGCGCAATACTCTTGGGCGCTGCTCCCTTCTCCTGCTGATTCCTAGG 94  
Db 466 GAGGCTACGCTTTAGCAGATGATGGAGTGCTCTGCATCCCAAGTAAATACCTTGT 525

Qy 95 TCAGGGTTTACCAGTCT 111  
Db 526 GGAACGATACCACTGCT.542

RESULT 232  
AX401899  
LOCUS Rattus norvegicus mRNA for protein C precursor. 1543 bp linear ROD 12-NOV-2003  
DEFINITION Rattus norvegicus mRNA for protein C precursor.  
ACCESSION X64336 S40352  
VERSION X64336.1 GI:56962  
SOURCE Rattus norvegicus (Norway rat)  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
1 (bases 1 to 1543)  
Okafuji, T., Maekawa, K., Nawa, K. and Marumoto, Y.  
The cDNA cloning and mRNA expression of rat protein C  
Biochim. Biophys. Acta 1131 (3), 329-332 (1992)  
PUBMED 92329550  
REFERENCE 2 (bases 1 to 1543)  
Okafuji, T.  
Direct Submission  
Submitted (03-FEB-1992) Okafuji, T., Mol. Biology Research Lab, Daiichi Pharmaceutical Co Ltd, 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134, JAPAN  
On Nov 19, 2003 this sequence version replaced gi:251769.  
LOCATION/Qualifiers  
1. .1543  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/strain="Wistar"  
/db\_xref="taxon:10116"  
/clone="28000"  
49. .1434  
/codon\_start=1  
/product="protein C precursor"  
/protein\_id="CAA45617.1"  
/db\_xref="GI:56963"  
/db\_xref="GDB:P31394"  
/translation="MMQPRIFLLFASTWIGISGVSAHPDPVFSSSGSAHQVLVRANS  
FLVSRAGSLERECMBEIECFEAQEIFQNVSDTLAFWIKYFDGQCCTPPDLHQCDS  
PCCHGTCTIDGLGFCSCDKWGEFRFCQCEQVQDCRVKNGGCVHYCLEFRGRCT  
CAGYELADHMHCRPTVFPCKLWKRTDKKRNFKRIDIDPEDEBELGLERIVNGT  
TKGDSFPAQILLDSKKLACGLVITSWILTAACHLSSSKKLTVRLCEYDLRRDRD

Query Match 0.9%; Score 17.8; DB 1; Length 1543;  
Best Local Similarity 62.2%; Pred. No. 2.9e+02;  
Matches 28; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

Qy 1792 TTGTATCTCTCAGTGAGGCTTCTCTCTGAGTCTCTGCTGGTGTGGT 1836  
Db 1268 TGGCTCTCTTTCGGGACCTGCTTCTGCTGGGCTGTGAGCT 1312

RESULT 233  
RNPROC Rattus norvegicus mRNA for protein C precursor. 1543 bp mRNA linear ROD 12-NOV-2003  
LOCUS Rattus norvegicus mRNA for protein C precursor.  
DEFINITION Rattus norvegicus mRNA for protein C precursor.  
ACCESSION X64336 S40352  
VERSION X64336.1 GI:56962  
SOURCE Rattus norvegicus (Norway rat)  
Eukaryota; Metazoa; Chordata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Rattus.  
1 (bases 1 to 1543)  
Okafuji, T., Maekawa, K., Nawa, K. and Marumoto, Y.  
The cDNA cloning and mRNA expression of rat protein C  
Biochim. Biophys. Acta 1131 (3), 329-332 (1992)  
PUBMED 92329550  
REFERENCE 2 (bases 1 to 1543)  
Okafuji, T.  
Direct Submission  
Submitted (03-FEB-1992) Okafuji, T., Mol. Biology Research Lab, Daiichi Pharmaceutical Co Ltd, 16-13 Kitakasai 1-Chome, Edogawa-ku, Tokyo 134, JAPAN  
On Nov 19, 2003 this sequence version replaced gi:251769.  
LOCATION/Qualifiers  
1. .1543  
/organism="Rattus norvegicus"  
/mol\_type="mRNA"  
/strain="Wistar"  
/db\_xref="taxon:10116"  
/clone="28000"  
49. .1434  
/codon\_start=1  
/product="protein C precursor"  
/protein\_id="CAA45617.1"  
/db\_xref="GI:56963"  
/db\_xref="GDB:P31394"  
/translation="MMQPRIFLLFASTWIGISGVSAHPDPVFSSSGSAHQVLVRANS  
FLVSRAGSLERECMBEIECFEAQEIFQNVSDTLAFWIKYFDGQCCTPPDLHQCDS  
PCCHGTCTIDGLGFCSCDKWGEFRFCQCEQVQDCRVKNGGCVHYCLEFRGRCT  
CAGYELADHMHCRPTVFPCKLWKRTDKKRNFKRIDIDPEDEBELGLERIVNGT  
TKGDSFPAQILLDSKKLACGLVITSWILTAACHLSSSKKLTVRLCEYDLRRDRD

[illegible]

WELDLIDIKELVHNYRNSNDIALRLISQATLSKTIIVPICLNSGLAQLSQAQ  
QETVVTGMYGQSDKVKDGRNRRTFILFIRIPLAARDNCQVNNVVSENMLCAGIIG  
DTRDADGDSGGPMVFRGTFWGLVSMGEGCHLNNYGVYTKVGSYLKWIHSYIG  
BRDVLKSPKL"  
49..147  
169..1431  
/product="protein C"  
1514..1519

Query Match 0.9%; Score 17.8; DB 1; Length 1543;  
Best Local Similarity 62.2%; Pred. No. 2.9e+02;  
Matches 28; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 1792 TTGTAATTCGACGAGCGCTGTCTCTGAGGTCCTGTTGGGTT 1836  
Db 1269 TGGTCTTCTTCGGGGTACCTGGTTCCTGCGGCGCTGGTGAGCT 1312

RESULT 234  
AX147505/c  
LOCUS AX147505 1551 bp DNA linear PAT 08-JUN-2001  
DEFINITION Sequence 59 from Patent WO0136632.  
ACCESSION AX147505  
VERSION AX147505.1 GI:14346662  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Levine, Z., David, A., Azar, I., Khosravi, R. and Bernstein, J.  
TITLE Variants of alternative splicing  
JOURNAL Patent: WO 0136632-A 59 25-MAY-2001;  
COMPUGEN LTD. (IL)  
FEATURES  
Location/Qualifiers  
1..1551  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.8; DB 1; Length 1551;  
Best Local Similarity 45.0%; Pred. No. 2.9e+02;  
Matches 67; Conservative 0; Mismatches 82; Indels 0; Gaps 0;

QY 1242 TATCTAGAGTCTCTTCTTCTCCACTATTGTGACAGAAAGTTTCTTAACTGACGTA 1301  
Db 1208 TTCCAGGCTCTCTCATTTACCTCCCTCTGTTCTTCTTCTTCTTCTTCTTCTTCT 1149  
QY 1302 GTCTGCTGACATCTGAGTCTCTTGGAGTCTGTAGCATCTGTGCGGCTCTTCTTA 1361  
Db 1148 CTCTTCCCTTACAGAAATGACAGAAAGTCCATGACAGCTTCACAGGCGGTAGCT 1089  
QY 1362 CATTGTGATTTCTATTGGAAGTCCAGG 1390  
Db 1088 CTTCTTGGAGGCTTGGGCTATCCAG 1060

RESULT 235  
AX264997/c  
LOCUS AX264997 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2388 from Patent WO0173002.  
ACCESSION AX264997  
VERSION AX264997.1 GI:16513796  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL Patent: WO 0173002-A 2388 04-OCT-2001;

UNIVERSITY OF DELAWARE (US)  
Location/Qualifiers  
1..121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTTACATTTTCATAGTTTCTTTAATGGATTTCATTT 1978  
Db 121 TACTCAGTGTCTTTCAGTGTCTTCAAAACTTCTCGTCTTCTTCAAAACTACTTT 62  
QY 1979 CCTC 1982  
Db 61 CTTC 58

RESULT 236  
AX264998  
LOCUS AX264998 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2389 from Patent WO0173002.  
ACCESSION AX264998  
VERSION AX264998.1 GI:16513797  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL Patent: WO 0173002-A 2389 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
Location/Qualifiers  
1..121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTCCTCCAGTATTTACATTTTCATAGTTTCTTTAATGGATTTCATTT 1978  
Db 1 TACTCAGTGTCTTTCAGTGTCTTCAAAACTTCTCGTCTTCTTCAAAACTACTTT 60  
QY 1979 CCTC 1982  
Db 61 CTTC 64

RESULT 237  
AX265001/c  
LOCUS AX265001 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2392 from Patent WO0173002.  
ACCESSION AX265001  
VERSION AX265001.1 GI:16513800  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Euthera; Primates; Catarrhini; Homnidae; Homo.

REFERENCE  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL Patent: WO 0173002-A 2392 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)

FEATURES source Location/Qualifiers  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAAATGGATTATTTCATTT 1978  
Db 114 TACTCACTGTTCTTCAGTGTTTCAAAAACCTCTCGTCTTCTTCAAAACTACACTTTT 55  
QY 1979 CCTC 1982  
Db 54 CTC 51  
RESULT 240  
AX265006  
LOCUS 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2397 from Patent WO0173002.  
ACCESSION AX265006  
VERSION AX265006.1 GI:16513805  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 2397 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAAATGGATTATTTCATTT 1978  
Db 8 TACTCACTGTTCTTCAGTGTTTCAAAAACCTCTCGTCTTCTTCAAAACTACACTTTT 67  
QY 1979 CCTC 1982  
Db 68 CTC 71  
RESULT 241  
AX265009/c  
LOCUS 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2400 from Patent WO0173002.  
ACCESSION AX265009  
VERSION AX265009.1 GI:16513808  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 2400 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .121

FEATURES source Location/Qualifiers  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAAATGGATTATTTCATTT 1978  
Db 115 TACTCACTGTTCTTCAGTGTTTCAAAAACCTCTCGTCTTCTTCAAAACTACACTTTT 56  
QY 1979 CCTC 1982  
Db 55 CTC 52  
RESULT 238  
AX265002  
LOCUS 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2393 from Patent WO0173002.  
ACCESSION AX265002  
VERSION AX265002.1 GI:16513801  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 2393 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"  
Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTACATTTTCATAGGTTCTTTAAATGGATTATTTCATTT 1978  
Db 7 TACTCACTGTTCTTCAGTGTTTCAAAAACCTCTCGTCTTCTTCAAAACTACACTTTT 66  
QY 1979 CCTC 1982  
Db 67 CTC 70  
RESULT 239  
AX265005/c  
LOCUS 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2396 from Patent WO0173002.  
ACCESSION AX265005  
VERSION AX265005.1 GI:16513804  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM  
Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE  
1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
JOURNAL stranded oligonucleotides  
Patent: WO 0173002-A 2396 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES Location/Qualifiers  
source  
1. .121

/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTTCATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978  
D5 108 TACTCAGTGTCTTTTCAGTGTCTTTCAAAAAGTCTCGTGTCTTCTTCAAAACTACACTTTT 49  
QY 1979 CCTC 1982  
D5 48 CTTC 45

RESULT 242  
AX265010  
LOCUS AX265010 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2401 from Patent WO0173002.  
ACCESSION AX265010  
VERSION AX265010.1 GI:16513809  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2401 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTTCATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978  
D5 14 TACTCAGTGTCTTTTCAGTGTCTTTCAAAAAGTCTCGTGTCTTCTTCAAAACTACACTTTT 73  
QY 1979 CCTC 1982  
D5 74 CTTC 77

RESULT 243  
AX265013/c  
LOCUS AX265013 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2404 from Patent WO0173002.  
ACCESSION AX265013  
VERSION AX265013.1 GI:16513812  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2404 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"

/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTTCATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978  
D5 106 TACTCAGTGTCTTTTCAGTGTCTTTCAAAAAGTCTCGTGTCTTCTTCAAAACTACACTTTT 47  
QY 1979 CCTC 1982  
D5 46 CTTC 43

RESULT 244  
AX265014  
LOCUS AX265014 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2405 from Patent WO0173002.  
ACCESSION AX265014  
VERSION AX265014.1 GI:16513813  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2405 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGTATTTCATTTTCATAGGTTCTTTAATGGATTATTCATTT 1978  
D5 16 TACTCAGTGTCTTTTCAGTGTCTTTCAAAAAGTCTCGTGTCTTCTTCAAAACTACACTTTT 75  
QY 1979 CCTC 1982  
D5 76 CTTC 79

RESULT 245  
AX265025/c  
LOCUS AX265025 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2416 from Patent WO0173002.  
ACCESSION AX265025  
VERSION AX265025.1 GI:16513824  
KEYWORDS Homo sapiens (human)  
SOURCE  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2416 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"

/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGATTATTCATTTTCATAGTTTCTTTAATGGATTATTCATTT 1978  
|||||  
Db 103 TACTCAGTGTCTTTCAGTGTCTTTCAAAACTTCTCGTCTCTTCTCAAACTACACTTTT 44  
QY 1979 CCTC 1982  
|||  
Db 43 CTTC 40

RESULT 246  
AX265026  
LOCUS AX265026 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2417 from Patent WO0173002.  
ACCESSION AX265026  
VERSION AX265026.1 GI:16513825  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2417 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGATTATTCATTTTCATAGTTTCTTTAATGGATTATTCATTT 1978  
|||||  
Db 19 TACTCAGTGTCTTTCAGTGTCTTTCAAAACTTCTCGTCTCTTCTCAAACTACACTTTT 78  
QY 1979 CCTC 1982  
|||  
Db 79 CTTC 82

RESULT 247  
AX265017/c  
LOCUS AX265017 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2408 from Patent WO0173002.  
ACCESSION AX265017  
VERSION AX265017.1 GI:16513816  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2408 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGATTATTCATTTTCATAGTTTCTTTAATGGATTATTCATTT 1978  
|||||  
Db 102 TACTCAGTGTCTTTCAGTGTCTTTCAAAACTTCTCGTCTCTTCTCAAACTACACTTTT 43  
QY 1979 CCTC 1982  
|||  
Db 42 CTTC 39

RESULT 248  
AX265018  
LOCUS AX265018 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2409 from Patent WO0173002.  
ACCESSION AX265018  
VERSION AX265018.1 GI:16513817  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2409 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

Query Match 0.9%; Score 17.6; DB 1; Length 121;  
Best Local Similarity 54.7%; Pred. No. 3.1e+02;  
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;  
QY 1919 TACTCATTTCCTCCAGATTATTCATTTTCATAGTTTCTTTAATGGATTATTCATTT 1978  
|||||  
Db 20 TACTCAGTGTCTTTCAGTGTCTTTCAAAACTTCTCGTCTCTTCTCAAACTACACTTTT 79  
QY 1979 CCTC 1982  
|||  
Db 80 CTTC 83

RESULT 249  
AX265029/c  
LOCUS AX265029 121 bp DNA linear PAT 26-OCT-2001  
DEFINITION Sequence 2420 from Patent WO0173002.  
ACCESSION AX265029  
VERSION AX265029.1 GI:16513828  
KEYWORDS  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1  
AUTHORS Kniec, E.B., Gamper, H.B. and Rice, M.C.  
TITLE Targeted chromosomal genomic alterations with modified single  
stranded oligonucleotides  
JOURNAL Patent: WO 0173002-A 2420 04-OCT-2001;  
UNIVERSITY OF DELAWARE (US)  
FEATURES  
source  
1. .121  
/organism="Homo sapiens"  
/mol\_type="unassigned DNA"  
/db\_xref="taxon:9606"

```
Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTTCTCCAGTATTTCATTTTCATAGGTTCTTTTAATGGAATTTATTCATTT 1978
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 102 TACTCAGTCTTTTCAGTGTTCACAAAACCTTCCTCGTCTTCTTCAAAACTACACTTTT 43
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
    |||||
Db 42 CTC 39

RESULT 250
AX265030
LOCUS AX265030 121 bp DNA linear PAT 26-OCT-2001
DEFINITION Sequence 2421 from Patent WO0173002.
ACCESSION AX265030
VERSION AX265030.1 GI:16513829
KEYWORDS
SOURCE Homo sapiens (human)
ORGANISM Homo sapiens
          Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
          Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE 1
AUTHORS Kmiec, E.B., Gamper, H.B. and Rice, M.C.
TITLE Targeted chromosomal genomic alterations with modified single
        stranded oligonucleotides
JOURNAL Patent: WO 0173002-A 2421 04-OCT-2001;
        UNIVERSITY OF DELAWARE (US)
FEATURES
    source      1..121
                /organism="Homo sapiens"
                /mol_type="unassigned DNA"
                /db_xref="taxon:9606"

Query Match      0.9%; Score 17.6; DB 1; Length 121;
Best Local Similarity 54.7%; Pred. No. 3.1e+02;
Matches 35; Conservative 0; Mismatches 29; Indels 0; Gaps 0;

QY 1919 TACTCATTTTCTCCAGTATTTCATTTTCATAGGTTCTTTTAATGGAATTTATTCATTT 1978
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 20 TACTCAGTCTTTTCAGTGTTCACAAAACCTTCCTCGTCTTCTTCAAAACTACACTTTT 79
    ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||

QY 1979 CCTC 1982
    |||||
Db 80 CTC 83

Search completed: August 9, 2004, 16:48:35
Job time : 634 secs
```



OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:48:23 ; Search time 786 Seconds

(without alignments)  
3.881 Million cell updates/sec

Title: us-10-664-775-3

Perfect score: 2003

Sequence: 1 agcttccagagagacttca.....tcaaggaccttttatgaatt 2003

Scoring table: IDENTITY\_NUC

Gapop 10.0 , Gapext 0.5

Searched: 1612 seqs, 761539 residues

Total number of hits satisfying chosen parameters: 3224

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : rngdb.\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	43	2.1	2422	1	AAQ80296
C 2	43	2.1	2422	1	AAV02230
C 3	43	2.1	2422	1	AAZ57385
C 4	43	2.1	2422	1	AAZ57385
C 5	43	2.1	2422	1	AAZ57385
C 6	43	2.1	2422	1	AAZ57385
C 7	43	2.1	2422	1	AAZ57385
C 8	43	2.1	2422	1	AAZ57385
C 9	43	2.1	2422	1	AAZ57385
C 10	43	2.1	2422	1	AAZ57385
C 11	43	2.1	2422	1	AAZ57385
C 12	43	2.1	2422	1	AAZ57385
C 13	43	2.1	2422	1	AAZ57385
C 14	41.6	2.1	2177	1	AAZ57385
C 15	41.6	2.1	2438	1	AAZ57385
C 16	32.4	1.6	300	1	AAZ57385
C 17	25.6	1.3	254	1	AAZ57385
C 18	25.4	1.3	237	1	AAZ57385
C 19	25.2	1.3	1843	1	AAZ57385
C 20	25.2	1.3	1843	1	AAZ57385
C 21	25.2	1.3	1843	1	AAZ57385
C 22	24.2	1.2	267	1	AAZ57385
C 23	24.2	1.2	267	1	AAZ57385
C 24	24.2	1.2	267	1	AAZ57385
C 25	24.2	1.2	267	1	AAZ57385
C 26	23.8	1.2	868	1	AAZ57385
C 27	23.8	1.2	868	1	AAZ57385
C 28	23.4	1.2	612	1	AAZ57385
C 29	23.4	1.2	612	1	AAZ57385
C 30	23	1.1	306	1	AAZ57385
C 31	23	1.1	1507	1	AAZ57385
C 32	23	1.1	1507	1	AAZ57385
C 33	23	1.1	1507	1	AAZ57385

34	22.8	1.1	433	1	ACH20452	Human adult liver
35	22.8	1.1	1151	1	AD08286	Human secreted pro
36	22.2	1.1	301	1	AA119676	Probe #9609 for ge
37	22.2	1.1	301	1	ABA64702	Human fetal liver
38	22.2	1.1	301	1	AA144871	Probe #13557 used
39	22.2	1.1	301	1	ABA46822	Human breast cell
40	22.2	1.1	301	1	ABA31826	Probe #10292 for g
41	22.2	1.1	301	1	AAK38868	Human bone marrow
42	22.2	1.1	301	1	AAK13137	Human brain expres
43	22.2	1.1	301	1	ABS38453	Human liver single
44	22.2	1.1	301	1	AA105395	Probe #5386 used t
45	22.2	1.1	301	1	ABS12949	Human genome-deriv
46	22	1.1	385	1	AA04575	Human secreted pro
47	22	1.1	612	1	ABQ47969	Oligonucleotide fo
48	22	1.1	612	1	ABQ47968	Oligonucleotide fo
49	21.6	1.1	253	1	AAQ70944	Single nucleotide
50	21.6	1.1	254	1	ABV98470	Human pancreatic c
51	21.4	1.1	283	1	AAV28290	Galanin receptor G
52	21.4	1.1	283	1	AAV32651	Galanin receptor G
53	21.4	1.1	283	1	AAV44930	Galanin receptor G
54	21.4	1.1	283	1	ABK14060	Rat galanin recept
55	21.4	1.1	1129	1	AAZ21354	Human cDNA sequenc
56	21.4	1.1	1129	1	ACD23963	Novel human secret
57	21.4	1.1	1129	1	ACA67104	cDNA encoding huma
58	21.4	1.1	1129	1	ACA03713	cDNA encoding huma
59	21.4	1.1	1129	1	ABX89251	DNA encoding novel
60	21.4	1.1	1129	1	ACD41905	Human secreted/tra
61	21.4	1.1	1129	1	ACA04134	Human cDNA encodi
62	21.4	1.1	1129	1	ADA45740	Novel human secret
63	21.4	1.1	1129	1	ADA76171	Human PRO polynucl
64	21.4	1.1	1129	1	ADA18821	Human PRO polynucl
65	21.4	1.1	1129	1	ADA61444	Homo sapiens. Nov
66	21.4	1.1	1129	1	ADB19229	Novel human secret
67	21.4	1.1	1129	1	ADB27770	cDNA encoding huma
68	21.4	1.1	1129	1	ADA86249	Novel human secret
69	21.4	1.1	1129	1	ADB15813	Human PRO polynucl
70	21.4	1.1	1129	1	ADA47599	Human PRO polynucl
71	21.4	1.1	1129	1	ADA67394	Human PRO polynucl
72	21.4	1.1	1129	1	ADB30401	cDNA encoding huma
73	21.4	1.1	1129	1	ADA85697	Novel human secret
74	21.4	1.1	1129	1	ADA96909	Human PRO polynucl
75	21.4	1.1	1129	1	ADA79213	Human PRO polynucl
76	21.4	1.1	1129	1	ADA87352	Novel human secret
77	21.4	1.1	1129	1	ADA16554	Human PRO polynucl
78	21.4	1.1	1129	1	ADA91646	Novel human secret
79	21.4	1.1	1129	1	ADB14709	Human PRO polynucl
80	21.4	1.1	1129	1	ADB18670	Novel human secret
81	21.4	1.1	1129	1	ADA93885	Human PRO polynucl
82	21.4	1.1	1129	1	ADB19781	Novel human secret
83	21.4	1.1	1129	1	ADB13093	Human PRO polynucl
84	21.4	1.1	1129	1	ACD98534	Novel human secret
85	21.4	1.1	1129	1	ADA74347	Human PRO polynucl
86	21.4	1.1	1129	1	ADB24580	Human PRO polynucl
87	21.4	1.1	1129	1	ADA82104	Human PRO polynucl
88	21.4	1.1	1129	1	ADA75067	Human PRO polynucl
89	21.4	1.1	1129	1	ADA85145	Novel human secret
90	21.4	1.1	1129	1	ADA84593	Novel human secret
91	21.4	1.1	1129	1	ADB29849	cDNA encoding huma
92	21.4	1.1	1129	1	ADA80377	Human PRO polynucl
93	21.4	1.1	1129	1	ADA75619	Human PRO polynucl
94	21.4	1.1	1129	1	ADA46844	Human PRO polynucl
95	21.4	1.1	1129	1	ADB25140	Human PRO polynucl
96	21.4	1.1	1129	1	ADA93316	Human PRO polynucl
97	21.4	1.1	1129	1	ADB26666	cDNA encoding huma
98	21.4	1.1	1129	1	ADB30953	Human PRO polynucl
99	21.4	1.1	1129	1	ADA60881	Homo sapiens. Nov
100	21.4	1.1	1129	1	ADB24028	Human PRO polynucl
101	21.4	1.1	1129	1	ADA96357	Human PRO polynucl
102	21.4	1.1	1129	1	ADA80929	Human PRO polynucl
103	21.4	1.1	1129	1	ADA95805	Human PRO polynucl
104	21.4	1.1	1129	1	ADB26114	cDNA encoding huma
105	21.4	1.1	1129	1	ADB21599	Novel human secret
106	21.4	1.1	1129	1	ADA77378	Human PRO polynucl

C 107	21.4	1.1	1129	1	ADBL8118	cdNA encoding huma	Novel human secret
C 108	21.4	1.1	1129	1	ADA86601	Novel human secret	cdNA encoding huma
C 109	21.4	1.1	1129	1	ADA87904	Novel human secret	Human PRO polynucl
C 110	21.4	1.1	1129	1	ADA46292	Novel human secret	Human PRO polynucl
C 111	21.4	1.1	1129	1	ADB28322	cdNA encoding huma	Human PRO polynucl
C 112	21.4	1.1	1129	1	ADB28874	cdNA encoding huma	Human PRO polynucl
C 113	21.4	1.1	1129	1	ADA76826	Human PRO polynucl	Human PRO polynucl
C 114	21.4	1.1	1129	1	ADA88456	Novel human secret	cdNA encoding huma
C 115	21.4	1.1	1129	1	ADA97461	Human PRO polynucl	Novel human secret
C 116	21.4	1.1	1129	1	ADB27218	cdNA encoding huma	Novel human secret
C 117	21.4	1.1	1129	1	ADB22151	Novel human secret	cdNA encoding huma
C 118	21.4	1.1	1129	1	ADA66842	Human PRO polynucl	Human PRO polynucl
C 119	21.4	1.1	1129	1	ADB22703	Human PRO polynucl	Human PRO polynucl
C 120	21.4	1.1	1129	1	ADB23476	Human PRO polynucl	Human PRO polynucl
C 121	21.4	1.1	1129	1	ADA92198	Novel human secret	Human PRO polynucl
C 122	21.4	1.1	1129	1	ADB15261	Human PRO polynucl	Novel human secret
C 123	21.4	1.1	1129	1	ADB38513	Novel human secret	Human PRO polynucl
C 124	21.4	1.1	1129	1	ADB37961	Novel human secret	Human PRO polynucl
C 125	21.4	1.1	1129	1	ADB66433	Novel human secret	Human PRO polynucl
C 126	21.4	1.1	1129	1	ADB89513	Human PRO polynucl	cdNA encoding huma
C 127	21.4	1.1	1129	1	ADB90245	Human PRO polynucl	cdNA encoding huma
C 128	21.4	1.1	1129	1	ADB33346	Human PRO polynucl	cdNA encoding huma
C 129	21.4	1.1	1129	1	ADB46969	Novel human secret	cdNA encoding huma
C 130	21.4	1.1	1129	1	ADB86576	Human PRO polynucl	Human PRO polynucl
C 131	21.4	1.1	1129	1	ADB77181	Novel human secret	Human PRO polynucl
C 132	21.4	1.1	1129	1	ADB34338	Human PRO polynucl	Human PRO polynucl
C 133	21.4	1.1	1129	1	ADB35442	Human PRO polynucl	Human PRO polynucl
C 134	21.4	1.1	1129	1	ADB33786	Human PRO polynucl	Human PRO polynucl
C 135	21.4	1.1	1129	1	ADB34890	Human PRO polynucl	Plasmid pLN174 for
C 136	21.4	1.1	1129	1	ADB35994	Human PRO polynucl	Novel murine poly
C 137	21.4	1.1	1129	1	ADB46389	Novel human secret	EST clone EA90. H
C 138	21.4	1.1	1129	1	ADC50262	Novel human secret	Bovine EST associa
C 139	21.4	1.1	1129	1	ADC71809	Novel human secret	Probe #10127 for g
C 140	21.4	1.1	1129	1	ADC59788	Novel human secret	Human foetal liver
C 141	21.4	1.1	1129	1	ADC53795	Novel human secret	Probe #14080 used
C 142	21.4	1.1	1129	1	ADC57149	Novel human secret	Human breast cell
C 143	21.4	1.1	1129	1	ADC60340	Novel human secret	Probe #10790 for g
C 144	21.4	1.1	1129	1	ADC50815	Novel human secret	Human bone marrow
C 145	21.4	1.1	1129	1	ADC65342	Human PRO polynucl	Human brain expres
C 146	21.4	1.1	1129	1	ADC54440	Novel human secret	Human liver single
C 147	21.4	1.1	1129	1	ADC53401	Novel human secret	Probe #5889 used t
C 148	21.4	1.1	1129	1	ADC58924	Novel human secret	Human genome-deriv
C 149	21.4	1.1	1129	1	ADC55802	Novel human secret	Human breast cance
C 150	21.4	1.1	1129	1	ADC59372	Novel human secret	Probe #1685 for ge
C 151	21.4	1.1	1129	1	ADC03045	Novel human secret	Human foetal liver
C 152	21.4	1.1	1129	1	ADC90038	Novel human secret	Probe #1748 used t
C 153	21.4	1.1	1129	1	ADC69457	cdNA encoding huma	Human breast cell
C 154	21.4	1.1	1129	1	ADC48346	Human PRO polynucl	Probe #1682 for ge
C 155	21.4	1.1	1129	1	ADD09875	Human PRO polynucl	Human bone marrow
C 156	21.4	1.1	1129	1	ADD04450	Novel human secret	Human brain expres
C 157	21.4	1.1	1129	1	ADC80406	Novel human secret	Human liver single
C 158	21.4	1.1	1129	1	ADD10913	Human PRO polynucl	Probe #1672 used t
C 159	21.4	1.1	1129	1	ADC47794	Human PRO polynucl	Human genome-deriv
C 160	21.4	1.1	1129	1	ADC79854	Novel human secret	cdNA encoding huma
C 161	21.4	1.1	1129	1	ADD09323	Human PRO polynucl	Mutant blood coagu
C 162	21.4	1.1	1129	1	ADD41036	Novel human secret	Mutant blood coagu
C 163	21.4	1.1	1129	1	ADD52175	cdNA encoding huma	Wild-type human bl
C 164	21.4	1.1	1129	1	ADD52915	cdNA encoding huma	Mutant blood coagu
C 165	21.4	1.1	1129	1	ADD53467	Novel human secret	Mutant blood coagu
C 166	21.4	1.1	1129	1	ADD51623	cdNA encoding huma	Mutant blood coagu
C 167	21.4	1.1	1129	1	ADD02422	Human PRO polynucl	Human Factor VIIa
C 168	21.4	1.1	1129	1	ADD01856	Human PRO polynucl	Factor VIII. Homo
C 169	21.4	1.1	1129	1	ADD54038	Novel human secret	Human Factor VIIa
C 170	21.4	1.1	1129	1	ADD92355	Human PRO polynucl	HIV/HIV immunoco
C 171	21.4	1.1	1129	1	ADD91251	Human PRO polynucl	Plasmid pLN174 for
C 172	21.4	1.1	1129	1	ADE03865	Human PRO polynucl	Human secreted pro
C 173	21.4	1.1	1129	1	ADE32162	Novel human secret	Single nucleotide
C 174	21.4	1.1	1129	1	ADE22094	cdNA encoding huma	DNA clone originat
C 175	21.4	1.1	1129	1	ADB79318	cdNA encoding huma	Human prostate exp
C 176	21.4	1.1	1129	1	ADE41854	Human PRO polynucl	Human prostate exp
C 177	21.4	1.1	1129	1	ADE17671	Human PRO polynucl	cdNA encoding mous
C 178	21.4	1.1	1129	1	ADD91803	Novel human secret	
C 179	21.4	1.1	1129	1	ADB33266	Novel human secret	

[illegible]

Db 1886 TGTGTGATCCGTGTGTGTCATATCTCTGTGTGTGTCATGCGGTGTGTGTGTGCA 1827

QY 1072 TCTGTGTGTGT 1082

Db 1826 TCCATGTGTGT 1816

RESULT 3

AAZ57385/c

ID AAZ57385 standard; cDNA; 2422 BP.

XX AC AAZ57385;

XX DT 05-APR-2000 (first entry)

XX DE Factor VII encoding cDNA SEQ ID NO:1.

XX KW Factor VII; catalytic active site; blood coagulation; plasma; Factor X;

XX KW Factor IX; vasotrophic; antithrombotic; anticoagulant; myocardial injury;

XX KW post-ischaemic reperfusion; platelet deposition; thrombus formation;

XX KW vascular potency; ss.

XX OS Unidentified.

XX FH Key

XX FT CDS

XX FT 28..1375

XX FT /\*tag= a

XX FT /product= "Factor VII"

XX PN US5997864-A.

XX PD 07-DEC-1999.

XX PF 06-JUN-1997; 97US-00871003.

XX PR 28-FEB-1991; 91US-00662920.

XX PR 21-MAY-1993; 93US-00065725.

XX PR 23-MAY-1994; 94MO-US005779.

XX PR 24-OCT-1994; 94US-00327690.

XX PR 07-JUN-1995; 95US-00475845.

XX PR 07-JUN-1996; 96US-00860289.

XX PA (NOVO ) NOVO-NORDISK AS.

XX PA (ZYMO ) ZYMOGENETICS INC.

XX PI Hart CE, Petersen LC, Hedner U, Rasmussen ME;

XX DR WPI; 2000-104599/09.

XX DR P-PSDB; AAY67967.

XX PT Inhibition or minimization of myocardial injury associated with post-ischemic reperfusion.

XX PS Disclosure; Col 43-48; 34pp; English.

XX CC The present invention describes a method for the inhibition or minimisation of myocardial injury associated with post-ischaemic reperfusion by administering factor VII, which has at least 1 modification in its catalytic triad (therefore inhibiting the ability of factor VII to activate plasma factor X or IX). The method can be used for inhibiting or minimising myocardial injury and for imparting regional myocardial blood flow associated with post-ischaemic reperfusion. It can also be used for inhibiting blood coagulation, platelet deposition, thrombus formation and maintaining or improving vascular patency. Factor VII can be administered at relatively low doses and does not produce undesirable side effects. Further it acts specifically at sites of injury. The present sequence encodes factor VII

XX SQ Sequence 2422 BP; 596 A; 712 C; 692 G; 422 T; 0 U; 0 Other;

Query Match 2.1%; Score 43; DB 1; Length 2422;

Best Local Similarity 58.0%; Pred. No. 4.3e-05;

Matches 76; Conservative 0; Mismatches 55; Indels 0; Gaps 0;

QY 952 TGTGTGAAATATCAATGACGACAGTGTGTGGAATCTTGTATCTTGCACCTGTGAAGTG 1011

Db 1946 TGTGCATATCTTATCTATGCGTGTGTCATCGTGTGTTCGTATCTCTGTGACCATCTG 1887

QY 1012 TG 1071

Db 1886 TGTGTGCAATCCGTGCA 1827

QY 1072 TCTGTGTGTGT 1082

Db 1826 TCCATGTGTGT 1816

RESULT 4

AAF57099/c

ID AAF57099 standard; cDNA; 2422 BP.

XX AC AAF57099;

XX DT 14-MAY-2001 (first entry)

XX DE Human Factor VII polypeptide encoding cDNA.

XX KW Factor VIIa; thrombus; vascular patency; blood coagulation; Factor X;

XX KW plasma factor; Factor IX; myocardial injury; human; Factor VII; ss.

XX OS Homo sapiens.

XX FH Key

XX FT CDS

XX FT 41..1375

XX FT /\*tag= a

XX FT sig\_peptide

XX FT 41..154

XX FT mat\_peptide

XX FT 155..1372

XX FT /\*tag= c

XX PN US6183743-B1.

XX PD 06-FEB-2001.

XX PF 20-AUG-1999; 99US-00378907.

XX PR 28-FEB-1991; 91US-00662920.

XX PR 28-FEB-1992; 92MO-US001636.

XX PR 21-MAY-1993; 93US-00065725.

XX PR 23-MAY-1994; 94MO-US005779.

XX PR 24-OCT-1994; 94US-00327690.

XX PR 07-JUN-1995; 95US-00475845.

XX PR 07-JUN-1996; 96US-00660289.

XX PR 06-JUN-1997; 97US-00871003.

XX PA (ZYMO ) ZYMOGENETICS INC.

XX PA (NOVO ) NOVO NORDISK AS.

XX PI Hart CE, Petersen LC, Hedner U, Rasmussen ME;

XX DR WPI; 2001-201993/20.

XX DR P-PSDB; AAB61992.

XX PT Use of modified human factor VIIa with a covalent modification in its catalytic center, to inhibit thrombus formation or to maintain vascular patency.

XX PS Example; Col 43-48; 34pp; English.

XX CC The invention relates to the use of modified human Factor VIIa for inhibiting thrombus formation, or maintaining or improving vascular patency in a patient. The modified factor VIIa comprises a covalent modification in its catalytic center which effectively interrupts the blood coagulation cascade. The modifications render Factor VIIa substantially unable to activate plasma factor IX or X. The modified factor VIIa can be used for preventing or treating myocardial injury





Qy	1072	TCTGTG	1082
D <sub>b</sub>	1887	TCCATGTG	1877

RESULT 8  
AAZ56118/c  
ID AAZ56118 standard; DNA: 2462 BP.

AAZ56118;	
15-SEP-2003	(revised)
27-MAR-2000	(first entry)

Vitamin-K-dependent coagulation factor VII/VIIa coding sequence.

Vitamin-K-dependent coagulation factor; tumour associated vasculature; carcinoma; benign prostatic hyperplasia; diabetic retinopathy; vascular restenosis; arteriovenous malformation; meningoma; haemangioma; neovascular glaucoma; psoriasis; cytostatic; antiadipetic; vasotrophic; ophthalmological; antipsoriasis; factor VII/VIII; ss.

unidentified.

US6004555-A;

21-DEC-1999.

07-JUN-1995; 95US-00487427.

05-MAR-1992; 92US-00846349.

02-MAR-1994; 94US-00205330.  
11-JUL-1994; 94US-00273567.

(SCRI ) SCRIPPS RES INST.

(TEXA) UNIV TEXAS SYSTEM.  
Edgington TS, Thorpe PE;

WPI; 2000-072047/06.

## Bispecific binding

associated vasculature are useful for treating cancer.  
Example 9; Col 127-130; 83pp; English.

This is the coding sequence for Factor

coagulation factor. This coagulation factor can be used in the formation of coagulants. Mutated versions of this sequence can be used in the method for delivering a coagulant to a tumour-associated vasculature using bispecific binding ligands which promote blood coagulation. The binding ligand consists of a binding region that binds to a surface-expressed, surface accessible or surface-localised component of a tumour cell, intratumoural vasculature or tumour associated stroma. The binding region is linked to a coagulating agent which is a coagulation factor (e.g. tissue factor). The second binding region comprises an antibody or an antigen binding region of an antibody. The method is used for delivering an exogenous or an endogenous coagulation factor to tumour-associated vasculature which is benign or malignant. The method can be used to treat cancer by promoting specific blood coagulation in the vasculature of the tumour relative to the vasculature in nontumour sites. Vascularised tumours are usually solid tumours, particularly carcinomas which require a vascular component to provide oxygen and nutrients. The ligands are suitable to treat benign and malignant diseases with a vascular component, including benign prostatic hyperplasia, diabetic retinopathy, vascular restenosis, arteriovenous malformations, meningioma, haemangioma, neovascular glaucoma and psoriasis. The ligands can also be used in standard binding assays *in vitro*. Bispecific ligands can be designed which are capable of binding to vascular endothelial cells and disease-associated agents such as activated platelets. Certain disease-associated agents are similar in different diseases and in different tumours, making it possible to treat numerous diseases and different types of cancer with one pharmaceutical, therefore an agent







2007 10102 10103 10104 10105 10106 10107 10108 10109 10110 10111 10112 10113 10114 10115 10116 10117 10118 10119 10120 10121 10122 10123 10124 10125 10126 10127 10128 10129 10130 10131 10132 10133 10134 10135 10136 10137 10138 10139 10140 10141 10142 10143 10144 10145 10146 10147 10148 10149 10150 10151 10152 10153 10154 10155 10156 10157 10158 10159 10160 10161 10162 10163 10164 10165 10166 10167 10168 10169 10170 10171 10172 10173 10174 10175 10176 10177 10178 10179 10180 10181 10182 10183 10184 10185 10186 10187 10188 10189 10190 10191 10192 10193 10194 10195 10196 10197 10198 10199 10200 10201 10202 10203 10204 10205 10206 10207 10208 10209 10210 10211 10212 10213 10214 10215 10216 10217 10218 10219 10220 10221 10222 10223 10224 10225 10226 10227 10228 10229 10230 10231 10232 10233 10234 10235 10236 10237 10238 10239 10240 10241 10242 10243 10244 10245 10246 10247 10248 10249 10250 10251 10252 10253 10254 10255 10256 10257 10258 10259 10260 10261 10262 10263 10264 10265 10266 10267 10268 10269 10270 10271 10272 10273 10274 10275 10276 10277 10278 10279 10280 10281 10282 10283 10284 10285 10286 10287 10288 10289 10290 10291 10292 10293 10294 10295 10296 10297 10298 10299 10300 10301 10302 10303 10304 10305 10306 10307 10308 10309 10310 10311 10312 10313 10314 10315 10316 10317 10318 10319 10320 10321 10322 10323 10324 10325 10326 10327 10328 10329 10330 10331 10332 10333 10334 10335 10336 10337 10338 10339 10340 10341 10342 10343 10344 10345 10346 10347 10348 10349 10350 10351 10352 10353 10354 10355 10356 10357 10358 10359 10360 10361 10362 10363 10364 10365 10366 10367 10368 10369 10370 10371 10372 10373 10374 10375 10376 10377 10378 10379 10380 10381 10382 10383 10384 10385 10386 10387 10388 10389 10390 10391 10392 10393 10394 10395 10396 10397 10398 10399 10400 10401 10402 10403 10404 10405 10406 10407 10408 10409 10410 10411 10412 10413 10414 10415 10416 10417 10418 10419 10420 10421 10422 10423 10424 10425 10426 10427 10428 10429 10430 10431 10432 10433 10434 10435 10436 10437 10438 10439 10440 10441 10442 10443 10444 10445 10446 10447 10448 10449 10450 10451 10452 10453 10454 10455 10456 10457 10458 10459 10460 10461 10462 10463 10464 10465 10466 10467 10468 10469 10470 10471 10472 10473 10474 10475 10476 10477 10478 10479 10480 10481 10482 10483 10484 10485 10486 10487 10488 10489 10490 10491 10492 10493 10494 10495 10496 10497 10498 10499 10500 10501 10502 10503 10504 10505 10506 10507 10508 10509 10510 10511 10512 10513 10514 10515 10516 10517 10518 10519 10520 10521 10522 10523 10524 10525 10526 10527 10528 10529 10530 10531 10532 10533 10534 10535 10536 10537 10538 10539 10540 10541 10542 10543 10544 10545 10546 10547 10548 10549 10550 10551 10552 10553 10554 10555 10556 10557 10558 10559 10560 10561 10562 10563 10564 10565 10566 10567 10568 10569 10570 10571 10572 10573 10574 10575 10576 10577 10578 10579 10580 10581 10582 10583 10584 10585 10586 10587 10588 10589 10590 10591 10592 10593 10594 10595 10596 10597 10598 10599 10600 10601 10602 10603 10604 10605 10606 10607 10608 10609 10610 10611 10612 10613 10614 10615 10616 10617 10618 10619 10620 10621 10622 10623 10624 10625 10626 10627 10628 10629 10630 10631 10632 10633 10634 10635 10636 10637 10638 10639 10640 10641 10642 10643 10644 10645 10646 10647 10648 10649 10650 10651 10652 10653 10654 10655 10656 10657 10658 10659 10660 10661 10662 10663 10664 10665 10666 10667 10668 10669 10670 10671 10672 10673 10674 10675 10676 10677 10678 10679 10680 10681 10682 10683 10684 10685 10686 10687 10688 10689 10690 10691 10692 10693 10694 10695 10696 10697 10698 10699 10700 10701 10702 10703 10704 10705 10706 10707 10708 10709 10710 10711 10712 10713 10714 10715 10716 10717 10718 10719 10720 10721 10722 10723 10724 10725 10726 10727 10728 10729 10730 10731 10732 10733 10734 10735 10736 10737 10738 10739 10740 10741 10742 10743 10744 10745 10746 10747 10748 10749 10750 10751 10752 10753 10754 10755 10756 10757 10758 10759 10760 10761 10762 10763 10764 10765 10766 10767 10768 10769 10770 10771 10772 10773 10774 10775 10776 10777 10778 10779 10780 10781 10782 107

400 1012







Query Match  
1.3%; Score 25.2; DB 1; Length 1843;

anti-coagulants protein C and antithrombin III, human alpha-1-antitrypsin, PEA-3 protein and reporter proteins such as luciferase.



SQL	Sequence	267 BP; 3 A; 151 C; 4 G; 109 T; 0 U; 0 Other;
	Query Match	1.2%; Score 24.2; DB 1; Length 267;
	Best Local Similarity	45.5%; Pred. No. 5.2;
	Matches	86; Conservative 0; Mismatches 103; Indels 0; Gaps 0;
QY	1620	CCTGCTTTGACCTGCTTCCTTCCTCCCTTCCTCTATCTCTTTGGTTTTGCATAGTGTCTC 1679
Db	78	CCCTTCCTCCTCCT 137
QY	1680	TGGCTTCCTGAGTGTTTTATGCTCGATATTATTAGACTTAACATTTCTTTGACCAAGG 1739
Db	138	TCT 197
QY	1740	TATCCATTCTCTTAATCTTGTCTTCACGCGCTGAGATTCCTCTCTCTATCTCTTTGATTTC 1799
Db	198	CCCTCCCT 257
QY	1800	TGTCAGTGA 1808
Db	258	TTCCTGGGA 266
RESULT 24		
ABS45294		
ID	ABS45294	standard; DNA; 267 BP.
XX	AC	ABS45294;
XX	AC	
XX	DT	25-FEB-2003 (first entry)
XX	XX	Human liver single exon probe, SEQ ID NO 20284.
DE	XX	
XX	XX	Human; single exon nucleic acid probe; liver; cirrhosis;
KW	KW	hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
KW	KW	coronary heart disease; ss.
OS	OS	Homo sapiens.
XX	XX	
PN	PN	WO200157273-A2.
XX	XX	
PD	PD	09-AUG-2001.
XX	XX	
PF	PF	30-JAN-2001; 2001WO-US000664.
XX	XX	
PR	PR	04-FEB-2000; 2000US-0180312P.
XX	XX	26-MAY-2000; 2000US-0207456P.
PR	PR	30-JUN-2000; 2000US-00608408.
XX	XX	03-AUG-2000; 2000US-00632365.
PR	PR	21-SEP-2000; 2000US-0234587P.
XX	XX	27-SEP-2000; 2000US-0236359P.
PR	PR	04-OCT-2000; 2000GB-00024263.
XX	XX	
PA	PA	(MOLE-) MOLECULAR DYNAMICS INC.
XX	XX	
PI	PI	Penn SG, Hanzel DK, Chen W, Rank DR;
XX	XX	
XX	XX	WPI; 2001-498898/53.
DR	DR	
XX	XX	Human genome-derived single exon nucleic acid probes useful for analyzing
PPT	PPT	gene expression in human adult liver.
XX	XX	
PF	PF	Claim 4; SEQ ID NO 20284; 658pp; English.
XX	XX	
CC	CC	The invention relates to a single exon nucleic acid probe (SENP) (I) for
CC	CC	measuring human gene expression in a sample derived from human adult
CC	CC	liver comprising one of 13109 defined nucleotide sequences given in the
CC	CC	specification (or complements/ fragments). The probe hybridises at high
CC	CC	stringency to a nucleic acid molecule expressed in the human adult liver.
CC	CC	(I) may be used for predicting, measuring and displaying gene expression
CC	CC	in samples derived from human adult liver. The genes identified may be
CC	CC	involved in genetic liver diseases such as cirrhosis,
CC	CC	hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is









XX PA (EPIG-) EPIGENOMICS AG.  
 XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;  
 XX PR WPI; 2002-371829/40.  
 XX DR  
 XX PT Determining the degree of cytosine methylation in genomic DNA, useful for  
 PT diagnosis and prognosis, comprises selective hybridization of amplicons  
 PT from chemically treated DNA.  
 XX PS  
 XX Claim 12; 56pp + Sequence Listing; 56pp; German.  
 XX CC This invention describes a novel method for determining the degree of  
 CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a  
 CC genomic sample of DNA. The sample is treated chemically to convert  
 CC cytosine (C) but not methylated C, to uracil, then part of the genomic  
 CC DNA that contains the target C is amplified to form a labeled amplicon.  
 CC The amplicon is hybridised to two classes, each with at least one member,  
 CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the  
 CC degree of hybridisation to both classes is determined from the label on  
 CC the amplicon. From the ratio of labels hybridised to the two classes of  
 CC oligomers, the degree of methylation is calculated. The method is used:  
 CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs  
 CC and of a wide range of diseases, e.g. cancer, disorders of the central  
 CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,  
 CC particularly by detecting mutations or single nucleotide polymorphisms  
 CC (SNP's); and (ii) for differentiation of cell or tissue types and for  
 CC investigating cell differentiation. The method allows the methylation  
 CC status of many C residues to be determined simultaneously. ABQ13410-  
 CC ABQ54121 represent genomic DNA sequences used to illustrate the method  
 CC for determining the degree of cytosine methylation described in the  
 CC disclosure of the invention  
 XX SQ Sequence 612 BP; 88 A; 72 C; 216 G; 236 T; 0 U; 0 Other;

Query Match 1.2%; Score 23.4; DB 1; Length 612;  
 Best Local Similarity 46.2%; Pred. No. 11;  
 Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;  
 QY 1499 GTGGGGAGTTTCTTTCCGGTCCCAATCTATTGGTGTGTTGATGCTTCTGTACCTTGA 1558  
 DB 431 GGGGGTCTTTTTCGTTTCGGGGTGATTTCTGTTTGGCGATGTTTTTATTTTAGG 490  
 QY 1559 TAGGCATCTCTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTCTGAAATATTTT 1618  
 DB 491 TACGCGTTTTTTCGTCGGTCTGATCGCGTATGTCGGTTTTTATATTAGAAATACGAT 550  
 QY 1619 CCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCTCTTGGTTTTT 1667  
 DB 551 TTGTAAGTATATTAGGGTGTTTTTTTTAAATTTTAAAGGAGTTTTT 599

RESULT 29  
 ABQ47967/c  
 ID ABQ47967 standard; DNA; 612 BP.  
 XX AC ABQ47967;  
 XX DT 12-JUL-2002 (first entry)  
 XX DE Oligonucleotide for detecting cytosine methylation SEQ ID NO 34558.  
 XX KW Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;  
 KW drug; side effect; cancer; central nervous system; cardiovascular;  
 KW gastrointestinal; respiratory system; single nucleotide polymorphism;  
 KW SNP; cell differentiation; ds.  
 XX OS Homo sapiens.  
 XX PN WO200218632-A2.  
 XX PD 07-MAR-2002.

XX PF 01-SEP-2001; 2001WO-EP010074.  
 XX PR 01-SEP-2000; 2000DE-01043826.  
 XX PR 05-SEP-2000; 2000DE-01044543.  
 XX PA (EPIG-) EPIGENOMICS AG.  
 XX PI Olek A, Piepenbrock C, Berlin K, Guetig D;  
 XX PR WPI; 2002-371829/40.  
 XX DR  
 XX PT Determining the degree of cytosine methylation in genomic DNA, useful for  
 PT diagnosis and prognosis, comprises selective hybridization of amplicons  
 PT from chemically treated DNA.  
 XX PS  
 XX Claim 12; 56pp + Sequence Listing; 56pp; German.  
 XX CC This invention describes a novel method for determining the degree of  
 CC methylation of a particular cytosine in a motif 5'-CpG-3', present in a  
 CC genomic sample of DNA. The sample is treated chemically to convert  
 CC cytosine (C) but not methylated C, to uracil, then part of the genomic  
 CC DNA that contains the target C is amplified to form a labeled amplicon.  
 CC The amplicon is hybridised to two classes, each with at least one member,  
 CC of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the  
 CC degree of hybridisation to both classes is determined from the label on  
 CC the amplicon. From the ratio of labels hybridised to the two classes of  
 CC oligomers, the degree of methylation is calculated. The method is used:  
 CC (i) for diagnosis and/or prognosis of side effects of therapeutic drugs  
 CC and of a wide range of diseases, e.g. cancer, disorders of the central  
 CC nervous, cardiovascular, gastrointestinal and respiratory systems etc.,  
 CC particularly by detecting mutations or single nucleotide polymorphisms  
 CC (SNP's); and (ii) for differentiation of cell or tissue types and for  
 CC investigating cell differentiation. The method allows the methylation  
 CC status of many C residues to be determined simultaneously. ABQ13410-  
 CC ABQ54121 represent genomic DNA sequences used to illustrate the method  
 CC for determining the degree of cytosine methylation described in the  
 CC disclosure of the invention  
 XX SQ Sequence 612 BP; 236 A; 216 C; 72 G; 88 T; 0 U; 0 Other;

Query Match 1.2%; Score 23.4; DB 1; Length 612;  
 Best Local Similarity 46.2%; Pred. No. 11;  
 Matches 78; Conservative 0; Mismatches 91; Indels 0; Gaps 0;  
 QY 1499 GTGGGGAGTTTCTTTCCGGTCCCAATCTATTGGTGTGTTGATGCTTCTGTACCTTGA 1558  
 DB 182 GGGGGTCTTTTTCGTTTCGGGGTGATTTCTGTTTGGCGATGTTTTTATTTTAGG 123  
 QY 1559 TAGGCATCTCTTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTCTGAAATATTTT 1618  
 DB 122 TACGCGTTTTTTCGTCGGTCTGATCGCGTATGTCGGTTTTTATATTAGAAATACGAT 63  
 QY 1619 CCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCTCTTGGTTTTT 1667  
 DB 62 TTGTAAGTATATTAGGGTGTTTTTTTTAAATTTTAAAGGAGTTTTT 14

RESULT 30  
 AAT40850/c  
 ID AAT40850 standard; cDNA; 306 BP.  
 XX AC AAT40850;  
 XX DT 16-MAR-1997 (first entry)  
 XX DE Serine protease nfsP8-299 gene.  
 XX KW Flea; midgut; serine protease; nfsP8-299; recombinant vaccine;  
 KW domestic animal; infestation; insecticide; protease-inhibitor;  
 KW controlled release formulation; synergist; ss.  
 XX OS Siphonaptera sp.

XX FH Key Location/Qualifiers  
FT unsure 1. .90  
FT /tag= a  
FT /note= "Back-translated from N-terminal part of PfSP8-99  
FT (AAW01205)"  
FT unsure 91. .276  
FT /tag= b  
FT /note= "Corresponds to nfSP8-186 (AAT40826, claim 70)"  
FT unsure 277. .299  
FT /tag= c  
FT /note= "Back-translated from C-terminal part of PfSP8-99  
FT (AAW01205)"  
XX WO9611706-A1.  
XX 25-APR-1996.  
XX 18-OCT-1995; 95WO-US014442.  
XX 18-OCT-1994; 94US-00326773.  
XX 07-JUN-1995; 95US-00482130.  
XX 07-JUN-1995; 95US-00484211.  
XX 07-JUN-1995; 95US-00485443.  
XX 07-JUN-1995; 95US-00485455.  
XX (HESK-) HESKA CORP.  
XX Grieve RB, Rushlow KE, Hunter SW, Frank GR, Stiegler GL, Heath A;  
XX Yamaraka M, Arfsten A, Dale B;  
XX WPI; 1996-221762/22.  
XX P-PSDB; AAW01205.  
XX DNA encoding Flea serine protease and aminopeptidase - useful in vaccines  
XX to protect animals from flea infestation.  
XX Claim 70; Page 182; 241pp; English.  
XX This sequence (nfSP8-299) encodes a flea midgut serine protease (PfSP8-  
XX 99), and has been isolated from a flea cDNA library by PCR using primers  
XX AAT40862-63 and hybridisation with probe AAT40866, based on conserved  
XX serine protease sequences. The sequence contains sequence AAT40826 (nfSP8  
XX -186), which spans 2 conserved serine protease sequences. The sequence  
XX shown has been derived from the encoded protein sequence (N- and C-  
XX terminal regions) and internal sequence AAT40826, since the appropriate  
XX page is missing from the specification. The sequence may be used to  
XX produce a recombinant vaccine for protection of domestic animals from  
XX flea infestation, or in isolation of protease-inhibitors which may be  
XX used in controlled release formulations to reduce the flea burden on and  
XX around the animal. The inhibitors may be included in insecticidal  
XX compositions to increase efficacy of other active compounds, by reducing  
XX proteolytic activity in the flea midgut  
XX Sequence 306 BP; 83 A; 30 C; 72 G; 56 T; 0 U; 65 Other;  
Query Match 1.1%; Score 23; DB 1; Length 306;  
Best Local Similarity 58.5%; Pred. No. 12;  
Matches 38; Conservative 1; Mismatches 26; Indels 0; Gaps 0;  
QY 142 CCAGGTAGGGGCACTACCGCATCCCTCTCTCCAAACACTCTTCTTCTTCTTC 201  
Db 280 CYTGGCAAGTGCTTTTCCACCATCCATTCCTCTGACACATCTGTCTTCAATTC 221  
QY 202 TATCT 206  
Db 220 CATT 216  
RESULT 31  
AAA54031/c  
ID AAA54031 standard; DNA; 1507 BP.  
XX

AA54031;  
08-FEB-2001 (first entry)  
Human factor X coding sequence.  
Vitamin K dependent protein; VKDP; gamma-carboxylation; chimeric protein;  
fusion protein; coagulation factor; Factor X; Factor VII; Protein S;  
Factor IX; Protein C; prothrombin; blood clotting; haemophilia; human;  
ds.  
Homo sapiens.  
WO200054787-A1.  
21-SEP-2000.  
16-MAR-2000; 2000WO-US006934.  
16-MAR-1999; 99US-0124609P.  
(CHIL-) CHILDRENS HOSPITAL PHILADELPHIA.  
(DINC-) UNIV NORTH CAROLINA.  
High KA, Camire RM, Larson PU, Stafford DW;  
WPI; 2000-638152/61.  
Chimeric DNA for optimizing gamma carboxylation of vitamin K-dependent  
protein useful for treating diseases associated with the protein.  
comprises sequence encoding propeptide fused to sequence encoding the  
protein.  
Disclosure; Fig 6a; 60pp; English.  
Efficient processing and release of mature two-chain factor X into the  
circulation requires: removal of the signal sequence; formation of  
disulfide bonds; modification of amino terminal glutamic acid residues,  
to gamma-carboxyglutamic acid; modification of one aspartic acid in the  
first epidermal growth factor (EGF) domain to Beta-hydroxyaspartic acid;  
addition of N- and O-linked oligosaccharides to the activation peptide;  
removal of an internal tripeptide to yield two-chain factor X and removal  
of the propeptide just prior to secretion. While some of these  
modifications do not appear essential for factor X function the removal  
of the signal sequence, propeptide, internal tripeptide and full gamma-  
carboxylation are all steps which are important requisites for the  
production of biologically active factor X/Fxa. Isolated chimeric  
polynucleotides are described which encode a propeptide fused to a  
nucleic acid sequence encoding a vitamin K-dependent protein (VKDP). The  
fusion proteins encoded are vitamin K-dependent protein gamma-  
carboxylation enhancers and are useful for optimising the gamma-  
carboxylation of a VKDP to produce a fully gamma-carboxylated VKDP. The  
fusion proteins and recombinant cells expressing them are useful for  
alleviating a VKDP associated disease. The fusion constructs result in  
the production of fully gamma-carboxylated mature VKDPs, which are  
biologically active. The invention encompasses all combinations of  
propeptide sequences (modified or not) and VKDP's. This sequence encodes  
the signal, propeptide and mature protein sequence of human Factor X  
Sequence 1507 BP; 394 A; 429 C; 446 G; 238 T; 0 U; 0 Other;  
Query Match 1.1%; Score 23; DB 1; Length 1507;  
Best Local Similarity 60.3%; Pred. No. 17;  
Matches 38; Conservative 0; Mismatches 25; Indels 0; Gaps 0;  
QY 1528 TTGGTGTTTGTATGCTTCTTGTACCTTGATGAGCATCTCTTCTCAAGGTAGGAAT 1587  
Db 1506 TTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTGTAGTGGGATCTCACTTATGAGAGAGCT 1447  
QY 1588 TTT 1590  
Db 1446 TAT 1444



AD008286;  
 08-AUG-2001 (first entry)  
 Human secreted protein-encoding gene 4 cDNA clone HWHI10, SEQ ID NO: 14.  
 Human; secreted protein; proliferative disorder; cancer; tumour; asthma; foetal abnormality; developmental abnormality; haematopoietic disorder; immune system disorder; AIDS; autoimmune disease; rheumatoid arthritis; Parkinson's disease; cognitive disorder; schizophrenia; skin disorder; psoriasis; sepsis; diabetes; atherosclerosis; cardiovascular disorder; inflammation; neurological disorder; Alzheimer's disease; food additive; angionenic disorder; kidney disorder; gastrointestinal disorder; allergy; pregnancy-related disorder; endocrine disorder; infection; wound healing; cell culture; chemotaxis; vulnery; binding partner identification; gene therapy; ss.  
 Homo sapiens.  

Key	Location/Qualifiers
CDS	42..914
FT	/*tag= a
FT	/product= "Human secreted protein precursor"
FT	42..107
FT	/*tag= b
FT	108..911
FT	/*tag= c
FT	/product= "Mature human secreted protein"

 WO2001036440-A1.  
 25-MAY-2001.  
 15-NOV-2000; 2000WO-US031282.  
 19-NOV-1999; 9BUS-0166414P.  
 21-JUL-2000; 2000US-0219665P.  
 (HUMA-) HUMAN GENOME SCI INC.  
 Ruben SM, Komatsoulis GA, Birse CE, Moore PA;  
 WPL; 2001-343795/36.  
 P-FSDB; AA030821.  
 Isolated nucleic acid molecule encoding a human secreted protein is used in preventing, treating or ameliorating a medical condition.  
 Claim 1; Page 440-441; 553pp; English.  
 AD008283-AD08355 represent cDNAs corresponding to 23 human secreted protein genes, and AA030818-AA03870 represent the proteins they encode. AA03871-AA03896 represent human secreted protein fragments or variants. The secreted proteins and their genes are useful for preventing, treating or ameliorating medical conditions, e.g., by protein or gene therapy. Pathological conditions can be diagnosed by determining the amount of the new protein in a sample or by determining the presence of mutations in the new genes. Specific uses are described for each of the 23 genes, based on the tissues in which they are most highly expressed, and include developing products for the diagnosis or treatment of proliferative disorders, cancer, tumours, foetal and developmental abnormalities, haematopoietic disorders, diseases of the immune system, AIDS, autoimmune diseases (e.g., rheumatoid arthritis), inflammation, allergies, neurological disorders (e.g., Alzheimer's disease, Parkinson's disease), cognitive disorders, schizophrenia, asthma, skin disorders (e.g., psoriasis), sepsis, diabetes, atherosclerosis, cardiovascular disorders, angionenic disorders, kidney disorders, gastrointestinal disorders, pregnancy-related disorders, endocrine disorders and infectious diseases. The proteins can also be used to aid wound healing and epithelial cell proliferation, to prevent skin aging due to sunburn, to maintain organs before transplantation, for supporting cell culture of primary tissues, to regenerate tissues, to identify their cognate ligands or binding partners, and in chemotaxis, and can be used as a food additive or



```

QY      1696 CCTGGAT 1692
DB      217 TCTAGCT 211

RESULT 38
AAI44871/c
ID      AAI44871 standard; DNA; 301 BP.
XX
XX
AC      AAI44871;
XX
DT      17-OCT-2001 (first entry)
XX
DE      Probe #13557 used to measure gene expression in human placenta sample.
XX
KW      Probe; microarray; human; placenta; antenatal diagnosis;
KW      genetic disorder; ss.
XX
OS      Homo sapiens.
XX
FN      WO2000157272-A2.
XX
PD      09-AUG-2001.
XX
XX
XX      30-JAN-2001; 2001WO-US0000653.
XX
PR      04-FEB-2000; 2000US-0180312P.
PR      26-MAY-2000; 2000US-0207456P.
PR      30-JUN-2000; 2000US-00608408.
PR      03-AUG-2000; 2000US-00632366.
PR      21-SEP-2000; 2000US-0234687P.
PR      27-SEP-2000; 2000US-0236359P.
PR      04-OCT-2000; 2000GB-00024263.
XX
PA      (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI      Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX      WPI; 2001-488897/53.
XX
PT      Human genome-derived single exon nucleic acid probes useful for analyzing
PT      gene expression in human placenta.
XX
PS      Claim 25; SEQ ID NO 13557; 654pp; English.
XX
CC      The present invention relates to single exon nucleic acid probes (SENP).
CC      The present sequence is one such probe. The probes are useful for
CC      producing a microarray for predicting, measuring and displaying gene
CC      expression in samples derived from human placenta. The probes are useful
CC      for antenatal diagnosis of human genetic disorders
XX
SQ      Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
      Query Match      1.1%; Score 22.2; DB 1; Length 301;
      Best Local Similarity 58.2%; Pred. No. 20;
      Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY      1626 TTGACCTGCTTCTCCCTCTCTATTCCTTTGCTTTTGCATAGTGTCTCGCTT 1685
DB      277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCGCT 218

QY      1686 CCTGGAT 1692
DB      217 TCTAGCT 211

RESULT 39
ABA46822/c
ID      ABA46822 standard; DNA; 301 BP.
XX
XX
AC      ABA46822;
XX
DT      01-FEB-2002 (first entry)

```

```

XX      Human breast cell single exon nucleic acid probe #5517.
DE
XX      Human; microarray; single exon probe; gene expression; breast; disease;
KW      cancer; ss.
XX
XX      Homo sapiens.
OS
XX      WO2000157271-A2.
FN
XX      09-AUG-2001.
PD
XX      30-JAN-2001; 2001WO-US0000662.
XX
PR      04-FEB-2000; 2000US-0180312P.
PR      26-MAY-2000; 2000US-0207456P.
PR      30-JUN-2000; 2000US-00608408.
PR      03-AUG-2000; 2000US-00632366.
PR      21-SEP-2000; 2000US-0234687P.
PR      27-SEP-2000; 2000US-0236359P.
PR      04-OCT-2000; 2000GB-00024263.
XX
PA      (MOLE-) MOLECULAR DYNAMICS INC.
XX
PI      Penn SG, Hanzel DK, Chen W, Rank DR;
XX
XX      WPI; 2001-496933/54.
XX
PT      New spatially-addressable set of single exon nucleic acid probes, useful
PT      for measuring gene expression in sample derived from human breast,
PT      comprises number of single exon nucleic acid probes.
XX
PS      Claim 4; SEQ ID NO 5517; 327pp + Sequence Listing; English.
XX
CC      The invention relates to a spatially-addressable set of single exon
CC      nucleic acid probes for measuring gene expression in a sample derived
CC      from human breast and BT 474 cells. The method involves contacting the
CC      probes with a collection of detectably labelled nucleic acids derived
CC      from mRNA of human breast, and then measuring the label bound to each
CC      probe of the microarray. The probes are useful for verifying the
CC      expression of regions of genomic DNA predicted to encode proteins. They
CC      are useful for gene discovery, and for determining predisposition and/or
CC      prognosing breast disease. Gene expression analysis is useful for
CC      assessing the toxicity of chemical agents on cells. The microarray of
CC      this invention presents a far greater diversity of probes for measuring
CC      gene expression, with far less bias than expressed sequence tag
CC      microarrays. The method is suitable for rapid production of functional
CC      information from genomic sequence. The present sequence is a single exon
CC      nucleic acid probe of the invention. Note: The sequence data for this
CC      patent did not form part of the printed specification, but was obtained
CC      in electronic format directly from WIPO at
CC      ftp.wipo.int/pub/published_pct_sequences
XX
SQ      Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;
      Query Match      1.1%; Score 22.2; DB 1; Length 301;
      Best Local Similarity 58.2%; Pred. No. 20;
      Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;

QY      1626 TTGACCTGCTTCTCCCTCTCTATTCCTTTGCTTTTGCATAGTGTCTCGCTT 1685
DB      277 TCTCGCTGCTTACCTCTCGCTCTCAATTTCTTCTCTCTCTCTCTCTCTCGCT 218

QY      1686 CCTGGAT 1692
DB      217 TCTAGCT 211

RESULT 40
ABA31826/c
ID      ABA31826 standard; DNA; 301 BP.
XX
XX      ABA31826;
AC
XX
DT

```







XX 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI WPI; 2001-483446/52.  
XX  
XX Single exon nucleic acid probes for analyzing gene expression in human  
PI brains.  
XX  
PS Example 4; SEQ ID NO 13128; 650pp + Sequence Listing; English.  
XX  
CC The present invention provides a number of single exon nucleic acid  
CC probes which are derived from genomic sequences expressed in the human  
CC brain. They can be used to measure gene expression in brain cell samples,  
CC which may enable the diagnosis and improved treatment of nervous system  
CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,  
CC epilepsy and cancers. The present sequence is one of the probes of the  
CC invention  
XX  
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;  
Query Match 1.1%; Score 22.2; DB 1; Length 301;  
Best Local Similarity 58.2%; Pred. No. 20;  
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;  
QY 1626 TTGACCTGCTTCTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685  
Db 277 TCTGCTGCTTACCTCTGCTCTCAATTTCTTCTCTCTCTCTCTGCGGT 218  
QY 1686 CTTGGAT 1692  
Db 217 TCTAGCT 211  
RESULT 43  
ABS38453/C  
ID ABS38453 standard; DNA; 301 BP.  
XX  
AC ABS38453;  
XX  
DT 25-FEB-2003 (first entry)  
XX  
DE Human liver single exon probe, SEQ ID No 13443.  
XX  
KW Human; single exon nucleic acid probe; liver; cirrhosis;  
KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;  
KW coronary heart disease; ss.  
XX  
CS Homo sapiens.  
OS WO200157273-A2.  
PN 09-AUG-2001.  
PD 30-JAN-2001; 2001WO-US000664.  
PF 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI WPI; 2001-483446/52.

XX (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
XX WPI; 2001-488898/53.  
XX  
XX Human genome-derived single exon nucleic acid probes useful for analyzing  
XX gene expression in human adult liver.  
XX  
XX Claim 4; SEQ ID NO 13443; 658pp; English.  
XX  
CC The invention relates to a single exon nucleic acid probe (SENP) (I) for  
CC measuring human gene expression in a sample derived from human adult  
CC liver, comprising one of 13109 defined nucleotide sequences given in the  
CC specification (or complements/ fragments). The probe hybridises at high  
CC stringency to a nucleic acid molecule expressed in the human adult liver.  
CC (\*) may be used for predicting, measuring and displaying gene expression  
CC in samples derived from human adult liver. The genes identified may be  
CC involved in genetic liver diseases such as cirrhosis,  
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is  
CC associated with coronary heart disease. ABS51005 represent human  
CC liver single exon nucleic acid probes of the invention. Note: The  
CC sequence information for this patent does not appear in the printed  
CC specification but was obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;  
Query Match 1.1%; Score 22.2; DB 1; Length 301;  
Best Local Similarity 58.2%; Pred. No. 20;  
Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;  
QY 1626 TTGACCTGCTTCTCCCTCTCTATTCCTTTGTTTGCATAGTCTCTGGCTT 1685  
Db 277 TCTGCTGCTTACCTCTGCTCTCAATTTCTTCTCTCTCTCTGCGGT 218  
QY 1686 CTTGGAT 1692  
Db 217 TCTAGCT 211  
RESULT 44  
AAI05395/C  
ID AAI05395 standard; DNA; 301 BP.  
XX  
AC AAI05395;  
XX  
DT 09-OCT-2001 (first entry)  
XX  
DE Probe #5396 used to measure gene expression in human breast sample.  
XX  
KW Probe; human; breast disease; breast cancer; development disorder; ss;  
KW inflammatory disease; proliferative breast disease; non-carcinoma tumour.  
XX  
CS Homo sapiens.  
OS WO200157270-A2.  
PN 09-AUG-2001.  
PD 29-JAN-2001; 2001WO-US000661.  
PF 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI WPI; 2001-488898/53.

XX WPI; 2001-476286/51.  
 XX Novel single exon nucleic acid probe used to measuring gene expression in  
 XX a human breast.  
 XX Claim 25; SEQ ID NO 5386; 322pp; English.  
 XX The present invention relates to novel single exon nucleic acid probes.  
 XX The present sequence is one such probe. The probes are useful for  
 XX measuring human gene expression in a human breast sample, where the probe  
 XX hybridizes at high stringency to a nucleic acid expressed in the human  
 XX breast. The probes are useful for predicting, diagnosing, grading,  
 XX staging, monitoring and prognosing diseases of the human breast,  
 XX particularly those diseases with polygenic aetiology. The diseases  
 XX include: breast cancer, disorders of development, inflammatory diseases  
 XX of the breast, fibrocystic changes, proliferative breast disease and non-  
 XX carcinoma tumours. Note: The sequence data for this patent did not form  
 XX part of the printed specification, but was obtained in electronic format  
 XX directly from WIFO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 22.2; DB 1; Length 301;  
 Best Local Similarity 58.2%; Pred. No. 20;  
 Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;  
 QY 1626 TTGACCTGCTTCTCCCTTCCTTATTCCTTTGTTTTCATAGTCTCTGGCTT 1685  
 DB 277 TCTGCGCTGCTTACTCTGCGCTCTCAATTCTCTCTCTCTCTCTCTCTCT 218  
 QY 1686 CTTGGAT 1692  
 DB 217 TCTAGCT 211  
 RESULT 45  
 ABS12949/C  
 ID ABS12949 standard; DNA; 301 BP.  
 AC ABS12949;  
 XX 19-AUG-2002 (first entry)  
 DE Human genome-derived single exon probe ORF from lung SEQ ID NO 12940.  
 XX Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;  
 KW chronic obstructive pulmonary disease; interstitial lung disease;  
 KW familial idiopathic pulmonary fibrosis; neurofibromatosis;  
 KW tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;  
 KW Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;  
 KW pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;  
 KW pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;  
 KW primary ciliary dyskinesia; pulmonary hypertension;  
 KW hyaline membrane disease; open reading frame; ORF.  
 XX Homo sapiens.  
 OS  
 PN WO200186003-A2.  
 XX 15-NOV-2001.  
 XX 30-JAN-2001; 2001WO-US000665.  
 XX 04-FEB-2000; 2000US-0180312P.  
 PR 26-MAY-2000; 2000US-0207456P.  
 PR 30-JUN-2000; 2000US-C0608408.  
 PR 03-AUG-2000; 2000US-C0632366.  
 PR 21-SEP-2000; 2000US-0234687P.  
 PR 27-SEP-2000; 2000US-0236359P.  
 PR 04-OCT-2000; 2000GB-00024263.  
 XX (MOLE-) MOLECULAR DYNAMICS INC.

XX Penn SG, Hanzel DK, Chen W, Rank DR;  
 XX WPI; 2002-114183/15.  
 XX Spatially-addressable set of single exon nucleic acid probes, used to  
 XX measure gene expression in human lung samples.  
 XX Claim 4; SEQ ID NO 12940; 634pp; English.  
 XX The invention relates to a spatially-addressable set of single exon  
 XX nucleic acid probes for measuring gene expression in a sample derived  
 XX from human lung comprising single exon nucleic acid probes having one of  
 XX 12614 nucleic acid sequences mentioned in the specification, or their  
 XX complements or the 12387 open reading frames derived from the 12614  
 XX probes. Also included are a microarray comprising the novel set of probes  
 XX; the novel set of probes which hybridise at high stringency to a nucleic  
 XX acid expressed in the human lung; measuring gene expression in a sample  
 XX derived from human lung, comprising (a) contacting the array with a  
 XX collection of detectably labeled nucleic acids derived from human lung  
 XX mRNA, and (b) measuring the label detectably bound to each probe of the  
 XX array; identifying exons in a eukaryotic genome, comprising (a)  
 XX algorithmically predicting at least one exon from genomic sequences of  
 XX the eukaryote; and (b) detecting specific hybridisation of detectably  
 XX labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,  
 XX having a fragment identical to the predicted exon, the probe is included  
 XX in the above mentioned microarray; assigning exons to a single gene,  
 XX comprising (a) identifying exons from genomic sequence by the method  
 XX above and (b) measuring the expression of each of the exons in several  
 XX tissues and/or cell types using hybridisation to a single exon  
 XX microarrays having a probe with the exon, where a common pattern of  
 XX expression of the exons in the tissues and/or cell types indicates that  
 XX the exons should be assigned to a single gene; a peptide comprising one  
 XX of 12011 sequences, mentioned in the specification, or encoded by the  
 XX probes/open reading frames (ORF). The probes are used for gene expression  
 XX analysis, and for identifying exons in a gene, particularly using human  
 XX lung derived mRNA and for the study of lung diseases such as asthma, lung  
 XX cancer, chronic obstructive pulmonary disease (COPD), interstitial lung  
 XX disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,  
 XX tuberous sclerosis, Gaucher's disease, Niemann-Pick disease, Hermansky-  
 XX Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary  
 XX histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,  
 XX Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary  
 XX dyskinesia, pulmonary hypertension and hyaline membrane disease. The  
 XX present sequence is a single exon probe open reading frame of the  
 XX invention. Note: The sequence data for this patent did not form part of  
 XX the printed specification, but was obtained in electronic format directly  
 XX from WIFO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX Sequence 301 BP; 100 A; 54 C; 118 G; 29 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 22.2; DB 1; Length 301;  
 Best Local Similarity 58.2%; Pred. No. 20;  
 Matches 39; Conservative 0; Mismatches 28; Indels 0; Gaps 0;  
 QY 1626 TTGACCTGCTTCTCCCTTCCTTATTCCTTTGTTTTCATAGTCTCTGGCTT 1685  
 DB 277 TCTGCGCTGCTTACTCTGCGCTCTCAATTCTCTCTCTCTCTCTCTCTCT 218  
 QY 1686 CTTGGAT 1692  
 DB 217 TCTAGCT 211  
 RESULT 46  
 AAC04575/C  
 ID AAC04575 standard; cDNA; 385 BP.  
 XX AAC04575;  
 XX 06-OCT-2000 (first entry)  
 XX Human secreted protein 5' EST, SEQ ID NO: 8650.

XX Human; 5' EST; expressed sequence tag; secreted protein; cDNA isolation;  
KW gene therapy; chromosome mapping; ss.  
XX Homo sapiens.  
XX EPI033401-A2.  
XX 06-SEP-2000.  
XX 21-FEB-2000; 2000EP-00200610.  
XX 26-FEB-1999; 99US-0122487P.  
XX (GSET ) GENSET.  
XX Dumas Milne Edwards J, Duclert A, Giordano J;  
XX MPI; 2000-500381/45.  
XX New nucleic acid that is a 5' expressed sequence tag (5' EST) for  
XX obtaining cDNAs and genomic DNAs that correspond to 5'ESTs and for  
XX diagnostic, forensic, gene therapy and chromosome mapping procedures.  
XX Claim 1; SEQ ID NO 8650; 71pp + Sequence Listing; English.  
XX The present sequence is one of a large number of 5' ESTs derived from  
XX mRNAs encoding secreted proteins. No ORF has yet been conclusively  
XX identified within the present sequence. The 5' ESTs were prepared from  
XX total human RNAs or polyA+ RNAs derived from 30 differentiated tissues. EST  
XX sequences usually correspond mainly to the 3' untranslated region (UTR)  
XX of the mRNA because they are often obtained from oligo-dT primed cDNA  
XX libraries. Such ESTs are not well suited for isolating cDNA sequences  
XX derived from the 5' ends of mRNAs and even in those cases where longer  
XX cDNA sequences have been obtained, the full 5' UTR is rarely included. 5'  
XX ESTs are derived from mRNAs with intact 5' ends and can therefore be used  
XX to obtain full length cDNAs and genomic DNAs. 5' ESTs are also used in  
XX diagnostic, forensic, gene therapy and chromosome mapping procedures.  
XX They are used to obtain upstream regulatory sequences and to design  
XX expression and secretion vectors  
XX  
XX Sequence 385 BP; 69 A; 105 C; 126 G; 80 T; 0 U; 5 Other;  
Query Match 1.1%; Score 22; DB 1; Length 385;  
Best Local Similarity 57.1%; Pred. No. 24;  
Matches 40; Conservative 0; Mismatches 30; Indels 0; Gaps 0;  
OY 111 TCTCTCTCCCTTCTCTAACAACCTCTGGGCCAGGGTAGGGCACTACCGCATTCCTC 170  
Db 135 TCTCACATCCCGAGCTCCCAACATCCGAGACTGGATGATGAGGGSCACGCCACATGCACC 76  
OY 171 TCTCTTCCAA 180  
Db 75 CCACAGACAA 66  
RESULT 47  
ABQ47969/c  
ID ABQ47969 standard; DNA; 612 BP.  
XX AC ABQ47969;  
XX 12-JUL-2002 (first entry)  
XX Oligonucleotide for detecting cytosine methylation SEQ ID NO 34560.  
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;  
KW drug; side effect; cancer; central nervous system; cardiovascular;  
KW gastrointestinal; respiratory system; single nucleotide polymorphism;  
KW SNP; cell differentiation; ds.  
XX Homo sapiens.  
OS

PN WO200218632-A2.  
XX 07-MAR-2002.  
XX 01-SEP-2001; 2001WO-EP010074.  
XX 01-SEP-2000; 2000DE-01043826.  
XX 05-SEP-2000; 2000DE-01044543.  
XX (EPIG-) EPIGENOMICS AG.  
XX Olek A, Piepenbrock C, Berlin K, Guetig D;  
XX MPI; 2002-371829/40.  
XX Determining the degree of cytosine methylation in genomic DNA, useful for  
XX diagnosis and prognosis, comprises selective hybridization of amplicons  
XX from chemically treated DNA.  
XX Claim 12; 56pp + Sequence Listing; 56pp; German.  
XX This invention describes a novel method for determining the degree of  
XX methylation of a particular cytosine in a motif 5'-CpG-3', present in a  
XX genomic sample of DNA. The sample is treated chemically to convert  
XX cytosine (C) but not methylated C, to uracil, then part of the genomic  
XX DNA that contains the target C is amplified to form a labeled amplicon.  
XX The amplicon is hybridised to two classes, each with at least one member,  
XX of oligonucleotides and/or peptide-nucleic acid (PNA) oligomers and the  
XX degree of hybridisation to both classes is determined from the label on  
XX the amplicon. From the ratio of labels hybridised to the two classes of  
XX oligomers, the degree of methylation is calculated. The method is used:  
XX (i) for diagnosis and/or prognosis of side effects of therapeutic drugs  
XX and of a wide range of diseases, e.g. cancer, disorders of the central  
XX nervous, cardiovascular, gastrointestinal and respiratory systems etc.,  
XX particularly by detecting mutations or single nucleotide polymorphisms  
XX (SNPs); and (ii) for differentiation of cell or tissue types and for  
XX investigating cell differentiation. The method allows the methylation  
XX status of many C residues to be determined simultaneously. ABQ13410-  
XX ABQ54121 represent genomic DNA sequences used to illustrate the method  
XX for determining the degree of cytosine methylation described in the  
XX disclosure of the invention  
XX  
XX Sequence 612 BP; 232 A; 219 C; 72 G; 89 T; 0 U; 0 Other;  
Query Match 1.1%; Score 22; DB 1; Length 612;  
Best Local Similarity 49.2%; Pred. No. 27;  
Matches 58; Conservative 0; Mismatches 60; Indels 0; Gaps 0;  
OY 961 TTATCAATGACGAGTGTGTTGTCGATCTCTGTTATCTTGTGACCTGTGAGTGTTGTGT 1020  
Db 258 TTTCGAGGAGTATGTTTTTTTGTATTTTTTTTAGGGAGTTCGGTCGTAGTTTTT 199  
OY 1021 GT 1078  
Db 198 TTAGGAACGGCTTGGCGCTCGGCTCGGTAGGACGTCGTGGGTTTTTTTTTGGGT 141  
RESULT 48  
ABQ47968  
ID ABQ47968 standard; DNA; 612 BP.  
XX AC ABQ47968;  
XX 12-JUL-2002 (first entry)  
XX Oligonucleotide for detecting cytosine methylation SEQ ID NO 34559.  
XX Human; cytosine methylation; 5'-CpG-3'; uracil; cytosine; diagnosis;  
KW drug; side effect; cancer; central nervous system; cardiovascular;  
KW gastrointestinal; respiratory system; single nucleotide polymorphism;  
KW SNP; cell differentiation; ds.  
XX Homo sapiens.  
OS



PR 31-JAN-2001; 2001US-0265682P.  
 PR 09-FEB-2001; 2001US-0267568P.  
 PR 21-MAR-2001; 2001US-0278651P.  
 PR 28-APR-2001; 2001US-0287112P.  
 PR 16-MAY-2001; 2001US-0291631P.  
 PR 12-JUL-2001; 2001US-0305484P.  
 PR 20-AUG-2001; 2001US-0313999P.  
 PR 27-NOV-2001; 2001US-0333626P.  
 XX (CORI-) CORIXA CORP.  
 XX Benson DR, Kalos MD, Lodes MJ, Persing DH, Hepler WT, Jiang Y;  
 PI WPI; 2002-627435/67.  
 XX  
 XX New isolated polynucleotide and pancreatic tumor polypeptides, useful for  
 PT diagnosing, preventing and/or treating cancer, particularly pancreatic  
 PT cancer.  
 XX  
 PS Claim 1; SEQ ID NO 3878; 300pp + Sequence Listing; English.  
 XX  
 CC The invention relates to an isolated polynucleotide (I) comprising: (a)  
 CC any of a group of over 4000 nucleotide sequences (ABV94628-ABV99145); (b)  
 CC complements of (a); (c) sequences consisting of at least 20 contiguous  
 CC residues of (a); (d) sequences that hybridize to (a), under moderately  
 CC stringent conditions; (e) sequences having at least 75% or 90% identity  
 CC to (a); or (f) degenerate variants of (a). Polypeptides (ABP86596-  
 CC ABP86837) encoded by (I) and oligonucleotide can be used to detect cancer  
 CC in a patient and compositions comprising polypeptides, polynucleotides,  
 CC antibodies, fusion proteins, T cell populations and antigen presenting  
 CC cells expressing the polypeptide are useful in treating pancreatic cancer  
 CC and stimulating an immune response. The polynucleotides can be used as  
 CC probes or primers for nucleic acid hybridisation, in the design and  
 CC preparation of ribozyme molecules for inhibiting expression of the tumour  
 CC polypeptides and proteins in the tumour cells, in vaccines and for gene  
 CC therapy. Note: The sequence data for this patent did not form part of the  
 CC printed specification, but was obtained in electronic format directly  
 CC from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
 XX  
 SQ Sequence 254 BP; 61 A; 74 C; 84 G; 35 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.6; DB 1; Length 254;  
 Best Local Similarity 47.7%; Pred. No. 28;  
 Matches 63; Conservative 0; Mismatches 69; Indels 0; Gaps 0;

Qy 1742 TCACATTTCTTCTATCTTGTCTTCACTGCTGAGATTCTCTCTCTATCTCTTTGTATCTCG 1801  
 Db 247 TCAGTTCCTCTCTCTTGTGCGCTTGCCTCAGGCTATGCCACCTTCTCTCGCCCTT 188

Qy 1802 TCAGTGGGCTTCTCTGAGTCTCTGTGGTCTTATTTTCATTTCCAGATTTC 1861  
 Db 187 CCAGGCCGCTTGTCAATGTGAGGATGCGGTCCCTACAGCTGGCCCTGGCAGGTTTCC 129

Qy 1862 CTTTCAGTTTGGG 1873  
 Db 127 CTGCAGTATGAG 116

RESULT 51  
 AAV28290  
 ID AAV28290 standard; cDNA; 283 BP.  
 XX  
 AC AAV28290;  
 XX  
 DT 24-NOV-1998 (first entry)  
 XX  
 DE Galanin receptor GALR2 DNA probe.  
 XX  
 KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;  
 KW cognitive disorder; therapy; probe; ss.  
 XX  
 OS Rattus sp.

PN WO9829440-A1.  
 XX  
 PD 09-JUL-1998.  
 XX  
 PF 18-DEC-1997; 97WO-US023891.  
 XX  
 PR 27-DEC-1996; 96US-0033851P.  
 XX  
 PA (MERI) MERCK & CO INC.  
 XX (UYTE-) UNIV TEXAS HEALTH SCI SAN ANTONIO.  
 XX  
 PI Tan CP, Kolakowski LF;  
 XX  
 DR WPI; 1998-388038/33.  
 DR P-PSDB; AAW61461.  
 XX  
 XX New mouse galanin receptor, GALR2, - useful to identify agonists and  
 PT antagonists to treat conditions involving galanin, e.g. for treating  
 PT obesity, pain or cognitive disorders.  
 XX  
 PS Example 1; Fig 6; 56pp; English.  
 XX  
 CC This PCR fragment was used as a probe to screen a rat hypothalamus cDNA  
 CC library. 2 Independent clones, named 27A (see AAV28288) and 16.6, were  
 CC obtained. Clone 27A codes for a novel full-length rat galanin receptor,  
 CC designated GALR2 (see AAW61461). The invention provides methods for  
 CC identifying ligands particular to mouse GALR2 (see AAW61463). Such  
 CC ligands may be useful therapeutically e.g. to treat obesity or cognitive  
 CC disorders involving excess galanin or to treat pain or anorexia involving  
 CC insufficient galanin  
 XX  
 SQ Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 283;  
 Best Local Similarity 61.8%; Pred. No. 33;  
 Matches 34; Conservative 0; Mismatches 21; Indels 0; Gaps 0;

Qy 58 TGGGGCTGCTGCTCTTCTCCCTGCTCTGATTCTCTAGGCTGAGGTTTACCACTGCTC 112  
 Db 112 TCGGGCGCTGCTCTGCGCTGCTCTCTAGTGGCGAGGGCTGCACCTACGC 166

RESULT 52  
 AAV32651  
 ID AAV32651 standard; cDNA; 283 BP.  
 XX  
 AC AAV32651;  
 XX  
 DT 24-NOV-1998 (first entry)  
 XX  
 DE Galanin receptor GALR2 DNA probe.  
 XX  
 KW Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;  
 KW cognitive disorder; therapy; probe; ss.  
 XX  
 OS Rattus sp.  
 XX  
 PN WO9829439-A1.  
 XX  
 PD 09-JUL-1998.  
 XX  
 PF 18-DEC-1997; 97WO-US023890.  
 XX  
 PR 27-DEC-1996; 96US-0033851P.  
 XX  
 PA (MERI) MERCK & CO INC.  
 XX  
 PI Tan C, Sullivan K;  
 XX  
 DR WPI; 1998-388037/33.  
 XX  
 PT New galanin receptor, GALR2 - useful, e.g. to identify agonists and  
 PT antagonists, therapeutically to treat conditions involving excess or

PT insufficient galanin such as obesity.

PS Example 1; Fig 6; 57pp; English.

XX This PCR fragment was used as a probe to screen a rat hypothalamus cDNA library. 2 independent clones, named 27A (see AAV42648) and 16.6, were obtained. Clone 27A codes for a novel full-length rat galanin receptor, designated GALR2 (see AAW49002). The invention provides methods for identifying ligands particular to GALR2. Such ligands may be useful therapeutically e.g. to treat obesity or cognitive disorders involving excess galanin or to treat pain or anorexia involving insufficient galanin

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 283;

Best Local Similarity 61.8%; Pred. No. 33; Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTCTGCGCCCTGCTCCTTACGTGGGCGAGGCTGCACCTACGC 166

RESULT 53

AAV4930

ID AAV4930 standard; cDNA; 283 BP.

XX AAV4930;

XX 24-NOV-1998 (first entry)

XX Galanin receptor GALR2 DNA probe.

XX Galanin receptor; GALR2; rat; ligand; obesity; anorexia; pain;

XX cognitive disorder; therapy; probe; ss.

XX Rattus sp.

XX WO9829441-A1.

XX 09-JUL-1998.

XX 18-DEC-1997; 97WO-US023892.

XX 27-DEC-1996; 96US-0033851P.

XX (MERI ) MERCK & CO INC.

XX (UYTE-) UNIV TEXAS HEALTH SCI CENT SAN ANTONIO.

XX (UTOR ) UNIV TORONTO.

XX Sullivan K, Kolakowski LF, Odowd B;

XX WPI; 1998-388039/33.

XX New human galanin receptor, GALR2, - useful to identify agonists and antagonists to treat conditions involving galanin, e.g. for treatment of obesity or cognitive disorders.

XX Example 1; Fig 6; 57pp; English.

XX This PCR fragment was used as a probe to screen a rat hypothalamus cDNA library. 2 independent clones, named 27A (see AAV4929) and 16.6, were obtained. Clone 27A codes for a novel full-length rat galanin receptor, designated GALR2 (see AAW61385). The invention provides methods for identifying ligands particular to human GALR2 (see AAW61386). Such ligands may be useful therapeutically e.g. to treat obesity or cognitive disorders involving excess galanin or to treat pain or anorexia involving insufficient galanin

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 283;

Best Local Similarity 61.8%; Pred. No. 33;

Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTCTGCGCCCTGCTCCTTACGTGGGCGAGGCTGCACCTACGC 166

RESULT 55

AAS21354/C

ID AAS21354 standard; cDNA; 1129 BP.

XX AAS21354;

XX 24-OCT-2001 (first entry)

XX Human cDNA sequence encoding for PRO4327 polypeptide.

XX

Best Local Similarity 61.8%; Pred. No. 33; Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTCTGCGCCCTGCTCCTTACGTGGGCGAGGCTGCACCTACGC 166

RESULT 54

ABK14060

ID ABK14060 standard; cDNA; 283 BP.

XX ABK14060;

XX 08-MAY-2002 (first entry)

XX Rat galanin receptor 2 (GALR2) cDNA probe.

XX Galanin receptor 2; GALR2; probe; ss; rat; obesity; pain; anorectic;

XX cognitive disorder; analgesic; neuroprotective.

XX Rattus sp.

XX US6337206-B1.

XX 08-JAN-2002.

XX 18-DEC-1997; 97US-00993424.

XX 18-DEC-1997; 97US-00993424.

XX (MERI ) MERCK & CO INC.

XX (TEXA ) UNIV TEXAS SYSTEM.

XX Tan C, Kolakowski LF;

XX WPI; 2002-163241/21.

XX New nucleic acid encoding mouse galanin receptor 2, useful in assays for identifying galanin receptor 2 ligands for treating obesity, pain and cognitive disorders.

XX Disclosure; Fig 6; 48pp; English.

XX The invention relates to mouse galanin receptor 2 (GALR2) and the nucleic acid encoding the novel polypeptide. The sequences are useful in assays for identifying GALR2 ligands that are useful for treating obesity, pain and cognitive disorders. The sequences are also useful for identifying agonists, antagonists, suppressors or inducers of GALR2. This sequence represents a cDNA probe used to isolate rat GALR2, used in the methods of the invention

XX Sequence 283 BP; 27 A; 116 C; 84 G; 56 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 283;

Best Local Similarity 61.8%; Pred. No. 33;

Mismatches 34; Conservative 0; Indels 21; Gaps 0;

QY 58 TGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGCTGAGGTTACCACTGCTC 112

Db 112 TCGGGCCGCTGCTCTGCGCCCTGCTCCTTACGTGGGCGAGGCTGCACCTACGC 166

RESULT 55

AAS21354/C

ID AAS21354 standard; cDNA; 1129 BP.

XX AAS21354;

XX 24-OCT-2001 (first entry)

XX Human cDNA sequence encoding for PRO4327 polypeptide.

XX





PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US020111.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 23-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 08-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 08-NOV-2000; 2000WO-US023328.  
 PR 10-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030973.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 05-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00806889.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00865028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017052.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI: 2003-341980/32.  
 DR P-PSDB; ABO17726.  
 DR  
 XX  
 PS Claim 2; Fig 221; 660pp; English.  
 XX  
 CC The invention describes an isolated nucleic acid (I) comprising, or which  
 CC has 80 % sequence identity to, or the full-length coding sequence of, one  
 CC of 275 nucleotide sequences, and which encodes a corresponding  
 CC polypeptide selected from 275 amino acid sequences, where all sequences  
 CC are given in the specification. The polypeptide encoded by (I) is used to  
 CC detect PRO polypeptides, link a bioactive molecule to a cell expressing a  
 CC PRO polypeptide, modulate a biological activity of a cell, stimulate the  
 CC release of tumour necrosis factor (TNF)-alpha from human blood, modulate  
 CC the uptake of glucose or free fatty acid by cells, stimulate or inhibit  
 CC the proliferation or differentiation of cells or gene expression,  
 CC stimulate the release of proteoglycans, stimulate the release of cytokine  
 CC from peripheral blood mononuclear cells, inhibit the binding of A-peptide  
 CC to factor VIIA, or detect the presence of tumour in a mammal. The nucleic  
 CC acid and polypeptide encoded by it, are useful for treating inflammatory  
 CC diseases, organ failure, atherosclerosis, cardiac injury, infertility,  
 CC birth defects, premature aging, acquired immunodeficiency syndrome  
 CC (AIDS), cancer, or diabetic complications. The nucleic acid is useful as  
 CC hybridisation probes, in chromosome and gene mapping, and in generating  
 CC antisense RNA or DNA. The polypeptides are useful as pharmaceuticals,  
 CC diagnostics, biosensors or bioreactors. Both are useful in tissue typing.  
 CC This sequence encodes a novel human secreted and transmembrane PRO  
 CC polypeptide  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1881  
 |||||  
 Db 1129 TTTTTCATTTTTCATTCAGTGGCACACAGCGTGGGTTTATT 1083  
 |||||  
 RESULT 57  
 ACA67104/c  
 ID ACA67104 standard; cDNA; 1129 BP.  
 AC ACA67104;  
 XX  
 XX  
 DT 23-JUN-2003 (first entry)  
 XX cDNA encoding human PRO polypeptide #111.  
 DE Human; PRO polypeptide; secreted and transmembrane protein;  
 KW anti-PRO antibody; diagnostic assay; gene expression; diabetes;  
 KW



bone disorder; cartilage disorder; rheumatoid arthritis; obesity;  
sports injury; osteoarthritis; hyper-insulinaemia; hypo-insulinaemia;  
hearing loss; coagulation disorder; stroke; heart attack; cardiac;  
antidiabetic; anorectic; vulnary; antiarthritic; osteopathic;  
antirheumatic; auditory; cerebroprotective; angiogenic; gene; ss.

Homo sapiens.

US2003004311-A1.

02-JAN-2003.

19-DEC-2001; 2001US-00028072.

18-JUN-1997; 97US-0049911P.

26-AUG-1997; 97US-0056974P.

17-SEP-1997; 97US-0059113P.

17-SEP-1997; 97US-0059115P.

17-SEP-1997; 97US-0059117P.

17-SEP-1997; 97US-0059122P.

17-SEP-1997; 97US-0059184P.

18-SEP-1997; 97US-0059263P.

19-SEP-1997; 97US-0059332P.

19-SEP-1997; 97US-0059588P.

24-SEP-1997; 97US-0059836P.

17-OCT-1997; 97US-0062250P.

17-OCT-1997; 97US-0062285P.

17-OCT-1997; 97US-0062287P.

17-OCT-1997; 97US-0063755P.

24-OCT-1997; 97US-0062814P.

24-OCT-1997; 97US-0063045P.

24-OCT-1997; 97US-0063082P.

27-OCT-1997; 97US-0063127P.

27-OCT-1997; 97US-0063327P.

27-OCT-1997; 97US-0063329P.

28-OCT-1997; 97US-0063350P.

28-OCT-1997; 97US-0063561P.

29-OCT-1997; 97US-0063704P.

29-OCT-1997; 97US-0063733P.

29-OCT-1997; 97US-0063738P.

03-NOV-1997; 97US-0064248P.

12-NOV-1997; 97US-0065186P.

17-NOV-1997; 97US-0065846P.

21-NOV-1997; 97US-0066364P.

24-NOV-1997; 97US-0066453P.

24-NOV-1997; 97US-0066511P.

24-NOV-1997; 97US-0066770P.

11-DEC-1997; 97US-0069212P.

11-DEC-1997; 97US-0069278P.

16-DEC-1997; 97US-0069334P.

23-JAN-1998; 98US-0073320P.

04-FEB-1998; 98US-0073612P.

09-FEB-1998; 98US-0074086P.

09-FEB-1998; 98US-0074092P.

12-MAR-1998; 98US-0077791P.

20-MAR-1998; 98US-0078910P.

25-MAR-1998; 98US-0079294P.

27-MAR-1998; 98US-0079663P.

31-MAR-1998; 98US-0079728P.

31-MAR-1998; 98US-0080165P.

12-JUN-1998; 98WO-US012456.

14-JUL-1998; 98WO-US014552.

28-AUG-1998; 98WO-US017888.

10-SEP-1998; 98WO-US018824.

14-SEP-1998; 98WO-US019093.

14-SEP-1998; 98WO-US019094.

14-SEP-1998; 98WO-US019177.

16-SEP-1998; 98WO-US019330.

17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.  
29-OCT-1998; 98WO-US022991.  
29-OCT-1998; 98WO-US022992.  
20-NOV-1998; 98WO-US024855.  
01-DEC-1998; 98WO-US025108.  
05-JAN-1999; 98WO-US000106.  
08-MAR-1999; 98WO-US005028.  
10-MAR-1999; 98WO-US005190.  
20-APR-1999; 98WO-US008615.  
14-MAY-1999; 98WO-US010733.  
02-JUN-1999; 98WO-US012252.  
01-SEP-1999; 98WO-US020111.  
08-SEP-1999; 98WO-US020594.  
13-SEP-1999; 98WO-US020944.  
15-SEP-1999; 98WO-US021090.  
15-SEP-1999; 98WO-US021547.  
05-OCT-1999; 98WO-US023089.  
29-NOV-1999; 98WO-US028214.  
30-NOV-1999; 98WO-US028313.  
30-NOV-1999; 98WO-US028409.  
01-DEC-1999; 98WO-US028301.  
01-DEC-1999; 98WO-US028634.  
02-DEC-1999; 98WO-US028551.  
02-DEC-1999; 98WO-US028564.  
16-DEC-1999; 98WO-US028565.  
20-DEC-1999; 98WO-US030095.  
20-DEC-1999; 98WO-US030911.  
30-DEC-1999; 98WO-US030999.  
30-DEC-1999; 98WO-US031243.  
30-DEC-1999; 98WO-US031274.  
05-JAN-2000; 2000WO-US000219.  
06-JAN-2000; 2000WO-US000277.  
11-FEB-2000; 2000WO-US000376.  
18-FEB-2000; 2000WO-US003565.  
18-FEB-2000; 2000WO-US004341.  
22-FEB-2000; 2000WO-US004342.  
22-FEB-2000; 2000WO-US004414.  
24-FEB-2000; 2000WO-US004914.  
24-FEB-2000; 2000WO-US005004.  
01-MAR-2000; 2000WO-US005601.  
02-MAR-2000; 2000WO-US005746.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-352836/33.

P-PSDB; ABU80980.

New isolated PRO polypeptide useful for treating diabetes, rheumatoid  
arthritis, sports injuries, obesity, hearing loss in mammals, stroke, or  
heart attack.

Claim 2; Fig 221; 643pp; English.

The present invention relates to the isolation of novel human PRO  
polypeptides, and the polynucleotide sequences encoding them. The PRO  
polypeptides are secreted and transmembrane proteins. The PRO  
polypeptides and polynucleotides are useful for preparing a medicament  
useful in the treatment of diabetes, bone and/or cartilage disorders  
(e.g. rheumatoid arthritis, sports injuries, osteoarthritis), obesity,  
hyper- or hypo-insulinaemia, hearing loss, and coagulation disorders  
(e.g. stroke, heart attack). Anti-PRO antibodies are useful in diagnostic  
assays for PRO, by detecting its expression in specific cells, tissues or  
serum, and for affinity purification of PRO from recombinant cell culture  
or natural sources. ACA68994:ACA67268 represent cDNA sequences encoding  
the human PRO polypeptides of the invention. Note: The sequence data for  
this patent was obtained in electronic format directly from the USPTO web  
site at [seqdata.uspto.gov/paipsIDEntry.html](http://seqdata.uspto.gov/paipsIDEntry.html)

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;



[illegible]



CC	full-length coding sequence of the nucleotide sequences given in the
CC	specification, or of the DNA deposited under any of the American Type
CC	Culture Collection (ATCC) Accession Numbers listed in the specification.
CC	Also included are a vector comprising the novel nucleic acid, a host cell
CC	comprising the vector, producing a PRO polypeptide, the isolated PRO
CC	polypeptides detailed above, a chimaeric molecule comprising the PRO
CC	polypeptide of fused to a heterologous amino acid sequence, an anti-PRO
CC	antibody, detecting a PRO polypeptide in a sample suspected of containing
CC	the PRO polypeptide, linking a bioactive molecule to a cell expressing a
CC	PRO polypeptide, modulating at least one biological activity of a cell
CC	expressing a PRO polypeptide, stimulating the release of tumour necrosis
CC	factor-alpha (TNF-alpha) from human blood, (or proteoglycans from
CC	cartilage or cytokine from peripheral blood mononuclear cells (PBMC)),
CC	modulating the uptake of glucose or FFA by skeletal muscle cells or
CC	adipocyte cells, stimulating the proliferation or differentiation of
CC	chondrocyte cells (or proliferation of or gene expression in pericyte
CC	cells), stimulating the proliferation of inner ear utricular supporting
CC	cells (or of T-lymphocyte cells, or of endothelial cells), inhibiting the
CC	binding of A-peptide to factor VIIA, or differentiation of adipocyte
CC	cells, detecting the presence of a tumour in a mammal and an
CC	oligonucleotide probe derived from any of the nucleotide sequences given
CC	in the specification. The polynucleotide is useful in molecular biology,
CC	including uses as hybridisation probes, in chromosome and gene mapping,
CC	in generating antisense RNA and DNA, and in gene therapy. The
CC	polynucleotide may also be used in preparing PRO polypeptides by
CC	recombinant techniques, and in generating either transgenic animals or
CC	knock-out animals which, in turn, are useful in the development and
CC	screening of therapeutically useful reagents. The PRO polypeptide or the
CC	antibody is used in preparing a medicament for treating a condition
CC	responsive to the polypeptide or antibody, such as tumours, and in
CC	various diagnostic assays. The present sequence encodes a PRO polypeptide
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match            1.1%; Score 21.4; DB 1; Length 1129;	
Best Local Similarity   66.0%; Pred. No. 45;	
Matches   31; Conservative   0; Mismatches   16; Indels   0; Gaps   0;	
QY	1835 TTCTTAATTTTTCATTCCAGATTTCCVTCAGTTGGGTGTTTGTTT 1881
DB	1129 TTTTTTTTTTTTTTTTTCAGTCGCACACAGCGTGGGTTTTATT 1083
RESULT 61	
ACAA04134/C	
ID	ACAA04134 standard; cDNA; 1129 BP.
XC	
AC	ACAA04134;
XX	
DT	27-MAY-2003 (first entry)
DE	Human cDNA encoding a secreted/transmembrane protein, SEQ ID 221.
XX	
KW	Human; ss; gene; secreted protein; transmembrane protein; PRO;
KW	Inflammatory disease; organ failure; atherosclerosis; cardiac injury;
KW	infertility; birth defects; premature aging; AIDS; biosensor;
KW	acquired immunodeficiency syndrome; cancer; diabetic complication;
KW	bioreactor; tumour.
XX	
OS	Homo sapiens.
OS	
US	US2003032155-A1.
FN	
XX	
PD	13-FEB-2003.
PF	
XX	
PP	03-MAY-2002; 2002US-00137865.
XX	
PR	31-MAR-1997; 97WO-US005230.
PR	12-JUN-1996; 98WO-US024245.
PR	14-JUL-1998; 98WO-US014552.
PR	28-AUG-1998; 98WO-US017888.
PR	10-SEP-1998; 98WO-US018824.
PR	14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 27-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 29-OCT-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 08-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US021547.  
 PR 29-OCT-1999; 99WO-US023089.  
 PR 30-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 11-FEB-2000; 2000WO-US000376.  
 PR 18-FEB-2000; 2000WO-US003565.  
 PR 22-FEB-2000; 2000WO-US004342.  
 PR 24-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 01-MAR-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 10-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006319.  
 PR 20-MAR-2000; 2000WO-US006884.  
 PR 21-MAR-2000; 2000WO-US007377.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015284.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 01-NOV-2000; 2000WO-US030873.  
 PR 10-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US032678.  
 PR 28-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 05-JUN-2001; 2001WO-US017800.  
 PR 01-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882836.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-331925/31.  
 DR P-PSDB; ABU66956.  
 XX New secreted and transmembrane nucleic acids and polypeptides, designated  
 as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
 cardiac injury, infertility, birth defects, premature aging, AIDS, or  
 cancer.  
 PS Claim 2; Fig 221; 659pp; English.  
 CC The invention relates to an isolated nucleic acid comprising, or which is  
 at least 80% identical to, or the full-length coding sequence of, any of  
 the 275 nucleotide sequences, encoding the corresponding PRO polypeptide  
 (one of 275 secreted or transmembrane proteins). The nucleic acid further  
 comprises the full-length coding sequence of the DNA deposited under  
 American Type Culture Collection (ATCC) accession number in a list given  
 in the specification. Also included are vectors and host cells for  
 producing PRO proteins, PRO fusion proteins, anti-PRO antibodies, PRO  
 extracellular domains and mature sequences, methods of detecting PRO  
 proteins, methods for stimulating the release of TNF-alpha (tumour  
 necrosis factor alpha) from human blood, (and the proliferation of  
 differentiation of chondrocyte cells, the release or proteoglycans from  
 expression in pericyte cells, the release or proteoglycans from  
 cartilage, proliferation of inner ear utricular supporting cells, the  
 proliferation of T-lymphocyte cells, the release of a cytokine from  
 peripheral blood mononuclear cells (PBMC), or the proliferation of  
 endothelial cells), a method for modulating the uptake of glucose or free  
 fatty acid (FFA) by skeletal muscle cells, a method for inhibiting the  
 binding of A-peptide to factor VIIA, or the differentiation of adipocyte  
 cells, a method for detecting the presence of a tumour in a mammal and an  
 oligonucleotide probe derived from any of the nucleotide sequences cited  
 above. The nucleic acids and polypeptides are useful for treating  
 inflammatory diseases, organ failure, atherosclerosis, cardiac injury,  
 infertility, birth defects, premature aging, AIDS (acquired  
 immunodeficiency syndrome), cancer, or diabetic complications. The  
 nucleic acids are useful as hybridisation probes, in chromosome and gene  
 mapping, and in generating antisense RNA or DNA. The polypeptides are  
 useful as pharmaceuticals, diagnostics, biosensors or bioeffectors. Both  
 are useful in tissue typing. The present sequence encodes a PRO protein  
 of the invention  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Qy 1935 TTCTAATTTTTCATTCACAGATTCTCTCAGTTTGGTTTGT 1881  
 Db 1129 TTTTTCATTTTTCATTCACAGATTCTCTCAGTTTGGTTTGT 1083

RESULT 62  
 ADA45740/c  
 ID ADA45740 standard; cDNA; 1129 BP.  
 XX  
 AC ADA45740;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003022328-A1.  
 XX  
 PD 30-JAN-2003.  
 XX  
 PF 16-APR-2002; 2002US-0013904.  
 XX  
 PP 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021144.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 20-NOV-1998; 98WO-US025108.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 98WO-US000106.  
 PR 08-MAR-1999; 98WO-US005028.  
 PR 10-MAR-1999; 98WO-US008190.  
 PR 20-APR-1999; 98WO-US008615.  
 PR 02-JUN-1999; 98WO-US010733.  
 PR 14-MAY-1999; 98WO-US020111.  
 PR 01-SEP-1999; 98WO-US020594.  
 PR 08-SEP-1999; 98WO-US020944.  
 PR 13-SEP-1999; 98WO-US021090.  
 PR 15-SEP-1999; 98WO-US021547.  
 PR 15-SEP-1999; 98WO-US023089.  
 PR 29-NOV-1999; 98WO-US028214.  
 PR 30-NOV-1999; 98WO-US028313.  
 PR 30-NOV-1999; 98WO-US028409.  
 PR 01-DEC-1999; 98WO-US028301.  
 PR 01-DEC-1999; 98WO-US028634.  
 PR 02-DEC-1999; 98WO-US028551.  
 PR 02-DEC-1999; 98WO-US028564.  
 PR 02-DEC-1999; 98WO-US028565.  
 PR 16-DEC-1999; 98WO-US030095.  
 PR 20-DEC-1999; 98WO-US030911.  
 PR 20-DEC-1999; 98WO-US030999.  
 PR 22-DEC-1999; 98WO-US030720.  
 PR 30-DEC-1999; 98WO-US031243.

PR 30-DEC-1999; 98WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003565.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUN-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US0006520.  
 PR 01-MAR-2001; 2001WO-US0006566.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 29-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00308827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI: 2003-584997/55.  
 DR P-PSDB; ADA45741.  
 XX  
 XX Novel secreted and transmembrane polypeptide for modulating biological  
 PT activity of cell expressing the polypeptide, identifying agonists or  
 PT antagonists of polypeptide, and as molecular weight markers.  
 XX





XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Fied. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

OY 1835 TTCTAATTTTTCATTTCCAGATTTTCCTTCAGTTGGGTTTGT 1881  
 |||||  
 Db 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1083

RESULT 64  
 ADA18821/c  
 ID ADA18821 standard; cDNA; 1129 BP.  
 XX  
 AC ADA18821;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polynucleotide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; blood; chondrocyte cell; lung;  
 KW colon; breast; prostate; rectum; cervix; liver; tumour; cancer;  
 KW glucose uptake; FFA; adipocyte cell; pericyte cell; proteoglycan;  
 KW cartilage; inner ear utricular supporting cell; cytokine; A-peptide;  
 KW factor VIIa; endothelial cell.  
 XX  
 OS Homo sapiens.  
 XX  
 FN US2003054517-A1.  
 XX  
 PD 20-MAR-2003.  
 XX  
 PF 08-MAY-2002; 2002US-00141755.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 20-NOV-1998; 98WO-US022992.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028634.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.

PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882836.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001US-00886342.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001US-00887879.  
 PR 29-JUN-2001; 2001US-00887879.  
 PR 09-JUL-2001; 2001US-00887879.  
 PR 18-JUL-2001; 2001US-00887879.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PR  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-687639/65.  
 DR P-PSDB; ADA76172.  
 XX  
 PT New isolated nucleic acid encoding a secreted and transmembrane  
 PT polypeptide, designated e.g. PRO114 or PRO4978, useful in chromosome and  
 PT gene mapping, in generating antisense RNA and DNA, and in gene therapy.  
 XX  
 PS Claim 2; Fig 221; 659pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems.  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.



XX 13-MAR-2003.  
PD 15-APR-2002; 2002US-00123362.  
PF 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019033.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022291.  
XX 29-OCT-1998; 98WO-US022592.  
XX 20-NOV-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.  
XX 20-APR-1999; 99WO-US008615.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 01-SEP-1999; 99WO-US020111.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US020944.  
XX 15-SEP-1999; 99WO-US021030.  
XX 15-SEP-1999; 99WO-US021547.  
XX 05-OCT-1999; 99WO-US023089.  
XX 29-NOV-1999; 99WO-US028214.  
XX 30-NOV-1999; 99WO-US028313.  
XX 01-DEC-1999; 99WO-US028409.  
XX 01-DEC-1999; 99WO-US028301.  
XX 01-DEC-1999; 99WO-US028634.  
XX 02-DEC-1999; 99WO-US028551.  
XX 02-DEC-1999; 99WO-US028564.  
XX 02-DEC-1999; 99WO-US028565.  
XX 16-DEC-1999; 99WO-US030095.  
XX 20-DEC-1999; 99WO-US030911.  
XX 20-DEC-1999; 99WO-US030999.  
XX 22-DEC-1999; 99WO-US030720.  
XX 30-DEC-1999; 99WO-US031243.  
XX 30-DEC-1999; 99WO-US031274.  
XX 05-JAN-2000; 2000WO-US000219.  
XX 06-JAN-2000; 2000WO-US000277.  
XX 06-JAN-2000; 2000WO-US000376.  
XX 11-FEB-2000; 2000WO-US003565.  
XX 18-FEB-2000; 2000WO-US004341.  
XX 22-FEB-2000; 2000WO-US004342.  
XX 24-FEB-2000; 2000WO-US004414.  
XX 24-FEB-2000; 2000WO-US004914.  
XX 01-MAR-2000; 2000WO-US005004.  
XX 02-MAR-2000; 2000WO-US005601.  
XX 02-MAR-2000; 2000WO-US005746.  
XX 10-MAR-2000; 2000WO-US005841.  
XX 10-MAR-2000; 2000WO-US006319.  
XX 15-MAR-2000; 2000WO-US006884.  
XX 21-MAR-2000; 2000WO-US007377.  
XX 21-MAR-2000; 2000WO-US007532.  
XX 30-MAR-2000; 2000WO-US008439.  
XX 17-MAY-2000; 2000WO-US013705.  
XX 22-MAY-2000; 2000WO-US014042.  
XX 30-MAY-2000; 2000WO-US014941.  
XX 02-JUN-2000; 2000WO-US015264.  
XX 28-JUL-2000; 2000WO-US020710.  
XX 11-AUG-2000; 2000WO-US022031.  
XX 23-AUG-2000; 2000WO-US023522.  
XX 24-AUG-2000; 2000WO-US023328.  
XX 08-NOV-2000; 2000WO-US030952.  
XX 10-NOV-2000; 2000WO-US030873.

PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00803706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00818744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI: 2003-695892/66.  
P-PSDS; ADA61445.

New PRO nucleic acid and encode polypeptides, are useful for  
manufacturing a medicament for diagnosing or treating cancer.

Claim 2; Fig 221; 660pp; English.

The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PBMC cells, for inhibiting the binding of A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes

Mon Aug 9 17:47:19 2004

10664775-3.rng

Page 44

CC a novel human secreted and transmembrane PRO polypeptide.  
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
SQ

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTTCTAATTTTTCATTCACGATTTCTTCAGTTTGGGTTTGTGTT 1881  
Db 1129 TTTTITTTTTTTTTTTCAGCTGGCACACAGCTGGTTTATT 1083

RESULT 66  
ADBI9229/c  
ID ADBI9229 standard; cDNA; 1129 BP.  
XX  
AC ADBI9229;  
DT  
XX 20-NOV-2003 (first entry)  
DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; cell differentiation stimulator;  
KW Cell differentiation inhibitor; cytokin.

OS Homo sapiens.  
XX  
XX US2003068796-A1.  
XX 10-APR-2003.  
XX 15-APR-2002; 2002US-00123261.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1996; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030065.

PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006866.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00892636.  
PR 19-JUN-2001; 2001US-00883342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deenoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-695927/66.  
DR P-PSDB; ADBI9230.

PT Novel secreted and transmembrane PRO polypeptides useful for stimulating  
PI the release of tumor necrosis factor alpha and detecting the presence of  
XX a tumor in a mammal.

PS Claim 2; Fig 221; 660pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTAATTTTTCATTTCCAGATTTCTTCAGTTGGGTTTGT 1881

Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 67

ID ADB27770/C

XX ADB27770 standard; cDNA; 1129 BP.

XX ADB27770;

XX 20-NOV-2003 (first entry)

XX cDNA encoding human PRO polypeptide #111.

XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX US2003082704-A1.

XX 01-MAY-2003.

XX 24-APR-2002; 2002US-00131819.

XX 09-DEC-1999; 99US-0170262P.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-765415/72.

XX P-PSDB; ADB27771.

XX New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.

XX Claim 2; Fig 221; 637pp; English.

XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis

XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTAATTTTTCATTTCCAGATTTCTTCAGTTGGGTTTGT 1881

Db 1129 TTTTITTTTTTTTTTTTCAGCTGGCACACAGGCTGGGTTTATT 1083

RESULT 68

ADA86249/C

ID ADA86249 standard; cDNA; 1129 BP.

XX ADA86249;

XX 20-NOV-2003 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003082711-A1.

XX 01-MAY-2003.

XX 16-MAY-2002; 2002US-00147508.

XX 02-JUL-1998; 98US-0091519P.

XX 02-JUN-1999; 99WO-US012252.

XX 07-JUL-1999; 99US-0143048P.

XX 25-AUG-1999; 99US-00380137.

XX 30-MAR-2000; 2000WO-US0008439.

PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-786914/74.  
 DR P-PSDB; ADA86250.  
 XX  
 XX New PRO nucleic acid, useful for preparing a composition for treating  
 PT e.g., tumor or for tissue typing.  
 XX  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TCTCAATTTTTCATTCAGATTCTCTCAGTTGGGTTTGT 1881  
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGACACAGCGTGGTTTATT 1083  
 RESULT 69  
 ADB15813/C  
 ID ADB15813 standard, cDNA; 1129 BP.  
 AC ADB15813;  
 XX  
 XX 20-NOV-2003 (first entry)  
 DT  
 XX Human PRO polynucleotide #111.  
 DE  
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose- FFA

KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 OS  
 XX US2003087350-A1.  
 PN  
 XX 08-MAY-2003.  
 PD  
 XX 22-APR-2002; 2002US-00127821.  
 BF  
 XX 04-AUG-1998; 98US-0095301P.  
 PR  
 XX 02-JUN-1999; 99WO-US012252.  
 PR  
 XX 25-AUG-1999; 99US-00180137.  
 PR  
 XX 30-MAR-2000; 2000WO-US008439.  
 PR  
 XX 01-DEC-2000; 2000WO-US032678.  
 PR  
 XX 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-786914/74.  
 DR P-PSDB; ADB15814.  
 XX  
 XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
 PT and for manufacturing a medicament for diagnosing or treating tumor.  
 PT  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems.  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Qy 1835 TTCTTAATTTTTCATTTCAGATTCTCTTCAGTTTGGTTTGGTTT 1881  
ID ADA47599 standard; cDNA; 1129 BP.  
Db 1129 TTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTTATTTT 1083

RESULT 70  
ADA47599/c  
ADA47599 standard; cDNA; 1129 BP.  
AC ADA47599;  
AD 20-NOV-2003 (first entry)  
DT Human PRO polynucleotide #11.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
XX tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; parietal cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

OS Homo sapiens.  
XX  
XX US2003073215-A1.  
XX  
XX 17-APR-2003.  
XX  
XX 07-MAY-2002; 2002US-00140925.

XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017898.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019033.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.

PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00865028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-644801/61.  
DR P-PSDB; ADA47600.

XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
XX in gene therapy, detecting the presence of tumor in a mammal, or  
PT







PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034356.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 18-MAY-2001; 2001US-00854280.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US020116.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-0028072.  
XX (GETH) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-695926/66.  
XX P-PSDB; ADA67395.  
XX  
XX Novel isolated PRO secreted and transmembrane polypeptides useful for  
PT stimulating the release of tumor necrosis factor-alpha from human blood  
PT and detecting the presence of a tumor in a mammal.  
XX  
XX Claim 2; Fig 22; 660pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
XX transmembrane polypeptides) and the polynucleotides encoding them. The  
XX invention also relates to an antibody which specifically binds to a PRO  
XX polypeptide, a method for stimulating the release of tumor necrosis  
XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
XX proliferation or differentiation of chondrocyte cells and a method for  
XX detecting the presence of a tumor in a mammal (e.g. adrenal, lung,  
XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
XX polynucleotides are useful in molecular biology, including uses as  
XX hybridisation probes, in chromosome and gene mapping, in generating  
XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
XX be used in preparing PRO polypeptides by recombinant techniques and in  
XX generating either transgenic animals or knock-out animals which are  
XX useful in the development and screening of therapeutically useful  
XX reagents. The PRO polypeptides or antibodies are used in preparing a  
XX medicament for treating a condition responsive to the polypeptides or  
XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
XX of human microvascular endothelial cells, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating differentiation of adipocyte cells, for stimulating  
XX proliferation of or gene expression in pericyte cells, for stimulating  
XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
XX cells, for inducing endothelial cell tube formation and for treating  
XX various bone and/or cartilage disorders such as sports injuries and  
XX arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at seqdata.uspto.gov/sequence.html.  
XX  
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Oy 1035 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1881  
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTATT 1083

RESULT 72  
ADB30401/c  
ID ADB30401 standard; cDNA; 1129 BP.  
XX ADB30401;  
XX  
XX 20-NOV-2003 (first entry)  
XX cDNA encoding human PRO polypeptide #111.

Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.

XX Homo sapiens.  
XX OS  
XX US2003068794-A1.  
XX  
XX 10-APR-2003.  
XX  
XX 15-APR-2002; 2002US-00123155.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.  
XX 29-OCT-1998; 98WO-US022992.  
XX 29-OCT-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.  
XX 20-APR-1999; 99WO-US008615.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 01-SEP-1999; 99WO-US020111.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US020944.

```
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 05-JAN-2000; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 06-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000WO-US032759.
PR 28-FEB-2001; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 01-MAR-2001; 2001WO-US006520.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017600.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUL-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00908827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.

16-AUG-2001; 2001US-00931836.
19-DEC-2001; 2001US-00028072.
(GETH) GENENTECH INC.
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
WPI; 2003-708391/67.
P-PSDB; ADB30402.
New isolated PRO polypeptides e.g. PRO1801 and PRO1114, useful in the
preparation of a medicament for treating a condition responsive to PRO
polypeptide, and as therapeutic agents e.g. vaccines.
Claim 2; Fig 221; 660pp; English.
The invention relates to isolated human PRO polypeptides (secreted and
transmembrane polypeptides) and the polynucleotides encoding them. The
invention also relates to an antibody which specifically binds to a PRO
polypeptide, a method for stimulating the release of tumour necrosis
factor-alpha (TNF-alpha) from human blood, a method for stimulating the
proliferation or differentiation of chondrocyte cells and a method for
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
polynucleotides are useful in molecular biology, including uses as
hybridisation probes, in chromosome and gene mapping, in generating
antisense RNA and DNA and in gene therapy. The polynucleotides may also
be used in preparing PRO polypeptides by recombinant techniques and in
generating either transgenic animals or knock-out animals which are
useful in the development and screening of therapeutically useful
reagents. The PRO polypeptides or antibodies are used in preparing a
medicament for treating a condition responsive to the polypeptides or
antibodies, such as tumours, for stimulating and inhibiting proliferation
of human microvascular endothelial cells, for modulating the uptake of
glucose or FFA by skeletal muscle cells or adipocyte cells, for
stimulating differentiation of adipocyte cells, for stimulating
proliferation of or gene expression in pericyte cells, for stimulating
the proliferation of inner ear utricular supporting cells or T-lymphocyte
cells, for inducing endothelial cell tube formation and for treating
various bone and/or cartilage disorders such as sports injuries and
arthritis. PRO polypeptides which stimulate the release of proteoglycans
from cartilage are useful for treating sports-related joint problems,
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
polypeptides are also useful for treating various mammalian haemoglobin-
associated disorders such as various thalassaemias and conditions which
may benefit from enhanced local immune system cell infiltration. This
sequence encodes a human PRO polypeptide of the invention. Note: The
sequence data for this patent is also available in electronic format from
the USPTO website at seqdata.uspto.gov.
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
Query Match 1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. NO. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGTGTTT 1881
||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCAGACAGCGCTGGTTTATT 1083
||||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
RESULT 73
ADA85697/c
ID ADA85697 standard; cDNA; 1129 BP.
AC ADA85697;
XX
XX 20-NOV-2003 (first entry)
DE Novel human secreted and transmembrane protein PRO4327 cDNA.
XX
```

KW Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 XX Homo sapiens.  
 XX  
 XX US2003082693-A1.  
 XX  
 XX 01-MAY-2003.  
 XX  
 XX 22-APR-2002; 2002US-00127843.  
 XX  
 XX 05-JUN-2000; 2000US-0209832P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 DR WPI; 2003-786907/74.  
 DR P-PSDB; ADA85698.  
 XX  
 XX New PRO nucleic acid, useful for preparing a composition for treating  
 PT e.g., tumor or for tissue typing.  
 XX  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from BMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTATTTTTCATTCACAGATTTCCTTCAGTTGGCTTTGTTT 1881  
 DB 1129 TTTTITTTTTTTTTTTTCACGTCGCACAGCTGGGTTTATT 1083

RESULT 74

ADA96909/C  
 ID ADA96909 standard; cDNA; 1129 BP.  
 XX  
 XX AC ADA96909;  
 XX  
 XX 20-NOV-2003 (first entry)  
 XX  
 XX Human PRO polynucleotide #111.  
 XX  
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX  
 XX Homo sapiens.  
 XX  
 XX US2003082705-A1.  
 XX  
 XX 01-MAY-2003.  
 XX  
 XX 24-APR-2002; 2002US-00131829.  
 XX  
 XX 09-DEC-1999; 99US-0170262P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755112/71.  
 DR P-PSDB; ADA96910.  
 XX  
 XX New PRO nucleic acid, useful for preparing a composition for treating  
 PT e.g., tumor or for tissue typing.  
 XX  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and

CC	arthritis. PRO polypeptides which stimulate the release of proteoglycans
CC	from cartilage are useful for treating sports-related joint problems,
CC	articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO
CC	polypeptides are also useful for treating various mammalian haemoglobin-
CC	-associated disorders such as various thalassaemias and conditions which
CC	may benefit from enhanced local immune system cell infiltration. Note:
CC	sequence represents a human PRO polynucleotide of the invention. Note:
CC	The sequence data for this patent is also available in electronic format
CC	from USPTO at seqdata.uspto.gov/sequence.html.
XX	
SQ	Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
	Query Match            1.1%; Score 21.4; DB 1; Length 1129;
	Best Local Similarity 66.0%; Pred. No. 45;
	Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
QY	1835 TTCTTAATTTTTCATTTCAGATTTCCTCAGTTTGCGTTTGTGTTT 1881
DB	1129 TTTTTTTTTTTTTTTTTTTTCAGCTGGCACACAGCTGGGTTTTATT 1083
RESULT 75	
ADA79213/c	
ID ADA79213 standard; cDNA; 1129 BP.	
XX AC ADA79213;	
XX DT	
XX DT	
XX DE	
XX DE	Human PRO polynucleotide #111.
XX XX	Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
KW liver; microvascular endothelial cell; glucose; FFA;	
KW skeletal muscle cell; adipocyte cell; pericyte cell;	
KW inner ear utricular supporting cell; T-lymphocyte cell;	
KW endothelial cell tube formation; bone disorder; cartilage disorder;	
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;	
KW immune system cell infiltration.	
XX XX	
OS Homo sapiens.	
XX XX	
PX US2003082763-A1.	
PX PN	
PX PD	01-MAY-2003.
PX PF	17-APR-2002; 2002US-00124818.
PX XX	
PR 31-MAR-1997; 97WO-US005230.	
PR 12-JUN-1998; 98WO-US014556.	
PR 14-JUL-1998; 98WO-US014552.	
PR 28-AUG-1998; 98WO-US017888.	
PR 10-SEP-1998; 98WO-US018824.	
PR 14-SEP-1998; 98WO-US019093.	
PR 14-SEP-1998; 98WO-US019094.	
PR 14-SEP-1998; 98WO-US019177.	
PR 16-SEP-1998; 98WO-US019330.	
PR 17-SEP-1998; 98WO-US019437.	
PR 07-OCT-1998; 98WO-US021141.	
PR 29-OCT-1998; 98WO-US022931.	
PR 29-OCT-1998; 98WO-US022932.	
PR 20-NOV-1998; 98WO-US024855.	
PR 01-DEC-1998; 98WO-US025108.	
PR 05-JAN-1999; 98WO-US000106.	
PR 08-MAR-1999; 98WO-US005028.	
PR 10-MAR-1999; 98WO-US005190.	
PR 20-APR-1999; 98WO-US008615.	
PR 14-MAY-1999; 98WO-US010733.	
PR 02-JUN-1999; 98WO-US012252.	
PR 01-SEP-1999; 98WO-US020111.	
PR 08-SEP-1999; 98WO-US020594.	
PR 13-SEP-1999; 98WO-US020944.	
PR 15-SEP-1999; 98WO-US021090.	
PR 18-SEP-1999; 98WO-US021547.	
PR 05-OCT-1999; 98WO-US023089.	
PR 29-NOV-1999; 98WO-US028214.	
PR 30-NOV-1999; 98WO-US028313.	
PR 30-NOV-1999; 98WO-US028409.	
PR 01-DEC-1999; 98WO-US028301.	
PR 01-DEC-1999; 98WO-US028634.	
PR 02-DEC-1999; 98WO-US028551.	
PR 02-DEC-1999; 98WO-US028565.	
PR 02-DEC-1999; 98WO-US030095.	
PR 16-DEC-1999; 98WO-US030911.	
PR 20-DEC-1999; 98WO-US030999.	
PR 22-DEC-1999; 98WO-US030720.	
PR 30-DEC-1999; 98WO-US031243.	
PR 30-DEC-1999; 98WO-US031274.	
PR 05-JAN-2000; 2000WO-US000219.	
PR 06-JAN-2000; 2000WO-US000376.	
PR 11-FEB-2000; 2000WO-US003565.	
PR 18-FEB-2000; 2000WO-US004341.	
PR 18-FEB-2000; 2000WO-US004342.	
PR 22-FEB-2000; 2000WO-US004414.	
PR 24-FEB-2000; 2000WO-US004914.	
PR 24-FEB-2000; 2000WO-US005004.	
PR 01-MAR-2000; 2000WO-US005601.	
PR 02-MAR-2000; 2000WO-US005746.	
PR 02-MAR-2000; 2000WO-US005841.	
PR 10-MAR-2000; 2000WO-US006189.	
PR 15-MAR-2000; 2000WO-US006384.	
PR 20-MAR-2000; 2000WO-US007377.	
PR 21-MAR-2000; 2000WO-US007532.	
PR 30-MAR-2000; 2000WO-US008439.	
PR 17-MAY-2000; 2000WO-US013705.	
PR 22-MAY-2000; 2000WO-US014042.	
PR 30-MAY-2000; 2000WO-US014941.	
PR 02-JUN-2000; 2000WO-US015264.	
PR 28-JUL-2000; 2000WO-US020710.	
PR 11-AUG-2000; 2000WO-US022031.	
PR 23-AUG-2000; 2000WO-US023522.	
PR 24-AUG-2000; 2000WO-US023328.	
PR 08-NOV-2000; 2000WO-US030952.	
PR 10-NOV-2000; 2000WO-US030873.	
PR 01-DEC-2000; 2000WO-US032678.	
PR 20-DEC-2000; 2000US-00747259.	
PR 20-DEC-2000; 2000WO-US034956.	
PR 28-FEB-2001; 2001US-00796498.	
PR 28-FEB-2001; 2001WO-US006520.	
PR 01-MAR-2001; 2001WO-US006666.	
PR 09-MAR-2001; 2001US-00802706.	
PR 14-MAR-2001; 2001US-00808689.	
PR 22-MAR-2001; 2001US-00816744.	
PR 05-APR-2001; 2001US-00828366.	
PR 10-MAY-2001; 2001US-00854208.	

PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755116/71.  
DR P-PSDB; ADA79214.  
DR  
XX  
XX New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
PT in detection and treatment of cancer and in modulating the uptake of  
PT glucose or free fatty acid by skeletal muscle cells or adipocyte cells.  
XX  
XX Claim 2; Fig 221; 659pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
SQ Sequence 1129' BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TCTTAAATTTTTCATTTCCAGATTCTCTCAGTTGGGTTTGT 1881  
|||||  
DB 1129 TTTTATTTTATTTTTCAGCTGGCACAGCGCTGGGTTTAT 1083  
|||||

RESULT 76  
ADA87352/c  
ID ADA87352 standard; cDNA; 1129 BP.  
XX  
XX ADA87352;  
XX  
XX 20-NOV-2003 (first entry)  
DI  
XX  
XX  
DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; cell differentiation stimulator;  
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
XX US2003087345-A1.  
XX  
XX 08-MAY-2003.  
PD  
XX  
XX 16-APR-2002; 2002US-00123907.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 16-SEP-1998; 98WO-US019177.  
PR 17-SEP-1998; 98WO-US019330.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US0005028.  
PR 10-MAR-1999; 99WO-US0005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US022089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.

20-MAR-2000; 2000WO-US007377.  
 21-MAR-2000; 2000WO-US007532.  
 30-MAR-2000; 2000WO-US008439.  
 17-MAY-2000; 2000WO-US013705.  
 22-MAY-2000; 2000WO-US014042.  
 30-MAY-2000; 2000WO-US014941.  
 02-JUN-2000; 2000WO-US015264.  
 28-JUL-2000; 2000WO-US020710.  
 11-AUG-2000; 2000WO-US022031.  
 23-AUG-2000; 2000WO-US023522.  
 24-AUG-2000; 2000WO-US023328.  
 08-NOV-2000; 2000WO-US030952.  
 10-NOV-2000; 2000WO-US030873.  
 01-DEC-2000; 2000WO-US032678.  
 20-DEC-2000; 2000US-00747259.  
 20-DEC-2000; 2000WO-US034956.  
 28-FEB-2001; 2001US-00796498.  
 28-FEB-2001; 2001WO-US006520.  
 01-MAR-2001; 2001WO-US006666.  
 09-MAR-2001; 2001US-00802706.  
 14-MAR-2001; 2001US-00808689.  
 22-MAR-2001; 2001US-00816744.  
 05-APR-2001; 2001US-00828366.  
 10-MAY-2001; 2001US-00854208.  
 10-MAY-2001; 2001US-00854280.  
 18-MAY-2001; 2001US-00860216.  
 25-MAY-2001; 2001US-00866028.  
 25-MAY-2001; 2001US-00866034.  
 25-MAY-2001; 2001WO-US017092.  
 01-JUN-2001; 2001US-00872035.  
 01-JUN-2001; 2001WO-US017800.  
 05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00882636.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019592.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00934836.  
 19-DEC-2001; 2001US-00028072.  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-786937/74.  
 P-PSDB; ADA87353.  
 New PRO nucleic acid, useful for manufacturing a medicament for  
 diagnosing or treating tumor.  
 Claim 2; Fig 221; 638pp; English.  
 The invention describes 305 nucleic acids encoding PRO (secreted and  
 transmembrane) polypeptides (I). (I) is useful for stimulating the  
 release of TNF-alpha from human blood, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells, for modulating the uptake of  
 stimulating the proliferation or differentiation of chondrocyte cells,  
 for stimulating the proliferation of or gene expression in pericyte  
 cells, for stimulating the release of proteoglycans from cartilage, for  
 stimulating the proliferation of inner ear utricular supporting cells,  
 for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 the release of a cytokine from PMC cells, for inhibiting the binding of  
 A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
 cells, for stimulating proliferation of endothelial cells, for detecting  
 the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 prostate, rectal, cervical or liver tumour. The oligonucleotide probes

are useful for isolating genomic and cDNA nucleotide sequences or  
 antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 in assays to identify other proteins or molecules involved in binding  
 interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 Db 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083  
 ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
 RESULT 77  
 ADB16554/c  
 ID ADB16554 standard; cDNA; 1129 BP.  
 XX  
 AC ADB16554;  
 XX 20-NOV-2003 (first entry)  
 XX Human PRO polynucleotide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003087349-A1.  
 XX  
 PD 08-MAY-2003.  
 XX  
 PF 19-APR-2002; 2002US-00125928.  
 XX  
 PR 19-JUN-1998; 98US-0089947P.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 25-AUG-1999; 99US-00380137.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-786940/74.  
 DR P-PSDB; ADB16555.  
 XX  
 PT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide,  
 and for manufacturing a medicament for diagnosing or treating tumor.





KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; hemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX  
OS Homo sapiens.  
XX  
XX US2003087351-A1.  
XX  
XX 08-MAY-2003.  
XX  
XX 22-APR-2002; 2002US-00127822.  
XX  
XX 17-JUN-1998; 98US-0089532P.  
XX 02-JUN-1999; 99WO-US012252.  
XX 25-AUG-1999; 99US-00380137.  
XX 30-NOV-1999; 99WO-US028313.  
XX 01-DEC-2000; 2000WO-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-786942/74.  
XX P-PSDB; ADB14710.  
XX  
XX New PRO nucleic acid, useful for manufacturing a medicament for  
PT diagnosing or treating tumor.  
XX  
XX Claim 2; Fig 221; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence represents a human PRO polynucleotide of the invention. Note:  
CC The sequence data for this patent is also available in electronic format  
CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. NO. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
QY 1835 TTTTAAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881  
DB 1129 TTTTAAATTTTTCATTTTCAGTTTTCCTTCAGTTTGGGTTTGT 1083  
RESULT 80  
ADBI8670/c  
ID ADBI8670 standard; cDNA; 1129 BP.  
XX  
XX ADBI8670;  
XX  
XX 20-NOV-2003 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO4327 cDNA.  
DE Human; secreted and transmembrane protein; PRO; Gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokin.  
XX  
XX Homo sapiens.  
XX  
XX US2003073211-A1.  
XX  
XX 17-APR-2003.  
XX  
XX 15-APR-2002; 2002US-00123292.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018924.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.  
XX 20-NOV-1998; 98WO-US024955.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.  
XX 20-APR-1999; 99WO-US008615.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 01-SEP-1999; 99WO-US020394.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US021090.  
XX 15-SEP-1999; 99WO-US021547.  
XX 05-OCT-1999; 99WO-US023089.  
XX 29-NOV-1999; 99WO-US028214.  
XX 30-NOV-1999; 99WO-US028313.  
XX 30-NOV-1999; 99WO-US028409.  
XX 01-DEC-1999; 99WO-US028501.  
XX 01-DEC-1999; 99WO-US028634.  
XX 02-DEC-1999; 99WO-US028851.  
XX 02-DEC-1999; 99WO-US028564.  
XX 02-DEC-1999; 99WO-US028565.  
XX 16-DEC-1999; 99WO-US030095.  
XX 20-DEC-1999; 99WO-US030911.  
XX 20-DEC-1999; 99WO-US030939.  
XX 22-DEC-1999; 99WO-US030720.  
XX 30-DEC-1999; 99WO-US031243.







immune system cell infiltration.

Homo sapiens.

US2003082710-A1.

01-MAY-2003.

16-MAY-2002; 2002US-00147484.

09-DEC-1999; 99US-0170262P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-786913/74.

P-FSDE; ADB13094.

New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide, preparing a composition for treating e.g., tumor, or for tissue typing.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129; Best Local Similarity 66.0%; Pred. No. 45; Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1835 TTCTAAATTTTTCATTCAGATTTCCTTCAGTTGGTTTGTGTT 1881

1129 TTTTTCATTTTTCATTTTTCAGTTTCAGTTGGTTTGTGTT 1083

RESULT 84  
ACD98534/c  
ID ACD98534 standard; cDNA; 1129 BP.  
XX AC ACD98534;  
XX DT 26-SEP-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
XX KW Human; secreted and transmembrane protein; PRO; gene therapy;  
XX KM chromosome identification; tissue typing; gene; ss.  
XX OS Homo sapiens.  
XX FN US2003044945-A1.  
XX PD 06-MAR-2003.  
XX PF 10-MAY-2002; 2002US-00142419.  
XX PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 14-SEP-1998; 98WO-US019330.  
PR 16-SEP-1998; 98WO-US019437.  
PR 17-SEP-1998; 98WO-US021141.  
PR 07-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 29-OCT-1998; 98WO-US024855.  
PR 20-NOV-1998; 98WO-US025108.  
PR 01-DEC-1998; 98WO-US025106.  
PR 08-JAN-1999; 99WO-US005028.  
PR 08-MAR-1999; 99WO-US005190.  
PR 10-MAR-1999; 99WO-US008615.  
PR 20-APR-1999; 99WO-US010733.  
PR 14-MAY-1999; 99WO-US012552.  
PR 02-JUN-1999; 99WO-US020111.  
PR 01-SEP-1999; 99WO-US020594.  
PR 08-SEP-1999; 99WO-US020944.  
PR 13-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028402.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 20-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 03-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005745.

PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747359.  
 PR 28-FEB-2001; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00756498.  
 PR 01-MAR-2001; 2001WO-US006520.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00815744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 PA (GETH) GENENTECH INC.  
 XX Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-492275/46.  
 DR P-PSDB; ABC43259.  
 DR  
 XX  
 PT New transmembrane polypeptides and nucleic acids encoding the  
 PT polypeptides, useful in gene therapy, in chromosome identification, as  
 PT chromosome markers, or in generating probes.  
 XX  
 XX Claim 2; Fig 221; 660pp; English.  
 XX The invention describes an isolated nucleic acid encoding a PRO (secreted  
 CC and transmembrane) polypeptide. Nucleic acids which encode PRO can be  
 CC used to generate either transgenic animals or knock-out animals useful in  
 CC developing and screening of therapeutically useful reagents. The nucleic  
 CC acids may also be used in gene therapy, in chromosome identification, as  
 CC chromosome markers, or in generating probes. The PRO polypeptides are  
 CC useful as molecular markers for protein electrophoresis, and the isolated  
 CC nucleic acids may be used for recombinantly expressing those markers. The  
 CC PRO polypeptides and nucleic acids may also be used in tissue typing.  
 CC Anti-PRO antibodies are useful in diagnostic assays for PRO, and in

CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. This sequence encodes a novel human secreted and transmembrane  
 CC PRO polypeptide  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TCTTAATTTTTCATTCACAGATTTTCCTTCAGTTGGGTTTGGTTT 1881  
 Db 1129 TTTTTCATTTTTCATTCACAGATTTTCCTTCAGTTGGGTTTGGTTT 1083  
 RESULT 85  
 ADA74347/C  
 ID ADA74347 standard; cDNA; 1129 BP.  
 XX  
 AC ADA74347;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Human PRO polynucleotide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumor necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003068798-A1.  
 XX  
 PD 10-APR-2003.  
 XX  
 PF 07-MAY-2002; 2002US-00140928.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.

(GETH ) GENENTECH INC.

### Query Match

```
Query Match      1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0
```

[illegible]

RESULT 86

ADB24580/c  
ID ADB24580 standard; cDNA; 1129 BP.

AC ADB24580;

DT 20-NOV-2003 (first entry)

Human PRO polynucleotide SEQ ID NO 221.

Human; gene; ss; pRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; carvix; liver; microvascular endothelial cell; glucose; FFA;

KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003077713-A1.  
 XX  
 XX 24-APR-2003.  
 XX  
 XX 22-APR-2002; 2002US-00127839.  
 XX  
 XX 05-JUN-2000; 2000US-0209832P.  
 XX  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX  
 XX 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 XX WPI: 2003-755066/71.  
 XX  
 XX P-PSDB; ADB24581.  
 XX  
 XX New isolated, secreted and transmembrane PRO polypeptides and nucleic  
 XX acids, useful for the diagnosis, prevention and/or treatment of tumors,  
 XX such as lung, colon, breast, prostate, rectal, cervical and/or liver  
 XX tumors.  
 XX  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 XX transmembrane polypeptides) and the polynucleotides encoding them. The  
 XX invention also relates to an antibody which specifically binds to a PRO  
 XX polypeptide, a method for stimulating the release of tumour necrosis  
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 XX proliferation or differentiation of chondrocyte cells and a method for  
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 XX polynucleotides are useful in molecular biology, including uses as  
 XX hybridisation probes, in chromosome and gene mapping, in generating  
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 XX be used in preparing PRO polypeptides by recombinant techniques and in  
 XX generating either transgenic animals or knock-out animals which are  
 XX useful in the development and screening of therapeutically useful  
 XX reagents. The PRO polypeptides or antibodies are used in preparing a  
 XX medicament for treating a condition responsive to the polypeptides or  
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
 XX of human microvascular endothelial cells, for modulating the uptake of  
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 XX stimulating differentiation of adipocyte cells, for stimulating  
 XX the proliferation or gene expression in pericyte cells, for stimulating  
 XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 XX cells, for inducing endothelial cell tube formation and for treating  
 XX various bone and/or cartilage disorders such as sports injuries and  
 XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 XX from cartilage are useful for treating sports-related joint problems,  
 XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 XX polypeptides are also useful for treating various mammalian haemoglobin-  
 XX associated disorders such as various thalassaemias and conditions which  
 XX may benefit from enhanced local immune system cell infiltration. This  
 XX sequence represents a human PRO polynucleotide of the invention. Note:  
 XX The sequence data for this patent is also available in electronic format  
 XX from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 XX

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 Qy 1835 TTCTTAATTTTTCATTTCCAGATTCCTTCAGTTGGGTTTCTTT 1881  
 Db 1129 TTTTCTTTTCTTTTTCAGTGGCACACAGCGTGGTTTATT 1083  
 RESULT 87  
 ADA82104/C  
 ID ADA82104 standard; cDNA; 1129 BP.  
 XX  
 XX ADA82104;  
 XX  
 XX 20-NOV-2003 (first entry)  
 XX  
 XX Human PRO polynucleotide #111.  
 XX  
 XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 XX tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 XX cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 XX liver; microvascular endothelial cell; pericyte cell; FFA;  
 XX skeletal muscle cell; adipocyte cell; glucocorticoid;  
 XX inner ear utricular supporting cell; T-lymphocyte cell;  
 XX endothelial cell tube formation; bone disorder; cartilage disorder;  
 XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 XX rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 XX immune system cell infiltration.  
 XX  
 XX Homo sapiens.  
 XX  
 XX US2003082701-A1.  
 XX  
 XX 01-MAY-2003.  
 XX  
 XX 23-APR-2002; 2002US-00128686.  
 XX  
 XX 31-AUG-1998; 98US-0098525P.  
 XX  
 XX 16-SEP-1998; 98US-0100634P.  
 XX  
 XX 02-JUN-1999; 99WO-US012252.  
 XX  
 XX 25-AUG-1999; 99US-00380137.  
 XX  
 XX 30-MAR-2000; 2000WO-US008439.  
 XX  
 XX 02-JUN-2000; 2000WO-US015264.  
 XX  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX  
 XX 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 XX WPI: 2003-755110/71.  
 XX  
 XX P-PSDB; ADA82105.  
 XX  
 XX PRO nucleic acid, useful for preparing a composition for treating e.g.,  
 XX tumor or for tissue typing.  
 XX  
 XX Claim 2; Fig 221; 637pp; English.  
 XX  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 XX transmembrane polypeptides) and the polynucleotides encoding them. The  
 XX invention also relates to an antibody which specifically binds to a PRO  
 XX polypeptide, a method for stimulating the release of tumour necrosis  
 XX factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 XX proliferation or differentiation of chondrocyte cells and a method for  
 XX detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 XX colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 XX polynucleotides are useful in molecular biology, including uses as  
 XX hybridisation probes, in chromosome and gene mapping, in generating  
 XX antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 XX be used in preparing PRO polypeptides by recombinant techniques and in  
 XX generating either transgenic animals or knock-out animals which are  
 XX useful in the development and screening of therapeutically useful  
 XX reagents. The PRO polypeptides or antibodies are used in preparing a  
 XX medicament for treating a condition responsive to the polypeptides or  
 XX antibodies, such as tumours, for stimulating and inhibiting proliferation  
 XX of human microvascular endothelial cells, for modulating the uptake of  
 XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 XX stimulating differentiation of adipocyte cells, for stimulating  
 XX the proliferation or gene expression in pericyte cells, for stimulating  
 XX the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 XX cells, for inducing endothelial cell tube formation and for treating  
 XX various bone and/or cartilage disorders such as sports injuries and  
 XX arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 XX from cartilage are useful for treating sports-related joint problems,  
 XX articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 XX polypeptides are also useful for treating various mammalian haemoglobin-  
 XX associated disorders such as various thalassaemias and conditions which  
 XX may benefit from enhanced local immune system cell infiltration. This  
 XX sequence represents a human PRO polynucleotide of the invention. Note:  
 XX The sequence data for this patent is also available in electronic format  
 XX from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 XX









CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
QY 1835 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTGGGTTTGT 1881  
Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083  
  
RESULT 90  
ADA84593/c  
ID ADA84593 standard; cDNA; 1129 BP.  
XX  
AC ADA84593;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
XX  
KW Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; EPA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX  
OS Homo sapiens.  
XX  
XX US2003082708-A1.  
XX  
XX 01-MAY-2003.  
XX  
XX 15-MAY-2002; 2002US-00146729.  
XX  
XX 05-JUN-2000; 2000US-0209832P.  
XX 01-DEC-2000; 2000WC-US032678.  
XX 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
XX  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PU, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI: 2003-786911/74.  
XX P-PSDB; ADA84594.  
XX  
XX New PRO nucleic acid, useful for preparing a composition for treating  
XX e.g. tumor or for tissue typing.  
XX  
XX Claim 2; Fig 221; 637pp; English.  
XX  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
XX transmembrane) polypeptides (I). (I) is useful for stimulating the  
XX release of TNF-alpha from human blood, for modulating the uptake of  
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for  
XX stimulating the proliferation or differentiation of chondrocyte cells,  
XX for stimulating the proliferation or gene expression in pericyte  
XX cells, for stimulating the release of or gene expression in pericyte  
XX cells, for stimulating the proliferation of inner ear utricular supporting cells,  
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating  
XX the release of a cytokine from FMC cells, for inhibiting the binding of  
XX A-peptide to factor VIIa, for inhibiting the differentiation of adipocyte  
XX cells, for stimulating proliferation of endothelial cells, for detecting  
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,  
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes

CC are useful for isolating genomic and cDNA nucleotide sequences or  
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
CC in assays to identify other proteins or molecules involved in binding  
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
CC and gene mapping, in generation of antisense RNA and DNA, in the  
CC preparation of PRO polypeptide, for generating transgenic animals or  
CC knockout animals which in turn are useful in the development and  
CC screening of therapeutically useful reagents, in gene therapy, for  
CC chromosome identification, as chromosome marker, and for generating  
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
CC detecting its expression in specific cells, tissues or serum, and for  
CC affinity purification of PRO from recombinant cell culture or natural  
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
CC a novel human secreted and transmembrane PRO polypeptide.  
XX  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
  
QY 1835 TTCTTAATTTTTCATTTCAGATTTCCTTCAGTTTGGGTTTGT 1881  
Db 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGGTTTATT 1083  
  
RESULT 91  
ADE29849/c  
ID ADE29849 standard; cDNA; 1129 BP.  
XX  
AC ADE29849;  
XX  
DT 20-NOV-2003 (first entry)  
XX  
DE cDNA encoding human PRO polypeptide #111.  
XX  
KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
XX  
XX US2003073214-A1.  
XX  
XX 17-APR-2003.  
XX  
XX 17-APR-2002; 2002US-00124822.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022931.  
XX 29-OCT-1998; 98WO-US022932.  
XX 20-NOV-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030939.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US000355.  
PR 22-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004344.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006339.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015284.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 10-NOV-2000; 2000WO-US030952.  
PR 01-DEC-2000; 2000WO-US030873.  
PR 20-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000WO-US047259.  
PR 28-FEB-2001; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806899.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00892636.  
PR 19-JUN-2001; 2001US-00896342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00897856.

PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX  
XX  
PI Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski FJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
WPI; 2003-720081/68.  
P-PSDB; ADB29850.  
DR  
XX  
XX  
PT Novel secreted and transmembrane PRO polypeptides useful for stimulating  
PT the release of tumor necrosis factor alpha and detecting the presence of  
PT a tumor in a mammal.  
XX  
PS Claim 2; Fig 221; 638pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTCACAGATTTCCTTCAGTTGGGTTTGT 1841  
|||||  
DB : 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083

RESULT 92  
ADA80377/c  
ID ADA80377 standard; CDNA; 1129 BP

AC ADA80377; PR 24-FEB-2000; 2000WO-US004914.  
XX 24-FEB-2000; 2000WO-US005004.  
DT 01-MAR-2000; 2000WO-US005601.  
XX 02-MAR-2000; 2000WO-US005746.  
DE 02-MAR-2000; 2000WO-US005841.  
XX 10-MAR-2000; 2000WO-US006319.  
XX 15-MAR-2000; 2000WO-US006884.  
KW 20-MAR-2000; 2000WO-US007377.  
KW 21-MAR-2000; 2000WO-US007532.  
KW 30-MAR-2000; 2000WO-US008439.  
KW 17-MAY-2000; 2000WO-US013705.  
KW 22-MAY-2000; 2000WO-US014042.  
KW 30-MAY-2000; 2000WO-US014941.  
KW 02-JUN-2000; 2000WO-US015264.  
KW 28-JUL-2000; 2000WO-US020710.  
KW 11-AUG-2000; 2000WO-US022031.  
KW 23-AUG-2000; 2000WO-US023522.  
KW 24-AUG-2000; 2000WO-US023328.  
KW 08-NOV-2000; 2000WO-US030952.  
KW 10-NOV-2000; 2000WO-US030873.  
KW 01-DEC-2000; 2000WO-US032678.  
KW 20-DEC-2000; 2000US-00747259.  
KW 20-DEC-2000; 2000WO-US034956.  
KW 28-FEB-2001; 2001US-00796498.  
KW 28-FEB-2001; 2001WO-US006520.  
KW 01-MAR-2001; 2001WO-US006666.  
KW 09-MAR-2001; 2001US-00803706.  
KW 14-MAR-2001; 2001US-00809689.  
KW 22-MAR-2001; 2001US-00816744.  
KW 05-APR-2001; 2001US-00828366.  
KW 10-MAY-2001; 2001US-00854208.  
KW 18-MAY-2001; 2001US-00860216.  
KW 25-MAY-2001; 2001US-00866028.  
KW 25-MAY-2001; 2001US-00866034.  
KW 25-MAY-2001; 2001WO-US017092.  
KW 01-JUN-2001; 2001US-00872035.  
KW 01-JUN-2001; 2001WO-US017800.  
KW 05-JUN-2001; 2001US-00874503.  
KW 14-JUN-2001; 2001US-00882636.  
KW 19-JUN-2001; 2001US-00886342.  
KW 20-JUN-2001; 2001WO-US019692.  
KW 21-JUN-2001; 2001US-00887879.  
KW 22-JUN-2001; 2001WO-US020116.  
KW 29-JUN-2001; 2001WO-US021066.  
KW 09-JUL-2001; 2001WO-US021735.  
KW 18-JUL-2001; 2001US-00908827.  
KW 06-AUG-2001; 2001US-00924419.  
KW 09-AUG-2001; 2001US-00927796.  
KW 16-AUG-2001; 2001US-00931836.  
KW 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755115/71.  
DR P-PSDB; ADA80378.  
XX New PRO polypeptides useful for treating diabetes, hyper- or hypo-  
PT insulinemia, sports injuries, arthritis, obesity, stroke, heart attack,  
PT various coagulation disorders and tumors.  
XX Claim 2; Fig 221; 638pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for

Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS US2003082761-A1.  
PN 01-MAY-2003.  
XX 12-APR-2002; 2002US-00121061.  
PF 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022391.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030811.  
PR 20-DEC-1999; 99WO-US030939.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US0003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.



KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

OS Homo sapiens.

XX US2003073210-A1.

PN 17-APR-2003.

PD 11-APR-2002; 2002US-00121045.

PF 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

PR 28-AUG-1998; 98WO-US014552.

PR 14-JUL-1998; 98WO-US017888.

PR 10-SEP-1998; 98WO-US018824.

PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.

PR 14-SEP-1998; 98WO-US019177.

PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.

PR 07-OCT-1998; 98WO-US021141.

PR 29-OCT-1998; 98WO-US022991.

PR 29-OCT-1998; 98WO-US022992.

PR 20-NOV-1998; 98WO-US024855.

PR 01-DEC-1998; 98WO-US025108.

PR 05-JAN-1999; 99WO-US000106.

PR 08-MAR-1999; 99WO-US005028.

PR 10-MAR-1999; 99WO-US005190.

PR 20-APR-1999; 99WO-US008615.

PR 14-MAY-1999; 99WO-US010733.

PR 02-JUN-1999; 99WO-US012252.

PR 01-SEP-1999; 99WO-US020211.

PR 08-SEP-1999; 99WO-US020594.

PR 13-SEP-1999; 99WO-US020944.

PR 15-SEP-1999; 99WO-US021090.

PR 15-SEP-1999; 99WO-US021547.

PR 05-OCT-1999; 99WO-US023089.

PR 29-NOV-1999; 99WO-US028214.

PR 30-NOV-1999; 99WO-US028313.

PR 30-NOV-1999; 99WO-US028409.

PR 01-DEC-1999; 99WO-US028301.

PR 01-DEC-1999; 99WO-US028634.

PR 02-DEC-1999; 99WO-US028551.

PR 02-DEC-1999; 99WO-US028564.

PR 16-DEC-1999; 99WO-US030095.

PR 20-DEC-1999; 99WO-US030911.

PR 20-DEC-1999; 99WO-US030929.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US000356.  
PR 18-FEB-2000; 2000WO-US000341.  
PR 18-FEB-2000; 2000WO-US000342.  
PR 22-FEB-2000; 2000WO-US000414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 10-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006319.  
PR 20-MAR-2000; 2000WO-US006884.  
PR 21-MAR-2000; 2000WO-US007377.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 18-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00909827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-644800/61.  
XX P-PSDB; ADA46845.  
XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PT PRO4978, useful in molecular biology, chromosome and gene mapping, in  
PT generating antisense RNA and DNA, and in gene therapy.  
XX Claim 2; Fig 221; 638pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation











PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019084.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 01-DEC-1998; 98WO-US025106.  
PR 08-MAR-1999; 98WO-US025028.  
PR 10-MAR-1999; 98WO-US025190.  
PR 20-APR-1999; 98WO-US020615.  
PR 14-MAY-1999; 98WO-US010733.  
PR 02-JUN-1999; 98WO-US012252.  
PR 01-SEP-1999; 98WO-US020111.  
PR 08-SEP-1999; 98WO-US020594.  
PR 13-SEP-1999; 98WO-US020944.  
PR 15-SEP-1999; 98WO-US021090.  
PR 05-OCT-1999; 98WO-US021547.  
PR 15-OCT-1999; 98WO-US023089.  
PR 28-NOV-1999; 98WO-US028214.  
PR 30-NOV-1999; 98WO-US028313.  
PR 30-NOV-1999; 98WO-US028409.  
PR 01-DEC-1999; 98WO-US028301.  
PR 01-DEC-1999; 98WO-US028634.  
PR 02-DEC-1999; 98WO-US028551.  
PR 02-DEC-1999; 98WO-US028564.  
PR 02-DEC-1999; 98WO-US028565.  
PR 16-DEC-1999; 98WO-US030095.  
PR 20-DEC-1999; 98WO-US030911.  
PR 20-DEC-1999; 98WO-US030999.  
PR 22-DEC-1999; 98WO-US030720.  
PR 30-DEC-1999; 98WO-US031243.  
PR 30-DEC-1999; 98WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 18-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 20-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US020231.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030973.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
PA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-786990/74.  
XX P-PSDB; ADB30954.  
XX  
XX Novel isolated PRO polypeptide useful for treating diabetes, hyper- or  
PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
PT attack, various coagulation disorders, tumors.  
XX  
XX Claim 2; Fig 221; 638pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumor necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from

15-SEP-1999; 99WO-US021547.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-695893/66.

XX DR P-PSDB; ADA60882.

XX PT New secreted and transmembrane PRO polypeptide and nucleic acid, useful

XX PT for manufacturing a medicament for diagnosing or treating tumor.

XX PS Claim 2; Fig 221; 659pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

XX CC transmembrane) polypeptides (I). (I) is useful for stimulating the

XX CC release of TNF-alpha from human blood, for modulating the uptake of

XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX CC stimulating the proliferation or differentiation of chondrocyte cells,

XX CC for stimulating the proliferation of or gene expression in pericyte

XX CC cells, for stimulating the release of proteoglycans from cartilage, for

XX CC stimulating the proliferation of inner ear utricular supporting cells,

XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

XX CC the release of a cytokine from PBMC cells, for inhibiting the binding of

XX CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

XX CC cells, for stimulating proliferation of endothelial cells, for detecting

XX CC the presence of tumor in a mammal. The tumor is lung, colon, breast,

XX CC prostate, rectal, cervical or liver tumor. The oligonucleotide probes

XX CC are useful for isolating genomic and cDNA nucleotide sequences or

XX CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful

XX CC in assays to identify other proteins or molecules involved in binding

XX CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome

XX CC and gene mapping, in generation of antisense RNA and DNA, in the

XX CC preparation of PRO polypeptide, for generating transgenic animals or

XX CC knockout animals which in turn are useful in the development and

XX CC screening of therapeutically useful reagents, in gene therapy, for

XX CC chromosome identification, as chromosome marker, and for generating

XX CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

XX CC detecting its expression in specific cells, tissues or serum, and for

XX CC affinity purification of PRO from recombinant cell culture or natural

XX CC sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX immune system cell infiltration.

OS Homo sapiens.

XX US2003077714-A1.

XX PD 24-APR-2003.

XX EF 22-APR-2002; 2002US-00127901.

XX PR 17-JUN-1998; 98US-0089599P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 30-NOV-1999; 99WO-US028313.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-755069/71.

XX DR P-PSDB; ADE24029.

XX PT New isolated, secreted and transmembrane PRO polypeptides and nucleic

XX PT acids, useful for the diagnosis, prevention and/or treatment of tumors,

XX PT such as lung, colon, breast, prostate, rectal, cervical and/or liver

XX PT tumors.

XX PS Claim 2; Fig 221; 637pp; English.

XX CC The invention relates to isolated human PRO polypeptides (secreted and

XX CC transmembrane polypeptides) and the polynucleotides encoding them. The

XX CC invention also relates to an antibody which specifically binds to a PRO

XX CC polypeptide, a method for stimulating the release of tumor necrosis

XX CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

XX CC proliferation or differentiation of chondrocyte cells and a method for

XX CC detecting the presence of a tumor in a mammal (e.g. adrenal, lung,

XX CC colon, breast, prostate, rectal, kidney, cervical and liver tumors). The

XX CC polynucleotides are useful in molecular biology, including uses as

XX CC hybridisation probes, in chromosome and gene mapping, in generating

XX CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

XX CC be used in preparing PRO polypeptides by recombinant techniques and in

XX CC generating either transgenic animals or knock-out animals which are

XX CC useful in the development and screening of therapeutically useful

XX CC reagents. The PRO polypeptides or antibodies are used in preparing a

XX CC medicament for treating a condition responsive to the polypeptides or

XX CC antibodies, such as tumors, for stimulating and inhibiting the uptake of

XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX CC stimulating differentiation of adipocyte cells, for stimulating

XX CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

XX CC cells, for inducing endothelial cell tube formation and for treating

XX CC various bone and/or cartilage disorders such as sports injuries and

XX CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

XX CC from cartilage are useful for treating sports-related joint problems, PRO

XX CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

XX CC polypeptides are also useful for treating various mammalian haemoglobin-

XX CC associated disorders such as various thalassaemias and conditions which

XX CC may benefit from enhanced local immune system cell infiltration. This

XX CC sequence represents a human PRO polynucleotide of the invention. Note:

XX CC The sequence data for this patent is also available in electronic format

XX CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

■



PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000WO-US034936.  
 PR 28-FEB-2001; 2001WO-US0796498.  
 PR 29-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001WO-US0802706.  
 PR 14-MAR-2001; 2001US-00808689.  
 PR 22-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 10-MAY-2001; 2001US-00854280.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019692.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 23-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI: 2003-755114/71.  
 DR P-PSDB; ADA93806.  
 XX  
 XX New isolated PRO polypeptides, useful for treating diabetes, hyper- or  
 PT hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart  
 PT attack, various coagulation disorders and tumors.  
 XX  
 XX Claim 2; Fig 221; 638pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC the proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis, PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCCTAATTTTTCATTTCCAGATTTCCTTCAGTTTCGGTTTGTGTT 1881  
 |||||  
 Db 1129 TTTTITTTTTTTTTTTTTCAGCTGCACACAGCTGGGTTTATT 1083  
 |||||  
 RESULT 104  
 ADB26114/c  
 ID ADB26114 standard; cDNA; 1129 BP.  
 XX  
 AC ADB26114;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE cDNA encoding human PRO polypeptide #111.  
 XX  
 KW Human; Gene: ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003082760-A1.  
 XX  
 PD 01-MAY-2003.  
 XX  
 XX 12-APR-2002; 2002US-00121056.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005190.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.

15-SEP-1999; 99WO-US021090.  
 15-SEP-1999; 99WO-US021547.  
 05-OCT-1999; 99WO-US023089.  
 29-NOV-1999; 99WO-US028214.  
 30-NOV-1999; 99WO-US028313.  
 30-NOV-1999; 99WO-US028409.  
 01-DEC-1999; 99WO-US028301.  
 01-DEC-1999; 99WO-US028634.  
 02-DEC-1999; 99WO-US028551.  
 02-DEC-1999; 99WO-US028564.  
 02-DEC-1999; 99WO-US028565.  
 16-DEC-1999; 99WO-US030095.  
 20-DEC-1999; 99WO-US030911.  
 20-DEC-1999; 99WO-US030999.  
 22-DEC-1999; 99WO-US030720.  
 30-DEC-1999; 99WO-US031243.  
 30-DEC-1999; 99WO-US031274.  
 05-JAN-2000; 2000WO-US000219.  
 06-JAN-2000; 2000WO-US000277.  
 06-JAN-2000; 2000WO-US000376.  
 11-FEB-2000; 2000WO-US003565.  
 18-FEB-2000; 2000WO-US004341.  
 18-FEB-2000; 2000WO-US004342.  
 22-FEB-2000; 2000WO-US004414.  
 24-FEB-2000; 2000WO-US004914.  
 24-FEB-2000; 2000WO-US005004.  
 01-MAR-2000; 2000WO-US005001.  
 02-MAR-2000; 2000WO-US005746.  
 02-MAR-2000; 2000WO-US005841.  
 02-MAR-2000; 2000WO-US006319.  
 15-MAR-2000; 2000WO-US006884.  
 20-MAR-2000; 2000WO-US007377.  
 21-MAR-2000; 2000WO-US007532.  
 30-MAR-2000; 2000WO-US008439.  
 17-MAY-2000; 2000WO-US011705.  
 20-MAY-2000; 2000WO-US014042.  
 30-MAY-2000; 2000WO-US014941.  
 02-JUN-2000; 2000WO-US015264.  
 28-JUL-2000; 2000WO-US020710.  
 11-AUG-2000; 2000WO-US022031.  
 23-AUG-2000; 2000WO-US023522.  
 26-AUG-2000; 2000WO-US023328.  
 08-NOV-2000; 2000WO-US030952.  
 10-NOV-2000; 2000WO-US030873.  
 01-DEC-2000; 2000WO-US032678.  
 20-DEC-2000; 2000WO-US032679.  
 28-FEB-2001; 2000WO-US034956.  
 28-FEB-2001; 2001WO-US006520.  
 01-MAR-2001; 2001WO-US006566.  
 09-MAR-2001; 2001US-00802706.  
 14-MAR-2001; 2001US-00808689.  
 22-MAR-2001; 2001US-00816744.  
 05-APR-2001; 2001US-00828366.  
 10-MAY-2001; 2001US-00854208.  
 18-MAY-2001; 2001US-00860216.  
 25-MAY-2001; 2001US-00866028.  
 25-MAY-2001; 2001US-00866034.  
 25-MAY-2001; 2001WO-US017092.  
 01-JUN-2001; 2001US-00872035.  
 01-JUN-2001; 2001WO-US017800.  
 05-JUN-2001; 2001US-00874503.  
 14-JUN-2001; 2001US-00882536.  
 19-JUN-2001; 2001US-00886342.  
 20-JUN-2001; 2001WO-US019692.  
 21-JUN-2001; 2001US-00887879.  
 22-JUN-2001; 2001WO-US020116.  
 29-JUN-2001; 2001WO-US021066.  
 09-JUL-2001; 2001WO-US021735.  
 18-JUL-2001; 2001US-00908827.  
 06-AUG-2001; 2001US-00924419.  
 09-AUG-2001; 2001US-00927796.  
 16-AUG-2001; 2001US-00931836.  
 19-DEC-2001; 2001US-00028072.  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, Deforge L, Deanoyers L, Filvaroff E, Gao W;  
 Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-777204/73.  
 P-PSDB; ADB26115.  
 New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 in gene therapy, detecting the presence of tumor in a mammal, or  
 modulating the uptake of glucose or free fatty acid by skeletal muscle  
 cells or adipocyte cells.  
 Claim 2; Fig 221; 659pp; English.  
 The invention relates to isolated human PRO polypeptides (secreted and  
 transmembrane polypeptides) and the polynucleotides encoding them. The  
 invention also relates to an antibody which specifically binds to a PRO  
 polypeptide, a method for stimulating the release of tumor necrosis  
 factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 proliferation or differentiation of chondrocyte cells and a method for  
 detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 polynucleotides are useful in molecular biology, including uses as  
 hybridisation probes, in chromosome and gene mapping, in generating  
 antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 be used in preparing PRO polypeptides by recombinant techniques and in  
 generating either transgenic animals or knock-out animals which are  
 useful in the development and screening of therapeutically useful  
 reagents. The PRO polypeptides or antibodies are used in preparing a  
 medicament for treating a condition responsive to the polypeptides or  
 antibodies, such as tumours, for stimulating and inhibiting proliferation  
 of human microvascular endothelial cells, for modulating the uptake of  
 glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 stimulating differentiation of adipocyte cells, for stimulating  
 proliferation of or gene expression in pericyte cells, for stimulating  
 the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 cells, for inducing endothelial cell tube formation and for treating  
 various bone and/or cartilage disorders such as sports injuries and  
 arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 from cartilage are useful for treating sports-related joint problems, PRO  
 articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 polypeptides are also useful for treating various mammalian haemoglobin-  
 associated disorders such as various thalassaemias and conditions which  
 may benefit from enhanced local immune system cell infiltration. This  
 sequence encodes a human PRO polypeptide of the invention. Note: The  
 sequence data for this patent is also available in electronic format from  
 the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
 Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTCAGTTGGTTTGTGTT 1881  
 DB 1129 TTTTCTTTTTCATTTTTCAGTGGCAGACAGGCTGGTTTATT 1083  
 RESULT 105  
 ADB21599/c  
 ID ADB21599 standard; cDNA; 1129 BP.  
 XX  
 AC ADB21599;  
 XX  
 DT 20-NOV-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.



XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW Glucose uptake modulator; FFA uptake modulator;  
KW Cell proliferation stimulator; cell differentiation stimulator;  
KW Cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW Gene therapy; chromosome identification; chromosome marker.  
XX Homo sapiens.  
XX US2003082765-A1.  
XX 01-MAY-2003.  
XX 17-MAY-2002; 2002US-00147492.  
XX 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US016824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 23-OCT-1998; 98WO-US022991.  
PR 23-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 08-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 23-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 05-JAN-2000; 2000WO-US000277.  
PR 11-FEB-2000; 2000WO-US000376.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 10-MAR-2000; 2000WO-US006319.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015364.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747359.  
PR 20-DEC-2000; 2000WO-US034556.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI: 2003-786920/74.  
P-PSDB; ADB21600.  
XX New secreted and transmembrane PRO polypeptide useful for detecting the  
presence of tumor in a mammal, or modulating the uptake of glucose or  
free fatty acid by skeletal muscle cells or adipocyte cells.  
Claim 2; Fig 221; 638pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF-alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from BMC cells, for inhibiting the binding of  
a-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast.



```
CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes
CC are useful for isolating genomic and cDNA nucleotide sequences or
CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful
CC in assays to identify other proteins or molecules involved in binding
CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome
CC and gene mapping, in generation of antisense RNA and DNA, in the
CC preparation of PRO polypeptide, for generating transgenic animals or
CC knockout animals which in turn are useful in the development and
CC screening of therapeutically useful reagents, in gene therapy, for
CC chromosome identification, as chromosome marker, and for generating
CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
CC detecting its expression in specific cells, tissues or serum, and for
CC affinity purification of PRO from recombinant cell culture or natural
CC sources. (I) and (II) are useful for tissue typing. This sequence encodes
CC a novel human secreted and transmembrane PRO polypeptide.
XX
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match      1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. No. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCCTAATTTTTCATTTCCAGATTTCCTCAGTTTGGTTTGT 1881
DB 1129 TTTTTTTTTTTTTTTTCAGCTGCACACAGGCTGGTTTATT 1083

RESULT 106
ADA77378/c
ID ADA77378 standard; cDNA; 1129 BP.
XX
AC ADA77378;
XX
DT 20-NOV-2003 (first entry)
XX
DE Human PRO polynucleotide #111.
XX
KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW liver; microvascular endothelial cell; glucose; FFA;
KW skeletal muscle cell; adipocyte cell; pericyte cell;
KW inner ear utricular supporting cell; T-lymphocyte cell;
KW endothelial cell tube formation; bone disorder; cartilage disorder;
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;
KW immune system cell infiltration.
XX
OS Homo sapiens.
XX
PN US2003068797-A1.
XX
PD 10-APR-2003.
XX
PF 07-MAY-2002; 2002US-00140921.
XX
PR 31-MAR-1997; 97WO-US005230.
PR 12-JUN-1998; 98WO-US012456.
PR 14-JUL-1998; 98WO-US014552.
PR 28-AUG-1998; 98WO-US017888.
PR 10-SEP-1998; 98WO-US018824.
PR 14-SEP-1998; 98WO-US019093.
PR 14-SEP-1998; 98WO-US019094.
PR 14-SEP-1998; 98WO-US019177.
PR 16-SEP-1998; 98WO-US019330.
PR 17-SEP-1998; 98WO-US019437.
PR 17-SEP-1998; 98WO-US021141.
PR 29-OCT-1998; 98WO-US022992.
PR 29-OCT-1998; 98WO-US022992.
PR 20-NOV-1998; 98WO-US024855.
PR 01-DEC-1998; 98WO-US025108.
PR 05-JAN-1999; 98WO-US000106.
PR 08-MAR-1999; 99WO-US005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US012252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 23-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028651.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 06-JAN-2000; 2000WO-US000277.
PR 11-FEB-2000; 2000WO-US000376.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 24-FEB-2000; 2000WO-US005004.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 23-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032578.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00802706.
PR 14-MAR-2001; 2001US-00808659.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854208.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00866028.
PR 25-MAY-2001; 2001US-00866034.
PR 01-JUN-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 05-JUN-2001; 2001WO-US017800.
PR 14-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.
PR 20-JUN-2001; 2001WO-US019692.
```

21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00508827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-625489/59.  
P-PSDB; ADA77379.  
Novel isolated, secreted and transmembrane PRO polypeptides e.g. PRO1801  
and PRO114, useful in the preparation of a medicament for treating a  
condition responsive to PRO polypeptide, and as therapeutic agents e.g.  
vaccines.  
Claim 2; Fig 22i; 659pp; English.  
The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating  
differentiation of adipocyte cells, for stimulating the proliferation  
of inner ear utricular supporting cells or T-lymphocyte cells, for inducing  
endothelial cell tube formation and for treating arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems,  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence represents a human PRO polynucleotide of the invention. Note:  
The sequence data for this patent is also available in electronic format  
from USPTO at seqdata.uspto.gov/sequence.html.  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
QY 1835 TTTCTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGT 1881  
Db 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1083  
RESULT 107  
ADB18118/c

ID AD18118 standard; cDNA; 1129 BP.  
XX AD18118;  
AC AD18118;  
XX 20-NOV-2003 (first entry)  
DT 20-NOV-2003 (first entry)  
DE cDNA encoding human PRO polypeptide #111.  
XX Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX Homo sapiens.  
OS US2003077710-A1.  
PN 24-APR-2003.  
PD 22-APR-2002; 2002US-00127825.  
PF 22-OCT-1998; 98US-0105169P.  
XX 01-SEP-1999; 99WO-US020111.  
PR 18-OCT-1999; 99US-00403297.  
CC 30-NOV-1999; 99WO-US028313.  
CC 18-FEB-2000; 2000WO-US004342.  
CC 01-DEC-2000; 2000WO-US032678.  
CC 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-755065/71.  
DR P-PSDB; ADB18119.  
DR New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
in gene therapy, in chromosome and gene mapping, as chromosome markers,  
in tissue typing, and in identifying chromosomes.  
XX Claim 2; Fig 22i; 637pp; English.  
The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating the  
proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating





20-DEC-2000; 200CUS-00747259.  
20-DEC-2000; 200CWO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006666.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00806889.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017092.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882636.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUN-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00524419.  
16-AUG-2001; 2001US-00527796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.  
  
(GETH ) GENENTECH INC.  
  
Baker KP, Beresini M, DeForge L, Deanovers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
  
WPI; 2003-521853/49.  
P-PSDB; ADA46293.  
  
New PRO nucleic acid, useful for preparing a composition for treating  
e.g., tumor.  
  
Claim 2; Fig 221; 200pp; English.  
  
The invention describes 305 nucleic acids encoding PRO (secreted and transmembrane) polypeptides (I). (I) is useful for stimulating the release of TNF-alpha from human blood, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating the proliferation or differentiation of chondrocyte cells, for stimulating the proliferation of or gene expression in pericyte cells, for stimulating the release of proteoglycans from cartilage, for stimulating the proliferation of inner ear utricular supporting cells, for stimulating the proliferation of T-lymphocyte cells, for stimulating the release of a cytokine from PWM cells for inhibiting the binding of A-peptide to factor viira, for inhibiting the differentiation of adipocyte cells, for stimulating proliferation of endothelial cells, for detecting the presence of tumour in a mammal. The tumour is lung, colon, breast, prostate, rectal, cervical or liver tumour. The oligonucleotide probes are useful for isolating genomic and cDNA nucleotide sequences or antisense probes. (I) is also useful as therapeutic agent. PRO is useful in assays to identify other proteins or molecules involved in binding interaction. A polynucleotide (II) encoding (I) is useful in chromosome and gene mapping, in generation of antisense RNA and DNA, in the preparation of PRO polypeptide, for generating transgenic animals or knockout animals which in turn are useful in the development and screening of therapeutically useful reagents, in gene therapy, for chromosome identification, as chromosome marker, and for generating probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g. detecting its expression in specific cells, tissues or serum, and for affinity purification of PRO from recombinant cell culture or natural sources. (I) and (II) are useful for tissue typing. This sequence encodes CC a novel human secreted and transmembrane PRO polypeptide.

```

XX  SQ      Sequence 1129 BP; 231 A; 369 C; 335.G; 194 T; 0 U; 0 Other;
Query Match      1.1%; Score 21.4; DB 1; Length 1129;
Best Local Similarity 66.0%; Pred. NO. 45;
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY      1835 TTTCTAATTTTTCATTTCACAGATTTCCCTTCAGTTGGGTTTGTTT 1881
Db      1129 TTTTCTTTTCTTTTTCAGCTGTCACACAGCTGGGTTTATT 1083

RESULT 111
ADB28322/c
ID      ADB28322 standard; cDNA; 1129 BP.
XX      ADB28322;
XX      20-NOV-2003 (first entry)
XX      cDNA encoding human PRO polypeptide #111.
XX      Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;
KW      tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;
KW      cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;
KW      liver; microvascular endothelial cell; glucose; FFA;
KW      skeletal muscle cell; adipocyte cell; pericyte cell;
KW      inner ear utricular supporting cell; T-lymphocyte cell;
KW      endothelial cell tube formation; bone disorder; cartilage disorder;
KW      sports injury; proteoglycan; articular cartilage defect; osteoarthritis;
KW      rheumatoid arthritis; haemoglobin-associated disorder thalassemia;
KW      immune system cell infiltration.
XX      Homo sapiens.
XX      OS
XX      US2003082699-A1.
XX      01-MAY-2003.
XX      22-APR-2002; 2002US-00127851.
XX      17-JUN-1998; 98US-0089593P.
XX      02-JUN-1999; 99WO-US012252.
XX      25-AUG-1999; 99US-00380137.
XX      30-NOV-1999; 99WO-US028313.
XX      PR 30-MAR-2000; 2000WO-US008439.
XX      PR 01-DEC-2000; 2000WO-US032678.
XX      PR 19-DEC-2001; 2001US-00028072.
XX      (GETH ) GENENTECH INC.
XX      Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;
XX      Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX      Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX      WPI; 2003-777202/73.
XX      P-ESDB; ADB28323.
XX      New PRO nucleic acid, useful for preparing a composition for treating
XX      e.g., tumor or for tissue typing.
XX      Claim 2; Fig 221; 637pp; English.
XX      The invention relates to isolated human PRO polypeptides (secreted and
XX      transmembrane polypeptides) and the polynucleotides encoding them. The
XX      invention also relates to an antibody which specifically binds to a PRO
XX      polypeptide, a method for stimulating the release of tumour necrosis
XX      factor-alpha (TNF-alpha) from human blood, a method for stimulating the
XX      proliferation or differentiation of chondrocyte cells and a method for
XX      detecting the presence of a tumour in a mammal (e.g. adrenal, lung,
XX      colon, breast, prostate, rectal, kidney, cervical and liver tumours). The
XX      polynucleotides are useful in molecular biology, including uses as
XX      hybridisation probes, in chromosome and gene mapping, in generating

```



KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
XX immune system cell infiltration.

OS Homo sapiens.

XX US2003059909-A1.

XX 27-MAR-2003.

XX 10-MAY-2002; 2002US-00143032.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 13-SEP-1999; 99WO-US020594.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 01-DEC-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028501.

XX 02-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 22-DEC-1999; 99WO-US030399.

XX 30-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

XX 11-FEB-2000; 2000WO-US000376.

XX 18-FEB-2000; 2000WO-US003565.

XX 18-FEB-2000; 2000WO-US004541.

XX 22-FEB-2000; 2000WO-US004342.

XX 24-FEB-2000; 2000WO-US004914.

XX 24-FEB-2000; 2000WO-US005004.

XX 01-MAR-2000; 2000WO-US005601.

XX 02-MAR-2000; 2000WO-US005746.

XX 10-MAR-2000; 2000WO-US006319.

XX 15-MAR-2000; 2000WO-US006884.

XX 20-MAR-2000; 2000WO-US007377.

XX 21-MAR-2000; 2000WO-US007532.

XX 30-MAR-2000; 2000WO-US008439.

XX 17-MAY-2000; 2000WO-US013705.

XX 22-MAY-2000; 2000WO-US014042.

XX 30-MAY-2000; 2000WO-US014941.

XX 02-JUN-2000; 2000WO-US015264.

PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US008520.  
PR 01-MAR-2001; 2001WO-US008666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-540684/51.  
P-PSDB; ADA76827.

New secreted and transmembrane nucleic acids and polypeptides, designated as PRO, useful for treating inflammation, organ failure, atherosclerosis, cardiac injury, infertility, birth defects, premature aging, AIDS, or cancer.

Claim 2; Fig 221; 660pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for



12-1441-1333;  
 33MO-USOIO/333



PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-743816/70.  
 DR P-PSDB; ADA88457.  
 XX  
 DR New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
 PT in gene therapy, detecting the presence of tumor in a mammal, or  
 PT modulating the uptake of glucose or free fatty acid by skeletal muscle  
 PT cells or adipocyte cells.  
 XX  
 PS Claim 2; Fig 221; 659pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from BMC cells, for inhibiting the binding of  
 CC A-peptide to factor V1FA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumor in a mammal. The tumor is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1935 TTCTTAATTTTTCATTCAGATTCTTCAGTTGGGTTTGT 1881  
 DB 1129 TTTTITTTTTTTTTTTCAGCTGGCACAGCGTGGTTTATT 1083  
 RESULT 115  
 ID ADA97461 standard; cDNA; 1129 BP.  
 AC ADA97461;  
 XX  
 XX 20-NOV-2003 (first entry)  
 DT  
 XX Human PRO polynucleotide #111.  
 XX

KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 OS  
 XX US2003082686-A1.  
 PN  
 XX 01-MAY-2003.  
 PD  
 XX 19-APR-2002; 2002US-00125926.  
 PF  
 XX 05-JUN-2000; 2000US-0209832P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 PA  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-755106/71.  
 DR P-PSDB; ADA97462.  
 XX  
 CC Isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
 CC PRO4978, useful in molecular biology, chromosome and gene mapping, in  
 CC generating antisense RNA and DNA, and in gene therapy.  
 PT  
 XX Claim 2; Fig 221; 666pp; English.  
 PS  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTCATTCACAGATTCCTTCAGTTGCGTTTCTTT 1881  
DB 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1083

RESULT 116  
ADB27218/C  
ID ADB27218 standard; cDNA; 1129 BP.  
XX AC ADB27218;  
XX DT 20-NOV-2003 (first entry)  
XX DE cDNA encoding human PRO polypeptide #111.  
XX KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; PFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; Proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; hemoglobin-associated disorder thalassemia;  
KW immune system cell infiltration.  
XX OS Homo sapiens.  
XX PN US2003022239-A1.  
XX PD 30-JAN-2003.  
XX PF 12-APR-2002; 2002US-00121049.  
XX PR 18-JUN-1997; 97US-0049911P.  
PR 26-AUG-1997; 97US-0056974P.  
PR 17-SEP-1997; 97US-0059113P.  
PR 17-SEP-1997; 97US-0059115P.  
PR 17-SEP-1997; 97US-0059117P.  
PR 17-SEP-1997; 97US-0059122P.  
PR 17-SEP-1997; 97US-0059184P.  
PR 18-SEP-1997; 97US-0059263P.  
PR 19-SEP-1997; 97US-0059352P.  
PR 19-SEP-1997; 97US-0059589P.  
PR 24-SEP-1997; 97US-0059836P.  
PR 17-OCT-1997; 97US-0062250P.  
PR 17-OCT-1997; 97US-0062285P.  
PR 17-OCT-1997; 97US-0062287P.  
PR 17-OCT-1997; 97US-0063755P.  
PR 24-OCT-1997; 97US-0062814P.  
PR 24-OCT-1997; 97US-0062816P.  
PR 24-OCT-1997; 97US-0063045P.  
PR 24-OCT-1997; 97US-0063082P.  
PR 24-OCT-1997; 97US-0063127P.  
PR 27-OCT-1997; 97US-0063327P.  
PR 27-OCT-1997; 97US-0063329P.  
PR 28-OCT-1997; 97US-0063550P.  
PR 28-OCT-1997; 97US-0063561P.  
PR 29-OCT-1997; 97US-0063704P.  
PR 29-OCT-1997; 97US-0063733P.  
PR 29-OCT-1997; 97US-0063735P.  
PR 29-OCT-1997; 97US-0063738P.  
PR 03-NOV-1997; 97US-0064248P.  
PR 07-NOV-1997; 97US-0064809P.  
PR 12-NOV-1997; 97US-0065186P.  
PR 17-NOV-1997; 97US-0065846P.  
PR 21-NOV-1997; 97US-0066364P.  
PR 24-NOV-1997; 97US-0066453P.

PR 24-NOV-1997; 97US-0066511P.  
PR 24-NOV-1997; 97US-0066770P.  
PR 11-DEC-1997; 97US-0069212P.  
PR 11-DEC-1997; 97US-0069278P.  
PR 11-DEC-1997; 97US-0069334P.  
PR 16-DEC-1997; 97US-0069694P.  
PR 23-JAN-1998; 98US-0072320P.  
PR 04-FEB-1998; 98US-0073612P.  
PR 09-FEB-1998; 98US-0074086P.  
PR 09-FEB-1998; 98US-0074092P.  
PR 12-MAR-1998; 98US-0077791P.  
PR 20-MAR-1998; 98US-0078910P.  
PR 25-MAR-1998; 98US-0079294P.  
PR 27-MAR-1998; 98US-0079663P.  
PR 27-MAR-1998; 98US-0079728P.  
PR 31-MAR-1998; 98US-0080165P.  
PR 09-APR-1998; 98US-0081229P.  
PR 14-APR-1998; 98US-0081695P.  
PR 15-APR-1998; 98US-0081817P.  
PR 15-APR-1998; 98US-0081818P.  
PR 24-APR-1998; 98US-0082999P.  
PR 28-APR-1998; 98US-0083322P.  
PR 29-APR-1998; 98US-0083545P.  
PR 07-MAY-1998; 98US-0084600P.  
PR 07-MAY-1998; 98US-0084627P.  
PR 07-MAY-1998; 98US-0084637P.  
PR 12-MAY-1998; 98US-0085149P.  
PR 13-MAY-1998; 98US-0085323P.  
PR 13-MAY-1998; 98US-0085338P.  
PR 15-MAY-1998; 98US-0085579P.  
PR 15-MAY-1998; 98US-0085697P.  
PR 15-MAY-1998; 98US-0085704P.  
PR 22-MAY-1998; 98US-0086414P.  
PR 22-MAY-1998; 98US-0086430P.  
PR 28-MAY-1998; 98US-0087106P.  
PR 04-JUN-1998; 98US-0088026P.  
PR 10-JUN-1998; 98US-0088730P.  
PR 10-JUN-1998; 98US-0088741P.  
PR 10-JUN-1998; 98US-0088810P.  
PR 11-JUN-1998; 98US-0088858P.  
PR 12-JUN-1998; 98US-0088858P.  
PR 17-JUN-1998; 98US-0089332P.  
PR 17-JUN-1998; 98US-0089599P.  
PR 18-JUN-1998; 98US-0089907P.  
PR 19-JUN-1998; 98US-0089947P.  
PR 23-JUN-1998; 98US-0090349P.  
PR 24-JUN-1998; 98US-0090429P.  
PR 24-JUN-1998; 98US-0090445P.  
PR 24-JUN-1998; 98US-0090538P.  
PR 26-JUN-1998; 98US-0090863P.  
PR 01-JUL-1998; 98US-0091160P.  
PR 02-JUL-1998; 98US-0091519P.  
PR 07-JUL-1998; 98US-0091982P.  
PR 14-JUL-1998; 98US-0091982P.  
PR 20-JUL-1998; 98US-0093339P.  
PR 30-JUL-1998; 98US-0094651P.  
PR 04-AUG-1998; 98US-0095285P.  
PR 04-AUG-1998; 98US-0095501P.  
PR 04-AUG-1998; 98US-0095502P.  
PR 04-AUG-1998; 98US-0095532P.  
PR 11-AUG-1998; 98US-0096143P.  
PR 11-AUG-1998; 98US-0096146P.  
PR 12-AUG-1998; 98US-0096329P.  
PR 17-AUG-1998; 98US-0096768P.  
PR 17-AUG-1998; 98US-0096773P.  
PR 17-AUG-1998; 98US-0096791P.  
PR 17-AUG-1998; 98US-0096891P.  
PR 17-AUG-1998; 98US-0096895P.  
PR 18-AUG-1998; 98US-0096960P.  
PR 19-AUG-1998; 98US-0097141P.  
PR 20-AUG-1998; 98US-0097218P.  
PR 26-AUG-1998; 98US-0097951P.

---



AC ADA66842;  
 XX 20-NOV-2003 (first entry)  
 DT Human PRO polynucleotide #111.  
 DE Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; RPA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX US2003068793-A1.  
 FN 10-APR-2003.  
 PD  
 XX 15-APR-2002; 2002US-00123108.  
 FF  
 XX 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.  
 PR 17-SEP-1998; 98WO-US019437.  
 PR 07-OCT-1998; 98WO-US021141.  
 PR 29-OCT-1998; 98WO-US022991.  
 PR 29-OCT-1998; 98WO-US022992.  
 PR 20-NOV-1998; 98WO-US024855.  
 PR 01-DEC-1998; 98WO-US025108.  
 PR 05-JAN-1999; 99WO-US000106.  
 PR 08-MAR-1999; 99WO-US005028.  
 PR 10-MAR-1999; 99WO-US005130.  
 PR 20-APR-1999; 99WO-US008615.  
 PR 14-MAY-1999; 99WO-US010733.  
 PR 02-JUN-1999; 99WO-US012252.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 08-SEP-1999; 99WO-US020594.  
 PR 13-SEP-1999; 99WO-US020944.  
 PR 15-SEP-1999; 99WO-US021090.  
 PR 15-SEP-1999; 99WO-US021547.  
 PR 05-OCT-1999; 99WO-US023089.  
 PR 29-NOV-1999; 99WO-US028214.  
 PR 30-NOV-1999; 99WO-US028313.  
 PR 30-NOV-1999; 99WO-US028409.  
 PR 01-DEC-1999; 99WO-US028301.  
 PR 01-DEC-1999; 99WO-US028624.  
 PR 02-DEC-1999; 99WO-US028551.  
 PR 02-DEC-1999; 99WO-US028564.  
 PR 02-DEC-1999; 99WO-US028565.  
 PR 16-DEC-1999; 99WO-US030095.  
 PR 20-DEC-1999; 99WO-US030911.  
 PR 20-DEC-1999; 99WO-US030999.  
 PR 22-DEC-1999; 99WO-US030720.  
 PR 30-DEC-1999; 99WO-US031243.  
 PR 30-DEC-1999; 99WO-US031274.  
 PR 05-JAN-2000; 2000WO-US000219.  
 PR 06-JAN-2000; 2000WO-US000277.  
 PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US003568.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 24-FEB-2000; 2000WO-US005004.  
 PR 01-MAR-2000; 2000WO-US005601.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 10-MAR-2000; 2000WO-US006319.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014941.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US020311.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030952.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001US-00796498.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006666.  
 PR 09-MAR-2001; 2001US-00802706.  
 PR 14-MAR-2001; 2001US-00808699.  
 PR 20-MAR-2001; 2001US-00816744.  
 PR 05-APR-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017800.  
 PR 03-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 20-JUN-2001; 2001US-00886342.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908827.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-695925/66.  
 DR P-PSDB; ADA66843.  
 DR  
 XX Novel secreted and transmembrane PRO polypeptides useful for stimulating  
 PT release of tumor necrosis factor-alpha from human blood and detecting the  
 PT presence of a tumor in a mammal.  
 XX Claim 2; Fig 22; 660pp; English.  
 PS The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for



The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. NO. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1835 TTCTTAATTTTTTCATTCCAGATTTCCCTTCAGTTGGGTTTGT 1881  
||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
1129 TTTTITTTTTTTTTTTTTCAGCTGCACACACGCTGGGTTTTATT 1083

RESULT 121  
ADA92198/c  
ID ADA92198 standard; cDNA; 1129 BP.  
XX AC ADA92198;  
XX AC ADA92198;  
XX DT 20-NOV-2003 (first entry)  
XX Novel human secreted and transmembrane protein PRO4327 CDNA.  
XX Human; secreted and transmembrane protein; PRO; gene; ss;  
KW Tumour necrosis factor alpha release; TNF-alpha release;  
KW glucose uptake modulator; FFA uptake modulator;  
KW cell proliferation stimulator; cell differentiation stimulator;  
KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.  
XX KW  
XX OS Homo sapiens.  
XX FN US2003082712-A1.  
XX PD 01-MAY-2003.  
XX PF 16-MAY-2002; 2002US-00147512.  
XX PR 15-MAY-1998; 98US-0085697P.  
PR 08-MAR-1999; 99WO-US005028.  
PR 25-AUG-1999; 99US-00380138.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX PA (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-786915/74.  
DR P-P8DB; ADA92199.  
XX PT New PRO nucleic acid, useful for preparing a composition for treating  
PT e.g., tumor or for tissue typing.  
XX PS Claim 2; Fig 221; 637pp; English.  
XX The invention describes 305 nucleic acids encoding PRO (secreted and  
CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
CC release of TNF-alpha from human blood, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating the proliferation or differentiation of chondrocyte cells,  
CC for stimulating the proliferation or gene expression in pericyte  
CC cells, for stimulating the release of proteoglycans from cartilage, for  
CC stimulating the proliferation of inner ear intracellular supporting cells,  
CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
CC the release of a cytokine from PMNC cells, for inhibiting the binding of  
CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
CC cells, for stimulating proliferation of endothelial cells, for detecting

Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour; cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix; liver; microvascular endothelial cell; glucose; RFA; skeletal muscle cell; adipocyte cell; pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell; endothelial cell tube formation; bone disorder; cartilage disorder; sports injury; proteoglycan; articular cartilage defect; osteoarthritis; rheumatoid arthritis; haemoglobin-associated disorder thalassemia; immune system cell infiltration.

Homo sapiens.

US2003077712-A1.

24-APR-2003.

22-APR-2002; 2002US-00127835.

20-OCT-1998; 98US-0104987P.

01-SEP-1999; 99WO-US020111.

18-OCT-1999; 99US-00403297.

18-FEB-2000; 2000WO-US0004342.

01-DEC-2000; 2000WO-US032679.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Deenoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI, 2003-755067/71.

P-PSDB; ADB23477.

New isolated, secreted and transmembrane PRO nucleic acid, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, rectal, cervical and/or liver tumors.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note:



omo sapiens.  
S2003082766-A1-

S2003082766-A1

S2003082766-A1



XX 01-MAY-2003.  
PD 30-MAY-2002; 2002US-00158782.  
XX 97WO-US005230.  
PF 98WO-US012456.  
XX 98WO-US014552.  
XX 98WO-US017888.  
XX 98WO-US018824.  
XX 98WO-US019093.  
XX 98WO-US019094.  
XX 98WO-US019094.  
XX 98WO-US019177.  
XX 98WO-US019330.  
XX 98WO-US019437.  
XX 98WO-US021141.  
XX 98WO-US022991.  
XX 98WO-US022992.  
XX 98WO-US024855.  
XX 98WO-US025108.  
XX 98WO-US000106.  
XX 98WO-US005028.  
XX 98WO-US005190.  
XX 98WO-US008615.  
XX 98WO-US010733.  
XX 98WO-US012252.  
XX 98WO-US020111.  
XX 98WO-US020594.  
XX 98WO-US020944.  
XX 98WO-US021090.  
XX 98WO-US021547.  
XX 98WO-US023089.  
XX 98WO-US028214.  
XX 98WO-US028313.  
XX 98WO-US028409.  
XX 98WO-US028301.  
XX 98WO-US028634.  
XX 98WO-US028551.  
XX 98WO-US028564.  
XX 98WO-US028565.  
XX 98WO-US030095.  
XX 98WO-US030911.  
XX 98WO-US030999.  
XX 98WO-US030720.  
XX 98WO-US031243.  
XX 98WO-US031274.  
XX 2000WO-US000219.  
XX 2000WO-US000277.  
XX 2000WO-US000376.  
XX 2000WO-US003565.  
XX 2000WO-US004341.  
XX 2000WO-US004342.  
XX 2000WO-US004414.  
XX 2000WO-US004414.  
XX 2000WO-US005004.  
XX 2000WO-US005601.  
XX 2000WO-US005746.  
XX 2000WO-US005841.  
XX 2000WO-US006319.  
XX 2000WO-US006684.  
XX 2000WO-US007377.  
XX 2000WO-US007532.  
XX 2000WO-US008439.  
XX 2000WO-US013705.  
XX 2000WO-US014042.  
XX 2000WO-US014941.  
XX 2000WO-US015264.  
XX 2000WO-US020710.  
XX 2000WO-US022031.  
XX 2000WO-US023522.  
XX 2000WO-US023328.  
XX 2000WO-US030952.  
XX 2000WO-US030873.

01-DEC-2000; 2000WO-US032678.  
20-DEC-2000; 2000US-00747259.  
20-DEC-2000; 2000WO-US034956.  
28-FEB-2001; 2001US-00796498.  
28-FEB-2001; 2001WO-US006520.  
01-MAR-2001; 2001WO-US006566.  
09-MAR-2001; 2001US-00802706.  
14-MAR-2001; 2001US-00806889.  
22-MAR-2001; 2001US-00816744.  
05-APR-2001; 2001US-00828366.  
10-MAY-2001; 2001US-00854208.  
10-MAY-2001; 2001US-00854280.  
18-MAY-2001; 2001US-00860216.  
25-MAY-2001; 2001US-00866028.  
25-MAY-2001; 2001US-00866034.  
25-MAY-2001; 2001WO-US017892.  
01-JUN-2001; 2001US-00872035.  
01-JUN-2001; 2001WO-US017800.  
05-JUN-2001; 2001US-00874503.  
14-JUN-2001; 2001US-00882536.  
19-JUN-2001; 2001US-00886342.  
20-JUN-2001; 2001WO-US019692.  
21-JUN-2001; 2001US-00887879.  
22-JUN-2001; 2001WO-US020116.  
29-JUL-2001; 2001WO-US021066.  
09-JUL-2001; 2001WO-US021735.  
18-JUL-2001; 2001US-00908827.  
06-AUG-2001; 2001US-00924419.  
09-AUG-2001; 2001US-00927796.  
16-AUG-2001; 2001US-00931836.  
19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.  
Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI; 2003-785921/74.  
P-PSDB; ADB38514.  
New secreted and transmembrane PRO polypeptides and nucleic acids, useful  
in gene therapy, detecting the presence of tumor in a mammal, or  
modulating the uptake of glucose or free fatty acid by skeletal muscle  
cells or adipocyte cells.  
Claim 2; Fig 221; 660pp; English.  
The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF-alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation of or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from PMBC cells, for inhibiting the binding of  
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast,  
prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
are useful for isolating genomic and cDNA nucleotide sequences or  
antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
in assays to identify other proteins or molecules involved in binding  
interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
and gene mapping, in generation of antisense RNA and DNA, in the  
preparation of PRO polypeptide, for generating transgenic animals or  
knockout animals which in turn are useful in the development and  
screening of therapeutically useful reagents, in gene therapy, for  
chromosome identification, as chromosome marker, and for generating  
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
detecting its expression in specific cells, tissues or serum, and for

CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881

Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 124

ADB37961/C

ID ADB37961 standard; cDNA; 1129 BP.

XX AC ADB37961;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW Cell proliferation stimulator; cell differentiation stimulator;

XX KW Cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW Gene therapy; chromosome identification; chromosome marker.

XX KW Homo sapiens.

XX OS US2003087347-A1.

XX FN 08-MAY-2003.

XX FF 19-APR-2002; 2002US-00125921.

XX PR 17-AUG-1998; 98US-0096791P.

XX PR 02-JUN-1999; 99WO-US012252.

XX PR 25-AUG-1999; 99US-00380137.

XX PR 30-MAR-2000; 2000WO-US008439.

XX PR 01-DEC-2000; 2000WO-US032678.

XX PR 19-DEC-2001; 2001US-00028072.

XX PA (GETH ) GENENTECH INC.

XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX PI Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX DR WPI; 2003-786938/74.

XX DR P-PSDB; ADB37962.

XX FT New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide

XX FT and for manufacturing a medicament for diagnosing or treating tumor.

XX PS Claim 2; Fig 221; 637pp; English.

XX CC The invention describes 305 nucleic acids encoding PRO (secreted and

XX CC transmembrane) polypeptides (I). (II) is useful for stimulating the

XX CC release of TNF-alpha from human blood, for modulating the uptake of

XX CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX CC stimulating the proliferation or differentiation of chondrocyte cells,

XX CC for stimulating the proliferation of or gene expression in pericyte

XX CC cells, for stimulating the release of proteoglycans from cartilage, for

XX CC stimulating the proliferation of inner ear utricular supporting cells,

XX CC for stimulating the proliferation of T-lymphocyte cells, for stimulating

XX CC the release of a cytokine from PBMC cells, for inhibiting the binding of

CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC and gene mapping. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC interaction. Preparation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.

XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

Qy 1835 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTGGGTTTGT 1881

Db 1129 TTTTITTTTTTTTTTTTTCAGCTGGCACACAGGCTGGTTTATT 1083

RESULT 125

ADB6433/C

ID ADB6433 standard; cDNA; 1129 BP.

XX AC ADB6433;

XX DT 04-DEC-2003 (first entry)

XX DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX KW Human; secreted and transmembrane protein; PRO; gene; ss;

XX KW Tumour necrosis factor alpha release; TNF-alpha release;

XX KW Glucose uptake modulator; FFA uptake modulator;

XX KW Cell proliferation stimulator; cell differentiation stimulator;

XX KW Cell differentiation inhibitor; cytokine release stimulator; tumour;

XX KW Lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX KW Cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX KW Gene therapy; chromosome identification; chromosome marker.

XX KW Homo sapiens.

XX OS US2003082689-A1.

XX FN 01-MAY-2003.

XX FF 22-APR-2002; 2002US-00127831.

XX PR 31-MAR-1997; 97WO-US005230.

XX PR 12-JUN-1998; 98WO-US012456.

XX PR 14-JUL-1998; 98WO-US014552.

XX PR 28-AUG-1998; 98WO-US017888.

XX PR 10-SEP-1998; 98WO-US018824.

XX PR 14-SEP-1998; 98WO-US019093.

XX PR 14-SEP-1998; 98WO-US019094.

XX PR 14-SEP-1998; 98WO-US019177.

XX PR 16-SEP-1998; 98WO-US019350.

XX PR 17-SEP-1998; 98WO-US019437.

XX PR 07-OCT-1998; 98WO-US021141.

XX PR 29-OCT-1998; 98WO-US022991.

XX PR 29-OCT-1998; 98WO-US022992.

XX PR 20-NOV-1998; 98WO-US024855.

XX PR 01-DEC-1998; 98WO-US025108.

XX PR 05-JAN-1999; 98WO-US000106.

```
PR 08-MAR-1999; 99WO-US0005028.
PR 10-MAR-1999; 99WO-US0005190.
PR 20-APR-1999; 99WO-US0008615.
PR 14-MAY-1999; 99WO-US010733.
PR 02-JUN-1999; 99WO-US0112252.
PR 01-SEP-1999; 99WO-US020111.
PR 08-SEP-1999; 99WO-US020594.
PR 13-SEP-1999; 99WO-US020944.
PR 15-SEP-1999; 99WO-US021090.
PR 15-SEP-1999; 99WO-US021547.
PR 05-OCT-1999; 99WO-US023089.
PR 29-NOV-1999; 99WO-US028214.
PR 30-NOV-1999; 99WO-US028313.
PR 30-NOV-1999; 99WO-US028409.
PR 01-DEC-1999; 99WO-US028301.
PR 01-DEC-1999; 99WO-US028634.
PR 02-DEC-1999; 99WO-US028551.
PR 02-DEC-1999; 99WO-US028564.
PR 02-DEC-1999; 99WO-US028565.
PR 16-DEC-1999; 99WO-US030095.
PR 20-DEC-1999; 99WO-US030911.
PR 20-DEC-1999; 99WO-US030999.
PR 22-DEC-1999; 99WO-US030720.
PR 30-DEC-1999; 99WO-US031243.
PR 30-DEC-1999; 99WO-US031274.
PR 05-JAN-2000; 2000WO-US000219.
PR 08-JAN-2000; 2000WO-US000277.
PR 08-JAN-2000; 2000WO-US000376.
PR 11-FEB-2000; 2000WO-US003565.
PR 18-FEB-2000; 2000WO-US004341.
PR 18-FEB-2000; 2000WO-US004342.
PR 22-FEB-2000; 2000WO-US004414.
PR 24-FEB-2000; 2000WO-US004914.
PR 01-MAR-2000; 2000WO-US005601.
PR 02-MAR-2000; 2000WO-US005746.
PR 02-MAR-2000; 2000WO-US005841.
PR 10-MAR-2000; 2000WO-US006319.
PR 15-MAR-2000; 2000WO-US006884.
PR 20-MAR-2000; 2000WO-US007377.
PR 21-MAR-2000; 2000WO-US007532.
PR 30-MAR-2000; 2000WO-US008439.
PR 17-MAY-2000; 2000WO-US013705.
PR 22-MAY-2000; 2000WO-US014042.
PR 30-MAY-2000; 2000WO-US014941.
PR 02-JUN-2000; 2000WO-US015264.
PR 28-JUL-2000; 2000WO-US020710.
PR 11-AUG-2000; 2000WO-US022031.
PR 24-AUG-2000; 2000WO-US023522.
PR 24-AUG-2000; 2000WO-US023328.
PR 08-NOV-2000; 2000WO-US030952.
PR 10-NOV-2000; 2000WO-US030873.
PR 01-DEC-2000; 2000WO-US032678.
PR 20-DEC-2000; 2000US-00747259.
PR 20-DEC-2000; 2000WO-US034956.
PR 28-FEB-2001; 2001US-00796498.
PR 28-FEB-2001; 2001WO-US006520.
PR 01-MAR-2001; 2001WO-US006666.
PR 09-MAR-2001; 2001US-00803706.
PR 14-MAR-2001; 2001US-00808689.
PR 22-MAR-2001; 2001US-00816744.
PR 05-APR-2001; 2001US-00828366.
PR 10-MAY-2001; 2001US-00854280.
PR 10-MAY-2001; 2001US-00854280.
PR 18-MAY-2001; 2001US-00860216.
PR 25-MAY-2001; 2001US-00860628.
PR 25-MAY-2001; 2001US-00866034.
PR 25-MAY-2001; 2001WO-US017092.
PR 01-JUN-2001; 2001US-00872035.
PR 01-JUN-2001; 2001WO-US017800.
PR 05-JUN-2001; 2001US-00874503.
PR 14-JUN-2001; 2001US-00882636.
PR 19-JUN-2001; 2001US-00886342.

PR 20-JUN-2001; 2001WO-US019692.
PR 21-JUN-2001; 2001US-00887879.
PR 22-JUN-2001; 2001WO-US020116.
PR 29-JUN-2001; 2001WO-US021066.
PR 09-JUL-2001; 2001WO-US021735.
PR 18-JUL-2001; 2001US-00308827.
PR 06-AUG-2001; 2001US-00924419.
PR 09-AUG-2001; 2001US-00927796.
PR 16-AUG-2001; 2001US-00931836.
PR 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX
XX WPI: 2003-786905/74.
XX P-PSDB; ADB66434.
XX
XX New PRO nucleic acid, useful for preparing a composition for treating
XX e.g. tumor or for tissue typing.
XX
XX Claim 2; Fig 221; 637pp; English.
XX
XX The invention describes 305 nucleic acids encoding PRO (secreted and
XX transmembrane) polypeptides (I). (I) is useful for stimulating the
XX release of TNF-alpha from human blood, for modulating the uptake of
XX glucose or FFA by skeletal muscle cells or adipocyte cells, for
XX stimulating the proliferation or differentiation of chondrocyte cells,
XX for stimulating the proliferation of or gene expression in pericyte
XX cells, for stimulating the release of proteoglycans from cartilage, for
XX stimulating the proliferation of inner ear utricular supporting cells,
XX for stimulating the proliferation of T-lymphocyte cells, for stimulating
XX the release of a cytokine from PBMC cells, for inhibiting the binding of
XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte
XX cells, for stimulating proliferation of endothelial cells, for detecting
XX the presence of tumour in a mammal. The tumour is lung, colon, breast,
XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes
XX are useful for isolating genomic and cDNA nucleotide sequences or
XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful
XX in assays to identify other proteins or molecules involved in binding
XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome
XX and gene mapping, in generation of antisense RNA and DNA, in the
XX preparation of PRO polypeptide, for generating transgenic animals or
XX knockout animals which in turn are useful in the development and
XX screening of therapeutically useful reagents, in gene therapy, for
XX chromosome identification, as chromosome marker, and for generating
XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.
XX detecting its expression in specific cells, tissues or serum, and for
XX affinity purification of PRO from recombinant cell culture or natural
XX sources. (I) and (II) are useful for tissue typing. This sequence encodes
XX a novel human secreted and transmembrane PRO polypeptide.
XX
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX
XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred.No. 45;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX
XX QY 1935 TTCTTAATTTTTCATTCAGATTTCCTTCAGTTTCGTTTCTTTT 1881
XX ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX DB 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT 1083
XX ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX
XX RESULT 126
XX ADB89513/C
XX ID ADB89513 standard; cDNA; 1129 BP.
XX
XX AC ADB89513;
XX
XX DT 04-DEC-2003 (first entry)
XX
```







CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.

XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 ADB46969/C

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881  
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGCGTGGTTTATT 1083

RESULT 129  
 ADB46969/C

ID ADB46969 standard; cDNA; 1129 BP.

XX  
 AC ADB46969;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX

DE Novel human secreted and transmembrane protein PRO4327 cDNA.

XX  
 KW Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW Glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.

XX  
 OS Homo sapiens.  
 XX  
 PN US2003082687-A1.  
 XX  
 PD 01-MAY-2003.  
 XX

PF 19-APR-2002; 2002US-00125930.  
 XX  
 PR 05-JUN-2000; 2000US-0209832P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX

PA (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-786904/74.  
 DR P-PSDB; ADB46970.  
 XX  
 XX  
 XX New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
 PRO4978, useful in molecular biology, chromosome and gene mapping, in  
 PT generating antisense RNA and DNA, and in gene therapy.

XX  
 PS Claim 2; Fig 221; 627pp; English.

XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for

CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.

XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 ADB8576/C

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTGGGTTTGT 1881  
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGCGTGGTTTATT 1083

RESULT 130  
 ADB8576/C

ID ADB8576 standard; cDNA; 1129 BP.

XX  
 AC ADB8576;  
 XX  
 DT 04-DEC-2003 (first entry)  
 XX

DE Human PRO polynucleotide #111.

XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.

XX  
 OS Homo sapiens.  
 XX  
 PN US2003082697-A1.  
 XX  
 PD 01-MAY-2003.  
 XX

PF 22-APR-2002; 2002US-00127849.  
 XX  
 PR 20-OCT-1998; 98US-0104987P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX

XX (GETH ) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;











XX	ADB34890;	
AC	04-DEC-2003 (first entry)	
XX	Human PRO polynucleotide SEQ ID NO 221.	
DT	Human; gens; ss; PRO; secreted polypeptide; transmembrane polypeptide;	
DE	tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;	
DE	cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;	
XX	liver; microvascular endothelial cell; glucose; FFA;	
KW	skeletal muscle cell; adipocyte cell; pericyte cell;	
KW	inner ear utricular supporting cell; T-lymphocyte cell;	
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	
KW	spots injury; proteoglycan; articular cartilage defect; osteoarthritis;	
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	
KW	immune system cell infiltration.	
XX	Homo sapiens.	
OS	US2003077718-A1.	
XX	24-APR-2003.	
PD	24-APR-2002; 2002US-00131823.	
PF	31-MAR-1997; 97WO-US0005230.	
XX	12-JUN-1998; 98WO-US012456.	
PR	14-JUL-1998; 98WO-US014552.	
PR	28-AUG-1998; 98WO-US017888.	
PR	10-SEP-1998; 98WO-US018824.	
PR	14-SEP-1998; 98WO-US019093.	
PR	14-SEP-1998; 98WO-US019094.	
PR	14-SEP-1998; 98WO-US019177.	
PR	16-SEP-1998; 98WO-US019330.	
PR	17-SEP-1998; 98WO-US019437.	
PR	07-OCT-1998; 98WO-US021141.	
PR	29-OCT-1998; 98WO-US022991.	
PR	29-OCT-1998; 98WO-US022992.	
PR	20-NOV-1998; 98WO-US024855.	
PR	01-DEC-1998; 98WO-US025108.	
PR	05-JAN-1999; 98WO-US000106.	
PR	08-MAR-1999; 99WO-US0005028.	
PR	10-MAR-1999; 99WO-US0005190.	
PR	20-APR-1999; 99WO-US008615.	
PR	14-MAY-1999; 99WO-US010733.	
PR	02-JUN-1999; 99WO-US012252.	
PR	01-SEP-1999; 98WO-US020111.	
PR	08-SEP-1999; 99WO-US020594.	
PR	13-SEP-1999; 99WO-US020944.	
PR	15-SEP-1999; 99WO-US021090.	
PR	15-SEP-1999; 99WO-US021547.	
PR	05-OCT-1999; 99WO-US023089.	
PR	29-NOV-1999; 99WO-US026214.	
PR	30-NOV-1999; 98WO-US028313.	
PR	30-NOV-1999; 99WO-US028409.	
PR	01-DEC-1999; 99WO-US028301.	
PR	01-DEC-1999; 99WO-US028634.	
PR	02-DEC-1999; 99WO-US028551.	
PR	02-DEC-1999; 99WO-US028554.	
PR	02-DEC-1999; 99WO-US028555.	
PR	16-DEC-1999; 98WO-US030095.	
PR	20-DEC-1999; 99WO-US030911.	
PR	20-DEC-1999; 99WO-US030999.	
PR	22-DEC-1999; 99WO-US030720.	
PR	30-DEC-1999; 99WO-US031243.	
PR	30-DEC-1999; 99WO-US031274.	
PR	05-JAN-2000; 2000WO-US000219.	
PR	06-JAN-2000; 2000WO-US000277.	
PR	06-JAN-2000; 2000WO-US000376.	
PR	11-FEB-2000; 2000WO-US003565.	
PR	18-FEB-2000; 2000WO-US004341.	
PR	18-FEB-2000; 2000WO-US004342.	

factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, PRO articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The sequence data for this patent is also available in electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

Sequence 1129 BP: 231 A: 369 C: 335 G: 194 T: 0 U: 0 Other:;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

```

Best Local Similarity 66.0%; Pred. No: 45;
Matches 31: Conservative 0: Mismatches 16: Indels 0: Gaps 0:

```

1835 TTCCTTAATTTTTCATTTCCAGATTCCCTTCAGTTTGGGTTTGT 1881

1129 TTTTCTTTTTTTCAGCTGGCACACAGGCTGGGTATT 1083

RESIST. 136

ADB35994/C

ID ADB35994 standard; cDNA; 1129 BP.

AC ADB35994;

DT 04-DEC-2011

XX  
Edgewood Community Center

XX

tumour necrosis factor- $\alpha$ ; TNF- $\alpha$ ; chondrocyte cell; tumour;  
cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
liver; microvascular endothelial cell; Glucose; PFA;  
skeletal muscle cell; adipocyte cell; pericyte cell;  
inner ear utricular supporting cell; T-lymphocyte cell;  
endothelial cell tube formation; bone disorder; cartilage disorder;  
sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
immune system cell infiltration.

XX  
QS  
Homo sapiens.

US  
XX  
PN

XXXXXX

PD 24-APR-2003.

XX  
PE 24-APR-2002: 2002US-00131830-

2  
 3  
 4  
 5  
 6  
 7  
 8  
 9  
 10  
 11  
 12  
 13  
 14  
 15  
 16  
 17  
 18  
 19  
 20  
 21  
 22  
 23  
 24  
 25  
 26  
 27  
 28  
 29  
 30  
 31  
 32  
 33  
 34  
 35  
 36  
 37  
 38  
 39  
 40  
 41  
 42  
 43  
 44  
 45  
 46  
 47  
 48  
 49  
 50  
 51  
 52  
 53  
 54  
 55  
 56  
 57  
 58  
 59  
 60  
 61  
 62  
 63  
 64  
 65  
 66  
 67  
 68  
 69  
 70  
 71  
 72  
 73  
 74  
 75  
 76  
 77  
 78  
 79  
 80  
 81  
 82  
 83  
 84  
 85  
 86  
 87  
 88  
 89  
 90  
 91  
 92  
 93  
 94  
 95  
 96  
 97  
 98  
 99  
 100  
 101  
 102  
 103  
 104  
 105  
 106  
 107  
 108  
 109  
 110  
 111  
 112  
 113  
 114  
 115  
 116  
 117  
 118  
 119  
 120  
 121  
 122  
 123  
 124  
 125  
 126  
 127  
 128  
 129  
 130  
 131  
 132  
 133  
 134  
 135  
 136  
 137  
 138  
 139  
 140  
 141  
 142  
 143  
 144  
 145  
 146  
 147  
 148  
 149  
 150  
 151  
 152  
 153  
 154  
 155  
 156  
 157  
 158  
 159  
 160  
 161  
 162  
 163  
 164  
 165  
 166  
 167  
 168  
 169  
 170  
 171  
 172  
 173  
 174  
 175  
 176  
 177  
 178  
 179  
 180  
 181  
 182  
 183  
 184  
 185  
 186  
 187  
 188  
 189  
 190  
 191  
 192  
 193  
 194  
 195  
 196  
 197  
 198  
 199  
 200  
 201  
 202  
 203  
 204  
 205  
 206  
 207  
 208  
 209  
 210  
 211  
 212  
 213  
 214  
 215  
 216  
 217  
 218  
 219  
 220  
 221  
 222  
 223  
 224  
 225  
 226  
 227  
 228  
 229  
 230  
 231  
 232  
 233  
 234  
 235  
 236  
 237  
 238  
 239  
 240  
 241  
 242  
 243  
 244  
 245  
 246  
 247  
 248  
 249  
 250  
 251  
 252  
 253  
 254  
 255  
 256  
 257  
 258  
 259  
 260  
 261  
 262  
 263  
 264  
 265  
 266  
 267  
 268  
 269  
 270  
 271  
 272  
 273  
 274  
 275  
 276  
 277  
 278  
 279  
 280  
 281  
 282  
 283  
 284  
 285  
 286  
 287  
 288  
 289  
 290  
 291  
 292  
 293  
 294  
 295  
 296  
 297  
 298  
 299  
 300  
 301  
 302  
 303  
 304  
 305  
 306  
 307  
 308  
 309  
 310  
 311  
 312  
 313  
 314  
 315  
 316  
 317  
 318  
 319  
 320  
 321  
 322  
 323  
 324  
 325  
 326  
 327  
 328  
 329  
 330  
 331  
 332  
 333  
 334  
 335  
 336  
 337  
 338  
 339  
 340  
 341  
 342  
 343  
 344  
 345  
 346  
 347  
 348  
 349  
 350  
 351  
 352  
 353  
 354  
 355  
 356  
 357  
 358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367  
 368  
 369  
 370  
 371  
 372  
 373  
 374  
 375  
 376  
 377  
 378  
 379  
 380  
 381  
 382  
 383  
 384  
 385  
 386  
 387  
 388  
 389  
 390  
 391  
 392  
 393  
 394  
 395  
 396  
 397  
 398  
 399  
 400  
 401  
 402  
 403  
 404  
 405  
 406  
 407  
 408  
 409  
 410  
 411  
 412  
 413  
 414  
 415  
 416  
 417  
 418  
 419  
 420  
 421  
 422  
 423  
 424  
 425  
 426  
 427  
 428  
 429  
 430  
 431  
 432  
 433  
 434  
 435  
 436  
 437  
 438  
 439  
 440  
 441  
 442  
 443  
 444  
 445  
 446  
 447  
 448  
 449  
 450  
 451  
 452  
 453  
 454  
 455  
 456  
 457  
 458  
 459  
 460  
 461  
 462  
 463  
 464  
 465  
 466  
 467  
 468  
 469  
 470  
 471  
 472  
 473  
 474  
 475  
 476  
 477  
 478  
 479  
 480  
 481  
 482  
 483  
 484  
 485  
 486  
 487  
 488  
 489  
 490  
 491  
 492  
 493  
 494  
 495  
 496  
 497  
 498  
 499  
 500  
 501  
 502  
 503  
 504  
 505  
 506  
 507  
 508  
 509  
 510  
 511  
 512  
 513  
 514  
 515  
 516  
 517  
 518  
 519  
 520  
 521  
 522  
 523  
 524  
 525  
 526

PR 09-DEC-1999; 99US-0170262P.

PR 01-DEC-2000; 2000WO-US032678.

(GETH ) GENENTECH INC.

Maaker KP, Beresini M, Deforge L, Denoyers L, Filvaroff E, Gao W, Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S, Smith V, Stewart TA, Tunas D, Watanabe CK, Wood WI, Zhang Z;

PI; 2003-755075/71.  
P-PSDB; ADB3595.  
new isolated, secreted and transmembrane PRO polypeptides and nucleic acids, useful for the diagnosis, prevention and/or treatment of tumors, such as lung, colon, breast, prostate, cervical and/or liver tumors.

Claim 2: Fig 221: 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are deficient in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating various bone and/or cartilage disorders such as sports injuries and arthritis. PRO polypeptides which stimulate the release of proteoglycans from cartilage are useful for treating sports-related joint problems, articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO polypeptides are also useful for treating various mammalian haemoglobin-associated disorders such as various thalassaemias and conditions which may benefit from enhanced local immune system cell infiltration. This sequence represents a human PRO polynucleotide of the invention. Note: The USPTO data for this patent is also available in electronic format. The USPTO data for this patent is also available in electronic format. The USPTO data for this patent is also available in electronic format.

00000000	1120	ED:	021	A:	368	C:	335	G:	194	T:	0	II:	0	Other:
----------	------	-----	-----	----	-----	----	-----	----	-----	----	---	-----	---	--------

sequence 1122 BF, 303 H, 333 G, 113

```

ry Match      1.1%; Score 21.4; DB 1; Length 1129;
t Local Similarity 66.0%; Pred. No. 45;
ches 31; Conservative 0; Mismatches 16; Indels 0; Gaps

```

1835 TTCTTAATTTTTTCAATTCCAGATTTCCTTCAGTTTGGGTTTGT 1881

DEPOSIT 137

ADB46389/C

ID ADB46389 standard; cDNA; 1129 BP.

XX

AC  
YY  
ADB465

04-DEC-2003 (first entry)

[illegible]

Novel human secreted and transmembrane protein PR04327



10664775-3.rng

Mon Aug 9 17:47:19 2004

CC Glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassaemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polynucleotide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TCTTAATTTTTCATTCACGATTTCTTCAGTTGGGTTTCTTT 1881  
 DB 1129 TTTTTCATTTTTCATTCACGATTTCTTCAGTTGGGTTTCTTT 1083  
 RESULT 139  
 ID ADC71809/c  
 AC ADC71809 standard; cDNA; 1129 BP.  
 XX  
 AC ADC71809;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003092107-A1.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 24-APR-2002; 2002US-0011828.  
 XX  
 PR 07-OCT-1998; 98US-0103315P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;  
 XX

DR  
 XX P-PSDB; ADC71810.  
 PT New secreted and transmembrane nucleic acids and polypeptides, designated  
 PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
 PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
 PT cancer.  
 XX  
 PS Claim 2; Fig 221; 637pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of antibodies or using a  
 CC reagent. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA (free fatty acid) by skeletal muscle cells, for  
 CC cells, for stimulating differentiation of adipocyte cells, for  
 CC stimulating proliferation of or gene expression in pericyte cells, for  
 CC stimulating the proliferation of inner ear utricular supporting cells or  
 CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
 CC treating various bone and/or cartilage disorders such as sports injuries  
 CC and arthritis. PRO polypeptides which stimulate the release of  
 CC proteoglycans from cartilage are useful for treating sports-related joint  
 CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
 CC arthritis. PRO polypeptides are also useful for treating various  
 CC mammalian haemoglobin-associated disorders such as various thalassaemias  
 CC and conditions which may benefit from enhanced local immune system cell  
 CC infiltration. This sequence represents a human PRO polynucleotide of the  
 CC invention. Note: The sequence data for this patent is also available in  
 CC electronic format from USPTO at seqdata.uspto.gov/sequence.html.  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TCTTAATTTTTCATTCACGATTTCTTCAGTTGGGTTTCTTT 1881  
 DB 1129 TTTTTCATTTTTCATTCACGATTTCTTCAGTTGGGTTTCTTT 1083  
 RESULT 140  
 ID ADC59788/c  
 AC ADC59788 standard; cDNA; 1129 BP.  
 XX  
 AC ADC59788;  
 XX  
 DT 18-DEC-2003 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; FFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003092107-A1.  
 XX  
 PD 15-MAY-2003.  
 XX  
 PF 24-APR-2002; 2002US-0011828.  
 XX  
 PR 07-OCT-1998; 98US-0103315P.  
 PR 01-SEP-1999; 99WO-US020111.  
 PR 18-OCT-1999; 99US-00403297.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CX, Wood WI, Zhang Z;  
 XX



KW rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
KW immune system cell infiltration; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX Homo sapiens.  
XX US2003092105-A1.  
XX 15-MAY-2003.  
XX 24-APR-2002; 2002US-00131821.  
XX 09-DEC-1999; 99US-0170262P.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI: 2003-801170/75.  
DR P-PSDB; ADC59789.  
XX  
XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
PT cancer.  
XX Claim 2; Fig 221; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA (free fatty acid) by skeletal muscle cells or adipocyte  
CC cells, for stimulating differentiation of adipocyte cells, for  
CC stimulating proliferation of or gene expression in pericyte cells, for  
CC stimulating the proliferation of inner ear utricular supporting cells or  
CC T-lymphocyte cells, for inducing endothelial cell tube formation and for  
CC treating various bone and/or cartilage disorders such as sports injuries  
CC and arthritis. PRO polypeptides which stimulate the release of  
CC proteoglycans from cartilage are useful for treating sports-related joint  
CC problems, articular cartilage defects, osteoarthritis and rheumatoid  
CC arthritis. PRO polypeptides are also useful for treating various  
CC mammalian haemoglobin-associated disorders such as various thalassaemias  
CC and conditions which may benefit from enhanced local immune system cell  
CC infiltration. This sequence represents a human PRO polynucleotide of the  
CC invention. Note: The sequence data for this patent is also available in  
CC electronic format from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
XX  
XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 66.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TTCTTAATTTTTCATTCCAGATTTCCTTCAGTTGGGTTTGTGTT 1881

DB 1129 TTTTTCATTTTTCATTTTCAGTGGCACAGCTGGGTTTATT 1083  
RESULT 141  
ID ADC52795/c  
XX ADC52795 standard; cDNA; 1129 BP.  
XX AC ADC52795;  
XX DT 18-DEC-2003 (first entry)  
XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.  
XX KW human; PRO; membrane bound protein; membrane bound receptor;  
KW cell proliferation; cell migration; cell differentiation;  
KW mitogenic factor; survival factor; cytotoxic factor;  
KW differentiation factor; neuropeptide; hormone; cell receptor;  
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.  
XX OS Homo sapiens.  
XX PN US2003087365-A1.  
XX PD 08-MAY-2003.  
XX 23-APR-2002; 2002US-00128689.  
PR 31-MAR-1997; 97WO-US005230.  
PR 12-JUN-1998; 98WO-US012456.  
PR 14-JUL-1998; 98WO-US014552.  
PR 28-AUG-1998; 98WO-US017888.  
PR 10-SEP-1998; 98WO-US018824.  
PR 14-SEP-1998; 98WO-US019093.  
PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 01-DEC-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 99WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 20-APR-1999; 2000WO-US006319.  
PR 14-MAY-1999; 99WO-US008615.  
PR 02-JUN-1999; 99WO-US010733.  
PR 01-SEP-1999; 99WO-US012252.  
PR 08-SEP-1999; 99WO-US020111.  
PR 13-SEP-1999; 99WO-US020594.  
PR 15-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 05-OCT-1999; 99WO-US021547.  
PR 29-NOV-1999; 99WO-US023089.  
PR 30-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 01-DEC-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 02-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 16-DEC-1999; 99WO-US028565.  
PR 20-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 22-DEC-1999; 99WO-US030999.  
PR 30-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.



R 11-FEB-2000; 2000WO-US003565.  
R 18-FEB-2000; 2000WO-US004341.  
R 18-FEB-2000; 2000WO-US004342.  
R 22-FEB-2000; 2000WO-US004414.  
R 24-FEB-2000; 2000WO-US004914.  
R 24-FEB-2000; 2000WO-US005094.  
R 01-MAR-2000; 2000WO-US005601.  
R 02-MAR-2000; 2000WO-US005746.  
R 02-MAR-2000; 2000WO-US005841.  
R 15-MAR-2000; 2000WO-US006884.  
R 20-MAR-2000; 2000WO-US007377.  
R 21-MAR-2000; 2000WO-US007532.  
R 30-MAR-2000; 2000WO-US008439.  
R 17-MAY-2000; 2000WO-US013705.  
R 22-MAY-2000; 2000WO-US014042.  
R 30-MAY-2000; 2000WO-US014941.  
R 02-JUN-2000; 2000WO-US015264.  
R 28-JUL-2000; 2000WO-US020710.  
R 11-AUG-2000; 2000WO-US022031.  
R 23-AUG-2000; 2000WO-US023522.  
R 24-AUG-2000; 2000WO-US023328.  
R 08-NOV-2000; 2000WO-US030952.  
R 10-NOV-2000; 2000WO-US030873.  
R 01-DEC-2000; 2000WO-US032678.  
R 20-DEC-2000; 2000US-00747259.  
R 20-DEC-2000; 2000WO-US034956.  
R 28-FEB-2001; 2001US-00796498.  
R 28-FEB-2001; 2001WO-US006520.  
R 01-MAR-2001; 2001WO-US006666.  
R 09-MAR-2001; 2001US-00802706.  
R 14-MAR-2001; 2001US-00808689.  
R 22-MAR-2001; 2001US-00816744.  
R 05-APR-2001; 2001US-00828366.  
R 10-MAY-2001; 2001US-00854208.  
R 18-MAY-2001; 2001US-00854280.  
R 18-MAY-2001; 2001US-00860216.  
R 25-MAY-2001; 2001US-00866028.  
R 25-MAY-2001; 2001US-00866034.  
R 25-MAY-2001; 2001WO-US017092.  
R 01-JUN-2001; 2001US-00872035.  
R 01-JUN-2001; 2001WO-US017800.  
R 05-JUN-2001; 2001US-00874503.  
R 14-JUN-2001; 2001US-00882636.  
R 19-JUN-2001; 2001US-00896342.  
R 20-JUN-2001; 2001WO-US019692.  
R 21-JUN-2001; 2001US-00887879.  
R 22-JUN-2001; 2001WO-US020116.  
R 29-JUN-2001; 2001WO-US021066.  
R 09-JUL-2001; 2001WO-US021735.  
R 18-JUL-2001; 2001US-00908827.  
R 06-AUG-2001; 2001US-00924419.  
R 09-AUG-2001; 2001US-00927796.  
R 16-AUG-2001; 2001US-00931836.  
R 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.  
Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff B, Gao W;  
Geritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart IA, Tumas D, Watanabe CK, Wood WI, Zhang Z,  
WPI; 2003-801150/75.  
P-PSDB; ADC52796.  
New PRO nucleic acid, useful for manufacturing a medicament for  
diagnosing or treating tumor.  
Claim 2; SEQ ID NO 221; 637pp; English.  
This invention relates to novel nucleic acids encoding human PRO secreted  
and transmembrane proteins. Extracellular proteins play important roles  
in the formation, differentiation and maintenance of multicellular  
organisms. The fate of many individual cells (for example proliferation,

CC and transmembrane proteins. Extracellular proteins play important roles  
CC in the formation, differentiation and maintenance of multicellular  
CC organisms. The fate of many individual cells (for example proliferation,  
CC migration or differentiation) is typically governed by information  
CC received from other cells and the immediate environment. The information  
CC is often transmitted by secreted polypeptides (for example mitogenic  
CC factors, survival factors, cytotoxic factors, differentiation factors,  
CC neuropeptides and hormones) which are received and interpreted by diverse  
CC cell receptors or membrane bound proteins. These membrane bound proteins  
CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
CC as in the blocking of receptor-ligand interactions. The current invention  
CC provides the amino acid sequences of novel human membrane bound receptors  
CC and proteins, along with the cDNA sequences encoding them. The novel  
CC proteins of the invention may have cytostatic activities through the  
CC stimulation of chondrocytes. The nucleic acids of the invention may be  
CC useful for the manufacture of a medicament for diagnosing or treating a  
CC tumour in a mammal. In addition, they may be useful for measuring or  
CC detecting the expression of a tumour associated gene. The present  
CC sequence is a cDNA sequence which encodes a human PRO protein of the  
CC invention.

SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
QY 1835 TTTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881  
DB 1129 TTTTITTTTTTTTTTTTTCAGTGCACACAGGCTGGGTTTATT 1083

RESULT 143  
ADC60340/c  
ID ADC60340 standard; cDNA; 1129 BP.  
XX ADC60340;  
XX  
XX  
XX 18-DEC-2003 (first entry)  
XX  
XX Novel human secreted and transmembrane protein PRO4327 cDNA.  
XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
XX transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
XX chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
XX rectum; kidney; cervix; liver; microvascular endothelial cell;  
XX glucose uptake modulator; FFA uptake modulator; cell proliferation;  
XX cell differentiation; skeletal muscle cell; adipocyte cell;  
XX pericyte cell; inner ear utricular supporting cell; T-lymphocyte cell;  
XX endothelial cell tube formation; bone disorder; cartilage disorder;  
XX sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
XX rheumatoid arthritis; haemoglobin-associated disorder; thalassaemia;  
XX immune system cell infiltration; chromosome mapping; gene mapping; ss.  
XX Gene therapy; chromosome identification; chromosome marker; gene; ss.  
XX Homo sapiens.  
XX  
XX  
XX US2003087367-A1.  
XX  
XX 08-MAY-2003.  
XX  
XX 24-APR-2002; 2002US-00131825.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 16-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.

07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 01-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028501.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 28-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806889.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-0086028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001US-00866034.







```
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127834.
XX 17-SEP-1998; 98US-0100710P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 30-NOV-1999; 99WO-US028313.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801144/75.
XX P-PSDB; ADCS8925.
XX New PRO nucleic acid, useful for preparing a recombinant PRO polypeptide
XX and for manufacturing a medicament for diagnosing or treating tumor.
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neurotrophins or hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred. No. 45;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX QY 1835 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTTGGGTTTGT 1881
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
XX RESULT 149
XX ADCS5802/c
XX ID ADC55802 standard; cDNA; 1129 BP.
XX AC ADC55802;
XX 18-DEC-2003 (first entry)
XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.
XX human; PRO; membrane bound protein; membrane bound receptor;
XX cell proliferation; cell migration; cell differentiation;
XX Mitogenic factor; survival factor; cytotoxic factor;
XX differentiation factor; neurotrophin; hormone; cell receptor;
```

```
KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; gene.
XX Homo sapiens.
XX US2003087360-A1.
XX 08-MAY-2003.
XX 22-APR-2002; 2002US-00127836.
XX 17-NOV-1998; 98US-0108802P.
XX 01-SEP-1999; 99WO-US020111.
XX 18-OCT-1999; 99US-00403297.
XX 18-FEB-2000; 2000WO-US004342.
XX 02-JUN-2000; 2000WO-US015264.
XX 23-AUG-2000; 2000WO-US023522.
XX 01-DEC-2000; 2000WO-US032678.
XX 19-DEC-2001; 2001US-00028072.
XX (GETH ) GENENTECH INC.
XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;
XX Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;
XX WPI; 2003-801145/75.
XX P-PSDB; ADCS5803.
XX New PRO nucleic acid, useful for manufacturing a medicament for
XX diagnosing or treating tumor.
XX Claim 2; SEQ ID NO 221; 637pp; English.
XX This invention relates to novel nucleic acids encoding human PRO secreted
XX and transmembrane proteins. Extracellular proteins play important roles
XX in the formation, differentiation and maintenance of multicellular
XX organisms. The fate of many individual cells (for example proliferation,
XX migration or differentiation) is typically governed by information
XX received from other cells and the immediate environment. The information
XX is often transmitted by secreted polypeptides (for example mitogenic
XX factors, survival factors, cytotoxic factors, differentiation factors,
XX neurotrophins or hormones) which are received and interpreted by diverse
XX cell receptors or membrane bound proteins. These membrane bound proteins
XX and receptors may be of use as pharmaceutical and diagnostic agents, such
XX as in the blocking of receptor-ligand interactions. The current invention
XX provides the amino acid sequences of novel human membrane bound receptors
XX and proteins, along with the cDNA sequences encoding them. The novel
XX proteins of the invention may have cytostatic activities through the
XX stimulation of chondrocytes. The nucleic acids of the invention may be
XX useful for the manufacture of a medicament for diagnosing or treating a
XX tumour in a mammal. In addition, they may be useful for measuring or
XX detecting the expression of a tumour associated gene. The present
XX sequence is a cDNA sequence which encodes a human PRO protein of the
XX invention.
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;
XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;
XX Best Local Similarity 66.0%; Pred. No. 45;
XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;
XX QY 1835 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTTGGGTTTGT 1881
XX Db ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
XX 1129 TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT TTTT
XX RESULT 150
XX ADCS8372/c
XX ID ADCS8372 standard; cDNA; 1129 BP.
XX AC ADCS8372;
XX 18-DEC-2003 (first entry)
```

XX DE Novel human secreted and transmembrane protein cDNA Seq ID221.  
 XX DE human; PRO; membrane bound protein; membrane bound receptor;  
 KW cell proliferation; cell migration; cell differentiation;  
 KW mitogenic factor; survival factor; cytotoxic factor;  
 KW differentiation factor; neuroepithelial; hormone; cell receptor;  
 KW receptor-ligand interaction; cytostatic; chondrocyte; tumour; ss; Gene.  
 XX OS Homo sapiens.  
 XX US2003087346-A1.  
 XX PD 08-MAY-2003.  
 XX PF 17-APR-2002; 2002US-00124815.  
 XX PR 09-DEC-1999; 99US-0170262P.  
 XX PR 01-DEC-2000; 2000WO-US032678.  
 XX PR 19-DEC-2001; 2001US-00028072.  
 XX PA (GETH ) GENENTECH INC.  
 XX PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerstensen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WL, Zhang Z;  
 XX DR WPI; 2003-801137/75.  
 XX DR P-PSDB; ADC58373.  
 XX PT Isolated nucleic acid for use in industrial applications has at least 80  
 PT percent nucleic acid sequence identity to nucleotide sequence that  
 PT encodes amino acid sequence selected from amino acid sequence group.  
 XX PS Claim 2; SEQ ID NO 221; 637pp; English.  
 XX CC This invention relates to novel nucleic acids encoding human PRO secreted  
 CC and transmembrane proteins. Extracellular proteins play important roles  
 CC in the formation, differentiation and maintenance of multicellular  
 CC organisms. The fate of many individual cells (for example proliferation,  
 CC migration or differentiation) is typically governed by information  
 CC received from other cells and the immediate environment. The information  
 CC is often transmitted by secreted polypeptides (for example mitogenic  
 CC factors, survival factors, cytotoxic factors, differentiation factors,  
 CC neuropeptides and hormones) which are received and interpreted by diverse  
 CC cell receptors or membrane bound proteins. These membrane bound proteins  
 CC and receptors may be of use as pharmaceutical and diagnostic agents, such  
 CC as in the blocking of receptor-ligand interactions. The current invention  
 CC provides the amino acid sequences of novel human membrane bound receptors  
 CC and proteins, along with the cDNA sequences encoding them. The novel  
 CC proteins of the invention may have cytostatic activities through the  
 CC stimulation of chondrocytes. The nucleic acids of the invention may be  
 CC useful for the manufacture of a medicament for diagnosing or treating a  
 CC tumour in a mammal. In addition, they may be useful for measuring or  
 CC detecting the expression of a tumour associated gene. The present  
 CC sequence is a cDNA sequence which encodes a human PRO protein of the  
 CC invention.  
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Fred. NO. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTGT 1881  
 DB 1129 TTTTTTTTTTTTTTTTCAGTGGCACACAGCGTGGGTTTATT 1083  
 RESULT 151  
 ADD03046/c  
 ID ADD03046 standard; cDNA; 1129 BP.  
 XX

AC ADD03046;  
 XX 01-JAN-2004 (first entry)  
 XX Novel human secreted and transmembrane protein PRO4327 cDNA.  
 XX Human; secreted and transmembrane protein; PRO; secreted polypeptide;  
 KW transmembrane polypeptide; tumour necrosis factor-alpha; TNF-alpha;  
 KW chondrocyte; tumour; cancer; adrenal; lung; colon; breast; prostate;  
 KW rectum; kidney; cervix; liver; microvascular endothelial cell;  
 KW glucose uptake modulator; PFA uptake modulator; cell proliferation;  
 KW cell differentiation; skeletal muscle cell; adipocyte cell;  
 KW pericytes cell; inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder; thalassemia;  
 KW immune system cell infiltration; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker; gene; ss.  
 XX OS Homo sapiens.  
 XX US2003092104-A1.  
 XX PD 15-MAY-2003.  
 XX PF 24-APR-2002; 2002US-00131817.  
 XX PR 31-MAR-1997; 97WO-US005230.  
 XX PR 12-JUN-1998; 98WO-US012456.  
 XX PR 14-JUL-1998; 98WO-US014552.  
 XX PR 28-AUG-1998; 98WO-US017888.  
 XX PR 10-SEP-1998; 98WO-US018824.  
 XX PR 14-SEP-1998; 98WO-US019093.  
 XX PR 14-SEP-1998; 98WO-US019094.  
 XX PR 14-SEP-1998; 98WO-US019177.  
 XX PR 16-SEP-1998; 98WO-US019330.  
 XX PR 17-SEP-1998; 98WO-US019437.  
 XX PR 07-OCT-1998; 98WO-US021141.  
 XX PR 29-OCT-1998; 98WO-US022991.  
 XX PR 29-OCT-1998; 98WO-US022992.  
 XX PR 20-NOV-1998; 98WO-US024855.  
 XX PR 01-DEC-1998; 98WO-US025108.  
 XX PR 05-JAN-1999; 99WO-US000106.  
 XX PR 08-MAR-1999; 99WO-US005028.  
 XX PR 10-MAR-1999; 99WO-US005190.  
 XX PR 20-APR-1999; 99WO-US008615.  
 XX PR 14-MAY-1999; 99WO-US010733.  
 XX PR 02-JUN-1999; 99WO-US012252.  
 XX PR 01-SEP-1999; 99WO-US020111.  
 XX PR 08-SEP-1999; 99WO-US020594.  
 XX PR 13-SEP-1999; 99WO-US020944.  
 XX PR 15-SEP-1999; 99WO-US021090.  
 XX PR 15-SEP-1999; 99WO-US021547.  
 XX PR 05-OCT-1999; 99WO-US023089.  
 XX PR 29-NOV-1999; 99WO-US028214.  
 XX PR 30-NOV-1999; 99WO-US028313.  
 XX PR 30-NOV-1999; 99WO-US028409.  
 XX PR 01-DEC-1999; 99WO-US028301.  
 XX PR 01-DEC-1999; 99WO-US028634.  
 XX PR 02-DEC-1999; 99WO-US028551.  
 XX PR 02-DEC-1999; 99WO-US028564.  
 XX PR 02-DEC-1999; 99WO-US028565.  
 XX PR 16-DEC-1999; 99WO-US030095.  
 XX PR 20-DEC-1999; 99WO-US030911.  
 XX PR 20-DEC-1999; 99WO-US030999.  
 XX PR 22-DEC-1999; 99WO-US030720.  
 XX PR 30-DEC-1999; 99WO-US031243.  
 XX PR 30-DEC-1999; 99WO-US031274.  
 XX PR 05-JAN-2000; 2000WO-US000219.  
 XX PR 06-JAN-2000; 2000WO-US000277.  
 XX PR 06-JAN-2000; 2000WO-US000375.  
 XX PR 11-FEB-2000; 2000WO-US003565.  
 XX PR 18-FEB-2000; 2000WO-US004341.































10-MAY-2002; 2002US-00142886.  
05-JUN-2000; 2000US-0209832P.  
01-DEC-2000; 2000WO-US032678.  
19-DEC-2001; 2001US-00028072.  
(GETH ) GENENTECH INC.  
Baker KP, Bersini M, Deforge L, Deenoyers L, Filvaroff E, Gao W;  
Grittens ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
WPI: 2003-875639/81.  
P-PSDB; ADD54039.  
New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or  
PRO4978, useful in molecular biology, chromosome and gene mapping, in  
generating antisense RNA and DNA, and in gene therapy.  
Claim 2; SEQ ID NO 221; 637bp; English.  
The invention describes 305 nucleic acids encoding PRO (secreted and  
transmembrane) polypeptides (I). (I) is useful for stimulating the  
release of TNF-alpha from human blood, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating the proliferation or differentiation of chondrocyte cells,  
for stimulating the proliferation or gene expression in pericyte  
cells, for stimulating the release of proteoglycans from cartilage, for  
stimulating the proliferation of inner ear utricular supporting cells,  
for stimulating the proliferation of T-lymphocyte cells, for stimulating  
the release of a cytokine from PBMC cells, for inhibiting the binding of  
A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
cells, for stimulating proliferation of endothelial cells, for detecting  
the presence of tumour in a mammal. The tumour is lung, colon, breast,  
prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
are useful for isolating genomic and cDNA nucleotide sequences or  
antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
in assays to identify other proteins or molecules involved in binding  
interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
and gene mapping, in generation of antisense RNA and DNA, in the  
preparation of PRO polypeptide, for generating transgenic animals or  
knockout animals which in turn are useful in the development and  
screening of therapeutically useful reagents, in gene therapy, for  
chromosome identification, as chromosome marker, and for generating  
probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
detecting its expression in specific cells, tissues or serum, and for  
affinity purification of PRO from recombinant cell culture or natural  
sources. (I) and (II) are useful for tissue typing. This sequence encodes  
a novel human secreted and transmembrane PRO polypeptide.  
Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
QY 1835 TCCTTAATTTTTCATTTCAGATTTTCCTTCAGTTTGGGTTTGTTT 1881  
||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||  
Db 1129 TTTTITTTTTTTTTTTTTTTCAGTGGCACACAGCGTGGTGTTTATT 1083  
RESULT 170  
ADD92355/c  
ID ADD92355 standard; cDNA; 1129 BP.  
XX  
AC ADD92355;  
XX  
DT 29-JAN-2004 (first entry)  
XX  
DE Human PRO polynucleotide #111.  
XX  
KW Human; gere; ss; PRO; secreted polypeptide; transmembrane polypeptide;







OS Homo sapiens.  
XX US2003199057-A1.  
XX 23-OCT-2003.  
XX  
XX  
XX 15-APR-2002; 2002US-00123213.  
XX  
XX 31-MAR-1997; 97WO-US005230.  
XX 12-JUN-1998; 98WO-US012456.  
XX 14-JUL-1998; 98WO-US014552.  
XX 28-AUG-1998; 98WO-US017888.  
XX 10-SEP-1998; 98WO-US018824.  
XX 14-SEP-1998; 98WO-US019093.  
XX 14-SEP-1998; 98WO-US019094.  
XX 14-SEP-1998; 98WO-US019177.  
XX 16-SEP-1998; 98WO-US019330.  
XX 17-SEP-1998; 98WO-US019437.  
XX 07-OCT-1998; 98WO-US021141.  
XX 29-OCT-1998; 98WO-US022991.  
XX 29-OCT-1998; 98WO-US022992.  
XX 20-NOV-1998; 98WO-US024855.  
XX 01-DEC-1998; 98WO-US025108.  
XX 05-JAN-1999; 99WO-US000106.  
XX 08-MAR-1999; 99WO-US005028.  
XX 10-MAR-1999; 99WO-US005190.  
XX 20-APR-1999; 99WO-US008615.  
XX 14-MAY-1999; 99WO-US010733.  
XX 02-JUN-1999; 99WO-US012252.  
XX 01-SEP-1999; 99WO-US020111.  
XX 08-SEP-1999; 99WO-US020594.  
XX 13-SEP-1999; 99WO-US020944.  
XX 15-SEP-1999; 99WO-US021090.  
XX 15-SEP-1999; 99WO-US021547.  
XX 05-OCT-1999; 99WO-US023089.  
XX 29-NOV-1999; 99WO-US028214.  
XX 30-NOV-1999; 99WO-US028313.  
XX 30-NOV-1999; 99WO-US028409.  
XX 01-DEC-1999; 99WO-US028301.  
XX 01-DEC-1999; 99WO-US028634.  
XX 02-DEC-1999; 99WO-US028551.  
XX 02-DEC-1999; 99WO-US028564.  
XX 02-DEC-1999; 99WO-US028565.  
XX 16-DEC-1999; 99WO-US030095.  
XX 20-DEC-1999; 99WO-US030911.  
XX 20-DEC-1999; 99WO-US030999.  
XX 22-DEC-1999; 99WO-US030720.  
XX 30-DEC-1999; 99WO-US031243.  
XX 30-DEC-1999; 99WO-US031274.  
XX 05-JAN-2000; 2000WO-US000219.  
XX 06-JAN-2000; 2000WO-US000277.  
XX 06-JAN-2000; 2000WO-US000376.  
XX 11-FEB-2000; 2000WO-US003565.  
XX 18-FEB-2000; 2000WO-US004341.  
XX 18-FEB-2000; 2000WO-US004342.  
XX 22-FEB-2000; 2000WO-US004414.  
XX 24-FEB-2000; 2000WO-US004914.  
XX 24-FEB-2000; 2000WO-US005004.  
XX 01-MAR-2000; 2000WO-US005501.  
XX 02-MAR-2000; 2000WO-US005746.  
XX 02-MAR-2000; 2000WO-US005841.  
XX 15-MAR-2000; 2000WO-US006884.  
XX 20-MAR-2000; 2000WO-US007377.  
XX 21-MAR-2000; 2000WO-US007532.  
XX 30-MAR-2000; 2000WO-US008439.  
XX 17-MAY-2000; 2000WO-US013705.  
XX 22-MAY-2000; 2000WO-US014042.  
XX 30-MAY-2000; 2000WO-US014941.  
XX 02-JUN-2000; 2000WO-US015264.  
XX 28-JUN-2000; 2000WO-US020710.  
XX 11-AUG-2000; 2000WO-US022031.  
XX 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2003-900167/82.  
DR P-PSDB; ADE03866.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 2; Fig 221; 637pp; English.  
CC The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 AC ADE32162;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE Novel human secreted and transmembrane protein PRO4327 cDNA.  
 XX  
 KW Human; secreted and transmembrane protein; PRO; gene; ss;  
 KW Tumour necrosis factor alpha release; TNF-alpha release;  
 KW glucose uptake modulator; FFA uptake modulator;  
 KW cell proliferation stimulator; cell differentiation stimulator;  
 KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
 KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
 KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
 KW gene therapy; chromosome identification; chromosome marker.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003194765-A1.  
 XX  
 PD 16-OCT-2003.  
 XX  
 PF 09-MAY-2002; 2002US-00142889.  
 XX  
 PR 03-MAR-2000; 2000US-0187202P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX  
 PA (GETH) GENENTECH INC.  
 XX  
 PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX  
 DR WPI; 2003-899784/82.  
 DR P-PSDB; ADE32163.  
 XX  
 PT Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 PT useful for treating pericyte-associated tumors, diabetes and various bone  
 PT and/or cartilage disorders, e.g. arthritis.  
 XX  
 PS Claim 2; SEQ ID NO 221; 636pp; English.  
 XX  
 CC The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,

CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from FMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC and gene mapping. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTTCCAGATTTCCTTCAGTTTCGGTTTGTGTTT 1881  
 DB 1129 TTTTITTTTTTTTTTTTTTTTTCAGTGGCACACAGCTGGGTTTTATT 1083  
 RESULT 174  
 ADE22094/c  
 ID ADE22094 standard; cDNA; 1129 BP.  
 XX  
 AC ADE22094;  
 XX  
 DT 29-JAN-2004 (first entry)  
 XX  
 DE cDNA encoding human PRO polypeptide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 PN US2003199056-A1.  
 XX  
 PD 23-OCT-2003.  
 XX  
 PF 15-APR-2002; 2002US-00123212.  
 XX  
 PR 31-MAR-1997; 97WO-US005230.  
 PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.  
 PR 14-SEP-1998; 98WO-US019094.  
 PR 14-SEP-1998; 98WO-US019177.  
 PR 16-SEP-1998; 98WO-US019330.

PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 98WO-US005028.  
PR 10-MAR-1999; 98WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020949.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 05-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030311.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 01-MAR-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006666.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-900166/82.  
DR P-PSDB; ADE22095.  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX Claim 2; Fig 221; 638pp; English.  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC the proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems, PRO  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at [seqdata.uspto.gov](http://seqdata.uspto.gov).  
XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;



[illegible]

PR 28-FEB-2001; 2001US-00796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00806689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00826366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019592.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
DR WPI; 2003-900155/82.  
DR E-PSDB; ADEI7672.  
XX  
XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
PT useful for treating pericyte-associated tumors, diabetes and various bone  
PT and/or cartilage disorders, e.g. arthritis.  
XX  
XX Claim 2; SEQ ID NO 221; 637pp; English.  
XX  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC Glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassemias and conditions which





KW cell differentiation inhibitor; cytokine release stimulator; tumour;  
KW lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;  
KW cervical tumour; liver tumour; chromosome mapping; gene mapping;  
KW gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

XX US2003194767-A1.

XX 16-OCT-2003.

XX 16-MAY-2002; 2002US-00147497.

XX 26-AUG-1998; 98US-0097951P.

XX 02-JUN-1999; 99WO-US012252.

XX 25-AUG-1999; 99WO-US0380137.

XX 30-MAR-2000; 2000WO-US008439.

XX 01-DEC-2000; 2000WO-US032678.

XX 19-DEC-2001; 2001US-00028072.

XX (GETH ) GENENTECH INC.

XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

XX Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;

XX WPI; 2003-899786/82.

XX P-PSDB; ADE33267.

XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,

XX useful for treating pericyte-associated tumors, diabetes and various bone

XX and/or cartilage disorders, e.g. arthritis.

XX Claim 2; SEQ ID NO 221; 636pp; English.

XX The invention describes 305 nucleic acids encoding PRO (secreted and

XX transmembrane) polypeptides (I). (I) is useful for stimulating the

XX release of TNF-alpha from human blood, for modulating the uptake of

XX glucose or FFA by skeletal muscle cells or adipocyte cells, for

XX stimulating the proliferation or differentiation of chondrocyte cells,

XX for stimulating the proliferation of or gene expression in paricycle

XX cells, for stimulating the release of proteoglycans from cartilage, for

XX stimulating the proliferation of inner ear utricular supporting cells,

XX for stimulating the proliferation of T-lymphocyte cells, for stimulating

XX the release of a cytokine from PBMC cells, for inhibiting the binding of

XX A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte

XX cells, for stimulating proliferation of endothelial cells, for detecting

XX the presence of tumour in a mammal. The tumour is lung, colon, breast,

XX prostate, rectal, cervical or liver tumour. The oligonucleotide probes

XX are useful for isolating genomic and cDNA nucleotide sequences or

XX antisense probes. (I) is also useful as therapeutic agent. PRO is useful

XX in assays to identify other proteins or molecules involved in binding

XX interaction. A polynucleotide (II) encoding (I) is useful in chromosome

XX and gene mapping, in generation of antisense RNA and DNA, in the

XX preparation of PRO polypeptide, for generating transgenic animals or

XX knockout animals which in turn are useful in the development and

XX screening of therapeutically useful reagents, in gene therapy, for

XX chromosome identification, as chromosome marker, and for generating

XX probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.

XX detecting its expression in specific cells, tissues or serum, and for

XX affinity purification of PRO from recombinant cell culture or natural

XX sources. (I) and (II) are useful for tissue typing. This sequence encodes

XX a novel human secreted and transmembrane PRO polypeptide.

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

XX Query Match 1.1%; Score 21.4; DB 1; Length 1129;

XX Best Local Similarity 66.0%; Pred. No. 45;

XX Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

QY 1835 TCTTAATTTTCATTTCAGATTCCTTCAGTTTGGTTTGTGT 1881

DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCGGTGTTTATT 1083

RESULT 180  
ADE33815/c

ID ADE33818 standard; cDNA; 1129 BP.

XX ADE33818;

AC ADE33818;

XX 29-JAN-2004 (first entry)

DT 29-JAN-2004 (first entry)

XX Novel human secreted and transmembrane protein PRO4327 cDNA.

DE Human; secreted and transmembrane protein; PRO; gene; ss;

XX Tumour necrosis factor alpha release; TNF-alpha release;

XX glucose uptake modulator; FFA uptake modulator;

XX cell proliferation stimulator; cell differentiation stimulator;

XX cell differentiation inhibitor; cytokine release stimulator; tumour;

XX lung tumour; colon tumour; breast tumour; prostate tumour; rectal tumour;

XX cervical tumour; liver tumour; chromosome mapping; gene mapping;

XX gene therapy; chromosome identification; chromosome marker.

XX Homo sapiens.

OS Homo sapiens.

XX US2003194791-A1.

XX 16-OCT-2003.

XX 11-APR-2002; 2002US-00121046.

XX 31-MAR-1997; 97WO-US005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US014552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 14-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US005028.

XX 10-MAR-1999; 99WO-US005190.

XX 20-MAR-1999; 2000WO-US006319.

XX 20-APR-1999; 99WO-US008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012252.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020944.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

XX 01-DEC-1999; 99WO-US028301.

XX 01-DEC-1999; 99WO-US028634.

XX 02-DEC-1999; 99WO-US028551.

XX 02-DEC-1999; 99WO-US028564.

XX 16-DEC-1999; 99WO-US030095.

XX 20-DEC-1999; 99WO-US030911.

XX 20-DEC-1999; 99WO-US030999.

XX 22-DEC-1999; 99WO-US030720.

XX 30-DEC-1999; 99WO-US031243.

XX 05-JAN-1999; 99WO-US031274.

XX 06-JAN-2000; 2000WO-US000219.

XX 06-JAN-2000; 2000WO-US000277.

PR 06-JAN-2000; 2000WO-US000376.  
 PR 11-FEB-2000; 2000WO-US000365.  
 PR 18-FEB-2000; 2000WO-US004341.  
 PR 18-FEB-2000; 2000WO-US004342.  
 PR 22-FEB-2000; 2000WO-US004414.  
 PR 24-FEB-2000; 2000WO-US004914.  
 PR 01-MAR-2000; 2000WO-US005004.  
 PR 02-MAR-2000; 2000WO-US005501.  
 PR 02-MAR-2000; 2000WO-US005746.  
 PR 02-MAR-2000; 2000WO-US005841.  
 PR 15-MAR-2000; 2000WO-US006884.  
 PR 20-MAR-2000; 2000WO-US007377.  
 PR 21-MAR-2000; 2000WO-US007532.  
 PR 30-MAR-2000; 2000WO-US008439.  
 PR 17-MAY-2000; 2000WO-US013705.  
 PR 22-MAY-2000; 2000WO-US014042.  
 PR 30-MAY-2000; 2000WO-US014541.  
 PR 02-JUN-2000; 2000WO-US015264.  
 PR 28-JUL-2000; 2000WO-US020710.  
 PR 11-AUG-2000; 2000WO-US022031.  
 PR 23-AUG-2000; 2000WO-US023522.  
 PR 24-AUG-2000; 2000WO-US023328.  
 PR 08-NOV-2000; 2000WO-US030352.  
 PR 10-NOV-2000; 2000WO-US030873.  
 PR 01-DEC-2000; 2000WO-US032578.  
 PR 20-DEC-2000; 2000US-00747259.  
 PR 20-DEC-2000; 2000WO-US034956.  
 PR 28-FEB-2001; 2001WO-US006520.  
 PR 01-MAR-2001; 2001WO-US006520.  
 PR 09-MAR-2001; 2001WO-US006566.  
 PR 14-MAR-2001; 2001US-00802706.  
 PR 22-MAR-2001; 2001US-00808689.  
 PR 05-APR-2001; 2001US-00816744.  
 PR 10-MAY-2001; 2001US-00828366.  
 PR 10-MAY-2001; 2001US-00854208.  
 PR 18-MAY-2001; 2001US-00854280.  
 PR 25-MAY-2001; 2001US-00860216.  
 PR 25-MAY-2001; 2001US-00866028.  
 PR 25-MAY-2001; 2001US-00866034.  
 PR 25-MAY-2001; 2001WO-US017092.  
 PR 01-JUN-2001; 2001US-00872035.  
 PR 01-JUN-2001; 2001WO-US017900.  
 PR 05-JUN-2001; 2001US-00874503.  
 PR 14-JUN-2001; 2001US-00882636.  
 PR 19-JUN-2001; 2001US-00886342.  
 PR 20-JUN-2001; 2001WO-US019592.  
 PR 21-JUN-2001; 2001US-00887879.  
 PR 22-JUN-2001; 2001WO-US020116.  
 PR 29-JUN-2001; 2001WO-US021066.  
 PR 09-JUL-2001; 2001WO-US021735.  
 PR 18-JUL-2001; 2001US-00908927.  
 PR 06-AUG-2001; 2001US-00924419.  
 PR 09-AUG-2001; 2001US-00927796.  
 PR 16-AUG-2001; 2001US-00931836.  
 PR 19-DEC-2001; 2001US-00028072.  
 (GETH ) GENENTECH INC.  
 Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 Gerlitsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 Smith V, Stewart TA, Tamas D, Watanabe CK, Wood WI, Zhang Z;  
 WPI; 2003-899790/82.  
 P-PSDB; ADE33819.  
 Two hundred and seventy five nucleic acids encoding PRO polypeptides.  
 useful for treating pericyte-associated tumors, diabetes and various bone  
 and/or cartilage disorders, e.g. arthritis.  
 Claim 2; SEQ ID NO 221; 636pp; English.  
 The invention describes 305 nucleic acids encoding PRO (secreted and  
 transmembrane) polypeptides (I). (I) is useful for stimulating the

CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from PMC cells, for inhibiting the binding of  
 CC A-peptide to factor VIIA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTCCAGATTCTCTTCAGTTGGTTGGTTTGT 1881  
 DB 1129 TTTTITTTTTTTTTTTTTCAGTGGCACACAGGCTGGTTTATT 1083  
 RESULT 181  
 ADD79870/c  
 ID ADD79870 standard; cDNA; 1129 BP.  
 XX AC ADD79870;  
 XX DT 29-JAN-2004 (first entry)  
 XX DE cDNA encoding human PRO polypeptide #111.  
 XX KW Human; Gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX OS Homo sapiens.  
 XX US US2003207417-A1.  
 XX PN 06-NOV-2003.  
 XX PD 07-MAY-2002; 2002US-00140805.  
 XX PF 31-MAR-1997; 97WO-US005230.  
 XX PR 12-JUN-1998; 98WO-US012456.  
 PR 14-JUL-1998; 98WO-US014552.  
 PR 28-AUG-1998; 98WO-US017888.  
 PR 10-SEP-1998; 98WO-US018824.  
 PR 14-SEP-1998; 98WO-US019093.

PR 14-SEP-1998; 98WO-US019094.  
PR 14-SEP-1998; 98WO-US019177.  
PR 16-SEP-1998; 98WO-US019330.  
PR 17-SEP-1998; 98WO-US019437.  
PR 07-OCT-1998; 98WO-US021141.  
PR 29-OCT-1998; 98WO-US022991.  
PR 29-OCT-1998; 98WO-US022992.  
PR 20-NOV-1998; 98WO-US024855.  
PR 01-DEC-1998; 98WO-US025108.  
PR 05-JAN-1999; 98WO-US000106.  
PR 08-MAR-1999; 99WO-US005028.  
PR 10-MAR-1999; 99WO-US005190.  
PR 10-MAR-1999; 2000WO-US006319.  
PR 20-APR-1999; 99WO-US008615.  
PR 14-MAY-1999; 99WO-US010733.  
PR 02-JUN-1999; 99WO-US012252.  
PR 01-SEP-1999; 99WO-US020111.  
PR 08-SEP-1999; 99WO-US020594.  
PR 13-SEP-1999; 99WO-US020944.  
PR 15-SEP-1999; 99WO-US021090.  
PR 15-SEP-1999; 99WO-US021547.  
PR 03-OCT-1999; 99WO-US023089.  
PR 29-NOV-1999; 99WO-US028214.  
PR 30-NOV-1999; 99WO-US028313.  
PR 30-NOV-1999; 99WO-US028409.  
PR 01-DEC-1999; 99WO-US028301.  
PR 01-DEC-1999; 99WO-US028634.  
PR 02-DEC-1999; 99WO-US028551.  
PR 02-DEC-1999; 99WO-US028564.  
PR 02-DEC-1999; 99WO-US028565.  
PR 16-DEC-1999; 99WO-US030095.  
PR 20-DEC-1999; 99WO-US030911.  
PR 20-DEC-1999; 99WO-US030999.  
PR 22-DEC-1999; 99WO-US030720.  
PR 30-DEC-1999; 99WO-US031243.  
PR 30-DEC-1999; 99WO-US031274.  
PR 05-JAN-2000; 2000WO-US000219.  
PR 06-JAN-2000; 2000WO-US000277.  
PR 06-JAN-2000; 2000WO-US000376.  
PR 11-FEB-2000; 2000WO-US003565.  
PR 18-FEB-2000; 2000WO-US004341.  
PR 18-FEB-2000; 2000WO-US004342.  
PR 22-FEB-2000; 2000WO-US004414.  
PR 24-FEB-2000; 2000WO-US004914.  
PR 24-FEB-2000; 2000WO-US005004.  
PR 01-MAR-2000; 2000WO-US005601.  
PR 02-MAR-2000; 2000WO-US005746.  
PR 02-MAR-2000; 2000WO-US005841.  
PR 15-MAR-2000; 2000WO-US006884.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032678.  
PR 20-DEC-2000; 2000US-0074259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001WO-US0796498.  
PR 28-FEB-2001; 2001WO-US006520.  
PR 01-MAR-2001; 2001WO-US006566.  
PR 03-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019692.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2003-875867/81.  
DR P-PSDB; ADD79871.  
XX  
PT New PRO nucleic acid, useful for manufacturing a medicament for  
diagnosing or treating tumor, for chromosome mapping or for tissue  
typing.  
XX  
PS Claim 2; Fig 221; 638pp; English.  
XX  
CC The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumor necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or  
antibodies, such as tumours, for stimulating and inhibiting proliferation  
of human microvascular endothelial cells, for modulating the uptake of  
glucose or FFA by skeletal muscle cells or adipocyte cells, for  
stimulating differentiation of adipocyte cells, for stimulating  
proliferation of or gene expression in pericyte cells, for stimulating  
the proliferation of inner ear utricular supporting cells or T-lymphocyte  
cells, for inducing endothelial cell tube formation and for treating  
various bone and/or cartilage disorders such as sports injuries and  
arthritis. PRO polypeptides which stimulate the release of proteoglycans  
from cartilage are useful for treating sports-related joint problems,  
articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
polypeptides are also useful for treating various mammalian haemoglobin-  
associated disorders such as various thalassemias and conditions which  
may benefit from enhanced local immune system cell infiltration. This  
sequence encodes a human PRO polypeptide of the invention. Note: The  
sequence data for this patent is also available in electronic format from  
the USPTO website at seqdata.uspto.gov.  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;





AC ADE42971;  
 XX 29-JAN-2004 (first entry)  
 XX Human PRO polynucleotide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003199033-A1.  
 XX  
 XX 23-OCT-2003.  
 XX  
 XX 28-MAY-2002; 2002US-00156845.  
 XX  
 XX 05-JUN-2000; 2000US-0209832P.  
 XX 01-DEC-2000; 2000WO-US032678.  
 XX 19-DEC-2001; 2001US-00028072.  
 XX  
 XX (GETH ) GENENTECH INC.  
 XX  
 XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
 XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 XX Smith V, Stewart RA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-900162/82.  
 XX P-PSDB; ADE42972.  
 XX  
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 XX useful for treating pericyte-associated tumors, diabetes and various bone  
 XX and/or cartilage disorders, e.g. arthritis.  
 XX  
 XX Claim 2; Fig 221; 636pp; English.  
 XX  
 CC The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems,  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).  
 XX  
 SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTTCTAATTTTTCATTTCCAGATTTCCTTCAGTTGGGTTTCTTT 1881  
 Db 1129 TTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTTCTTTT 1083  
 RESULT 186  
 ADD95760/C  
 ID ADD95760 standard; cDNA; 1129 BP.  
 XX  
 XX ADD95760;  
 XX  
 XX 29-JAN-2004 (first entry)  
 XX  
 XX Human PRO polynucleotide #111.  
 XX  
 KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
 KW immune system cell infiltration.  
 XX  
 OS Homo sapiens.  
 XX  
 XX US2003199059-A1.  
 XX  
 XX 23-OCT-2003.  
 XX  
 XX 15-APR-2002; 2002US-00123322.  
 XX  
 XX 31-MAR-1997; 97WO-US005230.  
 XX 12-JUN-1998; 98WO-US012456.  
 XX 14-JUL-1998; 98WO-US014552.  
 XX 28-AUG-1998; 98WO-US017888.  
 XX 10-SEP-1998; 98WO-US018824.  
 XX 14-SEP-1998; 98WO-US019093.  
 XX 14-SEP-1998; 98WO-US019094.  
 XX 14-SEP-1998; 98WO-US019177.  
 XX 16-SEP-1998; 98WO-US019330.  
 XX 17-SEP-1998; 98WO-US019437.  
 XX 07-OCT-1998; 98WO-US021141.  
 XX 29-OCT-1998; 98WO-US022991.  
 XX 20-NOV-1998; 98WO-US024855.  
 XX 01-DEC-1998; 98WO-US025108.  
 XX 05-JAN-1999; 99WO-US000106.  
 XX 08-MAR-1999; 99WO-US005028.  
 XX 10-MAR-1999; 99WO-US005190.  
 XX 20-APR-1999; 2000WO-US006319.  
 XX 14-MAY-1999; 99WO-US010733.  
 XX 02-JUN-1999; 99WO-US012252.  
 XX 01-SEP-1999; 99WO-US020111.  
 XX 08-SEP-1999; 99WO-US020594.  
 XX 13-SEP-1999; 99WO-US020944.  
 XX 15-SEP-1999; 99WO-US021090.  
 XX 15-SEP-1999; 99WO-US021547.  
 XX 05-OCT-1999; 99WO-US023089.





10664775-3.rng

Mon Aug 9 17:47:19 2004

KW	skeletal muscle cell; adipocyte cell; pericyte cell;	PR	17-MAY-2000; 2000WO-US013705.
KW	inner ear utricular supporting cell; T-lymphocyte cell;	PR	30-MAY-2000; 2000WO-US014042.
KW	endothelial cell tube formation; bone disorder; cartilage disorder;	PR	02-JUN-2000; 2000WO-US014541.
KW	sports injury; proteoglycan; articular cartilage defect; osteoarthritis;	PR	28-JUL-2000; 2000WO-US020710.
KW	rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;	PR	11-AUG-2000; 2000WO-US020321.
KW	immune system cell infiltration.	PR	23-AUG-2000; 2000WO-US023522.
XX		PR	24-AUG-2000; 2000WO-US023328.
OS	Homo sapiens.	PR	08-NOV-2000; 2000WO-US030952.
XX		PR	10-NOV-2000; 2000WO-US030873.
XX		PR	01-DEC-2000; 2000WO-US032678.
XX		PR	20-DEC-2000; 2000US-00747259.
PD		PR	20-DEC-2000; 2000WO-US034956.
XX		PR	28-FEB-2001; 2001US-00796498.
PF	19-APR-2002; 2002US-00125932.	PR	28-FEB-2001; 2001WO-US006520.
XX		PR	01-MAR-2001; 2001WO-US006566.
XX		PR	09-MAR-2001; 2001US-00802706.
PR	31-MAR-1997; 97WO-US005230.	PR	14-MAR-2001; 2001US-00816744.
PR	12-JUN-1998; 98WO-US012456.	PR	22-MAR-2001; 2001US-00828366.
PR	14-JUL-1998; 98WO-US014552.	PR	05-APR-2001; 2001US-00854280.
PR	28-AUG-1998; 98WO-US017888.	PR	10-MAY-2001; 2001US-00860216.
PR	10-SEP-1998; 98WO-US018824.	PR	18-MAY-2001; 2001US-00866028.
PR	14-SEP-1998; 98WO-US019093.	PR	25-MAY-2001; 2001US-00866034.
PR	14-SEP-1998; 98WO-US019177.	PR	25-MAY-2001; 2001WO-US017092.
PR	16-SEP-1998; 98WO-US019330.	PR	01-JUN-2001; 2001US-00872035.
PR	17-SEP-1998; 98WO-US019437.	PR	01-JUN-2001; 2001WO-US017800.
PR	07-OCT-1998; 98WO-US021141.	PR	05-JUN-2001; 2001US-00874503.
PR	29-OCT-1998; 98WO-US022991.	PR	14-JUN-2001; 2001US-00882636.
PR	29-OCT-1998; 98WO-US022992.	PR	19-JUN-2001; 2001US-00886342.
PR	20-NOV-1998; 98WO-US024855.	PR	20-JUN-2001; 2001WO-US015692.
PR	01-DEC-1998; 98WO-US025108.	PR	21-JUN-2001; 2001US-00887879.
PR	05-JAN-1999; 99WO-US000106.	PR	22-JUN-2001; 2001WO-US020116.
PR	08-MAR-1999; 99WO-US005028.	PR	29-JUN-2001; 2001WO-US021066.
PR	10-MAR-1999; 99WO-US005190.	PR	09-JUL-2001; 2001WO-US021735.
PR	10-MAR-1999; 2000WO-US006319.	PR	18-JUL-2001; 2001US-00908827.
PR	20-APR-1999; 99WO-US008615.	PR	06-AUG-2001; 2001US-00924419.
PR	14-MAY-1999; 99WO-US010733.	PR	09-AUG-2001; 2001US-00927796.
PR	02-JUN-1999; 99WO-US012252.	PR	16-AUG-2001; 2001US-00931836.
PR	01-SEP-1999; 99WO-US020111.	PR	19-DEC-2001; 2001US-00028072.
PR	08-SEP-1999; 99WO-US020394.	XX	
PR	13-SEP-1999; 99WO-US020944.	XX	
PR	15-SEP-1999; 99WO-US021090.	XX	
PR	15-SEP-1999; 99WO-US021547.	XX	
PR	05-OCT-1999; 99WO-US023089.	XX	
PR	29-NOV-1999; 99WO-US028214.	XX	
PR	30-NOV-1999; 99WO-US028313.	XX	
PR	30-NOV-1999; 99WO-US028409.	XX	
PR	01-DEC-1999; 99WO-US028301.	XX	
PR	01-DEC-1999; 99WO-US028634.	XX	
PR	02-DEC-1999; 99WO-US028551.	XX	
PR	02-DEC-1999; 99WO-US028564.	XX	
PR	16-DEC-1999; 99WO-US030095.	XX	
PR	20-DEC-1999; 99WO-US030911.	XX	
PR	20-DEC-1999; 99WO-US030999.	XX	
PR	22-DEC-1999; 99WO-US030720.	XX	
PR	30-DEC-1999; 99WO-US031243.	XX	
PR	30-DEC-1999; 99WO-US031274.	XX	
PR	05-JAN-2000; 2000WO-US000219.	XX	
PR	06-JAN-2000; 2000WO-US000277.	XX	
PR	11-FEB-2000; 2000WO-US000376.	XX	
PR	18-FEB-2000; 2000WO-US003565.	XX	
PR	18-FEB-2000; 2000WO-US004341.	XX	
PR	22-FEB-2000; 2000WO-US004342.	XX	
PR	24-FEB-2000; 2000WO-US004914.	XX	
PR	01-MAR-2000; 2000WO-US005004.	XX	
PR	02-MAR-2000; 2000WO-US005746.	XX	
PR	02-MAR-2000; 2000WO-US005841.	XX	
PR	15-MAR-2000; 2000WO-US006884.	XX	
PR	20-MAR-2000; 2000WO-US007377.	XX	
PR	21-MAR-2000; 2000WO-US007532.	XX	
PR	30-MAR-2000; 2000WO-US008439.	XX	

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2003-900169/82.  
P-PSDB; ADE22647.

Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
useful for treating pericyte-associated tumors, diabetes and various bone  
and/or cartilage disorders, e.g. arthritis.

Claim 2; Fig 221; 638pp; English.

The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in  
generating either transgenic animals or knock-out animals which are  
useful in the development and screening of therapeutically useful  
reagents. The PRO polypeptides or antibodies are used in preparing a  
medicament for treating a condition responsive to the polypeptides or



PD 16-OCT-2003.  
 XX 14-MAY-2002; 2002US-00145874.  
 XX 05-JUN-2000; 2000US-0209832P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 XX Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-899785/82.  
 DR P-PSDB; ADE32715.  
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 PT useful for treating pericyte-associated tumors, diabetes and various bone  
 PT and/or cartilage disorders, e.g. arthritis.  
 XX Claim 2; SEQ ID NO 221; 636pp; English.  
 XX The invention describes 305 nucleic acids encoding PRO (secreted and  
 CC transmembrane) polypeptides (I). (I) is useful for stimulating the  
 CC release of TNF-alpha from human blood, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating the proliferation or differentiation of chondrocyte cells,  
 CC for stimulating the proliferation of or gene expression in pericyte  
 CC cells, for stimulating the release of proteoglycans from cartilage, for  
 CC stimulating the proliferation of inner ear utricular supporting cells,  
 CC for stimulating the proliferation of T-lymphocyte cells, for stimulating  
 CC the release of a cytokine from BMC cells, for inhibiting the binding of  
 CC A-peptide to factor V1RA, for inhibiting the differentiation of adipocyte  
 CC cells, for stimulating proliferation of endothelial cells, for detecting  
 CC the presence of tumour in a mammal. The tumour is lung, colon, breast,  
 CC prostate, rectal, cervical or liver tumour. The oligonucleotide probes  
 CC are useful for isolating genomic and cDNA nucleotide sequences or  
 CC antisense probes. (I) is also useful as therapeutic agent. PRO is useful  
 CC in assays to identify other proteins or molecules involved in binding  
 CC interaction. A polynucleotide (II) encoding (I) is useful in chromosome  
 CC and gene mapping, in generation of antisense RNA and DNA, in the  
 CC preparation of PRO polypeptide, for generating transgenic animals or  
 CC knockout animals which in turn are useful in the development and  
 CC screening of therapeutically useful reagents, in gene therapy, for  
 CC chromosome identification, as chromosome marker, and for generating  
 CC probes. An anti-(I)-antibody is useful in diagnostic assays for PRO, e.g.  
 CC detecting its expression in specific cells, tissues or serum, and for  
 CC affinity purification of PRO from recombinant cell culture or natural  
 CC sources. (I) and (II) are useful for tissue typing. This sequence encodes  
 CC a novel human secreted and transmembrane PRO polypeptide.  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ  
 Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
 Best Local Similarity 66.0%; Pred. No. 45;  
 Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
 QY 1835 TTCTTAATTTTTCATTTCCAGATTCTTCAGTTGCGTTTCTTT 1881  
 |||||  
 Db 1129 TTTTITTTTTTTTTTTTCAGTTGCGACACAGCGTGGTTTATT 1083  
 |||||  
 RESULT 190  
 ADE42406/c  
 ID ADE42406 standard; cDNA; 1129 BP.  
 XX AC ADE42406;  
 XX DT 29-JAN-2004 (first entry)  
 XX Human PRO polynucleotide #111;  
 DE  
 XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
 KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
 KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
 KW liver; microvascular endothelial cell; glucose; FFA;  
 KW skeletal muscle cell; adipocyte cell; pericyte cell;  
 KW inner ear utricular supporting cell; T-lymphocyte cell;  
 KW endothelial cell tube formation; bone disorder; cartilage disorder;  
 KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
 KW rheumatoid arthritis; haemoglobin-associated disorder thalassemia;  
 KW immune system cell infiltration.  
 XX Homo sapiens.  
 OS  
 XX US2003199032-A1.  
 PN  
 XX 23-OCT-2003.  
 PD  
 XX 28-MAY-2002; 2002US-00156844.  
 XX 03-MAR-2000; 2000US-0187202P.  
 PR 01-DEC-2000; 2000WO-US032678.  
 PR 19-DEC-2001; 2001US-00028072.  
 XX (GETH ) GENENTECH INC.  
 PA Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;  
 PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
 PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
 XX WPI; 2003-900161/82.  
 DR P-PSDB; ADE42407.  
 XX Two hundred and seventy five nucleic acids encoding PRO polypeptides,  
 PT useful for treating pericyte-associated tumors, diabetes and various bone  
 PT and/or cartilage disorders, e.g. arthritis.  
 XX Claim 2; Fig 221; 636pp; English.  
 XX The invention relates to isolated human PRO polypeptides (secreted and  
 CC transmembrane polypeptides) and the polynucleotides encoding them. The  
 CC invention also relates to an antibody which specifically binds to a PRO  
 CC polypeptide, a method for stimulating the release of tumour necrosis  
 CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
 CC proliferation or differentiation of chondrocyte cells and a method for  
 CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
 CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
 CC polynucleotides are useful in molecular biology, including uses as  
 CC hybridisation probes, in chromosome and gene mapping, in generating  
 CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
 CC be used in preparing PRO polypeptides by recombinant techniques and in  
 CC generating either transgenic animals or knock-out animals which are  
 CC useful in the development and screening of therapeutically useful  
 CC reagents. The PRO polypeptides or antibodies are used in preparing a  
 CC medicament for treating a condition responsive to the polypeptides or  
 CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
 CC of human microvascular endothelial cells, for modulating the uptake of  
 CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
 CC stimulating differentiation of adipocyte cells, for stimulating  
 CC proliferation of or gene expression in pericyte cells, for stimulating  
 CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
 CC cells, for inducing endothelial cell tube formation and for treating  
 CC various bone and/or cartilage disorders such as sports injuries and  
 CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
 CC from cartilage are useful for treating sports-related joint problems, PRO  
 CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
 CC polypeptides are also useful for treating various mammalian haemoglobin-  
 CC associated disorders such as various thalassemias and conditions which  
 CC may benefit from enhanced local immune system cell infiltration. This  
 CC sequence represents a human PRO polynucleotide of the invention. Note:  
 CC The sequence data for this patent is also available in electronic format  
 CC from USPTO at seqdata.uspto.gov/sequence.html.  
 XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
 SQ











KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.

XX Homo sapiens.

XX OS

XX US2003100087-A1.

XX PD

XX 29-MAY-2003.

XX 16-APR-2002; 2002US-00123912.

XX 31-MAR-1997; 97WO-US0005230.

XX 12-JUN-1998; 98WO-US012456.

XX 14-JUL-1998; 98WO-US044552.

XX 28-AUG-1998; 98WO-US017888.

XX 10-SEP-1998; 98WO-US018824.

XX 14-SEP-1998; 98WO-US019093.

XX 14-SEP-1998; 98WO-US019094.

XX 16-SEP-1998; 98WO-US019177.

XX 16-SEP-1998; 98WO-US019330.

XX 17-SEP-1998; 98WO-US019437.

XX 07-OCT-1998; 98WO-US021141.

XX 29-OCT-1998; 98WO-US022991.

XX 29-OCT-1998; 98WO-US022992.

XX 20-NOV-1998; 98WO-US024855.

XX 01-DEC-1998; 98WO-US025108.

XX 05-JAN-1999; 99WO-US000106.

XX 08-MAR-1999; 99WO-US0005028.

XX 10-MAR-1999; 99WO-US0005190.

XX 20-APR-1999; 99WO-US0008615.

XX 14-MAY-1999; 99WO-US010733.

XX 02-JUN-1999; 99WO-US012552.

XX 01-SEP-1999; 99WO-US020111.

XX 08-SEP-1999; 99WO-US020594.

XX 13-SEP-1999; 99WO-US020594.

XX 15-SEP-1999; 99WO-US021090.

XX 15-SEP-1999; 99WO-US021547.

XX 05-OCT-1999; 99WO-US023089.

XX 29-NOV-1999; 99WO-US028214.

XX 30-NOV-1999; 99WO-US028313.

XX 30-NOV-1999; 99WO-US028409.

PR 15-MAR-2000; 2000WO-US006984.  
PR 20-MAR-2000; 2000WO-US007377.  
PR 21-MAR-2000; 2000WO-US007532.  
PR 30-MAR-2000; 2000WO-US008439.  
PR 17-MAY-2000; 2000WO-US013705.  
PR 22-MAY-2000; 2000WO-US014042.  
PR 30-MAY-2000; 2000WO-US014941.  
PR 02-JUN-2000; 2000WO-US015264.  
PR 28-JUL-2000; 2000WO-US020710.  
PR 11-AUG-2000; 2000WO-US022031.  
PR 23-AUG-2000; 2000WO-US023522.  
PR 24-AUG-2000; 2000WO-US023328.  
PR 08-NOV-2000; 2000WO-US030952.  
PR 10-NOV-2000; 2000WO-US030873.  
PR 01-DEC-2000; 2000WO-US032578.  
PR 20-DEC-2000; 2000US-00747259.  
PR 20-DEC-2000; 2000WO-US034956.  
PR 28-FEB-2001; 2001US-00796498.  
PR 01-MAR-2001; 2001WO-US006520.  
PR 09-MAR-2001; 2001US-00802706.  
PR 14-MAR-2001; 2001US-00808689.  
PR 22-MAR-2001; 2001US-00816744.  
PR 05-APR-2001; 2001US-00828366.  
PR 10-MAY-2001; 2001US-00854208.  
PR 10-MAY-2001; 2001US-00854280.  
PR 18-MAY-2001; 2001US-00860216.  
PR 25-MAY-2001; 2001US-00866028.  
PR 25-MAY-2001; 2001US-00866034.  
PR 25-MAY-2001; 2001WO-US017092.  
PR 01-JUN-2001; 2001US-00872035.  
PR 01-JUN-2001; 2001WO-US017800.  
PR 05-JUN-2001; 2001US-00874503.  
PR 14-JUN-2001; 2001US-00882636.  
PR 19-JUN-2001; 2001US-00886342.  
PR 20-JUN-2001; 2001WO-US019852.  
PR 21-JUN-2001; 2001US-00887879.  
PR 22-JUN-2001; 2001WO-US020116.  
PR 29-JUN-2001; 2001WO-US021066.  
PR 09-JUL-2001; 2001WO-US021735.  
PR 18-JUL-2001; 2001US-00908827.  
PR 06-AUG-2001; 2001US-00924419.  
PR 09-AUG-2001; 2001US-00927796.  
PR 16-AUG-2001; 2001US-00931836.  
PR 19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

WPI; 2004-0089956/01.

P-PSDB; ADD76407.

PT New PRO nucleic acid, useful for recombinantly producing a PRO  
PT polypeptide and for manufacturing a medicament for diagnosing or treating  
PT a tumor.

Claim 2; Fig 221; 638pp; English.

CC The invention relates to isolated human PRO polypeptides (secreted and  
transmembrane polypeptides) and the polynucleotides encoding them. The  
invention also relates to an antibody which specifically binds to a PRO  
polypeptide, a method for stimulating the release of tumour necrosis  
factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
proliferation or differentiation of chondrocyte cells and a method for  
detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
polynucleotides are useful in molecular biology, including uses as  
hybridisation probes, in chromosome and gene mapping, in generating  
antisense RNA and DNA and in gene therapy. The polynucleotides may also  
be used in preparing PRO polypeptides by recombinant techniques and in



immune system cell infiltration.

Homo sapiens.

US2003203440-A1.

30-OCT-2003.

29-MAY-2002; 2002US-00157798.

05-JUN-2000; 2000US-0209832P.

01-DEC-2000; 2000WO-US032678.

19-DEC-2001; 2001US-00028072.

(GETH ) GENENTECH INC.

Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W; Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S; Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z; WPI; 2004-021363/02.

F-PSDB; ADD86175.

New isolated nucleic acid encoding a PRO polypeptide, e.g. PRO1114 or PRO4978, useful in molecular biology, chromosome and gene mapping, in generating antisense RNA and DNA, and in gene therapy.

Claim 2; Fig 221; 637pp; English.

The invention relates to isolated human PRO polypeptides (secreted and transmembrane polypeptides) and the polynucleotides encoding them. The invention also relates to an antibody which specifically binds to a PRO polypeptide, a method for stimulating the release of tumour necrosis factor-alpha (TNF-alpha) from human blood, a method for stimulating the proliferation or differentiation of chondrocyte cells and a method for detecting the presence of a tumour in a mammal (e.g. adrenal, lung, colon, breast, prostate, rectal, kidney, cervical and liver tumours). The polynucleotides are useful in molecular biology, including uses as hybridisation probes, in chromosome and gene mapping, in generating antisense RNA and DNA and in gene therapy. The polynucleotides may also be used in preparing PRO polypeptides by recombinant techniques and in generating either transgenic animals or knock-out animals which are useful in the development and screening of therapeutically useful reagents. The PRO polypeptides or antibodies are used in preparing a medicament for treating a condition responsive to the polypeptides or antibodies, such as tumours, for stimulating and inhibiting proliferation of human microvascular endothelial cells, for modulating the uptake of glucose or FFA by skeletal muscle cells or adipocyte cells, for stimulating differentiation of adipocyte cells, for stimulating proliferation of or gene expression in pericyte cells, for stimulating the proliferation of inner ear utricular supporting cells or T-lymphocyte cells, for inducing endothelial cell tube formation and for treating

Query Match 1.1%; Score 21.4; DB 1; Length 1129;

Best Local Similarity 65.0%; Pred. No. 45;

Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;

1835 TCTTAAATTTTCATTTCAGATTCCTTCAGTTGGGTTTGT 1881

1129 TTTTATTTTATTTTATTTTTCAGTCGGCACACAGGCTGTTTAT 1083

RESULT 199

ADE75622/C

ID ADE75622 standard; cDNA; 1129 BP.

XX

AC ADE75622;

XX

DT 29-JAN-2004 (first entry)

XX

DE Human PRO polynucleotide #111.

XX

KW Human; gene: ss; PRO; secreted polypeptide; transmembrane polypeptide;

XX

KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;

XX

KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;

XX

KW liver; microvascular endothelial cell; glucose; FFA;

XX

KW skeletal muscle cell; adipocyte cell; pericyte cell;

XX

KW inner ear utricular supporting cell; T-lymphocyte cell;

XX

KW endothelial cell tube formation; bone disorder; cartilage disorder;

XX

KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;

XX

KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;

XX

XX immune system cell infiltration.

OS Homo sapiens.

XX

US2003211571-A1.

XX

PD 13-NOV-2003.

XX

PF 20-MAY-2002; 2002US-00152405.

XX

PR 03-MAR-2000; 2000US-0187202P.

XX

PR 01-DEC-2000; 2000WO-US032678.

XX

PR 19-DEC-2001; 2001US-00028072.

XX

XX (GETH ) GENENTECH INC.

XX

PI Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;

PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;

PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;

XX

WPI; 2004-051576/05.

P-PSDB; ADE75623.

DR

DR New secreted and transmembrane PRO polypeptide and nucleic acid encoding

PT it, for use in gene therapy, as diagnostic markers for the presence of a

PT disease condition, or as therapeutic targets for treating tumors,

PT diabetes, or arthritis.

XX

XX Claim 2; Fig 221; 637pp; English.

PS

CC The invention relates to isolated human PRO polypeptides (secreted and

CC transmembrane polypeptides) and the polynucleotides encoding them. The

CC invention also relates to an antibody which specifically binds to a PRO

CC polypeptide, a method for stimulating the release of tumour necrosis

CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the

CC proliferation or differentiation of chondrocyte cells and a method for

CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,

CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The

CC polynucleotides are useful in molecular biology, including uses as

CC hybridisation probes, in chromosome and gene mapping, in generating

CC antisense RNA and DNA and in gene therapy. The polynucleotides may also

CC be used in preparing PRO polypeptides by recombinant techniques and in

CC generating either transgenic animals or knock-out animals which are

CC useful in the development and screening of therapeutically useful

CC reagents. The PRO polypeptides or antibodies are used in preparing a

CC medicament for treating a condition responsive to the polypeptides or

CC antibodies, such as tumours, for stimulating and inhibiting proliferation

CC of human microvascular endothelial cells, for modulating the uptake of

CC glucose or FFA by skeletal muscle cells or adipocyte cells, for

CC stimulating differentiation of adipocyte cells, for stimulating

CC proliferation of or gene expression in pericyte cells, for stimulating

CC the proliferation of inner ear utricular supporting cells or T-lymphocyte

CC cells, for inducing endothelial cell tube formation and for treating

CC various bone and/or cartilage disorders such as sports injuries and

CC arthritis. PRO polypeptides which stimulate the release of proteoglycans

CC from cartilage are useful for treating sports-related joint problems. PRO

CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO

CC polypeptides are also useful for treating various mammalian haemoglobin-

CC associated disorders such as various thalassaemias and conditions which

CC may benefit from enhanced local immune system cell infiltration. This

CC sequence represents a human PRO polynucleotide of the invention. Note:

CC The sequence data for this patent is also available in electronic format

CC from USPTO at [seqdata.uspto.gov/sequence.html](http://seqdata.uspto.gov/sequence.html).

XX

XX Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;

SQ



PR 19-DEC-2001; 2001US-00028072.  
XX (GETH ) GENENTECH INC.  
PA Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
XX Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX WPI; 2004-020235/02.  
DR P-PSDB; ADE23751.  
XX  
XX New secreted and transmembrane nucleic acids and polypeptides, designated  
PT as PRO, useful for treating inflammation, organ failure, atherosclerosis,  
PT cardiac injury, infertility, birth defects, premature aging, AIDS, or  
XX cancer.  
XX  
XX Claim 2; Fig 221; 637pp; English.  
PS  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX  
SQ Sequence 1129 BP; 231 A; 369 C; 335 G; 194 T; 0 U; 0 Other;  
Query Match 1.1%; Score 21.4; DB 1; Length 1129;  
Best Local Similarity 66.0%; Pred. No. 45;  
Matches 31; Conservative 0; Mismatches 16; Indels 0; Gaps 0;  
QY 1835 TTTCTTAATTTTTCAGATTTTCCTTCAGTTTGGCTTTGTTT 1881  
DB 1129 TTTTCTTTTCTTTTTCAGCTGGCACACAGCTGGCTTTTATT 1083  
RESULT 202  
ADE24393/c  
ID ADE24393 standard; cDNA; 1129 BP.  
XX  
AC ADE24393;  
XX  
XX 29-JAN-2004 (first entry)  
DT  
XX cDNA encoding human PRO polypeptide #111.  
DE  
XX

KW Human; gene; ss; PRO; secreted polypeptide; transmembrane polypeptide;  
KW tumour necrosis factor-alpha; TNF-alpha; chondrocyte cell; tumour;  
KW cancer; adrenal; lung; colon; breast; prostate; rectum; kidney; cervix;  
KW liver; microvascular endothelial cell; glucose; FFA;  
KW skeletal muscle cell; adipocyte cell; pericyte cell;  
KW inner ear utricular supporting cell; T-lymphocyte cell;  
KW endothelial cell tube formation; bone disorder; cartilage disorder;  
KW sports injury; proteoglycan; articular cartilage defect; osteoarthritis;  
KW rheumatoid arthritis; haemoglobin-associated disorder thalassaemia;  
KW immune system cell infiltration.  
XX  
XX Homo sapiens.  
OS  
XX US2003092111-A1.  
PN  
XX 15-MAY-2003.  
PD  
XX  
XX 03-MAY-2002; 2002US-00137869.  
PF  
XX  
XX 03-MAR-2000; 2000US-0187202P.  
PR  
PR 01-DEC-2000; 2000WO-US032678.  
PR 19-DEC-2001; 2001US-00028072.  
XX  
XX (GETH ) GENENTECH INC.  
PA  
XX Baker KP, Beresini M, DeForge L, Desnoyers L, Filvaroff E, Gao W;  
PI Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;  
PI Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;  
XX  
XX WPI; 2004-020236/02.  
DR P-PSDB; ADE24394.  
XX  
XX New secreted and transmembrane nucleic acid useful for treating  
PT inflammation, organ failure, atherosclerosis, cardiac injury,  
PT infertility, birth defects, premature aging, acquired immunodeficiency  
PT syndrome, or cancer.  
XX  
XX Claim 2; Fig 221; 637pp; English.  
PS  
XX The invention relates to isolated human PRO polypeptides (secreted and  
CC transmembrane polypeptides) and the polynucleotides encoding them. The  
CC invention also relates to an antibody which specifically binds to a PRO  
CC polypeptide, a method for stimulating the release of tumour necrosis  
CC factor-alpha (TNF-alpha) from human blood, a method for stimulating the  
CC proliferation or differentiation of chondrocyte cells and a method for  
CC detecting the presence of a tumour in a mammal (e.g. adrenal, lung,  
CC colon, breast, prostate, rectal, kidney, cervical and liver tumours). The  
CC polynucleotides are useful in molecular biology, including uses as  
CC hybridisation probes, in chromosome and gene mapping, in generating  
CC antisense RNA and DNA and in gene therapy. The polynucleotides may also  
CC be used in preparing PRO polypeptides by recombinant techniques and in  
CC generating either transgenic animals or knock-out animals which are  
CC useful in the development and screening of therapeutically useful  
CC reagents. The PRO polypeptides or antibodies are used in preparing a  
CC medicament for treating a condition responsive to the polypeptides or  
CC antibodies, such as tumours, for stimulating and inhibiting proliferation  
CC of human microvascular endothelial cells, for modulating the uptake of  
CC glucose or FFA by skeletal muscle cells or adipocyte cells, for  
CC stimulating differentiation of adipocyte cells, for stimulating  
CC proliferation of or gene expression in pericyte cells, for stimulating  
CC the proliferation of inner ear utricular supporting cells or T-lymphocyte  
CC cells, for inducing endothelial cell tube formation and for treating  
CC various bone and/or cartilage disorders such as sports injuries and  
CC arthritis. PRO polypeptides which stimulate the release of proteoglycans  
CC from cartilage are useful for treating sports-related joint problems,  
CC articular cartilage defects, osteoarthritis and rheumatoid arthritis. PRO  
CC polypeptides are also useful for treating various mammalian haemoglobin-  
CC associated disorders such as various thalassaemias and conditions which  
CC may benefit from enhanced local immune system cell infiltration. This  
CC sequence encodes a human PRO polypeptide of the invention. Note: The  
CC sequence data for this patent is also available in electronic format from  
CC the USPTO website at seqdata.uspto.gov.  
XX







PR	07-OCT-1998;	98WO-US021141.	PR	25-MAY-2001;	2001WO-US017092.
PR	29-OCT-1998;	98WO-US022991.	PR	01-JUN-2001;	2001US-00872035.
PR	29-OCT-1998;	98WO-US022992.	PR	01-JUN-2001;	2001WO-US017800.
PR	20-NOV-1998;	98WO-US024855.	PR	05-JUN-2001;	2001US-00874503.
PR	01-DEC-1998;	98WO-US025108.	PR	14-JUN-2001;	2001US-00882636.
PR	05-JAN-1999;	99WO-US000106.	PR	19-JUN-2001;	2001US-00886342.
PR	08-MAR-1999;	99WO-US005028.	PR	20-JUN-2001;	2001WO-US019592.
PR	10-MAR-1999;	99WO-US005190.	PR	21-JUN-2001;	2001US-00887879.
PR	10-MAR-1999;	2000WO-US006319.	PR	22-JUN-2001;	2001WO-US020116.
PR	10-APR-1999;	99WO-US0008615.	PR	29-JUN-2001;	2001WO-US021066.
PR	14-MAY-1999;	99WO-US010733.	PR	09-JUL-2001;	2001WO-US021735.
PR	02-JUN-1999;	99WO-US012252.	PR	18-JUL-2001;	2001US-00908827.
PR	01-SEP-1999;	99WO-US020111.	PR	06-AUG-2001;	2001US-00924419.
PR	08-SEP-1999;	99WO-US020594.	PR	09-AUG-2001;	2001US-00927796.
PR	13-SEP-1999;	99WO-US020944.	PR	16-AUG-2001;	2001US-00931836.
PR	15-SEP-1999;	99WO-US021057.	PR	19-DEC-2001;	2001US-00028072.
PR	15-SEP-1999;	99WO-US021547.	XX		
PR	05-OCT-1999;	99WO-US023089.	PA	(GETH ) GENENTECH INC.	
PR	29-NOV-1999;	99WO-US028214.	XX		
PR	30-NOV-1999;	99WO-US028313.	PI	Baker KP, Beresini M, Deforge L, Desnoyers L, Filvaroff E, Gao W;	
PR	30-NOV-1999;	99WO-US028409.	PI	Gerritsen ME, Goddard A, Godowski PJ, Gurney AL, Sherwood S;	
PR	01-DEC-1999;	99WO-US028301.	PI	Smith V, Stewart TA, Tumas D, Watanabe CK, Wood WI, Zhang Z;	
PR	01-DEC-1999;	99WO-US028634.	XX		
PR	02-DEC-1999;	99WO-US028551.	DR	WPI; 2004-041360/04.	
PR	02-DEC-1999;	99WO-US028554.	PR	P-PSDB; ADE89085.	
PR	02-DEC-1999;	99WO-US028565.	XX		
PR	16-DEC-1999;	99WO-US030095.	PT	Novel isolated PRO polypeptide useful for treating diabetes, hyper- or	
PR	20-DEC-1999;	99WO-US030911.	PT	hypo-insulinemia, sports injuries, arthritis, obesity, stroke, heart	
PR	20-DEC-1999;	99WO-US030939.	PT	attack, various coagulation disorders, tumors.	
PR	22-DEC-1999;	99WO-US030720.	XX		
PR	30-DEC-1999;	99WO-US031243.	PS	Claim 2; SEQ ID NO 221; 638pp; English.	
PR	30-DEC-1999;	99WO-US031274.	XX		
PR	05-JAN-2000;	2000WO-US000219.	CC	The invention relates to isolated human PRO polypeptides (secreted and	
PR	06-JAN-2000;	2000WO-US000277.	CC	transmembrane polypeptides) and the polynucleotides encoding them. The	
PR	06-JAN-2000;	2000WO-US000376.	CC	invention also relates to an antibody which specifically binds to a PRO	
PR	11-FEB-2000;	2000WO-US003565.	CC	polypeptide, a method for stimulating the release of tumour necrosis	
PR	18-FEB-2000;	2000WO-US004341.	CC	factor-alpha (INF-alpha) from human blood, a method for stimulating the	
PR	18-FEB-2000;	2000WO-US004342.	CC	proliferation or differentiation of chondrocyte cells and a method for	
PR	22-FEB-2000;	2000WO-US004414.	CC	detecting the presence of a tumour in a mammal (e.g. adrenal, lung,	
PR	24-FEB-2000;	2000WO-US004914.	CC	colon, breast, prostate, rectal, kidney, cervical and liver tumours). The	
PR	24-FEB-2000;	2000WO-US005004.	CC	polynucleotides are useful in molecular biology, including uses as	
PR	01-MAR-2000;	2000WO-US005601.	CC	hybridisation probes, in chromosome and gene mapping, in generating	
PR	02-MAR-2000;	2000WO-US005746.	CC	antisense RNA and DNA and in gene therapy. The polynucleotides may also	
PR	02-MAR-2000;	2000WO-US005841.	CC	be used in preparing PRO polypeptides by recombinant techniques and in	
PR	15-MAR-2000;	2000WO-US006884.	CC	generating either transgenic animals or knock-out animals which are	
PR	20-MAR-2000;	2000WO-US007377.	CC	useful in the development and screening of therapeutically useful	
PR	21-MAR-2000;	2000WO-US007532.	CC	reagents. The PRO polypeptides or antibodies are used in preparing a	
PR	30-MAR-2000;	2000WO-US008439.	CC	medicament for treating a condition responsive to the polypeptides or	
PR	17-MAY-2000;	2000WO-US013705.	CC	antibodies, such as tumours, for stimulating and inhibiting proliferation	
PR	22-MAY-2000;	2000WO-US014042.	CC	of human microvascular endothelial cells, for modulating the uptake of	
PR	30-MAY-2000;	2000WO-US014941.	CC	glucose or FFA by skeletal muscle cells or adipocyte cells, for	
PR	02-JUN-2000;	2000WO-US015264.	CC	stimulating differentiation of adipocyte cells, for stimulating	
PR	28-JUL-2000;	2000WO-US020710.	CC	proliferation of or gene expression in pericyte cells, for stimulating	
PR	11-AUG-2000;	2000WO-US022031.	CC	the proliferation of inner ear utricular supporting cells or T-lymphocyte	
PR	23-AUG-2000;	2000WO-US023522.	CC	cells, for inducing	







PT Novel factor VII polypeptide, its derivatives useful for preparing  
PT medicament for treating bleeding episodes, or for enhancing normal  
PT hemostatic system, especially for treating hemophilia.  
XX  
XX  
PS Disclosure: Page 82-85; 96pp; English.

XX The invention discloses a human factor VII polypeptide, or a variant or  
CC derivative of it, where an amino acid has been modified. This change  
CC results in a polypeptide with the same or an increased activity when  
CC compared to recombinant wild type human Factor VIIa. Blood coagulation  
CC consists of a complex interaction of various blood components that  
CC eventually give rise to a fibrin clot. Initiation of the haemostatic  
CC process is mediated by the formation of a complex between tissue factor  
CC and Factor VIIa (the active form of the Factor VII zymogen). This complex  
CC activates Factors IX and X, converting prothrombin to thrombin, which  
CC activates Factors V and VIII leading to a full thrombin burst. The  
CC thrombin converts fibrinogen to fibrin resulting in formation of a fibrin  
CC clot. The Factor VII zymogen, or its derivative, can be modified in its  
CC catalytic centre to inhibit the ability of the factor VII polypeptide to  
CC activate plasma factor X or IX. The factor VII derivative is useful for  
CC preparing a medicament for the treatment of bleeding episodes, for the  
CC enhancement of the normal haemostatic system, especially for the  
CC treatment of haemophilia A or B and for inhibiting thrombus formation.  
CC The inactivated factor VII derivatives are useful for treating intimal  
CC hyperplasia, restenosis, cardiovascular emboli, platelet deposition  
CC disorders, percutaneous transluminal coronary angioplasty (PTCA), stroke,  
CC cancer, tumour metastasis, angiogenesis, ischaemia/reperfusion,  
CC rheumatoid arthritis, thrombolysis, arteriosclerosis, acute and chronic  
CC indications, such as inflammation, septic shock, hypotension, adult  
CC respiratory distress syndrome (ARDS) and myocardial infarction. The  
CC sequence presented is the plasmin, PLN174, which expresses the  
CC inactivated human coagulation Factor VII polypeptide

XX SQ Sequence 6098 BP; 1413 A; 1597 C; 1623 G; 1475 T; 0 U; 0 Other;

Query Match 1.1%; Score 21.4; DB 1; Length 6098;  
Best Local Similarity 49.5%; Pred. No. 60;  
Matches 55; Conservative 0; Mismatches 56; Indels 0; Gaps 0;

QY 1536 TTGTATGCTTCTTGACCTTGATAGGCACTCTTTCTCAAGGTAGGAAATTTTCTTT 1595  
DB 4429 TTTTACGGTCTCGCCCTTTTCTGCTTTCACATGTTCTTCTCGGTATCC 4488

QY 1596 TTGGTTTCTTGAAATATTTTCCCTGCTTTTGACCTGCTTCTCCCT 1646  
DB 4489 CCTGATCTGTGATACCGTATACCGCTTTTGAGTGAGCTGATACCGCT 4539

RESULT 208  
ABS68969/c  
ID ABS68969 standard; DNA; 305 BP.

XX AC ABS68969;  
XX  
XX DT 21-NOV-2002 (first entry)  
XX  
XX DE Novel murine polynucleotide isolated using gene trap technology #32.

XX Mouse; gene trapped sequence; GTS; functional genomic analysis;  
KW phage display system; gene chip; temporal gene expression;  
KW tissue specific gene expression; antisense inhibition; gene targeting;  
KW development disorder; cell differentiation disorder; aging; cancer;  
KW autoimmune disease; lupus; inflammatory disorder; skin disorder;  
KW degenerative disorder; ds.

XX Mus musculus.

OS US2002102543-A1.

XX PN 01-AUG-2002.

XX PD 30-NOV-2000; 2000US-00728445.

XX PF

PR 01-DEC-1999; 99US-0168358P.

XX (FRIE/) FRIEDRICH G.  
PA (ZAMB/) ZAMBROWICZ B.  
PA (SAND/) SANDS A T.

XX Friedrich G, Zambrowicz B, Sands AT;  
PI WPI; 2002-690598/74.

XX Novel murine polynucleotides that individually identify novel genes into  
PT which a retroviral gene trap vector has integrated, useful in genomic  
PT analysis and in discovery, development of therapeutic and diagnostic  
PT agents.

XX Claim 1; Page 36; 296pp; English.

XX The invention describes an isolated murine polynucleotide (I) comprising  
CC a contiguous stretch of at least 60 nucleotides of one of 265-677  
CC nucleotide 891 OMNIBANK gene trapped sequences (GTSs) (S), given in the  
CC specification. The novel genes and cells are useful in functional genomic  
CC analysis and in the discovery and development of new therapeutic and  
CC diagnostic agents and methods. (I) is useful for identifying the coding  
CC regions of the murine genome, to isolate cDNAs, genomic clones, or full-  
CC length genes/polynucleotides or homologues, heterologues, paralogues, or  
CC orthologues that are capable of hybridising to one or more of the GTSs  
CC under stringent conditions. (I) can be incorporated into a phase display  
CC system that can be used to screen for proteins, or other ligands, that  
CC are capable of binding an amino acid sequence encoded by an  
CC oligonucleotide or polynucleotide sequence in at least one of the TS  
CC sequences. (I) is useful in addressable arrays, such as gene chips, to  
CC identify and characterise temporal and tissue specific gene expression,  
CC to identify the gene of interest from many sources and for genetic  
CC manipulations such as antisense inhibition and gene targeting. Decreasing  
CC the level of expression of (I) and/or down regulating the activity of  
CC peptides or proteins encoded by (I) is useful for treating development  
CC and cell differentiation disorders, aging, cancer, autoimmune disease,  
CC lupus, inflammatory disorders, skin disorders and degenerative disorders.  
CC This sequence represents a murine cDNA isolated using gene trap  
CC technology

XX SQ Sequence 305 BP; 72 A; 96 C; 66 G; 70 T; 0 U; 1 Other;

Query Match 1.1%; Score 21.2; DB 1; Length 305;  
Best Local Similarity 60.3%; Pred. No. 38;  
Matches 35; Conservative 0; Mismatches 23; Indels 0; Gaps 0;

QY 42 CTGCTGGCAATACCTCTGGGGCTGCTGCTTCTCCCTGCTGATTCCTAGGGTGAGG 99  
DB 284 CTGCTTCAGAACCTGCTGCTGCTGCTGCTGACCGAGCTGGAGTCGAGTCGAGG 227

RESULT 209  
ABL76656/c  
ID ABL76656 standard; cDNA; 286 BP.

XX AC ABL76656;

XX DT 14-MAY-2002 (first entry)

XX Corn tassal-derived polynucleotide (cdps) SEQ ID NO:6030.

XX Corn; corn tassal-derived polynucleotide; cdps; hybrid breeding; CDPS;  
KW inheritance; characteristic; growth; development; disease resistance;  
KW environmental adaptability; quality; yield; molecular marker;  
KW multigene trait; plant breeding; corn tassal; gene; ss.

XX Zea mays.

OS US2001051335-A1.

XX PN 13-DEC-2001.

XX PD



PN US2002137139-A1.  
XX 26-SEP-2002.  
XX 24-SEP-2001; 2001US-00960352.  
XX 12-JAN-1999; 99US-0115707P.  
PR 11-JAN-2000; 2000US-00480902.  
XX (BYAT/) BYATT J C.  
PA (NATH/) NATHIALAGAN N.  
PA (TAON/) TAO N.  
PA (WARR/) WARREN W C.  
XX  
PI Byatt JC, Mathialagan N, Tao N, Warren WC;  
XX WPI; 2003-110599/10.  
XX  
XX New nucleic acid associated with lactation, and muscle and fat  
PT deposition, useful for genome mapping, gene identification and analysis,  
PT cattle breeding, or for genetically improving cattle.  
XX  
XX Claim 2; SEQ ID NO 2260; 245pp; English.  
XX  
XX The invention relates to a purified nucleic acid molecule associated with  
CC lactation or muscle and fat deposition (designated LMPD), derived from  
CC cattle, and the LMPD nucleic acid can specifically hybridize to a second  
CC nucleic acid molecule comprising any of 15112 nucleotide sequences,  
CC appearing as ABX34836-ABX49947, or complements of them. Also included are  
CC ; (1) a transformed cell having a nucleic acid comprising an LMPD nucleic  
CC acid linked to a promoter and a 3' non-translated sequence that  
CC functions in the cell to cause termination of transcription and addition  
CC of polyadenylated ribonucleotides to a 3' end of the mRNA molecule; and  
CC (2) determining a level or pattern of a molecule in a bovine cell or  
CC tissue comprising: (a) incubating a marker nucleic acid (comprising any  
CC of the 15112 nucleic acid sequences or its complement or fragment) with a  
CC complementary nucleic acid molecule obtained from the bovine cell or  
CC tissue, where hybridization between the marker nucleic acid and the  
CC complementary nucleic acid permits the detection of the molecule; and (b)  
CC detecting the level or pattern of the complementary nucleic acid; where  
CC the detection of the complementary nucleic acid is predictive of the  
CC level or pattern of the molecule. The LMPD nucleic acid is used for  
CC determining a level or pattern of a molecule in a bovine cell or tissue.  
CC It is useful for genome mapping, gene identification and analysis, cattle  
CC breeding, preparation of constructs for use in cattle gene expression, or  
CC for genetically improving cattle. The present sequence is one of the  
CC 15112 bovine LMPD EST (expressed sequence tag) nucleic acids. Note: The  
CC present sequence was not shown in the specification but was obtained in  
CC electronic format from the USPTO web site:  
CC seqdata.uspto.gov/sequence.html?docID=20020137139  
XX  
SQ Sequence 372 BP; 113 A; 73 C; 87 G; 99 T; 0 U; 0 Other;  
Query Match 1.0%; Score 21; DB 1; Length 372;  
Best Local Similarity 56.3%; Pred. No. 45;  
Matches 39; Conservative 0; Mismatches 30; Indels 0; Gaps 0;  
QY 1569 TTCTCAAGGTAGGAAATTTCTTTTGGTTTCTTGAATAATTTTCCCTGTTTT 1628  
Db 317 TATTTCAGCTCAGAGAAATTTTCATAGTTCGTATTGGAAATAATAGTCTCAGCAGGCT 258  
QY 1629 GACCTGCTT 1637  
Db 257 GAGCTTCTT 249  
RESULT 212  
AAI20194/C  
ID AAI20194 standard; DNA; 263 BP.  
XX  
XX AAI20194;  
XX  
DT 12-OCT-2001 (first entry).

XX DE Probe #10127 for gene expression analysis in human cervical cell sample.  
XX KW Probe; human; microarray; gene expression; cervical epithelial cell;  
XX KW cervical cancer; ss.  
XX OS Homo sapiens.  
XX PN WO200157278-A2.  
XX PD 09-AUG-2001.  
XX PF 30-JAN-2001; 2001WO-US000670.  
XX PR 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX (MOLE-) MOLECULAR DYNAMICS INC.  
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;  
XX WPI; 2001-488901/53.  
XX Human genome-derived single exon nucleic acid probes useful for analyzing  
PT gene expression in human cervical epithelial cells.  
XX PS Claim 25; SEQ ID NO 10127; 487pp; English.  
XX  
XX The present invention relates to human single exon nucleic acid probes  
CC (SENP). The present sequence is one such probe. The SENPs are derived  
CC from human HeLa cells. The SENPs can be used to produce a single exon  
CC microarray, which can be used for measuring human gene expression in a  
CC sample derived from human cervical epithelial cells. By measuring gene  
CC expression, the probes are therefore useful in grading and/or staging of  
CC diseases of the cervix, notably cervical cancer. Note: The sequence data  
CC for this patent did not form part of the printed specification, but was  
CC obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 263 BP; 91 A; 47 C; 102 G; 23 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 263;  
Best Local Similarity 52.3%; Pred. No. 47;  
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;  
QY 1614 ATTTTCCTGCTTTTGACCTGCTTCTTCCCTTCTCTATTCCTTTGTTTGCATAG 1673  
Db 251 AATTTCCTTCT 192  
QY 1674 TGCTCTGCTTCTCTGATGTTTATGC 1701  
Db 191 CTTCCTCCAGTTCAGTTGTCTTTTGCGC 164  
RESULT 213  
ABA65223/C  
ID ABA65223 standard; DNA; 263 BP.  
XX  
XX ABA65223;  
XX  
DT 01-FEB-2002 (first entry)  
XX Human foetal liver single exon nucleic acid probe #13528.  
XX KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.  
XX OS Homo sapiens.  
XX









```

Query Match      1.0%; Score 20.8; DB 1; Length 363;
Best Local Similarity 52.3%; Pred. No. 47;
Matches 46; Conservative 0; Mismatches 42; Indels 0; Gaps 0;

QY 1614 ATTTTCCTGCTTTTGACCTGCTCTTCCCTCTCTCTATTCCTTTGGTTTTTCGATAG 1673

```



CC obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCATTTGAGAAATTAATCAATGAGCA 973  
DB 182 ATAATATTCATTCAGTCATTCATTTTATTAATCAATGAGAAATTAATCAATTC 123  
QY 974 GTGTTTGTGGATCTTGTATCTTGTGCACTTGTGAAG 1009  
DB 122 CTGCTGGGACACTGTCGCTGGGTTTGTCCAG 87  
RESULT 224  
ABA53443/C  
ID ABA53443 standard; DNA; 474 BP.  
XX  
AC ABA53443;  
XX  
DT 01-FEB-2002 (first entry)  
XX  
DE Human foetal liver single exon nucleic acid probe #1748.  
XX  
KW Human; foetal liver; gene expression; single exon nucleic acid probe; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157277-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 30-JAN-2001; 2001WO-US000669.  
XX  
PR 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX  
PI Penn SG, Hanzel DK, Chen W, Rank DR;  
XX  
DR WPI; 2001-483447/52.  
XX  
PT Human genome-derived single exon nucleic acid probes useful for analyzing  
PT gene expression in human foetal liver.  
XX  
PS Claim 1; SEQ ID NO 1748; 639pp + Sequence Listing; English.  
XX  
CC The invention relates to a single exon nucleic acid probe for measuring  
CC human gene expression in a sample derived from human foetal liver. The  
CC single exon nucleic acid probes may be used for predicting, measuring and  
CC displaying gene expression in samples derived from human foetal liver. The  
CC present sequence is a single exon nucleic acid probe of the invention.  
CC Note: The sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCATTTGAGAAATTAATCAATGAGCA 973

DB 182 ATAATATTCATTCAGTCATTCATTTTATTAATCAATGAGAAATTAATCAATTC 123  
QY 974 GTGTTTGTGGATCTTGTATCTTGTGCACTTGTGAAG 1009  
DB 122 CTGCTGGGACACTGTCGCTGGGTTTGTCCAG 87  
RESULT 225  
AAI33062/C  
ID AAI33062 standard; DNA; 474 BP.  
XX  
AC AAI33062;  
XX  
DT 17-OCT-2001 (first entry)  
XX  
DE Probe #1748 used to measure gene expression in human placenta sample.  
XX  
KW Probe; microarray; human; placenta; antenatal diagnosis;  
KW Genetic disorder; ss.  
XX  
OS Homo sapiens.  
XX  
PN WO200157272-A2.  
XX  
PD 09-AUG-2001.  
XX  
PF 30-JAN-2001; 2001WO-US000663.  
XX  
PR 04-FEB-2000; 2000US-0180312P.  
PR 26-MAY-2000; 2000US-0207456P.  
PR 30-JUN-2000; 2000US-00608408.  
PR 03-AUG-2000; 2000US-00632366.  
PR 21-SEP-2000; 2000US-0234687P.  
PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX  
PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX  
PI Penn SG, Hanzel DK, Chen W, Rank DR;  
XX  
DR WPI; 2001-488897/53.  
XX  
PT Human genome-derived single exon nucleic acid probes useful for analyzing  
PT gene expression in human placenta.  
XX  
PS Claim 25; SEQ ID NO 1748; 654pp; English.  
XX  
CC The present invention relates to single exon nucleic acid probes (SENPs).  
CC The present sequence is one such probe. The probes are useful for  
CC producing a microarray for predicting, measuring and displaying gene  
CC expression in samples derived from human placenta. The probes are useful  
CC for antenatal diagnosis of human genetic disorders  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCATTTGAGAAATTAATCAATGAGCA 973  
DB 182 ATAATATTCATTCAGTCATTCATTTTATTAATCAATGAGAAATTAATCAATTC 123  
QY 974 GTGTTTGTGGATCTTGTATCTTGTGCACTTGTGAAG 1009  
DB 122 CTGCTGGGACACTGTCGCTGGGTTTGTCCAG 87  
RESULT 226  
ABA43030/C  
ID ABA43030 standard; DNA; 474 BP.  
XX

AC ABA43030;  
XX  
XX  
DT 01-FEB-2002 (first entry)  
XX  
DE Human breast cell single exon nucleic acid probe #1725.  
XX  
XX Human; microarray; single exon probe; gene expression; breast; disease;  
KW cancer; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200157271-A2.  
PN  
XX  
XX 09-AUG-2001.  
XX  
XX 30-JAN-2001; 2001WO-US000562.  
XX  
XX 04-FEB-2000; 2000US-0180312P.  
PR  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX 30-JUN-2000; 2000US-00608408.  
PR  
XX 03-AUG-2000; 2000US-00632366.  
PR  
XX 21-SEP-2000; 2000US-02334687P.  
PR  
XX 27-SEP-2000; 2000US-0236359P.  
PR  
XX 04-OCT-2000; 2000GB-00024263.  
XX  
XX (MOLE-) MOLECULAR DYNAMICS INC.  
PA  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI  
XX WPI; 2001-496933/54.  
XX  
XX New spatially-addressable set of single exon nucleic acid probes, useful  
PT for measuring gene expression in sample derived from human breast,  
PT comprises number of single exon nucleic acid probes.  
XX  
XX Claim 1; SEQ ID NO 1725; 327pp + Sequence Listing; English.  
XX  
XX The invention relates to a spatially-addressable set of single exon  
CC nucleic acid probes for measuring gene expression in a sample derived  
CC from human breast and BT 474 cells. The method involves contacting the  
CC probes with a collection of detectably labelled nucleic acids derived  
CC from mRNA of human breast, and then measuring the label bound to each  
CC probe of the microarray. The probes are useful for verifying the  
CC expression of regions of genomic DNA predicted to encode proteins. They  
CC are useful for gene discovery, and for determining predisposition and/or  
CC prognosing breast disease. Gene expression analysis is useful for  
CC assessing the toxicity of chemical agents on cells. The microarray of  
CC this invention presents a far greater diversity of probes for measuring  
CC gene expression, with far less bias than expressed sequence tag  
CC microarrays. The method is suitable for rapid production of functional  
CC information from genomic sequence. The present sequence is a single exon  
CC nucleic acid probe of the invention. Note: The sequence data for this  
CC patent did not form part of the printed specification, but was obtained  
CC in electronic format directly from WIPO at  
XX ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTTGATGATTTGAGATTTATCAATGAGCA 973  
DB 182 ATATATATCCATTCAGTGTGTCATTTCAATATAAATTTGATGAGGAAACAAAAATCAATTC 123  
QY 974 GTGTTTGGGATTTCTGTTATCTTGCACCTGTGAAG 1009  
DB 122 CTGTCCTGGGACACTGTCTGCTGGGTTTGTCCAG 87

RESULT 227  
ABA23216/c

ID ABA23216 standard; DNA; 474 BP.  
XX  
XX ABA23216;  
XX  
XX 23-JAN-2002 (first entry)  
DT  
XX  
DE Probe #1682 for gene expression analysis in human heart cell sample.  
XX  
XX Human; gene expression; heart; microarray; vascular system; probe;  
KW cardiovascular disease; hypertension; cardiac arrhythmia;  
KW congenital heart disease; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200157274-A2.  
PN  
XX  
XX 09-AUG-2001.  
XX  
XX 30-JAN-2001; 2001WO-US000666.  
XX  
XX 04-FEB-2000; 2000US-0180312P.  
PR  
XX 26-MAY-2000; 2000US-0207456P.  
PR  
XX 30-JUN-2000; 2000US-00608408.  
PR  
XX 03-AUG-2000; 2000US-00632366.  
PR  
XX 21-SEP-2000; 2000US-0234687P.  
PR  
XX 27-SEP-2000; 2000US-0236359P.  
PR  
XX 04-OCT-2000; 2000GB-00024263.  
XX  
XX (MOLE-) MOLECULAR DYNAMICS INC.  
PA  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI  
XX WPI; 2001-488899/53.  
XX  
XX Single exon nucleic acid probes for analyzing gene expression in human  
PT hearts.  
XX  
XX Claim 1; SEQ ID NO 1682; 530pp; English.  
XX  
XX The present invention relates to single exon nucleic acid probes for  
CC measuring human gene expression in a sample derived from human heart. The  
CC present sequence is one such probe. The probes may be used for  
CC predicting, measuring and displaying gene expression in samples derived  
CC from the human heart via microarrays. By measuring gene expression, the  
CC probes are useful for predicting, diagnosing, grading, staging,  
CC monitoring and prognosing diseases of the human heart and vascular system  
CC e.g. cardiovascular disease, hypertension, cardiac arrhythmias and  
CC congenital heart disease. Note: The sequence data for this patent did not  
CC form part of the printed specification, but was obtained in electronic  
XX format directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences

XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTTGATGATTTGAGATTTATCAATGAGCA 973  
DB 182 ATATATATCCATTCAGTGTGTCATTTCAATATAAATTTGATGAGGAAACAAAAATCAATTC 123  
QY 974 GTGTTTGGGATTTCTGTTATCTTGCACCTGTGAAG 1009  
DB 122 CTGTCCTGGGACACTGTCTGCTGGGTTTGTCCAG 87

RESULT 228  
AAK27166/c

ID AAK27166 standard; DNA; 474 BP.  
XX  
XX AAK27166;  
XX  
XX 06-NOV-2001 (first entry)  
DT



```
XX DE Human bone marrow expressed single exon probe SEQ ID NO: 1723.
XX KW Human; bone marrow expressed exon; gene expression analysis; probe;
XX KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX OS Homo sapiens.
XX PN WO200157276-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000668.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WIPI; 2001-488900/53.
XX PT Human genome-derived single exon nucleic acid probes useful for analyzing
XX PT gene expression in human bone marrow.
XX PS Example 4; SEQ ID NO 1723; 658pp + Sequence Listing; English.
XX CC The present invention provides a number of single exon nucleic acid
XX CC probes which are derived from genomic sequences expressed in the human
XX CC bone marrow. They can be used to measure gene expression in bone marrow
XX CC samples, which may enable the improved diagnosis and treatment of cancers
XX CC such as lymphoma, leukaemia and myeloma. The present sequence is one of
XX CC the probes of the invention
XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 914 ATCTTTTCTAGAGAAATTAGATCATTCAGTCATTCGATGTTGAGAAATTATCAATGAGCA 973
DB 182 ATATATTCCTCAGTCATTCATTTATTAATCACTTTGATGAGGAAACAAATCAATTC 123

QY 974 GTGTTTGGAATCTTGTATCTTGCACCTTGGAAG 1009
DB 122 CTGCTGGGACACTGTCTGCTGGGTTTGTCCAG 87

RESULT 229
AAK01714/c
ID AAK01714 standard; DNA; 474 BP.
XX AC AAK01714;
XX KW Human; brain expressed exon; gene expression analysis; probe; microarray;
XX KW Alzheimer's disease; multiple sclerosis; schizophrenia; epilepsy; cancer;
XX KW ss.
XX OS Homo sapiens.
XX PN WO200157275-A2.
XX PD 05-NOV-2001 (first entry)
XX DE Human brain expressed single exon probe SEQ ID NO: 1705.
XX KW Human; bone marrow expressed exon; gene expression analysis; probe;
XX KW microarray; cancer; leukaemia; lymphoma; myeloma; ss.
XX OS Homo sapiens.
XX PN WO200157275-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
XX PR 27-SEP-2000; 2000US-0236359P.
XX PR 04-OCT-2000; 2000GB-00024263.
XX PA (MOLE-) MOLECULAR DYNAMICS INC.
XX PI Penn SG, Hanzel DK, Chen W, Rank DR;
XX WIPI; 2001-483446/52.
XX PT Single exon nucleic acid probes for analyzing gene expression in human
XX PT brains.
XX PS Example 4; SEQ ID NO 1705; 650pp + Sequence Listing; English.
XX CC The present invention provides a number of single exon nucleic acid
XX CC probes which are derived from genomic sequences expressed in the human
XX CC brain. They can be used to measure gene expression in brain cell samples,
XX CC which may enable the diagnosis and improved treatment of nervous system
XX CC diseases such as Alzheimer's disease, multiple sclerosis, schizophrenia,
XX CC epilepsy and cancers. The present sequence is one of the probes of the
XX CC invention
XX SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.8; DB 1; Length 474;
Best Local Similarity 51.0%; Pred. No. 54;
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;

QY 914 ATCTTTTCTAGAGAAATTAGATCATTCAGTCATTCGATGTTGAGAAATTATCAATGAGCA 973
DB 182 ATATATTCCTCAGTCATTCATTTATTAATCACTTTGATGAGGAAACAAATCAATTC 123

QY 974 GTGTTTGGAATCTTGTATCTTGCACCTTGGAAG 1009
DB 122 CTGCTGGGACACTGTCTGCTGGGTTTGTCCAG 87

RESULT 230
ABS26749/c
ID ABS26749 standard; DNA; 474 BP.
XX AC ABS26749;
XX KW Human; single exon nucleic acid probe; liver; cirrhosis;
XX KW hyperlipoproteinaemia; hyperlipidaemia; hypercholesterolaemia;
XX KW coronary heart disease; ss.
XX OS Homo sapiens.
XX PN WO200157273-A2.
XX PD 09-AUG-2001.
XX PF 30-JAN-2001; 2001WO-US000664.
XX PR 04-FEB-2000; 2000US-0180312P.
XX PR 26-MAY-2000; 2000US-0207456P.
XX PR 30-JUN-2000; 2000US-00608408.
XX PR 03-AUG-2000; 2000US-00632366.
XX PR 21-SEP-2000; 2000US-0234687P.
```

PR 27-SEP-2000; 2000US-0236359P.  
PR 04-OCT-2000; 2000GB-00024263.  
XX (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
PI WPI; 2001-488898/53.  
XX Human genome-derived single exon nucleic acid probes useful for analyzing  
PT gene expression in human adult liver.  
XX Claim 1; SEQ ID NO 1739; 658bp; English.  
XX The invention relates to a single exon nucleic acid probe (SENP) (I) for  
CC measuring human gene expression in a sample derived from human adult  
CC liver, comprising one of 13109 defined nucleotide sequences given in the  
CC specification (or complements/ fragments). The probe hybridises at high  
CC stringency to a nucleic acid molecule expressed in the human adult liver.  
CC (I) may be used for predicting, measuring and displaying gene expression  
CC in samples derived from human adult liver. The genes identified may be  
CC involved in genetic liver diseases such as cirrhosis,  
CC hyperlipoproteinaemia, hyperlipidaemia and hypercholesterolaemia which is  
CC associated with coronary heart disease. ABS25011-ABS1005 represent human  
CC liver single exon nucleic acid probes of the invention. Note: The  
CC sequence information for this patent does not appear in the printed  
CC specification but was obtained in electronic format directly from WIPO at  
CC ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCATGTTGAGATTAATCAATGACCA 973  
DB 182 ATAATATTCATTCAGTGTCATTTTCAATATAACTTTGATGAGGAAACAAAAATCAATTC 123  
QY 974 GTGTTTGGGATTCCTTGTTATCTTGCACCTGTGGAAG 1009  
DB 122 CTGCTGGGGACATGCTGCTGGGTTTGTCCAG 87  
RESULT 231  
AAI01681/c  
ID AAI01681 standard; DNA; 474 BP.  
XX AA\*01681;  
XX  
XX 09-OCT-2001 (first entry)  
XX Probe #1672 used to measure gene expression in human breast sample.  
XX Probe; human; breast disease; breast cancer; development disorder; ss;  
XX inflammatory disease; proliferative breast disease; non-carcinoma tumour.  
XX Homo sapiens.  
XX  
XX WO200157270-A2.  
XX  
XX 09-AUG-2001.  
XX  
XX 29-JAN-2001; 2001WO-US000661.  
XX  
XX 04-FEB-2000; 2000US-0180312P.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 30-JUN-2000; 2000US-00608408.  
XX 03-AUG-2000; 2000US-00632366.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.  
XX 04-OCT-2000; 2000GB-00024263.

PA (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
XX WPI; 2001-476286/51.  
XX Novel single exon nucleic acid probe used to measuring gene expression in  
PT a human breast.  
XX  
XX Claim 25; SEQ ID NO 1672; 322bp; English.  
XX The present invention relates to novel single exon nucleic acid probes.  
XX The present sequence is one such probe. The probes are useful for  
CC measuring human gene expression in a human breast sample, where the probe  
CC hybridises at high stringency to a nucleic acid expressed in the human  
CC breast. The probes are useful for predicting, diagnosing, grading,  
CC staging, monitoring and prognosing diseases of the human breast,  
CC particularly those diseases with polygenic aetiology. The diseases  
CC include: breast cancer, disorders of development, inflammatory diseases  
CC of the breast, fibrocystic changes, proliferative breast disease and non-  
CC carcinoma tumours. Note: The sequence data for this patent did not form  
CC part of the printed specification, but was obtained in electronic format  
CC directly from WIPO at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
QY 914 ATCTTTTCTAGAGAAATTAAGATCATTCAGTCATTCATGTTGAGATTAATCAATGACCA 973  
DB 182 ATAATATTCATTCAGTGTCATTTTCAATATAACTTTGATGAGGAAACAAAAATCAATTC 123  
QY 974 GTGTTTGGGATTCCTTGTTATCTTGCACCTGTGGAAG 1009  
DB 122 CTGCTGGGGACATGCTGCTGGGTTTGTCCAG 87  
RESULT 232  
ABS01717/c  
ID ABS01717 standard; DNA; 474 BP.  
XX ABS01717;  
XX  
XX 19-AUG-2002 (first entry)  
XX Human genome-derived single exon probe from lung SEQ ID No 1708.  
XX  
XX Human; ds; single exon probe; asthma; lung cancer; COPD; ILD;  
XX chronic obstructive pulmonary disease; interstitial lung disease;  
XX familial idiopathic pulmonary fibrosis; neurofibromatosis;  
XX tuberous sclerosis; Gaucher's disease; Niemann-Pick disease;  
XX Hermansky-Pudlak syndrome; sarcoidosis; pulmonary haemosiderosis;  
XX pulmonary histiocytosis; lymphangioleiomyomatosis; Karagener syndrome;  
XX pulmonary alveolar proteinosis; fibrocystic pulmonary dysplasia;  
XX primary ciliary dyskinesia; pulmonary hypertension;  
XX hyaline membrane disease.  
XX  
XX Homo sapiens.  
XX  
XX WO200186003-A2.  
XX  
XX 15-NOV-2001.  
XX  
XX 30-JAN-2001; 2001WO-US000665.  
XX  
XX 04-FEB-2000; 2000US-0180312P.  
XX 26-MAY-2000; 2000US-0207456P.  
XX 30-JUN-2000; 2000US-00608408.  
XX 03-AUG-2000; 2000US-00632366.  
XX 21-SEP-2000; 2000US-0234687P.  
XX 27-SEP-2000; 2000US-0236359P.

PR 04-OCT-2000; 2000GB-00024263.  
XX (MOLE-) MOLECULAR DYNAMICS INC.  
XX Penn SG, Hanzel DK, Chen W, Rank DR;  
XX WPI; 2002-114183/15.  
XX  
PT Spatially-addressable set of single exon nucleic acid probes, used to  
PT measure gene expression in human lung samples.  
XX  
PS Claim 1; SEQ ID NO 1708; 634pp; English.  
XX  
CC The invention relates to a spatially-addressable set of single exon  
CC nucleic acid probes for measuring gene expression in a sample derived  
CC from human lung comprising single exon nucleic acid probes having one of  
CC 12614 nucleic acid sequences mentioned in the specification, or their  
CC complements or the 12387 open reading frames derived from the 12614  
CC probes. Also included are a microarray comprising the novel set of probes  
CC ; the novel set of probes which hybridise at high stringency to a nucleic  
CC acid expressed in the human lung; measuring gene expression in a sample  
CC derived from human lung, comprising (a) contacting the array with a  
CC collection of detectably labeled nucleic acids derived from human lung  
CC mRNA, and (b) measuring the label detectably bound to each probe of the  
CC array; identifying exons in a eukaryotic genome, comprising (a)  
CC algorithmically predicting at least one exon from genomic sequences of  
CC the eukaryote; and (b) detecting specific hybridisation of detectably  
CC labeled nucleic acids from eukaryote lung mRNA, to a single exon probe,  
CC having a fragment identical to the predicted exon, the probe is included  
CC in the above mentioned microarray; assigning exons to a single gene,  
CC comprising (a) identifying exons from genomic sequence by the method  
CC above and (b) measuring the expression of each of the exons in several  
CC tissues and/or cell types using hybridisation to a single exon  
CC microarrays having a probe with the exon, where a common pattern of  
CC expression of the exons in the tissues and/or cell types indicates that  
CC the exons should be assigned to a single gene; a peptide comprising one  
CC of 12011 sequences, mentioned in the specification, or encoded by the  
CC probes/open reading frames (ORF). The probes are used for gene expression  
CC analysis, and for identifying exons in a gene, particularly using human  
CC lung derived mRNA and for the study of lung diseases such as asthma, lung  
CC cancer, chronic obstructive pulmonary disease (COPD), interstitial lung  
CC disease (ILD), familial idiopathic pulmonary fibrosis, neurofibromatosis,  
CC tuberculous scleriosis, Gaucher's disease, Niemann-Pick disease, Hermansky-  
CC Pudlak syndrome, sarcoidosis, pulmonary haemosiderosis, pulmonary  
CC histiocytosis, lymphangioleiomyomatosis, pulmonary alveolar proteinosis,  
CC Karagener syndrome, fibrocystic pulmonary dysplasia, primary ciliary  
CC dyskinesia, pulmonary hypertension and hyaline membrane disease. The  
CC present sequence is a single exon probe of the invention. Note: The  
CC sequence data for this patent did not form part of the printed  
CC specification, but was obtained in electronic format directly from WIPO  
CC at ftp.wipo.int/pub/published\_pct\_sequences  
XX  
SQ Sequence 474 BP; 121 A; 114 C; 119 G; 120 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 20.8; DB 1; Length 474;  
Best Local Similarity 51.0%; Pred. No. 54;  
Matches 49; Conservative 0; Mismatches 47; Indels 0; Gaps 0;  
  
QY 914 ATCTTTTCAGAGAAATTAGATTCATTGAGTCATTGATCTTGCAGATTATCATGACGA 973  
DB 182 ATATATTCATTCAGTCAGTCATTTCATTATTAATTGATGAGGAAACAAATCATCTTC 123  
  
QY 974 GTGTTTGTGGAATCTTGTATCTTGCACCTTGTGAAG 1009  
DB 122 CTGTCTGGGACACTGTCTGCTGGGTGTTTGTCCAG 87  
  
RESULT 233  
AAAG1697/C  
ID AAA61697 standard; cDNA; 1036 BP.  
XX  
AC AAA61697;  
XX

DT 23-OCT-2000 (first entry)  
XX  
XX cDNA encoding human serine protease BSSP4 (hBSSP4) SEQ ID NO:5.  
XX  
XX BSSP4; serine protease; human; hBSSP4; mouse; mBSSP4; brain;  
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;  
KW oedema; dropsy; cancer; inflammation; prostate; testis; bone; ss.  
XX  
XX Homo sapiens.  
OS  
XX WO200031277-A1.  
PN  
XX 02-JUN-2000.  
PD  
XX 19-NOV-1999; 99WO-JP006472.  
PF  
XX 20-NOV-1998; 98JP-00347813.  
PR  
XX (FUSO ) FUSO PHARM IND LTD.  
PA  
XX Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;  
XX WPI; 2000-400084/34.  
PI  
XX P-PSDB; AAB11702.  
DR  
PT Serine protease BSSP4 and antibodies recognizing BSSP4 for assay and  
PT diagnosis of diseases in which BSSP4 expression is altered.  
XX  
PS Claim 6; Page 71-73; 111pp; Japanese.  
XX  
CC The invention relates to novel serine proteases designated BSSP4  
CC (AAB11700-B11709), and to nucleic acids encoding them (AAA61695-A61704,  
CC AAA61799). The invention also relates to vectors and transformants  
CC comprising BSSP4 nucleic acids; transgenic animals in which the  
CC expression level of BSSP4 can be varied; and an mBSSP4 knockout mouse.  
CC The invention additionally encompasses anti-BSSP4 antibodies and methods  
CC of production of such antibodies, methods of BSSP4 detection using the  
CC antibodies, and the use of BSSP4 proteins or fragments as diagnostic  
CC markers for certain medical conditions. Nucleotides encoding BSSP4 were  
CC initially isolated in a human brain cDNA library using degenerate PCR  
CC primers (AAA61714-A61715) based on conserved regions of serine proteases.  
CC The BSSP4 serine proteases and nucleotides encoding them are useful in  
CC detecting homologues, mutants and polymorphic variants in biological  
CC samples (e.g., blood, urine, brain, prostate gland and testis) as  
CC diagnostic markers for diseases associated with altered BSSP4 expression  
CC levels. Such diseases include Alzheimer's disease, oedema (dropsy),  
CC cancer or inflammation of brain, prostate, testis or bone. Sequences  
CC AAA61695-A61703 and AAA61799 represent cDNAs encoding human BSSP4  
CC variants (hBSSP4), and sequence AAA61704 represents cDNA encoding murine  
CC BSSP4 (mBSSP4)  
XX  
SQ Sequence 1036 BP; 205 A; 310 C; 301 G; 220 T; 0 U; 0 Other;  
  
Query Match 1.0%; Score 20.6; DB 1; Length 1036;  
Best Local Similarity 62.7%; Pred. No. 73;  
Matches 32; Conservative 0; Mismatches 19; Indels 0; Gaps 0;  
  
QY 1131 TTATTTATTCATTAATTTCTGAAATGTTGGTAACTTTAGATTGAAG 1181  
DB 1029 TTTTITTTTTTTTTTTTCTGGAGATAAATAATTATTGAAATTGGAG 979  
  
RESULT 234  
AAH19463/C  
ID AAH19463 standard; DNA; 1206 BP.  
XX  
XX AAH19463;  
XX  
XX 31-JUL-2001 (first entry)  
DT  
XX Mutant blood coagulant factor VII (FVII-31) coding sequence.  
XX  
XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;  
KW

KW mutant; ds.  
XX OS Homo sapiens.  
OS Synthetic.  
XX FH Key  
FT CDS Location/Qualifiers  
FT 1..1206  
FT /\*tag= a  
FT /product= "FVII-31"  
FT /partial  
FT /note= "No start codon given"  
XX JP2001061479-A.  
PN 13-MAR-2001.  
XX PD  
XX PF 24-AUG-1999; 99JP-00237610.  
XX PR 24-AUG-1999; 99JP-00237610.  
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.  
XX WPI; 2001-310677/33.  
XX P-PSDB; AAB84870.  
XX Mutant of blood coagulant factor VII, used for substitution therapy in the treatment of hemophilia.  
XX Disclosure; Page 19-20; 29pp; Japanese.  
XX The present invention relates to mutants of blood coagulant factor VII (FVII) or activated blood coagulant factor VII (FVIIa). The present sequence is the coding sequence for one such mutant FVII: VII-31. The mutants can be used as an agent for the substitution therapy of haemophilia inhibitor patients  
XX Sequence 1206 BP; 244 A; 359 C; 386 G; 217 T; 0 U; 0 Other;  
XX Query Match 1.0%; Score 20.6; DB 1; Length 1206;  
XX Best Local Similarity 59.3%; Pred. No. 76;  
XX Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 334 TTCAAATGCTTTTATCTGTCGAGACTGCTTCTTTGAAATATGTTCAATTTGG 392  
DB 444 TTTCGTCGCAATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGG 386  
XX  
XX RESULT 235  
XX AAH19464/c  
XX ID AAH19464 standard; DNA; 1206 BP.  
XX AC AAH19464;  
XX DT 31-JUL-2001 (first entry)  
XX DE Mutant blood coagulant factor VII (FVII-39) coding sequence.  
XX KW Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;  
XX mutant; ds.  
XX OS Homo sapiens.  
XX OS Synthetic.  
XX FH Key  
XX CDS Location/Qualifiers  
XX 1..1206  
XX /\*tag= a  
XX /product= "FVII-39"  
XX /partial  
XX /note= "No start codon given"  
XX JP2001061479-A.  
XX PN 13-MAR-2001.  
XX PD

XX 24-AUG-1999; 99JP-00237610.  
XX PR 24-AUG-1999; 99JP-00237610.  
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.  
XX WPI; 2001-310677/33.  
XX P-PSDB; AAB84871.  
XX Mutant of blood coagulant factor VII, used for substitution therapy in the treatment of hemophilia.  
XX Disclosure; Page 22-23; 29pp; Japanese.  
XX The present invention relates to mutants of blood coagulant factor VII (FVII) or activated blood coagulant factor VII (FVIIa). The present sequence is the coding sequence for one such mutant FVII: VII-39. The mutants can be used as an agent for the substitution therapy of haemophilia inhibitor patients  
XX Sequence 1206 BP; 247 A; 354 C; 387 G; 218 T; 0 U; 0 Other;  
XX Query Match 1.0%; Score 20.6; DB 1; Length 1206;  
XX Best Local Similarity 59.3%; Pred. No. 76;  
XX Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 334 TTCAAATGCTTTTATCTGTCGAGACTGCTTCTTTGAAATATGTTCAATTTGG 392  
DB 444 TTTCGTCGCAATTTCTTTTCTAGAAATAGGTATTTTCCACATGGATATTCACACTGG 386  
XX  
XX RESULT 236  
XX AAH19459/c  
XX ID AAH19459 standard; DNA; 1221 BP.  
XX AC AAH19459;  
XX DT 31-JUL-2001 (first entry)  
XX DE Wild-type human blood coagulant factor VII (FVII) coding sequence.  
XX KW Human; haemostatic; blood coagulant factor VII; FVII; haemophilia; ds.  
XX OS Homo sapiens.  
XX FH Key  
XX CDS Location/Qualifiers  
XX 1..1221  
XX /\*tag= a  
XX /product= "FVII"  
XX /partial  
XX /note= "No start codon given"  
XX JP2001061479-A.  
XX PN 13-MAR-2001.  
XX PD 24-AUG-1999; 99JP-00237610.  
XX PF 24-AUG-1999; 99JP-00237610.  
XX PR 24-AUG-1999; 99JP-00237610.  
XX PA (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.  
XX WPI; 2001-310677/33.  
XX P-PSDB; AAB84866.  
XX Mutant of blood coagulant factor VII, used for substitution therapy in the treatment of hemophilia.  
XX Example 1; Page 7-8; 29pp; Japanese.  
XX The present invention relates to mutants of blood coagulant factor VII (FVII) or activated blood coagulant factor VII (FVIIa). The present

CC sequence is the coding sequence for wild-type human FVII. The mutants can  
CC be used as an agent for the substitution therapy of haemophilia inhibitor  
CC patients  
XX  
SQ Sequence 1221 BP; 248 A; 362 C; 392 G; 219 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1221;  
Best Local Similarity 59.3%; Pred. No. 76;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGGTTTGAATATGATTCATTTGG 392  
Db 444 TTTCGTCGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 237  
AAH19460/c  
ID AAH19460 standard; DNA; 1221 BP.

XX AC AAH19460;  
XX  
DT 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-5) coding sequence.  
XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;  
XX mutant; ds.

XX Homo sapiens.  
XX Synthetic.

XX Key Location/Qualifiers  
XX CDS 1..1221  
XX FT /\*tag= a  
XX FT /product= "FVII-5"  
XX FT /partial  
XX FT /note= "No start codon given"

XX JP2001061479-A.  
XX  
PD 13-MAR-2001.

XX 24-AUG-1999; 99JP-00237610.  
XX

XX 24-AUG-1999; 99JP-00237610.  
XX

XX (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.  
XX  
DR WPI; 2001-310677/33.  
DR P-PSDB; AAB84867.

XX Mutant of blood coagulant factor VII, used for substitution therapy in  
XX the treatment of hemophilia.

XX Disclosure; Page 10-11; 29pp; Japanese.

XX The present invention relates to mutants of blood coagulant factor VII  
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present  
XX sequence is the coding sequence for one such mutant FVII: VII-5. In the  
XX wild-type protein (AAB84866), there is a disulphide bond (159Cys-164Cys).  
XX In VII-5, the disulphide bond is disrupted. The mutants can be used as an  
XX agent for the substitution therapy of haemophilia inhibitor patients

XX Sequence 1221 BP; 248 A; 365 C; 392 G; 216 T; 0 U; 0 Other;  
XX  
Query Match 1.0%; Score 20.6; DB 1; Length 1221;  
Best Local Similarity 59.3%; Pred. No. 76;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGGTTTGAATATGATTCATTTGG 392  
Db 444 TTTCGTCGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 238  
AAH19461/c

ID AAH19461 standard; DNA; 1221 BP.

XX AC AAH19461;

XX 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-6) coding sequence.

XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;  
XX mutant; ds.

XX Homo sapiens.  
XX Synthetic.

XX Key Location/Qualifiers  
XX CDS 1..1221  
XX FT /\*tag= a  
XX FT /product= "FVII-6"  
XX FT /partial  
XX FT /note= "No start codon given"

XX JP2001061479-A.

XX 13-MAR-2001.

XX 24-AUG-1999; 99JP-00237610.

XX 24-AUG-1999; 99JP-00237610.

XX (KAGA ) ZH KAGAKU & KESSEI RYOHO KENKYUSHO.

XX WPI; 2001-310677/33.

XX P-PSDB; AAB84868.

XX Mutant of blood coagulant factor VII, used for substitution therapy in  
XX the treatment of hemophilia.

XX Disclosure; Page 13-14; 29pp; Japanese.

XX The present invention relates to mutants of blood coagulant factor VII  
XX (FVII) or activated blood coagulant factor VII (FVIIa). The present  
XX sequence is the coding sequence for one such mutant FVII: VII-6. The  
XX mutants can be used as an agent for the substitution therapy of  
XX haemophilia inhibitor patients

XX Sequence 1221 BP; 248 A; 365 C; 391 G; 217 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.6; DB 1; Length 1221;  
Best Local Similarity 59.3%; Pred. No. 76;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTGCGAGACTGCTTTGGTTTGAATATGATTCATTTGG 392  
Db 444 TTTCGTCGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACCTGG 386

RESULT 239  
AAH19462/c

ID AAH19462 standard; DNA; 1221 BP.

XX AC AAH19462;

XX 31-JUL-2001 (first entry)

XX Mutant blood coagulant factor VII (FVII-30) coding sequence.

XX Human; haemostatic; blood coagulant factor VII; FVII; haemophilia;  
XX mutant; ds.

XX Homo sapiens.

OS	Synthetic.	PR	28-NOV-2001; 2001US-0334301P.
XX		PR	07-JUN-2002; 2002US-0387292P.
FH	Key	PR	25-JUN-2002; 2002US-0391777P.
CDS	Location/Qualifiers	PR	17-JUL-2002; 2002US-0396594P.
FT	1. .1221	PR	16-AUG-2002; 2002US-0404249P.
FT	/*tag= a	PR	28-AUG-2002; 2002US-0407527P.
FT	/product= "FVII-30"	XX	(NEOS-) NEOSE TECHNOLOGIES INC.
FT	/partial	XX	De Frees S, Zopf D, Bayer R, Bowe C, Hakes D, Chen X;
FT	/note= "No start codon given"	XX	WPI; 2003-449162/42.
XX		DR	P-PSDB; ABR55842.
XX		XX	Remodeling a peptide, by removing a saccharyl subunit from the peptide to form truncated glycan, and adding or deleting glycosyl groups to a peptide and/or adding modifying group of a peptide to remodel the peptide.
XX		XX	Example; Fig 55A; 900pp; English.
XX		XX	The invention relates to a cell-free, in vitro method of remodeling a peptide. The method involves removing a saccharyl subunit from the peptide, thus forming a truncated glycan, and contacting the truncated glycan with at least one glycosyltransferase and at least one glycosyl donor under conditions suitable to transfer at least one glycosyl donor to the truncated glycan, thus remodeling the peptide. Conjugates can be formed between a granulocyte colony stimulating factor (G-CSF) peptide, interferon alpha peptide, interferon beta peptide, Factor VIIa peptide, Factor IX peptide, follicle stimulating hormone peptide, erythropoietin (EPO) peptide, granulocyte macrophage colony stimulating factor (GM-CSF) peptide, interferon-gamma peptide, alpha-1-protease inhibitor (A-1-PI) peptide, beta-glucosidase peptide, tissue plasminogen activator (TPA) peptide, interleukin-2 (IL-2) peptide, Factor VIII peptide, TNFalpha receptor/immunoglobulin (Ig) G fusion peptide, urokinase peptide, anti-glycoprotein Iib/Iiia monoclonal antibody peptide, chimeric anti HER2 antibody peptide, anti-respiratory syncytial virus (RSV) F peptide, anti-CD20 antibody peptide, recombinant DNase peptide, anti-TNF alpha peptide, insulin peptide, hepatitis B surface antigen (HbsAg), human growth hormone (HGH) peptide, and a modifying group, where the modifying group is covalently attached to the peptide through an intact glycosyl linking group. The method is useful for a cell-free, in vitro method of remodeling the above mentioned peptides. The present sequence represents a human Factor VIIa encoding DNA
XX		XX	Sequence 1332 BP; 260 A; 405 C; 426 G; 241 T; 0 U; 0 Other;
SQ		SQ	Query Match 1.0%; Score 20.6; DB 1; Length 1332;
			Best Local Similarity 59.3%; Pred. No. 77;
			Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;
QY		QY	334 TTCAATGCTTTTATCTGTCGAGACTTGCTTTGTTTGAATATGATTCATTTGG 392
Db		Db	444 TTTCGTCGATTTCTTTTCTAGATAGGTATTTTCCACATGGATTCACACTGTGG 500
RESULT 240			
ACC78872/c			
ID	ACC78872 standard; DNA; 1332 BP.		
AC	ACC78872;		
XX			
DT	02-SEP-2003 (first entry)		
XX			
DE	Human Factor VIIa encoding DNA.		
XX			
KW	Peptide remodeling; glycoconjugation; glycosyltransferase; glycan;		
KW	Factor VIIa; human; gene; ds.		
XX			
OS	Homo sapiens.		
XX			
Key	Location/Qualifiers		
FH	1. .1332		
CDS	/*tag= a		
FT	/product= "Factor VIIa"		
FT			
XX			
PN	WO2003031464-A2.		
XX			
PD	17-APR-2003.		
XX			
PF	09-OCT-2002; 2002WO-US032263.		
XX			
PR	10-OCT-2001; 2001US-0328523P.		
PR	19-OCT-2001; 2001US-0344692P.		
PR	28-NOV-2001; 2001US-0334233P.		







(WHED ) WHITEHEAD INST BIOMEDICAL RES.



PT for detecting presence of prostate cancer, stage of prostate cancer.  
XX Claim 1; Page 1389; 11750pp; English.  
XX  
CC The invention relates to an isolated nucleic acid molecule (I) comprising  
CC a nucleotide sequence given in Tables 1-9 (ABV00010-ABV62213) of the  
CC specification or its complement. (I) is useful for: (a) assessing whether  
CC a patient is afflicted with prostate cancer; (b) monitoring the  
CC progression of prostate cancer in a patient; (c) assessing the efficacy  
CC of a test compound to inhibit prostate cancer in a patient; (d) assessing  
CC the efficacy of a therapy for inhibiting prostate cancer in a patient;  
CC (e) selecting a composition for inhibiting prostate cancer in a patient;  
CC (f) assessing the prostate cell carcinogenic potential of a compound; (g)  
CC determining whether prostate cancer has metastasized in a patient; (h)  
CC assessing the aggressiveness or indolence of prostate cancer in a patient  
CC ; (i) is also useful as a pharmacodynamic or pharmacogenomic marker  
XX  
SQ Sequence 397 BP; 85 A; 89 C; 82 G; 141 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.4; DB 1; Length 397;  
Best Local Similarity 52.3%; Pred. No. 67;  
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;  
QY 1097 TGTCTCTCCCTTTTGATTTTGGCTGGAATTATTATTATTTCTTGA 1156  
Db 34 TCTTCTTTGCACACACCTCAATGTTGCCCTGTCTTATTCTTCAAAAACCCATTAGCT 93  
QY 1157 TGTGGGTAAACATCTTTAGATTGAAGT 1182  
Db 94 CTGGGTAGCGTTTAAATAGGAATT 119

RESULT 250  
ID AAA61659 standard; cDNA; 717 BP.  
AC AAA61659;  
XX  
DT 23-OCT-2000 (first entry)  
XX  
DE cDNA encoding mouse serine protease BSSP2 (mBSSP2), SEQ ID NO:1.  
XX  
KW BSSP2; serine protease; mouse; mBSSP2; human; hBSSP2; brain;  
KW diagnostic marker; antibody; transgenic animal; Alzheimer's disease;  
KW epilepsy; cancer; inflammation; inflammatory disorder; infertility;  
KW prostatic hypertrophy; ss.

OS Mus sp.  
XX  
XX WO200031272-A1.  
XX  
XX 02-JUN-2000.  
XX  
XX 19-NOV-1999; 99WO-JP006475.  
XX  
XX 20-NOV-1998; 98JP-00347785.  
XX  
XX (FUSO ) FUSO PHARM IND LTD.  
XX  
XX Uemura H, Okui A, Kominami K, Yamaguchi N, Mitsui S;  
XX  
XX WPI; 2000-400082/34.  
XX  
XX P-PSDB; AAB11695.  
XX  
XX Serine protease BSSP2, useful in detecting homologs, mutants and  
XX polymorphic variants as markers for diagnosis of e.g. Alzheimer's  
XX disease, cancer, inflammation and prostate hypertrophy, using blood,  
XX urine or other tissues.  
XX  
XX Claim 2; Page 55-57; 92pp; Japanese.

XX The invention relates to novel serine proteases designated BSSP2  
XX (AAB11695-B11699), and to nucleic acids encoding them (AAA61659-A61663).  
CC

CC The invention also relates to vectors and transformants comprising BSSP2  
CC nucleic acids; transgenic animals in which the expression level of BSSP2  
CC can be varied; and an mBSSP2 knockout mouse. The invention additionally  
CC encompasses anti-BSSP2 antibodies and methods of production of such  
CC antibodies, methods of BSSP2 detection using the antibodies, and the use  
CC of BSSP2 proteins or fragments as diagnostic markers for certain medical  
CC conditions. Nucleotides encoding BSSP2 were initially isolated in a mouse  
CC brain cDNA library using degenerate PCR primers (AAA61673-AAA61674)  
CC based on conserved regions of serine proteases. The BSSP2 serine  
CC proteases and nucleotides encoding them are useful in detecting  
CC homologues, mutants and polymorphic variants in biological samples (e.g.,  
CC blood, urine, brain, prostate gland and testis) as diagnostic markers for  
CC conditions such as Alzheimer's disease, epilepsy, cancer, inflammation,  
CC infertility and prostatic hypertrophy. Sequences AAA61659-A61662  
CC represent cDNAs encoding murine BSSP2 variants (mBSSP2), and sequence  
CC AAA61663 represents cDNA encoding human BSSP2 (hBSSP2)

XX  
SQ Sequence 717 BP; 138 A; 204 C; 221 G; 154 T; 0 U; 0 Other;

Query Match 1.0%; Score 20.4; DB 1; Length 717;  
Best Local Similarity 52.3%; Pred. No. 77;  
Matches 45; Conservative 0; Mismatches 41; Indels 0; Gaps 0;  
QY 26 TATTTTCTTGAAGCTCTGCTGGCAATACTTCTGGGGCTGCTTCTCCCTGTCTGA 85  
Db 107 TAGTACTGCTGCCCACTGCATGTACAGTTTACAGCTGTCCCGCTATCCAGCTGGCGGG 166  
QY 86 TTCCTAGGGTGAGGGTTACCACTGCT 111  
Db 167 TTCATGCAGGGCTGGTCAAGCATGGT 192

Search completed: August 9, 2004, 17:01:34  
Job time : 790 secs



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.  
OM nucleic - nucleic search, using sw model  
Run on: August 9, 2004, 16:49:06 ; Search time 10 seconds  
(without alignments)  
3.696 Million cell updates/sec  
Title: us-10-664-775-3  
Perfect score: 2003  
Sequence: 1 agctttccagagacttca.....tcaaggacctttatgaatt 2003  
Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5  
Searched: 20 seqs, 9225 residues  
Total number of hits satisfying chosen parameters: 40  
Minimum DB seq length: 0  
Maximum DB seq length: 2000000000  
Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries  
Database : rniadb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20.6	1.0	1440	1	US-07-882-202A-3
C 2	20.6	1.0	1440	1	US-08-021-615A-3
C 3	20.6	1.0	1440	1	US-08-321-777-3
C 4	20.6	1.0	1440	1	US-09-009-217-13
C 5	20.6	1.0	1440	1	US-09-009-656-13
C 6	20.6	1.0	1440	1	PCT-US93-04493-3
C 7	16.6	0.8	1440	1	US-07-882-202A-3
C 8	16.6	0.8	1440	1	US-08-021-615A-3
C 9	16.6	0.8	1440	1	US-09-009-217-13
C 10	16.6	0.8	1440	1	US-09-009-656-13
C 11	16.6	0.8	1440	1	PCT-US93-04493-3
C 12	12.8	0.6	141	1	US-08-849-248-6
C 13	12.8	0.6	141	1	US-08-849-248-6
C 14	12.8	0.6	141	1	US-09-558-027-4
C 15	12.8	0.6	141	1	US-09-558-027-4
C 16	11.2	0.6	27	1	US-08-293-778-17
C 17	11.2	0.6	27	1	US-08-293-778-16
C 18	11.2	0.6	27	1	US-09-558-027-4
C 19	10.6	0.5	38	1	US-08-955-636-8
C 20	10.6	0.5	42	1	US-08-756-506-13
C 21	10.4	0.5	45	1	US-08-756-506-13
C 22	10.4	0.5	35	1	US-07-998-972A-7
C 23	10.4	0.5	35	1	US-08-463-953-7
C 24	10.4	0.5	35	1	US-08-462-261-7
C 25	10.4	0.5	35	1	PCT-US92-11357-7
C 26	9.8	0.5	27	1	US-08-293-778-16
C 27	9.4	0.5	27	1	US-08-293-778-17
C 28	9.4	0.5	35	1	US-07-998-972A-7
C 29	9.4	0.5	35	1	US-08-463-953-7
C 30	9.4	0.5	35	1	US-08-462-261-7
C 31	9.4	0.5	35	1	PCT-US92-11357-7
C 32	9.4	0.5	36	1	US-08-955-636-9
C 33	9.4	0.5	36	1	US-08-955-636-10

C 34 9.2 0.5 26 1 US-08-293-778-22 Sequence 22, Appl  
C 35 9.2 0.5 27 1 US-08-293-778-20 Sequence 20, Appl  
C 36 8.8 0.4 42 1 US-08-955-636-8 Sequence 8, Appl  
C 37 8.6 0.4 27 1 US-08-293-778-20 Sequence 20, Appl  
C 38 8.4 0.4 36 1 US-08-955-636-9 Sequence 9, Appl  
C 39 8.4 0.4 36 1 US-08-955-636-10 Sequence 10, Appl  
C 40 7.4 0.4 26 1 US-08-293-778-22 Sequence 22, Appl

ALIGNMENTS

RESULT 1  
US-07-882-202A-3/c  
; Sequence 3, Application US/07882202A  
; Patent No. 5374617  
; GENERAL INFORMATION:  
; APPLICANT: Morrissey, James H.  
; APPLICANT: Comp, Philip C.  
; TITLE OF INVENTION: Treatment of Bleeding with Modified  
; TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
; NUMBER OF SEQUENCES: 4  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Richards, Medlock & Andrews  
; STREET: 1201 Elm Street, Suite 4500  
; CITY: Dallas  
; STATE: Texas  
; COUNTRY: US  
; ZIP: 75270-2197  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: Patent in Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/882,202A  
; FILING DATE: 13-MAY-1992  
; CLASSIFICATION:  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Hansen, Eugenia S.  
; REGISTRATION NUMBER: 31,966  
; REFERENCE/DOCKET NUMBER: OMRP B34290  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 214-939-4500  
; TELEFAX: 214-939-4600  
; INFORMATION FOR SEQ ID NO: 3:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 1440 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: double  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
; HYPOTHETICAL: NO  
; ANTI-SENSE: NO  
; ORIGINAL SOURCE:  
; ORGANISM: Homo sapiens  
; TISSUE TYPE: Blood  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: 36..1433  
; OTHER INFORMATION: /note= "Coding portion of human  
; OTHER INFORMATION: factor VII cDNA"  
US-07-882-202A-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.85;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

OY 334 TTCAATGCTTTATCTGCGAGACTTCTTCTTTTGAATATGATTCATTTGG 392

Db 659 TTTCCTGCATTTCTTTTCTAGATAGGTATTTTCCACATGATTCACACTGG 601

10664775-3.rni

Mon Aug 9 17:47:19 2004

```

RESULT 2
US-08-021-615A-3/c
; Sequence 3, Application US/08021615A
; Patent No. 5504064
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; Tissue Factor in Combination with an Activator of
; FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/021.615A
; FILING DATE: 19-FEB-1993
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882.202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
;
US-08-021-615A-3
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGCCTTTGTTTGAATATGTTCAATTGG 392
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACCTGG 601

RESULT 3
US-08-321-777-3/c
; Sequence 3, Application US/08321777
; Patent No. 5504067
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp, Philip C.
; TITLE OF INVENTION: Treatment of Bleeding with Modified
; Tissue Factor in Combination with an Activator of
; FVII
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/321.777
; FILING DATE: 13-MAY-1992
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882.202
; FILING DATE: 13-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Hansen, Eugenia S.
; REGISTRATION NUMBER: 31,966
; REFERENCE/DOCKET NUMBER: OMRF B34290CIP
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4600
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; TISSUE TYPE: Blood
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 36..1433
; OTHER INFORMATION: /note= "Coding portion of human
; factor VII cDNA"
;
US-08-321-777-3
Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGCCTTTGTTTGAATATGTTCAATTGG 392
Db 659 TTGCTGGCAATTTCTTTTCTAGATAGGTATTTTCCACATGATATTCACCTGG 601

RESULT 4
US-09-009-217-13/c
; Sequence 13, Application US/09009217
; Patent No. 6132729
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND
; CHEMOTHERAPEUTIC METHODS AND COMPOSITIONS FOR COAGULATION
; TUMOR TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas

```



```

; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,217
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTTATCTGTCGAGACTTGTCTTTTGAATATGATATTCATTTGG 392
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGTATTTTCCACATGATATTCACCTGG 601

RESULT 5
US-09-009-656-13/c
; Sequence 13, Application US/09009656
; Patent No. 6132730
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E.
; APPLICANT: King, Steven W.
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: COMBINED TISSUE FACTOR AND FACTOR VIIa
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; TITLE OF INVENTION: TREATMENT
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: USA
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/009,656
; FILING DATE: Concurrently Herewith
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/042,427
; FILING DATE: 27-MAR-1997
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/036,205
; FILING DATE: 27-JAN-1997
; APPLICATION NUMBER: US 60/035,920
; FILING DATE: 22-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Hibler, David W.
; REGISTRATION NUMBER: 41,071
; REFERENCE/DOCKET NUMBER: UTSD:536
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 512/418-3000
; TELEFAX: 512/474-7577
; INFORMATION FOR SEQ ID NO: 13:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-009-217-13

Query Match 1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 0.85;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTTATCTGTCGAGACTTGTCTTTTGAATATGATATTCATTTGG 392
Db 659 TTGCTGGCAATTCCTTTTCTAGAAATAGTATTTTCCACATGATATTCACCTGG 601

RESULT 6
PCT-US93-04493-3/c
; Sequence 3, Application PC/TUS9304493
; GENERAL INFORMATION:
; APPLICANT: Morrissey, James H.
; APPLICANT: Comp. Philip C.
; TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or
; TITLE OF INVENTION: FVII Activator for Blood Coagulation
; NUMBER OF SEQUENCES: 4
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richards, Medlock & Andrews
; STREET: 1201 Elm Street, Suite 4500
; CITY: Dallas
; STATE: Texas
; COUNTRY: US
; ZIP: 75270-2197
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/04493
; FILING DATE: 19930512
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/882202
; FILING DATE: 13-MAY-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/021615
; FILING DATE: 19-FEB-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Trujillo, Doreen Y.
; REGISTRATION NUMBER: 35,719
; REFERENCE/DOCKET NUMBER: OMRF B34290CIPC/PCT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 214-939-4500
; TELEFAX: 214-939-4600
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 1440 base pairs

```

TYPE: NUCLEIC ACID  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433  
OTHER INFORMATION: /product= "Tissue Factor"  
OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"  
OTHER INFORMATION: /citation= ([1])  
PCT-US93-04493-3

Query Match 1.0%; Score 20.6; DB 1; Length 1440;  
Best Local Similarity 59.3%; Pred. No. 0.85; 24; Indels 0; Gaps 0;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATGCTTTATCTGTCGACACTGCTTTGTTTGAATATGATTCATTTTGG 392  
DB 659 TTGCTGCATTCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGG 601

RESULT 7  
US-07-882-202A-3  
Sequence 3, Application US/07882202A  
Patent No. 5374617  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
TITLE OF INVENTION: Treatment of Bleeding with Modified  
TITLE OF INVENTION: Tissue Factor in Combination with FVIIa  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/07882,202A  
FILING DATE: 13-MAY-1992  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882,202  
FILING DATE: 13-MAY-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Hansen, Eugenia S.  
REGISTRATION NUMBER: 31,966  
REFERENCE/DOCKET NUMBER: OMRP B34290  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433  
OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"  
OTHER INFORMATION: /citation= ([1])  
PCT-US93-04493-3

Query Match 0.8%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 1.2; 14; Indels 0; Gaps 0;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTCGCTTCCTCGATG 1693  
DB 58 TCCTTGCCTTCTGCTGGCTTCAGGCTGCTGCTG 96

RESULT 8  
US-08-021-615A-3  
Sequence 3, Application US/08021615A  
Patent No. 5504064  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
TITLE OF INVENTION: Treatment of Bleeding with Modified  
TITLE OF INVENTION: Tissue Factor in Combination with an Activator of  
TITLE OF INVENTION: FVII  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/021,615A  
FILING DATE: 19-FEB-1993  
CLASSIFICATION: 514  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882,202  
FILING DATE: 13-MAY-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Hansen, Eugenia S.  
REGISTRATION NUMBER: 31,966  
REFERENCE/DOCKET NUMBER: OMRP B34290CIP  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433  
OTHER INFORMATION: /note= "Coding portion of human factor VII cDNA"  
OTHER INFORMATION: /citation= ([1])  
PCT-US-021-615A-3

Query Match 0.8%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 1.2; 14; Indels 0; Gaps 0;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

ORDER OF SEQUENCES: 27  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Arnold, White & Durkee  
STREET: P.O. Box 4433

CITY: Houston  
STATE: Texas  
COUNTRY: USA  
ZIP: 77210  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/09/009,656  
FILING DATE: Concurrently Herewith  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/042,427  
FILING DATE: 27-MAR-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/036,205  
FILING DATE: 27-JAN-1997  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 60/035,920  
FILING DATE: 22-JAN-1997  
ATTORNEY/AGENT INFORMATION:  
NAME: Hibler, David W.  
REGISTRATION NUMBER: 41,071  
REFERENCE/DOCKET NUMBER: UTSD:537  
TELEPHONE: 512/418-3000  
TELEFAX: 512/474-7577  
INFORMATION FOR SEQ ID NO: 13:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
US-09-009-656-13  
Query Match 0.8%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 1655 TCCTTGGTTTTCGATAGTCTCTGGCTTCCTGGATG 1693  
DB 58 TCCTCTGCCTTCTCTGGCTTCAGGCTCGCTGGCTG 96  
RESULT 12  
PCT-US93-04493-3  
Sequence 3, Application PC/TUS9304493  
GENERAL INFORMATION:  
APPLICANT: Morrissey, James H.  
TITLE OF INVENTION: Truncated Tissue Factor and FVIIa or  
TITLE OF INVENTION: FVII Activator for Blood Coagulation  
NUMBER OF SEQUENCES: 4  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Richards, Medlock & Andrews  
STREET: 1201 Elm Street, Suite 4500  
CITY: Dallas  
STATE: Texas  
COUNTRY: US  
ZIP: 75270-2197  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US93/04493  
FILING DATE: 19930512  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/882202

FILING DATE: 13-MAY-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 08/021615  
FILING DATE: 19-FEB-1993  
ATTORNEY/AGENT INFORMATION:  
NAME: Trujillo, Doreen Y.  
REGISTRATION NUMBER: 35,719  
REFERENCE/DOCKET NUMBER: OVRF B34290CIPC/PCT  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 214-939-4500  
TELEFAX: 214-939-4600  
INFORMATION FOR SEQ ID NO: 3:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 1440 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: double  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
HYPOTHETICAL: NO  
ANTI-SENSE: NO  
ORIGINAL SOURCE:  
ORGANISM: Homo sapiens  
TISSUE TYPE: Blood  
FEATURE:  
NAME/KEY: CDS  
LOCATION: 36..1433  
OTHER INFORMATION: /product= "Tissue Factor"  
OTHER INFORMATION: /note= "Coding portion of human factor VIII cDNA"  
OTHER INFORMATION: /citation= {[1]}  
PCT-US93-04493-3  
Query Match 0.8%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 12;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;  
QY 1655 TCCTTGGTTTTCGATAGTCTCTGGCTTCCTGGATG 1693  
DB 58 TCCTCTGCCTTCTCTGGCTTCAGGCTCGCTGGCTG 96  
RESULT 13  
US-08-849-248-6/c  
Sequence 6, Application US/08849248  
Patent No. 5948759  
GENERAL INFORMATION:  
APPLICANT: Husbyn, Mette  
APPLICANT: Fischer, Peter  
APPLICANT: Orning, Lars  
TITLE OF INVENTION: Factor VII Fragment 82-128 and its use  
TITLE OF INVENTION: in blood clotting disorders  
NUMBER OF SEQUENCES: 6  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: Bacon and Thomas  
STREET: 625 Slaters Lane, 4th Floor  
CITY: Alexandria  
STATE: Virginia  
COUNTRY: USA  
ZIP: 22314  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.30 (EPO)  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/849,248  
FILING DATE: 27 Aug 1997  
INFORMATION FOR SEQ ID NO: 6:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 141 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: other nucleic acid

```
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

Query Match          0.6%; Score 12.8; DB 1; Length 141;
Best Local Similarity 70.8%; Pred. No. 61;
Matches 17; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 41 TCTGCTGGCAATCTCTCTGGGCT 64
   |||||
Db 25 TCAGCTGGTCATCTCTGGGCT 2

RESULT 14
US-08-849-248-6
; Sequence 6, Application US/08849248
; Patent No. 5948759
; GENERAL INFORMATION:
; APPLICANT: Husbvn, Mette
; APPLICANT: Fischer, Peter
; APPLICANT: Orning, Lars
; TITLE OF INVENTION: Factor VII Fragment 92-128 and its use
; TITLE OF INVENTION: in blood clotting disorders
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bacon and Thomas
; STREET: 625 Slaters Lane, 4th Floor
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: USA
; ZIP: 22314
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30 (EPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/849,248
; FILING DATE: 27 Aug 1997
; INFORMATION FOR SEQ ID NO: 6:
; LENGTH: 141 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "recombinant DNA"
US-08-849-248-6

Query Match          0.6%; Score 12.6; DB 1; Length 141;
Best Local Similarity 55.8%; Pred. No. 70;
Matches 24; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 1288 TTCTAGTGCAGTACTGCTGGCTGACATCTGTAGTCTTGA 1330
Db 97 TGCACGAGGGTACTCTGCTGGCAGACGGGGTCTCTGCA 139

RESULT 15
US-09-558-027-4/c
; Sequence 4, Application US/09558027
; Patent No. 6329176
; GENERAL INFORMATION:
; APPLICANT: Woldike, Helle
; APPLICANT: Wiberg, Finn
; APPLICANT: Nielsen, Lars
; TITLE OF INVENTION: Method for the Production of FVII
; FILE REFERENCE: 5565.204-US
; CURRENT APPLICATION NUMBER: US/09/558,027
; CURRENT FILING DATE: 2000-04-25
; PRIOR APPLICATION NUMBER: 60/108,065
; PRIOR FILING DATE: 1998-11-12
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 4
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Saccharomyces cerevisiae
US-09-558-027-4

Query Match          0.6%; Score 12; DB 1; Length 38;
Best Local Similarity 75.0%; Pred. No. 34;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 787 AGGGCCATTCTCTAGATA 806
   \ |||||
Db 31 AGCCCATTTCCCTAGACTA 12

RESULT 16
US-08-293-778-17/c
; Sequence 17, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560th disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DX 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agriis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-17

Query Match          0.6%; Score 11.2; DB 1; Length 27;
```

Best Local Similarity 81.2%; Pred. No. 47;  
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GCTTCCTGGATGTTT 1697  
DB 23 CGGTCTTGAAGATT 8

RESULT 17  
US-08-293-778-16  
; Sequence 16, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaissen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Agis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 16:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear  
; MOLECULE TYPE: cDNA  
US-08-293-778-16

Query Match 0.5%; Score 11; DB 1; Length 27;  
Best Local Similarity 100.0%; Pred. No. 57;  
Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1981 TCTTCAAGGAC 1991  
DB 11 TCTTCAAGGAC 21

Best Local Similarity 81.2%; Pred. No. 47;  
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1682 GCTTCCTGGATGTTT 1697  
DB 23 CGGTCTTGAAGATT 8

RESULT 18  
US-09-558-027-4  
; Sequence 4, Application US/09558027  
; Patent No. 6329176  
; GENERAL INFORMATION:  
; APPLICANT: Woldike, Helle  
; APPLICANT: Wiberg, Finn  
; APPLICANT: Nielsen, Lars  
; TITLE OF INVENTION: Method for the Production of FVII  
; FILE REFERENCE: 5565.204-US  
; CURRENT APPLICATION NUMBER: US/09/558,027  
; CURRENT FILING DATE: 2000-04-25  
; PRIOR APPLICATION NUMBER: 60/108,065  
; PRIOR FILING DATE: 1998-11-12  
; NUMBER OF SEQ ID NOS: 4  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 4  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Saccharomyces cerevisiae  
US-09-558-027-4

Query Match 0.5%; Score 11; DB 1; Length 38;  
Best Local Similarity 57.1%; Pred. No. 83;  
Matches 20; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 527 GACCTAACTGTTGGAGAGATGGGGTATTGAAGTA 561  
DB 4 GAATCACTAGTCTAGGAAATGGGCTCGCAGCA 38

RESULT 19  
US-08-955-636-8  
; Sequence 8, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelsestuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; TITLE OF INVENTION: POLYPEPTIDES  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;  
Best Local Similarity 64.0%; Pred. No. 1.3e+02;  
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGCCAGGTAGGGGCAC 156  
DB 2 CACTCCCGCTCCAGGCTGCTGGGAC 26

RESULT 20  
US-08-756-506-13/c  
; Sequence 13, Application US/08756506  
; Patent No. 5905185  
; GENERAL INFORMATION:  
; APPLICANT: Garner, Ian  
; APPLICANT: Cottingham, Ian R.  
; APPLICANT: Temperley, Simon M.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Prunkard, Donna E.

;; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
;; TITLE OF INVENTION: ANIMALS  
;; NUMBER OF SEQUENCES: 25  
;; CORRESPONDENCE ADDRESS:  
;; ADDRESSEE: ZymoGenetics, Inc.  
;; STREET: 1201 Eastlake Avenue East  
;; CITY: Seattle  
;; STATE: WA  
;; COUNTRY: USA  
;; ZIP: 98102  
;; COMPUTER READABLE FORM:  
;; MEDIUM TYPE: Floppy disk  
;; COMPUTER: IBM PC compatible  
;; OPERATING SYSTEM: PC-DOS/MS-DOS  
;; SOFTWARE: PatentIn Release #1.0, Version #1.25  
;; CURRENT APPLICATION DATA:  
;; APPLICATION NUMBER: US/08/756,506  
;; FILING DATE:  
;; CLASSIFICATION: 800  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Sawislak, Deborah A.  
;; REGISTRATION NUMBER: 37,438  
;; REFERENCE/DOCKET NUMBER: 95-28  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 206-442-6678  
;; TELEFAX: 206-442-6678  
;; INFORMATION FOR SEQ ID NO: 13:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 45 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; IMMEDIATE SOURCE:  
;; CLONE: ZC6337  
;; US-08-756-506-13  
;;  
Query Match 0.5%; Score 10.6; DB 1; Length 45;  
Best Local Similarity 57.8%; Pred. No. 1.3e+02;  
Matches 19; Conservative 0; Mismatches 14; Indels 0;  
Gaps 0;  
;;  
QY 135 TTCTGGCCAGGCTAGGCGACCTACCGCATTC 167  
Db 35 TGCTGCAAGCGCGCAGCGGCCAATCTCTTCC 3  
;;  
RESULT 21  
US-08-756-506-13  
; Sequence 13, Application US/08/756506  
; Patent No. 5905185  
; GENERAL INFORMATION:  
; APPLICANT: Garne, Ian  
; APPLICANT: Cottingham, Ian R.  
; APPLICANT: Temperley, Simon M.  
; APPLICANT: Foster, Donald C.  
; APPLICANT: Sprecher, Cindy A.  
; APPLICANT: Prunkard, Donna E.  
; TITLE OF INVENTION: PROTEIN C PRODUCTION IN TRANSGENIC  
; TITLE OF INVENTION: ANIMALS  
; NUMBER OF SEQUENCES: 25  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: ZymoGenetics, Inc.  
; STREET: 1201 Eastlake Avenue East  
; CITY: Seattle  
; STATE: WA  
; COUNTRY: USA  
; ZIP: 98102  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/756,506

;; FILING DATE:  
;; CLASSIFICATION: 800  
;; ATTORNEY/AGENT INFORMATION:  
;; NAME: Sawislak, Deborah A.  
;; REGISTRATION NUMBER: 37,438  
;; REFERENCE/DOCKET NUMBER: 95-28  
;; TELECOMMUNICATION INFORMATION:  
;; TELEPHONE: 206-442-6678  
;; TELEFAX: 206-442-6678  
;; INFORMATION FOR SEQ ID NO: 13:  
;; SEQUENCE CHARACTERISTICS:  
;; LENGTH: 45 base pairs  
;; TYPE: nucleic acid  
;; STRANDEDNESS: single  
;; TOPOLOGY: linear  
;; IMMEDIATE SOURCE:  
;; CLONE: ZC6337  
;; US-08-756-506-13  
;;  
Query Match 0.5%; Score 10.4; DB 1; Length 45;  
Best Local Similarity 60.7%; Pred. No. 1.6e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0;  
Gaps 0;  
;;  
QY 536 GTTGAGAGAAATGGGGTATTGAAGTAGC 563  
Db 10 GTTGGCGGCTTGGCGCGTTGCAGCACC 37  
;;  
RESULT 22  
US-07-998-972A-7/c  
; Sequence 7, Application US/07998972A  
; Patent No. 5476777  
; GENERAL INFORMATION:  
; APPLICANT: Holly, Richard D.  
; APPLICANT: Foster, Donald C.  
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN  
; NUMBER OF SEQUENCES: 48  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: Townsend and Townsend  
; STREET: One Market Plaza, Stewart Street Tower,  
; STREET: Twentieth Floor  
; CITY: San Francisco  
; STATE: CA  
; COUNTRY: USA  
; ZIP: 94105  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/07/998,972A  
; FILING DATE: 19921230  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/860,701  
; FILING DATE: 31-MAR-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/816,281  
; FILING DATE: 31-DEC-1991  
; ATTORNEY/AGENT INFORMATION:  
; NAME: Parmelee, Steven W.  
; REGISTRATION NUMBER: 31,990  
; REFERENCE/DOCKET NUMBER: 13952-12-2  
; TELECOMMUNICATION INFORMATION:  
; TELEPHONE: 206-467-9600  
; TELEFAX: 415-543-5043  
; INFORMATION FOR SEQ ID NO: 7:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 35 base pairs  
; TYPE: nucleic acid  
; STRANDEDNESS: single  
; TOPOLOGY: linear



```
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-07-998-972A-7

Query Match      0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1296 GCAGTAGTCTGGCCTGAC 1313
Db 21 GGAGTTGGCTCGCCGGAC 4

RESULT 23
US-08-463-953-7/c
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
US-08-462-261-7

Query Match      0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 72.2%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Qy 1296 GCAGTAGTCTGGCCTGAC 1313
Db 21 GGAGTTGGCTCGCCGGAC 4

RESULT 25
PCT-US92-11357-7/c
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```

ZIP: 94105  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: PCT/US92/11357  
FILING DATE: 19921230  
CLASSIFICATION:  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/860,701  
FILING DATE: 31-MAR-1992  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/816,281  
FILING DATE: 31-DEC-1991  
ATTORNEY/AGENT INFORMATION:  
NAME: Parmelee, Steven W  
REGISTRATION NUMBER: 31,990  
REFERENCE/DOCKET NUMBER: 13952-12-2  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 206-467-9600  
TELEFAX: 415-543-5043  
INFORMATION FOR SEQ ID NO: 7:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 35 base pairs  
TYPE: NUCLEIC ACID  
STRANDEDNESS: single  
TOPOLOGY: linear  
IMMEDIATE SOURCE:  
CLONE: ZC1324  
PCT-US92-11357-7

Query Match 0.5%; Score 10; DB 1; Length 35;  
Best Local Similarity 72.2%; Pred. No. 1.7e+02;  
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1296 GCAGTAGTCTGGCTGAC 1313  
DB 21 GCAGTTGGCTCGCGGAC 4

RESULT 26  
US-08-293-778-16/c  
Sequence 16, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87

FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/898,248  
FILING DATE: 12-JUN-1992  
ATTORNEY/AGENT INFORMATION:  
NAME: Agis, Cheryl H.  
REGISTRATION NUMBER: 34,086  
REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 16:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 27 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-08-293-778-16

Query Match 0.5%; Score 9.8; DB 1; Length 27;  
Best Local Similarity 66.7%; Pred. No. 1.6e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 447 GTCTGTAATATCTTAGTTC 467  
DB 21 GTCTTGAGATCTCCGGGC 1

RESULT 27  
US-08-293-778-17  
Sequence 17, Application US/08293778  
Patent No. 5580560  
GENERAL INFORMATION:  
APPLICANT: Nicolaisen, Else M.  
APPLICANT: Bjorn, Soren E.  
APPLICANT: Wiberg, Finn C.  
APPLICANT: Woodbury, Richard  
TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa  
NUMBER OF SEQUENCES: 26  
CORRESPONDENCE ADDRESS:  
ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.  
STREET: 405 Lexington Avenue, 62nd Floor  
CITY: New York  
STATE: New York  
COUNTRY: United States of America  
ZIP: 10174-6201  
COMPUTER READABLE FORM:  
MEDIUM TYPE: Floppy disk  
COMPUTER: IBM PC compatible  
OPERATING SYSTEM: PC-DOS/MS-DOS  
SOFTWARE: Patent In Release #1.0, Version #1.25  
CURRENT APPLICATION DATA:  
APPLICATION NUMBER: US/08/293,778  
FILING DATE:  
CLASSIFICATION: 435  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US/08/104,509  
FILING DATE:  
APPLICATION NUMBER: DK 3235/87  
FILING DATE: 25-JUN-1987  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: US 07/434,149  
FILING DATE: 13-NOV-1989  
PRIOR APPLICATION DATA:  
APPLICATION NUMBER: PCT/DK88/00103  
FILING DATE: 24-JUN-1988

10664775-3.rni

Mon Aug 9 17:47:19 2004

```

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-293-778-17

Query Match 0.5%; Score 9.4; DB 1; Length 27;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1981 TCTTCAAGGAC 1991
Db 11 TCTTCCAGGAC 21

RESULT 28
US-07-998-972A-7
; Sequence 7, Application US/07998972A
; Patent No. 5476777
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 07/998,972A
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-293-778-17

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 CTTCCTGGATG 1693
Db 21 CTTCCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 07/998,972A
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-463-953-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.2e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 CTTCCTGGATG 1693
Db 21 CTTCCTGGAGG 31

RESULT 30
US-08-462-261-7

```

```

; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-07-998-972A-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 CTTCCTGGATG 1693
Db 21 CTTCCTGGAGG 31

RESULT 29
US-08-463-953-7
; Sequence 7, Application US/08463953
; Patent No. 5502034
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 19921230
; CLASSIFICATION: 435
; PRIOR APPLICATION NUMBER: US 08/463,953
; FILING DATE: 12-JUN-1992
; APPLICATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; US-08-463-953-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1683 CTTCCTGGATG 1693
Db 21 CTTCCTGGAGG 31

RESULT 30
US-08-462-261-7

```

```
; Sequence 7, Application US/08462261
; Patent No. 5527692
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/462,261
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/998,972
; FILING DATE: 30-DEC-1992
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; US-08-462-261-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGGATG 1693
Db 21 CTTCTGGGAGG 31

RESULT 31
PCT-US92-11357-7
; Sequence 7, Application PC/TUS9211357
; GENERAL INFORMATION:
; APPLICANT: Holly, Richard D.
; APPLICANT: Foster, Donald C.
; TITLE OF INVENTION: METHODS FOR PRODUCING THROMBIN
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend
; STREET: One Market Plaza, Stewart Street Tower,
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```

```
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/11357
; FILING DATE: 19921230
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/860,701
; FILING DATE: 31-MAR-1992
; APPLICATION NUMBER: US 07/816,281
; FILING DATE: 31-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Parmelee, Steven W
; REGISTRATION NUMBER: 31,990
; REFERENCE/DOCKET NUMBER: 13952-12-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 206-467-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 35 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; IMMEDIATE SOURCE:
; CLONE: ZC1324
; PCT-US92-11357-7

Query Match 0.5%; Score 9.4; DB 1; Length 35;
Best Local Similarity 90.9%; Pred. No. 2.7e+02;
Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1683 CTTCTGGGATG 1693
Db 21 CTTCTGGGAGG 31

RESULT 32
US-08-955-636-9
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
; US-08-955-636-9

Query Match 0.5%; Score 9.4; DB 1; Length 36;
Best Local Similarity 68.4%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 153 GCCTACCGGATTCCTCT 171
Db 13 GCCGTGCCGAGCTCTCT 31

RESULT 33
```

US-08-955-636-10/c  
; Sequence 10, Application US/08955636A  
; Patent No. 6017882  
; GENERAL INFORMATION:  
; APPLICANT: Nelsestuen, Gary  
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT  
; TITLE OF INVENTION: POLYPEPTIDES  
; FILE REFERENCE: 09531/002001  
; CURRENT APPLICATION NUMBER: US/08/955,636A  
; CURRENT FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 35  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 10  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Protein C mutagenic oligonucleotide  
US-08-955-636-10

Query Match 0.5%; Score 9.4; DB 1; Length 36;  
Best Local Similarity 68.4%; Pred. No. 2.7e+02;  
Matches 13; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 153 GCACTACCGCATTCCTCT 171  
Db 24 GCGTGCGCGAGCTCCT 6

RESULT 34  
US-08-293-778-22/c  
; Sequence 22, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs

REFERENCE/DOCKET NUMBER: 3129.224-US  
TELECOMMUNICATION INFORMATION:  
TELEPHONE: 212-867-0123  
TELEFAX: 212-867-0298  
INFORMATION FOR SEQ ID NO: 22:  
SEQUENCE CHARACTERISTICS:  
LENGTH: 26 base pairs  
TYPE: nucleic acid  
STRANDEDNESS: single  
TOPOLOGY: linear  
MOLECULE TYPE: cDNA  
US-08-293-778-22

Query Match 0.5%; Score 9.2; DB 1; Length 26;  
Best Local Similarity 78.6%; Pred. No. 2.5e+02;  
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1814 GTCTGTGAGTTCC 1827  
Db 25 GTCTCCGACCTTC 12

RESULT 35  
US-08-293-778-20  
; Sequence 20, Application US/08293778  
; Patent No. 5580560  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else M.  
; APPLICANT: Bjorn, Soren E.  
; APPLICANT: Wiberg, Finn C.  
; APPLICANT: Woodbury, Richard  
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII  
; NUMBER OF SEQUENCES: 26  
; CORRESPONDENCE ADDRESS:  
; ADDRESSEE: No. 5580560c No. 5580560disk of No. 5580560th America, Inc.  
; STREET: 405 Lexington Avenue, 62nd Floor  
; CITY: New York  
; STATE: New York  
; COUNTRY: United States of America  
; ZIP: 10174-6201  
; COMPUTER READABLE FORM:  
; MEDIUM TYPE: Floppy disk  
; COMPUTER: IBM PC compatible  
; OPERATING SYSTEM: PC-DOS/MS-DOS  
; SOFTWARE: PatentIn Release #1.0, Version #1.25  
; CURRENT APPLICATION DATA:  
; APPLICATION NUMBER: US/08/293,778  
; FILING DATE:  
; CLASSIFICATION: 435  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US/08/104,509  
; FILING DATE:  
; APPLICATION NUMBER: DK 3235/87  
; FILING DATE: 25-JUN-1987  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/434,149  
; FILING DATE: 13-NOV-1989  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: PCT/DK88/00103  
; FILING DATE: 24-JUN-1988  
; PRIOR APPLICATION DATA:  
; APPLICATION NUMBER: US 07/898,248  
; FILING DATE: 12-JUN-1992  
; NAME: Agtis, Cheryl H.  
; REGISTRATION NUMBER: 34,086  
; REFERENCE/DOCKET NUMBER: 3129.224-US  
; TELEPHONE: 212-867-0123  
; TELEFAX: 212-867-0298  
; INFORMATION FOR SEQ ID NO: 20:  
; SEQUENCE CHARACTERISTICS:  
; LENGTH: 27 base pairs

```
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match
Best Local Similarity 0.5%; Score 9.2; DB 1; Length 27;
Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 134 CTCTGGGCCAGG 147
Db 2 CTGCTGACCTGGG 15

RESULT 36
US-08-955-636-8/c
; Sequence 8, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-8

Query Match
Best Local Similarity 0.4%; Score 8.8; DB 1; Length 42;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTGAAGCCTCTGCTGGCAATACTTCTGGGCTG 65
Db 42 TTCTGGAGGAGCTCCGTCCAGCAGCCTTGAGCGG 7

RESULT 37
US-08-293-778-20/c
; Sequence 20, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIIa
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 55805600 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
```

```
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agtis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129,224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
; INFORMATION FOR SEQ ID NO: 20:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 27 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-293-778-20

Query Match
Best Local Similarity 0.4%; Score 8.6; DB 1; Length 27;
Matches 14; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 403 AGGGTGTGACAGAAGGTACAG 425
Db 27 AGGGCCGTGGCCGCCAGGTCCAG 5

RESULT 38
US-08-955-636-9/c
; Sequence 9, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-9

Query Match
Best Local Similarity 0.4%; Score 8.4; DB 1; Length 36;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 52 TACTTCTGGGCTCTGC 69
Db 35 TCTAGAGGAGTCTGGC 18

RESULT 39
US-08-955-636-10
; Sequence 10, Application US/08955636A
; Patent No. 6017882
; GENERAL INFORMATION:
```

```
; APPLICANT: Nelsestuen, Gary
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; TITLE OF INVENTION: POLYPEPTIDES
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/08/955,636A
; CURRENT FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 10
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-08-955-636-10

Query Match      0.4%; Score 8.4; DB 1; Length 36;
Best Local Similarity 66.7%; Pred. No. 4.4e+02;
Matches 12; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 52 TACTTCGGGCTGCTGC 69
Db 2 TCCTAGAGGAGCTGCGC 19

RESULT 40
US-08-293-778-22
; Sequence 22, Application US/08293778
; Patent No. 5580560
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else M.
; APPLICANT: Bjorn, Soren E.
; APPLICANT: Wiberg, Finn C.
; APPLICANT: Woodbury, Richard
; TITLE OF INVENTION: MODIFIED FACTOR VII/VIII
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5580560 No. 5580560disk of No. 5580560th America, Inc.
; STREET: 405 Lexington Avenue, 62nd Floor
; CITY: New York
; STATE: New York
; COUNTRY: United States of America
; ZIP: 10174-6201
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/293,778
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/104,509
; FILING DATE:
; APPLICATION NUMBER: DK 3235/87
; FILING DATE: 25-JUN-1987
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/434,149
; FILING DATE: 13-NOV-1989
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/DK88/00103
; FILING DATE: 24-JUN-1988
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/898,248
; FILING DATE: 12-JUN-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis, Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 3129.224-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-867-0298
```

```
; INFORMATION FOR SEQ ID NO: 22:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 26 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-293-778-22

Query Match      0.4%; Score 7.4; DB 1; Length 26;
Best Local Similarity 64.7%; Pred. No. 6.5e+02;
Matches 11; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 943 AGTCATTGATGTTGAGA 959
Db 6 AGTCACGGAGGTCGGA 22

Search completed: August 9, 2004, 16:49:17
Job time: 11 secs
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:49:40 ; Search time 26 Seconds  
(without alignments)

3.874 Million cell updates/sec

Title: us-10-664-775-3

Perfect score: 2003

Sequence: 1 agcttccagagacttca.....tcaaggacatttatgaatt 2003

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 0.5

Searched: 61 seqs, 25143 residues

Total number of hits satisfying chosen parameters: 122

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 250 summaries

Database : .rnpbdb.\*

Pred. No. is the number of results predicted by chance to have a  
score greater than or equal to the score of the result being printed,  
and is derived by analysis of the total score distribution.

# SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
C 1	20.6	1.0	1332	1	US-10-411-037-7 Sequence 7, Appl
C 2	20.6	1.0	1332	1	US-10-411-026-7 Sequence 7, Appl
C 3	20.6	1.0	1332	1	US-10-410-962-7 Sequence 7, Appl
C 4	20.6	1.0	1332	1	US-10-411-049-7 Sequence 7, Appl
C 5	20.6	1.0	1332	1	US-10-410-930-7 Sequence 7, Appl
C 6	20.6	1.0	1332	1	US-10-410-997-7 Sequence 7, Appl
C 7	20.6	1.0	1332	1	US-10-411-012-7 Sequence 7, Appl
C 8	20.6	1.0	1332	1	US-10-287-994-7 Sequence 7, Appl
C 9	20.6	1.0	1332	1	US-10-410-913-7 Sequence 13, Appl
C 10	20.6	1.0	1440	1	US-10-375-741-13 Sequence 12, Appl
C 11	20.6	1.0	2040	1	US-10-617-619-12 Sequence 9, Appl
C 12	20.6	1.0	2106	1	US-10-617-619-9 Sequence 35, Appl
C 13	17.8	0.9	1361	1	US-10-382-248-35 Sequence 8429, Ap
C 14	17	0.8	483	1	US-09-918-995-8429 Sequence 7, Appl
C 15	17	0.8	1332	1	US-10-411-037-7 Sequence 7, Appl
C 16	17	0.8	1332	1	US-10-411-026-7 Sequence 7, Appl
C 17	17	0.8	1332	1	US-10-410-962-7 Sequence 7, Appl
C 18	17	0.8	1332	1	US-10-411-049-7 Sequence 7, Appl
C 19	17	0.8	1332	1	US-10-410-930-7 Sequence 7, Appl
C 20	17	0.8	1332	1	US-10-410-997-7 Sequence 7, Appl
C 21	17	0.8	1332	1	US-10-411-012-7 Sequence 7, Appl
C 22	17	0.8	1332	1	US-10-287-994-7 Sequence 7, Appl
C 23	17	0.8	1332	1	US-10-410-913-7 Sequence 12, Appl
C 24	17	0.8	2040	1	US-10-617-619-12 Sequence 9, Appl
C 25	16.6	0.8	1338	1	US-09-782-587B-2 Sequence 4, Appl
C 26	16.6	0.8	1357	1	US-09-782-587B-4 Sequence 35, Appl
C 27	16.6	0.8	1361	1	US-10-382-248-35 Sequence 13, Appl
C 28	16.6	0.8	1440	1	US-10-375-741-13 Sequence 9, Appl
C 29	16.6	0.8	2106	1	US-10-617-619-9 Sequence 8429, Ap
C 30	16.4	0.8	483	1	US-09-918-995-8429 Sequence 9623, Ap
C 31	14.8	0.7	555	1	US-10-029-386-9623 Sequence 23323, A
C 32	14.6	0.7	222	1	US-10-029-386-9623 Sequence 9623, Ap
C 33	14.6	0.7	555	1	US-10-029-386-9623 Sequence 9623, Ap

14.2	0.7	60	1	US-10-272-665-22	Sequence 22, Appl
14.2	0.7	60	1	US-10-273-321-22	Sequence 22, Appl
14.2	0.7	60	1	US-10-272-756-22	Sequence 22, Appl
14.2	0.7	60	1	US-10-273-228-22	Sequence 22, Appl
14.2	0.7	100	1	US-10-272-665-107	Sequence 107, App
14.2	0.7	100	1	US-10-273-321-107	Sequence 107, App
14.2	0.7	100	1	US-10-272-756-107	Sequence 107, App
14.2	0.7	100	1	US-10-273-228-107	Sequence 107, App
14.2	0.7	100	1	US-10-272-665-106	Sequence 106, App
14.2	0.7	100	1	US-10-273-321-106	Sequence 106, App
14.2	0.7	100	1	US-10-272-756-106	Sequence 106, App
14.2	0.7	100	1	US-10-273-228-106	Sequence 106, App
14.2	0.7	1338	1	US-09-782-587B-2	Sequence 2, Appl
14.2	0.7	1357	1	US-09-782-587B-4	Sequence 4, Appl
12	0.6	222	1	US-10-029-386-23323	Sequence 23323, A
11.8	0.6	54	1	US-10-349-858-8	Sequence 8, Appl
11.6	0.6	32	1	US-10-281-727-6	Sequence 7, Appl
11.6	0.6	32	1	US-10-281-727-7	Sequence 7, Appl
11.4	0.6	38	1	US-10-398-422A-20	Sequence 20, Appl
11.4	0.6	38	1	US-09-969-357-2	Sequence 2, Appl
11.4	0.6	38	1	US-10-254-394-2	Sequence 2, Appl
11.2	0.6	33	1	US-09-951-121A-14	Sequence 14, Appl
11.2	0.6	33	1	US-09-951-121A-15	Sequence 15, Appl
11.2	0.6	33	1	US-10-295-682-14	Sequence 14, Appl
11.2	0.6	33	1	US-10-295-682-15	Sequence 15, Appl
10.6	0.5	36	1	US-09-951-121A-8	Sequence 8, Appl
10.6	0.5	36	1	US-09-951-121A-9	Sequence 9, Appl
10.6	0.5	36	1	US-10-255-032-8	Sequence 8, Appl
10.6	0.5	36	1	US-10-255-032-9	Sequence 9, Appl
10.6	0.5	36	1	US-10-295-682-8	Sequence 8, Appl
10.6	0.5	36	1	US-10-295-682-9	Sequence 9, Appl
10.6	0.5	42	1	US-09-803-810-8	Sequence 8, Appl
10.6	0.5	42	1	US-10-298-330-8	Sequence 8, Appl
10.6	0.5	60	1	US-10-272-665-23	Sequence 23, Appl
10.6	0.5	60	1	US-10-273-321-23	Sequence 23, Appl
10.6	0.5	60	1	US-10-272-756-23	Sequence 23, Appl
10.6	0.5	60	1	US-10-273-228-23	Sequence 23, Appl
10.4	0.5	36	1	US-10-281-727-2	Sequence 2, Appl
10.4	0.5	36	1	US-10-281-727-3	Sequence 3, Appl
10.2	0.5	38	1	US-10-398-422A-20	Sequence 20, Appl
10.2	0.5	38	1	US-09-969-357-2	Sequence 2, Appl
10.2	0.5	38	1	US-10-254-394-2	Sequence 2, Appl
10.2	0.5	35	1	US-10-109-498-5	Sequence 5, Appl
10	0.5	35	1	US-10-109-498-6	Sequence 6, Appl
10	0.5	60	1	US-10-272-665-22	Sequence 22, Appl
10	0.5	60	1	US-10-273-321-22	Sequence 22, Appl
10	0.5	60	1	US-10-272-756-22	Sequence 22, Appl
10	0.5	60	1	US-10-273-228-22	Sequence 22, Appl
10	0.5	100	1	US-10-272-665-107	Sequence 107, App
10	0.5	100	1	US-10-273-321-107	Sequence 107, App
10	0.5	100	1	US-10-272-756-107	Sequence 107, App
10	0.5	100	1	US-10-273-228-107	Sequence 107, App
10	0.5	100	1	US-10-272-665-106	Sequence 106, App
10	0.5	100	1	US-10-273-321-106	Sequence 106, App
10	0.5	100	1	US-10-272-756-106	Sequence 106, App
10	0.5	100	1	US-10-273-228-106	Sequence 106, App
9.8	0.5	36	1	US-09-951-121A-8	Sequence 8, Appl
9.8	0.5	36	1	US-09-951-121A-9	Sequence 9, Appl
9.8	0.5	36	1	US-10-255-032-8	Sequence 8, Appl
9.8	0.5	36	1	US-10-255-032-9	Sequence 9, Appl
9.8	0.5	36	1	US-10-295-682-8	Sequence 8, Appl
9.8	0.5	36	1	US-10-295-682-9	Sequence 9, Appl
9.8	0.5	54	1	US-10-349-858-8	Sequence 8, Appl
9.8	0.5	60	1	US-10-272-665-23	Sequence 23, Appl
9.8	0.5	60	1	US-10-273-321-23	Sequence 23, Appl
9.8	0.5	60	1	US-10-272-756-23	Sequence 23, Appl
9.8	0.5	60	1	US-10-273-228-23	Sequence 23, Appl
9.4	0.5	35	1	US-10-109-498-5	Sequence 5, Appl
9.4	0.5	35	1	US-10-109-498-6	Sequence 6, Appl
9.2	0.5	31	1	US-10-017-122-4	Sequence 4, Appl
9.2	0.5	34	1	US-09-951-121A-2	Sequence 2, Appl
9.2	0.5	34	1	US-09-951-121A-3	Sequence 3, Appl
9.2	0.5	34	1	US-10-295-682-2	Sequence 2, Appl

Sequence 3, Appli  
Sequence 2, Appli  
Sequence 3, Appli  
Sequence 14, Appli  
Sequence 15, Appli  
Sequence 14, Appli  
Sequence 15, Appli  
Sequence 8, Appli  
Sequence 6, Appli  
Sequence 7, Appli  
Sequence 4, Appli  
Sequence 2, Appli  
Sequence 3, Appli  
Sequence 3, Appli

## ALIGNMENTS

RESULT 1  
US-10-411-037-7/c  
; Sequence 7, Application US/10411037  
; Publication No. US20040043446A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bows, Caryn  
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A: REMODELING AND GLYCOCONJUGATION OF ALPHA  
; FILE REFERENCE: 040853-01-5082  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; PRIOR APPLICATION NUMBER: US 60/407,527  
; PRIOR FILING DATE: 2002-08-28  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-411-037-7

Query Match 1.0%; Score 20.6; DB 1; Length 1332;  
Best Local Similarity 59.3%; Pred. No. 2.2;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATATGTATTCAAATTTGG 392  
DB 558 TTTCGTGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 2  
US-10-411-026-7/c  
; Sequence 7, Application US/10411026  
; Publication No. US20040063911A1

GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
; FILE REFERENCE: 040853-01-5053  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-411-026-7

Query Match 1.0%; Score 20.6; DB 1; Length 1332;  
Best Local Similarity 59.3%; Pred. No. 2.2;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;  
QY 334 TTCAATTGCTTTTATCTGTCGAGACTTGTCTTTTGAATATGTATTCAAATTTGG 392  
DB 558 TTTCGTGCAATTCCTTTTCTAGATAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 3  
US-10-410-962-7/c  
; Sequence 7, Application US/10410962  
; Publication No. US20040077836A1  
; GENERAL INFORMATION:  
; APPLICANT: Neose Technologies, Inc.  
; APPLICANT: Defrees, Shawn  
; APPLICANT: Zopf, David  
; APPLICANT: Bayer, Robert  
; APPLICANT: Hakes, David  
; APPLICANT: Chen, Xi  
; APPLICANT: Bows, Caryn  
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND  
; FILE REFERENCE: 040853-01-5054  
; CURRENT FILING DATE: 2003-04-09  
; PRIOR APPLICATION NUMBER: US 60/328,523  
; PRIOR FILING DATE: 2001-10-10  
; PRIOR APPLICATION NUMBER: US 60/344,692  
; PRIOR FILING DATE: 2001-10-19  
; PRIOR APPLICATION NUMBER: US 60/387,292  
; PRIOR FILING DATE: 2002-06-07  
; PRIOR APPLICATION NUMBER: US 60/391,777  
; PRIOR FILING DATE: 2002-06-25  
; PRIOR APPLICATION NUMBER: US 60/396,594  
; PRIOR FILING DATE: 2002-07-17  
; PRIOR APPLICATION NUMBER: US 60/404,249  
; PRIOR FILING DATE: 2002-08-16  
; NUMBER OF SEQ ID NOS: 75  
; SOFTWARE: Patentin version 3.2  
; SEQ ID NO 7  
; LENGTH: 1332  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
US-10-410-962-7



```
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 1332
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-410-997-7

Query Match          1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGCGAGACTTGCCTTTCTTTGAAATATGTTATTCATTTTGG 392
DB 558 TTGCTGCAATTCCTTTTCTAGAAAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 7
US-10-411-012-7/c
/ Sequence 7, Application US/10411012
/ Publication No. US20040132640A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: Defrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
/ APPLICANT: Hakes, David
/ APPLICANT: Chen, Xi
/ APPLICANT: Bowe, Caryn
/ TITLE OF INVENTION: GLYCOPGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
/ FILE REFERENCE: 040853-01-5051
/ CURRENT APPLICATION NUMBER: US/10/411,012
/ CURRENT FILING DATE: 2003-04-09
/ PRIOR APPLICATION NUMBER: US 60/328,523
/ PRIOR FILING DATE: 2001-10-10
/ PRIOR APPLICATION NUMBER: US 60/344,692
/ PRIOR FILING DATE: 2001-10-19
/ PRIOR APPLICATION NUMBER: US 60/387,292
/ PRIOR FILING DATE: 2002-06-07
/ PRIOR APPLICATION NUMBER: US 60/391,777
/ PRIOR FILING DATE: 2002-06-25
/ PRIOR APPLICATION NUMBER: US 60/396,594
/ PRIOR FILING DATE: 2002-07-17
/ PRIOR APPLICATION NUMBER: US 60/404,249
/ PRIOR FILING DATE: 2002-08-16
/ PRIOR APPLICATION NUMBER: US 60/407,527
/ NUMBER OF SEQ ID NOS: 75
/ SOFTWARE: PatentIn version 3.2
/ SEQ ID NO 7
/ LENGTH: 1332
/ TYPE: DNA
/ ORGANISM: Homo sapiens
US-10-411-012-7

Query Match          1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTCCTTTATCTGCGAGACTTGCCTTTCTTTGAAATATGTTATTCATTTTGG 392
DB 558 TTGCTGCAATTCCTTTTCTAGAAAGGTATTTTCCACATGGATATTCACACTGTGG 500

RESULT 8
US-10-287-994-7/c
/ Sequence 7, Application US/10287994
/ Publication No. US20040137557A1
/ GENERAL INFORMATION:
/ APPLICANT: Neose Technologies, Inc.
/ APPLICANT: Defrees, Shawn
/ APPLICANT: Zopf, David
/ APPLICANT: Bayer, Robert
```

```
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-410-913-7

Query Match      1.0%; Score 20.6; DB 1; Length 1332;
Best Local Similarity 59.3%; Pred. No. 2.2; 24; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTCTCGAGACTTGCTTTGTTTGAATATGTAATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATCAACTGTGG 500

RESULT 10
US-10-375-741-13/c
; Sequence 13, Application US/10375741
; Publication No. US20030232753A1
; GENERAL INFORMATION:
; APPLICANT: Thorpe, Philip E
; APPLICANT: King, Steven W
; APPLICANT: Gao, Boning
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR
; FILE REFERENCE: 4001.001999
; CURRENT APPLICATION NUMBER: US/10/375,741
; CURRENT FILING DATE: 2003-02-27
; PRIOR APPLICATION NUMBER: 09/573,835
; PRIOR FILING DATE: 2000-05-18
; PRIOR APPLICATION NUMBER: 6,156,321
; PRIOR FILING DATE: 1998-01-20
; PRIOR APPLICATION NUMBER: 60/042,427
; PRIOR FILING DATE: 1997-03-27
; PRIOR APPLICATION NUMBER: 60/036,205
; PRIOR FILING DATE: 1997-01-27
; PRIOR APPLICATION NUMBER: 60/035,920
; PRIOR FILING DATE: 1997-01-22
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 13
; LENGTH: 1440
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-375-741-13

Query Match      1.0%; Score 20.6; DB 1; Length 1440;
Best Local Similarity 59.3%; Pred. No. 2.3; 24; Indels 0; Gaps 0;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTCTCGAGACTTGCTTTGTTTGAATATGTAATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 659 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATCAACTGTGG 601

RESULT 11
US-10-617-619-12/c
; Sequence 12, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaissen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 12
; LENGTH: 2040
; TYPE: DNA
```

```
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-12

Query Match      1.0%; Score 20.6; DB 1; Length 2040;
Best Local Similarity 59.3%; Pred. No. 3.1;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTCTCGAGACTTGCTTTGTTTGAATATGTAATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 558 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATCAACTGTGG 500

RESULT 12
US-10-617-619-9/c
; Sequence 9, Application US/10617619
; Publication No. US20040110929A1
; GENERAL INFORMATION:
; APPLICANT: Bjorn, Soren E
; APPLICANT: Nicolaissen, Else M
; APPLICANT: Jorgensen, Anker S
; TITLE OF INVENTION: TF Binding Compound
; FILE REFERENCE: 6455.200-US
; CURRENT APPLICATION NUMBER: US/10/617,619
; CURRENT FILING DATE: 2003-07-11
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099
; PRIOR FILING DATE: 2002-07-12
; PRIOR APPLICATION NUMBER: US 60/404,568
; PRIOR FILING DATE: 2002-08-19
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 9
; LENGTH: 2106
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-617-619-9

Query Match      1.0%; Score 20.6; DB 1; Length 2106;
Best Local Similarity 59.3%; Pred. No. 3.2;
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

Qy 334 TTCAATTGCTTTTATCTCTCGAGACTTGCTTTGTTTGAATATGTAATCAATTTGG 392
      ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
Db 624 TTGCTGGCATTCTTTTCTAGATAGTATTTTCCACATGGATATCAACTGTGG 566

RESULT 13
US-10-382-248-35/c
; Sequence 35, Application US/10382248
; Publication No. US20040058347A1
; GENERAL INFORMATION:
; APPLICANT: Alsobrook, et al.
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME
; FILE REFERENCE: 21402-568C
; CURRENT APPLICATION NUMBER: US/10/382,248
; CURRENT FILING DATE: 2003-03-05
; PRIOR APPLICATION NUMBER: 60/366,928
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/361,974
; PRIOR FILING DATE: 2002-03-06
; PRIOR APPLICATION NUMBER: 60/365,477
; PRIOR FILING DATE: 2002-03-19
; PRIOR APPLICATION NUMBER: 60/401,661
; PRIOR FILING DATE: 2002-08-06
; NUMBER OF SEQ ID NOS: 82
; SOFTWARE: CuraSeqList version 0.1
; SEQ ID NO 35
; LENGTH: 1361
; TYPE: DNA
```

```
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: CDS
; LOCATION: (45)...(1301)
US-10-382-248-35

Query Match          0.9%; Score 17.8; DB 1; Length 1361;
Best Local Similarity 58.5%; Pred. No. 18;
Matches 31; Conservative 0; Mismatches 22; Indels 0; Gaps 0;

QY 334 TTCATTCTCTTTATCTGTGAGACTGCTTTCTTTTGAATATGATTCAA 386
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 527 TTGCTGCATTCTCTTTTCTAGAAATAGGATTTTCCACATGATATTCAA 475

RESULT 14
US-09-918-995-8429
; Sequence 8429, Application US/09918995
; Publication No. US20030073623A1
; GENERAL INFORMATION:
; APPLICANT: Hyseq, Inc.
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED
; FROM VARIOUS CDNA LIBRARIES
; FILE REFERENCE: 20411-756
; CURRENT APPLICATION NUMBER: US/09/918,995
; PRIOR FILING DATE: 2001-07-30
; PRIOR APPLICATION NUMBER: US/09/235,076
; PRIOR FILING DATE: 1999-01-20
; NUMBER OF SEQ ID NOS: 38054
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8429
; LENGTH: 483
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)...(483)
; OTHER INFORMATION: n = A,T,C or G
US-09-918-995-8429

Query Match          0.8%; Score 17; DB 1; Length 483;
Best Local Similarity 59.2%; Pred. No. 17;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 122 TCCTCTGCCTCTCTGTTGGCTTCAGGCTGCCCTGGCTGAGTCTTCGT 170

RESULT 15
US-10-411-037-7
; Sequence 7, Application US/10411037
; Publication No. US20040043446A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: ALPHA GALACTOSIDASE A
; FILE REFERENCE: 040853-01-5082
; CURRENT APPLICATION NUMBER: US/10/411,037
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
```

```
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-037-7

Query Match          0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 23 TCCTCTGCCTCTCTGTTGGCTTCAGGCTGCCCTGGCTGAGTCTTCGT 71

RESULT 16
US-10-411-026-7
; Sequence 7, Application US/10411026
; Publication No. US20040063911A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: PROTEIN REMODELING METHODS AND PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5053
; CURRENT APPLICATION NUMBER: US/10/411,026
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-411-026-7

Query Match          0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
    ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| ||| |||
DB 23 TCCTCTGCCTCTCTGTTGGCTTCAGGCTGCCCTGGCTGAGTCTTCGT 71

RESULT 17
US-10-410-962-7
```

```
; Sequence 7, Application US/10410962
; Publication No. US20040077836A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GRANULOCYTE COLONY STIMULATING FACTOR: REMODELING AND
; FILE REFERENCE: 040853-01-5054
; CURRENT APPLICATION NUMBER: US/10/410,962
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-962-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCCTCTGGCTTCAGGGCTGCCTGCTGCAGTCTTCGT 71

RESULT 18
US-10-411-049-7
; Sequence 7, Application US/10411049
; Publication No. US20040082026A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON ALPHA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5055
; CURRENT APPLICATION NUMBER: US/10/411,049
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
```

```
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-049-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCCTCTGGCTTCAGGGCTGCCTGCTGCAGTCTTCGT 71

RESULT 19
US-10-410-930-7
; Sequence 7, Application US/10410930
; Publication No. US20040115168A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: INTERFERON BETA: REMODELING AND GLYCOCONJUGATION OF INTERFERON
; FILE REFERENCE: 040853-01-5056
; CURRENT APPLICATION NUMBER: US/10/410,930
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-930-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGGCTTCCTGGATGTTTATGCCT 1703
      ||||| ||||| ||||| ||||| ||||| ||||| ||||| ||||| |||||
Db 23 TCCTCTGCCTTCCTCTGGCTTCAGGGCTGCCTGCTGCAGTCTTCGT 71

RESULT 20
US-10-410-997-7
; Sequence 7, Application US/10410997
; Publication No. US20040126838A1
```



```
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: FOLLICLE STIMULATING HORMONE: REMODELING AND GLYCOCONJUGATION OF
; FILE REFERENCE: 040853-01-5059
; CURRENT APPLICATION NUMBER: US/10/410,997
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-997-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGCTTCCTCGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGCGCTGCTGCTGCAGTCTTCGT 71

RESULT 21
US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-997-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGCTTCCTCGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGCGCTGCTGCTGCAGTCTTCGT 71

US-10-411-012-7
; Sequence 7, Application US/10411012
; Publication No. US20040132640A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; APPLICANT: Bowe, Caryn
; TITLE OF INVENTION: GLYCOPEGYLATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE
; FILE REFERENCE: 040853-01-5051
; CURRENT APPLICATION NUMBER: US/10/411,012
; CURRENT FILING DATE: 2003-04-09
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-410-997-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGCTTCCTCGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGCGCTGCTGCTGCAGTCTTCGT 71

US-10-410-913-7
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
```

```
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 75
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-411-012-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGCTTCCTCGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGCGCTGCTGCTGCAGTCTTCGT 71

RESULT 22
US-10-287-994-7
; Sequence 7, Application US/10287994
; Publication No. US20040137557A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
; APPLICANT: Zopf, David
; APPLICANT: Bayer, Robert
; APPLICANT: Bowe, Caryn
; APPLICANT: Hakes, David
; APPLICANT: Chen, Xi
; TITLE OF INVENTION: REMODELING AND GLYCOCONJUGATION OF PEPTIDES
; FILE REFERENCE: 040853-01-5052-00
; CURRENT APPLICATION NUMBER: US/10/287,994
; CURRENT FILING DATE: 2002-11-05
; PRIOR APPLICATION NUMBER: US 60/328,523
; PRIOR FILING DATE: 2001-10-10
; PRIOR APPLICATION NUMBER: US 60/344,692
; PRIOR FILING DATE: 2001-10-19
; PRIOR APPLICATION NUMBER: US 60/387,292
; PRIOR FILING DATE: 2002-06-07
; PRIOR APPLICATION NUMBER: US 60/391,777
; PRIOR FILING DATE: 2002-06-25
; PRIOR APPLICATION NUMBER: US 60/396,594
; PRIOR FILING DATE: 2002-07-17
; PRIOR APPLICATION NUMBER: US 60/404,249
; PRIOR FILING DATE: 2002-08-16
; PRIOR APPLICATION NUMBER: US 60/407,527
; PRIOR FILING DATE: 2002-08-28
; NUMBER OF SEQ ID NOS: 62
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 7
; LENGTH: 1332
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-10-287-994-7

Query Match      0.8%; Score 17; DB 1; Length 1332;
Best Local Similarity 59.2%; Pred. No. 27;
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTCTCTGCTTCCTCGGATGTTTATGCCT 1703
DB 23 TCCTCTGCTTCTGCTTGGCTTCAGGCGCTGCTGCTGCAGTCTTCGT 71

RESULT 23
US-10-410-913-7
; Sequence 7, Application US/10410913
; Publication No. US20040142856A1
; GENERAL INFORMATION:
; APPLICANT: Neose Technologies, Inc.
; APPLICANT: DeFrees, Shawn
```

APPLICANT: Zopf, David  
APPLICANT: Bayer, Robert  
APPLICANT: Hakes, David  
APPLICANT: Chen, Xi  
APPLICANT: Bown, Caryn  
TITLE OF INVENTION: GLYCOCONJUGATION METHODS AND PROTEINS/PEPTIDES PRODUCED BY THE  
FILE REFERENCE: 040853-01-5081  
CURRENT APPLICATION NUMBER: US/10/410,913  
CURRENT FILING DATE: 2003-04-09  
PRIOR APPLICATION NUMBER: US 60/328,523  
PRIOR FILING DATE: 2001-10-10  
PRIOR APPLICATION NUMBER: US 60/344,692  
PRIOR FILING DATE: 2001-10-19  
PRIOR APPLICATION NUMBER: US 60/387,292  
PRIOR FILING DATE: 2002-06-07  
PRIOR APPLICATION NUMBER: US 60/391,777  
PRIOR FILING DATE: 2002-06-25  
PRIOR APPLICATION NUMBER: US 60/396,594  
PRIOR FILING DATE: 2002-07-17  
PRIOR APPLICATION NUMBER: US 60/404,249  
PRIOR FILING DATE: 2002-08-16  
PRIOR APPLICATION NUMBER: US 60/407,527  
PRIOR FILING DATE: 2002-08-28  
NUMBER OF SEQ ID NOS: 75  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 7  
LENGTH: 1332  
TYPE: DNA  
ORGANISM: Homo sapiens  
US-10-410-913-7

Query Match 0.8%; Score 17; DB 1; Length 1332;  
Best Local Similarity 59.2%; Pred. No. 27;  
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCAGGCTTCGCTGAGTCTTCGT 1703  
DB 23 TCCTCTGCTTCGCTTCAGGCTTCAGGCTTCGCTGAGTCTTCGT 71

RESULT 24  
US-10-617-619-12  
Sequence 12, Application US/10617619  
Publication No. US20040110929A1  
GENERAL INFORMATION:  
APPLICANT: Bjorn, Soren E  
APPLICANT: Nicolaisen, Else M  
APPLICANT: Jorgensen, Anker S  
TITLE OF INVENTION: T<sub>F</sub> Binding Compound  
FILE REFERENCE: 6455.200-US  
CURRENT APPLICATION NUMBER: US/10/617,619  
CURRENT FILING DATE: 2003-07-11  
PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01059  
PRIOR FILING DATE: 2002-07-12  
PRIOR APPLICATION NUMBER: US 60/404,568  
PRIOR FILING DATE: 2002-08-19  
NUMBER OF SEQ ID NOS: 13  
SOFTWARE: PatentIn version 3.2  
SEQ ID NO 12  
LENGTH: 2040  
TYPE: DNA  
ORGANISM: Artificial  
FEATURE:  
OTHER INFORMATION: Synthetic  
US-10-617-619-12

Query Match 0.8%; Score 17; DB 1; Length 2040;  
Best Local Similarity 59.2%; Pred. No. 23;  
Matches 29; Conservative 0; Mismatches 20; Indels 0; Gaps 0;

QY 1655 TCCTTGGTTTTCATAGTCTCTGGCTTCAGGCTTCGCTGAGTCTTCGT 1703

DB 23 TCCTCTGCTTCGCTTCAGGCTTCAGGCTTCGCTGAGTCTTCGT 71  
RESULT 25  
US-09-782-587B-2/c  
Sequence 2, Application US/09782587B  
Publication No. US20030096338A1  
GENERAL INFORMATION:  
APPLICANT: PEDERSEN, ANDERS H.  
APPLICANT: ANDERSON, KIM V.  
APPLICANT: BORNAES, CLAUS  
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
FILE REFERENCE: 31-001100US  
CURRENT APPLICATION NUMBER: US/09/782,587B  
CURRENT FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: PA 2000 00218  
PRIOR FILING DATE: 2000-02-11  
PRIOR APPLICATION NUMBER: 60/184,036  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: 60/241,916  
PRIOR FILING DATE: 2000-10-18  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 2  
LENGTH: 1338  
TYPE: DNA  
ORGANISM: Homo sapiens  
FEATURE:  
NAME/KEY: CDS  
LOCATION: (115)..(1332)  
US-09-782-587B-2

Query Match 0.8%; Score 16.6; DB 1; Length 1338;  
Best Local Similarity 64.1%; Pred. No. 31;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1122 GCCTGGGAATTATTATTATTATTCATATTTCTTGAATGTG 1160  
DB 567 GCCTGGGGTTTGTCTAGCGTTCGCTTTCTAGAATGGG 529

RESULT 26  
US-09-782-587B-4/c  
Sequence 4, Application US/09782587B  
Publication No. US20030096338A1  
GENERAL INFORMATION:  
APPLICANT: PEDERSEN, ANDERS H.  
APPLICANT: ANDERSON, KIM V.  
APPLICANT: BORNAES, CLAUS  
TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
FILE REFERENCE: 31-001100US  
CURRENT APPLICATION NUMBER: US/09/782,587B  
CURRENT FILING DATE: 2002-03-26  
PRIOR APPLICATION NUMBER: PA 2000 00218  
PRIOR FILING DATE: 2000-02-11  
PRIOR APPLICATION NUMBER: 60/184,036  
PRIOR FILING DATE: 2000-02-22  
PRIOR APPLICATION NUMBER: 60/241,916  
PRIOR FILING DATE: 2000-10-18  
NUMBER OF SEQ ID NOS: 19  
SOFTWARE: PatentIn Ver. 2.1  
SEQ ID NO 4  
LENGTH: 1357  
TYPE: DNA  
ORGANISM: Artificial Sequence  
FEATURE:  
OTHER INFORMATION: Description of Artificial Sequence: Expression  
OTHER INFORMATION: cassette for expression of FVII in mammalian cells  
US-09-782-587B-4

Query Match 0.8%; Score 16.6; DB 1; Length 1357;  
Best Local Similarity 64.1%; Pred. No. 31;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

US-10-375-741-13

Query Match 0.8%; Score 16.6; DB 1; Length 1440;  
Best Local Similarity 64.1%; Pred. No. 30;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCCTGGATG 1693  
DB 58 TCCTCTGCTTCTGTTGGCTTCAGGGCTGCTGGCTG 96

RESULT 29

US-10-617-619-9

; Sequence 9, Application US/10617619  
; Publication No. US20040110929A1  
; GENERAL INFORMATION:  
; APPLICANT: Bjorn, Soren E  
; APPLICANT: Nicolaisen, Else M  
; APPLICANT: Jorgensen, Anker S  
; TITLE OF INVENTION: TF Binding Compound  
; FILE REFERENCE: 6455.200-US  
; CURRENT APPLICATION NUMBER: US/10/617,619  
; PRIOR FILING DATE: 2003-07-11  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2002 01099  
; PRIOR FILING DATE: 2002-07-12  
; PRIOR APPLICATION NUMBER: US 60/404,568  
; PRIOR FILING DATE: 2002-08-19  
; NUMBER OF SEQ ID NOS: 13  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 9  
; LENGTH: 2106  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic

US-10-617-619-9

Query Match 0.8%; Score 16.6; DB 1; Length 2106;  
Best Local Similarity 64.1%; Pred. No. 23;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCCTGGATG 1693  
DB 23 TCCTCTGCTTCTGTTGGCTTCAGGGCTGCTGGCTG 61

RESULT 30

US-09-918-995-8429/c

; Sequence 8429, Application US/09918995  
; Publication No. US20030073623A1  
; GENERAL INFORMATION:  
; APPLICANT: Hyseq, Inc.  
; TITLE OF INVENTION: NOVEL NUCLEIC ACID SEQUENCES OBTAINED  
; FILE REFERENCE: 20411-756  
; CURRENT APPLICATION NUMBER: US/09/918,995  
; PRIOR FILING DATE: 2001-07-30  
; PRIOR APPLICATION NUMBER: US/09/235,076  
; PRIOR FILING DATE: 1999-01-20  
; NUMBER OF SEQ ID NOS: 38054  
; SOFTWARE: FastSeq for Windows Version 3.0  
; SEQ ID NO 8429  
; LENGTH: 483  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: misc feature  
; LOCATION: (1)...(483)  
; OTHER INFORMATION: n = A,T,C or G

US-09-918-995-8429

Query Match 0.8%; Score 16.4; DB 1; Length 483;  
Best Local Similarity 55.2%; Pred. No. 27;

US-10-382-248-35

QY 1122 GGCTTGAATATTATTATTCATATTCTTGAATG 1160  
DB 580 GCCCTGGGTTTGCTAGGTTCCGCTTCTAGAAATGG 542

RESULT 27

US-10-382-248-35

; Sequence 35, Application US/10382248  
; Publication No. US20040058347A1  
; GENERAL INFORMATION:  
; APPLICANT: Alsbrook, et al.  
; TITLE OF INVENTION: NOVEL PROTEINS AND NUCLEIC ACIDS ENCODING SAME  
; FILE REFERENCE: 21402-568C  
; CURRENT APPLICATION NUMBER: US/10/382,248  
; CURRENT FILING DATE: 2003-03-05  
; PRIOR APPLICATION NUMBER: 60/366,928  
; PRIOR FILING DATE: 2002-03-22  
; PRIOR APPLICATION NUMBER: 60/361,974  
; PRIOR FILING DATE: 2002-03-06  
; PRIOR APPLICATION NUMBER: 60/365,477  
; PRIOR FILING DATE: 2002-03-19  
; PRIOR APPLICATION NUMBER: 60/401,661  
; PRIOR FILING DATE: 2002-08-06  
; NUMBER OF SEQ ID NOS: 82  
; SOFTWARE: CuraseqList version 0.1  
; SEQ ID NO 35  
; LENGTH: 1361  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; NAME/KEY: CDS  
; LOCATION: (45)...(1301)

US-10-382-248-35

Query Match 0.8%; Score 16.6; DB 1; Length 1361;  
Best Local Similarity 64.1%; Pred. No. 31;  
Matches 25; Conservative 0; Mismatches 14; Indels 0; Gaps 0;

QY 1655 TCCTTTGGTTTTCATAGTGTCTCTGGCTTCCTGGATG 1693  
DB 67 TCCTCTGCTTCTGTTGGCTTCAGGGCTGCTGGCTG 105

RESULT 28

US-10-375-741-13

; Sequence 13, Application US/10375741  
; Publication No. US20030232753A1  
; GENERAL INFORMATION:  
; APPLICANT: Thorpe, Philip E  
; APPLICANT: King, Steven W  
; APPLICANT: Gao, Boring  
; TITLE OF INVENTION: TISSUE FACTOR METHODS AND COMPOSITIONS FOR COAGULATION AND TUMOR  
; FILE REFERENCE: 4001.001999  
; CURRENT APPLICATION NUMBER: US/10/375,741  
; CURRENT FILING DATE: 2003-02-27  
; PRIOR APPLICATION NUMBER: 09/573,835  
; PRIOR FILING DATE: 2000-05-18  
; PRIOR APPLICATION NUMBER: 6,156,321  
; PRIOR FILING DATE: 1998-01-20  
; PRIOR APPLICATION NUMBER: 60/042,427  
; PRIOR FILING DATE: 1997-03-27  
; PRIOR APPLICATION NUMBER: 60/036,205  
; PRIOR FILING DATE: 1997-01-27  
; PRIOR APPLICATION NUMBER: 60/035,920  
; PRIOR FILING DATE: 1997-01-22  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: PatentIn version 3.1  
; SEQ ID NO 13  
; LENGTH: 1440  
; TYPE: DNA  
; ORGANISM: Homo sapiens

	Matches	32;	Conservative	0;	Mismatches	26;	Indels	0;	Gaps	0;
Qy	580	AGTCAATATG	TGATTT	TAGCTG	AGCTGCTG	CTTTT	TATGA	CACTTGG	TGCAT	TG 637
Db	415	AGGACTGG	AGCTGG	TCC	TTG	CAGGAG	CCCC	CAATTC	TGGC	ATGAGGCACACTG 358

RESULT 31  
 US-10-029-386-9623  
 ; Sequence 9623, Application US/10029386  
 ; Publication No. US20030194704A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Penn, Sharon G.  
 ; APPLICANT: Rank, David R.  
 ; APPLICANT: Hanzel, David K.  
 ; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR  
 ; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO  
 ; FILE REFERENCE: AEOMICA-X-2  
 ; CURRENT APPLICATION NUMBER: US/10/029,386  
 ; CURRENT FILING DATE: 2001-12-20  
 ; NUMBER OF SEQ ID NOS: 34288  
 ; SOFTWARE: Annonmax Sequence Listing Engine vers. 1.1  
 ; SEQ ID NO 9623  
 ; LENGTH: 555  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 ; FEATURE:  
 ; OTHER INFORMATION: MAP TO CHR13.3  
 ; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7  
 ; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1  
 ; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46  
 ; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2  
 ; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95  
 ; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3  
 ; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 7.00e-63  
 ; OTHER INFORMATION: NT HIT: J02933.1, EVALUE 0.00e+00  
 ; OTHER INFORMATION: EST\_HUMAN HIT: AL531727.1, EVALUE 5.00e-76  
 US-10-029-386-9623

Query Match	0.7%;	Score 14.8;	DB 1;	Length 555;
Best Local Similarity	56.0%;	Pred. No. 70;		
Matches	28; Conservative	0; Mismatches	22; Indels	0; Gaps
OY	149	TAGGGGCACATACCGCATTCCTCTCTCTTCCAAACACTTCTATTTCCTGA	197	
DB	12	TGGGAGATCTCCCACTCCTCGGTACTGCTGCAGGCAGTCTCGGTATCA	61	

```

RESULT 32
US-10-029-386-23323/c
; Sequence 23323, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharron G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR C
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOMICA-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1
; SEQ ID NO 23323
; LENGTH: 222
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW. SIGNAL = 1.2

```

```

; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: NT_HIT: G114783796, EVALUAE 1.00e-122
; OTHER INFORMATION: EST_HUMAN_HIT: A4531727.1, EVALUAE 3.00e-26
; OTHER INFORMATION: SWISSPROT_HIT: P08709, EVALUAE 3.00e-37
; US-10-029-386-23323

```

	Query Match	0.7%	Score 14.6;	DB 1;	Length 222;
	Best Local Similarity	54.7%;	Pred. No. 60;		
	Matches 29;	Conservative	0;	Mismatches 24;	Indels 0;
	Gaps	0;			
Qy	1799	CTTTCAGTGAGGCTGTCTCTGAGGTTCCGTGTGGTTCCTTAATTTTCAAT	1851		
Db	152	CTGCCCGAAGCGGCGTCTCTGTGAGGACGCTGGCCCTCGTGGCTCTCTCAAT	100		

```

RESULT 33
US-10-029-386-9623/c
; Sequence 9623, Application US/10029386
; Publication No. US20030194704A1
; GENERAL INFORMATION:
; APPLICANT: Penn, Sharon G.
; APPLICANT: Rank, David R.
; APPLICANT: Hanzel, David K.
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC A
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO
; FILE REFERENCE: AEOmica-X-2
; CURRENT APPLICATION NUMBER: US/10/029,386
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 34288
; SOFTWARE: Annonax Sequence Listing Engine vers. 1.1
; SEQ ID NO 9623
; LENGTH: 555
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION: MAP TO CHR13.3
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 1.3
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUAE 7.00e-63
; OTHER INFORMATION: NT HIT: J02933.1, EVALUAE 0.00e+00
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUAE 5.00e-76
US-10-029-386-9623

```

	Query Match	0.7%	Score 14.6;	DB 1;	Length 555;
	Best Local Similarity	54.7%;	Prod. No. 75;		
	Matches 29;	Conservative	0;	Mismatches 24;	Indels 0; Gaps 0;
QY	1799	CTGTGAGTGAGGCTTCTCTGAGGTTCTCTGTGGTCTTCTTAATTTTCATT	1851		
Db	188	TTGCCCGAACGAGCTTCTCTGAGAGGAGCGTGGCTTCGTGGCTTCTCATTT	136		

```

RESULT 34
US-10-272-665-22/c
; Sequence 22, Application US/10272665
; Publication No. US20030180748A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING
; TITLE OF INVENTION: GENETIC MARKERS
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176

```

Mon Aug 9 17:47:20 2004

```

; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-756-22

```

```

Query Match 0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

```

```

Qy 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 58 TGTGGCCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

```

RESULT 37

```

US-10-273-228-22/c
; Sequence 22, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-228-22

```

```

Query Match 0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

```

```

Qy 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 58 TGTGGCCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

```

RESULT 38

```

US-10-272-665-107/c

```

```

; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-272-665-22

```

```

Query Match 0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

```

```

Qy 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 58 TGTGGCCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

```

RESULT 35

```

US-10-273-321-22/c
; Sequence 22, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; PRIOR FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 22
; LENGTH: 60
; TYPE: DNA
; ORGANISM: Homo Sapien
; FEATURE:
; OTHER INFORMATION: Probe
US-10-273-321-22

```

```

Query Match 0.7%; Score 14.2; DB 1; Length 60;
Best Local Similarity 62.9%; Pred. No. 29;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

```

```

Qy 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 58 TGTGGCCTCCACTGTCTCCCTTGCAGGAGTCCTT 24

```

RESULT 36

```

US-10-272-756-22/c
; Sequence 22, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C

```

```
; Sequence 107, Application US/10272665
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-107

Query Match      0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 39
US-10-273-321-107/c
; Sequence 107, Application US/10273321
; Publication No. US20030180749A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-107

Query Match      0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4
```

```
RESULT 40
US-10-272-756-107/c
; Sequence 107, Application US/10272756
; Publication No. US20030190644A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-107

Query Match      0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4

RESULT 41
US-10-273-228-107/c
; Sequence 107, Application US/10273228
; Publication No. US20030207297A1
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107

Query Match      0.7%; Score 14.2; DB 1; Length 100;
Best Local Similarity 62.9%; Pred. No. 45;
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659
Db 38 TGTGGGCTCCACTGTCCCTTGCAGGAGTCCTT 4
```

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4  
|||||

## RESULT 42

US-10-272-665-106/c  
; Sequence 106, Application US/10272665  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033E  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 45;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659  
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4  
|||||

## RESULT 43

US-10-273-321-106/c  
; Sequence 106, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033B  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 45;

Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659  
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4  
|||||

## RESULT 44

US-10-272-756-106/c  
; Sequence 106, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033C  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-106

Query Match 0.7%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 45;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 1625 TTTTGACCTGCTTCTTCCCTTCTCTATTCCTT 1659  
|||||

Db 38 TGTGGGCTCCACTGTCCCTTCGAGGATCCTT 4  
|||||

## RESULT 45

US-10-273-228-106/c  
; Sequence 106, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033D  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 106  
; LENGTH: 100  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-106



Query Match 0.7%; Score 14.2; DB 1; Length 100;  
Best Local Similarity 62.9%; Pred. No. 45;  
Matches 22; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

Qy 1625 TTTGACCTGCTTCTCCCTCTCTCTATTCCTT 1659  
Db 38 TGTGGGCTCCACTGTCCCTCTGAGGAGTCCTT 4

RESULT 46  
US-09-782-587B-2  
; Sequence 2, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUS  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 2  
; LENGTH: 1338  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; NAME/KEY: CDS  
; LOCATION: (115)..(1332)  
US-09-782-587B-2

Query Match 0.7%; Score 14.2; DB 1; Length 1338;  
Best Local Similarity 70.4%; Pred. No. 38;  
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 42 CTGCTGGCAATACCTCTGGGGCTGCTG 68  
Db 22 CTCTGTGCTGTCTCTGGGGCTGCAG 48

RESULT 47  
US-09-782-587B-4  
; Sequence 4, Application US/09782587B  
; Publication No. US20030096338A1  
; GENERAL INFORMATION:  
; APPLICANT: PEDERSEN, ANDERS H.  
; APPLICANT: ANDERSON, KIM V.  
; APPLICANT: BORNAES, CLAUS  
; TITLE OF INVENTION: FACTOR VII OR VIIA-LIKE MOLECULES  
; FILE REFERENCE: 31-001100US  
; CURRENT APPLICATION NUMBER: US/09/782,587B  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: PA 2000 00218  
; PRIOR FILING DATE: 2000-02-11  
; PRIOR APPLICATION NUMBER: 60/184,036  
; PRIOR FILING DATE: 2000-02-22  
; PRIOR APPLICATION NUMBER: 60/241,916  
; PRIOR FILING DATE: 2000-10-18  
; NUMBER OF SEQ ID NOS: 19  
; SOFTWARE: PatentIn Ver. 2.1  
; SEQ ID NO 4  
; LENGTH: 1357  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Expression  
OTHER INFORMATION: cassette for expression of FVII in mammalian cells  
US-09-782-587B-4

Query Match 0.7%; Score 14.2; DB 1; Length 1357;  
Best Local Similarity 70.4%; Pred. No. 37;  
Matches 19; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 42 CTGCTGGCAATACCTCTGGGGCTGCTG 68  
Db 35 CTCTGTGCTGTCTCTGGGGCTGCAG 61

RESULT 48  
US-10-029-386-23323  
; Sequence 23323, Application US/10029386  
; Publication No. US20030194704A1  
; GENERAL INFORMATION:  
; APPLICANT: Penn, Sharron G.  
; APPLICANT: Rank, David R.  
; APPLICANT: Hanzel, David K.  
; TITLE OF INVENTION: HUMAN GENOME-DERIVED SINGLE EXON NUCLEIC ACID PROBES USEFUL FOR  
; TITLE OF INVENTION: EXPRESSION ANALYSIS TWO  
; FILE REFERENCE: AEMICA-X-2  
; CURRENT APPLICATION NUMBER: US/10/029,386  
; CURRENT FILING DATE: 2001-12-20  
; NUMBER OF SEQ ID NOS: 34288  
; SOFTWARE: Annomax Sequence Listing Engine vers. 1.1  
; SEQ ID NO 23323  
; LENGTH: 222  
; TYPE: DNA  
; ORGANISM: Homo sapiens  
; FEATURE:  
; INFORMATION: MAP TO CHR13.3  
; OTHER INFORMATION: EXPRESSED IN ADULT LIVER, SIGNAL = 3.7  
; OTHER INFORMATION: EXPRESSED IN BRAIN, SIGNAL = 1  
; OTHER INFORMATION: EXPRESSED IN LUNG, SIGNAL = 0.46  
; OTHER INFORMATION: EXPRESSED IN BONE MARROW, SIGNAL = 1.2  
; OTHER INFORMATION: EXPRESSED IN PLACENTA, SIGNAL = 0.95  
; OTHER INFORMATION: EXPRESSED IN HEART, SIGNAL = 1.3  
; OTHER INFORMATION: NT HIT: g14783796, EVALUE 1.00e-122  
; OTHER INFORMATION: EST HUMAN HIT: AL531727.1, EVALUE 3.00e-26  
; OTHER INFORMATION: SWISSPROT HIT: P08709, EVALUE 3.00e-37  
US-10-029-386-23323

Query Match 0.6%; Score 12; DB 1; Length 222;  
Best Local Similarity 58.3%; Pred. No. 2.1e+02;  
Matches 21; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

Qy 657 AAGATTGCAATGCTCTTCTGCTGATTTTCCTTG 692  
Db 112 ACGAAGCCAGGCTCTCTCAGAGACGTCGTTTCG 147

RESULT 49  
US-10-349-858-8/c  
; Sequence 8, Application US/10349858  
; Publication No. US20030220247A1  
; GENERAL INFORMATION:  
; APPLICANT: The Children's Hospital of Philadelphia  
; APPLICANT: HIGH, KATHERINE A.  
; APPLICANT: CAMIRE, RODNEY M.  
; APPLICANT: LARSON, PETER J.  
; APPLICANT: STAFFORD, DARREL W.  
; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT C  
; TITLE OF INVENTION: FACTORS  
; FILE REFERENCE: 018743-0301425  
; CURRENT APPLICATION NUMBER: US/10/349,858  
; CURRENT FILING DATE: 2003-01-22  
; PRIOR APPLICATION NUMBER: 09/526,947  
; PRIOR FILING DATE: 2000-03-16  
; PRIOR APPLICATION NUMBER: 60/124,609  
; PRIOR FILING DATE: 1999-03-16

```
; NUMBER OF SEQ ID NOS: 22
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 8
; LENGTH: 54
; TYPE: DNA
; ORGANISM: Homo sapiens
US-10-349-858-8

Query Match      0.6%; Score 11.8; DB 1; Length 54;
Best Local Similarity 69.8%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 1819 TGAGGTTCTCTGTTGGGTTCTTAA 1841
    ||||| ||||| ||||| |||||
Db 29 TGGGCTTCTCTCTGGGTACGAA 7

RESULT 50
US-10-281-727-6/C
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-6

Query Match      0.6%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1893 TTCCACTTTCAGTCTCTG 1910
    ||||| ||||| ||||| |||||
Db 26 TCCACCTTCGTTCTCTG 9

RESULT 51
US-10-281-727-7
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; TITLE OF INVENTION: Polypeptides
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; CURRENT FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; PRIOR FILING DATE: 2001-11-15
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 21 TAATATATTTCCTTGAAGCCTCTCTGTCGC 49
    ||||| ||||| ||||| |||||
Db 10 TAAAACGCTTTCCTGGAGGAGCTCGGGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
US-10-398-422A-20

Query Match      0.6%; Score 11.6; DB 1; Length 32;
Best Local Similarity 77.8%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1893 TTCCACTTTCAGTCTCTG 1910
    ||||| ||||| ||||| |||||
Db 7 TCCACCTTCGTTCTCTG 24

RESULT 52
US-10-398-422A-20
; Sequence 20, Application US/10398422A
; Publication No. US20040058413A1
; GENERAL INFORMATION:
; APPLICANT: Nicolaisen, Else Marie
; APPLICANT: Nielsen, Lars Soegaard
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins
; FILE REFERENCE: 6270.204-US
; CURRENT APPLICATION NUMBER: US/10/398,422A
; CURRENT FILING DATE: 2003-09-02
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; PRIOR APPLICATION NUMBER: PCT/DR01/00635
; PRIOR FILING DATE: 2001-10-02
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 20
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: synthetic
US-10-398-422A-20

Query Match      0.6%; Score 11.4; DB 1; Length 38;
Best Local Similarity 62.1%; Pred. No. 1.9e+02;
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 21 TAATATATTTCCTTGAAGCCTCTCTGTCGC 49
    ||||| ||||| ||||| |||||
Db 10 TAAAACGCTTTCCTGGAGGAGCTCGGGCC 38

RESULT 53
US-09-969-357-2
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; CURRENT FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
US-10-398-422A-20
```

; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262  
; PRIOR FILING DATE: 2001-02-16  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430  
; PRIOR FILING DATE: 2001-03-14  
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751  
; PRIOR FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: US 60/238,944  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/271,581  
; PRIOR FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: US 60/276,322  
; PRIOR FILING DATE: 2001-03-16  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: Patent in version 3.2  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-969-357-2

Query Match 0.6%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 1.9e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;  
QY 21 TAATATATTTCTTGAAGCCTCTGCTGGC 49  
Db 10 TAAACGCTTCTCTGGAGGAGCTGCGGCC 38

RESULT 54  
US-10-254-394-2  
; Sequence 2, Application US/10254394  
; Publication No. US20030096368A1  
; GENERAL INFORMATION:  
; APPLICANT: Knudsen, Ida Molgaard  
; TITLE OF INVENTION: Method for Production of Recombinant  
; FILE REFERENCE: 6480-500-US  
; CURRENT APPLICATION NUMBER: US/10/254,394  
; PRIOR FILING DATE: 2002-09-25  
; PRIOR APPLICATION NUMBER: PCT/DK01/00632  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PCT/DK01/00634  
; PRIOR FILING DATE: 2001-10-02  
; PRIOR APPLICATION NUMBER: PA 2002 00460  
; PRIOR FILING DATE: 2002-03-26  
; PRIOR APPLICATION NUMBER: 60/374,855  
; NUMBER OF SEQ ID NOS: 2  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-254-394-2

Query Match 0.6%; Score 11.4; DB 1; Length 38;  
Best Local Similarity 62.1%; Pred. No. 1.9e+02;  
Matches 18; Conservative 0; Mismatches 11; Indels 0; Gaps 0;  
QY 21 TAATATATTTCTTGAAGCCTCTGCTGGC 49  
Db 10 TAAACGCTTCTCTGGAGGAGCTGCGGCC 38

RESULT 55  
US-09-951-121A-14/c  
; Sequence 14, Application US/09951121A

; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 14  
; LENGTH: 33  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-14

Query Match 0.6%; Score 11.2; DB 1; Length 33;  
Best Local Similarity 66.7%; Pred. No. 2e+02;  
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
QY 1295 TGCAGTAGTCTGGCCTGACATCTG 1318  
Db 31 TGCAGGAGTCTTGGCGCCATCCG 8

RESULT 56  
US-09-951-121A-15  
; Sequence 15, Application US/09951121A  
; Publication No. US20030104978A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
; FILE REFERENCE: 6224.200-US  
; CURRENT APPLICATION NUMBER: US/09/951,121A  
; CURRENT FILING DATE: 2001-09-13  
; PRIOR APPLICATION NUMBER: PA 2000 01361  
; PRIOR FILING DATE: 2000-09-13  
; PRIOR APPLICATION NUMBER: 60/236,455  
; PRIOR FILING DATE: 2000-09-29  
; NUMBER OF SEQ ID NOS: 17  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 15  
; LENGTH: 33  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Synthetic  
US-09-951-121A-15

Query Match 0.6%; Score 11.2; DB 1; Length 33;  
Best Local Similarity 66.7%; Pred. No. 2e+02;  
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;  
QY 1295 TGCAGTAGTCTGGCCTGACATCTG 1318  
Db 3 TGCAGGAGTCTTGGCGCCATCCG 26

RESULT 57  
US-10-295-692-14/c  
; Sequence 14, Application US/10295682  
; Publication No. US20030100740A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; APPLICANT: Olsen, Ole Hvilsted  
; TITLE OF INVENTION: Human Coagulation Factor VII Variants

```
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 14
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-14

Query Match          0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1295 TGCAGTACTGCGCTGACATCTG 1318
Db 31 TGCAGGAGTCTTCCGCCATCCG 8

RESULT 58
US-10-295-682-15
; Sequence 15, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 15
; LENGTH: 33
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-15

Query Match          0.6%; Score 11.2; DB 1; Length 33;
Best Local Similarity 66.7%; Pred. No. 2e+02;
Matches 16; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1295 TGCAGTACTGCGCTGACATCTG 1318
Db 3 TGCAGGAGTCTTCCGCCATCCG 26

RESULT 59
US-09-951-121A-8/c
; Sequence 8, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
```

```
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-8

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCTCTGAA 1912
Db 33 CACGTTGAGGACCTGGA 17

RESULT 60
US-09-951-121A-9
; Sequence 9, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951,121A
; CURRENT FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-9

Query Match          0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCTCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 61
US-10-255-032-8/c
; Sequence 8, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: No. US20030100075A10 No. US20030100075A1disk A/S
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
```

```
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII
US-10-255-032-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCCTGAA 1912
Db 33 CACGTTGAGGACCTGGA 17

RESULT 62
US-10-255-032-9
; Sequence 9, Application US/10255032
; Publication No. US20030100075A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII POLYPEPTIDES
; FILE REFERENCE: 6357-WO
; CURRENT APPLICATION NUMBER: US/10/255,032
; CURRENT FILING DATE: 2002-09-24
; PRIOR APPLICATION NUMBER: DK PA 2001 01413
; PRIOR FILING DATE: 2001-09-27
; NUMBER OF SEQ ID NOS: 9
; SOFTWARE: Patentin version 3.1
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-255-032-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 63
US-10-295-682-8/c
; Sequence 8, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: HUMAN COAGULATION FACTOR VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-8

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 64
US-10-295-682-9
; Sequence 9, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; CURRENT FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; PRIOR FILING DATE: 2000-09-29
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 9
; LENGTH: 36
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-9

Query Match      0.5%; Score 10.6; DB 1; Length 36;
Best Local Similarity 76.5%; Pred. No. 3.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1896 CACTTTCAGGTCCTGAA 1912
Db 4 CACGTTGAGGACCTGGA 20

RESULT 65
US-09-803-810-8
; Sequence 8, Application US/09803810
; Publication No. US20010018414A1
; GENERAL INFORMATION:
; APPLICANT: Nelsetuen, Gary L.
; TITLE OF INVENTION: MODIFIED VITAMIN K-DEPENDENT
; FILE REFERENCE: 09531/002001
; CURRENT APPLICATION NUMBER: US/09/803,810
; CURRENT FILING DATE: 2001-03-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.5%; Score 10.6; DB 1; Length 42;
Best Local Similarity 64.0%; Pred. No. 3.7e+02;
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGCCAGGCTAGGGGCAC 156
Db 2 CACTCCCGCTCCAGGCTGCTGGAC 26

RESULT 66
US-10-298-330-8
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
```

GENERAL INFORMATION:  
; APPLICANT: Nelstuen, Gary L.  
; TITLE OF INVENTION: Modified Vitamin K-Dependent  
; FILE REFERENCE: 09531-127001  
; CURRENT APPLICATION NUMBER: US/10/298,330  
; CURRENT FILING DATE: 2002-11-18  
; PRIOR APPLICATION NUMBER: 09/497,591  
; PRIOR FILING DATE: 2000-02-03  
; PRIOR APPLICATION NUMBER: 09/302,239  
; PRIOR FILING DATE: 1999-04-29  
; PRIOR APPLICATION NUMBER: 08/955,636  
; PRIOR FILING DATE: 1997-10-23  
; NUMBER OF SEQ ID NOS: 27  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 8  
; LENGTH: 42  
; TYPE: DNA  
; ORGANISM: Artificial Sequence  
; FEATURE:  
; OTHER INFORMATION: Primer  
US-10-298-330-8

Query Match 0.5%; Score 10.6; DB 1; Length 42;  
Best Local Similarity 64.0%; Pred. No. 3.7e+02;  
Matches 16; Conservative 0; Mismatches 9; Indels 0; Gaps 0;

QY 132 CACTTCTGGGCGAGGTAGGGGCAC 156  
DB 2 CACTCCCGCTCAGGCTCTGGGAC 26

RESULT 67  
US-10-272-665-23/c  
; Sequence 23, Application US/10272665  
; Publication No. US20030180748A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033E  
; CURRENT APPLICATION NUMBER: US/10/272,665  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 4.4e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCTTGTATCTTGCACTTGTGAAGTGTGTGTG 1019  
DB 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGTG 2

RESULT 68  
US-10-273-321-23/c  
; Sequence 23, Application US/10273321

Publication No. US20030180749A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273,321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 4.4e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCTTGTATCTTGCACTTGTGAAGTGTGTGTG 1019  
DB 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGTG 2

RESULT 69  
US-10-272-756-23/c  
; Sequence 23, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PO  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 4.4e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCTTGTATCTTGCACTTGTGAAGTGTGTGTG 1019  
DB 42 TGACGATGCCGTCAGGTACACGTCGCCCGGTAGTGGTG 2

RESULT 70  
US-10-273-228-23/c  
; Sequence 23, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:  
; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-23

Query Match 0.5%; Score 10.6; DB 1; Length 60;  
Best Local Similarity 53.7%; Pred. No. 4.4e+02;  
Matches 22; Conservative 0; Mismatches 19; Indels 0; Gaps 0;

QY 979 TGTGGATTCCTGTACTTCACCTTGTGAAGTGTGTGTG 1019  
DB 42 TGACAGTCCCGTACGTACACGTCGCCCGGTAGTGGGTG 2

RESULT 71  
US-10-281-727-2/c  
; Sequence 2, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 2  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-2

Query Match 0.5%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 60.7%; Pred. No. 3.9e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1805 GTGAGGCTTGTCTGTGAGGTCCTGTG 1832  
DB 35 GGGAGTCTCCACGTCGCGTTCCTGTG 8

RESULT 72  
US-10-281-727-3  
; Sequence 3, Application US/10281727  
; Publication No. US20030130191A1  
; GENERAL INFORMATION:  
; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Human Coagulation Factor VII  
; FILE REFERENCE: 6410.200-US  
; CURRENT APPLICATION NUMBER: US/10/281,727  
; CURRENT FILING DATE: 2002-10-28  
; PRIOR APPLICATION NUMBER: PA 2001 01627  
; PRIOR FILING DATE: 2001-11-02  
; PRIOR APPLICATION NUMBER: 60/335,383  
; PRIOR FILING DATE: 2001-11-15  
; NUMBER OF SEQ ID NOS: 7  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 3  
; LENGTH: 36  
; TYPE: DNA  
; ORGANISM: Unknown  
; FEATURE:  
; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII  
US-10-281-727-3

Query Match 0.5%; Score 10.4; DB 1; Length 36;  
Best Local Similarity 60.7%; Pred. No. 3.9e+02;  
Matches 17; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 1805 GTGAGGCTTGTCTGTGAGGTCCTGTG 1832  
DB 2 GGGAGTCTCCACGTCGCGTTCCTGTG 29

RESULT 73  
US-10-398-422A-20/c  
; Sequence 20, Application US/10398422A  
; Publication No. US20040058413A1  
; GENERAL INFORMATION:  
; APPLICANT: Nicolaisen, Else Marie  
; APPLICANT: Nielsen, Lars Soegaard  
; TITLE OF INVENTION: Method for the Production of Vitamin K-Dependent Proteins  
; FILE REFERENCE: 6270.204-US  
; CURRENT APPLICATION NUMBER: US/10/398,422A  
; CURRENT FILING DATE: 2003-09-02  
; PRIOR APPLICATION NUMBER: Danish application PA 2000 01456  
; PRIOR FILING DATE: 2000-10-02  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00262  
; PRIOR FILING DATE: 2001-02-16  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00430  
; PRIOR FILING DATE: 2001-03-14  
; PRIOR APPLICATION NUMBER: Danish application PA 2001 00751  
; PRIOR FILING DATE: 2001-05-14  
; PRIOR APPLICATION NUMBER: US 60/238,944  
; PRIOR FILING DATE: 2000-10-10  
; PRIOR APPLICATION NUMBER: US 60/271,581  
; PRIOR FILING DATE: 2001-02-26  
; PRIOR APPLICATION NUMBER: US 60/276,322  
; PRIOR FILING DATE: 2001-03-16  
; PRIOR APPLICATION NUMBER: PCT/DK01/00635  
; PRIOR FILING DATE: 2001-10-02  
; NUMBER OF SEQ ID NOS: 20  
; SOFTWARE: PatentIn version 3.2  
; SEQ ID NO 20  
; LENGTH: 38  
; TYPE: DNA  
; ORGANISM: Artificial  
; FEATURE:  
; OTHER INFORMATION: synthetic  
US-10-398-422A-20

Query Match 0.5%; Score 10.2; DB 1; Length 38;



```

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGTCGCAATACCTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 74
US-09-969-357-2/c
; Sequence 2, Application US/09969357
; Publication No. US20020137673A1
; GENERAL INFORMATION:
; APPLICANT: Novo Nordisk Pharmaceuticals, Inc.
; APPLICANT: Pingel, Hans K
; APPLICANT: Klausen, Niels K
; TITLE OF INVENTION: Factor VII Glycoforms
; FILE REFERENCE: 6207.510-US
; CURRENT APPLICATION NUMBER: US/09/969,357
; PRIOR FILING DATE: 2002-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2000 01456
; PRIOR FILING DATE: 2000-10-02
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00262
; PRIOR FILING DATE: 2001-02-16
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00430
; PRIOR FILING DATE: 2001-03-14
; PRIOR APPLICATION NUMBER: Danish Application No. PA 2001 00751
; PRIOR FILING DATE: 2001-05-14
; PRIOR APPLICATION NUMBER: US 60/238,944
; PRIOR FILING DATE: 2000-10-10
; PRIOR APPLICATION NUMBER: US 60/271,581
; PRIOR FILING DATE: 2001-02-26
; PRIOR APPLICATION NUMBER: US 60/276,322
; PRIOR FILING DATE: 2001-03-16
; NUMBER OF SEQ ID NOS: 2
; SOFTWARE: PatentIn version 3.2
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-969-357-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGTCGCAATACCTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 75
US-10-254-394-2/c
; Sequence 2, Application US/10254394
; Publication No. US20030096366A1
; GENERAL INFORMATION:
; APPLICANT: Knudsen, Ida Molgaard
; TITLE OF INVENTION: Method for Production of Recombinant
; FILE REFERENCE: 6480.500-US
; CURRENT APPLICATION NUMBER: US/10/254,394
; PRIOR FILING DATE: 2002-09-25
; PRIOR APPLICATION NUMBER: PCT/DK01/00632
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PCT/DK01/00634
; PRIOR FILING DATE: 2001-10-02
; PRIOR APPLICATION NUMBER: PA 2002 00460
; PRIOR FILING DATE: 2002-03-26
; PRIOR APPLICATION NUMBER: 60/374,855
; PRIOR FILING DATE: 2002-10-04
; NUMBER OF SEQ ID NOS: 2

```

```

; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 38
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-254-394-2

Query Match      0.5%; Score 10.2; DB 1; Length 38;
Best Local Similarity 58.1%; Pred. No. 4.6e+02;
Matches 18; Conservative 0; Mismatches 13; Indels 0; Gaps 0;

QY 35 GAAGCCTCTGTCGCAATACCTTCTGGGCTG 65
    |||||
Db 34 GCAGCTCCTCCAGGAAGCGTTTATAGCGCG 4

RESULT 76
US-10-109-498-5/c
; Sequence 5, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 5
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer
US-10-109-498-5

Query Match      0.5%; Score 10; DB 1; Length 35;
Best Local Similarity 55.9%; Pred. No. 5.1e+02;
Matches 19; Conservative 0; Mismatches 15; Indels 0; Gaps 0;

QY 573 GTGTGTGAGCTCAATATGTGATTTAGCTGTAGC 605
    |||||
Db 34 GTCAGTGAGGACCCAGCGACAGTGCAGCGGAGC 1

RESULT 77
US-10-109-498-6
; Sequence 6, Application US/10109498
; Publication No. US20030044908A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Coagulation Factor VII Derivatives
; FILE REFERENCE: 6286.200-US
; CURRENT APPLICATION NUMBER: US/10/109,498
; PRIOR FILING DATE: 2002-03-22
; PRIOR APPLICATION NUMBER: 60/281,261
; PRIOR FILING DATE: 2001-04-03
; PRIOR APPLICATION NUMBER: PA 2001 00477
; PRIOR FILING DATE: 2001-03-22
; NUMBER OF SEQ ID NOS: 20
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Nucleotide Primer

```



```
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 22
/ LENGTH: 60
/ TYPE: DNA
/ ORGANISM: Homo Sapien
/ FEATURE:
/ OTHER INFORMATION: Probe
US-10-273-228-22
```

```
Query Match          0.5%; Score 10; DB 1; Length 60;
Best Local Similarity 72.2%; Pred. No. 5.9e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 40 GGGACAGTGGAGGCCAC 57
```

```
RESULT 82
US-10-272-665-107
/ Sequence 107, Application US/10272665
/ Publication No. US20030180748A1
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033E
/ CURRENT APPLICATION NUMBER: US/10/272,665
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-272-665-107
```

```
Query Match          0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

```
RESULT 83
US-10-273-321-107
/ Sequence 107, Application US/10273321
/ Publication No. US20030180749A1
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033B
/ CURRENT APPLICATION NUMBER: US/10/273,321
```

```
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-273-321-107
```

```
Query Match          0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

```
RESULT 84
US-10-272-756-107
/ Sequence 107, Application US/10272756
/ Publication No. US20030190644A1
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
/ FILE REFERENCE: 24736-2033C
/ CURRENT APPLICATION NUMBER: US/10/272,756
/ CURRENT FILING DATE: 2002-10-15
/ PRIOR APPLICATION NUMBER: 09/687,483
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/217,658
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 60/159,176
/ PRIOR FILING DATE: 1999-10-13
/ PRIOR APPLICATION NUMBER: 60/217,251
/ PRIOR FILING DATE: 2000-07-10
/ PRIOR APPLICATION NUMBER: 09/663,968
/ PRIOR FILING DATE: 2000-09-19
/ NUMBER OF SEQ ID NOS: 118
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 107
/ LENGTH: 100
/ TYPE: DNA
/ ORGANISM: Homo sapien
US-10-272-756-107
```

```
Query Match          0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

```
RESULT 85
US-10-273-228-107
/ Sequence 107, Application US/10273228
/ Publication No. US20030207297A1
/ GENERAL INFORMATION:
/ APPLICANT: Braun et al.
/ TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC
```

```
; GENERAL INFORMATION:
; FILE REFERENCE: 24736-2033D
; CURRENT APPLICATION NUMBER: US/10/273,228
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 107
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-228-107
```

```
Query Match      0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

## RESULT 86

```
US-10-272-665-106
; Sequence 106, Application US/10272665
; Publication No. US20030180748A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033E
; CURRENT APPLICATION NUMBER: US/10/272,665
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-665-106
```

```
Query Match      0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

## RESULT 87

```
US-10-273-321-106
; Sequence 106, Application US/10273321
; Publication No. US20030180749A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033B
; CURRENT APPLICATION NUMBER: US/10/273,321
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-273-321-106
```

```
Query Match      0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

## RESULT 88

```
US-10-272-756-106
; Sequence 106, Application US/10272756
; Publication No. US20030190644A1
```

```
; GENERAL INFORMATION:
; APPLICANT: Braun et al.
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P
; FILE REFERENCE: 24736-2033C
; CURRENT APPLICATION NUMBER: US/10/272,756
; CURRENT FILING DATE: 2002-10-15
; PRIOR APPLICATION NUMBER: 09/687,483
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/217,658
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 60/159,176
; PRIOR FILING DATE: 1999-10-13
; PRIOR APPLICATION NUMBER: 60/217,251
; PRIOR FILING DATE: 2000-07-10
; PRIOR APPLICATION NUMBER: 09/663,968
; PRIOR FILING DATE: 2000-09-19
; NUMBER OF SEQ ID NOS: 118
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 106
; LENGTH: 100
; TYPE: DNA
; ORGANISM: Homo sapien
US-10-272-756-106
```

```
Query Match      0.5%; Score 10; DB 1; Length 100;
Best Local Similarity 72.2%; Pred. No. 4.8e+02;
Matches 13; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
```

```
QY 139 GGGCCAGGTAGGGGCAC 156
    ||| ||| ||| ||| |||
Db 20 GGGACAGTGGAGGCCAC 37
```

## RESULT 89



; PRIOR APPLICATION NUMBER: DK PA 2001 01413  
 ; PRIOR FILING DATE: 2001-09-27  
 ; NUMBER OF SEQ ID NOS: 9  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 9  
 ; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: DNA primer for preparation of E296V/M298Q-FVII  
 US-10-255-032-9

Query Match 0.5%; Score 9.8; DB 1; Length 36;  
 Best Local Similarity 58.6%; Pred. No. 5.9e+02;  
 Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTCTCTCTCTCTCCCTTTCTCTAAC 132  
 |||||  
 Db 35 CCACGGCCCTGTGTCTCCAGGTCTCTCAAC 7

RESULT 94  
 US-10-295-682-8  
 ; Sequence 8, Application US/10295682  
 ; Publication No. US20030100740A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Persson, Egon  
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
 ; FILE REFERENCE: 6224.200-US  
 ; CURRENT APPLICATION NUMBER: US/10/295,682  
 ; CURRENT FILING DATE: 2002-11-15  
 ; PRIOR APPLICATION NUMBER: PA 2000 01361  
 ; PRIOR FILING DATE: 2000-09-13  
 ; PRIOR APPLICATION NUMBER: 60/236,455  
 ; PRIOR FILING DATE: 2000-09-29  
 ; NUMBER OF SEQ ID NOS: 17  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 8  
 ; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 US-10-295-682-8

Query Match 0.5%; Score 9.8; DB 1; Length 36;  
 Best Local Similarity 58.6%; Pred. No. 5.9e+02;  
 Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTCTCTCTCTCTCCCTTTCTCTAAC 132  
 |||||  
 Db 2 CCACGGCCCTGTGTCTCCAGGTCTCTCAAC 30

RESULT 95  
 US-10-295-682-9/c  
 ; Sequence 9, Application US/10295682  
 ; Publication No. US20030100740A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Persson, Egon  
 ; TITLE OF INVENTION: Human Coagulation Factor VII Variants  
 ; FILE REFERENCE: 6224.200-US  
 ; CURRENT APPLICATION NUMBER: US/10/295,682  
 ; CURRENT FILING DATE: 2002-11-15  
 ; PRIOR APPLICATION NUMBER: PA 2000 01361  
 ; PRIOR FILING DATE: 2000-09-13  
 ; PRIOR APPLICATION NUMBER: 60/236,455  
 ; PRIOR FILING DATE: 2000-09-29  
 ; NUMBER OF SEQ ID NOS: 17  
 ; SOFTWARE: FastSeq for Windows Version 4.0  
 ; SEQ ID NO 9

; LENGTH: 36  
 ; TYPE: DNA  
 ; ORGANISM: Artificial Sequence  
 ; FEATURE:  
 ; OTHER INFORMATION: Synthetic  
 US-10-295-682-9

Query Match 0.5%; Score 9.8; DB 1; Length 36;  
 Best Local Similarity 58.6%; Pred. No. 5.9e+02;  
 Matches 17; Conservative 0; Mismatches 12; Indels 0; Gaps 0;

QY 104 CCACGTCTCTCTCTCTCCCTTTCTCTAAC 132  
 |||||  
 Db 35 CCACGGCCCTGTGTCTCCAGGTCTCTCAAC 7

RESULT 96  
 US-10-349-858-8  
 ; Sequence 8, Application US/10349858  
 ; Publication No. US20030220247A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: The Children's Hospital of Philadelphia  
 ; APPLICANT: HIGH, KATHERINE A.  
 ; APPLICANT: CAMIRE, RODNEY M.  
 ; APPLICANT: LARSON, PETER J.  
 ; APPLICANT: STAFFORD, DARREL W.  
 ; TITLE OF INVENTION: ENHANCED GAMMA-CARBOXYLATION OF RECOMBINANT VITAMIN K-DEPENDENT (C  
 ; FILE REFERENCE: 018743-0301425  
 ; CURRENT APPLICATION NUMBER: US/10/349,858  
 ; CURRENT FILING DATE: 2003-01-22  
 ; PRIOR APPLICATION NUMBER: 09/526,947  
 ; PRIOR FILING DATE: 2000-03-16  
 ; PRIOR APPLICATION NUMBER: 60/124,609  
 ; PRIOR FILING DATE: 1999-03-16  
 ; NUMBER OF SEQ ID NOS: 22  
 ; SOFTWARE: PatentIn version 3.1  
 ; SEQ ID NO 8  
 ; LENGTH: 54  
 ; TYPE: DNA  
 ; ORGANISM: Homo sapiens  
 US-10-349-858-8

Query Match 0.5%; Score 9.8; DB 1; Length 54;  
 Best Local Similarity 84.6%; Pred. No. 6.4e+02;  
 Matches 11; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 11 AGAGACTTCTATAA 23  
 |||||  
 Db 1 AGAGCTCTTCGTAA 13

RESULT 97  
 US-10-272-665-23  
 ; Sequence 23, Application US/10272665  
 ; Publication No. US20030180748A1  
 ; GENERAL INFORMATION:  
 ; APPLICANT: Braun et al.  
 ; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING P  
 ; FILE REFERENCE: 24736-2033E  
 ; CURRENT APPLICATION NUMBER: US/10/272,665  
 ; CURRENT FILING DATE: 2002-10-15  
 ; PRIOR APPLICATION NUMBER: 09/687,483  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/217,658  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 60/159,176  
 ; PRIOR FILING DATE: 1999-10-13  
 ; PRIOR APPLICATION NUMBER: 60/217,251  
 ; PRIOR FILING DATE: 2000-07-10  
 ; PRIOR APPLICATION NUMBER: 09/663,968  
 ; PRIOR FILING DATE: 2000-09-19

; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-665-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 6.4e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583  
|||||  
Db 4 CCCACTACCGGGCAGGTGT 24

## RESULT 98

US-10-273-321-23  
; Sequence 23, Application US/10273321  
; Publication No. US20030180749A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033B  
; CURRENT APPLICATION NUMBER: US/10/273.321  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-321-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 6.4e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583  
|||||  
Db 4 CCCACTACCGGGCAGGTGT 24

## RESULT 99

US-10-272-756-23  
; Sequence 23, Application US/10272756  
; Publication No. US20030190644A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033C  
; CURRENT APPLICATION NUMBER: US/10/272,756  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251

; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-272-756-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 6.4e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583  
|||||  
Db 4 CCCACTACCGGGCAGGTGT 24

## RESULT 100

US-10-273-228-23  
; Sequence 23, Application US/10273228  
; Publication No. US20030207297A1  
; GENERAL INFORMATION:

; APPLICANT: Braun et al.  
; TITLE OF INVENTION: METHODS FOR GENERATING DATABASES AND DATABASES FOR IDENTIFYING PC  
; FILE REFERENCE: 24736-2033D  
; CURRENT APPLICATION NUMBER: US/10/273,228  
; CURRENT FILING DATE: 2002-10-15  
; PRIOR APPLICATION NUMBER: 09/687,483  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/217,658  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 60/159,176  
; PRIOR FILING DATE: 1999-10-13  
; PRIOR APPLICATION NUMBER: 60/217,251  
; PRIOR FILING DATE: 2000-07-10  
; PRIOR APPLICATION NUMBER: 09/663,968  
; PRIOR FILING DATE: 2000-09-19  
; NUMBER OF SEQ ID NOS: 118  
; SOFTWARE: FastSeq for Windows Version 4.0  
; SEQ ID NO 23  
; LENGTH: 60  
; TYPE: DNA  
; ORGANISM: Homo sapien  
US-10-273-228-23

Query Match 0.5%; Score 9.8; DB 1; Length 60;  
Best Local Similarity 66.7%; Pred. No. 6.4e+02;  
Matches 14; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 563 CCCACTATCTGTGTGAGGT 583  
|||||  
Db 4 CCCACTACCGGGCAGGTGT 24

## RESULT 101

US-10-109-498-5  
; Sequence 5, Application US/10109498  
; Publication No. US20030044908A1  
; GENERAL INFORMATION:

; APPLICANT: Persson, Egon  
; TITLE OF INVENTION: Coagulation Factor VII Derivatives  
; FILE REFERENCE: 6286.200-US  
; CURRENT APPLICATION NUMBER: US/10/109,498  
; CURRENT FILING DATE: 2002-03-22  
; PRIOR APPLICATION NUMBER: 60/281,261  
; PRIOR FILING DATE: 2001-04-03  
; PRIOR APPLICATION NUMBER: PA 2001 00477  
; PRIOR FILING DATE: 2001-03-22  
; NUMBER OF SEQ ID NOS: 20

Matches	17;	Conservative	0;	Mismatches	13;	Indels	0;	Gaps
QY	1514	TCCGGTCCAATCTATTGGTGTGTTTGTATG	1543					
DB	2	TCCGTGGTGCCATGAGGGGTACTCTCTG	31					
RESULT 104								
US-09-951-121A-2								
Sequence 2, Application US/09951121A								
Publication No. US20030104978A1								
GENERAL INFORMATION:								
APPLICANT: Persson, Egon								
TITLE OF INVENTION: Human Coagulation Factor VII Variants								
FILE REFERENCE: 6224.200-US								
CURRENT APPLICATION NUMBER: US/09/951,121A								
CURRENT FILING DATE: 2001-09-13								
PRIOR APPLICATION NUMBER: PA 2000 01361								
PRIOR FILING DATE: 2000-09-13								
PRIOR APPLICATION NUMBER: 60/236,455								
PRIOR FILING DATE: 2000-09-29								
NUMBER OF SEQ ID NOS: 17								
SOFTWARE: FastSeq for Windows Version 4.0								
SEQ ID NO 2								
LENGTH: 34								
TYPE: DNA								
ORGANISM: Artificial Sequence								
FEATURE:								
OTHER INFORMATION: Synthetic								
US-09-951-121A-2								
Query Match 0.5%; Score 9.2; DB 1; Length 34;								
Best Local Similarity 63.6%; Pred. No. 8.2e+02;								
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0								
QY	1006	GAAGTGTGTGTGTGTGTGTG	1027					
DB	3	GAATTGTGGGGCGCGGTGTG	24					
RESULT 105								
US-09-951-121A-3/c								
Sequence 3, Application US/09951121A								
Publication No. US20030104978A1								
GENERAL INFORMATION:								
APPLICANT: Persson, Egon								
TITLE OF INVENTION: Human Coagulation Factor VII Variants								
FILE REFERENCE: 6224.200-US								
CURRENT APPLICATION NUMBER: US/09/951,121A								
CURRENT FILING DATE: 2001-09-13								
PRIOR APPLICATION NUMBER: PA 2000 01361								
PRIOR FILING DATE: 2000-09-13								
PRIOR APPLICATION NUMBER: 60/236,455								
PRIOR FILING DATE: 2000-09-29								
NUMBER OF SEQ ID NOS: 17								
SOFTWARE: FastSeq for Windows Version 4.0								
SEQ ID NO 3								
LENGTH: 34								
TYPE: DNA								
ORGANISM: Artificial Sequence								
FEATURE:								
OTHER INFORMATION: Synthetic								
US-09-951-121A-3								
Query Match 0.5%; Score 9.2; DB 1; Length 34;								
Best Local Similarity 63.8%; Pred. No. 8.2e+02;								
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0								
QY	1006	GAAGTGTGTGTGTGTGTG	1027					
DB	32	GAATTGTGGGGCGCGGTGTG	11					

Matches	17;	Conservative	0;	Mismatches	13;	Indels	0;	Gaps
QY	1514	TCGGTCCAAATCTATTGCTGTTTGTATG	1543					
DB	2	TCCTGTCGGTGCCATGAGGGGTACTCTCTG	31					
RESULT 104								
US-09-951-121A-2								
Sequence 2, Application US/09951121A								
Publication No. US20030104978A1								
GENERAL INFORMATION:								
APPLICANT: Persson, Egon								
TITLE OF INVENTION: Human Coagulation Factor VII Variants								
FILE REFERENCE: 6224.200-US								
CURRENT APPLICATION NUMBER: US/09/951,121A								
CURRENT FILING DATE: 2001-09-13								
PRIOR APPLICATION NUMBER: PA 2000 01361								
PRIOR FILING DATE: 2000-09-13								
PRIOR APPLICATION NUMBER: 60/236,455								
PRIOR FILING DATE: 2000-09-29								
NUMBER OF SEQ ID NOS: 17								
SOFTWARE: FastSeq for Windows Version 4.0								
SEQ ID NO 2								
LENGTH: 34								
TYPE: DNA								
ORGANISM: Artificial Sequence								
FEATURE:								
OTHER INFORMATION: Synthetic								
US-09-951-121A-2								
Query Match 0.5%; Score 9.2; DB 1; Length 34;								
Best Local Similarity 63.6%; Pred. No. 8.2e+02;								
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0								
QY	1006	GAAGTGTGTGTGTGTGTGTGTG	1027					
DB	3	GAATTGTGGGGCGCGGTGTG	24					
RESULT 105								
US-09-951-121A-3/c								
Sequence 3, Application US/09951121A								
Publication No. US20030104978A1								
GENERAL INFORMATION:								
APPLICANT: Persson, Egon								
TITLE OF INVENTION: Human Coagulation Factor VII Variants								
FILE REFERENCE: 6224.200-US								
CURRENT APPLICATION NUMBER: US/09/951,121A								
CURRENT FILING DATE: 2001-09-13								
PRIOR APPLICATION NUMBER: PA 2000 01361								
PRIOR FILING DATE: 2000-09-13								
PRIOR APPLICATION NUMBER: 60/236,455								
PRIOR FILING DATE: 2000-09-29								
NUMBER OF SEQ ID NOS: 17								
SOFTWARE: FastSeq for Windows Version 4.0								
SEQ ID NO 3								
LENGTH: 34								
TYPE: DNA								
ORGANISM: Artificial Sequence								
FEATURE:								
OTHER INFORMATION: Synthetic								
US-09-951-121A-3								
Query Match 0.5%; Score 9.2; DB 1; Length 34;								
Best Local Similarity 63.8%; Pred. No. 8.2e+02;								
Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0								
QY	1006	GAAGTGTGTGTGTGTGTGTGTG	1027					
DB	32	GAATTGTGGGGCGCGGTGTG	11					



## RESULT 106

US-10-295-682-2

; Sequence 2, Application US/10295682

; Publication No. US20030100740A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants

; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/10/295,682

; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361

; PRIOR FILING DATE: 2000-09-13

; PRIOR APPLICATION NUMBER: 60/236,455

; PRIOR FILING DATE: 2000-09-29

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 34

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-295-682-2

## Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 34;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTGTG 1027

-Db 3 GAATTGTGGGGCGCGGTGTG 24

## RESULT 107

US-10-295-682-3/c

; Sequence 3, Application US/10295682

; Publication No. US20030100740A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII Variants

; FILE REFERENCE: 6224.200-US

; CURRENT APPLICATION NUMBER: US/10/295,682

; CURRENT FILING DATE: 2002-11-15

; PRIOR APPLICATION NUMBER: PA 2000 01361

; PRIOR FILING DATE: 2000-09-13

; PRIOR APPLICATION NUMBER: 60/236,455

; PRIOR FILING DATE: 2000-09-29

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 34

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Synthetic

US-10-295-682-3

## Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 34;

Matches 14; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1006 GAAGTGTGTGTGTGTGTGTGTG 1027

-Db 32 GAATTGTGGGGCGCGGTGTG 11

## RESULT 108

US-10-281-727-2

; Sequence 2, Application US/10281727

; Publication No. US20030130191A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII

; TITLE OF INVENTION: Polypeptides

; FILE REFERENCE: 6410.200-US

; CURRENT APPLICATION NUMBER: US/10/281,727

; CURRENT FILING DATE: 2002-10-28

; PRIOR APPLICATION NUMBER: PA 2001 01627

; PRIOR FILING DATE: 2001-11-02

; PRIOR APPLICATION NUMBER: 60/335,383

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 2

; LENGTH: 36

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-2

## Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 36;

Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 862 TGGATGCAGCAGTA 875

-Db 2 TGCCTGCAGCAGGA 15

## RESULT 109

US-10-281-727-3/c

; Sequence 3, Application US/10281727

; Publication No. US20030130191A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

; APPLICANT: Olsen, Ole Hvilsted

; TITLE OF INVENTION: Human Coagulation Factor VII

; TITLE OF INVENTION: Polypeptides

; FILE REFERENCE: 6410.200-US

; CURRENT APPLICATION NUMBER: US/10/281,727

; CURRENT FILING DATE: 2002-10-28

; PRIOR APPLICATION NUMBER: PA 2001 01627

; PRIOR FILING DATE: 2001-11-02

; PRIOR APPLICATION NUMBER: 60/335,383

; PRIOR FILING DATE: 2001-11-15

; NUMBER OF SEQ ID NOS: 7

; SOFTWARE: FastSeq for Windows Version 4.0

; SEQ ID NO 3

; LENGTH: 36

; TYPE: DNA

; ORGANISM: Unknown

; FEATURE:

; OTHER INFORMATION: DNA primer for preparation of S314E/K316H-FVII

US-10-281-727-3

## Query Match

Best Local Similarity 0.5%; Score 9.2; DB 1; Length 36;

Matches 11; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 862 TGGATGCAGCAGTA 875

-Db 35 TGCCTGCAGCAGGA 22

## RESULT 110

US-09-951-121A-14

; Sequence 14, Application US/09951121A

; Publication No. US20030104978A1

; GENERAL INFORMATION:

; APPLICANT: Persson, Egon

```

: APPLICANT: Olsen, Ole Hvilsted
:
: TITLE OF INVENTION: Human Coagulation Factor VII Variants
:
: FILE REFERENCE: 6224.200-US
:
: CURRENT APPLICATION NUMBER: US/10/295.682
:
: CURRENT FILING DATE: 2002-11-15
:

```

```
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Protein C mutagenic oligonucleotide
US-09-803-810-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 9.8e+02;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 65
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCGG 7

RESULT 115
US-10-298-330-8/c
; Sequence 8, Application US/10298330
; Publication No. US20030100506A1
; GENERAL INFORMATION:
; APPLICANT: Nelsestuen, Gary L.
; TITLE OF INVENTION: Modified Vitamin K-Dependent
; FILE REFERENCE: 09531-127001
; CURRENT APPLICATION NUMBER: US/10/298,330
; PRIOR FILING DATE: 2002-11-18
; PRIOR APPLICATION NUMBER: 09/497,591
; PRIOR FILING DATE: 2000-02-03
; PRIOR APPLICATION NUMBER: 09/302,239
; PRIOR FILING DATE: 1999-04-29
; PRIOR APPLICATION NUMBER: 08/955,636
; PRIOR FILING DATE: 1997-10-23
; NUMBER OF SEQ ID NOS: 27
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 42
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Primer
US-10-298-330-8

Query Match      0.4%; Score 8.8; DB 1; Length 42;
Best Local Similarity 52.8%; Pred. No. 9.8e+02;
Matches 19; Conservative 0; Mismatches 17; Indels 0; Gaps 0;

QY 30 TTCTTGAAGCCTCTGCTGGCAATACTTCTGGGGCTG 65
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 42 TTCTGGAGGAGCTCCGTCGCCAGCAGCCTGGAGCGG 7

RESULT 116
US-10-281-727-6
; Sequence 6, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 6
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION:
US-10-281-727-6

Query Match      0.4%; Score 8.4; DB 1; Length 32;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 866 TGCAGCAGTA 875
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 29 TGCAGCAGGA 20

RESULT 117
US-10-281-727-7/c
; Sequence 7, Application US/10281727
; Publication No. US20030130191A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII
; FILE REFERENCE: 6410.200-US
; CURRENT APPLICATION NUMBER: US/10/281,727
; PRIOR FILING DATE: 2002-10-28
; PRIOR APPLICATION NUMBER: PA 2001 01627
; PRIOR FILING DATE: 2001-11-02
; PRIOR APPLICATION NUMBER: 60/335,383
; NUMBER OF SEQ ID NOS: 7
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 32
; TYPE: DNA
; ORGANISM: Unknown
; FEATURE:
; OTHER INFORMATION: DNA primer for preparation of S314E-FVII
US-10-281-727-7

Query Match      0.4%; Score 8.4; DB 1; Length 32;
Best Local Similarity 90.0%; Pred. No. 1.2e+03;
Matches 9; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 866 TGCAGCAGTA 875
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
Db 29 TGCAGCAGGA 20

RESULT 118
US-10-017-122-4/c
; Sequence 4, Application US/10017122
; Publication No. US20030087244A1
; GENERAL INFORMATION:
; APPLICANT: McCarthy, Jeanette
; TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF VASCULAR DISEASE
; FILE REFERENCE: MMI-007
; CURRENT APPLICATION NUMBER: US/10/017,122
; PRIOR FILING DATE: 2001-12-14
; PRIOR APPLICATION NUMBER: 60/327,487
; PRIOR FILING DATE: 2001-10-09
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 4
; LENGTH: 31
; TYPE: DNA
; ORGANISM: Homo sapiens
; FEATURE:
; OTHER INFORMATION:
US-10-017-122-4

Query Match      0.4%; Score 8.2; DB 1; Length 31;
Best Local Similarity 61.9%; Pred. No. 1.3e+03;
Matches 13; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 1278 CAGAAAGTTTCTAAGTGCA 1298
    ||||| ||| ||| ||| ||| ||| ||| ||| |||
```

```
Db 31 CAGAGAGTACCCCTCATGGCA 11

RESULT 119
US-09-951-121A-2/c
; Sequence 2, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-2

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTGTGGTGCATA 650
Db 31 TTGTGGGCACA 21

RESULT 120
US-09-951-121A-3
; Sequence 3, Application US/09951121A
; Publication No. US20030104978A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/09/951.121A
; PRIOR FILING DATE: 2001-09-13
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-09-951-121A-3

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTGTGGTGCATA 650
Db 31 TTGTGGGCACA 21

RESULT 121
US-10-295-682-2/c
; Sequence 2, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Olsen, Ole Hvilsted
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 2
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-2

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTGTGGTGCATA 650
Db 31 TTGTGGGCACA 21

RESULT 122
US-10-295-682-3
; Sequence 3, Application US/10295682
; Publication No. US20030100740A1
; GENERAL INFORMATION:
; APPLICANT: Persson, Egon
; TITLE OF INVENTION: Human Coagulation Factor VII Variants
; FILE REFERENCE: 6224.200-US
; CURRENT APPLICATION NUMBER: US/10/295,682
; PRIOR FILING DATE: 2002-11-15
; PRIOR APPLICATION NUMBER: PA 2000 01361
; PRIOR FILING DATE: 2000-09-13
; PRIOR APPLICATION NUMBER: 60/236,455
; NUMBER OF SEQ ID NOS: 17
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 3
; LENGTH: 34
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic
US-10-295-682-3

Query Match 0.4%; Score 7.8; DB 1; Length 34;
Best Local Similarity 81.8%; Pred. No. 1.4e+03;
Matches 9; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 640 TTGTGGTGCATA 650
Db 4 TTGTGGGCACA 14

Search completed: August 9, 2004, 16:50:07
Job time : 27 secs
```



GenCore version 5.1.6  
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 9, 2004, 16:50:27 ; Search time 3 seconds  
(without alignments)  
3.679 Million cell updates/sec

Title: US-10-664-775-3  
Perfect score: 2003  
Sequence: 1 aggttcacagagacttca.....tcaaggacctttatgaatt 2003

Scoring table: IDENTITY NUC  
Gapop 10.0 , Gapext 0.5

Searched: 4 seqs, 2755 residues

Total number of hits satisfying chosen parameters: 8

Minimum DB seq length: 0  
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%  
Maximum Match 100%  
Listing first 250 summaries

Database : rstdb:\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

#### SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
C 1	20.6	1.0	1201	1	AL531727
C 2	19.8	1.0	645	1	AI116939
C 3	18	0.9	1201	1	AL531727
4	17	0.8	300	1	AU099140
C 5	16.3	0.8	609	1	AI099321
6	14.4	0.7	609	1	AI099321
C 7	13.6	0.7	300	1	AU099140
8	13.6	0.7	645	1	AI116939

#### ALIGNMENTS

RESULT 1  
AL531727/c  
LOCUS  
DEFINITION AL531727 Homo sapiens FETAL LIVER Homo sapiens cDNA clone  
CSODM003YI01 5-PRIME, mRNA sequence.  
ACCESSION AL531727  
VERSION AL531727.2 GI:31069559  
KEYWORDS EST.  
SOURCE Homo sapiens (human)  
ORGANISM Homo sapiens  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
REFERENCE 1 (bases 1 to 1201)  
Li, W.B., Gruber, C., Jesse, J. and Polayes, D.  
Full-length cDNA libraries and normalization  
Unpublished (2001)  
On Feb 13, 2001 this sequence version replaced gi:12795220.  
Contact: Genoscope  
Genoscope - Centre National de Sequencage  
BP 191 91006 EVRY cedex - France

Email: seqref@genoscope.cns.fr, Web : www.genoscope.cns.fr  
Library was constructed by Life Technologies, a division of Invitrogen. This sequence belongs to sequence cluster 7252.f For more information about this cluster, see

http://www.genoscope.cns.fr/cgi-bin/Cluster.cgi?seq=CSODM003AE01QPI&cluster=7252.f. Contact : Feng Liang Email : fliang@lifetech.com URL : http://fulllength.invitrogen.com/Invitrogen Corporation 1600 Faraday Avenue Genoscope sequence ID : CSODM003AE01QPI.

#### FEATURES

Location/Qualifiers  
1..1201  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="CSODM003YI01"  
/tissue\_type="FETAL LIVER"  
/dev\_stage="fetal"  
/clone\_lib="Homo sapiens FETAL LIVER"  
/note="Organ: liver; Vector: pCMVSPORT\_6; 1st strand cDNA was primed with a NotI-oligo (dT) primer. Five prime end enriched, double-strand cDNA was digested with Not I and cloned into the Not I and EcoRV sites of the pCMVSPORT 6 vector. Library was not normalized."

Query Match 1.0%; Score 20.6; DB 1; Length 1201;  
Best Local Similarity 59.3%; Fred. No. 0.32;  
Matches 35; Conservative 0; Mismatches 24; Indels 0; Gaps 0;

QY 334 TTCAATTGCTTTTATCTGCGAGACTTGGCTTTTGTGTTTGAATATGTTCAATTGCG 392  
DB 648 TTTCGTGCAATTCCTTTTCTAGATAGGATATTTCCACATGGATATTCACCTGCG 590

#### RESULT 2

AI116939/c

LOCUS

DEFINITION

AI116939.1 GI:3517263

EST.

KEYWORDS

SOURCE

Mus musculus

ORGANISM

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.

REFERENCE

AUTHORS

Marra, M., Hillier, L., Allen, M., Bowles, M., Dietrich, N., Dubuque, T., Geisler, S., Kucaba, T., Lacy, M., Le, M., Martin, J., Morris, M., Schellenberg, K., Steptoe, M., Tan, F., Underwood, K., Moore, B., Theising, B., Wylie, T., Lennon, G., Soares, B., Wilson, R. and Waterston, R.

TITLE

JOURNAL

COMMENT

Unpublished (1996)

Contact: Marra M/Mouse EST Project

WashU-HMI Mouse EST Project

Washington University School of Medicine

4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108

Tel: 314 286 1800

Fax: 314 286 1810

Email: mouseest@watson.wustl.edu

This clone is available royalty-free through LNL ; contact the

IMAGE Consortium (info@image.llnl.gov) for further information.

MGI:930178

Seq primer: custom primer used

High quality sequence stop: 483.

Location/Qualifiers

1..645

/organism="Mus musculus"

/mol\_type="mRNA"

/strain="C57BL"

/db\_xref="taxon:10090"

/clone="IMAGE:1481822"

FEATURES

source



TITLE  
JOURNAL  
COMMENT

The WashU-HHMI Mouse EST Project  
Unpublished (1996)  
Contact: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930865  
Seq primer: custom primer used  
High quality sequence stop: 289.

FEATURES  
source

1..609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DralIII  
(CAGCTGTG); Site 2: DraIII (CAGCATGTG); 1st strand cDNA  
was primed with an oligo(dT) primer  
[ATGTGGCCTTTTCTTTTCTTTT]; double-stranded cDNA was  
ligated to a DraIII adaptor [TGTGGCCTACTGG], digested  
and cloned into distinct DraIII sites of the pME18S-FL3  
vector (5' site CAGCTGTG, 3' site CAGCATGTG). XhoI should  
be used to isolate the cDNA insert. Size selection was  
performed to exclude fragments <1.5kb. Library  
constructed by Dr. Sumio Sugano (University of Tokyo  
Institute of Medical Science). Custom primers for  
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end  
primer CGACCTGCAGCTCGAGACA."

Query Match 0.8%; Score 16.3; DB 1; Length 609;  
Best Local Similarity 63.5%; Pred. No. 4.3;  
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

QY 60 GGCGTGTGCTTCTCCCTGCTGATCTCAGGTGAGGTTAC-CAGTGTCTCTTC 118  
|||||  
DB 209 GGGCTCTTGAAGATCTCCGGGCTCTCTCAAGGAGCACTGTTCTCTCATTTGCACTCTCTC 150  
|||||

QY 119 TCC 121  
|||  
DB 149 TCC 147

RESULT 6  
AI099321  
LOCUS

AI099321 609 bp mRNA linear EST 20-AUG-1998  
IMAGE:1482509 5', similar to gb:W13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN); mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE

AI099321.1 GI:3448846  
Mus musculus (house mouse)

ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
1 (bases 1 to 609)  
Marra,M., Haller,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.

REFERENCE  
AUTHORS

The WashU-HHMI Mouse EST Project  
Unpublished (1996)

TITLE  
JOURNAL

CONTACT: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930865  
Seq primer: custom primer used  
High quality sequence stop: 289.

FEATURES  
source

1..609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DralIII  
(CAGCTGTG); Site 2: DraIII (CAGCATGTG); 1st strand cDNA  
was primed with an oligo(dT) primer  
[ATGTGGCCTTTTCTTTTCTTTT]; double-stranded cDNA was  
ligated to a DraIII adaptor [TGTGGCCTACTGG], digested  
and cloned into distinct DraIII sites of the pME18S-FL3  
vector (5' site CAGCTGTG, 3' site CAGCATGTG). XhoI should  
be used to isolate the cDNA insert. Size selection was  
performed to exclude fragments <1.5kb. Library  
constructed by Dr. Sumio Sugano (University of Tokyo  
Institute of Medical Science). Custom primers for  
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end  
primer CGACCTGCAGCTCGAGACA."

Query Match 0.8%; Score 16.3; DB 1; Length 609;  
Best Local Similarity 63.5%; Pred. No. 4.3;  
Matches 40; Conservative 0; Mismatches 22; Indels 1; Gaps 1;

QY 60 GGCGTGTGCTTCTCCCTGCTGATCTCAGGTGAGGTTAC-CAGTGTCTCTTC 118  
|||||  
DB 209 GGGCTCTTGAAGATCTCCGGGCTCTCTCAAGGAGCACTGTTCTCTCATTTGCACTCTCTC 150  
|||||

QY 119 TCC 121  
|||  
DB 149 TCC 147

RESULT 6  
AI099321  
LOCUS

AI099321 609 bp mRNA linear EST 20-AUG-1998  
IMAGE:1482509 5', similar to gb:W13232 COAGULATION FACTOR VII  
PRECURSOR (HUMAN); mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE

AI099321.1 GI:3448846  
Mus musculus (house mouse)

ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Mus.  
1 (bases 1 to 609)  
Marra,M., Haller,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,  
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,  
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,  
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and  
Waterston,R.

REFERENCE  
AUTHORS

The WashU-HHMI Mouse EST Project  
Unpublished (1996)

TITLE  
JOURNAL

CONTACT: Marra M/Mouse EST Project  
WashU-HHMI Mouse EST Project  
Washington University School of Medicine  
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108  
Tel: 314 286 1800  
Fax: 314 286 1810  
Email: mouseest@wustl.edu  
This clone is available royalty-free through LNL; contact the  
IMAGE Consortium (info@image.llnl.gov) for further information.  
MGI:930865  
Seq primer: custom primer used  
High quality sequence stop: 289.

FEATURES  
source

1..609  
/organism="Mus musculus"  
/mol\_type="mRNA"  
/strain="C57BL"  
/db\_xref="taxon:10090"  
/clone="IMAGE:1482509"  
/sex="female"  
/dev\_stage="adult"  
/lab\_host="DH10B"  
/clone\_lib="Sugano mouse liver mlia"  
/notes="Organ: liver; Vector: pME18S-FL3; Site 1: DralIII  
(CAGCTGTG); Site 2: DraIII (CAGCATGTG); 1st strand cDNA  
was primed with an oligo(dT) primer  
[ATGTGGCCTTTTCTTTTCTTTT]; double-stranded cDNA was  
ligated to a DraIII adaptor [TGTGGCCTACTGG], digested  
and cloned into distinct DraIII sites of the pME18S-FL3  
vector (5' site CAGCTGTG, 3' site CAGCATGTG). XhoI should  
be used to isolate the cDNA insert. Size selection was  
performed to exclude fragments <1.5kb. Library  
constructed by Dr. Sumio Sugano (University of Tokyo  
Institute of Medical Science). Custom primers for  
sequencing: 5' end primer CTCTGCTCTAAAGCTCG and 3' end  
primer CGACCTGCAGCTCGAGACA."

Query Match 0.7%; Score 14.4; DB 1; Length 609;  
Best Local Similarity 65.6%; Pred. No. 7.3;  
Matches 21; Conservative 0; Mismatches 11; Indels 0; Gaps 0;

QY 413 CAAGAAGGTACAGCTCTTTGTTGTTGGTGA 444  
|||||  
DB 360 CAAGAATGAACAGTGTGATCTGTGCATGA 391  
|||||

RESULT 7  
AU099140/c  
LOCUS

AU099140 300 bp mRNA linear EST 05-APR-2001  
Sugano Homo sapiens cDNA library Homo sapiens cDNA clone  
HEP20983 similar to Human factor VII serine protease precursor mRNA  
clone lambda-HVII2463, mRNA sequence.

ACCESSION  
VERSION  
KEYWORDS  
SOURCE

AU099140.1 GI:13550269  
Homo sapiens (human)

ORGANISM  
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
Mammalia; Eutheria; Primates; Catarrhini; Homnidae; Homo.  
1 (bases 1 to 300)  
Hata,H., Ota,T., Isogai,T., Tanaka,T., Nakamura,Y., Morishita,S.,  
Okubo,K., Suyama,A. and Sugano,S.

REFERENCE  
AUTHORS

In silico mapping of the 5'-ends of human mRNAs using full-length  
enriched and 5'-end enriched cDNA libraries constructed by  
Oligo-capping method  
Unpublished (2001)  
Contact: Yutaka Suzuki  
Department of Virology  
Institute of Medical Science, University of Tokyo  
4-6-1, Shirokanedai, Minatoku, Tokyo 108-8639, Japan  
Email: yusuzuki@ims.u-tokyo.ac.jp  
Suzuki,Y., Yoshitomo-Nakagawa,K., Maruyama,K., Suyama,A. and



